FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Fitzsimons, MG
Dilley, JD
Moser, C
Walker, JD
AF Fitzsimons, Michael G.
Dilley, Joshua D.
Moser, Chris
Walker, Jennifer D.
TI Analysis of 43 Intraoperative Cardiac Surgery Case Cancellations
SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
LA English
DT Article
DE anesthesia; health economics; patient safety; case cancellation;
complications
ID OPERATING-ROOM; CANNULATION
AB Objective: Late cancellation of surgery cases imposes significant emotional distress on the patient and their family and results in wasted resources, including loss of operating room and personnel time. This study was designed to determine the causes of cancellation, preventability, total operating room time, and postoperative destination.
Design: This study was a retrospective review of the 43 cardiac surgical cases that were cancelled while the patient was in the operating room (OR) but prior to surgical incision.
Setting: The cases were performed at the Massachusetts General Hospital, a teaching hospital of Harvard Medical School.
Participants: Forty-three out of 5,110 scheduled cardiac cases were identified that were cancelled after the patient had entered the operating room between January 1, 2010 and December 31, 2013.
Interventions: No interventions were made. This was a retrospective study.
Measurements and Main Results: The most common causes of cancellation included a change in the patient's health status (44%), problems associated with central catheter placement (18.6%), and unsatisfactory donor organs for planned transplantation (12%). The majority were inpatients (65%) prior to the procedure. The cumulative OR time for all cancelled cases was 5,374 minutes (89 hours and 34 minutes).
Conclusions: The reason for cancellation, preventability, total operating room time, and postoperative destination were determined. The information can be utilized to decrease the number of future cancellations. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Fitzsimons, Michael G.; Dilley, Joshua D.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
[Moser, Chris] Lahey Hosp & Med Ctr, Dept Anesthesiol, Burlington, MA USA.
[Walker, Jennifer D.] UMass Mem Med Ctr, Dept Cardiac Surg, Univ Campus, Worcester, MA USA.
RP Dilley, JD (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
EM joshuaddilley@gmail.com
NR 15
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1053-0770
EI 1532-8422
J9 J CARDIOTHOR VASC AN
JI J. Cardiothorac. Vasc. Anesth.
PD FEB
PY 2016
VL 30
IS 1
BP 19
EP 22
DI 10.1053/j.jvca.2015.08.007
PG 4
WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System;
Peripheral Vascular Disease
SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System
GA DD7KT
UT WOS:000370104100004
PM 26597766
ER
PT J
AU Dai, DW
Singh, I
Hershman, JM
AF Dai, David W.
Singh, Ishita
Hershman, Jerome M.
TI Lozenge-Induced Hypermineralcorticoid State--A Unique Case of Licorice
Lozenges Resulting in Hypertension and Hypokalemia
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
ID CORTISOL; RECEPTOR
C1 [Singh, Ishita] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Singh, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.; Singh, I (reprint author), West Los Angeles VA Med Ctr, VA Greater Los Angeles Healthcare Syst, Endocrinol 111D, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM isingh@mednet.ucla.edu
NR 13
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD FEB
PY 2016
VL 18
IS 2
BP 159
EP 160
DI 10.1111/jch.12633
PG 2
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DD5SQ
UT WOS:000369985100013
PM 26212733
ER
PT J
AU Schonfeld, DJ
Shekunov, J
Jellinek, M
Stein, MT
AF Schonfeld, David J.
Shekunov, Julia
Jellinek, Michael
Stein, Martin T.
TI A 9-Year-Old Girl Discovers That Her Mother Was Murdered
SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS
LA English
DT Editorial Material
DE bereavement; loss of parent; guilt; funeral participation; internal
representation
ID CHILDHOOD BEREAVEMENT; DEATH
AB CASE: Susan was a 9-year-old girl living with her mother; she had never met her father. Her mother returned one evening from her job as a cocktail waitress and Susan met her at the apartment door to let her know they had run out of cat food. Her mother said she would go and buy some the next morning because it was late and she was tired, but Susan insisted she go out that evening because the cat had not eaten all day. Her mother was fatally shot in the parking lot of the convenience store shortly thereafter; since there was no robbery involved, the police suspected it was someone that she knew. Susan's extended family had her move out of the apartment that evening and relocate to live with her aunt and uncle out-of-state. The transition happened quickly. Susan was unable to return to her apartment to pick up any additional belongings and never returned to say goodbye to her friends. The family decided she was too young to attend the funeral.Susan had trouble fitting in with her aunt and uncle's family; they had 2 children who were 8 and 6 years old, and Susan felt she was being treated like a baby. She resented having a bedtime (her mother allowed her to stay up as late as she wished), and she complained that the work at school was boring and her classmates were childish. When the family went to a festival in town, she left abruptly without telling them, which frightened Susan's aunt and uncle. They wanted to be supportive but felt that she needed more structure than her mother had provided her. Susan's aunt and uncle sought bereavement support for Susan from her pediatrician and parenting advice for themselves.
C1 [Schonfeld, David J.] Univ So Calif, Sch Social Work, Natl Ctr Sch Crisis & Bereavement, Los Angeles, CA 90089 USA.
[Schonfeld, David J.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Shekunov, Julia] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Jellinek, Michael] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Stein, Martin T.] Univ Calif San Diego, Rady Childrens Hosp, San Diego, CA 92103 USA.
RP Schonfeld, DJ (reprint author), Univ So Calif, Sch Social Work, Natl Ctr Sch Crisis & Bereavement, Los Angeles, CA 90089 USA.; Schonfeld, DJ (reprint author), Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
NR 2
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0196-206X
EI 1536-7312
J9 J DEV BEHAV PEDIATR
JI J. Dev. Behav. Pediatr.
PD FEB-MAR
PY 2016
VL 37
IS 2
BP 172
EP 174
DI 10.1097/DBP.0000000000000254
PG 3
WC Behavioral Sciences; Psychology, Developmental; Pediatrics
SC Behavioral Sciences; Psychology; Pediatrics
GA DD5OG
UT WOS:000369973000009
PM 26760376
ER
PT J
AU van Leeuwen, WF
Oflazoglu, K
Menendez, ME
Ring, D
AF van Leeuwen, Wouter F.
Oflazoglu, Kamilcan
Menendez, Mariano E.
Ring, David
TI Negative Ulnar Variance and Kienbock Disease
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Article
DE Kienbock disease; lunatomalacia; ulnar variance
ID INTRAOSSEOUS PRESSURE; POPULATION; MORPHOLOGY
AB Purpose To test the primary null hypothesis that there is no difference in mean ulnar variance (UV) scaled to the length of the capitates between 166 wrists with Kienbock disease and an equal number of matched controls and to test the secondary null hypothesis that mean scaled UV does not vary based on age, sex, or race in both Kienbock and control wrists.
Methods Ulnar variance was measured on posteroanterior radiographs of the wrist as the distance between a line through the midpoint between the volar and the dorsal edges of the ulnar margin of the radius and a line tangential to the most distal aspect of the carpal surface of the head of the ulna, both perpendicular to the longitudinal axis of the radius. Measurement of UV was scaled to the length of the capitate, resulting in a UV to capitate height (UV:CH) ratio.
Results We found a significant difference in mean UV:CH ratio between patients with Kienbock disease and a control group matched by age, sex, race, and limb. The prevalence of negative UV was high in both patients with Kienbock disease and matched controls. There were no differences in mean UV:CH ratio with respect to age, sex, or race among patients with Kienbock disease or matched controls.
Conclusions The precise role of ulna minus in the development of Kienbock disease remains uncertain and unanswered, given that many patients with Kienbock disease have neutral or positive UV. In addition, a large proportion of the normal population has negative UV, whereas Kienbock disease is rare. (Copyright (C) 2016 by the American Society for Surgery of the Hand. All rights reserved.)
Type of study/level of evidence Prognostic III.
C1 [van Leeuwen, Wouter F.; Oflazoglu, Kamilcan; Menendez, Mariano E.; Ring, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Hand & Upper Extrem Serv, Boston, MA USA.
RP Ring, D (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
OI Ring, David/0000-0002-6506-4879
NR 31
TC 2
Z9 3
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
EI 1531-6564
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD FEB
PY 2016
VL 41
IS 2
BP 214
EP 218
DI 10.1016/j.jhsa.2015.10.014
PG 5
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DD2UJ
UT WOS:000369777400008
PM 26686062
ER
PT J
AU Parrish, RC
Menendez, ME
Mudgal, CS
Jupiter, JB
Chen, NC
Ring, D
AF Parrish, Raymond C., II
Menendez, Mariano E.
Mudgal, Chaitanya S.
Jupiter, Jesse B.
Chen, Neal C.
Ring, David
TI Patient Satisfaction and its Relation to Perceived Visit Duration With a
Hand Surgeon
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Article
DE Doctor rush; empathy; expectations; patient satisfaction; visit duration
ID EMPATHY CARE MEASURE; PREOPERATIVE EXPECTATIONS; CONSUMER ASSESSMENT;
PATIENTS PERCEPTION; HEALTH LITERACY; SPINE SURGERY; TIME SPENT; ITEM
BANK; PHYSICIAN; OUTCOMES
AB Purpose To determine whether patient perception of time spent with a hand surgeon relates to patient satisfaction after a single new-patient office visit.
Methods Prior to each visit, 112 consecutive new patients predicted how much time they expected to spend with the surgeon. Following the visit, patients were asked to estimate the time spent with the surgeon, indicate whether the surgeon appeared rushed, and rate their overall satisfaction with the surgeon. Wait time and actual visit duration were measured. Patients also completed a sociodemographic survey, the Consultation and Relational Empathy Measure, the Newest Vital Sign Health Literacy test, and 3 Patient-Reported Outcomes Measurement Information System-based questionnaires: Upper Extremity Function, Pain Interference, and Depression. Multivariable logistic and linear regression models were used to determine predictors of patient satisfaction, patient-perceived surgeon rush, and high previsit expectations of visit duration.
Results Patient satisfaction was not associated with perceived visit duration but did correlate strongly with patient-rated surgeon empathy and symptoms of depression. Neither visit duration nor previsit expectations of visit length were determinants of patient-perceived surgeon rush. Only surgeon empathy was associated. Less-educated patients anticipated needing more time with the surgeon.
Conclusions Patient satisfaction with the surgeon and with the time spent during the office visit was primarily linked to surgeon empathy rather than to visit duration or previsit expectation of visit length. Efforts to make hand surgery office visits more patient-centered should focus on improving dialogue quality, and not necessarily on making visits longer. Copyright (C) 2016 by the American Society for Surgery of the Hand. All rights reserved.
C1 [Parrish, Raymond C., II; Menendez, Mariano E.; Mudgal, Chaitanya S.; Jupiter, Jesse B.; Chen, Neal C.; Ring, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg, Boston, MA USA.
RP Ring, D (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Yawkey Ctr, 55 Fruit St,Suite 2100, Boston, MA 02114 USA.
EM dring@partners.org
OI Ring, David/0000-0002-6506-4879
NR 32
TC 3
Z9 3
U1 1
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
EI 1531-6564
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD FEB
PY 2016
VL 41
IS 2
BP 257
EP 262
DI 10.1016/j.jhsa.2015.11.015
PG 6
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DD2UJ
UT WOS:000369777400015
PM 26718069
ER
PT J
AU Oflazoglu, K
Mellema, JJ
Menendez, ME
Mudgal, CS
Ring, D
Chen, NC
AF Oflazoglu, Kamilcan
Mellema, Jos J.
Menendez, Mariano E.
Mudgal, Chaitanya S.
Ring, David
Chen, Neal C.
TI Prevalence of and Factors Associated With Major Depression in Patients
With Upper Extremity Conditions
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Article
DE Depression; hand; orthopedics; prevalence; upper extremity
ID ORTHOPEDIC TRAUMA PATIENTS; ITEM BANK; OUTCOMES; PAIN; DISABILITY;
SEVERITY; SYMPTOMS; INJURY; PHQ-9
AB Purpose To determine the prevalence of an estimated diagnosis of major depression in patients with upper extremity conditions and factors that help identify patients who might benefit from psychological treatment.
Methods In this observational cross-sectional study, 190 patients completed questionnaires measuring symptoms of depression with the Patient Health Questionnaire, upper extremity disability with the Patient-Reported Outcomes Measurement Information System Upper Extremity, pain interference with the Patient-Reported Outcomes Measurement Information System Pain Interference, and health anxiety with the Short Health Anxiety Inventory.
Results The estimated prevalence of an estimated diagnosis of major depression (Patient Health Questionnaire 9 >= 10) among this group of patients was 12%. Having multiple pain conditions, a history of depression, and greater limitation from pain for daily activities were independently associated with an estimated diagnosis of major depression.
Conclusions The finding that 1 in 8 patients presenting to a hand surgeon have untreated or undertreated symptoms of depression sufficient to qualify for an estimated diagnosis of major depression emphasizes the importance of assessing for depression at all levels of care. Copyright (C) 2016 by the American Society for Surgery of the Hand. All rights reserved.
C1 [Oflazoglu, Kamilcan; Mellema, Jos J.; Menendez, Mariano E.; Mudgal, Chaitanya S.; Ring, David; Chen, Neal C.] Harvard Univ, Sch Med, Dept Orthoped Surg, Massachusetts Gen Hosp,Hand & Upper Extrem Serv, Boston, MA 02114 USA.
RP Ring, D (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partnets.org
OI Ring, David/0000-0002-6506-4879
NR 31
TC 0
Z9 0
U1 3
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
EI 1531-6564
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD FEB
PY 2016
VL 41
IS 2
BP 263
EP 269
DI 10.1016/j.jhsa.2015.11.019
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DD2UJ
UT WOS:000369777400016
PM 26723479
ER
PT J
AU Calderwood, AH
Schroy, PC
Kluge, MA
Cabral, HJ
Burgess, JF
AF Calderwood, Audrey H.
Schroy, Paul C., III
Kluge, Matthew A.
Cabral, Howard J.
Burgess, James F., Jr.
TI Predictors of Adherence to Post-Polypectomy Surveillance Colonoscopy
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Article
DE Adherence; screening; colorectal cancer; ambulatory care
ID SOCIETY TASK-FORCE; AMERICAN-CANCER-SOCIETY; COLORECTAL-CANCER;
CONSENSUS UPDATE; MEDICARE BENEFICIARIES; ADENOMATOUS POLYPS;
GUIDELINES; POPULATION; PREVENTION; RESECTION
AB Objective. To identify predictors of adherence with surveillance colonoscopy at a safety-net hospital. Methods. We evaluated average-risk patients aged 50-75 with adenomas diagnosed at screening colonoscopy between 1/1/05-12/31/07. The primary outcome was on-time follow-up defined as attendance at surveillance colonoscopy within 5.5 years of screening colonoscopy. Results. Among 881 patients, of whom 38% were English-speaking non-Hispanic Blacks, 38.3% attended on-time surveillance colonoscopy. In unadjusted analyses, >= 3 PCP visits after baseline colonoscopy (OR 3.6 [2.5-5.0]), "adenoma" on the EMR problem list (OR 2.2 [1.6-2.9]), and Charlson Index >= 1 (OR 1.4 [1.0-1.8]) were associated with adherence. "Adenoma" on the EMR problem list remained significant in multivariable analyses (aOR 1.8 [1.3-2.5]). A significant interaction was observed between ethnicity/language and PCP visits (p=.003). Conclusion. Many adenoma-bearing patients fail to attend surveillance colonoscopy in a safety-net setting. Adding "adenomas" to the EMR problem list improved attendance, suggesting that system-level interventions can increase adherence.
C1 [Calderwood, Audrey H.; Schroy, Paul C., III] Boston Univ, Sch Med, Dept Med, Gastroenterol Sect, Boston, MA 02215 USA.
[Kluge, Matthew A.] Boston Univ, Sch Med, Boston, MA 02215 USA.
[Cabral, Howard J.] Boston Univ, Dept Biostat, Boston, MA 02215 USA.
[Burgess, James F., Jr.] VA Boston Healthcare Syst, Boston, MA USA.
[Burgess, James F., Jr.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA.
RP Calderwood, AH (reprint author), Boston Univ, Sch Med, Dept Med, Gastroenterol Sect, Boston, MA 02215 USA.; Calderwood, AH (reprint author), 85 East Concord St,Room 7724, Boston, MA 02118 USA.
EM Audrey.calderwood@bmc.org
NR 39
TC 0
Z9 0
U1 1
U2 2
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
EI 1548-6869
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD FEB
PY 2016
VL 27
IS 1
BP 261
EP 279
DI 10.1353/hpu.2016.0028
PG 19
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA DC9BD
UT WOS:000369514400022
PM 27763469
ER
PT J
AU Hochman, M
Briggs-Malonson, M
Wilkes, E
Bergman, J
Daskivich, LP
Moin, T
Brook, I
Ryan, GW
Brook, RH
Mangione, CM
AF Hochman, Michael
Briggs-Malonson, Medell
Wilkes, Erin
Bergman, Jonathan
Daskivich, Lauren Patty
Moin, Tannaz
Brook, Ilanit
Ryan, Gery W.
Brook, Robert H.
Mangione, Carol M.
TI Fostering a Commitment to Quality: Best Practices in Safety-net
Hospitals
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Article
DE Quality improvement; safety-net; community
ID HEALTH REFORM; OF-CARE; 1990S
AB In 2007, the Martin Luther King, Jr.-Harbor Hospital (MLK-Harbor), which served a large safety-net population in South Los Angeles, closed due to quality challenges. Shortly thereafter, an agreement was made to establish a new hospital, Martin Luther King, Jr. Community Hospital (MLKCH), to serve the unmet needs of the community. To assist the newly appointed MLKCH Board of Directors in building a culture of quality, we conducted a series of interviews with five high-performing hospital systems. In this report, we describe our findings. The hospitals we interviewed achieved a culture of quality by: 1) developing guiding principles that foster quality; 2) hiring and retaining personnel who are stewards of quality; 3) promoting efficient resource utilization; 4) developing a well-organized quality improvement infrastructure; and 5) cultivating integrated, patient-centric care. The institutions highlighted in this report provide important lessons for MLKCH and other safety-net institutions.
C1 [Hochman, Michael; Bergman, Jonathan; Daskivich, Lauren Patty; Brook, Robert H.; Mangione, Carol M.] Univ Calif Los Angeles, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA USA.
[Hochman, Michael; Daskivich, Lauren Patty] US Dept Vet Affairs, Los Angeles, CA USA.
[Hochman, Michael] AltaMed Hlth Serv, 2040 Camfield Ave, Los Angeles, CA 90040 USA.
[Briggs-Malonson, Medell] Univ Calif Los Angeles, David Geffen Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA 90095 USA.
[Briggs-Malonson, Medell] Martin Luther King Jr Community Hosp, Los Angeles, CA USA.
[Wilkes, Erin] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Wilkes, Erin; Daskivich, Lauren Patty] Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA.
[Bergman, Jonathan] US Dept Vet Affairs, Vet Hlth Affairs, Los Angeles, CA USA.
[Bergman, Jonathan] Olive View UCLA Med Ctr, Sylmar, CA 91342 USA.
[Moin, Tannaz] Univ Calif Los Angeles, David Geffen Sch Med, Vet Hlth Affairs, Los Angeles, CA USA.
[Brook, Ilanit] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA 90033 USA.
[Ryan, Gery W.] Pardee RAND Grad Sch, Santa Monica, CA USA.
[Brook, Robert H.] Univ Calif Los Angeles, David Geffen Sch Med, US Dept Vet Affairs, Pardee RAND Grad Sch, Los Angeles, CA 90095 USA.
[Brook, Robert H.; Mangione, Carol M.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Los Angeles, CA 90024 USA.
RP Hochman, M (reprint author), Univ Calif Los Angeles, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA USA.; Hochman, M (reprint author), US Dept Vet Affairs, Los Angeles, CA USA.; Hochman, M (reprint author), AltaMed Hlth Serv, 2040 Camfield Ave, Los Angeles, CA 90040 USA.
EM meh1979@gmail.com
FU Robert Wood Johnson Foundation Clinical Scholars Program; U.S.
Department of Veterans Affairs; National Research Award Program,
National Institutes of Health
FX We would like to thank the numerous people who helped us with this
project including, but not limited to, Ken Wells, MD, MPH; Loretta
Jones, MA; the original Martin Luther King, Jr. Community Hospital Board
of Directors (Manuel A. Abascal, JD; Elaine Batchlor, MD, MPH; Linda
Griego, BA; Paul King, MHA; Michael Madden, MA; Robert Margolis, MD and
James Yoshioka, BS); those who graciously allowed us to interview them
at Denver Health, Grady Health, Harlem Hospital Center, Mount Sinai
Health System, and Virginia Mason Medical Center; and the Robert Wood
Johnson Foundation Clinical Scholars Program, the U.S. Department of
Veterans Affairs, and the National Research Award Program, National
Institutes of Health, for supporting our efforts.
NR 23
TC 0
Z9 0
U1 2
U2 6
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
EI 1548-6869
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD FEB
PY 2016
VL 27
IS 1
BP 293
EP 307
DI 10.1353/hpu.2016.0008
PG 15
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA DC9BD
UT WOS:000369514400024
PM 27763471
ER
PT J
AU Peters, AT
West, AE
Eisner, L
Baek, J
Deckersbach, T
AF Peters, Amy T.
West, Amy E.
Eisner, Lori
Baek, Jihyun
Deckersbach, Thilo
TI The Burden of Repeated Mood Episodes in Bipolar I Disorder Results From
the National Epidemiological Survey on Alcohol and Related Conditions
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Article
DE Bipolar; depression; functioning
ID TREATMENT ENHANCEMENT PROGRAM; STEP-BD; PERSONALITY-DISORDERS; EARLY
INTERVENTION; STAGING MODEL; FOLLOW-UP; NEUROPROGRESSION; ILLNESS;
PHENOMENOLOGY; RECURRENCE
AB The aim of this study was to examine the association between previous mood episodes and clinical course/functioning in a community sample (National Epidemiological Survey on Alcohol and Related Conditions [NESARC]). Subjects (n = 909) met Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, criteria for bipolar I disorder and provided data on number of previous episode recurrences. Number of previous mood episodes was used to predict outcomes at wave 1 and wave 2 of the NESARC. Previous mood episodes accounted for small but unique variance in outcomes. Recurrence was associated with poorer functioning, psychiatric and medical comorbidity, and increased odds of suicidality, disability, unemployment, and hospitalization at wave 1. Recurrences were associated with greater risk for new onset suicidality, psychiatric comorbidity, disability, unemployment, and poor functioning by wave 2. The course of bipolar disorder does worsen with progressive mood episodes but is attenuated in community, relative to clinical samples. Interventions to prevent future relapse may be particularly important to implement early in the course of illness.
C1 [Peters, Amy T.; West, Amy E.] Univ Illinois, Chicago, IL USA.
[Eisner, Lori; Baek, Jihyun; Deckersbach, Thilo] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Eisner, Lori; Baek, Jihyun; Deckersbach, Thilo] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Deckersbach, T (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 149-2628,Bldg 149,13th St,2nd Floor, Charlestown, MA 02129 USA.
EM tdeckersbach@partners.org
FU National Institutes of Mental Health; NARSAD; Tourette Syndrome
Association; International OCD Foundation; Tufts University; MGH
Psychiatry Academy; BrainCells Inc; Systems Research and Applications
Corporation; Boston University; Catalan
FX Amy Peters has received funding from the National Institutes of Mental
Health. Amy West has received funding from the National Institutes of
Mental Health, honoraria from the National Institute of Health (grant
review), Northwestern University (Grand Rounds), and University of Lund
(academic talk). Thilo Deckersbach has received funding from the
National Institutes of Mental Health. Thilo Deckersbach has also
received funding from NARSAD, the Tourette Syndrome Association, the
International OCD Foundation, and Tufts University. He has received
honoraria, consultation fees and/or royalties from the MGH Psychiatry
Academy, BrainCells Inc, Systems Research and Applications Corporation,
Boston University, the Catalan.
NR 38
TC 1
Z9 1
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0022-3018
EI 1539-736X
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD FEB
PY 2016
VL 204
IS 2
BP 87
EP 94
DI 10.1097/NMD.0000000000000425
PG 8
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DD5NP
UT WOS:000369971100003
PM 26588078
ER
PT J
AU Armour, C
Contractor, A
Shea, T
Elhai, JD
Pietrzak, RH
AF Armour, Cherie
Contractor, Ateka
Shea, Tracie
Elhai, Jon D.
Pietrzak, Robert H.
TI Factor Structure of the PTSD Checklist for DSM-5 Relationships Among
Symptom Clusters, Anger, and Impulsivity
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Article
DE PTSD; PCL-5; anger; impulsivity; DSM-5; confirmatory factor analysis
ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE DEPENDENT INPATIENTS;
CONFIRMATORY FACTOR-ANALYSIS; CLINIC-REFERRED YOUTH; 5 FACTOR MODEL;
UNDERLYING DIMENSIONS; EARTHQUAKE SURVIVORS; MALE VETERANS; PSYCHOMETRIC
PROPERTIES; EMOTION DYSREGULATION
AB Scarce data are available regarding the dimensional structure of Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) posttraumatic stress disorder (PTSD) symptoms and how factors relate to external constructs. We evaluated six competing models of DSM-5 PTSD symptoms, including Anhedonia, Externalizing Behaviors, and Hybrid models, using confirmatory factor analyses in a sample of 412 trauma-exposed college students. We then examined whether PTSD symptom clusters were differentially related to measures of anger and impulsivity using Wald chi-square tests. The seven-factor Hybrid model was deemed optimal compared with the alternatives. All symptom clusters were associated with anger; the strongest association was between externalizing behaviors and anger (r = 0.54). All symptom clusters, except reexperiencing and avoidance, were associated with impulsivity, with the strongest association between externalizing behaviors and impulsivity (r = 0.49). A seven-factor Hybrid model provides superior fit to DSM-5 PTSD symptom data, with the externalizing behaviors factor being most strongly related to anger and impulsivity.
C1 [Armour, Cherie] Univ Ulster, Sch Psychol, Coleraine Campus, Coleraine BT52 1SA, Londonderry, North Ireland.
[Contractor, Ateka; Elhai, Jon D.] Univ Toledo, Dept Psychol, Toledo, OH USA.
[Contractor, Ateka; Shea, Tracie] Brown Univ, Warren Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA.
[Shea, Tracie] Vet Affairs Med Ctr, Providence, RI USA.
[Elhai, Jon D.] Univ Toledo, Dept Psychiat, Toledo, OH USA.
[Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Pietrzak, Robert H.] VA Connecticut Healthcare Syst, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, US Dept Vet Affairs, West Haven, CT USA.
RP Armour, C (reprint author), Univ Ulster, Sch Psychol, Coleraine Campus, Coleraine BT52 1SA, Londonderry, North Ireland.
EM armour.cherie@gmail.com
OI Armour, Cherie/0000-0001-7649-3874
NR 68
TC 2
Z9 2
U1 9
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0022-3018
EI 1539-736X
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD FEB
PY 2016
VL 204
IS 2
BP 108
EP 115
DI 10.1097/NMD.0000000000000430
PG 8
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DD5NP
UT WOS:000369971100006
PM 26669984
ER
PT J
AU Schofield, CA
Dea Moore, C
Hall, A
Coles, ME
AF Schofield, Casey A.
Dea Moore, Crystal
Hall, Anna
Coles, Meredith E.
TI Understanding Perceptions of Anxiety Disorders and Their Treatment
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Article
DE Anxiety; depression; treatment perceptions; mental health literacy
ID MENTAL-HEALTH LITERACY; COMORBIDITY SURVEY REPLICATION; SELF-EFFICACY;
PSYCHOLOGICAL TREATMENTS; DISSEMINATING TREATMENT; SOCIAL PHOBIA;
HELP-SEEKING; YOUNG-PEOPLE; ATTITUDES; BELIEFS
AB Characterizing areas of limited knowledge about anxiety disorders and their treatment may help inform treatment dissemination efforts and public health programming. In a sample of 626 adults recruited via Amazon's Mechanical Turk, this study evaluated 1) perceptions of symptoms of anxiety disorders and depression, 2) perceived usefulness of coping approaches (i.e., professional and non-professional help), and 3) awareness of available resources. Results indicated that participants generally recognized that symptoms warranted professional help, and recognition was associated with self-efficacy for seeking mental health care, but not with participants' own symptoms. Furthermore, participants perceived psychotherapy to be the most useful coping approach. Of concern is the perception that symptoms are the result of personal weakness (particularly among male participants and for social anxiety disorder), as well as limited knowledge about publicly available resources. In all, results suggest that there are areas for growth regarding mental health literacy for anxiety disorders.
C1 [Schofield, Casey A.; Dea Moore, Crystal] Skidmore Coll, 815 North Broadway, Saratoga Springs, NY 12866 USA.
[Hall, Anna] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Coles, Meredith E.] SUNY Binghamton, Binghamton, NY USA.
RP Schofield, CA (reprint author), Skidmore Coll, 815 North Broadway, Saratoga Springs, NY 12866 USA.
EM cschofie@skidmore.edu
NR 41
TC 0
Z9 0
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0022-3018
EI 1539-736X
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD FEB
PY 2016
VL 204
IS 2
BP 116
EP 122
DI 10.1097/NMD.0000000000000433
PG 7
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DD5NP
UT WOS:000369971100007
PM 26669982
ER
PT J
AU Hiar, S
Thomas, CL
Hinton, DE
Salles, J
Goutaudier, N
Olliac, B
Bui, E
AF Hiar, Soraya
Thomas, Charmaine L.
Hinton, Devon E.
Salles, Juliette
Goutaudier, Nelly
Olliac, Bertrand
Bui, Eric
TI Somatic Symptoms Mediate the Relationship Between Trauma During the Arab
Spring and Quality of Life Among Tunisians
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Article
DE PTSD; peritraumatic distress; peritraumatic dissociation; cross-cultural
validity
ID POSTTRAUMATIC STRESS; PTSD; REFUGEES; INVENTORY; ACCIDENT; VALIDITY;
VICTIMS
AB This study examined the relationship between peritraumatic reactions, posttraumatic stress disorder (PTSD) symptoms, somatic complaints, and quality of life in Tunisians exposed to the events of the Arab Spring. Participants (n = 60) completed an online survey 1 year after the events, assessing peritraumatic distress, peritraumatic dissociation, PTSD symptoms, somatic complaints, and physical and mental quality of life. Results showed that peritraumatic dissociation was independently associated with increased PTSD symptoms and somatic complaints 12 months after the events. Multiple mediator mediation analyses revealed that somatic complaints (not PTSD symptoms) were the only independent mediators of the relationships between peritraumatic dissociation and both physical and mental quality of life. Assessing peritraumatic dissociation soon after trauma exposure among the North African population might help identify individuals at risk for PTSD. Furthermore, the impact of trauma on quality of life may be better explained by somatic complaints than PTSD symptoms among North Africans.
C1 [Hiar, Soraya; Thomas, Charmaine L.; Salles, Juliette] Univ Toulouse, Dept Psychiat, Toulouse, France.
[Thomas, Charmaine L.] Univ Calgary, Dept Psychol, Calgary, AB T2N 1N4, Canada.
[Hinton, Devon E.; Bui, Eric] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hinton, Devon E.; Bui, Eric] Harvard Univ, Sch Med, Boston, MA USA.
[Goutaudier, Nelly] Univ Toulouse, Dept Psychol, Toulouse, France.
[Olliac, Bertrand] Ctr Hosp Esquirol, Dept Psychiat, Limoges, France.
[Olliac, Bertrand] INSERM, UMR 1094, Dept Trop Neuroepidemiol, Limoges, France.
RP Bui, E (reprint author), Red Sox Fdn & Massachusetts Gen Hosp Home Base Pr, One Bowdoin Sq,6th Floor,Suite 650, Boston, MA 02114 USA.; Bui, E (reprint author), Massachusetts Gen Hosp, Ctr Anxiety & Traumat Str Disorders, One Bowdoin Sq,6th Floor,Suite 650, Boston, MA 02114 USA.
EM tebui@mgh.harvard.edu
FU Red Sox Foundation; Massachusetts General Hospital Home Base Program;
Highland Street Foundation
FX Dr. Bui's research effort was supported by the Red Sox Foundation &
Massachusetts General Hospital Home Base Program and the Highland Street
Foundation.
NR 17
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0022-3018
EI 1539-736X
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD FEB
PY 2016
VL 204
IS 2
BP 153
EP 155
DI 10.1097/NMD.0000000000000446
PG 3
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DD5NP
UT WOS:000369971100012
PM 26825265
ER
PT J
AU Chou, R
Gordon, DB
de Leon-Casasola, OA
Rosenberg, JM
Bickler, S
Brennan, T
Carter, T
Cassidy, CL
Chittenden, EH
Degenhardt, E
Griffith, S
Manworren, R
McCarberg, B
Montgomery, R
Murphy, J
Perkal, MF
Suresh, S
Sluka, K
Strassels, S
Thirlby, R
Viscusi, E
Walco, GA
Warner, L
Weisman, SJ
Wu, CL
AF Chou, Roger
Gordon, Debra B.
de Leon-Casasola, Oscar A.
Rosenberg, Jack M.
Bickler, Stephen
Brennan, Tim
Carter, Todd
Cassidy, Carla L.
Chittenden, Eva Hall
Degenhardt, Ernest
Griffith, Scott
Manworren, Renee
McCarberg, Bill
Montgomery, Robert
Murphy, Jamie
Perkal, Melissa F.
Suresh, Santhanam
Sluka, Kathleen
Strassels, Scott
Thirlby, Richard
Viscusi, Eugene
Walco, Gary A.
Warner, Lisa
Weisman, Steven J.
Wu, Christopher L.
TI Management of Postoperative Pain: A Clinical Practice Guideline From the
American Pain Society, the American Society of Regional Anesthesia and
Pain Medicine, and the American Society of Anesthesiologists' Committee
on Regional Anesthesia, Executive Committee, and Administrative Council
SO JOURNAL OF PAIN
LA English
DT Article
DE Postoperative pain management; clinical practice guidelines; analgesia;
education; multi-modal therapy; patient assessment; regional analgesia;
neuraxial analgesia
ID TOTAL KNEE ARTHROPLASTY; CRUCIATE LIGAMENT RECONSTRUCTION;
PATIENT-CONTROLLED ANALGESIA; RANDOMIZED CONTROLLED-TRIAL; ELECTRICAL
NERVE-STIMULATION; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INTRAARTICULAR
BUPIVACAINE INFUSION; PERSISTENT POSTSURGICAL PAIN; LIDOCAINE-PRILOCAINE
CREAM; PLACEBO-CONTROLLED TRIAL
AB Most patients who undergo surgical procedures experience acute postoperative pain, but evidence suggests that less than half report adequate postoperative pain relief. Many preoperative, intra-operative, and postoperative interventions and management strategies are available for reducing and managing postoperative pain. The American Pain Society, with input from the American Society of Anesthesiologists, commissioned an interdisciplinary expert panel to develop a clinical practice guideline to promote evidence-based, effective, and safer postoperative pain management in children and adults. The guideline was subsequently approved by the American Society for Regional Anesthesia. As part of the guideline development process, a systematic review was commissioned on various aspects related to various interventions and management strategies for postoperative pain. After a review of the evidence, the expert panel formulated recommendations that addressed various aspects of postoperative pain management, including preoperative education, perioperative pain management planning, use of different pharmacological and nonpharmacological modalities, organizational policies, and transition to outpatient care. The recommendations are based on the underlying premise that optimal management begins in the preoperative period with an assessment of the patient and development of a plan of care tailored to the individual and the surgical procedure involved. The panel found that evidence supports the use of multimodal regimens in many situations, although the exact components of effective multi modal care will vary depending on the patient, setting, and surgical procedure. Although these guidelines are based on a systematic review of the evidence on management of postoperative pain, the panel identified numerous research gaps. Of 32 recommendations, 4 were assessed as being supported by high-quality evidence, and 11 (in the areas of patient education and perioperative planning, patient assessment, organizational structures and policies, and transitioning to outpatient care) were made on the basis of low-quality evidence. (C) 2016 by the American Pain Society
C1 [Chou, Roger] Oregon Hlth & Sci Univ, Pacific Northwest Evidence Based Practice Ctr, Dept Med, Portland, OR 97201 USA.
[Chou, Roger] Oregon Hlth & Sci Univ, Pacific Northwest Evidence Based Practice Ctr, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
[Gordon, Debra B.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.
[de Leon-Casasola, Oscar A.] Roswell Pk Canc Inst, Dept Anesthesiol & Pain Med, Buffalo, NY 14263 USA.
[de Leon-Casasola, Oscar A.] SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14260 USA.
[Rosenberg, Jack M.] Univ Michigan, Vet Integrated Serv Network, Dept Vet Affairs, Ann Arbor, MI 48109 USA.
[Rosenberg, Jack M.] Univ Michigan, Dept Phys Med, Ann Arbor, MI 48109 USA.
[Rosenberg, Jack M.] Univ Michigan, Dept Rehabil & Anesthesiol, Ann Arbor, MI 48109 USA.
[Bickler, Stephen] Univ Calif San Diego, Pediat Surg, San Diego, CA 92103 USA.
[Brennan, Tim] Univ Iowa Hosp & Clin, Dept Anesthesia, Iowa City, IA 52242 USA.
[Carter, Todd] Univ Cincinnati, Dept Anesthesia, Cincinnati, OH USA.
[Cassidy, Carla L.] Vet Hlth Adm, Dept Vet Affairs, Washington, DC USA.
[Chittenden, Eva Hall] Massachusetts Gen Hosp, Dept Palliat Care, Boston, MA 02114 USA.
[Degenhardt, Ernest] United States Army Med Command, Qual Management Div, San Antonio, TX USA.
[Griffith, Scott] Walter Reed Army Med Ctr, Crit Care Med, Bethesda, MD USA.
[Manworren, Renee] Univ Connecticut, Sch Med, Dept Pediat, Mansfield, CT USA.
[McCarberg, Bill] Amer Acad Pain Med, San Diego, CA USA.
[Montgomery, Robert] Univ Colorado, Dept Anesthesiol, Denver, CO 80202 USA.
[Murphy, Jamie; Wu, Christopher L.] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA.
[Perkal, Melissa F.] Vet Affairs Med Ctr, Dept Surg, West Haven, CT USA.
[Suresh, Santhanam] Childrens Hosp Chicago, Dept Pediat Anesthesia, Chicago, IL USA.
[Sluka, Kathleen] Univ Iowa, Dept Phys Therapy & Rehabil, Iowa City, IA USA.
[Strassels, Scott] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA.
[Thirlby, Richard] Virginia Mason Med Ctr, Bariatr Weight Loss Surg Ctr, Seattle, WA 98101 USA.
[Viscusi, Eugene] Thomas Jefferson Univ, Dept Anesthesiol, Philadelphia, PA 19107 USA.
[Walco, Gary A.] Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, Seattle, WA USA.
[Warner, Lisa] Dept Veteran Affairs, Phoenix, AZ USA.
[Weisman, Steven J.] Childrens Hosp Wisconsin, Dept Anesthesiol, Wauwatosa, WI USA.
RP Chou, R (reprint author), 3181 SW Sam Jackson Pk Rd,Mail Code BICC, Portland, OR 97239 USA.
EM chour@ohsu.edu
FU American Pain Society
FX Funding for this guideline was provided by the American Pain Society.
The guideline was submitted for approval by the partnering
organizations, but the content of the guideline is the sole
responsibility of the authors and panel members.
NR 320
TC 36
Z9 42
U1 11
U2 27
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD FEB
PY 2016
VL 17
IS 2
BP 131
EP 157
DI 10.1016/j.jpain.2015.12.008
PG 27
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DD7NO
UT WOS:000370111600001
PM 26827847
ER
PT J
AU Barolet, D
Christiaens, F
Hamblin, MR
AF Barolet, Daniel
Christiaens, Francois
Hamblin, Michael R.
TI Infrared and skin: Friend or foe
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE Infrared (IR); IR-A; Photobiomodulation; MMP-1; Photoprevention;
Irradiance
ID HUMAN DERMAL FIBROBLASTS; BIPHASIC DOSE-RESPONSE; LEVEL LIGHT THERAPY;
PHOTODYNAMIC THERAPY; CELLULAR-RESPONSE; SUN PROTECTION; HAIRLESS MICE;
EXPOSURE TIME; SHADOW RULE; IN-VIVO
AB In the last decade, it has been proposed that the sun's IR-A wavelengths might be deleterious to human skin and that sunscreens, in addition to their desired effect to protect against UV-B and UV-A, should also protect against IR-A (and perhaps even visible light). Several studies showed that NIR may damage skin collagen content via an increase in MMP-1 activity in the same manner as is known for UVR. Unfortunately, the artificial NIR light sources used in such studies were not representative of the solar irradiance.
Yet, little has been said about the other side of the coin. This article will focus on key information suggesting that IR-A may be more beneficial than deleterious when the skin is exposed to the appropriate irradiance/dose of IR-A radiation similar to daily sun exposure received by people in real life.
IR-A might even precondition the skin a process called photoprevention from an evolutionary standpoint since exposure to early morning IR-A wavelengths in sunlight may ready the skin for the coming mid-day deleterious UVR.
Consequently IR-A appears to be the solution, not the problem. It does more good than bad for the skin. It is essentially a question of intensity and how we can learn from the sun. (C) 2016 The Authors. Published by Elsevier B.V.
C1 [Barolet, Daniel] McGill Univ, Dept Med, Div Dermatol, Montreal, PQ H3A 1A1, Canada.
[Barolet, Daniel] RoseLab Skin Opt Lab, Laval, PQ H7T 0G3, Canada.
[Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Barolet, D (reprint author), RoseLab Skin Opt Lab, Div Dermatol, 3333 100th Ave,Suite 200, Laval, PQ H7T 0G3, Canada.
EM daniel.barolet@mcgill.ca
FU US NIH [R01AI050875]
FX DB & FC have no conflicts of interest. MRH was supported by US NIH grant
R01AI050875.
NR 64
TC 8
Z9 8
U1 5
U2 17
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD FEB
PY 2016
VL 155
BP 78
EP 85
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA DD7GC
UT WOS:000370090700011
PM 26745730
ER
PT J
AU Augustine, MB
Swift, KM
Harris, SR
Anderson, EJ
Hand, RK
AF Augustine, Mary Beth
Swift, Kathie M.
Harris, Stephanie R.
Anderson, Ellen J.
Hand, Rosa K.
TI Integrative Medicine: Education, Perceived Knowledge, Attitudes, and
Practice among Academy of Nutrition and Dietetics Members
SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS
LA English
DT Editorial Material
ID REGISTERED DIETITIANS; ALTERNATIVE MEDICINE; DIETARY-SUPPLEMENTS;
FUNCTIONAL FOODS; COMPLEMENTARY; COMPETENCES; PROGRAMS; POSITION
C1 [Augustine, Mary Beth; Swift, Kathie M.; Harris, Stephanie R.] Acad Nutr & Dietet, Integrat & Funct Med Dietet Practice Grp, Chicago, IL USA.
[Augustine, Mary Beth] Mt Sinai Beth Israel, New York, NY USA.
[Swift, Kathie M.] Integrat & Funct Nutr Acad, Palm Harbor, FL USA.
[Harris, Stephanie R.] Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA.
[Anderson, Ellen J.] Acad Nutr & Dietet, Dietet Practice Based Res Network Oversight Comm, Chicago, IL USA.
[Anderson, Ellen J.] Massachusetts Gen Hosp, Metab & Nutr Res, Boston, MA 02114 USA.
[Hand, Rosa K.] Acad Nutr & Dietet, Dietet Practice Based Res Network, 120 S Riverside Plaza,Suite 2000, Chicago, IL 60606 USA.
RP Hand, RK (reprint author), Acad Nutr & Dietet, Dietet Practice Based Res Network, 120 S Riverside Plaza,Suite 2000, Chicago, IL 60606 USA.
EM rhand@eatright.org
NR 22
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2212-2672
EI 2212-2680
J9 J ACAD NUTR DIET
JI J. Acad. Nutr. Diet.
PD FEB
PY 2016
VL 116
IS 2
BP 319
EP 329
DI 10.1016/j.jand.2015.08.015
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DD0KH
UT WOS:000369608400016
PM 26387076
ER
PT J
AU Harvey, HB
Tomov, E
Babayan, A
Dwyer, K
Boland, S
Pandharipande, PV
Halpern, EF
Alkasab, TK
Hirsch, JA
Schaefer, PW
Boland, GW
Choy, G
AF Harvey, H. Benjamin
Tomov, Elena
Babayan, Astrid
Dwyer, Kathy
Boland, Sam
Pandharipande, Pari V.
Halpern, Elkan F.
Alkasab, Tarik K.
Hirsch, Joshua A.
Schaefer, Pamela W.
Boland, Giles W.
Choy, Garry
TI Radiology Malpractice Claims in the United States From 2008 to 2012:
Characteristics and Implications
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Radiology; medical malpractice; malpractice; liability; damages; policy;
regulation; law
ID DIGITAL BREAST TOMOSYNTHESIS; COMPUTER-AIDED DETECTION;
MEDICAL-MALPRACTICE; CLINICAL INFORMATION; SCREENING MAMMOGRAPHY;
ACCURACY; LITIGATION; CANCER; SUITS; PERFORMANCE
AB Purpose: The aim of this study was to compare the frequency and liability costs associated with radiology malpractice claims relative to other medical services and to evaluate the clinical context and case disposition associated with radiology malpractice claims.
Methods: This HIPAA-compliant study was exempted from institutional review board approval. The Comparative Benchmarking System database, a repository of more than 300,000 medical malpractice cases in the United States, was queried for closed claims over a five-year period (2008-2012). Claims were categorized by the medical service primarily responsible for the claim and the paid total loss. For all cases in which radiology was the primary responsible service, the case abstracts were evaluated to determine injury severity, claimant type by setting, claim allegation, process of care involved, case disposition, modality involved, and body section. Intracategory comparisons were made on the basis of the frequency of indemnity payment and total indemnity payment for paid cases, using chi(2) and Wilcoxon rank-sum tests.
Results: Radiology was the eighth most likely responsible service to be implicated in a medical malpractice claim, with a median total paid loss (indemnity payment plus defense cost plus administrative expense) per closed case of $30,091 (mean, $205,619 +/- $508,883). Radiology claims were most commonly associated with high- and medium-severity injuries (93.3% [820 of 879]; 95% confidence interval [CI], 91.7%-94.95%), the outpatient setting (66.3% [581 of 876]; 95% CI, 63.0%-69.2%), and diagnosis-related allegations (ie, failure to diagnose or delayed diagnosis) (57.3% [504 of 879]; 95% CI, 54.0%-60.6%). A high proportion of claims pertained to cancer diagnoses (44.0% [222 of 504]; 95% CI, 39.7%-48.3%). A total of 62.3% (548 of 879; 95% CI, 59.1%-65.5%) of radiology claims were closed without indemnity payments; 37.7% (331 of 879; 95% CI, 34.5%-40.9%) were closed with a median indemnity payment of $175,000 (range, $112-$6,691,762; mean $481,094 +/- $727,636).
Conclusions: Radiology malpractice claims most commonly involve diagnosis-related allegations in the outpatient setting, particularly cancer diagnoses, with approximately one-third of claims resulting in payouts to the claimants.
C1 [Harvey, H. Benjamin; Boland, Sam; Pandharipande, Pari V.; Alkasab, Tarik K.; Hirsch, Joshua A.; Schaefer, Pamela W.; Boland, Giles W.; Choy, Garry] Massachusetts Gen Hosp, Dept Radiol, 39 Melrose St,Unit 2, Boston, MA USA.
[Harvey, H. Benjamin; Pandharipande, Pari V.; Halpern, Elkan F.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Harvey, H. Benjamin; Pandharipande, Pari V.; Halpern, Elkan F.; Alkasab, Tarik K.; Hirsch, Joshua A.; Schaefer, Pamela W.; Boland, Giles W.; Choy, Garry] Harvard Univ, Sch Med, Boston, MA USA.
[Tomov, Elena; Babayan, Astrid; Dwyer, Kathy] CRICO Risk Management Fdn, Cambridge, MA USA.
RP Harvey, HB (reprint author), Massachusetts Gen Hosp, Dept Radiol, 39 Melrose St,Unit 2, Boston, MA USA.
EM hbharvey@partners.org
OI Boland, Samuel/0000-0001-6470-5470; Tomov, Elena/0000-0002-7972-3222
FU Medtronic; Carefusion; Medical Imaging and Technology Alliance
FX Ms. Tomov, Dr. Babayan, and Ms. Dwyer are employees of CRICO Risk
Management Foundation, which provided professional liability insurance
for some of the analyzed claims; Dr. Hirsch reports personal fees from
Medtronic and Carefusion and Dr. Pandharipande reports grants from
Medical Imaging and Technology Alliance, outside the submitted work.
NR 36
TC 0
Z9 0
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD FEB
PY 2016
VL 13
IS 2
BP 124
EP 130
DI 10.1016/j.jacr.2015.07.013
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DD4FL
UT WOS:000369877800009
PM 26454772
ER
PT J
AU Murphey, MD
Roberts, CC
Bencardino, JT
Appel, M
Arnold, E
Chang, EY
Dempsey, ME
Fox, MG
Fries, IB
Greenspan, BS
Hochman, MG
Jacobson, JA
Mintz, DN
Newman, JS
Rosenberg, ZS
Rubin, DA
Small, KM
Weissman, BN
AF Murphey, Mark D.
Roberts, Catherine C.
Bencardino, Jenny T.
Appel, Marc
Arnold, Erin
Chang, Eric Y.
Dempsey, Molly E.
Fox, Michael G.
Fries, Ian Blair
Greenspan, Bennett S.
Hochman, Mary G.
Jacobson, Jon A.
Mintz, Douglas N.
Newman, Joel S.
Rosenberg, Zehava S.
Rubin, David A.
Small, Kirstin M.
Weissman, Barbara N.
TI ACR Appropriateness Criteria Osteonecrosis of the Hip
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Appropriateness criteria; osteonecrosis; adult; child; MRI; radiograph
ID CALVE-PERTHES-DISEASE; FEMORAL-HEAD OSTEONECROSIS;
SYSTEMIC-LUPUS-ERYTHEMATOSUS; SUBCHONDRAL INSUFFICIENCY FRACTURE;
CONTRAST-ENHANCED MRI; SICKLE-CELL-DISEASE; BONE-MARROW EDEMA; AVASCULAR
NECROSIS; ASYMPTOMATIC OSTEONECROSIS; CORE DECOMPRESSION
AB Osteonecrosis of the hip (Legg-Calve-Perthes) is a common disease, with 10,000-20,000 symptomatic cases annually in the United States. The disorder affects both adults and children and is most frequently associated with trauma and corticosteroid usage. The initial imaging evaluation of suspected hip osteonecrosis is done using radiography. MRI is the most sensitive and specific imaging modality for diagnosis of osteonecrosis of the hip. The clinical significance of hip osteonecrosis is dependent on its potential for articular collapse. The likelihood of articular collapse is significantly increased with involvement of greater than 30%-50% of the femoral head area, which is optimally evaluated by MRI, often in the sagittal plane. Contrast-enhanced MRI may be needed to detect early osteonecrosis of the hip in pediatric patients, revealing hypoperfusion. In patients with a contraindication for MRI, use of either CT or bone scintigraphy with SPECT (single-photon emission CT) are alternative radiologic methods of assessment. Imaging helps guide treatment, which may include core decompression, osteotomy, and ultimately, need for joint replacement.
The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every three years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
C1 [Murphey, Mark D.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.
[Roberts, Catherine C.] Mayo Clin, Phoenix, AZ USA.
[Bencardino, Jenny T.] NYU Radiol Associates, New York, NY USA.
[Appel, Marc] Amer Acad Orthopaed Surgeons, James J Peters VA Med Ctr, Bronx, NY USA.
[Arnold, Erin] Amer Coll Rheumatol, Orthopaed & Rheumatol North Shore, Skokie, IL USA.
[Chang, Eric Y.] VA San Diego Healthcare Syst, San Diego, CA USA.
[Dempsey, Molly E.] Texas Scottish Rite Hosp Children, Dallas, TX 75219 USA.
[Fox, Michael G.] Univ Virginia Hlth Syst, Charlottesville, VA USA.
[Fries, Ian Blair] Amer Acad Orthopaed Surgeons, Bone Spine & Hand Surg, Chartered, Brick, NJ USA.
[Greenspan, Bennett S.] Georgia Regents Univ, Med Coll Georgia, Augusta, GA USA.
[Hochman, Mary G.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Jacobson, Jon A.] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
[Mintz, Douglas N.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA.
[Newman, Joel S.] New England Baptist Hosp, Boston, MA USA.
[Rosenberg, Zehava S.] Hosp Joint Dis & Med Ctr, New York, NY USA.
[Rubin, David A.] Washington Univ, Sch Med, St Louis, MO USA.
[Small, Kirstin M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
RP Murphey, MD (reprint author), 1010 Wayne Ave Ste 320, Silver Spring, MD 20910 USA.
EM mmurphey@acr.org
OI Jacobson, Jon/0000-0002-3676-6628; Rosenberg MD,
Zehava/0000-0003-1902-6350
NR 68
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD FEB
PY 2016
VL 13
IS 2
BP 147
EP 155
DI 10.1016/j.jacr.2015.10.033
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DD4FL
UT WOS:000369877800014
PM 26846390
ER
PT J
AU Lu, MT
Rosman, DA
Wu, CC
Gilman, MD
Harvey, HB
Gervais, DA
Alkasab, TK
Shepard, JAO
Boland, GW
Pandharipande, PV
AF Lu, Michael T.
Rosman, David A.
Wu, Carol C.
Gilman, Matthew D.
Harvey, H. Benjamin
Gervais, Debra A.
Alkasab, Tarik K.
Shepard, Jo-Anne O.
Boland, Giles W.
Pandharipande, Pari V.
TI Radiologist Point-of-Care Clinical Decision Support and Adherence to
Guidelines for Incidental Lung Nodules
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Clinical decision support; lung nodule
ID FLEISCHNER SOCIETY GUIDELINES; PULMONARY NODULES; FINDINGS COMMITTEE;
SCREENING TRIAL; ABDOMINAL CT; WHITE PAPER; ORDER-ENTRY; MANAGEMENT;
QUALITY; APPROPRIATENESS
AB Purpose: To evaluate the effect of a workstation-integrated, point-of-care, clinical decision support (CDS) tool on radiologist adherence to radiology department guidelines for follow-up of incidental pulmonary nodules detected on abdominal CT.
Methods: The CDS tool was developed to facilitate adherence to department guidelines for managing pulmonary nodules seen on abdominal CT. In October 2012, the tool was deployed within the radiology department of an academic medical center and could be used for a given abdominal CT at the discretion of the interpreting radiologist. We retrospectively identified consecutive patients who underwent abdominal CT (in the period from January 2012 to April 2013), had no comparison CT scans available, and were reported to have a solid, noncalcified, pulmonary nodule. Concordance between radiologist follow-up recommendation and department guidelines was compared among three groups: patients scanned before implementation of the CDS tool; and patients scanned after implementation, with versus without use of the tool.
Results: A total of 409 patients were identified, including 268 for the control group. Overall, guideline concordance was higher after CDS tool implementation (92 of 141 [65%] versus 133 of 268 [50%], P=.003). This finding was driven by the subset of post-CDS implementation cases in which the CDS tool was used (57 of 141 [40%]). In these cases, guideline concordance was significantly higher (54 of 57 [95%]), compared with post-implementation cases in which CDS was not used (38 of 84 [45%], P<.001), and to a control group of patients from before implementation (133 of 268 [50%]; P<.001).
Conclusions: A point-of-care CDS tool was associated with improved adherence to guidelines for follow-up of incidental pulmonary nodules.
C1 [Lu, Michael T.] Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Lu, MT (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
EM mlu@mgh.harvard.edu
FU Harvey L. Neiman Health Policy Institute(R); American Roentgen Ray
Society
FX MTL reports research grant support from the Harvey L. Neiman Health
Policy Institute (R) and the American Roentgen Ray Society.
NR 32
TC 3
Z9 3
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD FEB
PY 2016
VL 13
IS 2
BP 156
EP 162
DI 10.1016/j.jacr.2015.09.029
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DD4FL
UT WOS:000369877800015
PM 26577875
ER
PT J
AU Boland, GW
Duszak, R
AF Boland, Giles W.
Duszak, Richard, Jr.
TI A Roadmap for Value-Based Payments
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
C1 [Boland, Giles W.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, 32 Fruit St, Boston, MA 02114 USA.
[Duszak, Richard, Jr.] Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA.
RP Boland, GW (reprint author), Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, 32 Fruit St, Boston, MA 02114 USA.
EM gboland@partners.org
RI Duszak, Richard/L-1811-2016
OI Duszak, Richard/0000-0003-0425-3008
NR 3
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD FEB
PY 2016
VL 13
IS 2
BP 170
EP 172
DI 10.1016/j.jacr.2015.10.003
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DD4FL
UT WOS:000369877800017
PM 26777737
ER
PT J
AU Golden, DW
Braunstein, S
Jimenez, RB
Mohindra, P
Spektor, A
Ye, JC
Bradley, KA
Chmura, SJ
Currey, A
Das, P
Du, K
Haas-Kogan, D
Howard, AR
Higgins, SA
Hung, AY
Kharofa, J
Krishnan, MS
MacDonald, SM
Mancini, BR
Parashar, B
Thaker, NG
Thomas, CR
Viswanathan, AN
Wheatley, M
AF Golden, Daniel W.
Braunstein, Steve
Jimenez, Rachel B.
Mohindra, Pranshu
Spektor, Alexander
Ye, Jason C.
Bradley, Kristin A.
Chmura, Steven J.
Currey, Adam
Das, Prajnan
Du, Kevin
Haas-Kogan, Daphne
Howard, Andrew R.
Higgins, Susan A.
Hung, Arthur Y.
Kharofa, Jordan
Krishnan, Monica S.
MacDonald, Shannon M.
Mancini, Brandon R.
Parashar, Bhupesh
Thaker, Nikhil G.
Thomas, Charles R., Jr.
Viswanathan, Akila N.
Wheatley, Matt
CA Radiation Oncology Educ
Radiation Oncology Educ
TI Multi-Institutional Implementation and Evaluation of a Curriculum for
the Medical Student Clerkship in Radiation Oncology
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Radiation oncology; undergraduate medical education; curriculum; medical
students
ID EDUCATION; KNOWLEDGE; INCREASE; TRIAL
AB Purpose: Radiation oncology curriculum development is challenging because of limited numbers of trainees at any single institution. The goal of this project is to implement and evaluate a standardized medical student clerkship curriculum following the multi institutional cooperative group research model.
Methods: During the 2013 academic year, a standardized curriculum was implemented at 11 academic medical centers consisting of three 1-hour lectures and a hands-on radiation treatment planning workshop. After the curriculum, students completed anonymous evaluations using Likert-type scales (1 = "not at all" to 5 = "extremely') and free responses. Evaluations asked students to rate their comfort, before and after the curriculum, with radiation oncology as a specialty, knowledge of radiotherapy planning methods, and ability to function as a radiation oncology resident. Nonparametric statistical tests were used in the analysis.
Results: Eighty-eight students at 11 academic medical centers completed the curriculum de novo, with a 72.7% (64 of 88) survey response rate. Fifty-seven students (89.1%) reported intent to pursue radiation oncology as their specialty. Median (interquartile range) student ratings of the importance of curricular content were as follows: overview, 4 (4-5); radiation biology/physics, 5 (4-5); practical aspects/emergencies, 5 (4-5); and planning workshop, 4 (4-5). Students reported that the curriculum helped them better understand radiation oncology as a specialty (5 [4-5]), increased specialty decision comfort (4 [3-5]), and would help the transition to radiation oncology residency (4 [4-5]). Students rated their specialty decision comfort significantly higher after completing the curriculum (4 [4-5] versus 5 [5-5]; P < .001).
Conclusions: A national standardized curriculum was successfully implemented at 11 academic medical centers, providing proof of principle that curriculum development can follow the multi-institutional cooperative group research model.
C1 [Golden, Daniel W.; Chmura, Steven J.; Howard, Andrew R.] Univ Chicago, Pritzker Sch Med, Dept Radiat & Cellular Oncol, 5758 South Maryland Ave,Mail Code 9006, Chicago, IL 60637 USA.
[Braunstein, Steve] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA.
[Jimenez, Rachel B.; MacDonald, Shannon M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Mohindra, Pranshu] Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA.
[Spektor, Alexander; Haas-Kogan, Daphne; Krishnan, Monica S.; Viswanathan, Akila N.] Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
[Spektor, Alexander; Haas-Kogan, Daphne; Krishnan, Monica S.; Viswanathan, Akila N.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
[Ye, Jason C.; Parashar, Bhupesh] New York Presbyterian Hosp, Weill Cornell Med Coll, Weill Cornell Med Ctr, Dept Radiat Oncol,Stich Radiat Oncol Ctr, New York, NY USA.
[Das, Prajnan; Thaker, Nikhil G.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.
[Higgins, Susan A.; Mancini, Brandon R.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA.
[Bradley, Kristin A.] Univ Wisconsin, Dept Human Oncol, Sch Med & Publ Hlth, Madison, WI USA.
[Hung, Arthur Y.; Thomas, Charles R., Jr.] Oregon Hlth & Sci Univ, Dept Radiat Med, Knight Canc Inst, Portland, OR 97201 USA.
[Kharofa, Jordan] Univ Cincinnati, Dept Radiat Oncol, Cincinnati, OH USA.
[Currey, Adam; Wheatley, Matt] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA.
[Du, Kevin] NYU, Dept Radiat Oncol, Perlmutter Canc Ctr, New York, NY USA.
RP Golden, DW (reprint author), Univ Chicago, Pritzker Sch Med, Dept Radiat & Cellular Oncol, 5758 South Maryland Ave,Mail Code 9006, Chicago, IL 60637 USA.
EM dgolden@radonc.uchicago.edu
FU Philips Healthcare/RSNA Education Scholar Grant; National Institutes of
Health Clinical Translational Science Awar [UL1 RR024999]; RSNA; RadOnc
Questions, LLC
FX This project was funded in part by the 2013 Philips Healthcare/RSNA
Education Scholar Grant and National Institutes of Health Clinical
Translational Science Award UL1 RR024999.; Dr Golden has received grants
from the RSNA and has a financial interest in RadOnc Questions, LLC. The
other authors have no conflicts of interest related to the material
discussed in this article.
NR 21
TC 3
Z9 3
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD FEB
PY 2016
VL 13
IS 2
BP 203
EP 209
DI 10.1016/j.jacr.2015.06.036
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DD4FL
UT WOS:000369877800026
ER
PT J
AU Misono, AS
Prabhakar, AM
Liu, RW
Shetty, SK
AF Misono, Alexander S.
Prabhakar, Anand M.
Liu, Raymond W.
Shetty, Sanjay K.
TI What Radiology Can Learn From the Management Consulting Industry
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
C1 [Misono, Alexander S.; Prabhakar, Anand M.; Liu, Raymond W.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Shetty, Sanjay K.] Steward Hlth Care Network, Boston, MA USA.
[Shetty, Sanjay K.] St Elizabeths Med Ctr, Dept Radiol, Boston, MA USA.
RP Misono, AS (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,Founders 216, Boston, MA 02114 USA.
EM amisono@mgh.harvard.edu
NR 11
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD FEB
PY 2016
VL 13
IS 2
BP 222
EP 225
DI 10.1016/j.jacr.2015.09.023
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DD4FL
UT WOS:000369877800029
PM 26846394
ER
PT J
AU Daly, MB
Pilarski, R
Axilbund, JE
Berry, M
Buys, SS
Crawford, B
Farmer, M
Friedman, S
Garber, JE
Khan, S
Klein, C
Kohlmann, W
Kurian, A
Litton, JK
Madlensky, L
Marcom, PK
Merajver, SD
Offit, K
Pal, T
Rana, H
Reiser, G
Robson, ME
Shannon, KM
Swisher, E
Voian, NC
Weitzel, JN
Whelan, A
Wick, MJ
Wiesner, GL
Dwyer, M
Kumar, R
Darlow, S
AF Daly, Mary B.
Pilarski, Robert
Axilbund, Jennifer E.
Berry, Michael
Buys, Saundra S.
Crawford, Beth
Farmer, Meagan
Friedman, Susan
Garber, Judy E.
Khan, Seema
Klein, Catherine
Kohlmann, Wendy
Kurian, Allison
Litton, Jennifer K.
Madlensky, Lisa
Marcom, P. Kelly
Merajver, Sofia D.
Offit, Kenneth
Pal, Tuya
Rana, Huma
Reiser, Gwen
Robson, Mark E.
Shannon, Kristen Mahoney
Swisher, Elizabeth
Voian, Nicoleta C.
Weitzel, Jeffrey N.
Whelan, Alison
Wick, Myra J.
Wiesner, Georgia L.
Dwyer, Mary
Kumar, Rashmi
Darlow, Susan
TI Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version
2.2015 Featured Updates to the NCCN Guidelines
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Review
ID PEUTZ-JEGHERS-SYNDROME; SEX CORD TUMOR; BRCA2 GERMLINE MUTATIONS;
CANCER-RISK; PANCREATIC-CANCER; ANNULAR TUBULES; PATHOLOGICAL FINDINGS;
CARCINOMA; ADENOCARCINOMA; PREVALENCE
AB The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling and risk assessment and management for hereditary cancer syndromes. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer and are intended to assist with clinical and shared decision-making. These NCCN Guidelines Insights summarize major discussion points of the 2015 NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meeting. Major discussion topics this year included multigene testing, risk management recommendations for less common genetic mutations, and salpingectomy for ovarian cancer risk reduction. The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer.
C1 [Daly, Mary B.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Pilarski, Robert] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Pilarski, Robert] Solove Res Inst, Columbus, OH USA.
[Axilbund, Jennifer E.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Berry, Michael] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA.
[Buys, Saundra S.; Kohlmann, Wendy] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Crawford, Beth] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
[Farmer, Meagan] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA.
[Friedman, Susan] FORCE Facing Our Risk Canc Empowered, San Francisco, CA USA.
[Garber, Judy E.; Rana, Huma] Dana Farber Brigham & Womens Canc Ctr, New York, NY USA.
[Khan, Seema] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Klein, Catherine] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA.
[Kurian, Allison] Stanford Canc Inst, Stanford, CA USA.
[Litton, Jennifer K.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Madlensky, Lisa] UC San Diego Moores Canc Ctr, San Diego, CA USA.
[Marcom, P. Kelly] Duke Canc Inst, Durham, NC USA.
[Marcom, P. Kelly] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Offit, Kenneth; Robson, Mark E.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Pal, Tuya] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Reiser, Gwen] Fred & Pamela Buffett Canc Ctr, Lincoln, NE USA.
[Shannon, Kristen Mahoney] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Weitzel, Jeffrey N.] Univ Washington, Med Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
[Voian, Nicoleta C.] Roswell Pk Canc Inst, Buffalo, NY USA.
[Weitzel, Jeffrey N.] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Whelan, Alison] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Whelan, Alison] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Wick, Myra J.] Mayo Clin, Ctr Canc, Rochester, MI USA.
[Wiesner, Georgia L.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Dwyer, Mary; Kumar, Rashmi; Darlow, Susan] Natl Comprehens Canc Network, New York, NY USA.
RP Daly, MB (reprint author), Fox Chase Canc Ctr, Philadelphia, PA USA.
OI Rana, Huma/0000-0002-1598-6752
FU AstraZeneca; Bayer Healthcare Pharmaceuticals Inc.; Bristol-Myers
Squibb; Clovis Oncology; Genentech; Novartis Oncology; Otsuka America
Pharmaceutical, Inc.; Seattle Genetics, Inc.; Takeda Oncology; Actelion
Pharmaceuticals US, Inc.; Astellas; Medivation, Inc.
FX This activity is supported by educational grants from AstraZeneca, Bayer
Healthcare Pharmaceuticals Inc., Bristol-Myers Squibb, Clovis Oncology,
Genentech, Novartis Oncology, Otsuka America Pharmaceutical, Inc.,
Seattle Genetics, Inc., and Takeda Oncology; support provided by
Actelion Pharmaceuticals US, Inc.; and by an independent educational
grant from Astellas and Medivation, Inc.
NR 46
TC 17
Z9 17
U1 0
U2 4
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD FEB
PY 2016
VL 14
IS 2
BP 153
EP 162
PG 10
WC Oncology
SC Oncology
GA DD0UA
UT WOS:000369634300006
PM 26850485
ER
PT J
AU Zelenetz, AD
Gordon, LI
Wierda, WG
Abramson, JS
Advani, RH
Andreadis, CB
Bartlett, N
Byrd, JC
Fayad, LE
Fisher, RI
Glenn, MJ
Habermann, TM
Harris, NL
Hernandez-Ilizaliturri, F
Hoppe, RT
Horwitz, SM
Kaminski, MS
Kelsey, CR
Kim, YH
Krivacic, S
LaCasce, AS
Lunning, M
Nademanee, A
Porcu, P
Press, O
Rabinovitch, R
Reddy, N
Reid, E
Roberts, K
Saad, AA
Sokol, L
Swinnen, LJ
Vose, JM
Yahalom, J
Zafar, N
Dwyer, M
Sundar, H
AF Zelenetz, Andrew D.
Gordon, Leo I.
Wierda, William G.
Abramson, Jeremy S.
Advani, Ranjana H.
Andreadis, C. Babis
Bartlett, Nancy
Byrd, John C.
Fayad, Luis E.
Fisher, Richard I.
Glenn, Martha J.
Habermann, Thomas M.
Harris, Nancy Lee
Hernandez-Ilizaliturri, Francisco
Hoppe, Richard T.
Horwitz, Steven M.
Kaminski, Mark S.
Kelsey, Christopher R.
Kim, Youn H.
Krivacic, Susan
LaCasce, Ann S.
Lunning, Matthew
Nademanee, Auayporn
Porcu, Pierluigi
Press, Oliver
Rabinovitch, Rachel
Reddy, Nishitha
Reid, Erin
Roberts, Kenneth
Saad, Ayman A.
Sokol, Lubomir
Swinnen, Lode J.
Vose, Julie M.
Yahalom, Joachim
Zafar, Nadeem
Dwyer, Mary
Sundar, Hema
TI Diffuse Large B-Cell Lymphoma Version 1.2016 Clinical Practice
Guidelines in Oncology
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID NON-HODGKINS-LYMPHOMA; POSITRON-EMISSION-TOMOGRAPHY; INVOLVED-FIELD
RADIOTHERAPY; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; DETUDE-DES-LYMPHOMES;
GRAY-ZONE LYMPHOMA; HIGH-DOSE THERAPY; NERVOUS-SYSTEM PROPHYLAXIS;
CHOP-LIKE CHEMOTHERAPY; SINGLE-INSTITUTION EXPERIENCE
AB Diffuse large B-cell lymphomas (DLBCL) are now considered a heterogeneous group of distinct molecular subtypes (germinal center B-cell DLBCL, activated B-cell DLBCL, and primary mediastinal large B-cell lymphoma (PMBL) with varied natural history and response to therapy. In addition, a subset of patients with DLBCL have concurrent MYC and/or BCL2 gene rearrangements (double-hit lymphomas; DHL) and others have a dual expression of both MYC and BCL2 proteins (double-expressing DLBCL; DEL). The standard of care for the treatment of patients with PMBL, DHL, or DEL has not been established. Adequate immunophenotyping and molecular testing (in selected circumstances) are necessary for the accurate diagnosis of different subtypes of DLBCL. The NCCN Guidelines included in this issue, part of the NCCN Guidelines for non-Hodgkin's lymphomas, address the diagnosis and management of DLBCL and its subtypes.
C1 [Zelenetz, Andrew D.; Horwitz, Steven M.] Mem Sloan Kettering Canc Ctr, Med Oncol, New York, NY 10065 USA.
[Zelenetz, Andrew D.; Horwitz, Steven M.] Mem Sloan Kettering Canc Ctr, Internal Med, New York, NY 10025 USA.
[Gordon, Leo I.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Hematol Hematol Oncol, Evanston, IL 60208 USA.
[Gordon, Leo I.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Bone Marrow Transplantat, Evanston, IL 60208 USA.
[Wierda, William G.; Fayad, Luis E.] Univ Texas MD Anderson Canc Ctr, Med Oncol, Houston, TX USA.
[Wierda, William G.; Fayad, Luis E.] Univ Texas MD Anderson Canc Ctr, Hematol Hematol Oncol, Houston, TX USA.
[Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Med Oncol, Boston, MA 02114 USA.
[Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Hematol Hematol Oncol, Boston, MA 02114 USA.
[Advani, Ranjana H.; Kim, Youn H.] Stanford Canc Inst, Med Oncol, Stanford, CA USA.
[Andreadis, C. Babis] UCSF Helen Diller Family Comprehens Canc Ctr, Hematol Hematol Oncol, San Francisco, CA USA.
[Andreadis, C. Babis] UCSF Helen Diller Family Comprehens Canc Ctr, Med Oncol, San Francisco, CA USA.
[Bartlett, Nancy] Barnes Jewish Hosp, Siteman Canc Ctr, Med Oncol, Washington, DC USA.
[Bartlett, Nancy] Washington Univ, Sch Med, Med Oncol, St Louis, MO 63130 USA.
[Byrd, John C.; Porcu, Pierluigi] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Hematol Hematol Oncol, Columbus, OH 43210 USA.
[Byrd, John C.; Porcu, Pierluigi] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Internal Med, Columbus, OH 43210 USA.
[Byrd, John C.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Bone Marrow Transplantat, Columbus, OH 43210 USA.
[Byrd, John C.; Porcu, Pierluigi] Solove Res Inst, Hematol Hematol Oncol, Columbus, OH USA.
[Byrd, John C.; Porcu, Pierluigi] Solove Res Inst, Internal Med, Columbus, OH USA.
[Byrd, John C.] Solove Res Inst, Bone Marrow Transplantat, Columbus, OH USA.
[Fayad, Luis E.] Univ Texas MD Anderson Canc Ctr, Internal Med, Houston, TX USA.
[Fisher, Richard I.] Fox Chase Canc Ctr, Hematol Hematol Oncol, Philadelphia, PA USA.
[Fisher, Richard I.] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA USA.
[Glenn, Martha J.] Univ Utah, Huntsman Canc Inst, Med Oncol, Salt Lake City, UT 84112 USA.
[Glenn, Martha J.] Univ Utah, Huntsman Canc Inst, Hematol Hematol Oncol, Salt Lake City, UT 84112 USA.
[Glenn, Martha J.] Univ Utah, Huntsman Canc Inst, Bone Marrow Transplantat, Salt Lake City, UT 84112 USA.
[Harris, Nancy Lee] Mayo Clin, Ctr Canc, Hematol Hematol Oncol, Rochester, MN USA.
[Harris, Nancy Lee] Mayo Clin, Ctr Canc, Bone Marrow Transplantat, Rochester, MI USA.
[Harris, Nancy Lee] Massachusetts Gen Hosp, Ctr Canc, Pathol, Boston, MA 02114 USA.
[Hernandez-Ilizaliturri, Francisco] Roswell Pk Canc Inst, Med Oncol, Buffalo, NY USA.
[Hoppe, Richard T.] Stanford Canc Inst, Radiotherapy Radiat Oncol, Stanford, CA USA.
[Kaminski, Mark S.] Univ Michigan, Ctr Comprehens Canc, Med Oncol, Ann Arbor, MI 48109 USA.
[Kelsey, Christopher R.] Duke Canc Inst, Radiotherapy Radiat Oncol, Durham, NC USA.
[Kim, Youn H.] Stanford Canc Inst, Dermatol, Stanford, CA USA.
[LaCasce, Ann S.] Dana Farber Brigham & Womens Canc Ctr, Med Oncol, Boston, MA USA.
[Lunning, Matthew] Fred & Pamela Buffett Canc Ctr, Internal Med, New York, NY USA.
[Nademanee, Auayporn] City Hope Comprehens Canc Ctr, Med Oncol, Duarte, CA USA.
[Nademanee, Auayporn] City Hope Comprehens Canc Ctr, Hematol Hematol Oncol, Duarte, CA USA.
[Nademanee, Auayporn] City Hope Comprehens Canc Ctr, Bone Marrow Transplantat, Duarte, CA USA.
[Porcu, Pierluigi] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Med Oncol, Columbus, OH 43210 USA.
[Porcu, Pierluigi] Solove Res Inst, Med Oncol, Columbus, OH USA.
[Press, Oliver] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Med Oncol, Seattle, WA USA.
[Press, Oliver] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Hematol Hematol Oncol, Seattle, WA USA.
[Rabinovitch, Rachel] Univ Colorado, Ctr Canc, Radiotherapy Radiat Oncol, Boulder, CO 80309 USA.
[Reddy, Nishitha] Vanderbilt Ingram Canc Ctr, Hematol Hematol Oncol, Nashville, TN USA.
[Reddy, Nishitha] Vanderbilt Ingram Canc Ctr, Bone Marrow Transplantat, Nashville, TN USA.
[Reid, Erin] UC San Diego Moores Canc Ctr, Hematol Hematol Oncol, San Diego, CA USA.
[Reid, Erin] UC San Diego Moores Canc Ctr, Bone Marrow Transplantat, San Diego, CA USA.
[Roberts, Kenneth] Smilow Canc Hosp, Yale Canc Ctr, Radiotherapy Radiat Oncol, New York, NY USA.
[Saad, Ayman A.] Univ Alabama Birmingham, Ctr Comprehens Canc, Hematol Hematol Oncol, Birmingham, AL USA.
[Saad, Ayman A.] Univ Alabama Birmingham, Ctr Comprehens Canc, Bone Marrow Transplantat, Birmingham, AL USA.
[Sokol, Lubomir] H Lee Moffitt Canc Ctr & Res Inst, Med Oncol, Tampa, FL USA.
[Sokol, Lubomir] H Lee Moffitt Canc Ctr & Res Inst, Hematol Hematol Oncol, Tampa, FL USA.
[Sokol, Lubomir] H Lee Moffitt Canc Ctr & Res Inst, Internal Med, Tampa, FL USA.
[Sokol, Lubomir] H Lee Moffitt Canc Ctr & Res Inst, Radiotherapy Radiat Oncol, Tampa, FL USA.
[Sokol, Lubomir] H Lee Moffitt Canc Ctr & Res Inst, Bone Marrow Transplantat, Tampa, FL USA.
[Swinnen, Lode J.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Hematol Hematol Oncol, Baltimore, MD USA.
[Swinnen, Lode J.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Bone Marrow Transplantat, Baltimore, MD USA.
[Vose, Julie M.] Fred & Pamela Buffett Canc Ctr, Hematol Hematol Oncol, Bethesda, MD USA.
[Vose, Julie M.] Fred & Pamela Buffett Canc Ctr, Bone Marrow Transplantat, Bethesda, MD USA.
[Yahalom, Joachim] Mem Sloan Kettering Canc Ctr, Radiotherapy Radiat Oncol, New York, NY USA.
[Zafar, Nadeem] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Pathol, Knoxville, TN 37996 USA.
[Dwyer, Mary; Sundar, Hema] NCCN, London, England.
RP Zelenetz, AD (reprint author), Mem Sloan Kettering Canc Ctr, Med Oncol, New York, NY 10065 USA.; Zelenetz, AD (reprint author), Mem Sloan Kettering Canc Ctr, Internal Med, New York, NY 10025 USA.
OI Saad, Ayman /0000-0003-0003-0130
FU NCI NIH HHS [P30 CA016672]
NR 172
TC 6
Z9 6
U1 0
U2 3
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD FEB
PY 2016
VL 14
IS 2
BP 196
EP 231
PG 36
WC Oncology
SC Oncology
GA DD0UA
UT WOS:000369634300011
PM 26850490
ER
PT J
AU Sheth, RA
Koottappillil, B
Kambadakone, A
Ganguli, S
Thabet, A
Mueller, PR
AF Sheth, Rahul A.
Koottappillil, Brian
Kambadakone, Avinash
Ganguli, Suvranu
Thabet, Ashraf
Mueller, Peter R.
TI A Quality Improvement Initiative to Reduce Catheter Exchange Rates for
Fluoroscopically Guided Gastrostomy Tubes
SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
LA English
DT Article
ID PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; RADIOLOGIC GASTROSTOMY;
SINGLE-CENTER; PEG TUBES; EXPERIENCE; PLACEMENT; GASTROJEJUNOSTOMY;
COMPLICATIONS; GASTROPEXY; OUTCOMES
AB Purpose: To evaluate the effectiveness of a data-driven quality improvement initiative to reduce catheter exchange rates.
Materials and Methods: A single-institution retrospective analysis of all percutaneous radiologic gastrostomy (PRG) placement and replacement procedures between January 2010 and July 2015 was conducted. A statistical model predicting the risk for catheter exchange for any reason and exchanges specifically for tube malfunction was created; a quality improvement plan to reduce catheter exchanges was designed and implemented in June 2014. The outcomes for subsequent PRG procedures from July 2014 through March 2015 were followed until July 2015.
Results: Between 2010 and June 2014, 1,144 primary PRG procedures and 442 replacement procedures were performed in 1,112 patients. Of the 442 exchange procedures, 289 were "rescue" procedures secondary to catheter malfunction. A quality improvement plan was implemented in June 2014 that encouraged primary gastrojejunostomy catheter and balloon-retained PRG catheter placement and placement of skin sutures in patients considered high risk for catheter dislodgment. From July 2014 through March 2015, 229 PRG catheters were placed, and 71 exchange procedures were performed through July 2015. There was a statistically significant decrease in the number of rescue exchanges performed secondary to catheter malfunction (P = .036).
Conclusions: Procedural and patient-specific risk factors for PRG complications were identified, and a statistical model to predict rates of minor complications was created. These findings were used to implement a quality improvement program that resulted in a decrease in PRG exchanges secondary to catheter malfunction.
C1 [Sheth, Rahul A.; Koottappillil, Brian; Kambadakone, Avinash; Ganguli, Suvranu; Thabet, Ashraf; Mueller, Peter R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Intervent Radiol,Dept Radiol, Gray 290,55 Fruit St, Boston, MA 02114 USA.
RP Sheth, RA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Intervent Radiol,Dept Radiol, Gray 290,55 Fruit St, Boston, MA 02114 USA.
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1051-0443
EI 1535-7732
J9 J VASC INTERV RADIOL
JI J. Vasc. Interv. Radiol.
PD FEB
PY 2016
VL 27
IS 2
BP 251
EP 259
DI 10.1016/j.jvir.2015.10.015
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular
Disease
SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System &
Cardiology
GA DD2UF
UT WOS:000369777000017
PM 26656959
ER
PT J
AU Lopez, E
Arellano, R
AF Lopez, Emilio
Arellano, Ronald
TI Neuroendocrine Malignancy Diagnosed via CT-Guided Percutaneous Biopsy of
an Isolated Abnormal Cardiophrenic Lymph Node: Case Report
SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
LA English
DT Letter
C1 [Lopez, Emilio; Arellano, Ronald] Massachusetts Gen Hosp, Div Intervent Radiol, 55 Fruit St, Boston, MA 02114 USA.
RP Lopez, E (reprint author), Massachusetts Gen Hosp, Div Intervent Radiol, 55 Fruit St, Boston, MA 02114 USA.
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1051-0443
EI 1535-7732
J9 J VASC INTERV RADIOL
JI J. Vasc. Interv. Radiol.
PD FEB
PY 2016
VL 27
IS 2
BP 289
EP 290
DI 10.1016/j.jvir.2015.09.015
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular
Disease
SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System &
Cardiology
GA DD2UF
UT WOS:000369777000025
PM 26830945
ER
PT J
AU Menon, MC
Ross, MJ
AF Menon, Madhav C.
Ross, Michael J.
TI Epithelial-to-mesenchymal transition of tubular epithelial cells in
renal fibrosis: a new twist on an old tale
SO KIDNEY INTERNATIONAL
LA English
DT Editorial Material
ID TISSUE GROWTH-FACTOR; KIDNEY FIBROSIS; DISEASE
AB Recent publications have questioned whether epithelial-to-mesenchymal transition of tubular epithelial cells is an important contributor to renal fibrosis. Two recent publications describe an intratubular epithelial-to-mesenchymal transition-like program of epithelial cell dedifferentiation that may contribute to the recruitment or proliferation of interstitial myofibroblasts after kidney injury.
C1 [Menon, Madhav C.] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA.
[Ross, Michael J.] James J Peters VA Med Ctr, Bronx, NY USA.
RP Ross, MJ (reprint author), Icahn Sch Med Mt Sinai, Div Nephrol, One Gustave L Levy Pl,Box 1243, New York, NY 10029 USA.
EM michael.ross@mssm.edu
NR 11
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD FEB
PY 2016
VL 89
IS 2
BP 263
EP 266
DI 10.1016/j.kint.2015.12.025
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA DD2TO
UT WOS:000369775300004
PM 26806826
ER
PT J
AU Nowak, N
Skupien, J
Niewczas, MA
Yamanouchi, M
Major, M
Croall, S
Smiles, A
Warram, JH
Bonventre, JV
Krolewski, AS
AF Nowak, Natalia
Skupien, Jan
Niewczas, Monika A.
Yamanouchi, Masayuki
Major, Melissa
Croall, Stephanie
Smiles, Adam
Warram, James H.
Bonventre, Joseph V.
Krolewski, Andrzej S.
TI Increased plasma kidney injury molecule-1 suggests early progressive
renal decline in non-proteinuric patients with type 1 diabetes
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE early progressive renal decline; markers of glomerular and tubular
damage; type 1 diabetes
ID GLOMERULAR-FILTRATION-RATE; ACID-BINDING PROTEIN; SERUM URIC-ACID;
NONPROTEINURIC PATIENTS; PREDICTS PROGRESSION; URINARY BIOMARKERS;
TUBULAR MARKERS; CYSTATIN-C; FOLLOW-UP; NEPHROPATHY
AB Progressively decreasing glomerular filtration rate (GFR), or renal decline, is seen in patients with type 1 diabetes (T1D) and normoalbuminuria or microalbuminuria. Here we examined the associations of kidney injury molecule-1 (KIM-1) in plasma and urine with the risk of renal decline and determine whether those associations are independent of markers of glomerular damage. The study group comprised patients with T1D from the 2nd Joslin Kidney Study of which 259 had normoalbuminuria and 203 had microalbuminuria. Serial measurements over 4 to 10 years of follow-up (median 8 years) of serum creatinine and cystatin C were used jointly to estimate eGFRcr-cys slopes and time of onset of CKD stage 3 or higher. Baseline urinary excretion of IgG(2) and albumin were used as markers of glomerular damage, and urinary excretion of KIM-1 and its plasma concentration were used as markers of proximal tubular damage. All patients had normal renal function at baseline. During follow-up, renal decline (eGFRcr-cys loss 3.3% or more per year) developed in 96 patients and 62 progressed to CKD stage 3. For both outcomes, the risk rose with increasing baseline levels of plasma KIM-1. In multivariable models, elevated baseline plasma KIM-1 was strongly associated with risk of early progressive renal decline, regardless of baseline clinical characteristics, serum TNFR1 or markers of glomerular damage. Thus, damage to proximal tubules may play an independent role in the development of early progressive renal decline in non-proteinuric patients with T1D.
C1 [Nowak, Natalia; Skupien, Jan; Niewczas, Monika A.; Yamanouchi, Masayuki; Major, Melissa; Croall, Stephanie; Smiles, Adam; Warram, James H.; Krolewski, Andrzej S.] Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.
[Nowak, Natalia; Skupien, Jan; Niewczas, Monika A.; Yamanouchi, Masayuki; Bonventre, Joseph V.; Krolewski, Andrzej S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Nowak, Natalia; Skupien, Jan] Jagiellonian Univ, Coll Med, Dept Metab Dis, Krakow, Poland.
[Bonventre, Joseph V.] Brigham & Women Hosp, Div Renal, Boston, MA USA.
RP Krolewski, AS (reprint author), Joslin Diabet Ctr, Sect Genet & Epidemiol, One Joslin Pl, Boston, MA 02215 USA.
EM andrzej.krolewski@joslin.harvard.edu
FU National Institutes of Health [DK-041526, DK-072381]; JDRF grant:
Biomarkers of Diabetic Nephropathy Collaborative Research Initiative (DN
Bio) [3-SRA-2015-106-Q-R]
FX This study was supported by National Institutes of Health grants:
DK-041526 to ASK, and DK-072381 to JVB. This study was supported by JDRF
grant: Biomarkers of Diabetic Nephropathy Collaborative Research
Initiative (DN Bio) No. 3-SRA-2015-106-Q-R to ASK.
NR 34
TC 8
Z9 8
U1 2
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD FEB
PY 2016
VL 89
IS 2
BP 459
EP 467
DI 10.1038/ki.2015.314
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA DD2TO
UT WOS:000369775300025
PM 26509588
ER
PT J
AU Shaw, AT
Gandhi, L
Gadgeel, S
Riely, GJ
Cetnar, J
West, H
Camidge, DR
Socinski, MA
Chiappori, A
Mekhail, T
Chao, BH
Borghaei, H
Gold, KA
Zeaiter, A
Bordogna, W
Balas, B
Puig, O
Henschel, V
Ou, SHI
AF Shaw, Alice T.
Gandhi, Leena
Gadgeel, Shirish
Riely, Gregory J.
Cetnar, Jeremy
West, Howard
Camidge, D. Ross
Socinski, Mark A.
Chiappori, Alberto
Mekhail, Tarek
Chao, Bo H.
Borghaei, Hossein
Gold, Kathryn A.
Zeaiter, Ali
Bordogna, Walter
Balas, Bogdana
Puig, Oscar
Henschel, Volkmar
Ou, Sai-Hong Ignatius
CA Study Investigators
TI Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung
cancer: a single-group, multicentre, phase 2 trial
SO LANCET ONCOLOGY
LA English
DT Article
ID ANAPLASTIC LYMPHOMA KINASE; BRAIN METASTASES; INHIBITOR; MODELS;
CHEMOTHERAPY; CERITINIB; CH5424802; CRITERIA; SAFETY
AB Background Alectinib-a highly selective, CNS-active, ALK inhibitor-showed promising clinical activity in crizotinibnaive and crizotinib-resistant patients with ALK-rearranged (ALK-positive) non-small-cell lung cancer (NSCLC). We aimed to assess the safety and effi cacy of alectinib in patients with ALK-positive NSCLC who progressed on previous crizotinib.
Methods We did a phase 2 study at 27 centres in the USA and Canada. We enrolled patients aged 18 years or older with stage IIIB-IV, ALK-positive NSCLC who had progressed after crizotinib. Patients were treated with oral alectinib 600 mg twice daily until progression, death, or withdrawal. The primary endpoint was the proportion of patients achieving an objective response by an independent review committee using Response Evaluation Criteria in Solid Tumors, version 1.1. Response endpoints were assessed in the response-evaluable population (ie, patients with measurable disease at baseline who received at least one dose of study drug), and effi cacy and safety analyses were done in the intention-to-treat population (all enrolled patients). This study is registered with ClinicalTrials. gov, number NCT01871805. The study is ongoing and patients are still receiving treatment.
Findings Between Sept 4, 2013, and Aug 4, 2014, 87 patients were enrolled into the study (intention-to-treat population). At the time of the primary analysis (median follow-up 4 . 8 months [IQR 3 . 3-7 . 1]), 33 of 69 patients with measurable disease at baseline had a confi rmed partial response; thus, the proportion of patients achieving an objective response by the independent review committee was 48% (95% CI 36-60). Adverse events were predominantly grade 1 or 2, most commonly constipation (31 [36%]), fatigue (29 [33%]), myalgia 21 [24%]), and peripheral oedema 20 [23%]). The most common grade 3 and 4 adverse events were changes in laboratory values, including increased blood creatine phosphokinase (seven [8%]), increased alanine aminotransferase (fi ve [6%]), and increased aspartate aminotransferase (four [5%]). Two patients died: one had a haemorrhage (judged related to study treatment), and one had disease progression and a history of stroke (judged unrelated to treatment).
C1 [Shaw, Alice T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Gandhi, Leena] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gadgeel, Shirish] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
[Riely, Gregory J.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
[Cetnar, Jeremy] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[West, Howard] Swedish Canc Ctr, Seattle, WA USA.
[Camidge, D. Ross] Univ Colorado, Boulder, CO 80309 USA.
[Socinski, Mark A.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Chiappori, Alberto] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Mekhail, Tarek] Florida Hosp Canc Inst, Orlando, FL USA.
[Chao, Bo H.] Ohio State Univ, Columbus, OH 43210 USA.
[Borghaei, Hossein] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
[Gold, Kathryn A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Zeaiter, Ali; Bordogna, Walter; Balas, Bogdana; Puig, Oscar; Henschel, Volkmar] F Hoffmann La Roche, Basel, Switzerland.
[Ou, Sai-Hong Ignatius] Univ Calif Irvine, Sch Med, Family Comprehens Canc Ctr, Orange, CA 92668 USA.
RP Shaw, AT (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM ASHAW1@mgh.harvard.edu
OI Gandhi, Leena/0000-0002-2398-9179
FU F Hoffmann-La Roche; US National Institutes of Health grant
[5R01CA164273]
FX This study was funded by F Hoffmann-La Roche. ATS is supported by a US
National Institutes of Health grant (5R01CA164273). Third-party
editorial assistance and graphic support, under the direction of the
authors, was provided by Joanna Musgrove of Gardiner-Caldwell
Communications, funded by F Hoffmann-La Roche.
NR 28
TC 86
Z9 91
U1 8
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
EI 1474-5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD FEB
PY 2016
VL 17
IS 2
BP 234
EP 242
DI 10.1016/S1470-2045(15)00488-X
PG 9
WC Oncology
SC Oncology
GA DD0MK
UT WOS:000369613900052
PM 26708155
ER
PT J
AU Vale, CL
Burdett, S
Rydzewska, LHM
Albiges, L
Clarke, NW
Fisher, D
Fizazi, K
Gravis, G
James, ND
Mason, MD
Parmar, MKB
Sweeney, CJ
Sydes, MR
Tombal, B
Tierney, JF
AF Vale, Claire L.
Burdett, Sarah
Rydzewska, Larysa H. M.
Albiges, Laurence
Clarke, Noel W.
Fisher, David
Fizazi, Karim
Gravis, Gwenaelle
James, Nicholas D.
Mason, Malcolm D.
Parmar, Mahesh K. B.
Sweeney, Christopher J.
Sydes, Matthew R.
Tombal, Bertrand
Tierney, Jayne F.
CA STOpCaP Steering Grp
TI Addition of docetaxel or bisphosphonates to standard of care in men with
localised or metastatic, hormone-sensitive prostate cancer: a systematic
review and meta-analyses of aggregate data
SO LANCET ONCOLOGY
LA English
DT Article
ID ANDROGEN-DEPRIVATION THERAPY; BONE-MINERAL DENSITY; RANDOMIZED
CONTROLLED-TRIAL; PHASE-III TRIAL; GETUG-AFU 15; ZOLEDRONIC ACID;
OPEN-LABEL; RADICAL PROSTATECTOMY; CLINICAL-TRIALS; PLUS DOCETAXEL
AB Background Results from large randomised controlled trials combining docetaxel or bisphosphonates with standard of care in hormone-sensitive prostate cancer have emerged. In order to investigate the effects of these therapies and to respond to emerging evidence, we aimed to systematically review all relevant trials using a framework for adaptive meta-analysis.
Methods For this systematic review and meta-analysis, we searched MEDLINE, Embase, LILACS, and the Cochrane Central Register of Controlled Trials, trial registers, conference proceedings, review articles, and reference lists of trial publications for all relevant randomised controlled trials (published, unpublished, and ongoing) comparing either standard of care with or without docetaxel or standard of care with or without bisphosphonates for men with high-risk localised or metastatic hormone-sensitive prostate cancer. For each trial, we extracted hazard ratios (HRs) of the effects of docetaxel or bisphosphonates on survival (time from randomisation until death from any cause) and failure-free survival (time from randomisation to biochemical or clinical failure or death from any cause) from published trial reports or presentations or obtained them directly from trial investigators. HRs were combined using the fixed-effect model (Mantel-Haenzsel).
Findings We identified five eligible randomised controlled trials of docetaxel in men with metastatic (M1) disease. Results from three (CHAARTED, GETUG-15, STAMPEDE) of these trials (2992 [93%] of 3206 men randomised) showed that the addition of docetaxel to standard of care improved survival. The HR of 0 . 77 (95% CI 0 . 68-0 . 87; p<0 . 0001) translates to an absolute improvement in 4-year survival of 9% (95% CI 5-14). Docetaxel in addition to standard of care also improved failure-free survival, with the HR of 0 . 64 (0 . 58-0 . 70; p<0 . 0001) translating into a reduction in absolute 4-year failure rates of 16% (95% CI 12-19). We identified 11 trials of docetaxel for men with locally advanced disease (M0). Survival results from three (GETUG-12, RTOG 0521, STAMPEDE) of these trials (2121 [53%] of 3978 men) showed no evidence of a benefit from the addition of docetaxel (HR 0 . 87 [95% CI 0 . 69-1 . 09]; p=0 . 218), whereas failure-free survival data from four (GETUG-12, RTOG 0521, STAMPEDE, TAX 3501) of these trials (2348 [59%] of 3978 men) showed that docetaxel improved failure-free survival (0 . 70 [0 . 61-0 . 81]; p<0 . 0001), which translates into a reduced absolute 4-year failure rate of 8% (5-10). We identified seven eligible randomised controlled trials of bisphosphonates for men with M1 disease. Survival results from three of these trials (2740 [88%] of 3109 men) showed that addition of bisphosphonates improved survival (0 . 88 [0 . 79-0 . 98]; p=0 . 025), which translates to 5% (1-8) absolute improvement, but this result was influenced by the positive result of one trial of sodium clodronate, and we found no evidence of a benefit from the addition of zoledronic acid (0 . 94 [0 . 83-1 . 07]; p=0 . 323), which translates to an absolute improvement in survival of 2% (-3 to 7). Of 17 trials of bisphosphonates for men with M0 disease, survival results from four trials (4079 [66%] of 6220 men) showed no evidence of benefit from the addition of bisphosphonates (1 . 03 [0 . 89-1 . 18]; p=0 . 724) or zoledronic acid (0 . 98 [0 . 82-1 . 16]; p=0 . 782). Failure-free survival definitions were too inconsistent for formal meta-analyses for the bisphosphonate trials.
C1 [Vale, Claire L.; Burdett, Sarah; Rydzewska, Larysa H. M.; Fisher, David; Parmar, Mahesh K. B.; Sydes, Matthew R.; Tierney, Jayne F.] UCL, MRC Clin Trials Unit, London WC2B 6NH, England.
[Albiges, Laurence; Fizazi, Karim] Inst Gustave Roussy, Paris, France.
[Clarke, Noel W.] Christie & Salford Royal NHS Fdn Trusts, Dept Urol, Manchester, Lancs, England.
[Gravis, Gwenaelle] Inst J Paoli I Calmettes, Dept Med Oncol, F-13009 Marseille, France.
[James, Nicholas D.] Univ Warwick, Warwick Canc Res Unit, Coventry CV4 7AL, W Midlands, England.
[James, Nicholas D.] Univ Birmingham, Sch Med, Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England.
[Mason, Malcolm D.] Cardiff Univ, Sch Med, Velindre Hosp, Cardiff CF10 3AX, S Glam, Wales.
[Sweeney, Christopher J.] Dana Farber Canc Inst, Lank Ctr Genitourinary Canc, Boston, MA 02115 USA.
[Tombal, Bertrand] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium.
RP Vale, CL (reprint author), UCL, MRC Clin Trials Unit, Meta Anal Grp, London WC2B 6NH, England.
EM claire.vale@ucl.ac.uk
OI Sydes, Matthew/0000-0002-9323-1371
FU UK Medical Research Council
FX The STOpCaP Steering Group thanks all patients who participated in the
trials and contributed to this research. The meta-analysis would not
have been possible without their participation or without the
institutions that carried out the trials. We thank the principal
investigators of the GETUG-15, CHAARTED, and STAMPEDE trials for
supplying additional information that we have used in these analyses.
The Project Management Group was funded by the UK Medical Research
Council.
NR 52
TC 32
Z9 32
U1 3
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
EI 1474-5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD FEB
PY 2016
VL 17
IS 2
BP 243
EP 256
DI 10.1016/S1470-2045(15)00489-1
PG 14
WC Oncology
SC Oncology
GA DD0MK
UT WOS:000369613900053
PM 26718929
ER
PT J
AU Woods, NF
Hohensee, C
Carpenter, JS
Cohen, L
Ensrud, K
Freeman, EW
Guthrie, KA
Joffe, H
LaCroix, AZ
Otte, JL
AF Woods, Nancy Fugate
Hohensee, Chancellor
Carpenter, Janet S.
Cohen, Lee
Ensrud, Kristine
Freeman, Ellen W.
Guthrie, Katherine A.
Joffe, Hadine
LaCroix, Andrea Z.
Otte, Julie L.
TI Symptom clusters among MsFLASH clinical trial participants
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE Hot flashes; Menopause; Mood; Pain; Sleep disturbances; Symptom clusters
ID RANDOMIZED CONTROLLED-TRIAL; EARLY POSTMENOPAUSE OBSERVATIONS; HEALTHY
MENOPAUSAL WOMEN; SLEEP QUALITY INDEX; MIDDLE-AGED WOMEN; HOT FLASHES;
VASOMOTOR SYMPTOMS; MUSCULOSKELETAL PAIN; OF-LIFE; TRANSITION
AB Objective:Our objective was to identify symptom clusters using standardized measures completed by participants in the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health clinical trial at baseline, including hot flash interference, and sleep, depressive, anxiety, and pain symptoms.Methods:Data from all women randomized to interventions and controls from Menopausal Strategies: Finding Lasting Answers to Symptoms and Health studies 1, 2, and 3 (N=899) were included; 797 with complete data were used in the analyses. Scores from standardized measures obtained at baseline included the following: Hot Flash-Related Daily Interference Scale, Insomnia Severity Index, Pittsburgh Sleep Quality Index, Patient Health Questionnaire-9 measure of depressed mood, Generalized Anxiety Disorder, and Brief Pain Inventory PEG scores (pain intensity [P], interference with enjoyment of life [E], and interference with daily activity [G]). Latent class analysis was used to identify symptom clusters using standardized scale scores and their established cut points.Results:We identified five classes using the Bayesian Information Criterion and the Akaike Information Criterion. Women in classes 1 and 2 had high hot flash interference levels relative to the others, and class 1 (10.5% of total) included severe hot flash interference, severe sleep symptoms, and moderately severe pain symptoms (hot flash, sleep, pain). In class 2 (14.1%), severe hot flash interference was paired with the severe sleep symptoms, and moderate to severe depressed and anxious mood symptoms and pain (hot flash, sleep, mood, pain). In class 3 (39.6%), women reported moderately severe sleep symptoms with moderate hot flash interference, and low severity mood and pain symptoms (hot flash, sleep). Those in class 4 (7.0%) reported moderate hot flash interference with severe levels of anxiety and depressed mood symptoms, but low levels of other symptoms (hot flash, mood). Women in class 5 (28.7%) reported the lowest levels of all the five symptoms (low severity symptoms).Conclusions:Women meeting hot flash frequency criteria for inclusion in clinical trials exhibited multiple co-occurring symptoms that clustered into identifiable groups according to symptom interference and severity. Variability of symptom profiles between the classes was evident, indicating that the classes were composed of differing symptom types and not simply differing severity levels. These symptom clusters may be useful phenotypes for differentiating treatment effects or evaluating associations with biomarkers or genes.
C1 [Woods, Nancy Fugate] Univ Washington, Biobehav Nursing, Seattle, WA 98195 USA.
[Hohensee, Chancellor; Guthrie, Katherine A.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Carpenter, Janet S.; Otte, Julie L.] Indiana Univ, Sch Nursing, Sci Nursing Care, Indianapolis, IN 46204 USA.
[Cohen, Lee] Ctr Womens Mental Hlth, Boston, MA USA.
[Cohen, Lee] Massachusetts Gen Hosp, Perinatal & Reprod Psychiat Clin Res Program, Boston, MA 02114 USA.
[Ensrud, Kristine] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA.
[Ensrud, Kristine] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA.
[Freeman, Ellen W.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Freeman, Ellen W.] Univ Penn, Perelman Sch Med, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA.
[Freeman, Ellen W.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Joffe, Hadine] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Joffe, Hadine] Dana Farber Canc Inst, Boston, MA 02115 USA.
[LaCroix, Andrea Z.] Univ Calif San Diego, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA.
RP Woods, NF (reprint author), Univ Washington, Biobehav Nursing, Seattle, WA 98195 USA.; Woods, NF (reprint author), Univ Washington, Seattle, WA 98195 USA.
EM nfwoods@u.washington.edu
FU NCRR NIH HHS [UL1RR02571]; NIA NIH HHS [U01AG032700, U01 AG032656, U01
AG032659, U01 AG032669, U01 AG032682, U01 AG032699, U01 AG032700,
U01AG032659, U01AG032669, U01AG032682, U01AG032699]
NR 40
TC 1
Z9 1
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1072-3714
EI 1530-0374
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD FEB
PY 2016
VL 23
IS 2
BP 158
EP 165
DI 10.1097/GME.0000000000000516
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DD5TX
UT WOS:000369988500009
PM 26506500
ER
PT J
AU Meyer, F
Freeman, MP
Petrillo, L
Barsky, M
Galvan, T
Kim, S
Cohen, L
Joffe, H
AF Meyer, Fremonta
Freeman, Marlene P.
Petrillo, Laura
Barsky, Maria
Galvan, Thania
Kim, Semmie
Cohen, Lee
Joffe, Hadine
TI Armodafinil for fatigue associated with menopause: an open-label trial
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE Fatigue; Menopause; Armodafinil; Modafinil; Hot flashes; Quality of life
ID CLIMACTERIC SYMPTOMS; WOMEN; EFFICACY; DEPRESSION; SLEEPINESS; SEVERITY;
QUESTIONNAIRE; CHEMOTHERAPY; NARCOLEPSY; MODAFINIL
AB Objective:This study aims to obtain preliminary data on the efficacy of armodafinil for improving menopause-related fatigue and quality of life.Methods:Women (aged 40-65 y) experiencing menopause-related fatigue received open-label armodafinil therapy (up to 150mg/d) for 4 weeks. Changes from baseline in Brief Fatigue Inventory score and Menopause-Specific Quality of Life (MENQOL) physical domain score were examined using the Wilcoxon signed rank test. Exploratory analyses examined the effects of armodafinil on hot flashes, overall quality of life, insomnia, depression, anxiety, and perceived cognitive performance. After open-label treatment, participants were randomized to double-blind continuation of armodafinil versus placebo for 2 weeks to examine whether treatment discontinuation would precipitate symptom recurrence.Results:Of 29 eligible participants, 20 women (69.0%) completed the trial. During treatment with armodafinil (mean dose, 120mg/d), median Brief Fatigue Inventory scores decreased by 57.7% from 5.2 (interquartile range [IQR], 4.6-6.2) to 2.2 (IQR, 1.1-4.4; P=0.0002), and median MENQOL physical domain scores decreased by 51.3% from 3.9 (IQR, 2.3-4.8) to 1.9 (IQR, 1.3-2.7; P=0.0001). Median hot flashes for 24hours decreased by 48.3% from 2.9 (IQR, 1.1-4.6) to 1.5 (IQR, 0.4-2.4; P=0.0005). Improvements in MENQOL total score (49%; P=0.0001), cognitive function (59.2%; P=0.0002), depressive symptoms (64.7%; P=0.0006), insomnia (72.7%; P=0.0012), and excessive sleepiness (57.1%; P=0.0006) were noted. Randomized continuation (n=10) or discontinuation (n=10) did not indicate group differences. Armodafinil was well-tolerated; three women (12%) were withdrawn for adverse events.Conclusions:These preliminary results suggest a therapeutic effect of armodafinil on fatigue affecting quality of life during menopause, and a potential benefit for other menopause-related symptoms.
C1 [Meyer, Fremonta; Galvan, Thania; Kim, Semmie; Joffe, Hadine] Brigham & Womens Hosp, Dept Psychiat, 75 Francis St, Boston, MA 02115 USA.
[Meyer, Fremonta; Joffe, Hadine] Dana Farber Canc Inst, Dept Psychooncol & Palliat Care, Boston, MA 02115 USA.
[Freeman, Marlene P.; Petrillo, Laura; Barsky, Maria; Cohen, Lee; Joffe, Hadine] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Joffe, H (reprint author), Brigham & Womens Hosp, BB232C,75 Francis St, Boston, MA 02115 USA.
EM hjoffe@partners.org
NR 30
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1072-3714
EI 1530-0374
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD FEB
PY 2016
VL 23
IS 2
BP 209
EP 214
DI 10.1097/GME.0000000000000505
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DD5TX
UT WOS:000369988500015
PM 26125538
ER
PT J
AU Burns, TM
Smith, GA
Allen, JA
Amato, AA
Arnold, WD
Barohn, R
Benatar, M
Bird, SJ
Bromberg, M
Chahin, N
Ciafaloni, E
Cohen, JA
Corse, A
Crum, BA
David, WS
Dimberg, E
De Sousa, EA
Donofrio, PD
Dyck, PJB
Engel, AG
Ensrud, ER
Ferrante, M
Freimer, M
Gable, KL
Gibson, S
Gilchrist, JM
Goldstein, JM
Gooch, CL
Goodman, BP
Gorelov, D
Gospe, SM
Goyal, NA
Guidon, AC
Guptill, JT
Gutmann, L
Gutmann, L
Gwathmey, K
Harati, Y
Harper, CM
Hehir, MK
Hobson-Webb, LD
Howard, JF
Jackson, CE
Johnson, N
Jones, SM
Juel, VC
Kaminski, HJ
Karam, C
Kennelly, KD
Khella, S
Khoury, J
Kincaid, JC
Kissel, JT
Kolb, N
Lacomis, D
Ladha, S
Larriviere, D
Lewis, RA
Li, YB
Litchy, WJ
Logigian, E
Lou, JS
MacGowen, DJL
Maselli, R
Massey, JM
Mauermann, ML
Mathews, KD
Meriggioli, MN
Miller, RG
Moon, JS
Mozaffar, T
Nations, SP
Nowak, RJ
Ostrow, LW
Pascuzzi, RM
Peltier, A
Ruzhansky, K
Richman, DP
Ross, MA
Rubin, DI
Russell, JA
Sachs, GM
Salajegheh, MK
Saperstein, DS
Scelsa, S
Selcen, D
Shaibani, A
Shieh, PB
Silvestri, NJ
Singleton, JR
Smith, BE
So, YT
Solorzano, G
Sorenson, EJ
Srinivasen, J
Tavee, J
Tawil, R
Thaisetthawatkul, P
Thornton, C
Trivedi, J
Vernino, S
Wang, AK
Webb, TA
Weiss, MD
Windebank, AJ
Wolfe, GI
AF Burns, Ted M.
Smith, Gordon A.
Allen, Jeffrey A.
Amato, Anthony A.
Arnold, W. David
Barohn, Richard
Benatar, Michael
Bird, Shawn J.
Bromberg, Mark
Chahin, Nizar
Ciafaloni, Emma
Cohen, Jeffrey A.
Corse, Andrea
Crum, Brian A.
David, William S.
Dimberg, Elliot
De Sousa, Eduardo A.
Donofrio, Peter D.
Dyck, P. James B.
Engel, Andrew G.
Ensrud, Erik R.
Ferrante, Mark
Freimer, Miriam
Gable, Karissa L.
Gibson, Summer
Gilchrist, James M.
Goldstein, Jonathan M.
Gooch, Clifton L.
Goodman, Brent P.
Gorelov, Dmitri
Gospe, Sidney M., Jr.
Goyal, Namita A.
Guidon, Amanda C.
Guptill, Jeffrey T.
Gutmann, Laurie
Gutmann, Ludwig
Gwathmey, Kelly
Harati, Yadollah
Harper, C. Michel, Jr.
Hehir, Michael K.
Hobson-Webb, Lisa D.
Howard, James F., Jr.
Jackson, Carlayne E.
Johnson, Nicholas
Jones, Sarah M.
Juel, Vern C.
Kaminski, Henry J.
Karam, Chafic
Kennelly, Kathleen D.
Khella, Sami
Khoury, Julie
Kincaid, John C.
Kissel, John T.
Kolb, Noah
Lacomis, David
Ladha, Shafeeq
Larriviere, Daniel
Lewis, Richard A.
Li, Yuebing
Litchy, William J.
Logigian, Eric
Lou, Jau-Shin
MacGowen, Daniel J. L.
Maselli, Ricardo
Massey, Janice M.
Mauermann, Michelle L.
Mathews, Katherine D.
Meriggioli, Matthew N.
Miller, Robert G.
Moon, Joon-Shik
Mozaffar, Tahseen
Nations, Sharon P.
Nowak, Richard J.
Ostrow, Lyle W.
Pascuzzi, Robert M.
Peltier, Amanda
Ruzhansky, Katherine
Richman, David P.
Ross, Mark A.
Rubin, Devon I.
Russell, James A.
Sachs, George M.
Salajegheh, Mohammad Kian
Saperstein, David S.
Scelsa, Stephen
Selcen, Duygu
Shaibani, Aziz
Shieh, Perry B.
Silvestri, Nicholas J.
Singleton, J. Rob
Smith, Benn E.
So, Yuen T.
Solorzano, Guillermo
Sorenson, Eric J.
Srinivasen, Jayashri
Tavee, Jinny
Tawil, Rabi
Thaisetthawatkul, Pariwat
Thornton, Charles
Trivedi, Jaya
Vernino, Steven
Wang, Annabel K.
Webb, Tyler A.
Weiss, Michael D.
Windebank, Anthony J.
Wolfe, Gil I.
TI EDITORIAL BY CONCERNED PHYSICIANS: UNINTENDED EFFECT OF THE ORPHAN DRUG
ACT ON THE POTENTIAL COST OF 3,4-DIAMINOPYRIDINE
SO MUSCLE & NERVE
LA English
DT Editorial Material
ID EATON MYASTHENIC SYNDROME; DOUBLE-BLIND; PLACEBO
C1 [Burns, Ted M.; Gwathmey, Kelly; Jones, Sarah M.; Solorzano, Guillermo] Univ Virginia, Dept Neurol, Charlottesville, VA 22908 USA.
[Smith, Gordon A.; Bromberg, Mark; Gibson, Summer; Johnson, Nicholas; Kolb, Noah; Singleton, J. Rob] Univ Utah, Dept Neurol, Salt Lake City, UT USA.
[Allen, Jeffrey A.] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA.
[Amato, Anthony A.; Salajegheh, Mohammad Kian] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Arnold, W. David] Ohio State Univ, Dept Neurol & Phys Med & Rehabil, Columbus, OH 43210 USA.
[Barohn, Richard] Univ Kansas, Dept Neurol, Kansas City, KS USA.
[Benatar, Michael] Univ Miami, Dept Neurol, Miami, FL USA.
[Bird, Shawn J.; Khella, Sami] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Chahin, Nizar] Univ Connecticut, Dept Neurol, Farmington, CT USA.
[Ciafaloni, Emma; Logigian, Eric; Tawil, Rabi; Thornton, Charles] Univ Rochester, Dept Neurol, Rochester, NY USA.
[Cohen, Jeffrey A.] Geisel Sch Med Dartmouth, Dept Neurol, Lebanon, NH USA.
[Corse, Andrea; Ostrow, Lyle W.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
[Crum, Brian A.; Dyck, P. James B.; Engel, Andrew G.; Harper, C. Michel, Jr.; Litchy, William J.; Mauermann, Michelle L.; Selcen, Duygu; Sorenson, Eric J.; Windebank, Anthony J.] Mayo Clin, Dept Neurol, Rochester, MN USA.
[David, William S.; Guidon, Amanda C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA.
[Dimberg, Elliot; Kennelly, Kathleen D.; Rubin, Devon I.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
[De Sousa, Eduardo A.; Moon, Joon-Shik; Webb, Tyler A.] Univ Oklahoma, Dept Neurol, Oklahoma City, OK USA.
[Donofrio, Peter D.; Peltier, Amanda] Vanderbilt Univ, Dept Neurol, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Ensrud, Erik R.] Boston Vet Affairs, Dept Neurol, Boston, MA USA.
[Ferrante, Mark] Univ Tennessee, Hlth Sci Ctr, Dept Neurol, Memphis, TN USA.
[Freimer, Miriam; Kissel, John T.] Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA.
[Gable, Karissa L.; Guptill, Jeffrey T.; Hobson-Webb, Lisa D.; Juel, Vern C.; Massey, Janice M.] Duke Univ, Dept Neurol, Durham, NC USA.
[Gilchrist, James M.] So Illinois Univ, Sch Med, Dept Neurol, Springfield, IL USA.
[Goldstein, Jonathan M.] Hosp Special Surg, Dept Neurol, 535 E 70th St, New York, NY 10021 USA.
[Gooch, Clifton L.] Univ S Florida, Dept Neurol, Tampa, FL 33620 USA.
[Goodman, Brent P.; Ross, Mark A.; Smith, Benn E.] Mayo Clin, Dept Neurol, Scottsdale, AZ USA.
[Gorelov, Dmitri] Crystal Run Healthcare, Middletown, NY USA.
[Gospe, Sidney M., Jr.; Weiss, Michael D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Goyal, Namita A.; Mozaffar, Tahseen] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA.
[Gutmann, Laurie; Gutmann, Ludwig; Mathews, Katherine D.] Univ Iowa, Div Neurol, Iowa City, IA USA.
[Harati, Yadollah] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Hehir, Michael K.] Univ Vermont, Dept Neurol, Burlington, VT USA.
[Howard, James F., Jr.; Karam, Chafic] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA.
[Jackson, Carlayne E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol & Otolaryngol, San Antonio, TX 78229 USA.
[Kaminski, Henry J.] George Washington Univ, Dept Neurol, Washington, DC USA.
[Khoury, Julie] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR USA.
[Kincaid, John C.; Pascuzzi, Robert M.] Indiana Univ, Dept Neurol, Indianapolis, IN 46204 USA.
[Lacomis, David] Univ Pittsburgh, Dept Neurol & Pathol, Pittsburgh, PA USA.
[Ladha, Shafeeq] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA.
[Larriviere, Daniel] Ochsner Neurosci Inst, Dept Neurol, New Orleans, LA USA.
[Lewis, Richard A.] Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA 90048 USA.
[Li, Yuebing; Tavee, Jinny] Cleveland Clin, Dept Neurol, Cleveland, OH 44106 USA.
[Lou, Jau-Shin] Univ N Dakota, Sanford Hlth, Dept Neurol, Fargo, ND USA.
[MacGowen, Daniel J. L.; Scelsa, Stephen] Mt Sinai Beth Israel Hosp, Dept Neurol, New York, NY USA.
[Maselli, Ricardo; Richman, David P.] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA.
[Meriggioli, Matthew N.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
[Miller, Robert G.] Calif Pacific Med Ctr, Dept Neurosci, San Francisco, CA USA.
[Nations, Sharon P.; Vernino, Steven] Univ Texas Southwestern, Dept Neurol & Neurotherapeut, Dallas, TX USA.
[Nowak, Richard J.; Trivedi, Jaya] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.
[Ruzhansky, Katherine] Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA.
[Russell, James A.; Srinivasen, Jayashri] Lahey Hosp & Med Ctr, Dept Neurol, Burlington, MA USA.
[Sachs, George M.] Brown Univ, Alpert Med Sch, Dept Neurol, Providence, RI 02912 USA.
[Saperstein, David S.] Phoenix Neurol Associates, Phoenix, AZ USA.
[Shaibani, Aziz] Nerve & Muscle Ctr Texas, Houston, TX USA.
[Shieh, Perry B.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Silvestri, Nicholas J.; Wolfe, Gil I.] SUNY Buffalo, Dept Neurol, Buffalo, NY 14260 USA.
[So, Yuen T.] Stanford Univ, Dept Neurol, Palo Alto, CA 94304 USA.
[Thaisetthawatkul, Pariwat] Univ Nebraska, Dept Neurol, Omaha, NE 68182 USA.
[Wang, Annabel K.] Vet Affairs Long Beach Healthcare Syst, Dept Neurol, Long Beach, CA USA.
RP Burns, TM (reprint author), Univ Virginia, Dept Neurol, Charlottesville, VA 22908 USA.
EM tmb8r@virginia.edu
RI Gooch, Clifton/M-1874-2016;
OI Gooch, Clifton/0000-0002-2210-2038; Howard, James/0000-0002-7136-8617;
Peltier, Amanda/0000-0003-1097-7715
NR 14
TC 2
Z9 2
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD FEB
PY 2016
VL 53
IS 2
BP 165
EP 168
DI 10.1002/mus.25009
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DD3RE
UT WOS:000369839500001
PM 26662952
ER
PT J
AU Benatar, M
Boylan, K
Jeromin, A
Rutkove, SB
Berry, J
Atassi, N
Bruijn, L
AF Benatar, Michael
Boylan, Kevin
Jeromin, Andreas
Rutkove, Seward B.
Berry, James
Atassi, Nazem
Bruijn, Lucie
TI ALS BIOMARKERS FOR THERAPY DEVELOPMENT: STATE OF THE FIELD AND FUTURE
DIRECTIONS
SO MUSCLE & NERVE
LA English
DT Review
DE ALS; biomarkers; disease progression; predictive; pharmacodynamic;
prognostic
ID AMYOTROPHIC-LATERAL-SCLEROSIS; ELECTRICAL-IMPEDANCE MYOGRAPHY;
TRANSCRANIAL MAGNETIC STIMULATION; NEUROFILAMENT HEAVY-CHAIN;
VOXEL-BASED MORPHOMETRY; UNIT NUMBER ESTIMATION; URIC-ACID LEVELS;
POSITRON-EMISSION-TOMOGRAPHY; SUBUNIT PNF-H; DISEASE PROGRESSION
AB Biomarkers have become the focus of intense research in the field of amyotrophic lateral sclerosis (ALS), with the hope that they might aid therapy development efforts. Notwithstanding the discovery of many candidate biomarkers, none have yet emerged as validated tools for drug development. In this review we present a nuanced view of biomarkers based on the perspective of the Food and Drug Administration; highlight the distinction between discovery and validation; describe existing and emerging resources; review leading biological fluid-based, electrophysiological, and neuroimaging candidates relevant to therapy development efforts; discuss lessons learned from biomarker initiatives in related neurodegenerative diseases; and outline specific steps that we, as a field, might take to hasten the development and validation of biomarkers that will prove useful in enhancing efforts to develop effective treatments for ALS patients. Most important among these is the proposal to establish a federated ALS Biomarker Consortium in which all interested and willing stakeholders may participate with equal opportunity to contribute to the broader mission of biomarker development and validation.
C1 [Benatar, Michael] Univ Miami, Dept Neurol, Miami, FL 33136 USA.
[Boylan, Kevin] Mayo Clin Jacksonville, Dept Neurol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
[Jeromin, Andreas] Iron Horse Diagnost, Scottsdale, AZ USA.
[Rutkove, Seward B.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.
[Berry, James; Atassi, Nazem] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Bruijn, Lucie] ALS Assoc, Washington, DC USA.
RP Benatar, M (reprint author), Univ Miami, Dept Neurol, Miami, FL 33136 USA.
EM mbenatar@miami.edu
FU CReATe Consortium, is part of the Rare Diseases Clinical Research
Network (RDCRN), an initiative of the ORDR, NCATS [U54-NS-092091];
NCATS; NINDS; Iron Horse Diagnostics, Inc.; Skulpt Inc.; Biogen; Voyager
Therapeutics; GSK; Cytokinetics; Brainstorm Cell Therapeutics; Novartis;
ALS Therapy Development Institute; ALS Association; MDA; NIH
FX We are grateful to Richard Robinson for his careful review and edits to
this manuscript. This work was supported in part by the CReATe
Consortium (U54-NS-092091), which is part of the Rare Diseases Clinical
Research Network (RDCRN), an initiative of the ORDR, NCATS. CReATe is
funded through collaboration between NCATS and NINDS. Andreas Jeromin is
a paid employee and shareholder of Iron Horse Diagnostics, Inc. Seward
Rutkove owns equity, receives consulting fees, and owns patent rights in
Skulpt Inc. Nazem Atassi receives consulting fees from Biogen. James D.
Berry has consulted with Biogen Idec and Neuraltus Pharmaceuticals and
has received research support from Voyager Therapeutics, GSK,
Cytokinetics, Brainstorm Cell Therapeutics, Novartis, ALS Therapy
Development Institute, ALS Association, MDA, and NIH.
NR 116
TC 4
Z9 5
U1 4
U2 22
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD FEB
PY 2016
VL 53
IS 2
BP 169
EP 182
DI 10.1002/mus.24979
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DD3RE
UT WOS:000369839500002
PM 26574709
ER
PT J
AU Heatwole, C
Bode, R
Johnson, NE
Dekdebrun, J
Dilek, N
Eichinger, K
Hilbert, JE
Logigian, E
Luebbe, E
Martens, W
Mcdermott, MP
Pandya, S
Puwanant, A
Rothrock, N
Thornton, C
Vickrey, BG
Victorson, D
Moxley, RT
AF Heatwole, Chad
Bode, Rita
Johnson, Nicholas E.
Dekdebrun, Jeanne
Dilek, Nuran
Eichinger, Katy
Hilbert, James E.
Logigian, Eric
Luebbe, Elizabeth
Martens, William
Mcdermott, Michael P.
Pandya, Shree
Puwanant, Araya
Rothrock, Nan
Thornton, Charles
Vickrey, Barbara G.
Victorson, David
Moxley, Richard T., III
TI MYOTONIC DYSTROPHY HEALTH INDEX: CORRELATIONS WITH CLINICAL TESTS AND
PATIENT FUNCTION
SO MUSCLE & NERVE
LA English
DT Article
DE muscle disease; myotonic dystrophy Type-1; patient-relevant;
patient-reported outcome measure; quality of life; therapeutic trial
ID QUALITY-OF-LIFE; FACIOSCAPULOHUMERAL MUSCULAR-DYSTROPHY; ACTIVITY
RATING-SCALES; ADULT MUSCLE DISEASE; NATURAL-HISTORY; THERAPEUTIC
TRIALS; DUCHENNE DYSTROPHY; ACTUALLY MEASURE; CTG REPEAT; RELIABILITY
AB Introduction: The Myotonic Dystrophy Health Index (MDHI) is a disease-specific patient-reported outcome measure. Here, we examine the associations between the MDHI and other measures of disease burden in a cohort of individuals with myotonic dystrophy type-1 (DM1). Methods: We conducted a cross-sectional study of 70 patients with DM1. We examined the associations between MDHI total and subscale scores and scores from other clinical tests. Participants completed assessments of strength, myotonia, motor and respiratory function, ambulation, and body composition. Participants also provided blood samples, underwent physician evaluations, and completed other patient-reported outcome measures. Results: MDHI total and subscale scores were strongly associated with muscle strength, myotonia, motor function, and other clinical measures. Conclusions: Patient-reported health status, as measured by the MDHI, is associated with alternative measures of clinical health. These results support the use of the MDHI as a valid tool to measure disease burden in DM1 patients.
C1 [Heatwole, Chad; Dekdebrun, Jeanne; Dilek, Nuran; Eichinger, Katy; Hilbert, James E.; Logigian, Eric; Luebbe, Elizabeth; Martens, William; Mcdermott, Michael P.; Pandya, Shree; Thornton, Charles; Moxley, Richard T., III] Univ Rochester, Med Ctr, Dept Neurol, 601 Elmwood Ave,Box 673, Rochester, NY 14642 USA.
[Bode, Rita] Psychometr Consultant, Chicago, IL USA.
[Johnson, Nicholas E.] Univ Utah, Salt Lake City, UT USA.
[Mcdermott, Michael P.] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA.
[Puwanant, Araya] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Rothrock, Nan; Victorson, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Med Ctr, Los Angeles, CA 90095 USA.
[Vickrey, Barbara G.] Greater Los Angeles VA HealthCare Syst, Los Angeles, CA USA.
RP Heatwole, C (reprint author), Univ Rochester, Med Ctr, Dept Neurol, 601 Elmwood Ave,Box 673, Rochester, NY 14642 USA.
EM chad_heatwole@urmc.rochester.edu
FU Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center
[NINDS U54NS48843]; Muscular Dystrophy Association; Saunders Family
Fund; Abrams Family Fund for Myotonic Dystrophy Research; University of
Rochester CTSA award from the National Center for Research Resources
[UL1 RR024160]; National Center for Advancing Translational Sciences of
the National Institutes of Health
FX Support for this research was provided by the Senator Paul D. Wellstone
Muscular Dystrophy Cooperative Research Center (NINDS U54NS48843), the
Muscular Dystrophy Association, the Saunders Family Fund, and the Abrams
Family Fund for Myotonic Dystrophy Research. The project described in
this publication was also supported by the University of Rochester CTSA
award number UL1 RR024160 from the National Center for Research
Resources and the National Center for Advancing Translational Sciences
of the National Institutes of Health. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health. Additional
information regarding the MDHI is available at the Neuromuscular
Institute of Quality-of-Life Studies and Outcome Measure Development
website www.QOLINSTITUTE.com and MDHI licensing opportunities can be
reviewed at: www.urmc.rochester.edu/techtransfer.
NR 47
TC 2
Z9 2
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD FEB
PY 2016
VL 53
IS 2
BP 183
EP 190
DI 10.1002/mus.24725
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DD3RE
UT WOS:000369839500003
PM 26044513
ER
PT J
AU Doench, JG
Fusi, N
Sullender, M
Hegde, M
Vaimberg, EW
Donovan, KF
Smith, I
Tothova, Z
Wilen, C
Orchard, R
Virgin, HW
Listgarten, J
Root, DE
AF Doench, John G.
Fusi, Nicolo
Sullender, Meagan
Hegde, Mudra
Vaimberg, Emma W.
Donovan, Katherine F.
Smith, Ian
Tothova, Zuzana
Wilen, Craig
Orchard, Robert
Virgin, Herbert W.
Listgarten, Jennifer
Root, David E.
TI Optimized sgRNA design to maximize activity and minimize off-target
effects of CRISPR-Cas9
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID HUMAN-CELLS; FUNCTIONAL GENOMICS; GENETIC SCREENS; RAF INHIBITION; CAS
NUCLEASES; RNA; DNA; IDENTIFICATION; SPECIFICITY; SYSTEMS
AB CRISPR-Cas9-based genetic screens are a powerful new tool in biology. By simply altering the sequence of the single-guide RNA (sgRNA), one can reprogram Cas9 to target different sites in the genome with relative ease, but the on-target activity and off-target effects of individual sgRNAs can vary widely. Here, we use recently devised sgRNA design rules to create human and mouse genome-wide libraries, perform positive and negative selection screens and observe that the use of these rules produced improved results. Additionally, we profile the off-target activity of thousands of sgRNAs and develop a metric to predict off-target sites. We incorporate these findings from large-scale, empirical data to improve our computational design rules and create optimized sgRNA libraries that maximize on-target activity and minimize off-target effects to enable more effective and efficient genetic screens and genome engineering.
C1 [Doench, John G.; Sullender, Meagan; Hegde, Mudra; Vaimberg, Emma W.; Donovan, Katherine F.; Smith, Ian; Tothova, Zuzana; Root, David E.] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Fusi, Nicolo; Listgarten, Jennifer] Microsoft Res New England, Cambridge, MA USA.
[Tothova, Zuzana] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA.
[Wilen, Craig; Orchard, Robert; Virgin, Herbert W.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
RP Doench, JG; Root, DE (reprint author), Broad Inst MIT & Harvard, Cambridge, MA USA.; Fusi, N; Listgarten, J (reprint author), Microsoft Res New England, Cambridge, MA USA.
EM jdoench@broadinstitute.org; fusi@microsoft.com; jennl@microsoft.com;
droot@broadinstitute.org
OI Sullender, Meagan/0000-0001-6666-8650; Wilen, Craig/0000-0003-2495-9403
FU NIH [5K12CA087723-12]; ASCO Young Investigator Award; LLS Special Fellow
Award; Next Generation Fund at the Broad Institute of MIT and Harvard
FX We thank M. Tomko, M. Greene, A. Brown, D. Alan and T. Green for
software engineering support, and T. Nguyen, N. Tran and X. Yang for
library production support (Broad Institute). Z.T. is funded by NIH
5K12CA087723-12, ASCO Young Investigator Award, LLS Special Fellow
Award. J.G.D. is a Merkin Institute Fellow and is supported by the Next
Generation Fund at the Broad Institute of MIT and Harvard.
NR 53
TC 68
Z9 71
U1 47
U2 100
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
EI 1546-1696
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD FEB
PY 2016
VL 34
IS 2
BP 184
EP +
DI 10.1038/nbt.3437
PG 12
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA DD0OK
UT WOS:000369619100021
PM 26780180
ER
PT J
AU Cristofaro, V
Carey, SD
Yalla, SV
Sullivan, MP
AF Cristofaro, Vivian
Carey, Sean D.
Yalla, Subbarao V.
Sullivan, Maryrose P.
TI CAVEOLAE-MEDIATED REGULATION OF ALPHA-1-ADRENOCEPTOR SUBTYPES IN
OVERACTIVE BLADDERS FROM SPONTANEOUSLY HYPERTENSIVE RATS
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Meeting Abstract
CT Winter Meeting of the
Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct
ion
CY FEB 23-27, 2016
CL New Orleans, LA
SP Soc Urodynam Female Pelv Med & Urogenital Reconstruct
C1 [Cristofaro, Vivian; Carey, Sean D.; Yalla, Subbarao V.; Sullivan, Maryrose P.] Harvard Univ, VA Boston Healthcare Syst, Sch Med, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
EI 1520-6777
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
PD FEB
PY 2016
VL 35
SU 1
MA BS31
BP S19
EP S19
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA DD2BF
UT WOS:000369726700033
ER
PT J
AU Doyle, C
Chung, YG
Schafer, M
Sack, B
Costa, K
Cristofaro, V
Sullivan, MP
Adam, RM
AF Doyle, Claire
Chung, Yeun Goo
Schaefer, Mattias
Sack, Bryan
Costa, Kyle
Cristofaro, Vivian
Sullivan, Maryrose P.
Adam, Rosalyn M.
TI INOSINE ATTENUATES SPONTANEOUS AND EVOKED ACTIVITY IN NEUROGENIC BLADDER
THROUGH AN ADENOSINE RECEPTOR-MEDIATED PATHWAY
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Meeting Abstract
CT Winter Meeting of the
Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct
ion
CY FEB 23-27, 2016
CL New Orleans, LA
SP Soc Urodynam Female Pelv Med & Urogenital Reconstruct
C1 [Doyle, Claire; Chung, Yeun Goo; Schaefer, Mattias; Sack, Bryan; Costa, Kyle; Adam, Rosalyn M.] Boston Childrens Hosp, Boston, MA USA.
[Doyle, Claire; Chung, Yeun Goo; Schaefer, Mattias; Sack, Bryan; Cristofaro, Vivian; Sullivan, Maryrose P.; Adam, Rosalyn M.] Harvard Univ, Sch Med, Boston, MA USA.
[Cristofaro, Vivian; Sullivan, Maryrose P.] VA Boston Healthcare Syst, West Roxbury, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
EI 1520-6777
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
PD FEB
PY 2016
VL 35
SU 1
MA BS18
BP S14
EP S14
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA DD2BF
UT WOS:000369726700020
ER
PT J
AU Hess, D
Raup, V
Hanske, J
Ozambela, M
Schmid, M
Thurmond, P
Varda, B
Trinh, QD
Eswara, J
AF Hess, Deborah
Raup, Valary
Hanske, Julian
Ozambela, Manuel
Schmid, Marianne
Thurmond, Portia
Varda, Briony
Quoc-Dien Trinh
Eswara, Jairam
TI PERIOPERATIVE OUTCOMES OF VESICOVAGINAL FISTULA REPAIR: VAGINAL VERSUS
ABDOMINAL SURGICAL APPROACH
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Meeting Abstract
CT Winter Meeting of the
Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct
ion
CY FEB 23-27, 2016
CL New Orleans, LA
SP Soc Urodynam Female Pelv Med & Urogenital Reconstruct
C1 [Hess, Deborah; Raup, Valary; Ozambela, Manuel; Varda, Briony; Quoc-Dien Trinh; Eswara, Jairam] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Hanske, Julian] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany.
[Schmid, Marianne] Ruhr Univ Bochum, Herne, Germany.
[Thurmond, Portia] VA Boston Healthcare Syst, West Roxbury, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
EI 1520-6777
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
PD FEB
PY 2016
VL 35
SU 1
MA NM122
BP S89
EP S89
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA DD2BF
UT WOS:000369726700219
ER
PT J
AU Kreydin, EI
Kim, MM
Oliver, JL
Cohen, SA
Ackerman, AL
Kim, JH
Raz, S
AF Kreydin, Evgeniy I.
Kim, Michelle M.
Oliver, Janine L.
Cohen, Seth A.
Ackerman, A. Lenore
Kim, Ja-Hong
Raz, Shlomo
TI HIGHER URINE LEVELS OF ENVIRONMENTAL TOXINS ARE ASSOCIATED WITH
INCREASED INCONTINENCE AND NOCTURIA IN MEN
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Meeting Abstract
CT Winter Meeting of the
Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct
ion
CY FEB 23-27, 2016
CL New Orleans, LA
SP Soc Urodynam Female Pelv Med & Urogenital Reconstruct
C1 [Kreydin, Evgeniy I.; Oliver, Janine L.; Cohen, Seth A.; Ackerman, A. Lenore; Kim, Ja-Hong; Raz, Shlomo] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Kim, Michelle M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
EI 1520-6777
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
PD FEB
PY 2016
VL 35
SU 1
MA NM15
BP S51
EP S51
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA DD2BF
UT WOS:000369726700117
ER
PT J
AU Kreydin, EI
Oliver, JL
Kim, MM
Ackerman, AL
Cohen, SA
Kim, JH
Raz, S
AF Kreydin, Evgeniy I.
Oliver, Janine L.
Kim, Michelle M.
Ackerman, A. Lenore
Cohen, Seth A.
Kim, Ja-Hong
Raz, Shlomo
TI 'TIL DEATH DO US PART: THE RELATIONSHIP BETWEEN URINARY INCONTINENCE AND
MARITAL STATUS AMONG US WOMEN AND MEN
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Meeting Abstract
CT Winter Meeting of the
Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct
ion
CY FEB 23-27, 2016
CL New Orleans, LA
SP Soc Urodynam Female Pelv Med & Urogenital Reconstruct
C1 [Kreydin, Evgeniy I.; Oliver, Janine L.; Ackerman, A. Lenore; Cohen, Seth A.; Kim, Ja-Hong; Raz, Shlomo] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Kim, Michelle M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
EI 1520-6777
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
PD FEB
PY 2016
VL 35
SU 1
MA NM14
BP S51
EP S51
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA DD2BF
UT WOS:000369726700116
ER
PT J
AU Vasquez, E
Bielenberg, D
Cristofaro, V
Sullivan, M
Adam, R
AF Vasquez, Evalynn
Bielenberg, Diane
Cristofaro, Vivian
Sullivan, Maryrose
Adam, Rosalyn
TI NEUROPILIN 2 DELETION ENHANCES DETRUSOR CONTRACTILITY UNDER CONDITIONS
OF BLADDER OUTLET OBSTRUCTION
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Meeting Abstract
CT Winter Meeting of the
Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct
ion
CY FEB 23-27, 2016
CL New Orleans, LA
SP Soc Urodynam Female Pelv Med & Urogenital Reconstruct
C1 [Vasquez, Evalynn; Bielenberg, Diane; Adam, Rosalyn] Boston Childrens Hosp, Boston, MA USA.
[Vasquez, Evalynn; Bielenberg, Diane] Harvard Univ, Sch Med, Boston, MA USA.
[Cristofaro, Vivian; Sullivan, Maryrose] VA Boston Healthcare Syst, West Roxbury, MA USA.
[Cristofaro, Vivian; Sullivan, Maryrose] Harvard Univ, Sch Med, West Roxbury, MA USA.
[Adam, Rosalyn] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
EI 1520-6777
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
PD FEB
PY 2016
VL 35
SU 1
MA BS25
BP S16
EP S17
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA DD2BF
UT WOS:000369726700027
ER
PT J
AU Jena, AB
Khullar, D
Ho, O
Olenski, AR
Blumenthal, DM
AF Jena, Anupam B.
Khullar, Dhruv
Ho, Oliver
Olenski, Andrew R.
Blumenthal, Daniel M.
TI Sex Differences in Academic Rank in US Medical Schools in 2014
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Editorial Material
ID PHYSICIAN-RESEARCHERS; GENDER-DIFFERENCES
AB The number of women entering medical schools in the United States has increased to the point where women make up half of all US graduates. However, sex disparities exist in senior faculty rank. Female physician researchers also earn less than do their male counterparts, even when adjusted for differences in academic productivity. Previous studies on this topic have several limitations, and none have considered these data along with factors such as experience, research funding, scientific authorship, and physician training. This study hypothesized that after adjustment for several factors-sex, age, years since residency completion, specialty, National Institutes of Health (NIH) research funding, scientific authorship, and clinical trial participation-sex differences in faculty rank would still exist.
A cross-sectional database of 1,005,419 physicians in the United States in 2014 was used to collect information. For each physician, data were assembled using NIH RePORT, PubMed, and ClinicalTrials.gov. Some of this information was self-verified by registered members, whereas some was supplied by institutions. The subgroup of registered members was analyzed first as those data were likely more accurate. Then, data on faculty rank, PubMed publications, clinical trial participation, and NIH funding weremanually confirmed for a random sample of 200. The data were analyzed using a multivariable logistic model to estimate the probability of full professorship as a function of the factors listed in the hypothesis. A subgroup was analyzed to compare differences in full professorship according to specialty and medical school research ranking (schools listed as top 20 in the United States according to US News & World Report in 2013 vs those not listed as top 20).
A total of 91,073 faculty members were included in the study. Of those, 66.5% were men. Compared with men, women were less likely to be full professors (11.9% [3623 of 30,464] vs 28.6% [17354 of 60,609]; absolute difference, -16.7%; 95% confidence interval [CI], -17.3% to -16.2%). Women tended to be specialized in internal medicine, obstetrics and gynecology, and pediatrics, on average, and were also younger and more recently completed residency. Representation of women at top 20 versus not top-ranked schools was similar (29.2% [8893 of 30,464] vs 28.3% [17,173 of 60,609]; difference, 0.9%; 95% CI, 0.7%-1.1%). Women were less likely than men to have conducted clinical trials (6.4% vs 8.8%; difference, -2.4% CI, -2.8% to 2.0%) and were also less likely to have NIH funding (6.8% vs 10.3%, difference, -3.5%; 95% CI, -2.8% to 2.0%). Women also had fewer first-or last-author publications than did their male peers (mean total, 11.6 vs 24.8, difference, -13.2; 95% CI, -13.6 to -12.7; mean first-or last-author publication; 5.9 vs 13.7; difference, -7.8; 95% CI, -8.1 to -7.5). Women were less likely to be full professor or associate or full professor by 2014 in 3 residency cohorts (1980, 1990, and 2000), and among faculty who were associate or full professor in 2014, fewer women than men were full professor across all cohorts.
After accounting for age, experience, specialty, and measures of research productivity, women were substantially less likely to be full professors in US medical schools. This study was limited by a number of factors, among those, the fact that it did not account for other leadership roles or administrative positions outside academic rank and did not account for sex differences in promotion.
C1 [Jena, Anupam B.; Ho, Oliver; Olenski, Andrew R.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Jena, Anupam B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Jena, Anupam B.] Natl Bur Econ Res, Cambridge, MA 02138 USA.
[Khullar, Dhruv] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Khullar, Dhruv; Blumenthal, Daniel M.] Harvard Univ, Sch Med, Boston, MA USA.
[Blumenthal, Daniel M.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Jena, AB (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.; Jena, AB (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.; Jena, AB (reprint author), Natl Bur Econ Res, Cambridge, MA 02138 USA.
NR 7
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7828
EI 1533-9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD FEB
PY 2016
VL 71
IS 2
BP 61
EP 62
DI 10.1097/01.ogx.0000480221.58767.1a
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DD4DW
UT WOS:000369873700001
ER
PT J
AU Dimitriou, D
Tsai, TY
Yue, B
Rubash, HE
Kwon, YM
Li, G
AF Dimitriou, D.
Tsai, T. -Y.
Yue, B.
Rubash, H. E.
Kwon, Y. -M.
Li, G.
TI Side-to-side variation in normal femoral morphology: 3D CT analysis of
122 femurs
SO ORTHOPAEDICS & TRAUMATOLOGY-SURGERY & RESEARCH
LA English
DT Article
DE Proximal femur; Asymmetry; Total hip arthroplasty; Offset; Anteversion;
Hip joint center; Geommetric morphometrics
ID TOTAL HIP-ARTHROPLASTY; JOINT; ANTEVERSION; ACCURACY; SYMMETRY
AB Background: The contralateral femur is often used as reference for reconstruction in unilateral hip joint pathology. The objective of this study was to quantify the side-to-side variation in proximal femur. We hypothesized that significant side-to-side differences exist between left and right femur with implications for preoperative planning and leg length discrepancy following hip arthroplasty.
Materials and methods: CT-based 3D femoral models were reconstructed for 122 paired femurs in 61 young healthy subjects (46.9 +/- 6.8 years) with no history of hip pathology. Side-to-side differences of several femoral morphologic parameters, including femoral head diameter, femoral anteversion, horizontal offset and femoral head center location, were compared and correlated with demographic factors using multiple linear regression.
Results: Significant side-to-side differences (P < 0.01) were found in femoral anteversion (4.3 +/- 3.8 degrees; range: 0.2 degrees to 17.3 degrees), horizontal offset (2.5 +/- 2.1 mm; range: 0.1 to 10.3 mm), and femoral head center location (7.1 +/- 3.8 mm; range: 0.5 to 19.4 mm). The difference in femoral anteversion was strongly correlated with the difference in neck diameter (R-2 = 0.79), whereas the difference in horizontal femoral offset was highly correlated with the head diameter difference (R-2 = 0.72). Femoral head center difference was correlated with the femoral anteversion, horizontal offset and neck-shaft-angle difference (R-2 = 0.82).
Discussion: Relying on the anatomic landmarks of the contralateral femur during hip arthroplasty may not necessarily result in restoration of native anatomy and leg-length. Knowledge of the baseline side-to-side asymmetry could provide a range of error that would be tolerable following hip reconstruction.
Level of evidence: Level IV.
Type of study: Retrospective observational study. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Dimitriou, D.; Tsai, T. -Y.; Rubash, H. E.; Kwon, Y. -M.; Li, G.] Harvard Univ, Massachusetts Gen Hosp, Dept Orthopaed Surg, Bioengn Lab,Med Sch Boston, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA.
[Yue, B.] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Orthoped, Shanghai 200030, Peoples R China.
RP Li, G (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Orthopaed Surg, Bioengn Lab,Med Sch Boston, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA.
EM gli1@mgh.harvard.edu
OI Dimitriou, Dimitris/0000-0002-9558-7080
NR 20
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER MASSON
PI MILANO
PA VIA PALEOCAPA 7, 20121 MILANO, ITALY
SN 1877-0568
J9 ORTHOP TRAUMATOL-SUR
JI Orthop. Traumatol.-Surg. Res.
PD FEB
PY 2016
VL 102
IS 1
BP 91
EP 97
DI 10.1016/j.otsr.2015.11.004
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DD6WC
UT WOS:000370064300015
PM 26867707
ER
PT J
AU Jemielita, TO
Leonard, MB
Baker, J
Sayed, S
Zemel, BS
Shults, J
Herskovitz, R
Denburg, MR
AF Jemielita, T. O.
Leonard, M. B.
Baker, J.
Sayed, S.
Zemel, B. S.
Shults, J.
Herskovitz, R.
Denburg, M. R.
TI Association of 25-hydroxyvitamin D with areal and volumetric measures of
bone mineral density and parathyroid hormone: impact of vitamin
D-binding protein and its assays
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bone mineral density; Parathyroid hormone; Vitamin D; Vitamin D-binding
protein
ID RANDOMIZED-CONTROLLED-TRIALS; NUTRITION EXAMINATION SURVEY; D
SUPPLEMENTATION; AFRICAN-AMERICAN; WHITE WOMEN; SERUM
25-HYDROXYVITAMIN-D; FRACTURE PREVENTION; NATIONAL-HEALTH; CALCIUM; MEN
AB A comparison of the association of different forms of 25-hydroxyvitamin D [25(OH)D] with parathyroid hormone (PTH) and with areal and volumetric bone mineral density (BMD) demonstrated that bioavailable and free 25(OH)D do not provide a better index of vitamin D status in terms of bone health compared to total 25(OH)D.
Introduction This study aims to compare measures of vitamin D-binding protein (DBP) using a monoclonal versus polyclonal ELISA and assess correlations of total versus estimated free and bioavailable 25(OH)D with BMD and PTH concentrations.
Methods DXA and peripheral quantitative CT (pQCT) scans were obtained in 304 adults (158 black, 146 white), ages 21-80 years. Free and bioavailable 25(OH)D were calculated from total 25(OH)D, DBP, and albumin concentrations. Multivariable linear regression with standardized beta coefficients was used to evaluate associations of bone measures and PTH with total, free, and bioavailable 25(OH)D.
Results Measures of DBP obtained using a monoclonal versus polyclonal ELISA were not correlated (r (s) = 0.02, p = 0.76). Free and bioavailable 25(OH)D based on the polyclonal assay were lower in black versus white participants (p < 0.0001); this race difference was not evident using the monoclonal assay. Adjusted for age, sex, calcium intake, and race, all forms of 25(OH)D were negatively associated with PTH, but the absolute coefficient was greatest for total 25(OH)D (-0.34, p < 0.001) versus free/bioavailable 25(OH)D (-0.18/-0.24 depending on DBP assay, p <= 0.003). In analyses stratified on race, none of the measures of 25(OH)D were associated with BMD across DXA and pQCT sites.
Conclusions The monoclonal versus polyclonal ELISA yielded highly discrepant measures of DBP, particularly among black individuals, likely related to established race differences in DBP polymorphisms. Contrary to prior studies, our findings indicate that using DBP to estimate bioavailable and free 25(OH)D does not provide a better index of vitamin D status in terms of bone health.
C1 [Jemielita, T. O.; Baker, J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Leonard, M. B.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Baker, J.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Sayed, S.; Herskovitz, R.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Zemel, B. S.; Shults, J.; Denburg, M. R.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.
RP Denburg, MR (reprint author), Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM denburgm@email.chop.edu
FU NIH [K23 DK093556, K24 DK076808, R01DK064966, T32DK060455]; Nephcure
Foundation-American Society of Nephrology Research Grant; Veterans
Affairs Clinical Science Research & Development Career Development Award
FX This project was supported by NIH Grants K23 DK093556 (MRD), K24
DK076808 (MBL and JS), R01DK064966 (MBL), and T32DK060455 (TJ). Dr.
Denburg was also funded by The Nephcure Foundation-American Society of
Nephrology Research Grant. The content is solely the responsibility of
the authors and does not necessarily represent the official views of the
NIH. Dr. Baker is supported by a Veterans Affairs Clinical Science
Research & Development Career Development Award. The contents of this
work do not represent the views of the Department of Veterans Affairs or
the United States Government. The funders had no role in the design and
conduct of the study; collection, management, analysis, and
interpretation of the data; or preparation, review, and approval of the
manuscript.
NR 53
TC 7
Z9 7
U1 1
U2 4
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
EI 1433-2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD FEB
PY 2016
VL 27
IS 2
BP 617
EP 626
DI 10.1007/s00198-015-3296-6
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DD6PN
UT WOS:000370046200020
PM 26359185
ER
PT J
AU Kaplan, AB
Kozin, ED
Remenschneider, A
Eftekhari, K
Jung, DH
Polley, DB
Lee, DJ
AF Kaplan, Alyson B.
Kozin, Elliott D.
Remenschneider, Aaron
Eftekhari, Kian
Jung, David H.
Polley, Daniel B.
Lee, Daniel J.
TI Amblyaudia: Review of Pathophysiology, Clinical Presentation, and
Treatment of a New Diagnosis
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Review
DE amblyaudia; conductive hearing loss; amblyopia; congenital hearing loss
ID CONDUCTIVE HEARING-LOSS; CHRONIC OTITIS-MEDIA; BILATERAL COCHLEAR
IMPLANTS; STEM AUDITORY NUCLEI; ACTION VIDEO GAME; QUALITY-OF-LIFE;
SOUND LOCALIZATION; BINAURAL HEARING; BINOCULAR VISION; SENSITIVE PERIOD
AB Objective Similar to amblyopia in the visual system, amblyaudia is a term used to describe persistent hearing difficulty experienced by individuals with a history of asymmetric hearing loss (AHL) during a critical window of brain development. Few clinical reports have described this phenomenon and its consequent effects on central auditory processing. We aim to (1) define the concept of amblyaudia and (2) review contemporary research on its pathophysiology and emerging clinical relevance.
Data Sources PubMed, Embase, and Cochrane databases.
Review Methods A systematic literature search was performed with combinations of search terms: amblyaudia, conductive hearing loss, sensorineural hearing loss, asymmetric, pediatric, auditory deprivation, and auditory development. Relevant articles were considered for inclusion, including basic and clinical studies, case series, and major reviews.
Conclusions During critical periods of infant brain development, imbalanced auditory input associated with AHL may lead to abnormalities in binaural processing. Patients with amblyaudia can demonstrate long-term deficits in auditory perception even with correction or resolution of AHL. The greatest impact is in sound localization and hearing in noisy environments, both of which rely on bilateral auditory cues. Diagnosis and quantification of amblyaudia remain controversial and poorly defined. Prevention of amblyaudia may be possible through early identification and timely management of reversible causes of AHL.
Implications for Practice Otolaryngologists, audiologists, and pediatricians should be aware of emerging data supporting amblyaudia as a diagnostic entity and be cognizant of the potential for lasting consequences of AHL. Prevention of long-term auditory deficits may be possible through rapid identification and correction.
C1 [Kaplan, Alyson B.; Kozin, Elliott D.; Remenschneider, Aaron; Jung, David H.; Polley, Daniel B.; Lee, Daniel J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Kaplan, Alyson B.; Kozin, Elliott D.; Remenschneider, Aaron; Jung, David H.; Polley, Daniel B.; Lee, Daniel J.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA.
[Eftekhari, Kian] Oculoplast Surg Inc, Salt Lake City, UT USA.
RP Kozin, ED (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, 243 Charles St, Boston, MA 02114 USA.
EM Elliott_Kozin@meei.harvard.edu
OI Polley, Daniel/0000-0002-5120-2409
FU NIDCD NIH HHS [R01 DC009836]
NR 99
TC 3
Z9 3
U1 6
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
EI 1097-6817
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD FEB
PY 2016
VL 154
IS 2
BP 247
EP 255
DI 10.1177/0194599815615871
PG 9
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA DD5VB
UT WOS:000369991600008
PM 26556464
ER
PT J
AU McMains, KC
AF McMains, Kevin Christopher
TI Response to "A Beacon of Emotional Resilience in a Storm of
Mistreatment?"
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Letter
C1 [McMains, Kevin Christopher] South Texas Vet Hlth Care Syst, Surg, San Antonio, TX USA.
RP McMains, KC (reprint author), South Texas Vet Hlth Care Syst, Surg, San Antonio, TX USA.
NR 5
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
EI 1097-6817
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD FEB
PY 2016
VL 154
IS 2
BP 398
EP 399
DI 10.1177/0194599815621529
PG 2
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA DD5VB
UT WOS:000369991600035
PM 26833650
ER
PT J
AU Bicket, MC
Hanna, GM
AF Bicket, Mark C.
Hanna, George M.
TI Intrathecal Pump Exposure to Electromagnetic Interference: A Report of
Device Interrogation following Multiple ECT Sessions
SO PAIN PHYSICIAN
LA English
DT Article
DE Baclofen; intrathecal drug delivery system; electromagnetic
interference; electroconvulsive therapy; safety; pump interrogation;
intrathecal pump; pump stall
ID DRUG-DELIVERY; SAFETY
AB Background: Intrathecal drug delivery systems represent an increasingly common treatment modality for patients with a variety of conditions, including chronic pain and spasticity. Pumps rely on electronic programming to properly control and administer highly concentrated medications. Electromagnetic interference (EMI) is a known exposure that may cause a potential patient safety issue stemming from direct patient injury, pump damage, or changes to pump operation or flow rate.
Objectives: The objective of our case report was to describe an approach to evaluating a patient with a pump prior to and following exposure to EMI from electroconvulsive therapy (ECT), as well as to document findings from device interrogations associated with this event.
Study Design: Case report.
Setting: Academic university-based pain management center.
Results: We present the case of a patient with an intrathecal pump who underwent multiple exposures to EMI in the form of 42 ECT sessions. Interrogation of the intrathecal drug delivery system revealed no safety issues following ECT sessions. At no time were error messages, unintentional changes in event logs, unintentional changes in pump settings, or evidence of pump stall or over-infusion noted.
Conclusion: Communication with multiple entities (patient, family, consulting physicians, and device manufacturer) and maintaining vigilance through device interrogation both before and after EMI exposure are appropriate safeguards to mitigate the risk and detect potential adverse events of EMI with intrathecal drug delivery systems. Given the infrequent reports of device exposure to ECT, best practices may be derived from experience with EMI exposure from magnetic resonance imaging (MRI). Although routine EMI exposure to intrathecal drug delivery systems should be avoided, we describe one patient with repeated exposure to ECT without apparent complication.
C1 [Bicket, Mark C.; Hanna, George M.] Massachusetts Gen Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02114 USA.
RP Bicket, MC (reprint author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 600 N Wolfe St, Baltimore, MD 21287 USA.
EM bicket@jhmi.edu
NR 7
TC 0
Z9 0
U1 0
U2 0
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD FEB
PY 2016
VL 19
IS 2
BP E343
EP E345
PG 3
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA DC1QI
UT WOS:000368991000009
PM 26815262
ER
PT J
AU Lai, ECC
Hsieh, CY
Wong, MB
Lin, SJ
Yang, YK
Yang, YHK
Setoguchi, S
AF Lai, Edward Chia-Cheng
Hsieh, Cheng-Yang
Wong, Monera B.
Lin, Swu-Jane
Yang, Yang-Kuang
Yang, Yea-Huei Kao
Setoguchi, Soko
TI Comparative risk of oral ulcerations among antipsychotics users -
population-based retrospective cohort study
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Article
DE antipsychotics; schizophrenia; oral health; aripiprazole; sulpiride;
olanzapine; quetiapine; pharmacoepidemiology
ID INDUCED SIALORRHEA; PHYSICAL-ACTIVITIES; OLDER-ADULTS; DRY MOUTH;
HEALTH; PREVALENCE; SCHIZOPHRENIA; OUTPATIENTS; XEROSTOMIA; MEDICATION
AB PurposeThe study aimed to evaluate the comparative risk of oral ulcerations among antipsychotic medications.
MethodsWe analyzed the National Health Insurance Research Database of Taiwan and included patients newly initiated with a single antipsychotic agent including haloperidol, sulpiride, olanzapine, quetiapine, risperidone, or amisulpride during 2002 to 2010. The outcome of interest was oral ulceration, defined by the presence diagnoses of stomatitis and mucositis, aphthous-like ulceration and oral burns, or dispensing of stomatological corticosteroids included triamcinolone, dexamethasone, hydrocortisone, and prednisolone. We conducted Cox proportional hazards regression to compare the risks of oral ulceration among antipsychotics.
ResultsThe rate of oral ulcerations was highest in the amisulpride group (217.7 per 1000 person-year), followed by quetiapine (193.9 per 1000 person-year), olanzapine (161.9 per 1000 person-year), sulpiride (147.1 per 1000 person-year), risperidone (115.6 per 1000 person-year), haloperidol (107.5 per 1000 person-year) and aripiprazole (49.8 per 1000 person-year). Compared with haloperidol users, the adjusted hazard ratio (AHR) was 1.40 (95% CI, 1.12-1.73) in olanzapine, 1.48 (95% CI, 1.30-1.69) in quetiapine, 1.27 (95% CI, 1.19-1.44) in sulpiride, 1.68 (95% CI, 0.97-2.59) in amisulpride, 1.02 (95% CI, 0.83-1.45) in risperidone, and 0.41 (95% CI, 0.24-0.72) in aripiprazole users by Cox regression model.
ConclusionOlanzapine, quetiapine, and sulpiride posed a higher risk, while aripiprazole posed a lower risk of oral ulcerations compared with haloperidol in subjects with newly initiated antipsychotic therapy. Risperidone and amisulpride tended to have higher risk of oral ulcerations, but this was not statistically significant. Copyright (c) 2015 John Wiley & Sons, Ltd.
C1 [Lai, Edward Chia-Cheng; Setoguchi, Soko] Duke Clin Res Inst, Durham, NC USA.
[Lai, Edward Chia-Cheng; Setoguchi, Soko] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA.
[Lai, Edward Chia-Cheng; Hsieh, Cheng-Yang; Yang, Yea-Huei Kao] Natl Cheng Kung Univ, Sch Pharm, Tainan 701, Taiwan.
[Lai, Edward Chia-Cheng; Hsieh, Cheng-Yang; Yang, Yea-Huei Kao] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Tainan 701, Taiwan.
[Lai, Edward Chia-Cheng; Yang, Yea-Huei Kao] Natl Cheng Kung Univ, Hlth Outcome Res Ctr, Tainan 701, Taiwan.
[Hsieh, Cheng-Yang] Tainan Sin Lau Hosp, Dept Neurol, Tainan, Taiwan.
[Wong, Monera B.] Massachusetts Gen Hosp, Geriatr Med Unit, Boston, MA 02114 USA.
[Lin, Swu-Jane] Univ Illinois, Coll Pharm, Dept Pharm Adm, Chicago, IL USA.
[Yang, Yang-Kuang] Natl Cheng Kung Univ Hosp, Dept Psychiat, Tainan 70428, Taiwan.
[Yang, Yang-Kuang] Natl Cheng Kung Univ, Coll Med, Tainan 70101, Taiwan.
RP Yang, YHK (reprint author), Natl Cheng Kung Univ, Sch Pharm, Coll Med, 1 Univ Rd, Tainan 701, Taiwan.; Yang, YHK (reprint author), Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Coll Med, 1 Univ Rd, Tainan 701, Taiwan.
EM yhkao@mail.ncku.edu.tw
NR 43
TC 0
Z9 0
U1 3
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD FEB
PY 2016
VL 25
IS 2
BP 123
EP 132
DI 10.1002/pds.3903
PG 10
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA DD6TA
UT WOS:000370056200002
PM 26549190
ER
PT J
AU Axon, RN
Cole, L
Moonan, A
Foster, R
Cawley, P
Long, L
Turley, CB
AF Axon, R. Neal
Cole, Laura
Moonan, Aunyika
Foster, Richard
Cawley, Patrick
Long, Laura
Turley, Christine B.
TI Evolution and Initial Experience of a Statewide Care Transitions Quality
Improvement Collaborative: Preventing Avoidable Readmissions Together
SO POPULATION HEALTH MANAGEMENT
LA English
DT Article
ID HOSPITAL READMISSION; HEART-FAILURE; REHOSPITALIZATIONS; RISK
AB Increasing scrutiny of hospital readmission rates has spurred a wide variety of quality improvement initiatives. The Preventing Avoidable Readmissions Together (PART) initiative is a statewide quality improvement learning collaborative organized by stakeholder organizations in South Carolina. This descriptive report focused on initial interventions with hospitals. Eligible participants included all acute care hospitals plus home health organizations, nursing facilities, hospices, and other health care organizations. Measures were degree of statewide participation, curricular engagement, adoption of evidence-based improvement strategies, and readmission rate changes. Fifty-nine of 64 (92%) acute care hospitals and 9 of 10 (90%) hospital systems participated in collaborative events. Curricular engagement included: webinars and coaching calls (49/59, 83%), statewide in-person meetings (35/59, 59%), regional in-person meetings (44/59, 75%), and individualized consultations (46/59, 78%). Among 34 (58%) participating hospitals completing a survey at the completion of Year 1, respondents indicated complete implementation of multidisciplinary rounding (58%), post-discharge telephone calls (58%), and teach-back (32%), and implementation in process of high-quality transition records (52%), improved discharge summaries (45%), and timely follow-up appointments (39%). A higher proportion of hospitals had significant decreases (10% relative change) in all-cause readmission rates for acute myocardial infarction (55.6% vs. 30.4%, P=0.01), heart failure (54.2% vs. 31.7%, P=0.09), and chronic obstructive pulmonary disease (41.7% vs. 33.3%, P=0.83) between 2011-2013 compared to earlier (2009-2011) trends. Focus on reducing readmissions is driving numerous, sometimes competing, quality improvement initiatives. PART successfully engaged the majority of acute care facilities in one state to harmonize and accelerate adoption of evidence-based care transitions strategies. (Population Health Management 2016;19:4-10)
C1 [Axon, R. Neal] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Axon, R. Neal; Cawley, Patrick] Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA.
[Cole, Laura; Moonan, Aunyika; Foster, Richard] South Carolina Hosp Assoc, Columbia, SC USA.
[Long, Laura] BlueCross BlueShield South Carolina, Columbia, SC USA.
[Turley, Christine B.] Hlth Sci S Carolina, Columbia, SC USA.
[Turley, Christine B.] Univ S Carolina, Sch Med, Columbia, SC USA.
RP Axon, RN (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA.; Axon, RN (reprint author), Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA.; Axon, RN (reprint author), 109 Bee St,Mail Code 111, Charleston, SC 29401 USA.
EM axon@musc.edu
NR 19
TC 1
Z9 1
U1 4
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1942-7891
EI 1942-7905
J9 POPUL HEALTH MANAG
JI Popul. Health Manag.
PD FEB 1
PY 2016
VL 19
IS 1
BP 4
EP 10
DI 10.1089/pop.2014.0182
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DD4DO
UT WOS:000369872900002
PM 26102592
ER
PT J
AU Yu, LL
Rodriguez, RA
Chen, LL
Chen, LY
Perry, G
McHardy, SF
Yeh, CK
AF Yu, Lili
Rodriguez, Roberto A.
Chen, L. Laurie
Chen, Liao Y.
Perry, George
McHardy, Stanton F.
Yeh, Chih-Ko
TI 1,3-propanediol binds deep inside the channel to inhibit water
permeation through aquaporins
SO PROTEIN SCIENCE
LA English
DT Article
DE ligand-protein interaction; aquaporin inhibitor; molecular dynamics
ID X-RAY-STRUCTURE; NEPHROGENIC DIABETES-INSIPIDUS; PLASMODIUM-FALCIPARUM;
MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; FREE-ENERGY; BRAIN; MICE;
AQUAGLYCEROPORIN; TRAFFICKING
AB Aquaporins and aquaglyceroporins (AQPs) are membrane channel proteins responsible for transport of water and for transport of glycerol in addition to water across the cell membrane, respectively. They are expressed throughout the human body and also in other forms of life. Inhibitors of human AQPs have been sought for therapeutic treatment for various medical conditions including hypertension, refractory edema, neurotoxic brain edema, and so forth. Conducting all-atom molecular dynamics simulations, we computed the binding affinity of acetazolamide to human AQP4 that agrees closely with in vitro experiments. Using this validated computational method, we found that 1,3-propanediol (PDO) binds deep inside the AQP4 channel to inhibit that particular aquaporin efficaciously. Furthermore, we used the same method to compute the affinities of PDO binding to four other AQPs and one aquaglyceroporin whose atomic coordinates are available from the protein data bank (PDB). For bovine AQP1, human AQP2, AQP4, AQP5, and Plasmodium falciparum PfAQP whose structures were resolved with high resolution, we obtained definitive predictions on the PDO dissociation constant. For human AQP1 whose PDB coordinates are less accurate, we estimated the dissociation constant with a rather large error bar. Taking into account the fact that PDO is generally recognized as safe by the US FDA, we predict that PDO can be an effective diuretic which directly modulates water flow through the protein channels. It should be free from the serious side effects associated with other diuretics that change the hydro-homeostasis indirectly by altering the osmotic gradients.
C1 [Yu, Lili; Rodriguez, Roberto A.; Chen, Liao Y.] Univ Texas San Antonio, Dept Phys, One UTSA Circle, San Antonio, TX 78249 USA.
[Chen, L. Laurie] Univ Texas SW Med Ctr Dallas, Sch Med, Dallas, TX 75390 USA.
[Perry, George] Univ Texas San Antonio, Dept Biol, San Antonio, TX 78249 USA.
[McHardy, Stanton F.] Univ Texas San Antonio, Dept Chem, San Antonio, TX 78249 USA.
[Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA.
[Yeh, Chih-Ko] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX 78229 USA.
[Yu, Lili] Yancheng Vocat Inst Hlth Sci, Dept Lab Med, Yancheng 224006, Jiangsu, Peoples R China.
RP Chen, LY (reprint author), Univ Texas San Antonio, Dept Phys, One UTSA Circle, San Antonio, TX 78249 USA.
EM Liao.chen@utsa.edu
RI Chen, Liao/B-8037-2009; Perry, George/A-8611-2009;
OI Chen, Liao/0000-0003-1911-8634; Perry, George/0000-0002-6547-0172;
Rodriguez, Roberto/0000-0002-3303-9564
FU NIH [GM 084834]
FX Grant sponsor: NIH; Grant number: GM 084834.
NR 62
TC 1
Z9 1
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0961-8368
EI 1469-896X
J9 PROTEIN SCI
JI Protein Sci.
PD FEB
PY 2016
VL 25
IS 2
BP 433
EP 441
DI 10.1002/pro.2832
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DD3JW
UT WOS:000369819500012
PM 26481430
ER
PT J
AU Rasmussen, V
Turnell, A
Butow, P
Juraskova, I
Kirsten, L
Wiener, L
Patenaude, A
Hoekstra-Weebers, J
Grassi, L
AF Rasmussen, Victoria
Turnell, Adrienne
Butow, Phyllis
Juraskova, Ilona
Kirsten, Laura
Wiener, Lori
Patenaude, Andrea
Hoekstra-Weebers, Josette
Grassi, Luigi
CA IPOS Res Committee
TI Burnout among psychosocial oncologists: an application and extension of
the effort-reward imbalance model
SO PSYCHO-ONCOLOGY
LA English
DT Article
ID CAREER-SUSTAINING BEHAVIORS; SELF-REPORTED HEALTH; PROFESSIONAL
PSYCHOLOGISTS; OVER-COMMITMENT; MENTAL-HEALTH; WORK; NURSES;
OVERCOMMITMENT; STRESS
AB ObjectivesBurnout is a significant problem among healthcare professionals working within the oncology setting. This study aimed to investigate predictors of emotional exhaustion (EE) and depersonalisation (DP) in psychosocial oncologists, through the application of the effort-reward imbalance (ERI) model with an additional focus on the role of meaningful work in the burnout process.
MethodsPsychosocial oncology clinicians (n=417) in direct patient contact who were proficient in English were recruited from 10 international psychosocial oncology societies. Participants completed an online questionnaire, which included measures of demographic and work characteristics, EE and DP subscales of the Maslach Burnout Inventory-Human Services Survey, the Short Version ERI Questionnaire and the Work and Meaning Inventory.
ResultsHigher effort and lower reward were both significantly associated with greater EE, although not DP. The interaction of higher effort and lower reward did not predict greater EE or DP. Overcommitment predicted both EE and DP but did not moderate the impact of effort and reward on burnout. Overall, the ERI model accounted for 33% of the variance in EE. Meaningful work significantly predicted both EE and DP but accounted for only 2% more of the variance in EE above and beyond the ERI model.
ConclusionsThe ERI was only partially supported as a useful framework for investigating burnout in psychosocial oncology professionals. Meaningful work may be a viable extension of the ERI model. Burnout among health professionals may be reduced by interventions aimed at increasing self-efficacy and changes to the supportive work environment. Copyright (c) 2015 John Wiley & Sons, Ltd.
C1 [Rasmussen, Victoria; Turnell, Adrienne; Butow, Phyllis; Juraskova, Ilona] Univ Sydney, Sch Psychol, Level 6 North,Lifehouse C39Z, Sydney, NSW 2006, Australia.
[Butow, Phyllis; Juraskova, Ilona; Kirsten, Laura] Univ Sydney, Sch Psychol, Ctr Med Psychol & Evidence Based Decis Making CeM, Sydney, NSW 2006, Australia.
[Butow, Phyllis] Univ Sydney, Psychooncol Cooperat Res Grp PoCoG, Sydney, NSW 2006, Australia.
[Kirsten, Laura] Sydney West Canc Network, Nepean Canc Care Ctr, Westmead, NSW, Australia.
[Wiener, Lori] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Patenaude, Andrea] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hoekstra-Weebers, Josette] Univ Groningen, Univ Med Ctr, Wenckebach Inst, Groningen, Netherlands.
[Grassi, Luigi] Univ Ferrara, Inst Psychiat, Dept Biomed & Special Surg Sci, I-44100 Ferrara, Italy.
RP Butow, P (reprint author), Univ Sydney, Sch Psychol, Level 6 North,Lifehouse C39Z, Sydney, NSW 2006, Australia.
EM phyllis.butow@sydney.edu.au
FU Intramural NIH HHS [Z99 CA999999]
NR 40
TC 2
Z9 2
U1 10
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2016
VL 25
IS 2
BP 194
EP 202
DI 10.1002/pon.3902
PG 9
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA DD5RH
UT WOS:000369981400010
PM 26239424
ER
PT J
AU Stewart, RW
Tuerk, PW
Metzger, IW
Davidson, TM
Young, J
AF Stewart, Regan W.
Tuerk, Peter W.
Metzger, Isha W.
Davidson, Tatiana M.
Young, John
TI A Decision-Tree Approach to the Assessment of Posttraumatic Stress
Disorder: Engineering Empirically Rigorous and Ecologically Valid
Assessment Measures
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE PTSD; assessment; screening; decision-tree analysis; veterans
ID ADMINISTERED PTSD SCALE; MENTAL-HEALTH; TREATMENT SEEKING; VIETNAM
VETERANS; ASSESSMENT TOOLS; PRIMARY-CARE; CLINICIAN; CLASSIFICATION;
SAMPLE; ADOLESCENTS
AB Structured diagnostic interviews are widely considered to be the optimal method of assessing symptoms of posttraumatic stress; however, few clinicians report using structured assessments to guide clinical practice. One commonly cited impediment to these assessment approaches is the amount of time required for test administration and interpretation. Empirically keyed methods to reduce the administration time of structured assessments may be a viable solution to increase the use of standardized and reliable diagnostic tools. Thus, the present research conducted an initial feasibility study using a sample of treatment-seeking military veterans (N = 1,517) to develop a truncated assessment protocol based on the Clinician-Administered Posttraumatic Stress Disorder (PTSD) Scale (CAPS). Decision-tree analysis was utilized to identify a subset of predictor variables among the CAPS items that were most predictive of a diagnosis of PTSD. The algorithm-driven, atheoretical sequence of questions reduced the number of items administered by more than 75% and classified the validation sample at 92% accuracy. These results demonstrated the feasibility of developing a protocol to assess PTSD in a way that imposes little assessment burden while still providing a reliable categorization.
C1 [Stewart, Regan W.; Tuerk, Peter W.; Metzger, Isha W.; Davidson, Tatiana M.; Young, John] Med Univ S Carolina, Dept Psychol & Behav Sci, 67 President St,2nd Floor,South Bldg,MSC 861, Charleston, SC 29425 USA.
[Tuerk, Peter W.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA.
[Young, John] Univ Mississippi, Dept Psychol, University, MS 38677 USA.
RP Stewart, RW (reprint author), Med Univ S Carolina, Dept Psychol & Behav Sci, 67 President St,2nd Floor,South Bldg,MSC 861, Charleston, SC 29425 USA.
EM stewartr@musc.edu
FU Career Development Award from the Department of Veterans Affairs,
Veterans Health Administration, Office of Research and Development,
Clinical Sciences Research and Development [CDA-2]
FX Peter W. Tuerk's contribution to this article was partially supported by
a Career Development Award (CDA-2) from the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development, Clinical Sciences Research and Development (principal
investigator: Peter W. Tuerk).
NR 70
TC 1
Z9 1
U1 3
U2 8
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
EI 1939-148X
J9 PSYCHOL SERV
JI Psychol. Serv.
PD FEB
PY 2016
VL 13
IS 1
BP 1
EP 9
DI 10.1037/ser0000069
PG 9
WC Psychology, Clinical
SC Psychology
GA DD0FJ
UT WOS:000369595500001
PM 26654473
ER
PT J
AU Keller, SM
Tuerk, PW
AF Keller, Stephanie M.
Tuerk, Peter W.
TI Evidence-Based Psychotherapy (EBP) Non-Initiation Among Veterans Offered
an EBP for Posttraumatic Stress Disorder
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE PTSD; treatment initiation; veterans; evidence-based psychotherapy
ID PROLONGED EXPOSURE THERAPY; COGNITIVE PROCESSING THERAPY;
MENTAL-HEALTH-SERVICES; TRAUMATIC BRAIN-INJURY; PTSD TREATMENT;
AFGHANISTAN VETERANS; IRAQ; CARE; IMPLEMENTATION; ADHERENCE
AB Current efforts to disseminate evidence-based psychotherapies (EBPs) for posttraumatic stress disorder (PTSD) in Veterans Affairs Medical Centers (VAMCs) have made effective treatment options more available throughout the system. Yet many veterans identified as likely to benefit from such services choose not to utilize them. The evidence base retarding factors that contribute to treatment initiation among those offered EBPs is still in its early-stages. The present study investigated clinical presentation, patient demographics, and environment of care factors as potential predictors of EBP treatment initiation among veterans offered such care,. The sample consisted of 324 Veterans (62% Operation Enduring Freedom [OEF]/Operation Iraqi Freedom [OM; 77% male; age M = 42.95 SD = 12.57 years), who attended an intake evaluation at a VAMC outpatient PTSD Clinical Team, were diagnosed with PTSD, and offered a course of EBP. Overall, 720 of veterans (11 = 232) who were offered an FOP initiated such treatment, and 28% of veterans (n = 92) did not initiate treatment. Veterans who initiated treatment were significantly older. Treatment initiation did not significantly differ by ethnicity, gender, or baseline PTSD severity. Significantly more veterans referred from mental health clinics initiated treatment than did veterans referred from primary care. This study examined treatment initiation among veterans who were offered FOP for PTSD. Rates of initiation differed across subgroups of veterans. Clinically, this suggests the need to tailor outreach efforts to younger veterans, OEF/OLF veterans, and veterans referred from primary care, and potentially including programming and education aimed at primary care referrers, to increase help-seeking.
C1 [Keller, Stephanie M.; Tuerk, Peter W.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA.
[Keller, Stephanie M.; Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA.
RP Keller, SM (reprint author), Ralph H Johnson VA Med Ctr, Menhil Hlth, 109 Bee St,116, Charleston, SC 29401 USA.
EM smp28@case.edu
FU CDA-2 award from the Department of Veteran Affairs, Veterans Health
Administration, Office of Research and Development, Clinical Sciences
Research and Development [NCT01031979]
FX Peter W. Tuerk's contribution to his research was supported in part by
funding from a CDA-2 award from the Department of Veteran Affairs,
Veterans Health Administration, Office of Research and Development,
Clinical Sciences Research and Development (principal investigator:
Peter W. Tuerk; NCT01031979).
NR 40
TC 0
Z9 0
U1 2
U2 3
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
EI 1939-148X
J9 PSYCHOL SERV
JI Psychol. Serv.
PD FEB
PY 2016
VL 13
IS 1
BP 42
EP 48
DI 10.1037/ser0000064
PG 7
WC Psychology, Clinical
SC Psychology
GA DD0FJ
UT WOS:000369595500005
PM 26654474
ER
PT J
AU Di Leone, BAL
Wang, JM
Kressin, N
Vogt, D
AF Di Leone, Brooke A. L.
Wang, Joyce M.
Kressin, Nancy
Vogt, Dawne
TI Women's Veteran Identity and Utilization of VA Health Services
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE veterans; identity; health services; veteran identity; mental health
ID POSTTRAUMATIC-STRESS-DISORDER; GROUP IDENTIFICATION; PSYCHOMETRIC
PROPERTIES; ADMINISTRATION CARE; SOCIAL IDENTITY; SELF-ESTEEM;
DEPRESSION; DEPLOYMENT; INVENTORY; GENDER
AB Women have participated in the United States military since its founding. However, until the mid-20th century, there had been limited recognition of women as official members of the military, and women remain a statistical minority within military and veteran populations. It is therefore important to better understand women's veteran identity (which we define here as one's self-concept as derived from their veteran status) and associated implications for service use and experiences in the Department of Veterans Affairs (VA) health care setting. The present research examined the centrality of, and positive regard for, women's veteran identity among 407 female veterans deployed in support of the recent wars in Iraq and Afghanistan. Data were collected via a mailed national survey. Positive regard for veteran identity, but not veteran identity centrality, was positively associated with participants' age and length of time spent in the military. Results also showed that the centrality of women's veteran identity was positively related to their choice to use VA for health care and their feelings of belonging within VA, and that veteran identity centrality and positive regard for veteran identity are differentially associated with participants' military experiences (e.g., combat exposure, deployment sexual harassment) and mental health symptomatology (e.g., depression).
C1 [Di Leone, Brooke A. L.; Vogt, Dawne] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Wang, Joyce M.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA.
[Kressin, Nancy] VA Boston Healthcare Syst, Hlth Serv Res & Dev Serv, Boston, MA USA.
[Wang, Joyce M.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Kressin, Nancy] Boston Univ, Sch Med, Gen Internal Med Sect, Boston, MA 02118 USA.
[Vogt, Dawne] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Wang, Joyce M.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
RP Di Leone, BAL (reprint author), Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, 3900 Woodland Ave,Annex Bldg,CHERP Suite 202, Philadelphia, PA 19147 USA.
EM brooke.dileone@va.gov
FU Department of Veterans Affairs Health Sciences Research and Development
Service [DHI 06-225-2]; Department of Veterans Affairs, Health Services
Research & Development Service [RCS 02-066-1]
FX This research was supported, in part, by a Department of Veterans
Affairs Health Sciences Research and Development Service grant (DHI
06-225-2; Gender, Stigma, and Other Barriers to Veterans Health
Administration (VITA) Use for Operation Enduring Freedom (OEF)/Operation
Iraqi Freedom (OIF) Veterans; PI: Dawne Vogt). Nancy Kressin is also
supported in part by a Research Career Scientist award from the
Department of Veterans Affairs, Health Services Research & Development
Service (RCS 02-066-1). The views expressed in this article are those of
the authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or the United States government.
NR 48
TC 2
Z9 2
U1 1
U2 4
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
EI 1939-148X
J9 PSYCHOL SERV
JI Psychol. Serv.
PD FEB
PY 2016
VL 13
IS 1
BP 60
EP 68
DI 10.1037/ser0000021
PG 9
WC Psychology, Clinical
SC Psychology
GA DD0FJ
UT WOS:000369595500008
PM 25729892
ER
PT J
AU Johnson, L
Shipherd, J
Walton, HM
AF Johnson, Laura
Shipherd, Jillian
Walton, Heather M.
TI The Psychologist's Role in Transgender-Specific Care With US Veterans
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE transgender; veteran; military; psychology; LOGT
ID MINORITY VETERANS; MENTAL-HEALTH; PROVIDERS; STRESS
AB Psychologists are integral to the care of transgender individuals. This article details the many roles for psychologists in transgender-specific care, including diagnosing and treating gender dysphoria; providing treatment for comorbid conditions; referring to medical services such as gender confirmation surgeries, voice modification, and cross-sex hormone therapies; serving as consultants within health care systems; and advocating for addressing harriers in systems in which transgender individuals live and work. Transgender veterans have unique experiences and vulnerabilities related to their military service that are detailed from a review of the literature, and we make the case that Veterans Health Administration (VITA) and community psychologists are well-positioned to provide care to transgender veterans (trans-vets). In this article, the authors describe the experiences that many trans-vets have faced, identify the importance of treatment for gender dysphoria (and draw the distinction between gender identity disorder and gender dysphoria) as well as psychologists' roles, and clarify which transgender-related services are available to eligible veterans though VHA per policy and how VHA providers have access to training to provide that care. In addition, we describe how veterans can connect to the VITA, even if they have (and want to continue working with) non-VITA psychologists or other community providers.
C1 [Johnson, Laura] Edith Nourse Rogers Mem Vet Hosp, Psychol Serv, Bedford, MA USA.
[Shipherd, Jillian] Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA USA.
[Shipherd, Jillian] Vet Affairs Boston Healthcare Syst, Boston, MA USA.
[Shipherd, Jillian] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Shipherd, Jillian] Vet Affairs Cent Off, Patient Care Serv, Washington, DC USA.
[Walton, Heather M.] Vet Affairs Boston Healthcare Syst, Psychol Serv, Brockton, MA USA.
[Walton, Heather M.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA.
RP Johnson, L (reprint author), USAF, 60 MDOS SGOW, Fairfield, CA 94535 USA.
EM laura.johnson9@va.gov
FU Department of Veterans Affairs, Veterans Health Administration
FX The views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs, U.S. Air Force, Department of Defense, or the U.S. government.
This material is based on work supported by the Department of Veterans
Affairs, Veterans Health Administration.
NR 36
TC 6
Z9 6
U1 3
U2 6
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
EI 1939-148X
J9 PSYCHOL SERV
JI Psychol. Serv.
PD FEB
PY 2016
VL 13
IS 1
BP 69
EP 76
DI 10.1037/ser0000030
PG 8
WC Psychology, Clinical
SC Psychology
GA DD0FJ
UT WOS:000369595500010
PM 25961643
ER
PT J
AU Jahn, DR
Bennett, ME
Park, SG
Gur, RE
Horan, WP
Kring, AM
Blanchard, JJ
AF Jahn, Danielle R.
Bennett, Melanie E.
Park, Stephanie G.
Gur, Raquel E.
Horan, William P.
Kring, Ann M.
Blanchard, Jack J.
TI The interactive effects of negative symptoms and social role functioning
on suicide ideation in individuals with schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Social anhedonia; Social closeness; Belonging; Moderation; Protective
factors
ID PSYCHIATRIC RATING-SCALE; RISK-FACTORS; DEPRESSIVE SYMPTOMS; COMPLETED
SUICIDE; DISORDERS; ANHEDONIA; LIFE; MOTIVATION; COMMUNITY; SPECTRUM
AB Findings regarding the protective effect of social role functioning on suicide ideation in individuals with schizophrenia have been mixed. One reason for such inconsistencies in the literature may be that individuals with prominent negative symptoms of schizophrenia may not experience a desire for social closeness, and therefore social role functioning may not influence suicide risk in these individuals. The aim of this study was to examine the moderating effects of self-reported desire for social closeness and interviewer-rated negative symptoms on the relationship between social role functioning and suicide ideation. Our sample consisted of 162 individuals who had been diagnosed with schizophrenia-spectrum disorders; all participants completed self-report questionnaires and clinician-administered interviews, and moderation hypotheses were tested with a non parametric procedure. The results indicated that motivation and pleasure-related negative symptoms moderated the relationship between social role functioning and suicide ideation; self-reported desire for social closeness and negative symptoms related to expression did not have such a moderating effect. Specifically, better social role functioning was associated with less suicide ideation only in those individuals who had low motivation and pleasure-related negative symptoms; no significant relationship was observed between social role functioning and suicide ideation among those with elevated motivation and pleasure-related negative symptoms. These findings suggest that assessing for negative symptoms and social role functioning may inform suicide risk assessments in individuals with schizophrenia, and improving social role functioning may reduce suicide ideation among those with few motivation and pleasure-related negative symptoms. (c) 2015 Elsevier B.V. All rights reserved.
C1 [Jahn, Danielle R.; Bennett, Melanie E.; Park, Stephanie G.] VA Maryland Hlth Care Syst, VA Capitol Hlth Care Network VISN 5, Mental Illness Res Educ & Clin Ctr, 10 N Greene St Annex Room 723A, Baltimore, MD 21201 USA.
[Jahn, Danielle R.; Bennett, Melanie E.; Park, Stephanie G.] Univ Maryland, Sch Med, Dept Psychiat, 737 W Lombard St,Suite 551, Baltimore, MD 21201 USA.
[Gur, Raquel E.] Univ Penn, Perelman Sch Med, Dept Psychiat, 10th Floor Gates Bldg, Philadelphia, PA 19104 USA.
[Horan, William P.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Jane & Terry Semel Inst Neurosci & Human Behav, 760 Westwood Plaza, Los Angeles, CA 90095 USA.
[Horan, William P.] VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 210,Mail Code 210A, Los Angeles, CA 90073 USA.
[Kring, Ann M.] Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall, Berkeley, CA 94720 USA.
[Blanchard, Jack J.] Univ Maryland, Dept Psychol, 1147 Biol Psychol Bldg, College Pk, MD 20742 USA.
RP Blanchard, JJ (reprint author), Univ Maryland, 1147 Biol Psychol Bldg, College Pk, MD 20742 USA.
EM danielle.jahn@va.gov; mbennett@p.sych.umaryland.edu;
stephanie.park3@va.gov; raquel@upenn.edu; horan@ucla.edu;
kring@berkeley.edu; jblancha@umd.edu
FU NIH [1R01MH082839]; Office of Academic Affiliations, Advanced Fellowship
Program in Mental Illness Research and Treatment, Department of Veterans
Affairs
FX This work was supported by NIH grant (1R01MH082839) to Dr. Blanchard.
Writing of this manuscript was supported by the Office of Academic
Affiliations, Advanced Fellowship Program in Mental Illness Research and
Treatment, Department of Veterans Affairs (Dr. Jahn and Dr. Park's
time). The funding sources had no role in study design or in the
collection, analysis and interpretation of data, or in the writing of
this report.
NR 43
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
EI 1573-2509
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD FEB
PY 2016
VL 170
IS 2-3
BP 271
EP 277
DI 10.1016/j.schres.2015.12.011
PG 7
WC Psychiatry
SC Psychiatry
GA DD0LS
UT WOS:000369612100006
PM 26746862
ER
PT J
AU Manchikanti, L
Kaye, AD
Hirsch, JA
AF Manchikanti, Laxmaiah
Kaye, Alan David
Hirsch, Joshua A.
TI Short-term Improvements in Disability Mediate Patient Satisfaction After
Epidural Corticosteroid Injections for Symptomatic Lumbar Spinal
Stenosis
SO SPINE
LA English
DT Letter
ID RANDOMIZED-TRIAL
C1 [Manchikanti, Laxmaiah] Univ Louisville, Louisville, KY 40292 USA.
[Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA.
[Kaye, Alan David] LSU Hlth Sci Ctr, Dept Anesthesia, New Orleans, LA USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Manchikanti, L (reprint author), Univ Louisville, Louisville, KY 40292 USA.; Manchikanti, L (reprint author), Pain Management Ctr Paducah, Paducah, KY USA.
EM drlm@thepainmd.com
NR 3
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362-2436
EI 1528-1159
J9 SPINE
JI SPINE
PD FEB
PY 2016
VL 41
IS 3
BP E183
EP E183
DI 10.1097/BRS.0000000000001357
PG 1
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA DD5VS
UT WOS:000369993400001
ER
PT J
AU Manchikanti, L
Kaye, AD
Hirsch, JA
AF Manchikanti, Laxmaiah
Kaye, Alan David
Hirsch, Joshua A.
TI Re: Suri, P. et al. Short-term Improvements in Disability Mediate
Patient Satisfaction After Epidural Corticosteroid Injections for
Symptomatic Lumbar Spinal Stenosis. Spine (Phila Pa 1976) 2015 May 22.
SO SPINE
LA English
DT Letter
ID RANDOMIZED-TRIAL
C1 [Manchikanti, Laxmaiah] Univ Louisville, Louisville, KY 40292 USA.
[Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA.
[Kaye, Alan David] LSU Hlth Sci Ctr, Dept Anesthesia, New Orleans, LA USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Manchikanti, L (reprint author), Univ Louisville, Louisville, KY 40292 USA.
EM drlm@thepainmd.com
NR 3
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362-2436
EI 1528-1159
J9 SPINE
JI SPINE
PD FEB
PY 2016
VL 41
IS 3
BP E183
EP E183
DI 10.1097/BRS.0000000000001357
PG 1
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA DD5VR
UT WOS:000369993300012
ER
PT J
AU Suri, P
Pashova, H
Heagerty, PJ
Jarvik, JG
Turner, JA
Bauer, Z
Annaswamy, M
Nedeljkovic, SS
Wasan, AD
Friedly, JL
AF Suri, Pradeep
Pashova, Hristina
Heagerty, Patrick J.
Jarvik, Jeffrey G.
Turner, Judith A.
Bauer, Zoya
Annaswamy, M.
Nedeljkovic, Srdjan S.
Wasan, Ajay D.
Friedly, Janna L.
TI Short-term Improvements in Disability Mediate Patient Satisfaction After
Epidural Corticosteroid Injections for Symptomatic Lumbar Spinal
Stenosis Reply
SO SPINE
LA English
DT Letter
ID TRIAL
C1 [Suri, Pradeep] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
Univ Washington, Seattle, WA 98195 USA.
Dallas VA Med Ctr, Dallas, TX USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
RP Suri, P (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA.
EM pradeep.suri@va.gov
NR 4
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362-2436
EI 1528-1159
J9 SPINE
JI SPINE
PD FEB
PY 2016
VL 41
IS 3
BP E183
EP E184
DI 10.1097/BRS.0000000000001142
PG 2
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA DD5VS
UT WOS:000369993400002
ER
PT J
AU Suri, P
Pashova, H
Heagerty, PJ
Jarvik, JG
Turner, JA
Bauer, Z
Annaswamy, TM
Nedeljkovic, SS
Wasan, AD
Friedly, JL
AF Suri, Pradeep
Pashova, Hristina
Heagerty, Patrick J.
Jarvik, Jeffrey G.
Turner, Judith A.
Bauer, Zoya
Annaswamy, Thiru M.
Nedeljkovic, Srdjan S.
Wasan, Ajay D.
Friedly, Janna L.
TI Re: Suri, P. et al. Short-term Improvements in Disability Mediate
Patient Satisfaction After Epidural Corticosteroid Injections for
Symptomatic Lumbar Spinal Stenosis. Spine (Phila Pa 1976) 2015 May 22.
Reply
SO SPINE
LA English
DT Letter
ID TRIAL
C1 [Suri, Pradeep] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
Univ Washington, Seattle, WA 98195 USA.
Dallas VA Med Ctr, Dallas, TX USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
RP Suri, P (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA.
EM pradeep.suri@va.gov
NR 4
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362-2436
EI 1528-1159
J9 SPINE
JI SPINE
PD FEB
PY 2016
VL 41
IS 3
BP E183
EP E184
DI 10.1097/BRS.0000000000001142
PG 2
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA DD5VR
UT WOS:000369993300013
ER
PT J
AU Monteith, LL
Menefee, DS
Forster, JE
Bahraini, NH
AF Monteith, Lindsey L.
Menefee, Deleene S.
Forster, Jeri E.
Bahraini, Nazanin H.
TI A Closer Examination of Sexual Trauma During Deployment: Not all Sexual
Traumas are Associated with Suicidal Ideation
SO SUICIDE AND LIFE-THREATENING BEHAVIOR
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; GENDER-DIFFERENCES; MENTAL-HEALTH;
MILITARY PERSONNEL; OEF/OIF VETERANS; FOLLOW-UP; ASSAULT; HARASSMENT;
EXPERIENCES; AFGHANISTAN
AB Military personnel can be exposed to a wide range of sexual traumawhile deployed, including sexual harassment and sexual assault. We examined whether different types of sexual trauma during deployment associated with recent suicidal ideation among previously deployed OEF/OIF/OND veterans admitted to trauma-focused treatment (n=199). More severe forms of sexual trauma (e.g., sexual assault) were significantly and positively associated with suicidal ideation. In contrast, sexual trauma involving verbal remarks (e.g., sexual harassment) was not associated with suicidal ideation. Our findings suggest that sexual harassment and sexual assault during deployment may be differentially associated with suicidal ideation.
C1 [Monteith, Lindsey L.; Forster, Jeri E.; Bahraini, Nazanin H.] VISN 19 MIRECC, Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO USA.
[Monteith, Lindsey L.; Bahraini, Nazanin H.] Univ Colorado, Dept Psychiat, Anschutz Med Campus, Aurora, CO USA.
[Menefee, Deleene S.] VISN 16 MIRECC, Michael F DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Menefee, Deleene S.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Forster, Jeri E.] Colorado Sch Publ Hlth, Aurora, CO USA.
RP Monteith, LL (reprint author), VISN 19 MIRECC, Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO USA.
EM lindsey.monteith@va.gov
FU Denver Veterans Affairs Medical Center; MEDVAMC; VISN 19 MIRECC in
Denver, Colorado; VISN 16 MIRECC in Houston, Texas
FX This material is the result of work supported with resources and the use
of facilities at the Denver Veterans Affairs Medical Center and VISN 19
MIRECC in Denver, Colorado, and the MEDVAMC and VISN 16 MIRECC in
Houston, Texas. The views expressed are those of the authors and do not
necessarily represent the views of the Department of Veterans Affairs or
the U.S. Government.
NR 26
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0363-0234
EI 1943-278X
J9 SUICIDE LIFE-THREAT
JI Suicide Life-Threat. Behav.
PD FEB
PY 2016
VL 46
IS 1
BP 46
EP 54
DI 10.1111/sltb.12171
PG 9
WC Psychiatry; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA DD7WS
UT WOS:000370136200005
PM 26096625
ER
PT J
AU Peroni, M
Golland, P
Sharp, GC
Baroni, G
AF Peroni, M.
Golland, P.
Sharp, G. C.
Baroni, G.
TI Stopping Criteria for Log-Domain Diffeomorphic Demons Registration: An
Experimental Survey for Radiotherapy Application
SO TECHNOLOGY IN CANCER RESEARCH & TREATMENT
LA English
DT Article
DE Optimization; Deformable registration; Demons; Stopping criteria
ID DEFORMABLE IMAGE REGISTRATION; HEAD; GPU
AB A crucial issue in deformable image registration is achieving a robust registration algorithm at a reasonable computational cost. Given the iterative nature of the optimization procedure an algorithm must automatically detect convergence, and stop the iterative process when most appropriate. This paper ranks the performances of three stopping criteria and six stopping value computation strategies for a Log-Domain Demons Deformable registration method simulating both a coarse and a fine registration. The analyzed stopping criteria are: (a) velocity field update magnitude, (b) mean squared error, and (c) harmonic energy. Each stoping condition is formualted so that the user defines a threshold , which quantifies the residual error that is acceptable for the particular problem and calculation strategy. In this work, we did not aim at assigning a value to e, but to give insights in how to evaluate and to set the threshold on a given exit strategy in a very popular registration scheme. Experi-ments on phantom and patient data demonstrate that comparing the optimization metric minimum over the most recent three iterations with the minimum over the fourth to sixth most recent iterations can be an appropriate algorithm stopping strategy. The harmonic energy was found to provide best trade-off between robustness and speed of convergence for the analyzed registration method at coarse registration, but was outperformed by mean squared error when all the original pixel information is used. This suggests the need of developing mathematically sound new convergence criteria in which both image and vector field information could be used to detect the actual convergence, which could be especially useful when considering multi-resolution registrations. Further work should be also dedicated to study same strategies performances in other deformable registration methods and body districts.
C1 [Peroni, M.; Baroni, G.] Politecn Milan, Dipartimento Elettron Informaz & Bioingn, I-20133 Milan, Italy.
[Golland, P.] MIT, Comp Sci & Artificial Intelligence Lab, Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Sharp, G. C.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Sharp, G. C.] Harvard Univ, Sch Med, Boston, MA USA.
[Baroni, G.] Ctr Nazl Adroterapia Oncol, Bioengn Unit, Pavia, Italy.
RP Peroni, M (reprint author), Politecn Milan, Dipartimento Elettron Informaz & Bioingn, I-20133 Milan, Italy.
EM marta.peroni@psi.ch
FU Rocca Fundation; National Alliance for Medical Image Computing (NAMIC),
NIH [2-U54EB005149-06]
FX This work was supported in part by the Rocca Fundation and the National
Alliance for Medical Image Computing (NAMIC), NIH Grant
2-U54EB005149-06. The authors would like to thank the Advanced
Radiotherapy Center, European Institute of Oncology, Milan, Italy for
providing dataset used in this project.
NR 18
TC 0
Z9 0
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-0346
EI 1533-0338
J9 TECHNOL CANCER RES T
JI Technol. Cancer Res. Treat.
PD FEB
PY 2016
VL 15
IS 1
BP 77
EP 90
DI 10.7785/tcrtexpress.2013.600269
PG 14
WC Oncology
SC Oncology
GA DD5OS
UT WOS:000369974200010
PM 24000996
ER
PT J
AU Pomerantseva, I
Bichara, DA
Tseng, A
Cronce, MJ
Cervantes, TM
Kimura, AM
Neville, CM
Roscioli, N
Vacanti, JP
Randolph, MA
Sundback, CA
AF Pomerantseva, Irina
Bichara, David A.
Tseng, Alan
Cronce, Michael J.
Cervantes, Thomas M.
Kimura, Anya M.
Neville, Craig M.
Roscioli, Nick
Vacanti, Joseph P.
Randolph, Mark A.
Sundback, Cathryn A.
TI Ear-Shaped Stable Auricular Cartilage Engineered from Extensively
Expanded Chondrocytes in an Immunocompetent Experimental Animal Model
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID IN-VITRO; PASSAGED CHONDROCYTES; TISSUE FORMATION; ACID SCAFFOLDS;
RECONSTRUCTION; FGF-2; VIVO; NEOCARTILAGE; INHIBITION; MATURATION
AB Advancement of engineered ear in clinical practice is limited by several challenges. The complex, largely unsupported, three-dimensional auricular neocartilage structure is difficult to maintain. Neocartilage formation is challenging in an immunocompetent host due to active inflammatory and immunological responses. The large number of autologous chondrogenic cells required for engineering an adult human-sized ear presents an additional challenge because primary chondrocytes rapidly dedifferentiate during in vitro culture. The objective of this study was to engineer a stable, human ear-shaped cartilage in an immunocompetent animal model using expanded chondrocytes. The impact of basic fibroblast growth factor (bFGF) supplementation on achieving clinically relevant expansion of primary sheep chondrocytes by in vitro culture was determined. Chondrocytes expanded in standard medium were either combined with cryopreserved, primary passage 0 chondrocytes at the time of scaffold seeding or used alone as control. Disk and human ear-shaped scaffolds were made from porous collagen; ear scaffolds had an embedded, supporting titanium wire framework. Autologous chondrocyte-seeded scaffolds were implanted subcutaneously in sheep after 2 weeks of in vitro incubation. The quality of the resulting neocartilage and its stability and retention of the original ear size and shape were evaluated at 6, 12, and 20 weeks postimplantation. Neocartilage produced from chondrocytes that were expanded in the presence of bFGF was superior, and its quality improved with increased implantation time. In addition to characteristic morphological cartilage features, its glycosaminoglycan content was high and marked elastin fiber formation was present. The overall shape of engineered ears was preserved at 20 weeks postimplantation, and the dimensional changes did not exceed 10%. The wire frame within the engineered ear was able to withstand mechanical forces during wound healing and neocartilage maturation and prevented shrinkage and distortion. This is the first demonstration of a stable, ear-shaped elastic cartilage engineered from auricular chondrocytes that underwent clinical-scale expansion in an immunocompetent animal over an extended period of time.
C1 [Pomerantseva, Irina; Tseng, Alan; Cronce, Michael J.; Cervantes, Thomas M.; Kimura, Anya M.; Neville, Craig M.; Vacanti, Joseph P.; Sundback, Cathryn A.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Pomerantseva, Irina; Bichara, David A.; Neville, Craig M.; Vacanti, Joseph P.; Randolph, Mark A.; Sundback, Cathryn A.] Harvard Univ, Sch Med, Boston, MA USA.
[Bichara, David A.; Randolph, Mark A.] Massachusetts Gen Hosp, Plast Surg Res Lab, Boston, MA 02114 USA.
[Roscioli, Nick] DSM Biomed Corp, Exton, PA USA.
RP Sundback, CA (reprint author), Massachusetts Gen Hosp, CPZN 4809,185 Cambridge St, Boston, MA 02114 USA.
EM csundback@partners.org
FU U.S. Army Medical Research and Materiel Command [W81XWH-12-1-0334];
Armed Forces Institute of Regenerative Medicine [W81XWH-08-2-0034]
FX This research was sponsored in part by the U.S. Army Medical Research
and Materiel Command award No. W81XWH-12-1-0334 and by the Armed Forces
Institute of Regenerative Medicine award No. W81XWH-08-2-0034. The
content of this article does not necessarily reflect the position or the
policy of the Government, and no official endorsement should be
inferred. The fibrous collagen scaffolds were generously provided by the
DSM Biomedical Corp. The authors would like to thank Drs. T. Hadlock and
M. Cheney for their valuable input on ear scaffold design and M. Johnson
and J. Beagle for excellent animal care assistance.
NR 45
TC 4
Z9 4
U1 2
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD FEB 1
PY 2016
VL 22
IS 3-4
BP 197
EP 207
DI 10.1089/ten.tea.2015.0173
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA DD5TS
UT WOS:000369987900002
PM 26529401
ER
PT J
AU Saxena, V
Kim, M
Keah, NM
Neuwirth, AL
Stoeckl, BD
Bickard, K
Restle, DJ
Salowe, R
Wang, MY
Steinberg, DR
Mauck, RL
AF Saxena, Vishal
Kim, Minwook
Keah, Niobra M.
Neuwirth, Alexander L.
Stoeckl, Brendan D.
Bickard, Kevin
Restle, David J.
Salowe, Rebecca
Wang, Margaret Ye
Steinberg, David R.
Mauck, Robert L.
TI Anatomic Mesenchymal Stem Cell-Based Engineered Cartilage Constructs for
Biologic Total Joint Replacement
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID HYALURONIC-ACID HYDROGELS; ARTICULAR-CARTILAGE; POROUS TANTALUM;
NUTRIENT CHANNELS; TISSUE; KNEE; REPAIR; BONE; REGENERATION; GROWTH
AB Cartilage has a poor healing response, and few viable options exist for repair of extensive damage. Hyaluronic acid (HA) hydrogels seeded with mesenchymal stem cells (MSCs) polymerized through UV crosslinking can generate functional tissue, but this crosslinking is not compatible with indirect rapid prototyping utilizing opaque anatomic molds. Methacrylate-modified polymers can also be chemically crosslinked in a cytocompatible manner using ammonium persulfate (APS) and N,N,N,N-tetramethylethylenediamine (TEMED). The objectives of this study were to (1) compare APS/TEMED crosslinking with UV crosslinking in terms of functional maturation of MSC-seeded HA hydrogels; (2) generate an anatomic mold of a complex joint surface through rapid prototyping; and (3) grow anatomic MSC-seeded HA hydrogel constructs using this alternative crosslinking method. Juvenile bovine MSCs were suspended in methacrylated HA (MeHA) and crosslinked either through UV polymerization or chemically with APS/TEMED to generate cylindrical constructs. Minipig porcine femoral heads were imaged using microCT, and anatomic negative molds were generated by three-dimensional printing using fused deposition modeling. Molded HA constructs were produced using the APS/TEMED method. All constructs were cultured for up to 12 weeks in a chemically defined medium supplemented with TGF-3 and characterized by mechanical testing, biochemical assays, and histologic analysis. Both UV- and APS/TEMED-polymerized constructs showed increasing mechanical properties and robust proteoglycan and collagen deposition over time. At 12 weeks, APS/TEMED-polymerized constructs had higher equilibrium and dynamic moduli than UV-polymerized constructs, with no differences in proteoglycan or collagen content. Molded HA constructs retained their hemispherical shape in culture and demonstrated increasing mechanical properties and proteoglycan and collagen deposition, especially at the edges compared to the center of these larger constructs. Immunohistochemistry showed abundant collagen type II staining and little collagen type I staining. APS/TEMED crosslinking can be used to produce MSC-seeded HA-based neocartilage and can be used in combination with rapid prototyping techniques to generate anatomic MSC-seeded HA constructs for use in filling large and anatomically complex chondral defects or for biologic joint replacement.
C1 [Saxena, Vishal; Kim, Minwook; Keah, Niobra M.; Neuwirth, Alexander L.; Stoeckl, Brendan D.; Bickard, Kevin; Restle, David J.; Salowe, Rebecca; Wang, Margaret Ye; Steinberg, David R.; Mauck, Robert L.] Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Stemmler Hall 36th St & Hamilton Walk, Philadelphia, PA 19104 USA.
[Saxena, Vishal; Kim, Minwook; Keah, Niobra M.; Neuwirth, Alexander L.; Stoeckl, Brendan D.; Steinberg, David R.; Mauck, Robert L.] Philadelphia Vet Affairs Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA.
[Kim, Minwook; Bickard, Kevin; Restle, David J.; Salowe, Rebecca; Wang, Margaret Ye; Mauck, Robert L.] Univ Penn, Dept Bioengn, Stemmler Hall 36th St & Hamilton Walk, Philadelphia, PA 19104 USA.
RP Mauck, RL (reprint author), Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Stemmler Hall 36th St & Hamilton Walk, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Philadelphia Vet Affairs Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA.; Mauck, RL (reprint author), Univ Penn, Dept Bioengn, Stemmler Hall 36th St & Hamilton Walk, Philadelphia, PA 19104 USA.
EM lemauck@mail.med.upenn.edu
FU National Institutes of Health [R01 EB008722]; Department of Veterans
Affairs [I01 RX000700]; Penn Center for Musculoskeletal Disorders [P30
AR050950]
FX This work was funded by the National Institutes of Health (R01
EB008722), the Department of Veterans Affairs (I01 RX000700), and the
Penn Center for Musculoskeletal Disorders (P30 AR050950).
NR 55
TC 1
Z9 1
U1 6
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD FEB 1
PY 2016
VL 22
IS 3-4
BP 386
EP 395
DI 10.1089/ten.tea.2015.0384
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA DD5TS
UT WOS:000369987900020
PM 26871863
ER
PT J
AU Karel, MJ
Sakai, EY
Molinari, V
Moye, J
Carpenter, B
AF Karel, Michele J.
Sakai, Erin Y.
Molinari, Victor
Moye, Jennifer
Carpenter, Brian
TI Training for Geropsychology Supervision and Practice: Perspectives of
Geropsychology Program Graduates
SO TRAINING AND EDUCATION IN PROFESSIONAL PSYCHOLOGY
LA English
DT Article
DE geropsychology; supervision; training; competencies; older adults
ID PROFESSIONAL GEROPSYCHOLOGY; COMPETENCE; PSYCHOLOGY; MODEL; BENCHMARKS;
WORKFORCE
AB Addressing the geropsychology workforce shortage requires ongoing training of psychologists to develop geropsychology competencies, as well as expanding the number of geropsychology supervisors to train them. This study surveyed graduates of geropsychology doctoral and postdoctoral training programs regarding their current geropsychology practice and supervision activities and perceptions of their own training preparation for these activities. One hundred psychologists (87 who had completed all formal training and 13 current postdoctoral fellows) responded to an online survey. Of those who had completed geropsychology training, 82% reported currently engaging in clinical care, and 55 reported providing supervision; more than half of clinical and supervision activities focused on older adults. Participants repotted generally strong quality of training to prepare them for providing geropsychology services; areas of more uneven preparation included family and group interventions and select consultation activities. Participants reported quite variable preparation for general supervision practice, and desire for more training and practice in supervisory roles. Geropsychology training programs may use feedback from graduates for ongoing program development, and professional geropsychology may wish to consider forums for enhancing geropsychology supervision skills.
C1 [Karel, Michele J.] Dept Vet Affairs, Mental Hlth Serv, Cent Off, Washington, DC USA.
[Sakai, Erin Y.; Carpenter, Brian] Washington Univ, St Louis, MO 63130 USA.
[Molinari, Victor] Univ S Florida, Sch Aging Studies, Tampa, FL 33620 USA.
[Moye, Jennifer] VA Boston Healthcare Syst, Geriatr Mental Hlth, Boston, MA USA.
[Moye, Jennifer] Harvard Univ, Sch Med, Psychol, Cambridge, MA 02138 USA.
RP Karel, MJ (reprint author), Dept Vet Affairs, Cent Off, Mental Hlth Serv 10P4M, 1575 1 St NW, Washington, DC 20420 USA.
EM michele.karel@va.gov
RI Moye, Jennifer/F-2240-2017
OI Moye, Jennifer/0000-0002-3434-347X
FU Council of Professional Geropsychology Training Programs; VA Boston
Healthcare System
FX THIS RESEARCH WAS SUPPORTED in part by a grant from the Council of
Professional Geropsychology Training Programs and from the VA Boston
Healthcare System. This material is the result of work supported with
the resources and the use of facilities at the VA Boston Healthcare
System. The following geropsychologists reviewed an initial draft of the
survey and provided invaluable feedback: Barry Edelstein, Amy Fiske,
Greg Hinrichsen, Erlene Rosowsky, and Susan Whitbourne. The authors also
wish to acknowledge the contributions of the many directors of clinical
training who assisted with survey distribution and survey participants
who generously shared then time and perspectives on training.
NR 32
TC 0
Z9 0
U1 0
U2 1
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1931-3918
EI 1931-3926
J9 TRAIN EDUC PROF PSYC
JI Train. Educ. Prof. Psychol.
PD FEB
PY 2016
VL 10
IS 1
BP 37
EP 44
DI 10.1037/tep0000101
PG 8
WC Psychology, Educational
SC Psychology
GA DD0FU
UT WOS:000369596600006
PM 27594967
ER
PT J
AU Nagasaka, Y
Wasner, G
Sharma, B
Fleischmann, K
AF Nagasaka, Yasuko
Wasner, Gunnar
Sharma, Balram
Fleischmann, Katharine
TI Harlequin Syndrome After Thoracic Paravertebral Block
SO A & A CASE REPORTS
LA English
DT Article
ID COEXISTING HARLEQUIN; CAROTID-ARTERY; AUTONOMIC DEFICIT;
HORNER-SYNDROMES; COLOR-CHANGE; DISSECTION; FACE; ANESTHESIA; NEURONS;
INFANT
AB Harlequin syndrome is characterized by the sudden onset of unilateral facial flushing and sweating, often preceded by exercise, excessive heat, or, rarely, regional anesthesia. Although the exact mechanism remains unclear, it is often referred to as transient or permanent interruption of the sympathetic nervous system. We present a case of Harlequin syndrome without Horner syndrome in a patient with unilateral right-sided facial flushing that started shortly after a left-sided thoracic paravertebral nerve block for a mastectomy. We discuss the interruption of the sympathetic and parasympathetic nervous system and the levels of spinal nerve block associated with a thoracic paravertebral nerve block.
C1 [Nagasaka, Yasuko; Fleischmann, Katharine] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
[Wasner, Gunnar] Univ Kiel, Neurol Outpatient Ctr, Kiel, Germany.
[Sharma, Balram] Lahey Hosp & Med Ctr, Anesthesiol, Burlington, MA USA.
RP Fleischmann, K (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
EM Fleischmann.Katharine@mgh.harvard.edu
NR 40
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2325-7237
J9 A A CASE REP
JI A A Case Rep.
PD FEB 1
PY 2016
VL 6
IS 3
BP 48
EP 51
DI 10.1213/XAA.0000000000000231
PG 4
WC Anesthesiology
SC Anesthesiology
GA DD0FG
UT WOS:000369595200003
PM 26513674
ER
PT J
AU Stanford, FC
Kyle, TK
AF Stanford, Fatima Cody
Kyle, Theodore K.
TI Obesity Education Beyond Nutrition Education: Thinking Farther Outside
the Box
SO ACADEMIC MEDICINE
LA English
DT Letter
C1 [Stanford, Fatima Cody] Massachusetts Gen Hosp, Weight Ctr, Dept Pediat, Dept Med,Div Gastroenterol,Med & Pediat, Boston, MA 02114 USA.
[Stanford, Fatima Cody] Massachusetts Gen Hosp, Weight Ctr, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Stanford, Fatima Cody] Harvard Univ, Sch Med, Med & Pediat, Boston, MA USA.
[Kyle, Theodore K.] ConscienHealth, Pittsburgh, PA USA.
[Kyle, Theodore K.] Obes Act Coalit, Tampa, FL USA.
RP Stanford, FC (reprint author), Massachusetts Gen Hosp, Weight Ctr, Dept Pediat, Dept Med,Div Gastroenterol,Med & Pediat, Boston, MA 02114 USA.; Stanford, FC (reprint author), Massachusetts Gen Hosp, Weight Ctr, Mongan Inst Hlth Policy, Boston, MA 02114 USA.; Stanford, FC (reprint author), Harvard Univ, Sch Med, Med & Pediat, Boston, MA USA.
EM fstanford@mgh.harvard.edu
OI Stanford, Fatima/0000-0003-4616-533X
NR 5
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-2446
EI 1938-808X
J9 ACAD MED
JI Acad. Med.
PD FEB
PY 2016
VL 91
IS 2
BP 164
EP 164
PG 1
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA DC5YP
UT WOS:000369297000012
PM 26813650
ER
PT J
AU Goroll, AH
AF Goroll, Allan H.
TI Recruiting Quarterbacks: Strategies for Revitalizing Training in Primary
Care Internal Medicine
SO ACADEMIC MEDICINE
LA English
DT Editorial Material
AB Current U.S. primary care workforce shortages and trainees' declining interest in primary care residency training, especially regarding primary care internal medicine, have many parallels with circumstances in the early 1970s, when modern adult primary care first emerged. Rediscovery of the lessons learned and the solutions developed at that time and applying them to the current situation have the potential to help engage a new generation of young physicians in the primary care mission. The author compares the internal medicine residency primary care track at the University of New Mexico, described by Brislen and colleagues in this issue, with the nation's first three-year primary care internal medicine residency track introduced at Massachusetts General Hospital in 1973. Strategies for addressing the challenges of primary care practice and improving learner attitudes toward the field are discussed. The author suggests that primary care physicians should be likened to quarterbacks rather than gatekeepers or providers to underscore the intensity of training, level of responsibility, degree of professionalism, and amount of compensation required for this profession. The advent of multidisciplinary team practice, modern health information technology, and fundamental payment reform promises to dramatically alter the picture of primary care, restoring its standing as one of the best job descriptions in medicine.
C1 [Goroll, Allan H.] Harvard Univ, Sch Med, Med, Boston, MA USA.
[Goroll, Allan H.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA.
RP Goroll, AH (reprint author), Massachusetts Gen Hosp, 15 Parkman St,Suite 645, Boston, MA 02114 USA.
EM ahgoroll@partners.org
NR 8
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-2446
EI 1938-808X
J9 ACAD MED
JI Acad. Med.
PD FEB
PY 2016
VL 91
IS 2
BP 168
EP 170
DI 10.1097/ACM.0000000000000891
PG 3
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA DC5YP
UT WOS:000369297000014
PM 26397701
ER
PT J
AU Calaman, S
Hepps, JH
Bismilla, Z
Carraccio, C
Englander, R
Feraco, A
Landrigan, CP
Lopreiato, JO
Sectish, TC
Starmer, AJ
Yu, CE
Spector, ND
West, DC
AF Calaman, Sharon
Hepps, Jennifer H.
Bismilla, Zia
Carraccio, Carol
Englander, Robert
Feraco, Angela
Landrigan, Christopher P.
Lopreiato, Joseph O.
Sectish, Theodore C.
Starmer, Amy J.
Yu, Clifton E.
Spector, Nancy D.
West, Daniel C.
CA I-Pass Study Educ Executive Comm
TI The Creation of Standard-Setting Videos to Support Faculty Observations
of Learner Performance and Entrustment Decisions
SO ACADEMIC MEDICINE
LA English
DT Article
ID CLINICAL SKILLS; TRIGGER FILMS; PROFESSIONAL ACTIVITIES; COMPETENCE;
MODEL; ASSESSMENTS; EDUCATION; RATINGS; STUDENT
AB Entrustable professional activities (EPAs) provide a framework to standardize medical education outcomes and advance competency-based assessment. Direct observation of performance plays a central role in entrustment decisions; however, data obtained from these observations are often insufficient to draw valid high-stakes conclusions. One approach to enhancing the reliability and validity of these assessments is to create videos that establish performance standards to train faculty observers. Little is known about how to create videos that can serve as standards for assessment of EPAs. The authors report their experience developing videos that represent five levels of performance for an EPA for patient handoffs. The authors describe a process that begins with mapping the EPA to the critical competencies needed to make an entrustment decision. Each competency is then defined by five milestones (behavioral descriptors of performance at five advancing levels). Integration of the milestones at each level across competencies enabled the creation of clinical vignettes that were converted into video scripts and ultimately videos. Each video represented a performance standard from novice to expert. The process included multiple assessments by experts to guide iterative improvements, provide evidence of content validity, and ensure that the authors successfully translated behavioral descriptions and vignettes into videos that represented the intended performance level for a learner. The steps outlined are generalizable to other EPAs, serving as a guide for others to develop videos to train faculty. This process provides the level of content validity evidence necessary to support using videos as standards for high-stakes entrustment decisions.
C1 [Calaman, Sharon; Spector, Nancy D.] St Christophers Hosp Children, 160 E Erie Ave, Philadelphia, PA 19130 USA.
[Calaman, Sharon] Drexel Univ, Coll Med, Dept Pediat, Philadelphia, PA 19104 USA.
[Hepps, Jennifer H.] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA.
[Hepps, Jennifer H.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA.
[Bismilla, Zia] Univ Toronto, Dept Pediat, Toronto, ON, Canada.
[Bismilla, Zia] Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
[Carraccio, Carol] Amer Board Pediat Inc, Competency Based Assessment, Chapel Hill, NC USA.
[Englander, Robert] Assoc Amer Med Coll, Competency Based Learning & Assessment, Washington, DC USA.
[Feraco, Angela] Harvard Univ, Sch Med, Dana Farber, Pediat Hematol Oncol, Boston, MA USA.
[Feraco, Angela] Harvard Univ, Sch Med, Boston Childrens Hosp, Canc & Blood Disorders Ctr, Boston, MA USA.
[Landrigan, Christopher P.] Harvard Univ, Sch Med, Dept Med & Pediat, Boston, MA USA.
[Landrigan, Christopher P.; Sectish, Theodore C.] Boston Childrens Hosp, Dept Med, Boston, MA USA.
[Landrigan, Christopher P.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Lopreiato, Joseph O.; Yu, Clifton E.] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA.
[Lopreiato, Joseph O.; Yu, Clifton E.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA.
[Sectish, Theodore C.; Starmer, Amy J.] Harvard Univ, Sch Med, Pediat, Boston, MA USA.
[Starmer, Amy J.] Boston Childrens Hosp, Boston, MA USA.
[Starmer, Amy J.] Oregon Hlth & Sci Univ, Dept Pediat, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97201 USA.
[Starmer, Amy J.] OHSU Doernbecher Childrens Hosp, Portland, OR USA.
[Spector, Nancy D.] Drexel Univ, Coll Med, Dept Pediat, Pediat, Philadelphia, PA 19104 USA.
[West, Daniel C.] Univ Calif San Francisco, Sch Med, Dept Pediat, Pediat, San Francisco, CA 94143 USA.
[West, Daniel C.] UCSF Benioff Childrens Hosp, San Francisco, CA USA.
RP Calaman, S (reprint author), St Christophers Hosp Children, 160 E Erie Ave, Philadelphia, PA 19130 USA.
EM Sharon.calaman@drexelmed.edu
FU U.S. Department of Health and Human Services, Office of the Assistant
Secretary for Planning and Evaluation [1R18AE000029-01]; Children's
Hospital Association; Academic Pediatric Association; American Academy
of Pediatrics; Society of Hospital Medicine; Oregon Comparative
Effectiveness Research K12 Program (Agency for Healthcare Research and
Quality) [1K12HS019456-01]; Medical Research Foundation of Oregon;
Physician Services Incorporated Foundation (of Ontario, Canada); Pfizer;
American Board of Pediatrics Foundation
FX The I-PASS Study is primarily supported by the U.S. Department of Health
and Human Services, Office of the Assistant Secretary for Planning and
Evaluation (1R18AE000029-01). The study was developed with input from
the Initiative for Innovation in Pediatric Education and the Pediatric
Research in Inpatient Settings Network (supported by the Children's
Hospital Association, the Academic Pediatric Association, the American
Academy of Pediatrics, and the Society of Hospital Medicine). A.J.S. was
supported by the Oregon Comparative Effectiveness Research K12 Program
(Agency for Healthcare Research and Quality, 1K12HS019456-01).
Additional funding for the I-PASS Study is provided by the Medical
Research Foundation of Oregon, Physician Services Incorporated
Foundation (of Ontario, Canada), and Pfizer (unrestricted medical
education grant). Computer modules used in the I-PASS curriculum were
developed by Concurrent Technologies Corporation. This project was also
supported by a contribution from the American Board of Pediatrics
Foundation.
NR 30
TC 3
Z9 3
U1 3
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-2446
EI 1938-808X
J9 ACAD MED
JI Acad. Med.
PD FEB
PY 2016
VL 91
IS 2
BP 204
EP 209
DI 10.1097/ACM.0000000000000853
PG 6
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA DC5YP
UT WOS:000369297000021
PM 26266461
ER
PT J
AU Fitzsimons, MG
Brookman, JC
Arnholz, SH
Baker, K
AF Fitzsimons, Michael G.
Brookman, Jason C.
Arnholz, Sarah H.
Baker, Keith
TI Attention-Deficit/Hyperactivity Disorder and Successful Completion of
Anesthesia Residency: A Case Report
SO ACADEMIC MEDICINE
LA English
DT Article
ID COGNITIVE-BEHAVIORAL THERAPY; MEDICATION-TREATED ADULTS;
LEARNING-DISABILITIES; STUDENTS; SYMPTOMS; SCHOOLS; ADHD
AB Cognitive and physical disabilities among anesthesia residents are not well studied. Cognitive disabilities may often go undiagnosed among trainees, and these trainees may struggle during their graduate medical education. Attention-deficit/hyperactivity disorder (ADHD) is an executive function disorder that may manifest as lack of vigilance, an inability to adapt to the rapid changes associated with anesthesia cases, distractibility, an inability to prioritize activities, and even periods of hyperfocusing, among other signs. Programs are encouraged to work closely with residents with such disabilities to develop an educational plan that includes accommodations for their unique learning practices while maintaining the critical aspects of the program. The authors present the management of a case of an anesthesia resident with a diagnosis of ADHD, the perspectives of the trainee, program director, clinical competency director, and the office of general counsel. This article also provides follow-up in the five years since completion of residency.
C1 [Fitzsimons, Michael G.; Baker, Keith] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
[Fitzsimons, Michael G.; Baker, Keith] Harvard Univ, Sch Med, Boston, MA USA.
[Brookman, Jason C.] Johns Hopkins Med, Dept Anesthesiol & Crit Care Med, Anesthesiol, Baltimore, MD USA.
[Arnholz, Sarah H.] Partners Healthcare Syst, Off Gen Counsel, Boston, MA USA.
RP Fitzsimons, MG (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
EM mfitzsimons@partners.org
NR 15
TC 2
Z9 2
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-2446
EI 1938-808X
J9 ACAD MED
JI Acad. Med.
PD FEB
PY 2016
VL 91
IS 2
BP 210
EP 214
DI 10.1097/ACM.0000000000000854
PG 5
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA DC5YP
UT WOS:000369297000022
PM 26244258
ER
PT J
AU Montine, TJ
Monsell, SE
Beach, TG
Bigio, EH
Bu, YQ
Cairns, NJ
Frosch, M
Henriksen, J
Kofler, J
Kukull, WA
Lee, EB
Nelson, PT
Schantz, AM
Schneider, JA
Sonnen, JA
Trojanowski, JQ
Vinters, HV
Zhou, XH
Hyman, BT
AF Montine, Thomas J.
Monsell, Sarah E.
Beach, Thomas G.
Bigio, Eileen H.
Bu, Yunqi
Cairns, Nigel J.
Frosch, Matthew
Henriksen, Jonathan
Kofler, Julia
Kukull, Walter A.
Lee, Edward B.
Nelson, Peter T.
Schantz, Aimee M.
Schneider, Julie A.
Sonnen, Joshua A.
Trojanowski, John Q.
Vinters, Harry V.
Zhou, Xiao-Hua
Hyman, Bradley T.
TI Multisite assessment of NIA-AA guidelines for the neuropathologic
evaluation of Alzheimer's disease
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Alzheimer's disease; Neuropathology; Methods; Whole-slide imaging;
Multisite
ID BRAINNET EUROPE CONSORTIUM; ASSOCIATION GUIDELINES; NATIONAL INSTITUTE;
AGREEMENT; PATHOLOGY
AB Introduction: Neuropathologic assessment is the current "gold standard" for evaluating the Alzheimer's disease (AD), but there is no consensus on the methods used.
Methods: Fifteen unstained slides (8 brain regions) from each of the 14 cases were prepared and distributed to 10 different National Institute on Aging AD Centers for application of usual staining and evaluation following recently revised guidelines for AD neuropathologic change.
Results: Current practice used in the AD Centers Program achieved robustly excellent agreement for the severity score for AD neuropathologic change (average weighted kappa = .88, 95% confidence interval: 0.77-0.95) and good-to-excellent agreement for the three supporting scores. Some improvement was observed with consensus evaluation but not with central staining of slides. Evaluation of glass slides and digitally prepared whole-slide images was comparable.
Discussion: AD neuropathologic evaluation as performed across AD Centers yields data that have high agreement with potential modifications for modest improvements. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
C1 [Montine, Thomas J.; Henriksen, Jonathan; Schantz, Aimee M.; Sonnen, Joshua A.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Monsell, Sarah E.; Bu, Yunqi; Kukull, Walter A.; Zhou, Xiao-Hua] Univ Washington, Natl Alzheimer Coordinating Ctr, Seattle, WA 98195 USA.
[Beach, Thomas G.] Banner Sun Hlth Res Inst, Civin Lab Neuropathol, Sun City, AZ USA.
[Bigio, Eileen H.] Northwestern Univ Feinberg, Sch Med, Cognit Neurol & Alzheimers Dis Ctr, Chicago, IL USA.
[Bigio, Eileen H.] Northwestern Univ Feinberg, Sch Med, Dept Pathol, Chicago, IL USA.
[Cairns, Nigel J.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
[Frosch, Matthew] Massachusetts Gen Hosp, CS Kubik Lab Neuropathol, Dept Pathol, Charlestown, MA USA.
[Kofler, Julia] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA.
[Lee, Edward B.; Trojanowski, John Q.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Pittsburgh, PA USA.
[Lee, Edward B.; Trojanowski, John Q.] Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Pittsburgh, PA USA.
[Lee, Edward B.; Trojanowski, John Q.] Univ Penn, Sch Med, Inst Aging, Pittsburgh, PA USA.
[Nelson, Peter T.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.
[Nelson, Peter T.] Univ Kentucky, Dept Pathol, Lexington, KY USA.
[Schneider, Julie A.] Rush Univ, Med Ctr, Dept Pathol, Chicago, IL 60612 USA.
[Schneider, Julie A.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
[Schneider, Julie A.] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA.
[Vinters, Harry V.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med Neuropathol, Los Angeles, CA 90095 USA.
[Vinters, Harry V.] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA.
[Vinters, Harry V.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Hyman, Bradley T.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA.
[Hyman, Bradley T.] Massachusetts Gen Hosp, Massachusetts Alzheimers Dis Res Ctr, Charlestown, MA USA.
[Sonnen, Joshua A.] Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA.
RP Montine, TJ (reprint author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
EM tmontine@u.washington.edu
FU National Institute on Aging, National Institutes of Health: National
Alzheimer's Coordinating Center [U01 AG016976]; National Institute on
Aging, National Institutes of Health: Alzheimer's Disease Centers [P50
AG05133, P50 AG05134, P50 AG05136, P50 AG05681, P30 AG10161, P30
AG10124, P30 AG13854, P50 AG16570, P30 AG19610, P30 AG28383, P01
AG03991]
FX This work was supported by the following grants from the National
Institute on Aging, National Institutes of Health: the, National
Alzheimer's Coordinating Center (U01 AG016976), Alzheimer's Disease
Centers (P50 AG05133, P50 AG05134, P50 AG05136, P50 AG05681, P30
AG10161, P30 AG10124, P30 AG13854, P50 AG16570, P30 AG19610, and P30
AG28383), and P01 AG03991. We thank Dr Kathleen Montine for editorial
assistance.
NR 15
TC 3
Z9 3
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD FEB
PY 2016
VL 12
IS 2
BP 164
EP 169
DI 10.1016/j.jalz.2015.07.492
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA DC9EI
UT WOS:000369523500008
PM 26327235
ER
PT J
AU Ismail, Z
Smith, EE
Geda, Y
Sultzer, D
Brodaty, H
Smith, G
Aguera-Ortiz, L
Sweet, R
Miller, D
Lyketsos, CG
AF Ismail, Zahinoor
Smith, Eric E.
Geda, Yonas
Sultzer, David
Brodaty, Henry
Smith, Gwenn
Agueera-Ortiz, Luis
Sweet, Rob
Miller, David
Lyketsos, Constantine G.
CA ISTAART Neuropsychiat Symptoms Pro
TI Neuropsychiatric symptoms as early manifestations of emergent dementia:
Provisional diagnostic criteria for mild behavioral impairment
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Dementia; FTD; Alzheimer's disease; MCI; MBI; Neuropsychiatric symptoms
of dementia; NPS; Behavior; Behaviour; Agitation; Psychosis;
Disinhibition; Apathy; Depression; BPSD
ID ALZHEIMERS ASSOCIATION WORKGROUPS; COGNITIVE IMPAIRMENT; FRONTOTEMPORAL
DEMENTIA; NATIONAL INSTITUTE; CACHE COUNTY; RISK-FACTORS; DISEASE;
PROGRESSION; AGITATION; PREDICTORS
AB Neuropsychiatric symptoms (NPS) are common in dementia and in predementia syndromes such as mild cognitive impairment (MCI). NPS in MCI confer a greater risk for conversion to dementia in comparison to MCI patients without NPS. NPS in older adults with normal cognition also confers a greater risk of cognitive decline in comparison to older adults without NPS. Mild behavioral impairment (MBI) has been proposed as a diagnostic construct aimed to identify patients with an increased risk of developing dementia, but who may or may not have cognitive symptoms. We propose criteria that include MCI in the MBI framework, in contrast to prior definitions of MBI. Although MBI and MCI can co-occur, we suggest that they are different and that both portend a higher risk of dementia. These MBI criteria extend the previous literature in this area and will serve as a template for validation of the MBI construct from epidemiologic, neurobiological, treatment, and prevention perspectives. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
C1 [Ismail, Zahinoor] Univ Calgary, Dept Psychiat, Calgary, AB, Canada.
[Ismail, Zahinoor; Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada.
[Ismail, Zahinoor] Univ Calgary, Mathison Ctr Mental Hlth Res & Educ, Calgary, AB, Canada.
[Ismail, Zahinoor; Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada.
[Geda, Yonas] Mayo Clin, Dept Psychiat, Scottsdale, AZ USA.
[Geda, Yonas] Mayo Clin, Dept Neurol, Scottsdale, AZ USA.
[Sultzer, David] VA Greater Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
[Sultzer, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Brodaty, Henry] Univ New S Wales, Ctr Hlth Brain Ageing, Sydney, NSW, Australia.
[Brodaty, Henry] Univ New S Wales, Dementia Collaborat Res Ctr, Sydney, NSW, Australia.
[Smith, Gwenn] Johns Hopkins Sch Med, Alzheimers Dis Res Ctr, Baltimore, MD USA.
[Agueera-Ortiz, Luis] Carlos III Inst Hlth, Alzheimer Ctr Reina Sofia Fdn, Res Unit, Madrid, Spain.
[Agueera-Ortiz, Luis] CIBERSAM, Madrid, Spain.
[Sweet, Rob] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Sweet, Rob] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Sweet, Rob] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA.
[Miller, David] Bracket Global, Wayne, PA USA.
[Lyketsos, Constantine G.] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD USA.
RP Ismail, Z (reprint author), Univ Calgary, Dept Psychiat, Calgary, AB, Canada.; Ismail, Z (reprint author), Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada.; Ismail, Z (reprint author), Univ Calgary, Mathison Ctr Mental Hlth Res & Educ, Calgary, AB, Canada.; Ismail, Z (reprint author), Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada.
EM zahinoor@gmail.com
FU Veterans Health Administration [BX000452]; NIH [MH071533, AG05133,
AG027224, P50AG005146]; Department of Veterans Affairs
FX The authors acknowledge The Alzheimer's Association ISTAART group for
reading and supporting these criteria. Article supported in part by
Veterans Health Administration Grant BX000452, and NIH grants MH071533,
AG05133, AG027224 (R.S.), and P50AG005146 to the Johns Hopkins
Alzheimer's Disease Research Center (C.G.L.) and by the Department of
Veterans Affairs (D.S. and R.S.). The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health, the Department of
Veterans Affairs, or the United States Government.
NR 52
TC 21
Z9 21
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD FEB
PY 2016
VL 12
IS 2
BP 195
EP 202
DI 10.1016/j.jalz.2015.05.017
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA DC9EI
UT WOS:000369523500011
PM 26096665
ER
PT J
AU Wall, CR
Stewart, AW
Camargo, CA
Scragg, R
Mitchell, EA
Ekeroma, A
Crane, J
Milne, T
Rowden, J
Horst, R
Grant, CC
AF Wall, Clare R.
Stewart, Alistair W.
Camargo, Carlos A., Jr.
Scragg, Robert
Mitchell, Edwin A.
Ekeroma, Alec
Crane, Julian
Milne, Tania
Rowden, Judy
Horst, Ronald
Grant, Cameron C.
TI Vitamin D activity of breast milk in women randomly assigned to vitamin
D-3 supplementation during pregnancy
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE breast milk; vitamin D; 25-hydroxyvitamin D; pregnancy; supplementation;
infant feeding
ID FED INFANTS; 25-HYDROXYVITAMIN-D; METABOLITES; LACTATION; CALCIUM
AB Background: Human milk is typically low in vitamin D activity (VDA). Whether the vitamin D content of breast milk at birth can be increased by supplementing the mother during pregnancy has not been reported to the best of our knowledge.
Objective: We examined the effect of vitamin D supplementation during pregnancy on breast-milk VDA in the first 2 mo of lactation.
Design: Breast-milk samples were obtained from women who were enrolled in a randomized, double-blinded, placebo-controlled trial. of vitamin D supplementation during pregnancy. Pregnant women were enrolled at 27 wk of gestation and randomly assigned to the following 3 groups: a placebo group, a group who received one dosage of daily oral vitamin D-3 (1000 IU), or a group who received 2 dosages of daily oral vitamin D-3 (2000 IU). Serum 25-hydroxy-vitamin D [25(OH)D] was measured at enrollment, at 36 wk of gestation, and in cord blood at birth. Study participants who were breastfeeding were invited to provide breast-milk samples for VDA measurement [concentration of vitamin D-2, vitamin D-3, 25(OH)D-2, and 25(OH)D-3] at 2 wk and 2 mo postpartum. A linear mixed model was used to compare breast-milk VDA between the 3 study groups.
Results: A total of 75 women provided breast-milk samples (44 women provided breast-milk samples at both 2 wk and 2 mo postpartum). The mean (95% CI) VDA at age 2 wk was 52 IU/L (12, 217 IU/L) in the placebo group, 51 IU/L (17, 151 IU/L) in the 1000-IU group, and 74 IU/L (25, 221 IU/L) in the 2000-IU group; and at age 2 mo, the mean (95% CI) VDA was 45 IU/L (16, 124 IU/L), 43 IU/L (18, 103 IU/L), and 58 IU/L (15, 224 IU/L), respectively. There was no significant interaction in VDA between the sample-collection time and treatment (P = 0.61), but there was a difference between lower- and higher-dosage treatment groups (P = 0.04).
Conclusion: Maternal vitamin D supplementation during pregnancy of 2000 IU/d (compared with 1000 IU/d and with a placebo) results in a higher VDA of breast milk >= 2 mo postpartum. This trial was registered at the Australian New Zealand Clinical Trials Registry as ACTRN12610000483055.
C1 [Wall, Clare R.] Univ Auckland, Discipline Nutr & Dietet, Auckland 1, New Zealand.
[Stewart, Alistair W.; Scragg, Robert] Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand.
[Mitchell, Edwin A.; Milne, Tania; Rowden, Judy; Grant, Cameron C.] Univ Auckland, Dept Pediat Child & Youth Hlth, Auckland 1, New Zealand.
[Ekeroma, Alec] Univ Auckland, Obstet & Gynecol, Auckland 1, New Zealand.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Emergency Med, Boston, MA USA.
[Crane, Julian] Univ Otago, Med, Wellington, New Zealand.
[Horst, Ronald] Heartland Assays LLC, Ames, IA USA.
[Grant, Cameron C.] Auckland Dist Hlth Beard, Starship Childrens Hosp, Auckland, New Zealand.
RP Wall, CR (reprint author), Univ Auckland, Discipline Nutr & Dietet, Auckland 1, New Zealand.
EM c.wall@auck-land.ac.nz
FU Health Research Council of New Zealand [09/215R]; University of Auckland
Faculty Research Development Grant; Cure Kids
FX Supported by the Health Research Council of New Zealand (grant number
09/215R). A University of Auckland Faculty Research Development Grant
provided the additional funding required for the analyses of breast milk
samples. EAM is supported by Cure Kids.
NR 22
TC 2
Z9 2
U1 1
U2 6
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD FEB
PY 2016
VL 103
IS 2
BP 382
EP 388
DI 10.3945/ajcn.115.114603
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DC8JJ
UT WOS:000369465400013
PM 26702121
ER
PT J
AU Mehta, AJ
Cassidy, A
Litonjua, AA
Sparrow, D
Vokonas, P
Schwartz, J
AF Mehta, Amar J.
Cassidy, Aedin
Litonjua, Augusto A.
Sparrow, David
Vokonas, Pantel
Schwartz, Joel
TI Dietary anthocyanin intake and age-related decline in lung function:
longitudinal findings from the VA Normative Aging Study
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE anthocyanins; clinical epidemiology; diet; flavonoids; lung function
tests
ID OBSTRUCTIVE PULMONARY-DISEASE; FOOD FREQUENCY QUESTIONNAIRE; NF-KAPPA-B;
OXIDATIVE STRESS; VENTILATORY FUNCTION; AIRWAY INFLAMMATION;
GENERAL-POPULATION; CONTROLLED-TRIAL; NATIONAL-HEALTH; GLOBAL BURDEN
AB Background: It is unknown whether habitual intake of dietary flavonoids, known for their antioxidative and anti-inflammatory properties, affects longitudinal change in lung function.
Objective: We investigated whether different flavonoid subclasses present in the habitual diet were associated with beneficial changes in lung function over time in the elderly.
Design: This longitudinal analysis included 839 participants from the VA (Veterans Affairs) Normative Aging Study whose lung function [forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC)] was measured at 2 and up to 5 visits between 1992 and 2008 (n = 2623 measurements). Yearly average intake of major flavonoid subclasses (anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polymers) was calculated from food-frequency questionnaires at each visit. We estimated adjusted differences in annual change in lung function associated with each flavonoid subclass, categorized into quartiles, in linear mixed-effects regression models after adjustment for lifestyle and dietary confounders.
Results: Strong inverse associations were found between anthocyanin intake and age-related decline in lung function. Independent of dietary and nondietary risk factors, slower rates of FEV1 and FVC decline by 23.6 (95% CI: 16.6, 30.7) and 37.3 (95% CI: 27.8, 46.8) mIJy, respectively, were observed in participants in the fourth quartile of intake compared with participants in the first quartile (P-trend < 0.0001). The protective associations observed for anthocyanin intake were present in both current/former and never smokers. Compared with no or very low intakes, an intake of >= 2 servings of anthocyanin-rich bluebenies/wk was associated with slower decline in FEV1 and FVC by 22.5 (95% CI: 10.8, 34.2) and 37.9 (95% CI: 22.1, 53.7) mL/y, respectively. To a lesser extent, higher flavan-3-ol intake was also associated with slower lung function decline.
Conclusions: An attenuation of age-related lung function decline was associated with higher dietary anthocyanin intake in this longitudinal sample of predominantly elderly men. Further prospective studies are needed to confirm these novel associations.
C1 [Mehta, Amar J.; Schwartz, Joel] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Cassidy, Aedin] Univ E Anglia, Norwich Med Sch, Dept Nutr, Norwich NR4 7TJ, Norfolk, England.
[Litonjua, Augusto A.; Sparrow, David] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA.
[Litonjua, Augusto A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
[Sparrow, David; Vokonas, Pantel] VA Boston Healthcare Syst, VA Normat Aging Study, Boston, MA USA.
[Sparrow, David; Vokonas, Pantel] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
RP Mehta, AJ (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
EM amehta@hsph.harvard.edu
FU National Institute of Environmental Health Sciences [ES014663-01A2]; US
Environmental Protection Agency [EPA R832416, R827353, R83241601];
Cooperative Studies Program/Epidemiology Research and Information Center
of the US Department of Veterans Affairs; Massachusetts Veterans
Epidemiology Research and Information Center, Boston, Massachusetts; NIH
[R01-AG002287, R01-AG018436, R29-AG007465]; VA Research Career Scientist
award; Royal Society Wolfson Research Merit Award; UK Biotechnology and
Biological Sciences Research Council (BBSRC) [BB/J004545/1]
FX Supported by the grants from the National Institute of Environmental
Health Sciences (ES014663-01A2) and from the US Environmental Protection
Agency (EPA R832416, R827353, and R83241601). The VA (Veterans Affairs)
Normative Aging Study is supported by the Cooperative Studies
Program/Epidemiology Research and Information Center of the US
Department of Veterans Affairs and is a component of the Massachusetts
Veterans Epidemiology Research and Information Center, Boston,
Massachusetts. Support was also provided by NIH grants R01-AG002287,
R01-AG018436, and R29-AG007465. This research was also supported by a VA
Research Career Scientist award to DS, a Royal Society Wolfson Research
Merit Award, and UK Biotechnology and Biological Sciences Research
Council funding (BBSRC reference BB/J004545/1) to AC. This is an open
access article distributed under the CC-BY license
(http://creativecommons.org/licenses/by/3.0/).
NR 58
TC 4
Z9 4
U1 3
U2 8
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD FEB
PY 2016
VL 103
IS 2
BP 542
EP 550
DI 10.3945/ajcn.115.121467
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DC8JJ
UT WOS:000369465400030
PM 26791184
ER
PT J
AU Castillo, JJ
Mulkey, F
Geyer, S
Kolitz, JE
Blum, W
Powell, BL
George, SL
Larson, RA
Stone, RM
AF Castillo, Jorge J.
Mulkey, Flora
Geyer, Susan
Kolitz, Jonathan E.
Blum, William
Powell, Bayard L.
George, Stephen L.
Larson, Richard A.
Stone, Richard M.
TI Relationship between obesity and clinical outcome in adults with acute
myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical
trials
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Article
ID ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; BODY-MASS INDEX;
DIFFERENTIATION SYNDROME; PROGNOSTIC-FACTORS; DOSE CHEMOTHERAPY;
OVERWEIGHT; IMPACT; METAANALYSIS; MORTALITY
AB Obesity has been previously suggested as an adverse prognostic marker in patients with acute leukemia. To evaluate the relationship between obesity and clinical outcome, disease-free survival (DFS) and overall survival (OS), in patients with acute myelogenous leukemia (AML), including acute promyelocytic leukemia (APL), we performed a pooled analysis of four CALGB (Alliance) clinical trials. Our study included 446 patients with APL from CALGB 9710, and 1,648 patients between 18 and 60 years of age with non-APL AML from CALGB 9621, 10503, and 19808. Obesity was defined as BMI >= 30 kg/m(2). Multivariate Cox proportional-hazard regression models were fitted for DFS and OS. Obesity was seen in 50% and 38% of APL and non-APL AML patients, respectively. In APL patients, obesity was associated with worse DFS (HR 1.53, 95% CI 1.03-2.27; P = 0.04) and OS (HR 1.72, 95% CI 1.15-2.58; P = 01) after adjusting for age, sex, performance status, race, ethnicity, treatment arm and baseline white blood cell count. Obesity was not significantly associated with DFS or OS in the non-APL AML patients. In conclusion, our study indicates that obesity has significant prognostic value for DFS and OS in APL patients, but not for non-APL AML patients. (C) 2015 Wiley Periodicals, Inc.
C1 [Castillo, Jorge J.; Stone, Richard M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, 44 Binney St, Boston, MA 02115 USA.
[Mulkey, Flora; George, Stephen L.] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA.
[Geyer, Susan] Univ S Florida, Hlth Informat Inst, Tampa, FL USA.
[Kolitz, Jonathan E.] Monter Canc Ctr, Lake Success, NY USA.
[Blum, William] Ohio State Univ, Ctr Comprehens Canc, Div Hematol, Columbus, OH 43210 USA.
[Powell, Bayard L.] Wake Forest Univ, Ctr Comprehens Canc, Sect Hematol & Oncol, Winston Salem, NC 27109 USA.
[Larson, Richard A.] Univ Chicago, Ctr Comprehens Canc, Sect Hematol & Oncol, Chicago, IL 60637 USA.
RP Castillo, JJ (reprint author), 450 Brookline Ave,M221, Boston, MA 02215 USA.
EM jorgej_castillo@dfci.harvard.edu
OI Larson, Richard/0000-0001-9168-3203; Castillo, Jorge/0000-0001-9490-7532
FU National Cancer Institute of the National Institutes of Health
[U10CA180821, U10CA180882]
FX Contract grant sponsor: National Cancer Institute of the National
Institutes of Health; Contract grant numbers: U10CA180821 and
U10CA180882 (to the Alliance for Clinical Trials in Oncology).
NR 30
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD FEB
PY 2016
VL 91
IS 2
BP 199
EP 204
DI 10.1002/ajh.24230
PG 6
WC Hematology
SC Hematology
GA DC7WG
UT WOS:000369430800014
PM 26526191
ER
PT J
AU Cohen, SL
Morris, SN
Brown, DN
Greenberg, JA
Walsh, BW
Gargiulo, AR
Isaacson, KB
Wright, KN
Srouji, SS
Anchan, RM
Vogell, AB
Einarsson, JI
AF Cohen, Sarah L.
Morris, Stephanie N.
Brown, Doug N.
Greenberg, James A.
Walsh, Brian W.
Gargiulo, Antonio R.
Isaacson, Keith B.
Wright, Kelly N.
Srouji, Serene S.
Anchan, Raymond M.
Vogell, Alison B.
Einarsson, Jon I.
TI Contained tissue extraction using power morcellation: prospective
evaluation of leakage parameters
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE hysterectomy; in-bag morcellation; laparoscopic surgery; myomectomy
ID LAPAROSCOPIC SUPRACERVICAL HYSTERECTOMY; QUALITY-OF-LIFE; UTERINE
LEIOMYOSARCOMA; ABDOMINAL HYSTERECTOMY; CONTROLLED-TRIAL; SURGERY;
MYOMECTOMY; SARCOMA; IMPACT; BAG
AB BACKGROUND: Safe tissue removal is a challenge for minimally invasive procedures such as myomectomy, supracervical hysterectomy, or total hysterectomy of a large uterine specimen. There is concern regarding disruption or dissemination of tissue during this process, which may be of particular significance in cases of undetected malignancy. Contained tissue extraction techniques have been developed in an effort to mitigate morcellation-related risks.
OBJECTIVE: The objective of the study was to quantify perioperative outcomes of contained tissue extraction using power morcellation, specifically evaluating parameters of tissue or fluid leakage from within the containment system.
STUDY DESIGN: This was a study including a multicenter prospective cohort of adult women who underwent minimally invasive hysterectomy or myomectomy using a contained power morcellation technique. Blue dye was applied to the tissue specimen prior to removal to help identify cases of fluid or tissue leakage from within the containment system.
RESULTS: A total of 76 patients successfully underwent the contained power morcellation protocol. Mean time for the contained morcellation procedure was 30.2 minutes (+/- 22.4). The mean hysterectomy specimen weight was 480.1 g (+/- 359.1), and mean myomectomy specimen weight was 239.1 g (+/- 229.7). The vast majority of patients (73.7%) were discharged home the same day of surgery. Final pathological diagnosis was benign in all cases. Spillage of dye or tissue was noted in 7 cases (9.2%), although containment bags were intact in each of these instances.
CONCLUSION: Findings are consistent with prior work demonstrating the feasibility of contained tissue extraction; however, further refinement of this technique is warranted.
C1 [Cohen, Sarah L.; Einarsson, Jon I.] Brigham & Womens Hosp, Div Minimally Invas Gynecol Surg, 75 Francis St, Boston, MA 02115 USA.
[Walsh, Brian W.; Gargiulo, Antonio R.; Srouji, Serene S.; Anchan, Raymond M.] Brigham & Womens Hosp, Div Reprod Endocrinol & Infertil, 75 Francis St, Boston, MA 02115 USA.
[Morris, Stephanie N.; Isaacson, Keith B.] Newton Wellesley Hosp, Div Minimally Invas Gynecol Surg, Newton, MA USA.
[Brown, Doug N.] Massachusetts Gen Hosp, Ctr Minimally Invas Gynecol Surg, Boston, MA 02114 USA.
[Greenberg, James A.] Brigham & Womens Faulkner Hosp, Dept Gynecol, Boston, MA USA.
[Wright, Kelly N.; Vogell, Alison B.] Lahey Hosp & Med Ctr, Dept Gynecol, Burlington, MA USA.
RP Cohen, SL (reprint author), Brigham & Womens Hosp, Div Minimally Invas Gynecol Surg, 75 Francis St, Boston, MA 02115 USA.
EM scohen20@partners.org
NR 22
TC 5
Z9 5
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD FEB
PY 2016
VL 214
IS 2
AR 257.e1-e6
DI 10.1016/j.ajog.2015.08.076
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DC9CJ
UT WOS:000369518200013
PM 26348384
ER
PT J
AU Gordon, MC
McKenna, DS
Stewart, TL
Howard, BC
Foster, KF
Higby, K
Cypher, RL
Barth, WH
AF Gordon, Michael C.
McKenna, David S.
Stewart, Theresa L.
Howard, Bobby C.
Foster, Kimberly F.
Higby, Kenneth
Cypher, Rebecca L.
Barth, William H.
TI Transvaginal cervical length scans to prevent prematurity in twins: a
randomized controlled trial
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE prematurity prevention; transvaginal cervical length; twins
ID PRETERM BIRTH; GESTATIONS; PREDICTION; ULTRASONOGRAPHY; PROGESTERONE;
METAANALYSIS; PREGNANCIES; CERCLAGE; WOMEN; RISK
AB BACKGROUND: Twin pregnancies are associated with an increased risk of perinatal morbidity and mortality primarily due to spontaneous preterm deliveries. The mean gestational age for delivery is 35.3 weeks and twins account for 23% of preterm births < 32 weeks. A number of strategies have been proposed to prevent preterm deliveries: tocolytics, bed rest, hospitalization, home uterine activity monitoring, cerclage, and most recently, progesterone. Unfortunately, none have proven effective. Recent metaanalyses and reviews suggest that transvaginal cervical length (TVCL) ultrasound in the second trimester is a powerful predictor of preterm birth among asymptomatic women. Indeed, TVCL has the highest positive and negative predictive values for determining the risk of spontaneous preterm delivery in twin pregnancies. It follows that TVCL assessment may allow identification of a subset of twin pregnancies that re better candidates for interventions intended to prevent prematurity.
OBJECTIVE: We sought to determine whether use of TVCL prolongs gestation in twin pregnancies.
STUDY DESIGN: This is a multicenter, randomized, controlled trial of 125 dichorionic or monochorionic/diamniotic twin pregnancies without prior preterm birth < 28 weeks. The study group (n = 63) had TVCL and digital exams monthly from 16-28 weeks and were managed with a standard algorithm for activity restriction and cerclage. The control group (n = 62) had monthly digital cervical examinations but no routine TVCL ultrasound examinations. The primary outcome was gestational age at delivery. Secondary outcomes included percentage of deliveries < 35 weeks, and maternal and neonatal outcomes.
RESULTS: The mean gestational age at delivery was 35.7 weeks (95% confidence interval [CI], 35.2-36.2) among those managed with TVCL and 35.5 weeks (95% CI, 34.7-36.4) among the control patients. The Kaplan-Meier estimates of deliveries < 38 weeks were not significantly different between groups. This was true whether we compared curves with a log-rank test (P =.67), Breslow test (P =.67), or Tarone-Ware test (P =.64). The percentage of deliveries < 35 0/7 weeks did not differ: 27.4% for subjects managed with routine TVCL and 28.6% for control subjects (relative risk, 0.96; 95% CI, 0.60-1.54). Our study had an 80% power to detect a 12-day difference in the gestational age at delivery with 95% confidence.
CONCLUSION: The overall mean length of gestation and the percentage of women delivering < 35 weeks did not differ between twin gestations managed with TVCL and digital exams monthly from 16-28 weeks with a standard algorithm for activity restriction and cerclage and controls who had monthly digital cervical examinations but no routine TVCL. Routine second-trimester transvaginal ultrasound assessment of cervical length is not associated with improved outcomes when incorporated into the standard management of otherwise low-risk twin pregnancies.
C1 [Gordon, Michael C.; Stewart, Theresa L.; Cypher, Rebecca L.; Barth, William H.] Wilford Hall USAF Med Ctr, Dept Obstet & Gynecol, Lackland AFB, TX USA.
[McKenna, David S.; Foster, Kimberly F.] Wright Patterson Med Ctr, Dept Obstet & Gynecol, Wright Patterson AFB, OH USA.
[McKenna, David S.] Wright State Univ, Dayton, OH 45435 USA.
[Howard, Bobby C.] Madigan Army Med Ctr, Dept Obstet & Gynecol, Tacoma, WA 98431 USA.
[Howard, Bobby C.] Univ Tennessee, Med Ctr, Dept Obstet & Gynecol, Knoxville, TN USA.
[Higby, Kenneth] Ctr Maternal Fetal Care, San Antonio, TX USA.
[Barth, William H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Div Maternal Fetal Med, Boston, MA USA.
RP Gordon, MC (reprint author), Wilford Hall USAF Med Ctr, Dept Obstet & Gynecol, Lackland AFB, TX USA.
EM packergord@aol.com
NR 18
TC 3
Z9 3
U1 2
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD FEB
PY 2016
VL 214
IS 2
AR 277.e1-e7
DI 10.1016/j.ajog.2015.08.065
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DC9CJ
UT WOS:000369518200026
PM 26363481
ER
PT J
AU Jakobiec, FA
AF Jakobiec, Frederick A.
TI Conjunctival Primary Acquired Melanosis: Is It Time for a New
Terminology?
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MALIGNANT MELANOCYTIC LESIONS; IN-SITU HYBRIDIZATION; SINE PIGMENTO;
NEVI; EXPRESSION; FEATURES; BENIGN; CLASSIFICATION; CRYOTHERAPY;
EXPERIENCE
AB PURPOSE: To review the diagnostic categories of a group of conditions referred to as "primary acquired melanosis."
DESIGN: Literature review on the subject and proposal of an alternative diagnostic schema with histopathologic and immunohistochemical illustrations.
METHODS: Standard hematoxylin-eosin-stained sections and immunohistochemical stains for MART-1, HMB-45, microphthalmia-associated transcriptioniactor (MiTF), and Ki-67 for calculating the proliferation index are illustrated.
RESULTS: "Melanosis" is an inadequate and misleading term because it does not distinguish between conjunctival intraepithelial melanin overproduction ("hyperpigmentation") and intraepithelial melanocytic proliferation. It is recommended that "intraepithelial melanocytic proliferation" be adopted for histopathologic diagnosis. Atypical proliferations are characterized either by bloated dendritic melanocytes with enlarged cell components (dendrites, cell bodies, and nuclei) or by epithelioid melanocytes without dendrites. Atypical polygonal or epithelioid pagetoid cells may reach higher levels of the epithelium beyond the basal layer. Immunohistochemistry defines the degree of melanocytic proliferation or the cellular shape (dendritic or nondendritic) (MART-1, HMB-45) or identifies the melanocytic nuclei (MiTF). Intraepithelial melanocytic proliferation without atypia represents increased numbers of normal-appearing dendritic melanocytes (hyperplasia or early neoplasia) that generally remain confined to the basal/basement membrane region. Intraepithelial nonproliferative melanocytic pigmentation signifies the usually small number of conjunctival basal dendritic melanocytes that synthesize increased amounts of melanin that is transferred to surrounding keratinocytes.
CONCLUSION: All pre- and postoperative biopsies of flat conjunctival melanocytic disorders should be evaluated immunohistochemically if there is any question regarding atypicality. This should lead to a clearer microscopic descriptive diagnosis that is predicated on an analysis of the participating cell types and their architectural patterns. This approach is conducive to a better appreciation of features indicating when to intervene therapeutically. An accurate early diagnosis should forestall unnecessary later. surgery. (C) 2016 by Elsevier Inc. All rights reserved.
C1 [Jakobiec, Frederick A.] Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, 243 Charles St Room 328, Boston, MA 02114 USA.
[Jakobiec, Frederick A.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
[Jakobiec, Frederick A.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, 243 Charles St Room 328, Boston, MA 02114 USA.
EM Fred_Jakobiec@meei.harvard.edu
NR 62
TC 4
Z9 4
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2016
VL 162
BP 3
EP 19
DI 10.1016/j.ajo.2015.11.003
PG 17
WC Ophthalmology
SC Ophthalmology
GA DC8JU
UT WOS:000369466500002
PM 26556007
ER
PT J
AU Rudnisky, CJ
Belin, MW
Guo, R
Ciolino, JB
AF Rudnisky, Christopher J.
Belin, Michael W.
Guo, Rong
Ciolino, Joseph B.
CA Boston Type 1 Keratoprosthesis
TI Visual Acuity Outcomes of the Boston Keratoprosthesis Type 1:
Multicenter Study Results
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COUNTING FINGERS; HAND MOTION; GLAUCOMA; ENDOPHTHALMITIS; COMPLICATIONS;
CATEGORIES; VISION
AB PURPOSE: To report logarithm of the minimal angle of resolution (logMAR) visual outcomes of the Boston keratoprosthesis type 1.
DESIGN: Prospective cohort study.
METHODS: Preoperative, intraoperative, and postoperative parameters of 300 eyes of 300 patients who underwent implantation of a Boston keratoprosthesis type 1 device between January 2003 and July 2008 by 1 of 19 surgeons at 18 medical centers were collected.
RESULTS: After an average of 17.1 +/- 14.8 months, visual acuity improved significantly (P < .0001) to a mean final value of 0.89 +/- 0.64 (20/150). There were also significantly fewer eyes with light perception (6.7%; n = 19; P < .0001), although 3.1% (n = 9) progressed to no light perception. There was no association between age (P = .08), sex (P = .959), operative side (P = .167), or failure (P = .494) and final visual acuity. The median time to achieve 20/200 visual acuity was 1 month (95% confidence interval 1.0-6.0) and it was retained for an average of 47.8 months. Multivariate analysis, controlling for preoperative visual acuity, demonstrated 2 factors associated with final visual outcome: chemical injury was associated with better final vision (P = .007), whereas age-related macular degeneration was associated with poorer vision (P < .0001).
CONCLUSIONS: The Boston keratoprosthesis type 1 is an effective device for rehabilitation in advanced ocular surface disease, resulting in a significant improvement in visual acuity. Eyes achieved a mean value of 20/150 (0.89 0.64 IogMAR units) after 6 months and this was relatively stable thereafter. The best visual prognosis is observed in chemical injury eyes, whereas the worst prognosis is in aniridia, although the latter has limited visual potential. (C) 2016 by Elsevier Inc. All rights reserved.
C1 [Rudnisky, Christopher J.] Univ Alberta, Dept Ophthalmol, Edmonton, AB, Canada.
[Belin, Michael W.] Univ Arizona, Dept Ophthalmol & Vis Sci, Tucson, AZ USA.
[Guo, Rong; Ciolino, Joseph B.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
RP Ciolino, JB (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM Joseph_Ciolino@meei.harvard.edu
FU NEI, BETHESDA, MARYLAND, USA [1K08EY019686-01]; Research to Prevent
Blindness, Inc, New York, New York; Alcon, Fort Worth, Texas, USA;
Bausch & Lomb, Rochester, New York, USA; Glaucoma Research Society of
Canada, East York, Ontario, Canada; National Institutes of Health,
Bethesda, Maryland, USA; Research to Prevent Blindness, New York, New
York, USA
FX THIS RESEARCH WAS FUNDED BY NEI 1K08EY019686-01, BETHESDA, MARYLAND, USA
(J.B.C.) AND A Career Development Award from Research to Prevent
Blindness, Inc, New York, New York (J.B.C.). Financial disclosures:
Chris J. Rudnisky: Alcon, Fort Worth, Texas, USA (speaking fees); Bausch
& Lomb, Rochester, New York, USA (speaking fees); Glaucoma Research
Society of Canada, East York, Ontario, Canada (grant); Novartis, Basel,
Switzerland (stock).; Merck, Kenilworth, New Jersey, USA (stock).
Michael W. Belin: Oculus, Wetzlar, Germany (consultancy); Joseph B.
Ciolino: ORA, Andover, Massachusetts, USA (consultancy); Massachusetts
Eye and Ear Infirmary, Boston, Massachusetts, USA (employment); National
Institutes of Health, Bethesda, Maryland, USA (grant support); Research
to Prevent Blindness, New York, New York, USA (grant support). The
following author has no financial disclosures: Rong Guo. All authors
attest that they meet the current ICMJE criteria for authorship.
NR 25
TC 2
Z9 2
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2016
VL 162
BP 89
EP 98
DI 10.1016/j.ajo.2015.10.023
PG 10
WC Ophthalmology
SC Ophthalmology
GA DC8JU
UT WOS:000369466500012
PM 26550696
ER
PT J
AU Feemster, LC
Curtis, JR
AF Feemster, Laura C.
Curtis, J. Randall
TI "We Understand the Prognosis, but We Live with Our Heads in the Clouds":
Understanding Patient and Family Outcome Expectations and Their
Influence on Shared Decision Making
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Editorial Material
ID ADVANCED CANCER; COMMUNICATION; PREFERENCES
C1 [Feemster, Laura C.] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA.
[Feemster, Laura C.; Curtis, J. Randall] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
[Curtis, J. Randall] Univ Washington, Cambia Palliat Care Ctr Excellence, Seattle, WA 98195 USA.
RP Feemster, LC (reprint author), VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA.; Feemster, LC (reprint author), Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
FU NHLBI NIH HHS [HL111116, K23 HL111116]
NR 14
TC 0
Z9 0
U1 4
U2 4
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD FEB 1
PY 2016
VL 193
IS 3
BP 239
EP 241
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA DC6UR
UT WOS:000369355600008
PM 26829423
ER
PT J
AU Kellum, JA
Chawla, LS
Keener, C
Singbartl, K
Palevsky, PM
Pike, FL
Yealy, DM
Huang, DT
Angus, DC
AF Kellum, John. A.
Chawla, Lakhmir S.
Keener, Christopher
Singbartl, Kai
Palevsky, Paul M.
Pike, Francis L.
Yealy, Donald M.
Huang, David T.
Angus, Derek C.
CA ProCESS & ProGReSS-AKI Investigato
TI The Effects of Alternative Resuscitation Strategies on Acute Kidney
Injury in Patients with Septic Shock
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE sepsis; septic shock; resuscitation; early goal-directed therapy; acute
kidney injury
ID CRITICALLY-ILL PATIENTS; CREATININE; MORTALITY; RECOVERY; CRITERIA;
TRIAL; CARE
AB Rationale: Septic shock is a common cause of acute kidney injury (AKI), and fluid resuscitation is a major part of therapy.
Objectives: To determine if structured resuscitation designed to alter fluid, blood, and vasopressor use affects the development or severity of AKI or outcomes.
Methods: Ancillary study to the ProCESS (Protocolized Care for Early Septic Shock) trial of alternative resuscitation strategies (two protocols vs. usual care) for septic shock.
Measurements and Main Results: We studied 1,243 patients and classified AKI using serum creatinine and urine output. We determined recovery status at hospital discharge, examined rates of renal replacement therapy and fluid overload, and measured biomarkers of kidney damage. Among patients without evidence of AKI at enrollment, 37.6% of protocolized care and 38.1% of usual care patients developed kidney injury (P = 0.90). AKI duration (P = 0.59) and rates of renal replacement therapy did not differ between study arms (6.9% for protocolized care and 4.3% for usual care; P = 0.08). Fluid overload occurred in 8.3% of protocolized care and 6.3% of usual care patients (P = 0.26). Among patients with severe AKI, complete and partial recovery was 50.7 and 13.2% for protocolized patients and 49.1 and 13.4% for usual care patients (P = 0.93). Sixty-day hospital mortality was 6.2% for patients without AKI, 16.8% for those with stage 1, and 27.7% for stages 2 to 3.
Conclusions: In patients with septic shock, AKI is common and associated with adverse outcomes, but it is not influenced by protocolized resuscitation compared with usual care.
C1 [Kellum, John. A.; Pike, Francis L.; Huang, David T.; Angus, Derek C.] Univ Pittsburgh, Dept Crit Care Med, CRISMA Ctr, Pittsburgh, PA 15261 USA.
[Kellum, John. A.; Chawla, Lakhmir S.; Singbartl, Kai; Palevsky, Paul M.] Univ Pittsburgh, Ctr Crit Care Nephrol, Pittsburgh, PA 15261 USA.
[Keener, Christopher] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
[Palevsky, Paul M.] Univ Pittsburgh, Dept Med, Renal Electrolyte Div, 930 Scaife Hall, Pittsburgh, PA 15261 USA.
[Yealy, Donald M.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15261 USA.
[Chawla, Lakhmir S.] Vet Affairs Med Ctr, Dept Med, Div Intens Care Med, 50 Irving St NW, Washington, DC 20422 USA.
[Chawla, Lakhmir S.] Vet Affairs Med Ctr, Div Nephrol, 50 Irving St NW, Washington, DC 20422 USA.
[Singbartl, Kai] Penn State Hershey Med Ctr, Dept Anesthesia, Hershey, PA USA.
[Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Med Serv, Renal Sect, Pittsburgh, PA USA.
RP Kellum, JA (reprint author), Univ Pittsburgh, Dept Crit Care Med, 3550 Terrace St,604 Scaife Hall, Pittsburgh, PA 15261 USA.
EM kellumja@ccm.upmc.edu
OI Palevsky, Paul/0000-0002-7334-5400
FU National Institutes of Health (NIH)/National Institute of Diabetes and
Digestive and Kidney Diseases grant [R01 DK083961]; NIH/National
Institute of General Medical Sciences grant [P50 GM076659]
FX Supported by National Institutes of Health (NIH)/National Institute of
Diabetes and Digestive and Kidney Diseases grant R01 DK083961 and
NIH/National Institute of General Medical Sciences grant P50 GM076659.
NR 19
TC 11
Z9 11
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD FEB 1
PY 2016
VL 193
IS 3
BP 281
EP 287
DI 10.1164/rccm.201505-0995OC
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA DC6UR
UT WOS:000369355600013
PM 26398704
ER
PT J
AU Pugmire, BS
Shailam, R
Sagar, P
Liu, B
Li, XH
Palmer, WE
Huang, AJ
AF Pugmire, Brian S.
Shailam, Randheer
Sagar, Pallavi
Liu, Bob
Li, Xinhua
Palmer, William E.
Huang, Ambrose J.
TI Initial Clinical Experience With Extremity Cone-Beam CT of the Foot and
Ankle in Pediatric Patients
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE cone-beam CT; musculoskeletal imaging; pediatric imaging; radiation dose
ID COMPUTED-TOMOGRAPHY; IMAGING TECHNIQUE; WEIGHT-BEARING; CBCT; SYSTEM;
WRIST; MSCT
AB OBJECTIVE. Extremity cone-beam CT (CBCT) scanners have become available for clinical use in the United States. The purpose of this study was to review an initial clinical experience with CBCT of the foot and ankle in pediatric patients.
MATERIALS AND METHODS. A retrospective review was conducted of all foot or ankle CBCT examinations performed on patients 18 years old and younger at one institution from August 1, 2013, through February 28, 2015. A t test was used to compare mean effective dose for CBCT with that for MDCT foot or ankle examinations of age-matched control subjects. To assess changes in utilization, a t test also was used to compare the mean numbers of foot or ankle CT examinations per month before and after installation of the CBCT scanner at the institution.
RESULTS. Thirty-four CBCT examinations were performed. The mean effective dose was 0.013 +/- 0.003 mSv compared with 0.023 +/- 0.020 mSv for MDCT of age-matched control subjects (p < 0.005). The mean numbers of foot or ankle CT examinations per month were 3.4 in the 18 months before and 3.8 in the 18 months after installation of the CBCT scanner (p = 0.28). The mean number of foot or ankle MDCT examinations per month decreased significantly (3.4 vs 1.9, p = 0.03) over the same period. In 56% of patients, CBCT revealed important findings that were not visible on contemporaneous radiographs. In 68% of patients, the CBCT findings affected clinical management.
CONCLUSION. CBCT of the foot or ankle of pediatric patients is a viable lower-dose alternative to MDCT that provides important information that may affect clinical management.
C1 [Pugmire, Brian S.; Palmer, William E.; Huang, Ambrose J.] Massachusetts Gen Hosp, Dept Radiol, Div Musculoskeletal Imaging & Intervent, 55 Fruit St,Yawkey 6E, Boston, MA 02114 USA.
[Shailam, Randheer; Sagar, Pallavi] Massachusetts Gen Hosp, Dept Radiol, Div Pediat Imaging, Boston, MA 02114 USA.
[Liu, Bob; Li, Xinhua] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Huang, AJ (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Musculoskeletal Imaging & Intervent, 55 Fruit St,Yawkey 6E, Boston, MA 02114 USA.
EM ajhuang@mgh.harvard.edu
NR 31
TC 0
Z9 0
U1 1
U2 1
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
EI 1546-3141
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD FEB
PY 2016
VL 206
IS 2
BP 431
EP 435
DI 10.2214/AJR.15.15099
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DC9PH
UT WOS:000369553000047
PM 26797374
ER
PT J
AU Platts-Mills, TF
Flannigan, SA
Bortsov, AV
Smith, S
Domeier, RM
Swor, RA
Hendry, PL
Peak, DA
Rathlev, NK
Jones, JS
Lee, DC
Keefe, FJ
Sloane, PD
McLean, SA
AF Platts-Mills, Timothy F.
Flannigan, Sean A.
Bortsov, Andrey V.
Smith, Samantha
Domeier, Robert M.
Swor, Robert A.
Hendry, Phyllis L.
Peak, David A.
Rathlev, Niels K.
Jones, Jeffrey S.
Lee, David C.
Keefe, Francis J.
Sloane, Philip D.
McLean, Samuel A.
TI Persistent Pain Among Older Adults Discharged Home From the Emergency
Department After Motor Vehicle Crash: A Prospective Cohort Study
SO ANNALS OF EMERGENCY MEDICINE
LA English
DT Article
ID WHIPLASH-ASSOCIATED DISORDERS; PERITRAUMATIC DISTRESS INVENTORY;
HAND-HELD DYNAMOMETRY; MUSCULOSKELETAL PAIN; PRIMARY-CARE; FUNCTIONAL
DECLINE; NONCANCER PAIN; UNITED-STATES; NECK PAIN; COLLISION
AB Study objective: Motor vehicle crashes are the second most common form of trauma among older adults. We seek to describe the incidence, risk factors, and consequences of persistent pain among older adults evaluated in the emergency department (ED) after a motor vehicle crash.
Methods: We conducted a prospective longitudinal study of patients aged 65 years or older who presented to one of 8 EDs after motor vehicle crash between June 2011 and June 2014 and were discharged home after evaluation. ED evaluation was done through in-person interview; follow-up data were obtained through mail-in survey or telephone call. Pain severity (0 to 10 scale) overall and for 15 parts of the body were assessed at each follow-up point. Principal component analysis was used to assess the dimensionality of the locations of pain data. Participants reporting pain severity greater than or equal to 4 attributed to the motor vehicle crash at 6 months were defined as having persistent pain.
Results: Of the 161 participants, 72% reported moderate to severe pain at the ED evaluation. At 6 months, 26% of participants reported moderate to severe motor vehicle crash-related pain. ED characteristics associated with persistent pain included acute pain severity; pain located in the head, neck, and jaw or lower back and legs; poor self rated health; less formal education; pre-motor vehicle crash depressive symptoms; and patient's expected time to physical recovery more than 30 days. Compared with individuals without persistent pain, those with persistent pain were substantially more likely at 6-month follow-up to have also experienced a decline in their capacity for physical function (73% versus 36%; difference=37%; 95% confidence interval [CI] 19% to 52%), a new difficulty with activities of daily living (42% versus 17%; difference=26%; 95% CI 10% to 43%), a 1-point or more reduction in overall self-rated health on a 5-point scale (54% versus 30%; difference=24%; 95% CI 6% to 41%), and a change in their living situation to obtain additional help (23% versus 8%; difference=15%; 95% CI 2% to 31%).
Conclusion: Among older adults discharged home from the ED post-evaluation after a motor vehicle crash, persistent pain is common and frequently associated with functional decline and disability.
C1 [Platts-Mills, Timothy F.; Flannigan, Sean A.; Smith, Samantha; McLean, Samuel A.] Univ N Carolina, Dept Emergency Med, Chapel Hill, NC USA.
[Platts-Mills, Timothy F.; Bortsov, Andrey V.; McLean, Samuel A.] Univ N Carolina, Dept Anesthesiol, Chapel Hill, NC USA.
[Sloane, Philip D.] Univ N Carolina, Dept Family Med, Chapel Hill, NC 27514 USA.
[Domeier, Robert M.] St Joseph Mercy Hosp, Dept Emergency Med, Ypsilanti, MI USA.
[Swor, Robert A.] William Beaumont Hosp, Dept Emergency Med, Royal Oak, MI 48072 USA.
[Hendry, Phyllis L.] Univ Florida Hlth, Dept Emergency Med, Jacksonville, FL USA.
[Peak, David A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Rathlev, Niels K.] Baystate Med Ctr, Dept Emergency Med, Springfield, MA USA.
[Jones, Jeffrey S.] Spectrum Hlth, Grand Rapids, MI USA.
[Lee, David C.] North Shore Hosp Syst, Dept Emergency Med, Manhasset, NY USA.
[Keefe, Francis J.] Duke Univ, Dept Psychol & Neurosci, Durham, NC USA.
RP Platts-Mills, TF (reprint author), Univ N Carolina, Dept Emergency Med, Chapel Hill, NC USA.; Platts-Mills, TF (reprint author), Univ N Carolina, Dept Anesthesiol, Chapel Hill, NC USA.
EM tplattsm@med.unc.edu
OI McLean, Samuel/0000-0001-9482-3582
FU National Institute on Aging [K32AG038548]
FX By Annals policy, all authors are required to disclose any and all
commercial, financial, and other relationships in any way related to the
subject of this article as per ICMJE conflict of interest guidelines
(see www.icmje.org). The authors have stated that no such relationships
exist and provided the following details: This study was supported by
National Institute on Aging grant K32AG038548 (to Dr. Platts-Mills).
NR 56
TC 6
Z9 6
U1 2
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-0644
J9 ANN EMERG MED
JI Ann. Emerg. Med.
PD FEB
PY 2016
VL 67
IS 2
BP 166
EP 176
DI 10.1016/j.annemergmed.2015.05.003
PG 11
WC Emergency Medicine
SC Emergency Medicine
GA DC3MW
UT WOS:000369124400007
PM 26092559
ER
PT J
AU Calcagno, C
Mulder, WJM
Nahrendorf, M
Fayad, ZA
AF Calcagno, Claudia
Mulder, Willem J. M.
Nahrendorf, Matthias
Fayad, Zahi A.
TI Systems Biology and Noninvasive Imaging of Atherosclerosis
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE atherosclerosis; cardiovascular diseases; inflammation; lipids; risk
factors
ID CORONARY-ARTERY-DISEASE; POSITRON-EMISSION-TOMOGRAPHY; INTIMA-MEDIA
THICKNESS; URINARY PROTEOMIC BIOMARKERS; GENOME-WIDE ASSOCIATION;
CONTRAST-ENHANCED MRI; GENETIC RISK SCORE; CELL LUNG-CANCER;
CARDIOVASCULAR-DISEASE; HEART-DISEASE
C1 [Calcagno, Claudia; Mulder, Willem J. M.; Fayad, Zahi A.] Icahn Sch Med Mt Sinai, Translat & Mol Imaging Inst, New York, NY 10029 USA.
[Mulder, Willem J. M.] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
[Nahrendorf, Matthias] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA USA.
RP Calcagno, C (reprint author), Icahn Sch Med Mt Sinai, Translat & Mol Imaging Inst, New York, NY 10029 USA.
EM claudia.calcagno@mssm.edu
FU Harold S. Geneen Charitable Trust Award [R01 EB009638, R01 HL071021, R01
HL118440, R01 HL125703]; NWO Vidi
FX This work was supported by R01 EB009638 (Z.A.F.), R01 HL071021 (Z.A.F.,
C.C.), R01 HL118440 (W.J.M.M.), R01 HL125703 (W.J.M.M.), Harold S.
Geneen Charitable Trust Award (Z.A.F.); NWO Vidi (W.J.M.M.).
NR 129
TC 2
Z9 2
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD FEB
PY 2016
VL 36
IS 2
BP E1
EP E8
DI 10.1161/ATVBAHA.115.306350
PG 8
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA DC8PZ
UT WOS:000369483400001
PM 26819466
ER
PT J
AU Sevy, S
Sher, L
AF Sevy, Serge
Sher, Leo
TI Gender differences in the dosing of antipsychotic medications
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Letter
C1 [Sevy, Serge; Sher, Leo] James J Peters VA Med Ctr, 130 West Kingsbridge Rd, New York, NY 10468 USA.
[Sher, Leo] Mt Sinai Sch Med, New York, NY USA.
RP Sevy, S (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd, New York, NY 10468 USA.
EM sevymd@gmail.com
NR 3
TC 0
Z9 0
U1 1
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0004-8674
EI 1440-1614
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
PD FEB
PY 2016
VL 50
IS 2
SI SI
BP 185
EP 186
DI 10.1177/0004867415609426
PG 3
WC Psychiatry
SC Psychiatry
GA DC5FQ
UT WOS:000369247300022
PM 26450940
ER
PT J
AU Walters, MC
De Castro, LM
Sullivan, KM
Krishnamurti, L
Kamani, N
Bredeson, C
Neuberg, D
Hassell, KL
Farnia, S
Campbell, A
Petersdorf, E
AF Walters, Mark C.
De Castro, Laura M.
Sullivan, Keith M.
Krishnamurti, Lakshmanan
Kamani, Naynesh
Bredeson, Christopher
Neuberg, Donna
Hassell, Kathryn L.
Farnia, Stephanie
Campbell, Andrew
Petersdorf, Effie
TI Indications and Results of HLA-Identical Sibling Hematopoietic Cell
Transplantation for Sickle Cell Disease
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Review
DE Sickle cell anemia; Hematopoietic cell transplant; HLA-identical
sibling; Transplant-related complications; Risks; Children
ID BONE-MARROW-TRANSPLANTATION; PULMONARY-HYPERTENSION; CONDITIONING
REGIMEN; THALASSEMIA MAJOR; REDUCED-TOXICITY; EXPERT PANEL; ANEMIA;
CHILDREN; ADULTS; SURVIVAL
AB Although a number of published trials exist of HLA-identical sibling hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) that span 2 decades, when and for whom this therapy should be pursued is a subject of debate. Assessments of the risks of transplant-related complications that include infertility and debilitating graft-versus-host disease and long-term quality of life after successful HCT, are difficult to perform without prospective trials in transplant and nontransplant cohorts. However, it is possible to assess the risk of mortality and to compare published rates of survival in individuals with SCD treated and not treated by HCT. In this brief review, projections about mortality risk based on recent published reports are reviewed and summarized. The published data show overall survival and event-free survival rates of 95% and 92%, respectively, in children treated by HLA-identical sibling HCT. The overall survival rates in the Center for International Blood and Marrow Transplant Research (N = 412) and European Blood and Marrow Transplant (N = 487) registries were 91% and 95%, respectively. These results provide broad support for the therapeutic value of HLA-identical sibling HCT for children with SCD and serve as the basis for a strong recommendation in favor of the option of HCT when a suitable donor is available. The experience of HLA-identical sibling HCT in adults with SCD is limited but appears to be similar to results in childien. These preliminary observations, however, warrant further investigation. (C) 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.
C1 [Walters, Mark C.] Univ Calif San Francisco, Benioff Childrens Hosp, Blood & Marrow Transplant Program, Oakland, CA 94609 USA.
[De Castro, Laura M.] Univ Pittsburgh, Med Ctr, Div Hematol & Oncol, Pittsburgh, PA USA.
[Sullivan, Keith M.] Duke Univ, Med Ctr, Blood & Marrow Transplant Program, Durham, NC USA.
[Krishnamurti, Lakshmanan] Emory Univ, Dept Pediat, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA.
[Kamani, Naynesh] AABB, Ctr Cellular Therapies & Res, Bethesda, MD USA.
[Bredeson, Christopher] Univ Ottawa, Ottawa Hosp Res Inst, Blood & Marrow Transplant Program, Ottawa, ON, Canada.
[Neuberg, Donna] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA.
[Hassell, Kathryn L.] Univ Colorado, Sch Med, Aurora, CO USA.
[Farnia, Stephanie] Natl Marrow Donor Program, Minneapolis, MN USA.
[Campbell, Andrew] Univ Michigan, Sch Med, Dept Pediat, Blood & Marrow Transplant Program,Div Pediat Hema, Ann Arbor, MI USA.
[Petersdorf, Effie] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Petersdorf, Effie] Univ Washington, Sch Med, Seattle, WA USA.
RP Walters, MC (reprint author), Univ Calif San Francisco, Benioff Childrens Hosp, 747 52nd St, Oakland, CA 94609 USA.
EM mwalters@mail.cho.org
FU NHLBI NIH HHS [R34 HL108761]
NR 46
TC 8
Z9 8
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2016
VL 22
IS 2
BP 207
EP 211
DI 10.1016/j.bbmt.2015.10.017
PG 5
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DC2JD
UT WOS:000369042100004
PM 26500093
ER
PT J
AU Pasquini, MC
Zhang, MJ
Medeiros, BC
Armand, P
Hui, ZH
Nishihori, T
Aljurf, MD
Akpek, G
Cahn, JY
Cairo, MS
Cerny, J
Copelan, EA
Deol, A
Freytes, CO
Gale, RP
Ganguly, S
George, B
Gupta, V
Hale, GA
Kamble, RT
Klumpp, TR
Lazarus, HM
Luger, SM
Liesveld, JL
Litzow, MR
Marks, DI
Martino, R
Norkin, M
Olsson, RF
Oran, B
Pawarode, A
Pulsipher, MA
Ramanathan, M
Reshef, R
Saad, AA
Saber, W
Savani, BN
Schouten, HC
Ringden, O
Tallman, MS
Uy, GL
Wood, WA
Wirk, B
Perez, WS
Batiwalla, M
Weisdorf, DJ
AF Pasquini, Marcelo C.
Zhang, Mei-Jie
Medeiros, Bruno C.
Armand, Philippe
Hui, Zhen-Huan
Nishihori, Taiga
Aljurf, Mahmoud D.
Akpek, Goerguen
Cahn, Jean-Yves
Cairo, Mitchell S.
Cerny, Jan
Copelan, Edward A.
Deol, Abhinav
Freytes, Cesar O.
Gale, Robert Peter
Ganguly, Siddhartha
George, Biju
Gupta, Vikas
Hale, Gregory A.
Kamble, Rammurti T.
Klumpp, Thomas R.
Lazarus, Hillard M.
Luger, Selina M.
Liesveld, Jane L.
Litzow, Mark R.
Marks, David I.
Martino, Rodrigo
Norkin, Maxim
Olsson, Richard F.
Oran, Betul
Pawarode, Attaphol
Pulsipher, Michael A.
Ramanathan, Muthalagu
Reshef, Ran
Saad, Ayman A.
Saber, Wael
Savani, Bipin N.
Schouten, Harry C.
Ringden, Olle
Tallman, Martin S.
Uy, Geoffrey L.
Wood, William A., Jr.
Wirk, Baldeep
Perez, Waleska S.
Batiwalla, Minoo
Weisdorf, Daniel J.
TI Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype
Myeloid Malignancies
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Monosomal karyotype; Acute myeloid leukemia; Myelodysplastic syndrome;
Allogeneic transplantation
ID ACUTE MYELOGENOUS LEUKEMIA; MYELODYSPLASTIC SYNDROMES;
REDUCED-INTENSITY; PROGNOSTIC VALUE; SCORING SYSTEM; ALLOGENEIC
TRANSPLANTATION; CYTOGENETIC ABNORMALITIES; MARROW-TRANSPLANTATION;
CONDITIONING REGIMEN; INTERNATIONAL BLOOD
AB The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. MK+AML was associated with higher disease relapse (hazard ratio, 1.98; P < .01), similar transplantation-related mortality (TRM) (hazard ratio, 1.01; P = .90), and worse survival (hazard ratio, 1.67; P < .01) compared with those outcomes for other cytogenetically defined AML. Among patients with MDS, MK+ MDS was associated with higher disease relapse (hazard ratio, 2.39; P < .01), higher TRM (hazard ratio, 1.80; P < .01), and worse survival (HR, 2.02; P < .01). Subset analyses comparing chromosome 7 abnormalities (del7/7q) with or without MK+ demonstrated higher mortality for MK+ disease in for both AML (hazard ratio, 1.72; P < .01) and MDS (hazard ratio, 1.79; P < .01). The strong negative impact of MK+ in myeloid malignancies was observed in all age groups and using either myeloablative or reduced-intensity conditioning regimens. Alternative approaches to mitigate disease relapse in this population are needed. (C) 2016 American Society for Blood and Marrow Transplantation.
C1 [Pasquini, Marcelo C.; Zhang, Mei-Jie; Hui, Zhen-Huan; Saber, Wael; Perez, Waleska S.] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
[Zhang, Mei-Jie] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA.
[Medeiros, Bruno C.] Stanford Univ, Sch Med, Dept Hematol, Stanford, CA 94305 USA.
[Armand, Philippe] Dana Farber Canc Inst, Dept Med Oncol Hematol Malignancies, Boston, MA 02115 USA.
[Nishihori, Taiga] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA.
[Aljurf, Mahmoud D.] King Faisal Specialist Hosp & Res Ctr, Dept Oncol, Riyadh 11211, Saudi Arabia.
[Akpek, Goerguen] Banner MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy Program, Gilbert, AZ USA.
[Cahn, Jean-Yves] Univ Hosp, Dept Hematol, Grenoble, France.
[Cairo, Mitchell S.] New York Med Coll, Dept Pediat, Div Pediat Hematol Oncol & Stem Cell Transplantat, Valhalla, NY 10595 USA.
[Cerny, Jan; Ramanathan, Muthalagu] UMass Mem Med Ctr, Dept Med, Worcester, MA USA.
[Copelan, Edward A.] Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA.
[Deol, Abhinav] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA.
[Freytes, Cesar O.] S Texas Vet Hlth Care Syst, Div Hematol & Oncol, San Antonio, TX USA.
[Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Gale, Robert Peter] Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Hematol Res Ctr, London, England.
[Ganguly, Siddhartha] Univ Kansas, Med Ctr, Div Hematol & Oncol, Blood & Marrow Transplantat, Kansas City, KS 66103 USA.
[George, Biju] Christian Med Coll & Hosp, Dept Haematol, Vellore, Tamil Nadu, India.
[Gupta, Vikas] Univ Hlth Network, Princess Margaret Canc Ctr, Blood & Marrow Transplant Program, Toronto, ON, Canada.
[Hale, Gregory A.] Univ S Florida, All Childrens Hosp, Dept Hematol Oncol, St Petersburg, FL 33701 USA.
[Kamble, Rammurti T.] Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA.
[Klumpp, Thomas R.] Thomas Jefferson Univ Hosp, Dept Med Oncol, Philadelphia, PA 19107 USA.
[Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA.
[Luger, Selina M.; Reshef, Ran] Univ Penn, Med Ctr, Abramson Canc Ctr, Dept Med, Philadelphia, PA 19104 USA.
[Liesveld, Jane L.] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA.
[Litzow, Mark R.] Mayo Clin, Div Hematol & Transplant Ctr, Rochester, MN USA.
[Marks, David I.] Univ Hosp Bristol NHS Trust, Pediat Bone Marrow Transplant, Bristol, Avon, England.
[Martino, Rodrigo] Hosp Santa Creu & Sant Pau, Div Clin Hematol, Barcelona, Spain.
[Norkin, Maxim] Univ Florida, Coll Med, Div Hematol Oncol, Gainesville, FL USA.
[Olsson, Richard F.; Ringden, Olle] Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden.
[Olsson, Richard F.] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden.
[Oran, Betul] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA.
[Pawarode, Attaphol] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Pulsipher, Michael A.] Univ So Calif, Keck Sch Med, Childrens Hosp Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90033 USA.
[Saad, Ayman A.] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA.
[Savani, Bipin N.] Vanderbilt Univ, Dept Med, Div Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Schouten, Harry C.] Acad Ziekenhuis, Dept Hematol, Maastricht, Netherlands.
[Ringden, Olle] Ctr Allogene Stem Cell Transplantat, Stockholm, Sweden.
[Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA.
[Uy, Geoffrey L.] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA.
[Wood, William A., Jr.] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA.
[Wirk, Baldeep] Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA.
[Batiwalla, Minoo] NHLBI, NIH, Hematol Branch, Bldg 10, Bethesda, MD 20892 USA.
[Weisdorf, Daniel J.] Univ Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA.
RP Pasquini, MC (reprint author), 9200 W Wisconsin Ave, Milwaukee, WI 52336 USA.
EM mpasquini@mcw.edu
FU Public Health Service from the National Cancer Institute (NCI)
[U24-CA076518]; Public Health Service from National Heart, Lung and
Blood Institute (NHLBI) [U24-CA076518]; Public Health Service from
National Institute of Allergy and Infectious Diseases (NIAID)
[U24-CA076518]; NHLBI [5U10HL069294]; NCI [5U10HL069294]; Health
Resources and Services Administration (HRSA/DHHS) [HHSH250201200016C];
Office of Naval Research [N00014-13-1-0039, N00014-14-1-0028]; Actinium
Pharmaceuticals; Allos Therapeutics, Inc.; Amgen, Inc.; Ariad; Be the
Match Foundation; Blue Cross and Blue Shield Association; Celgene
Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center;
Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture
Ltd.; Genentech, Inc.; Gentium SpA; Genzyme Corporation;
GlaxoSmithKline; Health Research, Inc. Roswell Park Cancer Institute;
HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children's
Foundation; Kiadis Pharma; Leukemia & Lymphoma Society; Medac GmbH;
Medical College of Wisconsin; Merck Co, Inc.; Millennium: The Takeda
Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow
Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.;
Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin
Elmer, Inc.; Remedy Informatics; Sanofi US; Seattle Genetics; Sigma-Tau
Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A
Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish
Orphan Biovitrum; Tarix Pharmaceuticals; TerumoBCT; Teva Neuroscience,
Inc.; THERAKOS, Inc.; University of Minnesota; University of Utah;
Wellpoint, Inc.
FX The CIBMTR is supported by Public Health Service Grant/Cooperative
Agreement U24-CA076518 from the National Cancer Institute (NCI), the
National Heart, Lung and Blood Institute (NHLBI) and the National
Institute of Allergy and Infectious Diseases (NIAID); a
grant/cooperative agreement 5U10HL069294 from NHLBI and NCI; a contract
HHSH250201200016C with Health Resources and Services Administration
(HRSA/DHHS); 2 grants N00014-13-1-0039 and N00014-14-1-0028 from the
Office of Naval Research; and grants from *Actinium Pharmaceuticals;
Allos Therapeutics, Inc.; *Amgen, Inc.; anonymous donation to the
Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue
Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.;
Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America,
Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.;*Gentium
SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell
Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff
Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma
Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.;
Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi
Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum
Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America
Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi
US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St.
Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.;
Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix
Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS, Inc.;
University of Minnesota; University of Utah; and *Wellpoint, Inc. The
views expressed in this article do not reflect the official policy or
position of the National Institute of Health, the Department of the
Navy, the Department of Defense, Health Resources and Services
Administration (HRSA) or any other agency of the United States
Government.
NR 44
TC 4
Z9 4
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2016
VL 22
IS 2
BP 248
EP 257
DI 10.1016/j.bbmt.2015.08.024
PG 10
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DC2JD
UT WOS:000369042100010
PM 26327629
ER
PT J
AU Mawardi, H
Glotzbecker, B
Richardson, P
Woo, SB
AF Mawardi, Hani
Glotzbecker, Brett
Richardson, Paul
Woo, Sook-Bin
TI Hematopoietic Cell Transplantation in Patients with Medication-Related
Osteonecrosis of the Jaws
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Hematopoietic cell transplantation; Osteonecrosis of the jaws
ID BISPHOSPHONATE-INDUCED OSTEONECROSIS; BONE-MARROW-TRANSPLANTATION;
BLOOD-STREAM INFECTION; HIGH-DOSE CHEMOTHERAPY; COUNCIL MYELOMA IX;
MULTIPLE-MYELOMA; RECIPIENTS; COMPLICATIONS; THERAPY; BACTEREMIA
AB Patients with medication-related osteonecrosis of the jaw (MRONJ) are at risk for developing infections and often require long-term antimicrobial therapy for management. It is unclear whether patients with multiple myeloma (MM) who develop MRONJ experience increased morbidity when they undergo hematopoietic cell transplantation (HCT). The aim of this study was to characterize the course of HCT in MM patients with MRONJ. A retrospective chart review was conducted for patients with MM and MRONJ who underwent HCT between December 2005 and December 2014. Data collected included bisphosphonate use, MRONJ stage, positive blood cultures, number of febrile days, and length of hospital stay. Eleven patients (median age, 61; range, 46 to 71) fulfilled the criteria. Patients received zoledronic acid (72.7%), pamidronate (18.1%), or a combination of both (9%). At the time of HCT, 10 patients were in stage 1 MRONJ with 1 in stage 0. All patients had only mandibular involvement. No patient developed pain/infection at the MRONJ site during hospitalization. Bacteremia with positive blood cultures for Staphylococcus aureus occurred in 3 patients (27.2%), and 4 patients (36.3%) developed fever lasting between 4 to 6 days (of who 1 had positive blood cultures). The median length of hospital stay was 17 days (range, 7 to 22 days). These data suggests that patients with MM and MRONJ who undergo HCT are not at increased risk of developing symptoms associated with the MRONJ site or HCT-related infectious complications, and their MRONJ is not worsened by HCT. (C) 2016 American Society for Blood and Marrow Transplantation.
C1 [Mawardi, Hani; Woo, Sook-Bin] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, 188 Longwood Ave, Boston, MA 02115 USA.
[Mawardi, Hani; Woo, Sook-Bin] Brigham & Womens Hosp, Dept Surg, Div Oral Med & Dent, 75 Francis St, Boston, MA 02115 USA.
[Mawardi, Hani] King Abdulaziz Univ, Fac Dent, Dept Oral Med, Jeddah 21413, Saudi Arabia.
[Glotzbecker, Brett] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Glotzbecker, Brett] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
[Richardson, Paul] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
[Richardson, Paul] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Myeloma Ctr, 44 Binney St, Boston, MA 02115 USA.
RP Mawardi, H (reprint author), Brigham & Womens Hosp, Div Oral Med & Dent, 75 Francis St, Boston, MA 02115 USA.
EM hmawardi@gmail.com
NR 40
TC 0
Z9 0
U1 17
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2016
VL 22
IS 2
BP 344
EP 348
DI 10.1016/j.bbmt.2015.08.021
PG 5
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DC2JD
UT WOS:000369042100022
PM 26303103
ER
PT J
AU Young, JAH
Logan, BR
Wu, J
Wingard, JR
Weisdorf, DJ
Mudrick, C
Knust, K
Horowitz, MM
Confer, DL
Dubberke, ER
Pergam, SA
Marty, FM
Strasfeld, LM
Brown, JM
Langston, AA
Schuster, MG
Kaul, DR
Martin, SI
Anasetti, C
AF Young, Jo-Anne H.
Logan, Brent R.
Wu, Juan
Wingard, John R.
Weisdorf, Daniel J.
Mudrick, Cathryn
Knust, Kristin
Horowitz, Mary M.
Confer, Dennis L.
Dubberke, Erik R.
Pergam, Steven A.
Marty, Francisco M.
Strasfeld, Lynne M.
Brown, Janice (Wes) M.
Langston, Amelia A.
Schuster, Mindy G.
Kaul, Daniel R.
Martin, Stanley I.
Anasetti, Claudio
CA Blood Marrow Transplant Clinical T
TI Infections after Transplantation of Bone Marrow or Peripheral Blood Stem
Cells from Unrelated Donors
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Infection; Unrelated donor transplantation; Bacteremia; Cytomegalovirus;
Aspergillosis; Pre-engraftment
ID VERSUS-HOST-DISEASE; ALLOGENEIC TRANSPLANTATION; ASPERGILLUS INFECTIONS;
CORD BLOOD; CYTOMEGALOVIRUS; RECIPIENTS; IMPACT; COMPLICATIONS;
MALIGNANCIES; DEPLETION
AB Infection is a major complication of hematopoietic cell transplantation. Prolonged neutropenia and graft versus-host disease are the 2 major complications with an associated risk for infection, and these complications differ according to the graft source. A phase 3, multicenter, randomized trial (Blood and Marrow Transplant Clinical Trials Network [BMT CTN] 0201) of transplantation of bone marrow (BM) versus peripheral blood stem cells (PBSC) from unrelated donors showed no significant differences in 2-year survival between these graft sources. In an effort to provide data regarding whether BM or PBSC could be used as a preferential graft source for transplantation, we report a detailed analysis of the infectious complications for 2 years after transplantation from the BMT CTN 0201 trial. A total of 499 patients in this study had full audits of infection data. A total of 1347 infection episodes of moderate or greater severity were documented in 384 (77%) patients; 201 of 249 (81%) of the evaluable patients had received a BM graft and 183 of 250 (73%) had received a PBSC graft. Of 1347 infection episodes, 373 were severe and 123 were life-threatening and/or fatal; 710 (53%) of these episodes occurred on the BM arm and 637 (47%) on the PBSC arm, resulting in a 2-year cumulative incidence 84.7% (95% confidence interval [CI], 79.6 to 89.8) for BM versus 79.7% (95% CI, 73.9 to 85.5) for PBSC, P = .013. The majority of these episodes, 810 (60%), were due to bacteria, with a 2-year cumulative incidence of 72.1% and 62.9% in BM versus PBSC recipients, respectively (P = .003). The cumulative incidence of bloodstream bacterial infections during the first 100 days was 44.8% (95% CI, 38.5 to 51.1) for BM versus 35.0% (95% CI, 28.9 to 41.1) for PBSC (P = .027). The total infection density (number of infection events/100 patient days at risk) was .67 for BM and .60 for PBSC. The overall infection density for bacterial infections was .4 in both arms; for viral infections, it was .2 in both arms; and for fungal parasitic infections, it was .04 and .05 for BM and PBSC, respectively. The cumulative incidence of infection before engraftment was 47.9% (95% CI, 41.5 to 53.9) for BM versus 32.8% (95% CI, 27.1 to 38.7) for PBSC (P = .002), possibly related to quicker neutrophil engraftment using PBSC. Infections remain frequent after unrelated donor hematopoietic cell transplantation, particularly after BM grafts. (C) 2016 American Society for Blood and Marrow Transplantation.
C1 [Young, Jo-Anne H.; Weisdorf, Daniel J.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA.
[Logan, Brent R.; Horowitz, Mary M.] Med Coll Wisconsin, MMH Dept Med, Div Biostat, BRL Inst Hlth & Soc, Milwaukee, WI 53226 USA.
[Wu, Juan; Mudrick, Cathryn; Knust, Kristin] EMMES Corp, Blood & Bone Marrow Transplant Clin Trials Networ, Rockville, MD USA.
[Wingard, John R.] Univ Florida, Dept Med, Shands Canc Ctr, Gainesville, FL USA.
[Confer, Dennis L.] Natl Marrow Donor Program, Minneapolis, MN USA.
[Dubberke, Erik R.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
[Pergam, Steven A.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
[Marty, Francisco M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Strasfeld, Lynne M.] Oregon Hlth & Sci Univ, Dept Med, Div Infect Dis, Portland, OR 97201 USA.
[Brown, Janice (Wes) M.] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA.
[Langston, Amelia A.] Emory Univ, Dept Med, Atlanta, GA 30322 USA.
[Schuster, Mindy G.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Kaul, Daniel R.] Univ Michigan, Dept Internal Med, Div Infect Dis, Ann Arbor, MI 48109 USA.
[Martin, Stanley I.] Ohio State Univ, Dept Internal Med, Div Infect Dis, Columbus, OH 43210 USA.
[Anasetti, Claudio] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA.
RP Young, JAH (reprint author), Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA.
EM vanbu004@umn.edu
FU National Heart, Lung, and Blood Institute; National Cancer Institute
[U10HL069294]; Office of Naval Research; National Marrow Donor Program
FX This study was supported by a grant from the National Heart, Lung, and
Blood Institute and the National Cancer Institute (U10HL069294), by the
Office of Naval Research, and by the National Marrow Donor Program.
Disclosure forms were provided by the authors. The authors thank the
transplantation center teams in the United States and Canada for
enrolling patients in this trial; the donor-center teams in the United
States, Canada, and Germany for recruiting the donors for the trial; and
the National Marrow Donor Program coordinating center for facilitating
the transplantations.
NR 27
TC 9
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2016
VL 22
IS 2
BP 359
EP 370
DI 10.1016/j.bbmt.2015.09.013
PG 12
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DC2JD
UT WOS:000369042100024
PM 26409243
ER
PT J
AU Cowan, AJ
Stevenson, PA
Cassaday, RD
Graf, SA
Fromm, JR
Wu, D
Holmberg, LA
Till, BG
Chauncey, TR
Smith, SD
Philip, M
Orozco, JJ
Shustov, AR
Green, DJ
Libby, EN
Bensinger, WI
Shadman, M
Maloney, DG
Press, OW
Gopal, AK
AF Cowan, Andrew J.
Stevenson, Philip A.
Cassaday, Ryan D.
Graf, Solomon A.
Fromm, Jonathan R.
Wu, David
Holmberg, Leona A.
Till, Brian G.
Chauncey, Thomas R.
Smith, Stephen D.
Philip, Mary
Orozco, Johnnie J.
Shustov, Andrei R.
Green, Damian J.
Libby, Edward N., III
Bensinger, William I.
Shadman, Mazyar
Maloney, David G.
Press, Oliver W.
Gopal, Ajay K.
TI Pretransplantation Minimal Residual Disease Predicts Survival in
Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell
Transplantation in Complete Remission
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Mantle cell lymphoma; Transplantation; Minimal residual disease;
Predictors; Survival
ID INTERNATIONAL PROGNOSTIC INDEX; PROGRESSION-FREE SURVIVAL;
NON-HODGKINS-LYMPHOMA; HIGH-DOSE THERAPY; FLOW-CYTOMETRY; MOLECULAR
REMISSION; RESPONSE ASSESSMENT; IMMUNOCHEMOTHERAPY; TOMOGRAPHY;
CLASSIFICATION
AB Autologous stem cell transplantation (ASCT) is standard therapy for mantle cell lymphoma (MCL) in remission after induction chemotherapy, with the best results for patients in complete remission (CR). We hypothesized that evaluation of minimal residual disease (MRD) before ASCT could further stratify outcomes for these patients. Patients with MCL who underwent ASCT in clinical CR between 1996 and 2011 with pretransplantation MRD testing were eligible. Presence of a clonal IgH rearrangement, t(11; 14) by PCR or positive flow cytometry from blood or bone marrow, was considered positive. An adjusted proportional hazards model for associations with progression-free (PFS) and overall survival (OS) was performed. Of 75 MCL patients in CR, 8 (11%) were MRD positive. MRD positivity was associated with shorter OS and PFS. The median OS for MRD-negative patients was not reached, with 82% survival at 5 years, whereas for the MRD-positive patients, median OS was 3.01 years (hazard ratio [HR], 4.04; P = .009), with a median follow-up of 5.1 years. The median PFS for MRD-negative patients was not reached with 75% PFS at 5 years, whereas for MRD-positive patients, it was 238 years (HR, 3.69; P = .002). MRD positivity is independently associated with poor outcomes after ASCT for MCL patients in CR. (C) 2016 American Society for Blood and Marrow Transplantation.
C1 [Cowan, Andrew J.; Stevenson, Philip A.; Cassaday, Ryan D.; Graf, Solomon A.; Holmberg, Leona A.; Till, Brian G.; Chauncey, Thomas R.; Smith, Stephen D.; Philip, Mary; Orozco, Johnnie J.; Shustov, Andrei R.; Green, Damian J.; Bensinger, William I.; Shadman, Mazyar; Press, Oliver W.; Gopal, Ajay K.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98195 USA.
[Fromm, Jonathan R.; Wu, David] Univ Washington, Dept Lab Med, Marrow Transplant Unit, Seattle, WA 98195 USA.
[Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Libby, Edward N., III] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA.
[Maloney, David G.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Transplantat Biol Dept, 1124 Columbia St, Seattle, WA 98104 USA.
RP Gopal, AK (reprint author), 825 Eastlake Ave E,MS G3-200, Seattle, WA 98109 USA.
EM agopal@u.washington.edu
FU NIH [P01CA044991, K24CA184039]; Lymphoma Research Foundation Mantle Cell
Lymphoma Research Initiative Clinical Scholar Award by the Leukemia and
Lymphoma Society; Mary Aileen Wright Memorial Fund; David and Patricia
Giuliani Family Foundation; [5T32 CA009515-30]
FX A.J.C. is supported by 5T32 CA009515-30. This work was supported by
research funding from NIH P01CA044991 and K24CA184039; Lymphoma Research
Foundation Mantle Cell Lymphoma Research Initiative Clinical Scholar
Award by the Leukemia and Lymphoma Society, to A.K.G.; the Mary Aileen
Wright Memorial Fund; the David and Patricia Giuliani Family Foundation;
and philanthropic gifts from Frank and Betty Vandermeer and Don and
Debbie Hunkins.
NR 34
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2016
VL 22
IS 2
BP 380
EP 385
DI 10.1016/j.bbmt.2015.08.035
PG 6
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DC2JD
UT WOS:000369042100027
PM 26348890
ER
PT J
AU Park, J
Cheng, JT
Ferguson, D
Maguluri, G
Chang, EW
Clancy, C
Lee, DJ
Iftimia, N
AF Park, Jesung
Cheng, Jeffrey T.
Ferguson, Daniel
Maguluri, Gopi
Chang, Ernest W.
Clancy, Caitlin
Lee, Daniel J.
Iftimia, Nicusor
TI Investigation of middle ear anatomy and function with combined video
otoscopy-phase sensitive OCT
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; TYMPANIC MEMBRANE; MOUSE COCHLEA;
HEARING-LOSS; LASER; AUDIOMETRY; VIBROMETRY; SURFACE
AB We report the development of a novel otoscopy probe for assessing middle ear anatomy and function. Video imaging and phase-sensitive optical coherence tomography are combined within the same optical path. A sound stimuli channel is incorporated as well to study middle ear function. Thus, besides visualizing the morphology of the middle ear, the vibration amplitude and frequency of the eardrum and ossicles are retrieved as well. Preliminary testing on cadaveric human temporal bone models has demonstrated the capability of this instrument for retrieving middle ear anatomy with micron scale resolution, as well as the vibration of the tympanic membrane and ossicles with sub-nm resolution. (C) 2016 Optical Society of America
C1 [Park, Jesung; Ferguson, Daniel; Maguluri, Gopi; Chang, Ernest W.; Clancy, Caitlin; Iftimia, Nicusor] Phys Sci Inc, 20 New England Business Ctr, Andover, MA 01810 USA.
[Cheng, Jeffrey T.; Lee, Daniel J.] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
RP Iftimia, N (reprint author), Phys Sci Inc, 20 New England Business Ctr, Andover, MA 01810 USA.
EM iftimia@psicorp.com
FU National Institute on Deafness and Other Communication Disorders (NIDCD)
[1R43DC013923]
FX This work was supported by a grant from the National Institute on
Deafness and Other Communication Disorders (NIDCD): 1R43DC013923.
NR 29
TC 2
Z9 2
U1 3
U2 8
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD FEB 1
PY 2016
VL 7
IS 2
BP 238
EP 250
DI 10.1364/BOE.7.000238
PG 13
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA DC5FN
UT WOS:000369247000001
PM 26977336
ER
PT J
AU Haindl, R
Trasischker, W
Wartak, A
Baumann, B
Pircher, M
Hitzenberger, CK
AF Haindl, Richard
Trasischker, Wolfgang
Wartak, Andreas
Baumann, Bernhard
Pircher, Michael
Hitzenberger, Christoph K.
TI Total retinal blood flow measurement by three beam Doppler optical
coherence tomography
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID DUAL-ANGLE; HUMAN EYE; VELOCITY; OCT; RESOLUTION; GLAUCOMA; VESSELS;
MIRROR; LIGHT
AB We present measurements of total retinal blood flow in healthy volunteers using a three beam Doppler optical coherence tomography (DOCT) technique. This technology has the advantage of a precise determination of the flow vector without the use of any a-priori information on the vessel geometry. Circular D-OCT scans around the optic disc were recorded and venous as well as arterial total blood flow was determined and compared for each subject. The reproducibility of the method was assessed in 6 subjects by repeated measurements. Only small deviations of around 6% between the measurements were found which indicates the high precision of the proposed method. (C) 2016 Optical Society of America
C1 [Haindl, Richard; Trasischker, Wolfgang; Wartak, Andreas; Baumann, Bernhard; Pircher, Michael; Hitzenberger, Christoph K.] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
[Trasischker, Wolfgang] Harvard Univ, Sch Med, Boston, MA USA.
[Trasischker, Wolfgang] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Haindl, R; Hitzenberger, CK (reprint author), Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
EM richard.haindl@meduniwien.ac.at; christoph.hitzenberger@meduniwien.ac.at
OI Baumann, Bernhard/0000-0001-6419-1932
FU Austrian Science Fund [P26553-N20]; Medical Imaging Cluster at the
Medical University of Vienna
FX This work was supported by the Austrian Science Fund [grant number
P26553-N20]. We are grateful to Magdalena Baratsits and Philipp Ken
Roberts, MD, Department of Ophthalmology, Medical University of Vienna,
for providing color fundus photos. Furthermore we want to thank the
Medical Imaging Cluster at the Medical University of Vienna for their
support.
NR 45
TC 9
Z9 9
U1 3
U2 6
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD FEB 1
PY 2016
VL 7
IS 2
BP 287
EP 301
DI 10.1364/BOE.7.000287
PG 15
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA DC5FN
UT WOS:000369247000005
PM 26977340
ER
PT J
AU Ughi, GJ
Gora, MJ
Swager, AF
Soomro, A
Grant, C
Tiernan, A
Rosenberg, M
Sauk, JS
Nishioka, NS
Tearney, GJ
AF Ughi, Giovanni J.
Gora, Michalina J.
Swager, Anne-Fre
Soomro, Amna
Grant, Catriona
Tiernan, Aubrey
Rosenberg, Mireille
Sauk, Jenny S.
Nishioka, Norman S.
Tearney, Guillermo J.
TI Automated segmentation and characterization of esophageal wall in vivo
by tethered capsule optical coherence tomography endomicroscopy
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID VOLUMETRIC LASER ENDOMICROSCOPY; BARRETTS-ESOPHAGUS;
GASTROINTESTINAL-TRACT; CLASSIFICATION; ATTENUATION; ENDOSCOPY; IMAGES;
TISSUE
AB Optical coherence tomography (OCT) is an optical diagnostic modality that can acquire cross-sectional images of the microscopic structure of the esophagus, including Barrett's esophagus (BE) and associated dysplasia. We developed a swallowable tethered capsule OCT endomicroscopy (TCE) device that acquires high-resolution images of entire gastrointestinal (GI) tract luminal organs. This device has a potential to become a screening method that identifies patients with an abnormal esophagus that should be further referred for upper endoscopy. Currently, the characterization of the OCT-TCE esophageal wall data set is performed manually, which is time-consuming and inefficient. Additionally, since the capsule optics optimally focus light approximately 500 mu m outside the capsule wall and the best quality images are obtained when the tissue is in full contact with the capsule, it is crucial to provide feedback for the operator about tissue contact during the imaging procedure. In this study, we developed a fully automated algorithm for the segmentation of in vivo OCT-TCE data sets and characterization of the esophageal wall. The algorithm provides a two-dimensional representation of both the contact map from the data collected in human clinical studies as well as a tissue map depicting areas of BE with or without dysplasia. Results suggest that these techniques can potentially improve the current TCE data acquisition procedure and provide an efficient characterization of the diseased esophageal wall. (C) 2016 Optical Society of America
C1 [Ughi, Giovanni J.; Gora, Michalina J.; Swager, Anne-Fre; Soomro, Amna; Grant, Catriona; Tiernan, Aubrey; Rosenberg, Mireille; Nishioka, Norman S.; Tearney, Guillermo J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Ughi, Giovanni J.; Gora, Michalina J.; Nishioka, Norman S.; Tearney, Guillermo J.] Harvard Univ, Sch Med, Boston, MA USA.
[Gora, Michalina J.; Sauk, Jenny S.] Strasbourg Univ, CNRS, ICube, Strasbourg, France.
[Nishioka, Norman S.] Massachusetts Gen Hosp, Dept Gastroenterol, Boston, MA 02114 USA.
[Tearney, Guillermo J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Tearney, Guillermo J.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Tearney, GJ (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.; Tearney, GJ (reprint author), Harvard Univ, Sch Med, Boston, MA USA.; Tearney, GJ (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.; Tearney, GJ (reprint author), MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
EM gtearney@partners.org
OI Ughi, Giovanni J./0000-0003-3354-0698
FU US National Institutes of Health [NIH R01CA103769]
FX This work was supported in part by US National Institutes of Health
grant NIH R01CA103769 (GJT).
NR 21
TC 8
Z9 8
U1 4
U2 11
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD FEB 1
PY 2016
VL 7
IS 2
BP 409
EP 419
DI 10.1364/BOE.7.000409
PG 11
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA DC5FN
UT WOS:000369247000015
PM 26977350
ER
PT J
AU Velasquez, GE
Cegielski, JP
Murray, MB
Yagui, MJA
Asencios, LL
Bayona, JN
Bonilla, CA
Jave, HO
Yale, G
Suarez, CZ
Sanchez, E
Rojas, C
Atwood, SS
Contreras, CC
Cruz, JS
Shin, SS
AF Velasquez, Gustavo E.
Cegielski, J. Peter
Murray, Megan B.
Yagui, Martin J. A.
Asencios, Luis L.
Bayona, Jaime N.
Bonilla, Cesar A.
Jave, Hector O.
Yale, Gloria
Suarez, Carmen Z.
Sanchez, Eduardo
Rojas, Christian
Atwood, Sidney S.
Contreras, Carmen C.
Cruz, Janeth Santa
Shin, Sonya S.
TI Impact of HIV on mortality among patients treated for tuberculosis in
Lima, Peru: a prospective cohort study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Tuberculosis; Human immunodeficiency virus; Clinical outcomes;
Mortality; Prospective cohort study; Operational research
ID MULTIDRUG-RESISTANT TUBERCULOSIS; ANTIRETROVIRAL THERAPY;
MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; INFECTED ADULTS;
RISK-FACTORS; OUTCOMES; PROGRAM; IMPLEMENTATION; PREDICTORS
AB Background: Human immunodeficiency virus (HIV)-associated tuberculosis deaths have decreased worldwide over the past decade. We sought to evaluate the effect of HIV status on tuberculosis mortality among patients undergoing treatment for tuberculosis in Lima, Peru, a low HIV prevalence setting.
Methods: We conducted a prospective cohort study of patients treated for tuberculosis between 2005 and 2008 in two adjacent health regions in Lima, Peru (Lima Ciudad and Lima Este). We constructed a multivariate Cox proportional hazards model to evaluate the effect of HIV status on mortality during tuberculosis treatment.
Results: Of 1701 participants treated for tuberculosis, 136 (8.0 %) died during tuberculosis treatment. HIV-positive patients constituted 11.0 % of the cohort and contributed to 34.6 % of all deaths. HIV-positive patients were significantly more likely to die (25.1 vs. 5.9 %, P < 0.001) and less likely to be cured (28.3 vs. 39.4 %, P = 0.003). On multivariate analysis, positive HIV status (hazard ratio [HR] = 6.06; 95 % confidence interval [CI], 3.96-9.27), unemployment (HR = 2.24; 95 % CI, 1.55-3.25), and sputum acid-fast bacilli smear positivity (HR = 1.91; 95 % CI, 1.10-3.31) were significantly associated with a higher hazard of death.
Conclusions: We demonstrate that positive HIV status was a strong predictor of mortality among patients treated for tuberculosis in the early years after Peru started providing free antiretroviral therapy. As HIV diagnosis and antiretroviral therapy provision are more widely implemented for tuberculosis patients in Peru, future operational research should document the changing profile of HIV-associated tuberculosis mortality.
C1 [Velasquez, Gustavo E.; Shin, Sonya S.] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA.
[Velasquez, Gustavo E.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Velasquez, Gustavo E.; Shin, Sonya S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Cegielski, J. Peter] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA.
[Murray, Megan B.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA.
[Murray, Megan B.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Murray, Megan B.; Atwood, Sidney S.; Shin, Sonya S.] Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA.
[Yagui, Martin J. A.] Inst Nacl Salud, Oficina Gen Invest & Transferencia Tecnol, Lima, Peru.
[Yagui, Martin J. A.] Univ Nacl Mayor San Marcos, Dept Acad Med Prevent & Salud Publ, Lima 14, Peru.
[Asencios, Luis L.] Inst Nacl Salud, Lab Nacl Referencia Micobacterias, Lima, Peru.
[Bayona, Jaime N.] World Bank Grp, Hlth Nutr & Populat, Washington, DC USA.
[Bonilla, Cesar A.; Jave, Hector O.] Minist Salud Peru, Estrategia Sanitaria Nacl Prevenc & Control TB, Lima, Peru.
[Yale, Gloria] Direcc Salud V Lima Ciudad, Programa Control TB, Lima, Peru.
[Suarez, Carmen Z.] Direcc Salud IV Lima Este, Programa Control TB, Lima, Peru.
[Sanchez, Eduardo] Hosp Nacl Hipolito Unanue, Serv Enfermedades Infecciosas & Trop, Lima, Peru.
[Rojas, Christian] Inst Nacl Cardiovasc Carlos Alberto Peschiera Car, Serv Neumol, Lima, Peru.
[Contreras, Carmen C.; Cruz, Janeth Santa; Shin, Sonya S.] Partners Hlth Socios Salud, Lima, Peru.
RP Velasquez, GE (reprint author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA.; Velasquez, GE (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
EM gvelasquez@bwh.harvard.edu
OI Velasquez, Gustavo/0000-0003-1438-0692
FU Bill and Melinda Gates Foundation; U.S. Centers for Disease Control and
Prevention; National Institute of Allergy and Infectious Diseases at the
National Institutes of Health [K23 AI054591, T32 AI007433]; Infectious
Diseases Society of America; Heiser Foundation; Division of Global
Health Equity at Brigham and Women's Hospital
FX This publication was supported by the Bill and Melinda Gates Foundation;
the U.S. Centers for Disease Control and Prevention; the National
Institute of Allergy and Infectious Diseases at the National Institutes
of Health (grant numbers K23 AI054591 to SSS and T32 AI007433 to GEV);
the Infectious Diseases Society of America; and the Heiser Foundation.
GEV received support for publication costs from the Division of Global
Health Equity at Brigham and Women's Hospital. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the U.S. Centers for Disease Control and Prevention,
the National Institutes of Health, or the institutions with which the
authors are affiliated. The funding sources played no role in the
design, collection, analysis, or interpretation of data; in the writing
of the manuscript; or in the decision to submit the manuscript for
publication.
NR 34
TC 0
Z9 0
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD FEB 1
PY 2016
VL 16
AR 45
DI 10.1186/s12879-016-1375-8
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA DC6YA
UT WOS:000369364300001
PM 26831140
ER
PT J
AU Gaffney, AW
Hang, JQ
Lee, MS
Su, L
Zhang, FY
Christiani, DC
AF Gaffney, Adam W.
Hang, Jing-Qing
Lee, Mi-Sun
Su, Li
Zhang, Feng-Ying
Christiani, David C.
TI Socioeconomic status is associated with reduced lung function in China:
an analysis from a large cross-sectional study in Shanghai
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Socioeconomic factors; Respiratory disease; Environmental health;
Epidemiology; China; Pulmonary function
ID RECOMBINANT HUMAN DEOXYRIBONUCLEASE; PARENTAL STRESS INCREASES;
SOLID-FUEL USE; PULMONARY-FUNCTION; AIR-POLLUTION; TRANSPORT
MICROENVIRONMENTS; RESPIRATORY HEALTH; EDUCATIONAL-LEVEL;
CYSTIC-FIBROSIS; SOCIAL-CLASS
AB Background: An inverse association between socioeconomic status and pulmonary function has emerged in many studies. However, the mediating factors in this relationship are poorly understood, and might be expected to differ between countries. We sought to investigate the relationship between socioeconomic status and lung function in China, a rapidly industrializing nation with unique environmental challenges, and to identify potentially-modifiable environmental mediators.
Methods: We used data from the Shanghai Putuo Study, a cross-sectional study performed in Shanghai, China. Participants completed a questionnaire and spirometry. The primary exposure was socioeconomic status, determined by education level. The primary outcomes were FEV1 and FVC percent predicted. Multiple linear regressions were used to test this association, and the percent explained by behavioral, environmental, occupational, and dietary variables was determined by adding these variables to a base model.
Results: The study population consisted of a total of 22,878 study subjects that were 53.3 % female and had a mean age of 48. In the final multivariate analysis, the effect estimates for FEV1 and FVC percent predicted for low socioeconomic status (compared to high) were statistically significant at a p-value of <0.01. Smoking, biomass exposure, mode of transportation to work, a diet low in fruits or vegetables, and occupational category partially attenuated the relationship between SES and lung function. In a fully-adjusted age-stratified analysis, the socioeconomic disparity in lung function widened with increasing age.
Conclusions: We found cross-sectional evidence of socioeconomic disparities in pulmonary function in Shanghai. These differences increased with age and were partially explained by potentially modifiable exposures.
C1 [Gaffney, Adam W.; Christiani, David C.] Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
[Hang, Jing-Qing; Zhang, Feng-Ying] Shanghai Putuo Dist Peoples Hosp, Shanghai, Peoples R China.
[Lee, Mi-Sun; Su, Li; Christiani, David C.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, 677 Huntington Ave, Boston, MA 02115 USA.
[Christiani, David C.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Gaffney, AW (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
EM agaffney@mgh.harvard.edu
FU National Institutes of Health Shanghai Putuo District People's Hospital
[T32 HL116275, ES000002]
FX National Institutes of Health (T32 HL116275 and ES000002) Shanghai Putuo
District People's Hospital
NR 40
TC 1
Z9 1
U1 3
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD FEB 1
PY 2016
VL 16
AR 96
DI 10.1186/s12889-016-2752-3
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DC8PF
UT WOS:000369480900001
PM 26832923
ER
PT J
AU Prebet, T
Sun, ZX
Ketterling, RP
Zeidan, A
Greenberg, P
Herman, J
Juckett, M
Smith, MR
Malick, L
Paietta, E
Czader, M
Figueroa, M
Gabrilove, J
Erba, HP
Tallman, MS
Litzow, M
Gore, SD
AF Prebet, Thomas
Sun, Zhuoxin
Ketterling, Rhett P.
Zeidan, Amer
Greenberg, Peter
Herman, James
Juckett, Mark
Smith, Mitchell R.
Malick, Lisa
Paietta, Elisabeth
Czader, Magdalena
Figueroa, Maria
Gabrilove, Janice
Erba, Harry P.
Tallman, Martin S.
Litzow, Mark
Gore, Steven D.
CA Eastern Cooperative Oncology Grp
North Amer Leukemia Intergrp
TI Azacitidine with or without Entinostat for the treatment of
therapy-related myeloid neoplasm: further results of the E1905 North
American Leukemia Intergroup study
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE myelodysplasia; acute myeloid leukaemia; azacitidine; histone
deacetylase inhibitor; therapy related
ID CONVENTIONAL CARE REGIMENS; LOW-DOSE DECITABINE; MYELODYSPLASTIC
SYNDROMES; SCORING SYSTEM; ADULTS; CANCER; TRIAL
AB Therapy-related myeloid neoplasms (tMN) are serious late effects of the treatment of cancer with poor response to conventional treatment. Azacitidine (AZA) has been used to treat patients with tMN but current data are retrospective. We present here 47 tMN patients prospectively enrolled as a specific cohort in the E1905 study. TheE1905 study was a randomized phase 2 study (NCT00313586) testing 10 d of AZA (50 mg/m(2)/d) +/- the histone deacetylase inhibitor entinostat (4 mg/m(2)/d PO day-3 and day-10). A total of 47 patients [29 therapy-related myelosyspastic syndrome (t-MDS) and 18 therapy-related acute myeloid leukaemia (t-AML)] were recruited to the study. 24 patients were treated with AZA monotherapy and 23 with AZA+ entinostat. The median number of administered cycles was 4, significantly higher in patients treated with AZA (6 cycles vs. 3 cycles, P = 0.008). Haematological normalization rates were 46% in monotherapy and 17% in the combination arm. Median overall survivals were 13 and 6 months, respectively. The novel 50 * 10 schedule of azacitidine appears effective, with response rates, when given as single agent, comparable to those for patients with de novo MDS/AML treated on the same protocol. However, the combination of AZA and entinostat was associated with increased toxicity and could not be recommended for treatment of tMN.
C1 [Prebet, Thomas; Zeidan, Amer; Gore, Steven D.] Yale Canc Ctr, Sect Hematol, 300 George St,7th Floor,RM 786, New Haven, CT 06511 USA.
[Sun, Zhuoxin] Dana Farber Canc Inst, ECOG ACRIN Biostat Ctr, Boston, MA 02115 USA.
[Ketterling, Rhett P.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Greenberg, Peter] Stanford Univ, Ctr Canc, Div Hematol, Stanford, CA 94305 USA.
[Herman, James; Malick, Lisa] Johns Hopkins Univ, Baltimore, MD USA.
[Juckett, Mark] Univ Wisconsin, Madison, WI USA.
[Smith, Mitchell R.] Cleveland Clin, Cleveland, OH 44106 USA.
[Paietta, Elisabeth] Montefiore Med Ctr, North Div, 111 E 210th St, Bronx, NY 10467 USA.
[Czader, Magdalena] Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA.
[Figueroa, Maria] Univ Michigan, Sch Med, Ann Arbor, MI USA.
[Gabrilove, Janice] Icahn Sch Med Mt Sinai, Sch Med, Tisch Canc Inst, New York, NY 10029 USA.
[Erba, Harry P.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Tallman, Martin S.] Mem Sloane Kettering Canc Ctr, Leukemia Serv, New York, NY USA.
[Litzow, Mark] Mayo Clin, Coll Med, Ctr Canc, Div Hematol, Rochester, MN USA.
RP Prebet, T (reprint author), Yale Canc Ctr, Sect Hematol, 300 George St,7th Floor,RM 786, New Haven, CT 06511 USA.
EM Thomas.prebet@yale.edu
OI Prebet, Thomas/0000-0002-6872-625X
FU Leukemia and Lymphoma Society of America [R01 CA125563501, R6034-08];
Fulbright Franco-American commission/Foundation Monahan, Paris, France
[CA32102, CA27057]; [K24 CA111717]
FX Supported by R01 CA125563501 (SG), R6034-08 from the Leukemia and
Lymphoma Society of America (SG), K24 CA111717 (SG) and a grant from the
Fulbright Franco-American commission/Foundation Monahan, Paris, France
(TP). CA32102 and CA27057 (HPE).
NR 24
TC 3
Z9 3
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD FEB
PY 2016
VL 172
IS 3
BP 384
EP 391
DI 10.1111/bjh.13832
PG 8
WC Hematology
SC Hematology
GA DC5WA
UT WOS:000369290100006
PM 26577691
ER
PT J
AU Ye, SA
Zhang, JM
Shen, J
Gao, Y
Li, Y
Choy, E
Cote, G
Harmon, D
Mankin, H
Gray, NS
Hornicek, FJ
Duan, ZF
AF Ye, Shunan
Zhang, Jianming
Shen, Jacson
Gao, Yan
Li, Ying
Choy, Edwin
Cote, Gregory
Harmon, David
Mankin, Henry
Gray, Nathanael S.
Hornicek, Francis J.
Duan, Zhenfeng
TI NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by
inhibiting P-glycoprotein (PGP1) function
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID TYROSINE KINASE INHIBITOR; DRUG-RESISTANCE; OVARIAN-CANCER; CELL-LINES;
CONCISE GUIDE; SOLID TUMORS; LUNG-CANCER; MECHANISMS; POTENT;
CHEMOTHERAPY
AB Background and purposeIncreased expression of P-glycoprotein (PGP1) is one of the major causes of multidrug resistance (MDR) in cancer, including in osteosarcoma, which eventually leads to the failure of cancer chemotherapy. Thus, there is an urgent need to develop effective therapeutic strategies to override the expression and function of PGP1 to counter MDR in cancer patients.
Experimental ApproachIn an effort to search for new chemical entities targeting PGP1-associated MDR in osteosarcoma, we screened a 500+ compound library of known kinase inhibitors with established kinase selectivity profiles. We aimed to discover potential drug synergistic effects among kinase inhibitors and general chemotherapeutics by combining inhibitors with chemotherapy drugs such as doxorubicin and paclitaxel. The human osteosarcoma MDR cell lines U2OSR2 and KHOSR2 were used for the initial screen and secondary mechanistic studies.
Key ResultsAfter screening 500+ kinase inhibitors, we identified NVP-TAE684 as the most effective MDR reversing agent. NVP-TAE684 significantly reversed chemoresistance when used in combination with doxorubicin, paclitaxel, docetaxel, vincristine, ET-743 or mitoxantrone. NVP-TAE684 itself is not a PGP1 substrate competitive inhibitor, but it can increase the intracellular accumulation of PGP1 substrates in PGP1-overexpressing cell lines. NVP-TAE684 was found to inhibit the function of PGP1 by stimulating PGP1 ATPase activity, a phenomenon reported for other PGP1 inhibitors.
Conclusions and ImplicationsThe application of NVP-TAE684 to restore sensitivity of osteosarcoma MDR cells to the cytotoxic effects of chemotherapeutics will be useful for further study of PGP1-mediated MDR in human cancer and may ultimately benefit cancer patients.
C1 [Ye, Shunan; Shen, Jacson; Gao, Yan; Choy, Edwin; Cote, Gregory; Harmon, David; Mankin, Henry; Hornicek, Francis J.; Duan, Zhenfeng] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Sarcoma & Connect Tissue Oncol, 100 Blossom St,Jackson 1115, Boston, MA 02114 USA.
[Zhang, Jianming; Li, Ying] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Boston, MA USA.
[Gray, Nathanael S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
RP Duan, ZF (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Sarcoma & Connect Tissue Oncol, 100 Blossom St,Jackson 1115, Boston, MA 02114 USA.
EM zduan@mgh.harvard.edu
OI Cote, Gregory/0000-0003-0181-886X
FU Gategno fund; Wechsler fund; Sarcoma Foundation of America (SFA);
National Cancer Institute (NCI)/National Institutes of Health (NIH)
[UO1, CA 151452]; Jennifer Hunter Yates Foundation; Kenneth Stanton Fund
FX This study was supported, in part, by grants from the Gategno and
Wechsler funds. Z.D. is supported, in part, through a grant from Sarcoma
Foundation of America (SFA) and a grant from National Cancer Institute
(NCI)/National Institutes of Health (NIH), UO1, CA 151452. Support was
also provided by the Jennifer Hunter Yates Foundation and the Kenneth
Stanton Fund.
NR 50
TC 3
Z9 3
U1 2
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD FEB
PY 2016
VL 173
IS 3
BP 613
EP 626
DI 10.1111/bph.13395
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DC3WM
UT WOS:000369149600016
PM 26603906
ER
PT J
AU Yin, PQ
Hong, Z
Yang, XJ
Chung, RT
Zhang, LL
AF Yin, Peiqi
Hong, Zhi
Yang, Xiaojie
Chung, Raymond T.
Zhang, Leiliang
TI A role for retromer in hepatitis C virus replication
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE HCV; NS5A; PI4P; Retromer; CIMPR
ID OXYSTEROL-BINDING-PROTEIN; CELLULAR COFACTORS; CARGO; COMPLEX; RECEPTOR;
TIP47; NS5A; TRAFFICKING; RECRUITMENT; PARTICLES
AB Hepatitis C virus (HCV) has infected over 170 million people worldwide. Phosphatidylinositol 4-phosphate (PI4P) is the organelle-specific phosphoinositide enriched at sites of HCV replication. Whether retromer, a PI4P-related host transport machinery, unloads its cargo at HCV replication sites remains inconclusive. We sought to characterize the role of retromer in HCV replication. Here, we demonstrated the interaction between retromer subunit Vps35 and HCV NS5A protein by immunoprecipitation and GST pulldown. Vps35 colocalized with NS5A and PI4P in both OR6 replicon and JFH1 infected Huh 7.5.1 cells. HCV replication was inhibited upon silencing retromer subunits. CIMPR, a typical retromer cargo, participated in HCV replication. Our data suggest that retromer component Vps35 is recruited by NS5A to viral replication sites where PI4P unloads CIMPR. These findings demonstrate a dependence role of retromer in HCV replication and identify retromer as a potential therapeutic target against HCV.
C1 [Yin, Peiqi; Hong, Zhi; Yang, Xiaojie; Zhang, Leiliang] Chinese Acad Med Sci, Inst Pathogen Biol, MOH Key Lab Syst Biol Pathogens, Beijing 100176, Peoples R China.
[Yin, Peiqi; Hong, Zhi; Yang, Xiaojie; Zhang, Leiliang] Peking Union Med Coll, Beijing 100176, Peoples R China.
[Chung, Raymond T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Div,Dept Med,Liver Ctr, Boston, MA 02114 USA.
RP Zhang, LL (reprint author), Chinese Acad Med Sci, Inst Pathogen Biol, MOH Key Lab Syst Biol Pathogens, Beijing 100176, Peoples R China.; Zhang, LL (reprint author), Peking Union Med Coll, Beijing 100176, Peoples R China.
EM armzhang@hotmail.com
FU National Natural Science Foundation of China [81301438, 81271832,
81471955]; National Science and Technology Major Project of China
[2013ZX10004-601]; Intramural Research Program of the Institute of
Pathogen Biology, CAMS [2013IPB104]; Program for Changjiang Scholars and
Innovative Research Team in University [IRT13007]; PUMC Youth Fund, the
Fundamental Research Funds for the Central Universities [3332013118];
NIH [DK098079, AI082630, DA033541]
FX This work was supported by Grants from National Natural Science
Foundation of China (81301438, 81271832, 81471955), National Science and
Technology Major Project of China (2013ZX10004-601), Intramural Research
Program of the Institute of Pathogen Biology, CAMS (2013IPB104), Program
for Changjiang Scholars and Innovative Research Team in University
(IRT13007), PUMC Youth Fund, the Fundamental Research Funds for the
Central Universities (3332013118), and NIH (DK098079, AI082630, and
DA033541). We thank Guangbo Yang for technical support. We thank Jing
Wang for critical review of the manuscript. We thank Charles Rice,
Francis Chisari, Masanori Ikeda, Nobuyuki Kato and Takaji Wakita for
reagents.
NR 45
TC 3
Z9 3
U1 1
U2 3
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD FEB
PY 2016
VL 73
IS 4
BP 869
EP 881
DI 10.1007/s00018-015-2027-7
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DC9IQ
UT WOS:000369535300012
PM 26298293
ER
PT J
AU Babic, A
Wolpin, BM
AF Babic, Ana
Wolpin, Brian M.
TI Circulating Exosomes in Pancreatic Cancer: Will They Succeed on the
Long, Littered Road to Early Detection Marker?
SO CLINICAL CHEMISTRY
LA English
DT Editorial Material
C1 [Babic, Ana; Wolpin, Brian M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Babic, Ana; Wolpin, Brian M.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Wolpin, BM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM bwolpin@partners.org
NR 5
TC 0
Z9 0
U1 4
U2 10
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
EI 1530-8561
J9 CLIN CHEM
JI Clin. Chem.
PD FEB
PY 2016
VL 62
IS 2
BP 307
EP 309
DI 10.1373/clinchem.2015.246538
PG 3
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA DC8KR
UT WOS:000369468900001
PM 26721295
ER
PT J
AU Romanos, GE
Biltucci, MT
Kokaras, A
Paster, BJ
AF Romanos, Georgios E.
Biltucci, Mary Therese
Kokaras, Alexis
Paster, Bruce J.
TI Bacterial Composition at the Implant-Abutment Connection under Loading
in vivo
SO CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH
LA English
DT Article
DE bacteria; immediate loading; implant-abutment interface; platform
switching
ID VITRO EVALUATION; INTERFACE; INFLAMMATION; PROSTHESES; MICROARRAY;
SYSTEMS; TIME
AB PurposePlatform-switched implants have been demonstrated to prevent bone loss after loading. The present study evaluated bacterial composition of sites from implant-abutment connections of immediately loaded implants, which were placed in the anterior mandible. Ten patients participated in this study.
Materials and MethodsA and B implant systems with two different prosthetic connections (Morse tapered vs internal polygonal butt-joint connections, respectively) were placed and loaded for 2 years. The abutments were removed (AB sample) after careful decontamination. Bacterial sampling of the abutments, inner part of the implants (before/visit 1 and after rinsing with chlorhexidine [CHX]/visit 2), and after new abutment connection and loading for 1 additional month, a new sampling (visit 3) was taken to compare the bacteria composition in association with the two connections. Bacterial profiles of samples were determined by using the human oral microbe identification microarray.
ResultsA total of 240 samples were analyzed taken at different time intervals. Nonparametric statistical analysis (Wilcoxon Rank sum) with uncorrected alpha (p<.05) and after corrections (Benjamini-Hochberg) found no statistical significance between the two connections. No significant changes in the overall microbial profiles were detected at the different time intervals. However, there were trends toward presence of periodontitis-associated species at the B implants in all samples (AB, visit 1, even after CHX irrigation) and after decontamination, abutment replacement, and 1-month loading period.
ConclusionsCHX irrigation does not seem to have any effect on decontamination of connections. As shown previously, there is significantly more bone loss around B implants compared with A implants. Although there was no statistical difference in the microbial profiles, there was indeed a trend for the presence of typical periodontal pathogens associated with the internal polygonal butt-joint connection. A possible scenario is that this connection tends to harbor the pathogens that may be involved in subsequent bone loss.
C1 [Romanos, Georgios E.] Univ Rochester, Eastman Inst Oral Hlth, Dept Periodontol, Rochester, NY USA.
[Biltucci, Mary Therese] Univ Rochester, Dept Dent, Rochester, NY USA.
[Kokaras, Alexis; Paster, Bruce J.] Forsyth Inst, Dept Microbiol, Cambridge, MA USA.
[Paster, Bruce J.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, 188 Longwood Ave, Boston, MA 02115 USA.
RP Romanos, GE (reprint author), Univ Rochester, Eastman Inst Oral Hlth, Dept Periodontol, Rochester, NY USA.; Romanos, GE (reprint author), SUNY Stony Brook, Sch Dent Med, Dept Dent Med, Dept Periodontol, 106 Rockland Hall, Stony Brook, NY 11794 USA.
EM georgios.romanos@stonybrook.edu
FU Dentsply-Implants
FX The authors would like to thank Dr. Robert Quivey Jr., PhD, and Roberta
Faustoferri (Center of Oral Biology, University of Rochester, Rochester,
NY) for their laboratory support in this study and Dr. Joerg Nonhoff
(Dentsply-Implants, Mannheim, Germany) for his scientific contribution
in this project. The study was supported by Dentsply-Implants.
NR 32
TC 5
Z9 6
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1523-0899
EI 1708-8208
J9 CLIN IMPLANT DENT R
JI Clin. Implant Dent. Relat. Res.
PD FEB
PY 2016
VL 18
IS 1
BP 138
EP 145
DI 10.1111/cid.12270
PG 8
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA DC6OM
UT WOS:000369339400016
PM 25195711
ER
PT J
AU ter Maaten, JM
Valente, MAE
Metra, M
Bruno, N
O'Connor, CM
Ponikowski, P
Teerlink, JR
Cotter, G
Davison, B
Cleland, JG
Givertz, MM
Bloomfield, DM
Dittrich, HC
van Veldhuisen, DJ
Hillege, HL
Damman, K
Voors, AA
AF ter Maaten, Jozine M.
Valente, Mattia A. E.
Metra, Marco
Bruno, Noemi
O'Connor, Christopher M.
Ponikowski, Piotr
Teerlink, John R.
Cotter, Gad
Davison, Beth
Cleland, John G.
Givertz, Michael M.
Bloomfield, Daniel M.
Dittrich, Howard C.
van Veldhuisen, Dirk J.
Hillege, Hans L.
Damman, Kevin
Voors, Adriaan A.
TI A combined clinical and biomarker approach to predict diuretic response
in acute heart failure
SO CLINICAL RESEARCH IN CARDIOLOGY
LA English
DT Article
DE Diuretic response; Heart failure; Biomarkers; Prediction
ID BLOOD UREA NITROGEN; PROGNOSTIC VALUE; THERAPY; ATHEROSCLEROSIS;
TRANSPORT; CHLORIDE; RECEPTOR
AB Poor diuretic response in acute heart failure is related to poor clinical outcome. The underlying mechanisms and pathophysiology behind diuretic resistance are incompletely understood. We evaluated a combined approach using clinical characteristics and biomarkers to predict diuretic response in acute heart failure (AHF).
We investigated explanatory and predictive models for diuretic response-weight loss at day 4 per 40 mg of furosemide-in 974 patients with AHF included in the PROTECT trial. Biomarkers, addressing multiple pathophysiological pathways, were determined at baseline and after 24 h. An explanatory baseline biomarker model of a poor diuretic response included low potassium, chloride, hemoglobin, myeloperoxidase, and high blood urea nitrogen, albumin, triglycerides, ST2 and neutrophil gelatinase-associated lipocalin (r (2) = 0.086). Diuretic response after 24 h (early diuretic response) was a strong predictor of diuretic response (beta = 0.467, P < 0.001; r (2) = 0.523). Addition of diuretic response after 24 h to biomarkers and clinical characteristics significantly improved the predictive model (r (2) = 0.586, P < 0.001).
Biomarkers indicate that diuretic unresponsiveness is associated with an atherosclerotic profile with abnormal renal function and electrolytes. However, predicting diuretic response is difficult and biomarkers have limited additive value. Patients at risk of poor diuretic response can be identified by measuring early diuretic response after 24 h.
C1 [ter Maaten, Jozine M.; Valente, Mattia A. E.; van Veldhuisen, Dirk J.; Hillege, Hans L.; Damman, Kevin; Voors, Adriaan A.] Univ Groningen, Dept Cardiol, Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
[Metra, Marco] Univ Brescia, Brescia, Italy.
[Bruno, Noemi] Univ Roma La Sapienza, Dept Cardiovasc Sci, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
[O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA.
[Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland.
[Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Cotter, Gad; Davison, Beth] Momentum Res, Durham, NC USA.
[Cleland, John G.] Univ Hull, Kingston Upon Hull, Yorks, England.
[Givertz, Michael M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA.
[Dittrich, Howard C.] Univ Iowa, Carver Coll Med, Cardiovasc Res Ctr, Iowa City, IA USA.
[Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands.
RP Voors, AA (reprint author), Univ Groningen, Dept Cardiol, Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM a.a.voors@umcg.nl
RI Ponikowski, Piotr/O-6454-2015;
OI Ponikowski, Piotr/0000-0002-3391-7064; Cleland, John/0000-0002-1471-7016
FU NovaCardia, Merck
FX The PROTECT trial was supported by NovaCardia, a subsidiary of Merck.
Alere and Singulex kindly provided assays and performed biomarker
measurements.
NR 27
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1861-0684
EI 1861-0692
J9 CLIN RES CARDIOL
JI Clin. Res. Cardiol.
PD FEB
PY 2016
VL 105
IS 2
BP 145
EP 153
DI 10.1007/s00392-015-0896-2
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DC5IM
UT WOS:000369254700006
PM 26280875
ER
PT J
AU Hall, GM
Shanmugan, S
Bleier, JIS
Jeganathan, AN
Epstein, AJ
Paulson, EC
AF Hall, G. M.
Shanmugan, S.
Bleier, J. I. S.
Jeganathan, A. N.
Epstein, A. J.
Paulson, E. C.
TI Colorectal specialization and survival in colorectal cancer
SO COLORECTAL DISEASE
LA English
DT Article
DE Colon cancer; rectal cancer; specialization; survival
ID II COLON-CANCER; HOSPITAL VOLUME; RECTAL-CANCER; UNITED-STATES;
STAGE-II; ADJUVANT THERAPY; SURGERY; OUTCOMES; PREDICTORS; RECURRENCE
AB AimIt is recognized that higher surgeon volume is associated with improved survival in colorectal cancer. However, there is a paucity of national studies that have evaluated the relationship between surgical specialization and survival.
MethodWe used the Surveillance, Epidemiology, and End Results Medicare cancer registry to examine the association between colorectal specialization (CRS) and disease-specific survival (DSS) between 2001 and 2009. A total of 21432 colon cancer and 5893 rectal cancer patients who underwent elective surgical resection between 2001 and 2009 were evaluated. Univariate and multivariate Cox survival analysis was used to identify the association between surgical specialization and cancer-specific survival.
ResultsColorectal specialists performed 16.3% of the colon and 27% of the rectal resections. On univariate analysis, specialization was associated with improved survival in Stage II and Stage III colon cancer and Stage II rectal cancer. In multivariate analysis, however, CRS was associated with significantly improved DSS only in Stage II rectal cancer [hazard ratio (HR) 0.70, P=0.03]. CRS was not significantly associated with DSS in either Stage I (colon HR 1.14, P=0.39; rectal HR 0.1.26, P=0.23) or Stage III (colon HR 1.06, P=0.52; rectal HR 1.08, P=0.55) disease. When analysis was limited to high volume surgeons only, the relationship between CRS and DSS was unchanged.
ConclusionsCRS is associated with improved DSS following resection of Stage II rectal cancer. A combination of factors may contribute to long-term survival in these patients, including appropriate surgical technique, multidisciplinary treatment decisions and guideline-adherent surveillance. CRS probably contributes positively to these factors resulting in improved survival.
C1 [Hall, G. M.; Shanmugan, S.; Bleier, J. I. S.; Paulson, E. C.] Univ Penn, Dept Gen Surg, Div Colon & Rectal Surg, Philadelphia, PA 19104 USA.
[Jeganathan, A. N.] Univ Penn, Dept Gen Surg, Philadelphia, PA 19104 USA.
[Epstein, A. J.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Epstein, A. J.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Paulson, E. C.] Philadelphia VA Med Ctr, Dept Gen Surg, Philadelphia, PA 19104 USA.
RP Paulson, EC (reprint author), Philadelphia VA Med Ctr, Surg Business Off, 3900 Woodland Ave,5th Floor, Philadelphia, PA 19104 USA.
EM paulsone@uphs.upenn.edu
NR 26
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8910
EI 1463-1318
J9 COLORECTAL DIS
JI Colorectal Dis.
PD FEB
PY 2016
VL 18
IS 2
BP O51
EP O60
DI 10.1111/codi.13246
PG 10
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA DD2GH
UT WOS:000369740200001
PM 26708838
ER
PT J
AU Kamran, SC
Hong, TS
Wo, JY
AF Kamran, Sophia C.
Hong, Theodore S.
Wo, Jennifer Y.
TI Advances in the Management of Gastric and Gastroesophageal Cancers
SO CURRENT ONCOLOGY REPORTS
LA English
DT Review
DE Gastric cancer; Gastroesophageal junction cancer; Radiation therapy;
Chemoradiation; Trimodality therapy
ID PHASE-III TRIAL; RANDOMIZED CONTROLLED-TRIAL; COMBINED-MODALITY THERAPY;
LYMPH-NODE DISSECTION; ESOPHAGEAL CANCER; PREOPERATIVE CHEMORADIATION;
PERIOPERATIVE CHEMOTHERAPY; ADJUVANT CAPECITABINE; JUNCTION CANCER;
OPEN-LABEL
AB Management of gastric and gastroesophageal cancers is a complex, evolving paradigm. Involvement of multimodality specialties is the key. In gastric cancer, data are conflicting with regard to the specific roles of surgery, chemotherapy, and radiation, particularly between Asian and Western studies. However, current ongoing phase III trials will further elucidate the optimal treatment for this heterogeneous disease. For resectable gastroesophageal junction (GEJ) tumors, the publication of a landmark study in 2012 out of the Netherlands revealed a clear benefit in the utilization of trimodality therapy. This changed practice almost immediately around the world. In unresectable gastroesophageal disease, chemoradiation has been firmly established as a paradigm for treatment. The optimal chemotherapy regimen is still in flux. However, for both gastric and GEJ tumors, technological breakthroughs in genomics and pharmacologic targeting will soon provide physicians more options in the armamentarium to fight these diseases and, one day, individually personalize treatment.
C1 [Kamran, Sophia C.] Harvard Univ, Sch Med, Harvard Radiat Oncol Program, Boston, MA USA.
[Hong, Theodore S.; Wo, Jennifer Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
RP Wo, JY (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
EM skamran@partners.org; tshong1@mgh.harvard.edu; jwo@mgh.harvard.edu
OI Kamran, Sophia/0000-0001-9283-6515
NR 44
TC 1
Z9 1
U1 2
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3790
EI 1534-6269
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD FEB
PY 2016
VL 18
IS 2
AR 13
DI 10.1007/s11912-015-0493-6
PG 9
WC Oncology
SC Oncology
GA DC5NB
UT WOS:000369266600006
PM 26769118
ER
PT J
AU Leung, MW
Goldfarb, S
Dizon, DS
AF Leung, Margaret W.
Goldfarb, Shari
Dizon, Don S.
TI Communication About Sexuality in Advanced Illness Aligns With a
Palliative Care Approach to Patient-Centered Care
SO CURRENT ONCOLOGY REPORTS
LA English
DT Review
DE Palliative care; Sexuality; Communication
ID CANCER-PATIENTS; OVARIAN-CANCER; LUNG-CANCER; HEALTH; INTIMACY;
SURVIVORS; SEX; BARRIERS; WOMEN; RECOMMENDATIONS
AB Treatment-related sexual complications are common in cancer patients although rarely discussed in the palliative care setting. Sexuality is an important survivorship issue and remains relevant even in the terminal setting. There are multiple barriers in dialoguing about intimacy and sexual functioning from the patient and provider perspectives. Palliative care providers, while not expected to be sexual health experts, can provide comprehensive patient-centered care by including sexual health as part of their evaluation. They can explore how sexual dysfunction can impair functioning and utilize an interdisciplinary approach to manage symptoms. Palliative care providers can help patients identify their goals of care and explore what anticipated sexual changes and treatrelated side effects are tolerable and intolerable to the patient's quality of life. Principles on addressing sexuality in the palliative setting and practical ways of incorporating sexual history into the palliative care assessment are provided.
C1 [Leung, Margaret W.] Kaiser Permanente, 1600 Eureka Rd, Roseville, CA 95661 USA.
[Dizon, Don S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA.
[Goldfarb, Shari] Mem Sloan Kettering Canc Ctr, Breast & Imaging Ctr, 300 East 66th St, New York, NY 10065 USA.
RP Leung, MW (reprint author), Kaiser Permanente, 1600 Eureka Rd, Roseville, CA 95661 USA.
EM margaret.w.leung@kp.org; goldfars@mskcc.org; ddizon@partners.org
FU NCI NIH HHS [P30 CA008748]
NR 53
TC 0
Z9 1
U1 3
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3790
EI 1534-6269
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD FEB
PY 2016
VL 18
IS 2
AR 11
DI 10.1007/s11912-015-0497-2
PG 6
WC Oncology
SC Oncology
GA DC5NB
UT WOS:000369266600004
PM 26769116
ER
PT J
AU Villar, J
Blanco, J
Kacmarek, RM
AF Villar, Jesus
Blanco, Jesus
Kacmarek, Robert M.
TI Current incidence and outcome of the acute respiratory distress syndrome
SO CURRENT OPINION IN CRITICAL CARE
LA English
DT Review
DE acute respiratory distress syndrome; incidence; outcome; protective
ventilation
ID ACUTE LUNG INJURY; PROSPECTIVE COHORT; BERLIN DEFINITION;
CLINICAL-TRIALS; INTENSIVE-CARE; TIDAL VOLUMES; MORTALITY; VENTILATION;
ARDS; METAANALYSIS
AB Purpose of review This article discusses recently published articles reporting the incidence and outcome of patients with the acute respiratory distress syndrome (ARDS). This is a difficult task since there is a marked variability regarding the methodology of the few, large epidemiological, and observational studies on ARDS.
Recent findings The review will mainly focus on publications from the past 18 months. We have reviewed new epidemiological studies reporting population-based incidence of ARDS. Also, we have reviewed the data on survival reported in observational and randomized controlled trials, discussed how the current ARDS definition modifies the true incidence of ARDS, and briefly mentioned recent approaches that appear to improve ARDS outcome.
Summary On the basis of current evidence, it seems that the incidence and overall hospital mortality of ARDS has not changed substantially in the last decade. Independent of the definition used for identification of ARDS patients, reported population-based incidence of ARDS is an order of magnitude lower in Europe than in the USA. Current hospital mortality of combined moderate and severe ARDS reported in observational studies is greater than 40%.
C1 [Villar, Jesus; Blanco, Jesus] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.
[Villar, Jesus] Hosp Univ Dr Negrin, Res Unit, Multidisciplinary Organ Dysfunct Evaluat Res Netw, Las Palmas Gran Canaria, Spain.
[Villar, Jesus] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr Biomed Sci, 30 Bond St, Toronto, ON M5B 1W8, Canada.
[Blanco, Jesus] Hosp Univ Rio Hortega, Intens Care Unit, Valladolid, Spain.
[Kacmarek, Robert M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Resp Care, Boston, MA USA.
[Kacmarek, Robert M.] Harvard Univ, Sch Med, Dept Anesthesia & Crit Care Med, Boston, MA USA.
RP Villar, J (reprint author), Hosp Univ Dr Negrin, Multidisciplinary Organ Dysfunct Evaluat Res Netw, Barranco Ballena S-N,4th Floor,South Wing, Las Palmas Gran Canaria 35019, Spain.
EM jesus.villar54@gmail.com
FU Instituto de Salud Carlos III, Spain [CB06/06/1088, PI10/0393,
PI13/0119]; Asociacion Cientifica Pulmon y Ventilacion Mecanica
FX This study is supported in part by Instituto de Salud Carlos III, Spain
(CB06/06/1088, PI10/0393, PI13/0119), and Asociacion Cientifica Pulmon y
Ventilacion Mecanica.
NR 34
TC 11
Z9 11
U1 5
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1070-5295
EI 1531-7072
J9 CURR OPIN CRIT CARE
JI Curr. Opin. Crit. Care
PD FEB
PY 2016
VL 22
IS 1
BP 1
EP 6
DI 10.1097/MCC.0000000000000266
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA DC9KD
UT WOS:000369539500001
PM 26645551
ER
PT J
AU Gong, MN
Thompson, BT
AF Gong, Michelle Ng
Thompson, B. Taylor
TI Acute respiratory distress syndrome: shifting the emphasis from
treatment to prevention
SO CURRENT OPINION IN CRITICAL CARE
LA English
DT Review
DE acute respiratory distress syndrome; clinical trials; prevention
ID ACUTE LUNG INJURY; RANDOMIZED CONTROLLED-TRIAL; INTENSIVE-CARE-UNIT;
CRITICALLY-ILL PATIENTS; LOWER TIDAL VOLUMES; SURGICAL-PATIENTS;
CLINICAL-TRIAL; MULTICENTER COHORT; PULMONARY-FUNCTION; SEVERE SEPSIS
AB Purpose of review Although results from clinical trials have advanced the treatment of acute respiratory distress syndrome (ARDS), mortality remains high. More recently, focus has shifted from treatment of ARDS to early identification and prevention in at-risk populations.
Recent findings There have been 30 published and registered clinical trials with either the primary or secondary goal of reducing ARDS.
Summary With this change in paradigm, come additional challenges and consideration in study design that depends not only on the intervention but also whether the intervention aims for a primary, secondary, or tertiary prevention of ARDS that targets a patient population for universal, selective, or indicated prevention. These epidemiologic concepts of prevention in public health also apply to ARDS and are relevant to the study population to target, the timing of the intervention relative to critical illness, the study design and outcomes to measure in an ARDS prevention study. This shift in focus is reflected by the new National Heart Lung Blood Institute Prevention and Early Treatment of Acute Lung Injury network, and signifies an overall movement away from reacting to and supporting acute organ failure after it is established to early detection and prevention in acute critical illness wherever and whenever it may occur.
C1 [Gong, Michelle Ng] Montefiore Med Ctr, Dept Med, Div Crit Care Med, Bronx, NY 10467 USA.
[Gong, Michelle Ng] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Thompson, B. Taylor] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Pulm & Crit Care Unit, Boston, MA USA.
RP Gong, MN (reprint author), Montefiore Med Ctr, Dept Med, Div Crit Care Med, Crit Care Med Adm Off, Ground Floor,Gold Zone,111 East 210th St, Bronx, NY 10467 USA.
EM mgong@montefiore.org
FU National Heart, Lung, Blood Institute (NHLBI) at the National Institute
of Health
FX The work is supported by the National Heart, Lung, Blood Institute
(NHLBI) at the National Institute of Health.
NR 59
TC 4
Z9 4
U1 2
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1070-5295
EI 1531-7072
J9 CURR OPIN CRIT CARE
JI Curr. Opin. Crit. Care
PD FEB
PY 2016
VL 22
IS 1
BP 21
EP 37
DI 10.1097/MCC.0000000000000275
PG 17
WC Critical Care Medicine
SC General & Internal Medicine
GA DC9KD
UT WOS:000369539500004
PM 26645554
ER
PT J
AU Levitsky, LL
AF Levitsky, Lynne L.
TI Nutrition and growth - a multitude of manifestations and room for
further investigation
SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
LA English
DT Editorial Material
ID ADIPOSE-TISSUE; LINEAR GROWTH; OBESITY; HEIGHT; FAT
C1 [Levitsky, Lynne L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Levitsky, LL (reprint author), Harvard Univ, Sch Med, Pediat, 175 Cambridge St,5th Floor, Boston, MA 02114 USA.; Levitsky, LL (reprint author), Massachusetts Gen Hosp, Pediat Endocrinol, 175 Cambridge St,5th Floor, Boston, MA 02114 USA.
EM LLevitsky@mgh.harvard.edu
NR 23
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1752-296X
EI 1752-2978
J9 CURR OPIN ENDOCRINOL
JI Curr. Opin. Endocrinol. Diabetes Obes.
PD FEB
PY 2016
VL 23
IS 1
BP 48
EP 50
DI 10.1097/MED.0000000000000223
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DD1BW
UT WOS:000369657100008
PM 26702850
ER
PT J
AU Meya, DB
Manabe, YC
Boulware, DR
Janoff, EN
AF Meya, David B.
Manabe, Yukari C.
Boulware, David R.
Janoff, Edward N.
TI The immunopathogenesis of cryptococcal immune reconstitution
inflammatory syndrome: understanding a conundrum
SO CURRENT OPINION IN INFECTIOUS DISEASES
LA English
DT Review
DE cryptococcus; cryptococcal meningitis; HIV; immunopathogenesis; immune
reconstitution inflammatory syndrome
ID ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; HIV-INFECTED PATIENTS;
RESOURCE-LIMITED SETTINGS; CENTRAL-NERVOUS-SYSTEM;
NECROSIS-FACTOR-ALPHA; CEREBROSPINAL-FLUID; RESTORATION DISEASE;
FUNGAL-INFECTIONS; PRIMARY IMMUNODEFICIENCIES
AB Purpose of reviewCryptococcal meningitis causes significant mortality among HIV-infected patients, despite antifungal therapy and use of antiretroviral therapy (ART). In patients with cryptococcal meningitis, ART is often complicated by immune reconstitution inflammatory syndrome (IRIS), manifesting as unmasking of previously unrecognized subclinical infection (unmasking CM-IRIS) or paradoxical worsening of symptoms in the central nervous system after prior improvement with antifungal therapy (paradoxical CM-IRIS). We review our current understanding of the pathogenesis of this phenomenon, focusing on unifying innate and adaptive immune mechanisms leading to the development of this often fatal syndrome.Recent findingsWe propose that HIV-associated CD4(+) T-cell depletion, chemokine-driven trafficking of monocytes into cerebrospinal fluid in response to cryptococcal meningitis, and poor localized innate cytokine responses lead to inadequate cryptococcal killing and clearance of the fungus. Subsequent ART-associated recovery of T-cell signaling and restored cytokine responses, characterized by IFN- production, triggers an inflammatory response. The inflammatory response triggered by ART is dysregulated because of impaired homeostatic and regulatory mechanisms, culminating in the development of CM-IRIS.SummaryDespite our incomplete understanding of the immunopathogenesis of CM-IRIS, emerging data exploring innate and adaptive immune responses could be exploited to predict, prevent and manage CM-IRIS and associated morbid consequences.
C1 [Meya, David B.] Makerere Univ, Infect Dis Inst, Kampala 22418, Uganda.
[Meya, David B.; Boulware, David R.] Univ Minnesota, Dept Med, Ctr Infect Dis & Microbiol Translat Res, Box 736 UMHC, Minneapolis, MN 55455 USA.
[Meya, David B.] Makerere Univ, Sch Med, Coll Hlth Sci, Kampala 22418, Uganda.
[Manabe, Yukari C.] Johns Hopkins Univ, Dept Med, Div Infect Dis, Baltimore, MD USA.
[Janoff, Edward N.] Univ Colorado, Mucosal & Vaccine Res Program Colorado MAVRC, Denver, CO 80202 USA.
[Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Meya, DB (reprint author), Makerere Univ, Infect Dis Inst, Coll Hlth Sci, Kampala 22418, Uganda.
EM david.meya@gmail.com
OI Boulware, David/0000-0002-4715-0060
FU National Institutes of Health [R01AI078934, U01AI089244, R21NS065713,
R01AI108479, T32AI055433, K24AI096925]; Welcome Trust Training Health
Researchers into Vocational Excellence (THRiVE) in East Africa [087540,
AI108479]; Veterans Affairs Research Service
FX This work supported by the National Institutes of Health (R01AI078934,
U01AI089244, R21NS065713, R01AI108479, T32AI055433) to D.M. and D.B.;
K24AI096925 to P.B.; the Welcome Trust Training Health Researchers into
Vocational Excellence (THRiVE) in East Africa, grant number 087540 to
D.M.; AI108479 to E.J.; and the Veterans Affairs Research Service.
NR 108
TC 2
Z9 2
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0951-7375
EI 1473-6527
J9 CURR OPIN INFECT DIS
JI Curr. Opin. Infect. Dis.
PD FEB
PY 2016
VL 29
IS 1
BP 10
EP 22
DI 10.1097/QCO.0000000000000224
PG 13
WC Infectious Diseases
SC Infectious Diseases
GA DC9NZ
UT WOS:000369549600002
PM 26658650
ER
PT J
AU Shepard, DS
Daley, MC
Neuman, MJ
Blaakman, AP
Mckay, JR
AF Shepard, Donald S.
Daley, Marilyn C.
Neuman, Matthew J.
Blaakman, Aaron P.
McKay, James R.
TI Telephone-based continuing care counseling in substance abuse treatment:
Economic analysis of a randomized trial
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Alcohol and cocaine dependence; Continuing care alternatives;
Telephone-based continuing care; Relapse prevention
ID BENEFIT-COST-ANALYSIS; RELAPSE PREVENTION; TREATMENT SERVICES; USE
DISORDERS; ALCOHOL-CONSUMPTION; ADDICTION TREATMENT; SMOKING-CESSATION;
PROBLEM DRINKERS; CLINICAL-TRIALS; FOLLOW-UP
AB Purpose: To investigate whether telephone-based continuing care (TEL) is a promising alternative to traditional face-to-face counseling for clients in treatment for substance abuse.
Methods: Patients with alcohol and/or cocaine dependence who had completed a 4-week intensive outpatient program were randomly assigned through urn randomization into one of three 12-week interventions: standard continuing care (STD), in-person relapse prevention (RP), or telephone-based continuing care (TEL). This study performed cost, cost-effectiveness, and cost-benefit analyses of TEL and RP compared to STD, using results from the randomized clinical trial with two years of follow up (359 participants). In addition, the study examined the potential moderating effect of baseline patient costs on economic outcomes.
Results: The study found that TEL was less expensive per client from the societal perspective ($569) than STD ($870) or RP ($1684). TEL also was also significantly more effective, with an abstinence rate of 57.1% compared to 46.7% for STD (p <0.05). Thus TEL dominated STD, with a highly favorable negative incremental cost-effectiveness ratio (-$1400 per abstinent year). TEL also proved favorable under a benefit-cost perspective.
Conclusions: TEL proved to be a cost-effective and cost-beneficial contributor to long-term recovery over two years. Because TEL dominated STD care interventions, wider adoption should be considered. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Shepard, Donald S.; Daley, Marilyn C.] Brandeis Univ, Heller Sch Social Policy & Management, Schneider Inst Hlth Policy, Waltham, MA 02454 USA.
[Neuman, Matthew J.] US Dept Vet Affairs, Program Evaluat & Resource Ctr, VA Palo Alto Hlth Care Syst, Menlo Pk Div, 795 Willow Rd, Menlo Pk, CA 94025 USA.
[Neuman, Matthew J.] US Dept Vet Affairs, Hlth Care Financing & Econ, VA Boston Hlth Care Syst, 150 South Huntington Ave, Boston, MA 02130 USA.
[Blaakman, Aaron P.] 203 Candia Lane, Cary, NC 27519 USA.
[McKay, James R.] Univ Penn, Dept Psychiat, Perelman Sch Med, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA.
[McKay, James R.] US Dept Vet Affairs, Crescenz VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
RP Shepard, DS (reprint author), Brandeis Univ, Heller Sch Social Policy & Management, Schneider Inst Hlth Policy, Waltham, MA 02454 USA.
EM shepard@brandeis.edu
FU NIAAA NIH HHS [R01 AA010341]; NIDA NIH HHS [R01 DA010262, K02 DA000361,
K24 DA029062]
NR 49
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD FEB 1
PY 2016
VL 159
BP 109
EP 116
DI 10.1016/j.drugalcdep.2015.11.034
PG 8
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA DC8LX
UT WOS:000369472200015
PM 26718395
ER
PT J
AU Lee, S
Ko, BJ
Gong, Y
Han, K
Lee, A
Han, BD
Yoon, YJ
Park, S
Kim, JH
Mantzoros, CS
AF Lee, Saehyun
Ko, Byung-Joon
Gong, Younghoon
Han, Kyungdo
Lee, Anna
Han, Byoung-Duck
Yoon, Yeo Joon
Park, Siyoung
Kim, Jung-Hyun
Mantzoros, Christos S.
TI Self-reported eating speed in relation to non-alcoholic fatty liver
disease in adults
SO EUROPEAN JOURNAL OF NUTRITION
LA English
DT Article
DE Eating behavior; Non-alcoholic fatty liver disease; Insulin resistance;
Obesity
ID AGED JAPANESE MEN; TYPE-2 DIABETES-MELLITUS; GLUCAGON-LIKE PEPTIDE-1;
INSULIN-RESISTANCE; ENERGY-INTAKE; GUT HORMONES; FAST LEADS; OBESITY;
WOMEN; RISK
AB Non-alcoholic fatty liver disease (NAFLD), known to be related to insulin resistance, has been the focus of intensive research efforts due to its increasing prevalence and clinical significance. Rapid eating behavior is another emerging health issue associated with insulin resistance. We aimed to clarify the correlation between self-reported eating speed and NAFLD, both known to be related to insulin resistance.
A cross-sectional study was conducted during routine medical checkups on 7,917 consecutively enrolled participants. Anthropometric, biochemical, nutritional, and social parameters were checked. The self-reported eating speed per their usual meal (< 5, 5-10, 10-15, and more than 15 min) was recorded by a registered dietitian.
The faster eating groups had a higher proportion of NAFLD, and the grade of NAFLD was advanced. After controlling for anthropometric, cardiometabolic, social, and nutritional parameters, the fastest eating group (< 5 min) showed an increased risk of NAFLD compared with the lowest eating speed group (a parts per thousand yen15 min) both in total [odds ratio (OR) 1.81, 95 % confidence interval (CI) 1.24-2.63] and the participants with BMI < 25 kg/m(2) (OR 1.79, 95 % CI 1.22-2.61). As the self-reported eating speed increased, the risk of NAFLD also increased in total and those with BMI < 25 kg/m(2) (P for trend < 0.001).
Fast eating is associated with an increased risk of the presence and grade of NAFLD in Korean adults, especially those with BMI < 25 kg/m(2), since presence of overweight or obesity may be overwhelming the effect on NAFLD.
C1 [Lee, Saehyun; Ko, Byung-Joon; Gong, Younghoon; Yoon, Yeo Joon; Park, Siyoung] Korea Univ, Dept Family Med, Coll Med, Seoul 136705, South Korea.
[Ko, Byung-Joon; Mantzoros, Christos S.] Harvard Univ, Div Endocrinol Diabet & Metab, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Ko, Byung-Joon] Sungkyunkwan Univ, Total Healthcare Ctr, Kangbuk Samsung Hosp, Sch Med, Seoul 100742, South Korea.
[Han, Kyungdo] Catholic Univ, Dept Biostat, Coll Med, Seoul 137701, South Korea.
[Lee, Anna] Univ Pacific, Sch Phys Assistant Studies, Coll Hlth Profess, Hillsboro, OR 97123 USA.
[Han, Byoung-Duck] SahmYook Med Ctr, Dept Family Med, Seoul 130711, South Korea.
[Kim, Jung-Hyun] Seoul Natl Univ, Grad Sch Publ Hlth, Dept Publ Hlth, Seoul 151742, South Korea.
[Mantzoros, Christos S.] Harvard Univ, Endocrinol Sect, Boston VA Healthcare Syst, Sch Med, Boston, MA 02130 USA.
RP Mantzoros, CS (reprint author), Harvard Univ, Div Endocrinol Diabet & Metab, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
EM cmantzor@bidmc.harvard.edu
NR 33
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1436-6207
EI 1436-6215
J9 EUR J NUTR
JI Eur. J. Nutr.
PD FEB
PY 2016
VL 55
IS 1
BP 327
EP 333
DI 10.1007/s00394-015-0851-z
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DC6DJ
UT WOS:000369309700031
PM 25648740
ER
PT J
AU Hoggatt, J
Hoggatt, AF
Tate, TA
Fortman, J
Pelus, LM
AF Hoggatt, Jonathan
Hoggatt, Amber F.
Tate, Tiffany A.
Fortman, Jeffrey
Pelus, Louis M.
TI Bleeding the laboratory mouse: Not all methods are equal
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
ID CLINICAL PATHOLOGY PARAMETERS; BLOOD COLLECTION; SAMPLING SITE; MICE;
PLEXUS; RATS
AB The laboratory mouse is the model most frequently used in hematologic studies and assessment of blood parameters across a broad range of disciplines. Often, analysis of blood occurs in a nonterminal manner. However, the small body size of the mouse limits collection based on volume, frequency, and accessible sites. Commonly used sites in the mouse include the retro-orbital sinus, facial vein, tail vein, saphenous vein, and heart. The method of blood acquisition varies considerably across laboratories and is often not reported in detail. In this study, we report significant alterations in blood parameters, particularly of total white blood cells, specific populations of dendritic cells and myeloid-derived suppressor cells, and hematopoietic progenitor cells, as a result of site and manner of sampling. Intriguingly, warming of mice prior to tail bleeding was found to significantly alter blood values. Our findings suggest that the same method should be used across an entire study, that mice should be warmed prior to tail bleeds to make levels uniform, and that accurate description of bleeding methods in publications should be provided to allow for interpretation of comparative reports and inter and intralaboratory experimental variability. Copyright (C) 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.
C1 [Hoggatt, Jonathan; Tate, Tiffany A.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Ctr Transplantat Sci,Med Sch, Boston, MA 02114 USA.
[Hoggatt, Amber F.] Harvard Univ, Sch Med, Ctr Comparat Med, Boston, MA USA.
[Fortman, Jeffrey] Univ Illinois, Biol Resources Lab, Chicago, IL USA.
[Pelus, Louis M.] Indiana Univ Sch Med, Microbiol & Immunol, Indianapolis, IN 46202 USA.
RP Hoggatt, J (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Transplantat Sci, 149 13th St CNY149,Room 5-301, Boston, MA 02129 USA.; Pelus, LM (reprint author), Indiana Univ Sch Med, Dept Microbiol & Immunol, 950 West Walnut St,R2-302, Indianapolis, IN 46202 USA.
EM hoggatt.jonathan@mgh.harvard.edu; lpelus@iupui.edu
FU NIH [HL069669, HL096305, HL007910, HL119559]
FX This work was supported by NIH Grants HL069669 and HL096305 to LMP. JH
was supported by NIH Training Grant HL007910 and is currently supported
by HL119559. Flow cytometry was performed in the Flow Cytometry Resource
Facility of the Indiana University Simon Cancer Center (NCI P30
CA082709).
NR 16
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
EI 1873-2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD FEB
PY 2016
VL 44
IS 2
BP 132
EP 137
DI 10.1016/j.exphem.2015.10.008
PG 6
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA DC8KY
UT WOS:000369469700007
PM 26644183
ER
PT J
AU Jensen, DM
Ohning, GV
Kovacs, TOG
Jutabha, R
Ghassemi, K
Dulai, GS
Machicado, GA
AF Jensen, Dennis M.
Ohning, Gordon V.
Kovacs, Thomas O. G.
Jutabha, Rome
Ghassemi, Kevin
Dulai, Gareth S.
Machicado, Gustavo A.
TI Natural history of definitive diverticular hemorrhage based on stigmata
of recent hemorrhage and colonoscopic Doppler blood flow monitoring for
risk stratification and definitive hemostasis
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID BLEEDING COLONIC DIVERTICULA; ENDOSCOPIC HEMOSTASIS; URGENT COLONOSCOPY;
SEVERE HEMATOCHEZIA; MASSIVE HEMORRHAGE; DIAGNOSIS; MANAGEMENT; VESSEL;
INJECTION; THERAPY
AB Background and Aims: Few prospective reports describe the short-term natural history of colon diverticular hemorrhage based on stigmata of recent hemorrhage, and none include blood flow detection for risk stratification or as a guide to definitive hemostasis. Our purposes were to report the 30-day natural history of definitive diverticular hemorrhage based on stigmata and to describe Doppler probe blood flow detection as a guide to definitive hemostasis.
Methods: Different cohorts of patients with severe diverticular bleeding and stigmata on urgent colonoscopy are reported. For 30-day natural history, patients were treated medically. If severe rebleeding occurred, they had surgical or angiographic treatment. We report natural history with major stigmata (active bleeding, visible vessel, or adherent clot) and no stigmata or flat spots after clots were washed away. We also report Doppler probe detection of arterial blood flow underneath stigmata before and after hemostasis in a recent cohort.
Results: For natural history, patients with major stigmata treated medically had 65.8% (25/38) rebleeding rates, and 44.7% (17/38) had intervention for hemostasis. Patients with spots or clean bases had no rebleeding. A Doppler probe detected arterial blood flow in 92% of major stigmatadnone after hemostasisdand there was no rebleeding.
Conclusions: (1) Patients with major stigmata treated medically had high rates of rebleeding and intervention for hemostasis. (2) Patients with clean diverticula or only flat spots had no rebleeding. (3) High rates of arterial blood flow were detected under major stigmata with a Doppler probe, but with obliteration by hemostasis no rebleeding occurred.
C1 [Jensen, Dennis M.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Ulcer Res & Educ,Dept Med Ronald Reagan UCLA, Digest Dis Res Ctr,Vet Affairs Greater Los Angele, Los Angeles, CA 90095 USA.
Vet Affairs West Los Angeles Med Ctr, Los Angeles, CA USA.
RP Jensen, DM (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr DDRC, Bldg 115,Room 318,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
FU Clinical Veterans Affairs Merit Review Grant, NIH [P30 AM41301]; Center
for Ulcer Research and Education Digestive Diseases Research Center core
grant; Vascular Technologies Incorporated (VTI)
FX These studies were supported partially by a Clinical Veterans Affairs
Merit Review Grant (D. Jensen, PI), NIH P30 AM41301, a Center for Ulcer
Research and Education Digestive Diseases Research Center core grant
(human studies core), and by Vascular Technologies Incorporated (VTI),
who donated colon Doppler endoscopic probes. D. Jensen is a consultant
for VTI and is a speaker for BSC. All other authors disclosed no
financial relationships relevant to this publication.
NR 33
TC 3
Z9 3
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
EI 1097-6779
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD FEB
PY 2016
VL 83
IS 2
BP 416
EP 423
DI 10.1016/j.gie.2015.07.033
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DC5AK
UT WOS:000369232000021
PM 26227931
ER
PT J
AU Pawlyk, BS
Bulgakov, OV
Sun, X
Adamian, M
Shu, X
Smith, AJ
Berson, EL
Ali, RR
Khani, S
Wright, AF
Sandberg, MA
Li, T
AF Pawlyk, B. S.
Bulgakov, O. V.
Sun, X.
Adamian, M.
Shu, X.
Smith, A. J.
Berson, E. L.
Ali, R. R.
Khani, S.
Wright, A. F.
Sandberg, M. A.
Li, T.
TI Photoreceptor rescue by an abbreviated human RPGR gene in a murine model
of X-linked retinitis pigmentosa
SO GENE THERAPY
LA English
DT Article
ID LEBER CONGENITAL AMAUROSIS; RETINAL DEGENERATION; EXON ORF15;
REPLACEMENT THERAPY; CANINE MODEL; MOUSE MODELS; MUTATIONS; CONE; ROD;
RP2
AB The X-linked RP3 gene codes for the ciliary protein RPGR and accounts for over 10% of inherited retinal degenerations. The critical RPGR-ORF15 splice variant contains a highly repetitive purine-rich linker region that renders it unstable and difficult to adapt for gene therapy. To test the hypothesis that the precise length of the linker region is not critical for function, we evaluated whether adeno-associated virus-mediated replacement gene therapy with a human ORF15 variant containing in-frame shortening of the linker region could reconstitute RPGR function in vivo. We delivered human RPGR-ORF15 replacement genes with deletion of most (314 codons, 'short form') or 1/3 (126 codons, 'long form') of the linker region to Rpgr null mice. Human RPGR-ORF15 expression was detected post treatment with both forms of ORF15 transgenes. However, only the long form correctly localized to the connecting cilia and led to significant functional and morphological rescue of rods and cones. Thus the highly repetitive region of RPGR is functionally important but that moderate shortening of its length, which confers the advantage of added stability, preserves its function. These findings provide a theoretical basis for optimizing replacement gene design in clinical trials for X-linked RP3.
C1 [Pawlyk, B. S.; Adamian, M.; Berson, E. L.; Sandberg, M. A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Berman Gund Lab Study Retinal Degenerat, Sch Med, Boston, MA USA.
[Bulgakov, O. V.; Sun, X.; Li, T.] NEI, 6 Ctr Dr, Bethesda, MD 20892 USA.
[Shu, X.; Wright, A. F.] Univ Edinburgh, MRC Human Genet Unit, Edinburgh, Midlothian, Scotland.
[Shu, X.] Glasgow Caledonian Univ, Dept Life Sci, Glasgow G4 0BA, Lanark, Scotland.
[Smith, A. J.; Ali, R. R.] UCL, Inst Ophthalmol, Dept Genet, London, England.
[Khani, S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Sch Med, Boston, MA USA.
RP Li, T (reprint author), NEI, 6 Ctr Dr, Bethesda, MD 20892 USA.; Pawlyk, BS (reprint author), Massachusetts Eye & Ear Infirm, Berman Gund Lab, 243 Charles St, Boston, MA 02114 USA.
EM Basil_Pawlyk@meei.harvard.edu; tiansen.li@nih.gov
FU National Eye Institute [EY10581]; NEI [5P30EY14104]; Foundation Fighting
Blindness; Foundation for Retina Research; Massachusetts Lions Eye
Research Fund; European Union (AAVEYE); UK Department of Health,
National Institute of Health Research BMRC for Ophthalmology; UK Fight
for Sight
FX We thank Dr Jeng-Shin Lee at the Research Vector Core at Harvard Medical
School for AAV vector packaging, and Drs Peter Colosi and Zhijian Wu at
the National Eye Institute for helpful discussions. This work was
supported by National Eye Institute grant EY10581, NEI core grant for
Vision Research (5P30EY14104), the Foundation Fighting Blindness, the
Foundation for Retina Research, the Massachusetts Lions Eye Research
Fund and by grants from the European Union (AAVEYE), the UK Department
of Health, National Institute of Health Research BMRC for Ophthalmology
and UK Fight for Sight.
NR 47
TC 4
Z9 4
U1 2
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD FEB
PY 2016
VL 23
IS 2
BP 196
EP 204
DI 10.1038/gt.2015.93
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity; Research & Experimental Medicine
GA DC9NY
UT WOS:000369549500010
PM 26348595
ER
PT J
AU Bregar, AJ
Growdon, WB
AF Bregar, Amy J.
Growdon, Whitfield B.
TI Emerging strategies for targeting PI3K in gynecologic cancer
SO GYNECOLOGIC ONCOLOGY
LA English
DT Review
DE Gynecologic cancer; PI3K pathway inhibition; mTOR inhibition;
Therapeutic resistance
ID CLEAR-CELL CARCINOMA; PHASE-II TRIAL; RECURRENT ENDOMETRIAL CARCINOMA;
EPITHELIAL OVARIAN-CANCER; UTERINE SEROUS CARCINOMA; ONCOLOGY-GROUP;
MAMMALIAN TARGET; HIGH-FREQUENCY; ONCOGENIC MUTATIONS; THERAPEUTIC
TARGET
AB Ovarian, endometrial and cervical cancers are the most prevalent gynecologic cancers in the United States and account for significant mortality. Translational research into these cancers has highlighted the distinctive molecular and genomic profiles of these cancers finding that, even within a disease site, the landscapes and drivers of neoplasia are distinctive. Despite this molecular diversity, activation of the phosphatidylinositol-3-kinase (PI3K) pathway appears to be conserved in subsets of these tumors, suggesting that strategies that antagonize mediators in this signaling cascade could offer anti-tumor efficacy. Extensive pre-clinical and clinical data have demonstrated that single agent targeted therapies lead to modest single agent activity of generally limited duration, even in the setting of innate PI3K pathway activation via mutation or amplification. These findings in the laboratory and clinic have prompted investigations into resistance pathways following PI3K pathway inhibition in order to understand escape pathways and restore tumor cell sensitivity. A next generation of clinical trial investigations will focus on novel combinations in order to define how these important therapeutics can be used in the clinic. This review will present preclinical data that supports the role of the PI3K pathway in ovarian, endometrial and cervical cancers, in addition to discussing the reported clinical trial experience with PI3K pathway inhibition. A specific focus will be on the rationale behind ongoing clinical trials utilizing novel agents in concert with PI3K pathway inhibitors to reverse resistance in populations with and without gain of function alterations in this oncogenic signaling cascade. (C) 2015 Elsevier Inc. All rights reserved.
C1 Massachusetts Gen Hosp, Dept Obstet & Gynecol, Vincent Ctr Reprod Biol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, Boston, MA 02114 USA.
RP Growdon, WB (reprint author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Vincent Dept Obstet & Gynecol, THR 901,55 Fruit St, Boston, MA 02114 USA.
EM wgrowdon@partners.org
NR 120
TC 0
Z9 0
U1 2
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD FEB
PY 2016
VL 140
IS 2
BP 333
EP 344
DI 10.1016/j.ygyno.2015.09.083
PG 12
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA DD1JV
UT WOS:000369678900024
PM 26432040
ER
PT J
AU Miller, SC
Mor, V
Burgess, JF
AF Miller, Susan C.
Mor, Vincent
Burgess, James F., Jr.
TI Studying Nursing Home Innovation: The Green House Model of Nursing Home
Care
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Culture change; person-centered care; nursing homes; innovation
ID CULTURE-CHANGE
C1 [Miller, Susan C.; Mor, Vincent] Brown Univ, Dept Hlth Serv Policy & Practice, Sch Publ Hlth, 121 South Main St,Room 619, Providence, RI 02912 USA.
[Miller, Susan C.; Mor, Vincent] Brown Univ, Ctr Gerontol & Hlth Care Res, Sch Publ Hlth, 121 South Main St,Room 619, Providence, RI 02912 USA.
[Burgess, James F., Jr.] Boston Univ, Ctr Healthcare Org & Implementat Res, VA Boston Healthcare Syst, Dept Hlth Law Policy & Management,Sch Publ Hlth, Boston, MA 02215 USA.
RP Miller, SC (reprint author), Brown Univ, Dept Hlth Serv Policy & Practice, Sch Publ Hlth, 121 South Main St,Room 619, Providence, RI 02912 USA.; Miller, SC (reprint author), Brown Univ, Ctr Gerontol & Hlth Care Res, Sch Publ Hlth, 121 South Main St,Room 619, Providence, RI 02912 USA.
EM susan_miller@brown.edu
FU NIA NIH HHS [R01 AG048940]
NR 22
TC 0
Z9 0
U1 4
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-9124
EI 1475-6773
J9 HEALTH SERV RES
JI Health Serv. Res.
PD FEB
PY 2016
VL 51
SU 1
BP 335
EP 343
DI 10.1111/1475-6773.12437
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA DC9HG
UT WOS:000369531300001
PM 26729237
ER
PT J
AU Sethi, S
Anzueto, A
Miravitlles, M
Arvis, P
Alder, J
Haverstock, D
Trajanovic, M
Wilson, R
AF Sethi, S.
Anzueto, A.
Miravitlles, M.
Arvis, P.
Alder, J.
Haverstock, D.
Trajanovic, M.
Wilson, R.
TI Determinants of bacteriological outcomes in exacerbations of chronic
obstructive pulmonary disease
SO INFECTION
LA English
DT Article
DE Bacteriological outcomes; Beta-lactams; Exacerbation of chronic
obstructive pulmonary disease; Fluoroquinolones; Risk factors; Systemic
corticosteroids
ID CHRONIC-BRONCHITIS; HAEMOPHILUS-INFLUENZAE; CONTROLLED-TRIAL;
GENE-EXPRESSION; COPD; MOXIFLOXACIN; INFLAMMATION; ANTIBIOTICS;
INFECTIONS; COLONIZATION
AB Changes in sputum microbiology following antibiotic treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), including patterns of bacteriological relapse and superinfection are not well understood. Sputum microbiology at exacerbation is not routinely performed, but pathogen presence and species are determinants of outcomes. Therefore, we determined whether baseline clinical factors could predict the presence of bacterial pathogens at exacerbation. Bacterial eradication at end of treatment (EOT) is associated with clinical resolution of exacerbation. We determined the clinical, microbiological and therapeutic factors that were associated with bacteriological eradication in AECOPD at EOT and in the following 8 weeks.
Sputum bacteriological outcomes (i.e., eradication, persistence, superinfection, reinfection) from AECOPD patients (N = 1352) who were randomized to receive moxifloxacin or amoxicillin/clavulanate in the MAESTRAL study were compared. Independent predictors of bacterial presence in sputum at exacerbation and determinants for bacteriological eradication were analyzed by logistic regression and receiver operating characteristic (ROC) analyses.
Significantly greater bacteriological eradication with moxifloxacin was mainly driven by superior Haemophilus influenzae eradication (P = 0.002, EOT). Baseline clinical factors were a weak predictor of the presence of pathogens in sputum (AUC(ROC) = 0.593). On multivariate analysis, poorer bacterial eradication was associated with antibiotic resistance (P = 0.0001), systemic steroid use (P = 0.0024) and presence of P. aeruginosa (P = 0.0282).
Since clinical prediction of bacterial presence in sputum at AECOPD is poor, sputum microbiological analysis should be considered for guiding antibiotic therapy in moderate-to-severe AECOPD, particularly in those who received concomitant systemic corticosteroids or are at risk for infection with antibiotic-resistant bacteria.
C1 [Sethi, S.] SUNY Buffalo, Div Pulm Crit Care & Sleep Med, Buffalo, NY 14260 USA.
[Sethi, S.] VA Med Res, 151,3495 Bailey Ave, Buffalo, NY 14215 USA.
[Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Miravitlles, M.] Hosp Univ Vall dHebron, Dept Pneumol, CIBER Enfermedades Resp CIBERES, Barcelona, Spain.
[Arvis, P.] Bayer HealthCare, Loos, France.
[Alder, J.; Haverstock, D.] Bayer HealthCare Pharmaceut, Whippany, NJ USA.
[Trajanovic, M.] Bayer Inc, Toronto, ON, Canada.
[Wilson, R.] Royal Brompton Hosp, Host Def Unit, London SW3 6LY, England.
RP Sethi, S (reprint author), SUNY Buffalo, Div Pulm Crit Care & Sleep Med, Buffalo, NY 14260 USA.; Sethi, S (reprint author), VA Med Res, 151,3495 Bailey Ave, Buffalo, NY 14215 USA.
EM ssethi@buffalo.edu
OI Miravitlles, Marc/0000-0002-9850-9520
FU Bayer HealthCare AG, Germany
FX Highfield Communication (Oxford, United Kingdom) provided editorial
assistance in preparation of this manuscript. This work was supported by
Bayer HealthCare AG, Germany.
NR 36
TC 1
Z9 1
U1 0
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8126
EI 1439-0973
J9 INFECTION
JI Infection
PD FEB
PY 2016
VL 44
IS 1
BP 65
EP 76
DI 10.1007/s15010-015-0833-3
PG 12
WC Infectious Diseases
SC Infectious Diseases
GA DC5ZJ
UT WOS:000369299000008
PM 26370552
ER
PT J
AU Petrou, SP
Davidiuk, AJ
Rawal, B
Arnold, M
Thiel, DD
AF Petrou, Steven P.
Davidiuk, Andrew J.
Rawal, Bhupendra
Arnold, Michelle
Thiel, David D.
TI Salvage autologous fascial sling after failed synthetic midurethral
sling: Greater than 3-year outcomes
SO INTERNATIONAL JOURNAL OF UROLOGY
LA English
DT Article
DE autologous fascial sling; failed midurethral sling; recurrent stress
urinary incontinence; repeat sling; salvage fascial sling
ID STRESS URINARY-INCONTINENCE; SURGERY; SUCCESS; WOMEN; TAPE
AB ObjectiveTo determine long-term surgical outcomes of salvage autologous fascial sling placement after a failed synthetic midurethral sling.
MethodsWomen who had undergone autologous fascial sling placement without concomitant pelvic surgery for a failed synthetic midurethral sling utilizing mesh with a minimum follow up of 36 months were identified. Charts were reviewed, and patients were contacted by telephone. Success was determined by the Patient Global Impression of Improvement. Secondary measures included the Incontinence Severity Index questionnaire, patient recommendation of the autologous fascial sling and need for further incontinence surgery.
ResultsA total of 35 patients met the criteria, and 21 were successfully contacted. Of those contacted, the median age at surgery was 67 years (range 53-81 years) and at the time of the survey was 75 years (range 63-84 years) with median follow up of 74 months (range 36-127 years). Preoperatively, 12 patients (57.1%) had urethral hypermobility and 13 patients (61.9%) had mixed urinary incontinence. Eight patients (38.1%) had concomitant sling excision with five of those combined with urethrolysis at the time of the salvage operation. Patient Global Impression of Improvement success was noted in 16 patients (76.2%). A total of 11 patients (52.4%) were dry or had slight incontinence by the Incontinence Severity Index. One patient required additional anti-incontinence surgery (4.8%). A total of 18 patients (85.7%) recommended the autologous fascial sling. No statistical impact was noted with sling excision (P = 0.62), mixed urinary incontinence (P = 0.61), age at surgery (P = 0.23), age at follow up (P = 0.15), length of follow up (P = 0.71) or first surgery type (transobturator tape vs retropubic; P = 1.00).
ConclusionsAutologous fascial sling provides reasonable long-term success as a salvage operation for failed midurethral slings.
C1 [Petrou, Steven P.; Davidiuk, Andrew J.; Thiel, David D.] Mayo Clin, Dept Urol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
[Rawal, Bhupendra] Mayo Clin, Div Biomed Stat & Informat, Jacksonville, FL 32224 USA.
[Arnold, Michelle] Mayo Clin, Dept Hlth Sci Res, Jacksonville, FL 32224 USA.
[Rawal, Bhupendra] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
RP Petrou, SP (reprint author), Mayo Clin, Dept Urol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
EM petrou.steven@mayo.edu
NR 17
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0919-8172
EI 1442-2042
J9 INT J UROL
JI Int. J. Urol.
PD FEB
PY 2016
VL 23
IS 2
BP 178
EP 181
DI 10.1111/iju.13003
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA DC3YJ
UT WOS:000369155700018
PM 26563492
ER
PT J
AU Upadhyay, GA
Singh, JP
AF Upadhyay, Gaurav A.
Singh, Jagmeet P.
TI Spinal Cord Stimulation for Heart Failure in the DEFEAT-HF Study Lost
Battle or Lasting Opportunities?
SO JACC-HEART FAILURE
LA English
DT Editorial Material
DE clinical trial results; heart failure; spinal cord stimulation
ID INTRACTABLE ANGINA-PECTORIS; VENTRICULAR-ARRHYTHMIAS; MODEL; PAIN;
MECHANISMS
C1 [Upadhyay, Gaurav A.] Univ Chicago Hosp, Heart Rhythm Ctr, Chicago, IL 60637 USA.
[Singh, Jagmeet P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Singh, JP (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol,Heart Ctr, 55 Fruit St, Boston, MA 02114 USA.
EM jsingh@mgh.harvard.edu
NR 23
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-1779
EI 2213-1787
J9 JACC-HEART FAIL
JI JACC-Heart Fail.
PD FEB
PY 2016
VL 4
IS 2
BP 137
EP 139
DI 10.1016/j.jchf.2015.11.007
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DC4LK
UT WOS:000369192200007
PM 26746373
ER
PT J
AU Maher, DP
White, PF
AF Maher, Dermot P.
White, Paul F.
TI Proposed mechanisms for association between opioid usage and cancer
recurrence after surgery
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Editorial Material
ID CELL LUNG-CANCER; ASSISTED THORACIC-SURGERY; RETROSPECTIVE ANALYSIS;
RADICAL PROSTATECTOMY; ANESTHETIC TECHNIQUE; PAIN MANAGEMENT;
BREAST-CANCER; TUMOR-GROWTH; INDUCED IMMUNOSUPPRESSION; NEURAXIAL
ANALGESIA
C1 [Maher, Dermot P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,GRB 444, Boston, MA 02114 USA.
[White, Paul F.] Cedars Sinai Med Ctr, Dept Anesthesiol, Los Angeles, CA 90048 USA.
[White, Paul F.] Univ Bologna, Inst Ortoped Rizzoli, I-40126 Bologna, Italy.
[White, Paul F.] White Mt Inst, The Sea Ranch, CA USA.
RP Maher, DP (reprint author), 8700 Beverly Blvd Room 4209, Los Angeles, CA 90048 USA.
EM dpmaher@mgh.harvard.edu; paul.white@cshs.org
NR 60
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0952-8180
EI 1873-4529
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD FEB
PY 2016
VL 28
BP 36
EP 40
DI 10.1016/j.jclinane.2015.05.010
PG 5
WC Anesthesiology
SC Anesthesiology
GA DC4MF
UT WOS:000369194300009
PM 26345433
ER
PT J
AU Zhu, JM
Hamel, D
Dhaliwal, G
Glass, M
Sharpe, B
Kim, B
Monash, B
AF Zhu, Jane M.
Hamel, David
Dhaliwal, Gurpreet
Glass, Marcia
Sharpe, Bradley
Kim, Benjamin
Monash, Bradley
TI Breakdown
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID HEMOLYTIC-ANEMIA
C1 [Zhu, Jane M.; Hamel, David; Dhaliwal, Gurpreet; Glass, Marcia; Sharpe, Bradley; Kim, Benjamin; Monash, Bradley] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Hamel, David; Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA.
RP Monash, B (reprint author), 533 Parnassus Ave,Box 0131, San Francisco, CA 94143 USA.
EM bradley.monash@ucsf.edu
NR 9
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
EI 1553-5606
J9 J HOSP MED
JI J. Hosp. Med.
PD FEB
PY 2016
VL 11
IS 2
BP 126
EP 129
DI 10.1002/jhm.2530
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA DC5VB
UT WOS:000369287500008
PM 26800656
ER
PT J
AU Goode, CJ
Ponte, PR
Havens, DS
AF Goode, Colleen J.
Ponte, Patricia Reid
Havens, Donna Sullivan
TI Residency for Transition Into Practice An Essential Requirement for New
Graduates From Basic RN Programs
SO JOURNAL OF NURSING ADMINISTRATION
LA English
DT Article
ID NURSE; TURNOVER; OUTCOMES
AB Nurse residency programs have been developed with the goal of helping newly licensed nurses successfully transition to independent practice. The authors propose that all newly licensed nurses hired in acute care hospitals be required to complete an accredited residency program. An evidence table examines the state of the science related to transition-to-practice programs and provides the basis for recommendations.
C1 [Goode, Colleen J.] Univ Colorado Denver, Coll Nursing, Healthcare Syst, 13120 E 19th Ave,C288-19, Aurora, CO 80045 USA.
[Ponte, Patricia Reid] Brigham & Womens Hosp, Patient Care Serv, 75 Francis St, Boston, MA 02115 USA.
[Ponte, Patricia Reid] Brigham & Womens Hosp, Dana Farber Canc Inst, Patient Care Serv, 75 Francis St, Boston, MA 02115 USA.
[Ponte, Patricia Reid] Brigham & Womens Hosp, Oncol Nursing & Clin Serv, 75 Francis St, Boston, MA 02115 USA.
[Havens, Donna Sullivan] Univ N Carolina, Sch Nursing, Healthcare Syst & Outcomes, Chapel Hill, NC USA.
RP Goode, CJ (reprint author), Univ Colorado Denver, Coll Nursing, Healthcare Syst, 13120 E 19th Ave,C288-19, Aurora, CO 80045 USA.
EM Colleen.Goode@ucdenver.edu
NR 30
TC 3
Z9 3
U1 3
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0002-0443
EI 1539-0721
J9 J NURS ADMIN
JI J. Nurs. Adm.
PD FEB
PY 2016
VL 46
IS 2
BP 82
EP 86
DI 10.1097/NNA.0000000000000300
PG 5
WC Nursing
SC Nursing
GA DC9EV
UT WOS:000369524800007
PM 26771476
ER
PT J
AU Hao, L
Huang, KH
Ito, K
Sae-Tan, S
Lambert, JD
Ross, AC
AF Hao, Lei
Huang, Kuan-Hsun
Ito, Kyoko
Sae-tan, Sudathip
Lambert, Joshua D.
Ross, A. Catharine
TI Fibroblast Growth Factor 21 (Fgf21) Gene Expression Is Elevated in the
Liver of Mice Fed a High-Carbohydrate Liquid Diet and Attenuated by a
Lipid Emulsion but Is Not Upregulated in the Liver of Mice Fed a
High-Fat Obesogenic Diet
SO JOURNAL OF NUTRITION
LA English
DT Article
DE fibroblast growth factor; high-carbohydrate diet; high-fat diet;
steatosis; exercise
ID PPAR-ALPHA; METABOLIC REGULATOR; FIBROBLAST-GROWTH-FACTOR-21;
RESTRICTION; EXERCISE; MEDIATOR; FGF-21
AB Background: Fibroblast growth factor 21 (FGF21) is a regulator of carbohydrate and lipid metabolism; however, the regulation of Fgf21 gene expression by diet remains incompletely understood.
Objective: We investigated the effect of a high-carbohydrate (HC) liquid diet, with and without supplementation with a lipid emulsion (LE), and of a high-fat diet (HFD) compared with a low-fat diet (LFD) on the regulation of Fgf21 gene expression in the liver of intact mice.
Methods: C57BL/6 male mice were fed standard feed pellets (SFPs), a purified HC liquid diet (adequate in calories and protein), or an HC liquid diet containing an LE at either 4% or 13.5% of energy for 5 wk (Expt. 1) or 1 wk (Expt. 2). In Expt. 3, mice were fed a purified LFD (similar to 10% fat) or HFD (similar to 60% fat) or were fed an HFD and given access to a running wheel for voluntary exercise for 16 wk.
Results: Fgf21 mRNA in liver and FGF21 protein in plasma were increased by 3.5- to 7-fold in HC mice compared with SFP mice (P < 0.001), whereas the LE dose-dependently attenuated the induction of Fgf21 expression (P < 0.05). After 16 wk, hepatic Fgf21 mRNA did not differ between LFD and HFD mice but was dramatically reduced in the HFD+exercise group to <20% of the level in the HFD group (P < 0.0001).
Conclusions: In mice, hepatic Fgf21 expression was upregulated by 1 and 5 wk of feeding a lipogenic HC diet but not by 16 wk of feeding an obesogenic HFD, whereas the addition of fat as an LE to the HC formula significantly reduced Fgf21 gene expression and the plasma FGF21 protein concentration. Our results support a strong and reversible response of hepatic Fgf21 expression to shifts in dietary glucose intake.
C1 [Hao, Lei; Huang, Kuan-Hsun; Ito, Kyoko; Ross, A. Catharine] Penn State Univ, Huck Inst Life Sci, Dept Nutr Sci, University Pk, PA 16802 USA.
[Sae-tan, Sudathip; Lambert, Joshua D.] Penn State Univ, Dept Food Sci, Huck Inst Life Sci, University Pk, PA 16802 USA.
[Ross, A. Catharine] Penn State Univ, Ctr Immunol & Infect Dis, Huck Inst Life Sci, University Pk, PA 16802 USA.
[Hao, Lei] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lab Lipid Med & Technol, Charlestown, MA 02129 USA.
[Ito, Kyoko] Jikei Univ, Dept Med, Tokyo, Japan.
[Sae-tan, Sudathip] Kasetsart Univ, Fac Agroind, Dept Food Sci & Technol, Bangkok, Thailand.
RP Ross, AC (reprint author), Penn State Univ, Huck Inst Life Sci, Dept Nutr Sci, University Pk, PA 16802 USA.; Ross, AC (reprint author), Penn State Univ, Ctr Immunol & Infect Dis, Huck Inst Life Sci, University Pk, PA 16802 USA.
EM acr6@psu.edu
FU Graduate Program in Nutrition, Graduate Program in Food Science, Dorothy
Foehr Huck Chair (ACR); NIH [CA90214, AT004678]; Baxter
FX Supported by funds from the Graduate Program in Nutrition, Graduate
Program in Food Science, Dorothy Foehr Huck Chair (ACR), and NIH grants
CA90214 (ACR) and AT004678 (JDL). Baxter Healthcare Corporation provided
the liquid diet (Clinimix E), vitamins, and lipid emulsion (Intralipid)
used in studies 1 and 2. A postdoctoral research award from Baxter to
the Department of Nutritional Sciences partially supported KI.
NR 25
TC 1
Z9 1
U1 1
U2 10
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD FEB
PY 2016
VL 146
IS 2
BP 184
EP 190
DI 10.3945/jn.115.216572
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DC9RD
UT WOS:000369557800002
PM 26764334
ER
PT J
AU Lerner, DP
Tseng, BP
Goldstein, LB
AF Lerner, David P.
Tseng, Bertrand P.
Goldstein, Larry B.
TI Development and Assessment of a Computer Algorithm for Stroke Vascular
Localization Using Components of the National Institutes of Health
Stroke Scale
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Ischemic stroke; computer-based model; acute stroke; localization
ID CEREBRAL INFARCTION; ISCHEMIC-STROKE; EXPERT SYSTEM; SCORE
AB Background: The National Institutes of Health Stroke Scale (NIHSS) was not intended to be used to determine the stroke's vascular distribution. The aim of this study was to develop, assess the reliability, and validate a computer algorithm based on the NIHSS for this purpose. Methods: Two cohorts of patients with ischemic stroke having similar distributions of Oxfordshire localizations (total anterior, partial anterior, lacunar, and posterior circulation) based on neuroimaging were identified. The first cohort (n = 40) was used to develop a computer algorithm for vascular localization using a modified version of the NIHSS (NIHSSLocalization [NIHSS-Loc]) that included the laterality of selected deficits; the second (n = 20) was used to assess the reliability of algorithm-based localizations compared to those of 2 vascular neurologists. The validity of the algorithm-based localizations was assessed in comparison to neuroimaging. Agreement was assessed using the unweighted kappa (kappa) statistic. Results: Agreement between the 2 raters using the standard NIHSS was slight to moderate (kappa =.36, 95% confidence interval [CI] .10-.61). Inter-rater agreement significantly improved to the substantial to almost perfect range using the NIHSS-Loc (kappa=.88, 95% CI .73-1.00). Agreement was perfect when the 2 raters entered the data into the NIHSS-Loc computer algorithm (kappa = 1.00, 95% CI 1.00-1.00). Agreement between the algorithm localization and neuroimaging results was fair to moderate (kappa = .59,95% CI .35-.84) and not significantly different from the localizations of either rater using the NIHSS-Loc. Conclusion: A computerized, modified version of the standard NIHSS can be used to reliably and validly assign the vascular distribution of an acute ischemic stroke.
C1 [Lerner, David P.] Massachusetts Gen Hosp, 55 Fruit St,WACC 720, Boston, MA 02114 USA.
[Tseng, Bertrand P.] Duke Univ, Med Ctr, Durham, NC USA.
[Goldstein, Larry B.] Univ Kentucky, KY Clin, Lexington, KY USA.
RP Lerner, DP (reprint author), Massachusetts Gen Hosp, 55 Fruit St,WACC 720, Boston, MA 02114 USA.
EM dplerner@mgh.harvard.edu
NR 17
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD FEB
PY 2016
VL 25
IS 2
BP 281
EP 287
DI 10.1016/j.jstrokecerebrovasdis.2015.09.029
PG 7
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA DC9YW
UT WOS:000369578500013
PM 26542823
ER
PT J
AU Chebib, I
Chang, CY
Kerr, DA
Deshpande, V
Nielsen, GP
AF Chebib, Ivan
Chang, Connie Y.
Kerr, Darcy A.
Deshpande, Vikram
Nielsen, G. Petur
TI Histopathology of So-Called Synovial Cysts of the Lumbar Spine
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 45
BP 15A
EP 15A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270700046
ER
PT J
AU Aplin, AC
Kohler, T
Nicosia, R
AF Aplin, Alfred C.
Kohler, Ted
Nicosia, Roberto
TI Human Plaque-Aortic Ring Co-Culture: A Novel Assay for the Study of
Atherosclerosis-Induced Angiogenesis
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Univ Washington, Seattle, WA 98195 USA.
VA Puget Sound HCS, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 316
BP 81A
EP 81A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270700317
ER
PT J
AU Fishbein, GA
Onozato, ML
Luk, A
Givertz, MM
Padera, RF
Iafrate, AJ
Mitchell, RN
AF Fishbein, Gregory A.
Onozato, Maristela L.
Luk, Adriana
Givertz, Michael M.
Padera, Robert F., Jr.
Iafrate, Anthony J.
Mitchell, Richard N.
TI Endothelial Cell Chimerism in Human Cardiac Allografts
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 320
BP 82A
EP 82A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270700321
ER
PT J
AU Mirkovic, J
Zhao, LN
Faquin, WC
Jo, VY
Krane, JF
AF Mirkovic, Jelena
Zhao, Liena
Faquin, William C.
Jo, Vickie Y.
Krane, Jeffrey F.
TI Risk-Stratified Triage of Salivary Gland Fine-Needle Aspiration
Specimens
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 428
BP 109A
EP 110A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270700429
ER
PT J
AU Nagymanyoki, Z
Karlon, W
Faquin, WC
Krane, JF
Lindeman, N
Hall, D
Sweeney, BJ
Ljung, BM
Balassanian, R
van Zante, A
AF Nagymanyoki, Zoltan
Karlon, William
Faquin, William C.
Krane, Jeffrey F.
Lindeman, Neal
Hall, Dimity
Sweeney, Brenda J.
Ljung, Britt-Marie
Balassanian, Ronald
van Zante, Annemieke
TI Comparison of Molecular Platforms for Detection of HPV in FNA Biopsies
of the Head and Neck
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
West Pacific Med Lab, Santa Fe Springs, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 431
BP 110A
EP 110A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270700432
ER
PT J
AU Pusztaszeri, M
Sadow, PM
Krane, JF
Daniels, G
Faquin, WC
AF Pusztaszeri, Marc
Sadow, Peter M.
Krane, Jeffrey F.
Daniels, Gilbert
Faquin, William C.
TI Fine-Needle Aspiration of Thyroid Malignancies Arising in Disease: A
Diagnostic Challenge?
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Univ Hosp Geneva, Geneva, Switzerland.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 441
BP 113A
EP 113A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270700442
ER
PT J
AU Rosenbaum, MW
Jones, M
Dudley, J
Le, L
Iafrate, AJ
Pitman, M
AF Rosenbaum, Matthew W.
Jones, Martin
Dudley, Jonathan
Le, Long
Iafrate, A. John
Pitman, Martha
TI Next Generation Sequencing Adds Value to the Pre-Operative Diagnosis of
Pancreatic Cysts
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Stanford Univ, Palo Alto, CA 94304 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 442
BP 113A
EP 113A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270700443
ER
PT J
AU Strickland, KC
Vivero, M
Jo, VY
Lowe, A
Hollowell, M
Qian, X
Wieczorek, T
French, CA
Teot, LA
Eszlinger, M
Paschke, R
Sadow, PM
Cibas, E
Barletta, JA
Krane, JF
AF Strickland, Kyle C.
Vivero, Marina
Jo, Vickie Y.
Lowe, Alarice
Hollowell, Monica
Qian, Xiaohuo
Wieczorek, Tad
French, Christopher A.
Teot, Lisa A.
Eszlinger, Markus
Paschke, Ralf
Sadow, Peter M.
Cibas, Edmund
Barletta, Justine A.
Krane, Jeffrey F.
TI The Cytologic Diagnosis of Non-Invasive Follicular Variant of Papillary
Thyroid Carcinoma: A Prospective Analysis
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Leipzig, D-04109 Leipzig, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 458
BP 117A
EP 118A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270700459
ER
PT J
AU Wang, H
Hoda, RS
Faquin, WC
Rossi, E
Hotchandani, N
Sun, T
Pusztaszeri, M
Bizzarro, T
Bongiovanni, M
Patel, V
Jhala, N
Gong, Y
AF Wang, He
Hoda, Raza S.
Faquin, William C.
Rossi, Esther
Hotchandani, Nihar
Sun, Tianlin
Pusztaszeri, Marc
Bizzarro, Tommaso
Bongiovanni, Massimo
Patel, Viren
Jhala, Nirag
Gong, Yun
TI Secondary Malignancies in Salivary Glands: A Multi-Institutional FNA
Cohort from Trans-Atlantic Academic Institutions
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Cattolica Sacro Cuore, Rome, Italy.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Hosp Geneva, Geneva, Switzerland.
Univ Lausanne, Lausanne, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 468
BP 120A
EP 120A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270700469
ER
PT J
AU Moy, A
Murali, M
Kroshinsky, D
Horn, T
Nazarian, R
AF Moy, Andrea
Murali, Mandakolathur
Kroshinsky, Daniela
Horn, Thomas
Nazarian, Rosalynn
TI Keratin 17 Expression and Immune Phenotype of Anti-TNF-alpha Refractory
Psoriasis and Anti-TNF-alpha Related Psoriasiform Dermatitis
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 [Moy, Andrea; Murali, Mandakolathur; Kroshinsky, Daniela; Horn, Thomas; Nazarian, Rosalynn] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 519
BP 133A
EP 133A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270700520
ER
PT J
AU Glomski, K
Sadow, PM
AF Glomski, Krzysztof
Sadow, Peter M.
TI Metastatic Follicular Thyroid Carcinoma: Retrospective Institutional
Experience and Insight into Primary Follicular Thyroid Neoplasia
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 579
BP 148A
EP 148A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270700580
ER
PT J
AU Paulson, V
Shivdasani, P
Howitt, BE
Ducar, M
Angell, T
Alexander, EK
Cibas, E
Krane, JF
Lindeman, N
Barletta, JA
AF Paulson, Vera
Shivdasani, Priyanka
Howitt, Brooke E.
Ducar, Matthew
Angell, Trevor
Alexander, Erik K.
Cibas, Edmund
Krane, Jeffrey F.
Lindeman, Neal
Barletta, Justine A.
TI Non-Invasive Follicular Variant of Papillary Thyroid Carcinoma Accounts
for over Half of Carcinomas Harboring RAS Mutations
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 599
BP 153A
EP 153A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270700600
ER
PT J
AU Agoston, A
Deshpande, V
Odze, R
AF Agoston, Agoston
Deshpande, Vikram
Odze, Robert
TI HPV is Not Involved in the Pathogenesis of Esophageal Squamous Cell and
Adenocarcinomas; Analysis Based on a Highly Sensitive and Highly
Specific RNA In-Situ Hybridization Technique
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 626
BP 160A
EP 160A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701009
ER
PT J
AU Ahn, S
Lee, SJ
Kim, YG
Hwang, CS
Kim, A
Shin, N
Choi, KU
Lee, CH
Huh, GY
Lauwers, GY
Park, DY
AF Ahn, Sangjeong
Lee, So Jeong
Kim, Young Geum
Hwang, Chung Su
Kim, Ahrong
Shin, Nari
Choi, Kyung Un
Lee, Chang Hun
Huh, Gi Young
Lauwers, Gregory Y.
Park, Do Youn
TI Molecular Classification in Gastric Cancer Using Immunohistochemistry
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Pusan Natl Univ, Sch Med, Pusan Natl Univ Hosp, Busan, South Korea.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 627
BP 160A
EP 160A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701010
ER
PT J
AU Alpert, L
Setia, N
Khalili, H
Lauwers, GY
AF Alpert, Lindsay
Setia, Namrata
Khalili, Hamed
Lauwers, Gregory Y.
TI Lymphocytic Colitis: Are There Pathologic Predictors of Response to
Therapy?
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Univ Chicago, Chicago, IL 60637 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 633
BP 161A
EP 161A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701016
ER
PT J
AU Deshpande, V
Mahadevan, KK
Lauwers, GY
Mattia, A
Zukerberg, L
Odze, R
AF Deshpande, Vikram
Mahadevan, Krishnan K.
Lauwers, Gregory Y.
Mattia, Antony
Zukerberg, Lawrence
Odze, Robert
TI LGR5 Expression in Barrett's Esophagus and Associated Neoplasia: Support
for Its Role as a Cancer Stem Cell and Diagnostic Marker
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 [Deshpande, Vikram; Mahadevan, Krishnan K.; Lauwers, Gregory Y.; Mattia, Antony; Zukerberg, Lawrence; Odze, Robert] Brigham & Womens Hosp, Massachusetts Gen Hosp, 75 Francis St, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 667
BP 169A
EP 169A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701050
ER
PT J
AU England, J
Swager, AF
Schlachter, S
Sundell, B
Bergman, JJGHM
Lauwers, GY
Odze, R
AF England, Jonathan
Swager, Anne-Fre
Schlachter, Simon
Sundell, Brian
Bergman, Jacques J. G. H. M.
Lauwers, Gregory Y.
Odze, Robert
TI Role of Mucosal Glands in the Progression of Neoplasia in Barrett's
Esophagus
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
NinePoint Med, Boston, MA USA.
Univ Amsterdam, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 672
BP 170A
EP 170A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701055
ER
PT J
AU Samore, W
Mahadevan, KK
Deshpande, V
AF Samore, Wesley
Mahadevan, Krishnan K.
Deshpande, Vikram
TI Line-1 Methylation Status Predicts Aggressive Behavior in Pancreatic
Endocrine Neoplasms
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 [Samore, Wesley; Mahadevan, Krishnan K.; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 782
BP 197A
EP 197A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701165
ER
PT J
AU Setia, N
Alpert, L
Lauwers, GY
AF Setia, Namrata
Alpert, Lindsay
Lauwers, Gregory Y.
TI WHO Morphologic Classification of Gastric Cancer Correlates with Protein
Expression Based Classification
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Univ Chicago, Chicago, IL 60637 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 792
BP 199A
EP 200A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701175
ER
PT J
AU Shih, AR
Bal, M
Zukerberg, L
Brown, I
Lauwers, GY
Liu, XL
Kelly, P
Oliva, E
Ahn, S
Kim, K
Deshpande, V
AF Shih, Angela R.
Bal, Munita
Zukerberg, Lawrence
Brown, Ian
Lauwers, Gregory Y.
Liu, Xiuli
Kelly, Paul
Oliva, Esther
Ahn, Soomin
Kim, Kyoung
Deshpande, Vikram
TI Hepatoid Carcinomas of the Gastrointestinal Tract: A Reappraisal of
Morphological and Immunohistochemical Features
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Tata Mem Hosp, Bombay 400012, Maharashtra, India.
Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia.
Cleveland Clin, Cleveland, OH 44106 USA.
Queens Univ Belfast, Royal Victoria Hosp, Belfast, Antrim, North Ireland.
Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea.
RI Brown, Ian/R-7763-2016
OI Brown, Ian/0000-0001-6329-2547
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 796
BP 200A
EP 201A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701179
ER
PT J
AU Shih, AR
Deshpande, V
Ferry, JA
Zukerberg, L
AF Shih, Angela R.
Deshpande, Vikram
Ferry, Judith A.
Zukerberg, Lawrence
TI Clinicopathologic Characteristics of Systemic Mastocytosis in the
Intestine
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 [Shih, Angela R.; Deshpande, Vikram; Ferry, Judith A.; Zukerberg, Lawrence] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 797
BP 201A
EP 201A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701180
ER
PT J
AU Williams, E
Zukerberg, L
Arora, K
Ting, DT
Deshpande, V
AF Williams, Erik
Zukerberg, Lawrence
Arora, Kshitij
Ting, David T.
Deshpande, Vikram
TI Epithelial to Mesenchymal Transition Predicts Distant Metastasis in
MMR-Intact Colonic Adenocarcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 [Williams, Erik; Zukerberg, Lawrence; Arora, Kshitij; Ting, David T.; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 821
BP 207A
EP 207A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701204
ER
PT J
AU Yilmaz, O
Agrawal, T
Kantekure, K
Suarez, Y
Yilmaz, O
Deshpande, V
AF Yilmaz, Osman
Agrawal, Tanupriya
Kantekure, Kanchan
Suarez, Yvelisse
Yilmaz, Omer
Deshpande, Vikram
TI WNT Signaling Markers, LGR5 and AXIN2, Show Unique Patterns of
Expression in Colonic Polyps
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Tufts Med Ctr, Boston, MA USA.
MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 831
BP 209A
EP 210A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701214
ER
PT J
AU Cyrta, J
Beltran, H
Prandi, D
Mosquera, JM
Benelli, M
Tomlins, SA
Elemento, O
Sboner, A
Garraway, L
Rubin, M
Demichelis, F
AF Cyrta, Joanna
Beltran, Himisha
Prandi, Davide
Mosquera, Juan Miguel
Benelli, Matteo
Tomlins, Scott A.
Elemento, Olivier
Sboner, Andrea
Garraway, Levi
Rubin, Mark
Demichelis, Francesca
TI Integrated Molecular Classifier Determines Transdifferentiation to
Neuroendocrine Prostate Cancer
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Cornell Univ, Weill Cornell Med, New York, NY 10021 USA.
Univ Trento, Trento, Italy.
Univ Michigan, Ann Arbor, MI 48109 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 889
BP 224A
EP 224A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701272
ER
PT J
AU Udager, A
Chinnaiyan, AM
Petimar, J
Cao, XH
Feng, FY
Loda, M
Ahearn, T
Kantoff, PW
Mucci, LA
Mehra, R
AF Udager, Aaron
Chinnaiyan, Arul M.
Petimar, Joshua
Cao, Xuhong
Feng, Felix Y.
Loda, Massimo
Ahearn, Thomas
Kantoff, Philip W.
Mucci, Lorelei A.
Mehra, Rohit
TI Overexpression of the Long Non-Coding RNA SChLAP1 Independently Predicts
Lethal Prostate Cancer
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Univ Michigan Hlth Syst, Ann Arbor, MI USA.
Michigan Ctr Translat Pathol, Ann Arbor, MI USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1065
BP 268A
EP 268A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701448
ER
PT J
AU Ye, HH
Sowalsky, AG
Schaefer, R
Yuan, X
Chen, SY
Gerrin, SJ
Montaser, L
Ma, F
Voznesensky, O
Cai, CM
Lis, R
Zhang, ZW
Loda, M
Taplin, ME
Balk, S
AF Ye, Huihui
Sowalsky, Adam G.
Schaefer, Rachel
Yuan, Xin
Chen, Shao-Yong
Gerrin, Sean J.
Montaser, Laleh
Ma, Fen
Voznesensky, Olga
Cai, Changmeng
Lis, Rosina
Zhang, Zhenwei
Loda, Massimo
Taplin, Mary-Ellen
Balk, Steven
TI Diversity of Resistance Mechanisms in Prostate Cancer after Neoadjuvant
Intense Androgen Deprivation Therapy
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1078
BP 271A
EP 271A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701461
ER
PT J
AU Basnet, KM
Bentley-Lewis, R
Wexler, D
Kilic, F
Roberts, D
AF Basnet, Kristen M.
Bentley-Lewis, Rhonda
Wexler, Deborah
Kilic, Fusun
Roberts, Drucilla
TI Intervillous Thrombi Are Increased in Placentas from Pregnancies
Complicated by Diabetes
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1096
BP 276A
EP 276A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701478
ER
PT J
AU Goh, R
Dal Cin, P
Chiang, S
Young, RH
Oliva, E
AF Goh, Ronald
Dal Cin, Paola
Chiang, Sarah
Young, Robert H.
Oliva, Esther
TI Myxoid Smooth Muscle Tumors of the Uterus: Clinicopathologic Study of 40
Cases
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Singapore Gen Hosp, Singapore, Singapore.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1133
BP 285A
EP 285A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701515
ER
PT J
AU Harrison, B
Chen, A
Toledo, G
Arora, K
Deshpande, V
Oliva, E
AF Harrison, Beth
Chen, Athena
Toledo, Gemma
Arora, Kshitij
Deshpande, Vikram
Oliva, Esther
TI The MELF Pattern of Myometrial Invasion in Endometrial Endometrioid
Carcinoma Displays a Mesenchymal Gene Expression Signature: A Case
Series
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 [Harrison, Beth; Chen, Athena; Toledo, Gemma; Arora, Kshitij; Deshpande, Vikram; Oliva, Esther] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1135
BP 285A
EP 285A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701517
ER
PT J
AU Howitt, BE
Sun, H
Roemer, MGM
Kelly, A
Chapuy, B
Aviki, EM
Pak, C
Gjini, E
Yang, YL
Lee, L
Viswanathan, A
Horowitz, N
Neuberg, D
Crum, CP
Lindeman, N
Kuo, F
Ligon, AH
Freeman, GJ
Hodi, FS
Shipp, MA
Rodig, S
AF Howitt, Brooke E.
Sun, Heather
Roemer, Margaretha G. M.
Kelly, Alyssa
Chapuy, Bjoern
Aviki, Emeline M.
Pak, Christine
Gjini, Evisa
Yang, Youling
Lee, Larissa
Viswanathan, Akila
Horowitz, Neil
Neuberg, Donna
Crum, Christopher P.
Lindeman, Neal
Kuo, Frank
Ligon, Azra H.
Freeman, Gordon J.
Hodi, F. Stephen
Shipp, Margaret A.
Rodig, Scott
TI Recurrent Gains of CD274 and PDCD1LG2 in Squamous Cell Carcinomas of
Cervix and Vulva
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1144
BP 287A
EP 288A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701526
ER
PT J
AU Ordulu, Z
McDonald, AG
De Nictolis, M
Garcia-Fernandez, E
Hardisson, D
Prat, J
Oliva, E
AF Ordulu, Zehra
McDonald, Anna G.
De Nictolis, Michele
Garcia-Fernandez, Eugenia
Hardisson, David
Prat, Jaime
Oliva, Esther
TI Intravenous Leiomyomatosis (IVL), from Molecular Genetics to Clinical
Biomarkers: A Study of 26 Cases
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
San Salvatore Hosp, Pesaro, Italy.
Hosp Univ La Paz, Madrid, Spain.
Wake Forest Baptist Med Ctr, Winston Salem, NC USA.
Hosp Sta Creu & St Pau, Barcelona, Spain.
RI Hardisson, David/E-2832-2010
OI Hardisson, David/0000-0002-2183-3699
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1195
BP 300A
EP 301A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701577
ER
PT J
AU Parkash, V
Malpica, A
Matias-Guiu, X
Oliva, E
McCluggage, WG
AF Parkash, Vinita
Malpica, Anais
Matias-Guiu, Xavier
Oliva, Esther
McCluggage, W. Glenn
TI Current Practices in the Processing, Diagnosis and Reporting of
Endometrial Carcinoma. Results of a Web Based Survey by the
International Society of Gynecological Pathologists (ISGyP)
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Yale Univ, Sch Med, Bridgeport Hosp, New Haven, CT USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Lleida, Hosp Univ Arnau de Vilanova, IRBLleida, Lleida, Spain.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1199
BP 301A
EP 302A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701581
ER
PT J
AU Pesci, A
Shih, AR
Oliva, E
AF Pesci, Anna
Shih, Angela R.
Oliva, Esther
TI Endocervical Adenocarcinoma (EEC): A Retrospective Study of 75 Cases
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Osped Sacro Cuore Don Calabria, Verona, Italy.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1201
BP 302A
EP 302A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701583
ER
PT J
AU Pires-Luis, AS
Bartosch, C
Meireles, C
Pinto, C
Lopes, JM
Shannon, KM
Teixeira, MR
Oliva, E
AF Pires-Luis, Ana S.
Bartosch, Carla
Meireles, Catarina
Pinto, Carla
Lopes, Jose M.
Shannon, Kristen M.
Teixeira, Manuel R.
Oliva, Esther
TI Hysterectomy Specimens of Patients with Lynch Syndrome:
Clinicopathologic Study of 70 Cases
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 IPO Porto, Oporto, Portugal.
CHSJ, Oporto, Portugal.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI Teixeira, Manuel/E-4885-2011
OI Teixeira, Manuel/0000-0002-4896-5982
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1203
BP 302A
EP 303A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701585
ER
PT J
AU Shih, AR
Liu, XL
Silva, A
Pesci, A
Soslow, R
Deshpande, V
Oliva, E
AF Shih, Angela R.
Liu, Xiuli
Silva, Annacarolina
Pesci, Anna
Soslow, Robert
Deshpande, Vikram
Oliva, Esther
TI Refined Characterization of Hepatoid Differentiation in Gynecologic
Tract Neoplasms
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Cleveland Clin, Cleveland, OH 44106 USA.
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1227
BP 309A
EP 309A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701609
ER
PT J
AU Silva, A
Bennett, JA
Ali-Fehmi, R
Bandyopadhyay, S
Oliva, E
AF Silva, Annacarolina
Bennett, Jennifer A.
Ali-Fehmi, Rouba
Bandyopadhyay, Sudeshna
Oliva, Esther
TI Ovarian Endometrioid Adenocarcinomas: Morphology, Associations and
Outcomes in 79 Patients
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Lahey Hosp & Med Ctr, Burlington, MA USA.
Wayne State Univ, Detroit, MI USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1228
BP 309A
EP 309A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270701610
ER
PT J
AU Pusztaszeri, M
Bordignon, P
McKee, T
Faquin, WC
AF Pusztaszeri, Marc
Bordignon, Patrizia
McKee, Thomas
Faquin, William C.
TI MYC and MYB Are Coexpressed in Adenoid Cystic Carcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Univ Hosp Geneva, Geneva, Switzerland.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1302
BP 327A
EP 328A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702043
ER
PT J
AU Sajed, D
Wu, CL
Nose, V
Deshpande, V
AF Sajed, Dipti
Wu, Chin-Lee
Nose, Vania
Deshpande, Vikram
TI Expression of an Androgen Receptor Splice Variant in Salivary Duct
Carcinoma: An Instrument of Resistance?
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 [Sajed, Dipti; Wu, Chin-Lee; Nose, Vania; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1306
BP 328A
EP 329A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702047
ER
PT J
AU Ahn, J
Rosado, FG
Sohani, AR
Vos, J
AF Ahn, Janice
Rosado, Flavia G.
Sohani, Aliyah R.
Vos, Jeffrey
TI Plasmablastic Lymphoma: Characterization of Tumor Microenvironment by
CD163 and PD1 Immunohistochemistry
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 W Virginia Univ, Morgantown, WV 26506 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1325
BP 333A
EP 333A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702066
ER
PT J
AU Bledsoe, J
Redd, R
Zukerberg, L
Abramson, J
Sohani, AR
AF Bledsoe, Jacob
Redd, Robert
Zukerberg, Lawrence
Abramson, Jeremy
Sohani, Aliyah R.
TI PDL1 and MUM1 Expression Are Associated with Outcome in Primary
Mediastinal Large B-cell Lymphoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1337
BP 336A
EP 337A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702078
ER
PT J
AU Bledsoe, J
Wallace, ZS
Stone, JH
Deshpande, V
Ferry, JA
AF Bledsoe, Jacob
Wallace, Zachary S.
Stone, John H.
Deshpande, Vikram
Ferry, Judith A.
TI Lymphoma in IgG4-Related Disease
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 [Bledsoe, Jacob; Wallace, Zachary S.; Stone, John H.; Deshpande, Vikram; Ferry, Judith A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1336
BP 336A
EP 336A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702077
ER
PT J
AU Griffin, GK
Lovitch, SB
Kelley, A
Roemer, MGM
Chapuy, B
Pak, C
Gjini, E
Freeman, GJ
Hodi, FS
Ligon, AH
Shipp, MA
Rodig, S
AF Griffin, Gabriel K.
Lovitch, Scott B.
Kelley, Alyssa
Roemer, Margaretha G. M.
Chapuy, Bjoern
Pak, Christine
Gjini, Evisa
Freeman, Gordon J.
Hodi, F. Stephen
Ligon, Azra H.
Shipp, Margaret A.
Rodig, Scott
TI Copy Number Gain of PD-L1 and PD-L2 in T-Cell/Histiocyte Rich Large
B-Cell Lymphoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1379
BP 348A
EP 348A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702120
ER
PT J
AU Hillen, L
Zukerberg, L
Deshpande, V
Cleven, AHG
Fathi, AT
Zur Hausen, A
Hasserjian, RP
AF Hillen, Lisa
Zukerberg, Lawrence
Deshpande, Vikram
Cleven, Arjen H. G.
Fathi, Amir T.
Zur Hausen, Axel
Hasserjian, Robert P.
TI Bone Marrow Morphology Predicts Response to Hypomethylating Agents
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Maastricht Univ, Med Ctr, NL-6200 MD Maastricht, Netherlands.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Leiden Univ, Med Ctr, Leiden, Netherlands.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1387
BP 350A
EP 350A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702128
ER
PT J
AU Margolskee, E
Oak, J
Arber, DA
Hasserjian, RP
Orazi, A
AF Margolskee, Elizabeth
Oak, Jean
Arber, Daniel A.
Hasserjian, Robert P.
Orazi, Attilio
TI Myelodysplastic Syndrome, Unclassifiable (MDS-U) with 1% Blasts Is a
Distinct Subgroup of MDS-U with a Poor Prognosis
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Weill Cornell Med Coll, New York, NY USA.
Stanford Univ, Stanford, CA 94305 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1427
BP 361A
EP 361A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702167
ER
PT J
AU Minkovsky, A
Morgan, EA
Charest, K
Schmidt, R
Briggs, D
Li, B
Pozdnyakova, O
AF Minkovsky, Alissa
Morgan, Elizabeth A.
Charest, Karry
Schmidt, Ryan
Briggs, Debra
Li, Betty
Pozdnyakova, Olga
TI Peripheral Blood Minimal Residual Disease Analysis by Flow Cytometry Has
High Concordance with Bone Marrow Analysis for Adult Patients with Acute
Lymphoblastic Leukemia
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1433
BP 362A
EP 363A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702173
ER
PT J
AU Pozdnyakova, O
Aster, JC
Kuo, F
Brown, R
Baltay, M
Hasserjian, RP
AF Pozdnyakova, Olga
Aster, Jon C.
Kuo, Frank
Brown, Ronald
Baltay, Michele
Hasserjian, Robert P.
TI Primary Myelofibrosis Displays an Inflammation-Associated Gene Profile
Distinct from Polycythemia Vera and Essential Thrombocythemia
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1462
BP 370A
EP 371A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702202
ER
PT J
AU Rogers, HJ
Hsi, ED
Tang, GL
Wang, S
Bueso-Ramos, CE
Lubin, D
Morrissette, JJD
Bagg, A
Cherukuri, DP
George, TI
Peterson, L
Liu, YC
Mathew, S
Orazi, A
Hasserjian, RP
AF Rogers, Heesun J.
Hsi, Eric D.
Tang, Guilin
Wang, Sa
Bueso-Ramos, Carlos E.
Lubin, Daniel
Morrissette, Jennifer J. D.
Bagg, Adam
Cherukuri, Durga P.
George, Tracy I.
Peterson, Loann
Liu, Yen-Chun
Mathew, Susan
Orazi, Attilio
Hasserjian, Robert P.
TI Most Myeloid Neoplasms with Deletion of Chromosome 16q Are Distinct from
Acute Myeloid Leukemia with inv(16)(p13.1q22)
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Cleveland Clin, Cleveland, OH 44106 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Univ New Mexico, Albuquerque, NM 87131 USA.
Northwestern Univ, Chicago, IL 60611 USA.
Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1473
BP 373A
EP 373A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702213
ER
PT J
AU Weinberg, OK
Hasserjian, RP
Li, B
Pozdnyakova, O
AF Weinberg, Olga K.
Hasserjian, Robert P.
Li, Betty
Pozdnyakova, Olga
TI Assessment of Myeloid And Monocytic Dysplasia by Flow Cytometry in De
Novo AML Helps Define an AML with Myelodysplasia-Related Changes
Category
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Boston Childrens Hosp, Boston, MA USA.
Massachussets Gen Hosp, Boston, MA USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1512
BP 383A
EP 383A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702251
ER
PT J
AU Wertheim, G
Luskin, M
Gimotty, PA
Smith, C
Loren, AW
Figueroa, M
Harrison, J
Sun, ZX
Tallman, MS
Paietta, EM
Litzow, MR
Levine, R
Melnick, AM
Fernandez, HF
Luger, SM
Carroll, M
Master, SR
AF Wertheim, Gerald
Luskin, Marlise
Gimotty, Phyllis A.
Smith, Catherine
Loren, Alison W.
Figueroa, Maria
Harrison, Jenna
Sun, Zhuoxin
Tallman, Martin S.
Paietta, Elisabeth M.
Litzow, Mark R.
Levine, Ross
Melnick, Ari M.
Fernandez, Hugo F.
Luger, Selina M.
Carroll, Martin
Master, Stephen R.
TI Integration of Multi-Locus DNA Methylation and Genetic Alterations
Outperforms Genetic Assessment Alone for Outcome Prediction in Adult
Patients with Acute Myeloid Leukemia
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
Univ Michigan, Sch Med, Ann Arbor, MI USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA.
Mayo Clin, Rochester, MN USA.
Moffit Canc Ctr, Tampa, FL USA.
Weill Cornell Med Coll, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1514
BP 384A
EP 384A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702253
ER
PT J
AU Wong, WH
Hasserjian, RP
Pozdnyakova, O
AF Wong, Waihay
Hasserjian, Robert P.
Pozdnyakova, Olga
TI Mutational Status Correlates with Distinct Histologic Features in
Philadelphia Chromosome (Ph)-Negative Myeloproliferative Neoplasms (MPN)
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1516
BP 384A
EP 384A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702255
ER
PT J
AU Tse, JY
Deshpande, V
Ferry, JA
Zukerberg, L
AF Tse, Julie Y.
Deshpande, Vikram
Ferry, Judith A.
Zukerberg, Lawrence
TI Histopathologic Features of T. Pallidum Infection Differ between the
Rectum and Anus
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 [Tse, Julie Y.; Deshpande, Vikram; Ferry, Judith A.; Zukerberg, Lawrence] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1546
BP 391A
EP 391A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702285
ER
PT J
AU Adam, B
Smith, RN
Kawai, T
Cosimi, AB
Colvin, RB
Mengel, M
AF Adam, Benjamin
Smith, R. Neal
Kawai, Tatsuo
Cosimi, A. Benedict
Colvin, Robert B.
Mengel, Michael
TI mRNA Diagnosis of Antibody-Mediated Rejection from Routine Paraffin
Sections of Renal Transplant Biopsies in a Nonhuman Primate Model
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Univ Alberta, Edmonton, AB, Canada.
Harvard Univ, Sch Med, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1585
BP 402A
EP 402A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702324
ER
PT J
AU Zhou, DL
Pozdnyakova, O
Dewar, R
Hasserjian, RP
Etman, A
Hoffman, R
Salama, ME
AF Zhou, Delu
Pozdnyakova, Olga
Dewar, Rajan
Hasserjian, Robert P.
Etman, Ali
Hoffman, Ronald
Salama, Mohamed E.
TI Central Histopathology Review of Essential Thrombocythemia and
Polycythemia Vera Bone Marrow Biopsies via Digital Tools in a Clinical
Trial on Pegylated Interferon Alfa-2a
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Univ Utah, Salt Lake City, UT USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1584
BP 402A
EP 402A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702323
ER
PT J
AU Faulkner-Jones, BE
Rosen, D
Rosen, S
Harrington, K
Law, C
AF Faulkner-Jones, Beverly E.
Rosen, Devin
Rosen, Seymour
Harrington, Kyle
Law, Charles
TI Maximizing Information from the Renal Biopsy: Computer-Generated
Three-Dimensional Constructs
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 BIDMC, Boston, MA USA.
Kitware Inc, Clifton Pk, NY USA.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1599
BP 405A
EP 405A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702337
ER
PT J
AU Agrawal, T
Yilmaz, O
Masia, R
Goyal, L
Zhu, A
Deshpande, V
AF Agrawal, Tanupriya
Yilmaz, Osman
Masia, Ricard
Goyal, Lipika
Zhu, Andrew
Deshpande, Vikram
TI Distinctive Morphologic Pattern and In Situ Hybridization for Albumin
Distinguishes Intrahepatic Cholangiocarcinoma from Metastatic
Adenocarcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Tufts Med Ctr, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 8
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1630
BP 413A
EP 413A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702368
ER
PT J
AU Miller, MB
Mir, S
Guleria, I
Chi, JH
Berkowitz, AL
Ligon, KL
AF Miller, Michael B.
Mir, Saad
Guleria, Indira
Chi, John H.
Berkowitz, Aaron L.
Ligon, Keith L.
TI Tumor-like Mass Arising as a Side Effect of Intrathecal Therapeutic Stem
Cell Injections
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1720
BP 434A
EP 434A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702458
ER
PT J
AU Gupta, R
Mahadevan, KK
Ferrone, CR
Ting, DT
Deshpande, V
AF Gupta, Rajib
Mahadevan, Krishnan K.
Ferrone, Cristina R.
Ting, David T.
Deshpande, Vikram
TI Quasimesenchymal Phenotype Predicts Distant Metastasis in Pancreatic
Ductal Adenocarcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1747
BP 441A
EP 441A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702485
ER
PT J
AU Lennerz, JK
Wang, CI
Doyle, L
Huynh, TG
Lindeman, N
Srivastava, A
Fernandez del-Castillo, C
Mino-Kenudson, M
AF Lennerz, Jochen K.
Wang, Charlotte I.
Doyle, Leona
Huynh, Tiffany G.
Lindeman, Neal
Srivastava, Amitabh
Fernandez del-Castillo, Carlos
Mino-Kenudson, Mari
TI Mutational Profiling of Oncocytic Intraductal Papillary Mucinous
Neoplasms (IPMN-o)
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1757
BP 443A
EP 443A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702495
ER
PT J
AU Taylor, M
Sajed, D
Williams, E
Ting, DT
Deshpande, V
AF Taylor, Martin
Sajed, Dipti
Williams, Erik
Ting, David T.
Deshpande, Vikram
TI LINE-1 RNA and ORF1p Protein Are Broadly Co-Expressed in Colon Cancer
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1821
BP 460A
EP 460A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270702559
ER
PT J
AU Huynh, TG
Gainor, JF
Nardi, V
Mino-Kenudson, M
AF Huynh, Tiffany G.
Gainor, Justin F.
Nardi, Valentina
Mino-Kenudson, Mari
TI Lung Adenocarcinomas with KRAS Mutations Are Biologically Heterogeneous
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 [Huynh, Tiffany G.; Gainor, Justin F.; Nardi, Valentina; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1871
BP 472A
EP 472A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270703023
ER
PT J
AU Matsubara, O
Jin, Y
Yamauchi, S
Yamanaka, K
Ishikawa, Y
Mark, EJ
AF Matsubara, Osamu
Jin, Yasuto
Yamauchi, Shuta
Yamanaka, Kazuteru
Ishikawa, Yuichi
Mark, Eugene J.
TI Programmed Death 1 (PD-1) and PD-L1 Expression in Lung Adenocarcinoma,
with Lower Expression in In Situ and Minimally Invasive Tumors and
Higher Expression in Larger and Invasive Tumors
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Japanese Fdn Canc Res, Inst Canc, Tokyo 170, Japan.
Hiratsuka Kyosai Hosp, Hiratsuka, Kanagawa, Japan.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1888
BP 476A
EP 476A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270703040
ER
PT J
AU Pal, P
Hammerman, P
Kwiatkowski, DJ
Johnson, BE
Sholl, LM
AF Pal, Prodipto
Hammerman, Peter
Kwiatkowski, David J.
Johnson, Bruce E.
Sholl, Lynette M.
TI ROS1 Immunohistochemistry as a Screen for ROS1 Rearrangements in Lung
Adenocarcinoma: Application in Clinical Practice
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1900
BP 478A
EP 478A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270703052
ER
PT J
AU Redig, AJ
Lydon, C
Janne, PA
Sholl, LM
AF Redig, Amanda J.
Lydon, Christine
Janne, Pasi A.
Sholl, Lynette M.
TI Evaluation of Genomic Complexity in Next-Generation Sequencing of T1 vs
Stage IV Non-Small Cell Lung Cancer
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1909
BP 480A
EP 480A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270703061
ER
PT J
AU Shih, AR
Muzikansky, A
Bozkurtlar, E
Chung, JH
Minami, Y
Hariri, LP
Moreira, A
Uruga, H
Wang, H
Yoshizawa, A
Mino-Kenudson, M
AF Shih, Angela R.
Muzikansky, Alona
Bozkurtlar, Emine
Chung, Jin-Haeng
Minami, Yuko
Hariri, Lida P.
Moreira, Andre
Uruga, Hironori
Wang, He
Yoshizawa, Akihiko
Mino-Kenudson, Mari
TI Reproducibility in Classification of Small Lung Adenocarcinomas: An
International Interobserver Study
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Marmara Univ, Istanbul, Turkey.
Seoul Natl Univ, Bundang Hosp, Songnam, South Korea.
Ibarakihigashi Natl Hosp, Natl Hosp Org, Naka, Ibaraki, Japan.
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
Temple Univ, Sch Med, Philadelphia, PA 19122 USA.
Kyoto Univ Hosp, Kyoto 606, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1920
BP 483A
EP 483A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270703072
ER
PT J
AU Sholl, LM
Pal, P
Alden, RS
Feeney, N
Paweletz, C
Sacher, A
Oxnard, GR
AF Sholl, Lynette M.
Pal, Prodipto
Alden, Ryan S.
Feeney, Nora
Paweletz, Cloud
Sacher, Adrian
Oxnard, Geoffrey R.
TI Predictors of High Levels of Mutant cfDNA in Plasma from Patients with
Advanced Lung Adenocarcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Belfer Ctr Appl Canc Sci, Boston, MA USA.
RI Sacher, Adrian/I-8080-2016
OI Sacher, Adrian/0000-0001-7865-2701
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1922
BP 483A
EP 483A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270703074
ER
PT J
AU Huck, A
Hong, C
DeLelys, ME
Preffer, FI
Sohani, AR
AF Huck, Amelia
Hong, Christine
DeLelys, Michelle E.
Preffer, Frederic I.
Sohani, Aliyah R.
TI A Triaging Strategy Using Absolute White Blood Cell Differential Counts
and Smear Morphology Improves Diagnostic Yield of Peripheral Blood Flow
Cytometry
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 St Barnabas Hosp, Livingston, NJ USA.
Harvard Univ, Cambridge, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 1974
BP 496A
EP 496A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270703126
ER
PT J
AU Guilmette, J
Faquin, WC
Nielsen, GP
Selig, M
Nose, V
Sadow, PM
AF Guilmette, Julie
Faquin, William C.
Nielsen, G. Petur
Selig, Martin
Nose, Vania
Sadow, Peter M.
TI Is Mammary Analogue Secretory Carcinoma of the Salivary Glands a
Distinct Entity from Acinic Cell Carcinoma: An Ultrastructural Study
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology
CY MAR 12-18, 2016
CL Seattle, WA
SP US & Canadian Acad Pathol
C1 Univ Montreal, Med Ctr, Montreal, PQ, Canada.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2016
VL 96
SU 1
MA 2041
BP 514A
EP 514A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA DC5OQ
UT WOS:000369270703193
ER
PT J
AU Nazha, A
Sekeres, MA
Garcia-Manero, G
Barnard, J
Al Ali, NH
Roboz, GJ
Steensma, DP
DeZern, AE
Zimmerman, C
Jabbour, EJ
Zell, K
List, AF
Kantarjian, HM
Maciejewski, JP
Komrokji, RS
AF Nazha, Aziz
Sekeres, Mikkael A.
Garcia-Manero, Guillermo
Barnard, John
Al Ali, Najla H.
Roboz, Gail J.
Steensma, David P.
DeZern, Amy E.
Zimmerman, Cassie
Jabbour, Elias J.
Zell, Katrina
List, Alan F.
Kantarjian, Hagop M.
Maciejewski, Jaroslaw P.
Komrokji, Rami S.
CA MDS Clinical Res Consortium
TI Outcomes of patients with myelodysplastic syndromes who achieve stable
disease after treatment with hypomethylating agents
SO LEUKEMIA RESEARCH
LA English
DT Article
DE MDS; Response; Stable disease; Hypomethylating agent
ID CONVENTIONAL CARE REGIMENS; PHASE-III; LEUKEMIA GROUP; AZACITIDINE;
DECITABINE; CANCER; TRIAL
AB Treatment with hypomethylating agents (HMAs) improves overall survival (OS) in patients who achieve a response of stable disease (SD) or better (complete remission [CR], partial remission [PR], or hematologic improvement [HI]). It is not well established if patients who achieve SD at 4-6 months of therapy should be offered different therapies to optimize their response or continue with the same regimen. Clinical data were obtained from the MDS Clinical Research Consortium database. SD was defined as no evidence of progression and without achievement of any other responses. Of 291 patients treated with AZA or DAC, 55% achieved their best response (BR) at 4-6 months. Among patients with SD at 4-6 months, 29 (20%) achieved a better response at a later treatment time point. Younger patients with lower bone marrow blast percentages, and intermediate risk per IPSS-R were more likely to achieve a better response (CR, PR, or HI) after SD at 4-6 months. Patients with SD who subsequently achieved CR had superior OS compared to patients who remained with SD (28.1 vs. 14.4 months, respectively, p =.04). In conclusion, patients treated with HMAs who achieves CR after a SD status had longer survival with continuous treatment after 6 months. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Nazha, Aziz; Sekeres, Mikkael A.; Zimmerman, Cassie; Maciejewski, Jaroslaw P.] Cleveland Clin, Leukemia Program, Taussig Canc Inst, Cleveland, OH 44106 USA.
[Garcia-Manero, Guillermo; Jabbour, Elias J.; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
[Barnard, John; Zell, Katrina] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA.
[Al Ali, Najla H.; List, Alan F.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA.
[Roboz, Gail J.] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA.
[Steensma, David P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
[DeZern, Amy E.] Johns Hopkins Univ, Sch Med, Div Hematol Malignancies Oncol, Baltimore, MD USA.
RP Komrokji, RS (reprint author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol Malignancies, 12902 Magnolia Dr, Tampa, FL 33612 USA.
EM Rami.komrokji@moffitt.org
FU Edward P. Evans Foundation
FX M.A.S., G.G.M., G.J.R., D.P.S., A.E.D., C.Z., S.L., J.P.M., and R.S.K.
all are grateful to receive support from the Edward P. Evans Foundation.
NR 12
TC 1
Z9 1
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145-2126
EI 1873-5835
J9 LEUKEMIA RES
JI Leuk. Res.
PD FEB
PY 2016
VL 41
BP 43
EP 47
DI 10.1016/j.leukres.2015.12.007
PG 5
WC Oncology; Hematology
SC Oncology; Hematology
GA DC5BZ
UT WOS:000369236900009
PM 26777537
ER
PT J
AU de Waal, L
Lewis, TA
Rees, MG
Tsherniak, A
Wu, XY
Choi, PS
Gechijian, L
Hartigan, C
Faloon, PW
Hickey, MJ
Tolliday, N
Carr, SA
Clemons, PA
Munoz, B
Wagner, BK
Shamji, AF
Koehler, AN
Schenone, M
Burgin, AB
Schreiber, SL
Greulich, H
Meyerson, M
AF de Waal, Luc
Lewis, Timothy A.
Rees, Matthew G.
Tsherniak, Aviad
Wu, Xiaoyun
Choi, Peter S.
Gechijian, Lara
Hartigan, Christina
Faloon, Patrick W.
Hickey, Mark J.
Tolliday, Nicola
Carr, Steven A.
Clemons, Paul A.
Munoz, Benito
Wagner, Bridget K.
Shamji, Alykhan F.
Koehler, Angela N.
Schenone, Monica
Burgin, Alex B.
Schreiber, Stuart L.
Greulich, Heidi
Meyerson, Matthew
TI Identification of cancer-cytotoxic modulators of PDE3A by predictive
chemogenomics
SO NATURE CHEMICAL BIOLOGY
LA English
DT Article
ID CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; HISTONE DEACETYLASE INHIBITOR;
MOLECULAR PHARMACOLOGY; SIGNALING COMPLEXES; DRUG-SENSITIVITY;
ANTICANCER DRUG; ANAGRELIDE; DISCOVERY; 3A; MECHANISMS
AB High cancer death rates indicate the need for new anticancer therapeutic agents. Approaches to discovering new cancer drugs include target-based drug discovery and phenotypic screening. Here, we identified phosphodiesterase 3A modulators as cell-selective cancer cytotoxic compounds through phenotypic compound library screening and target deconvolution by predictive chemogenomics. We found that sensitivity to 6-(4-(diethylamino)-3-nitrophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one, or DNMDP, across 766 cancer cell lines correlates with expression of the gene PDE3A, encoding phosphodiesterase 3A. Like DNMDP, a subset of known PDE3A inhibitors kill selected cancer cells, whereas others do not. Furthermore, PDE3A depletion leads to DNMDP resistance. We demonstrated that DNMDP binding to PDE3A promotes an interaction between PDE3A and Schlafen 12 (SLFN12), suggestive of a neomorphic activity. Coexpression of SLFN12 with PDE3A correlates with DNMDP sensitivity, whereas depletion of SLFN12 results in decreased DNMDP sensitivity. Our results implicate PDE3A modulators as candidate cancer therapeutic agents and demonstrate the power of predictive chemogenomics in small-molecule discovery.
C1 [de Waal, Luc; Lewis, Timothy A.; Rees, Matthew G.; Tsherniak, Aviad; Wu, Xiaoyun; Choi, Peter S.; Gechijian, Lara; Hartigan, Christina; Faloon, Patrick W.; Hickey, Mark J.; Tolliday, Nicola; Carr, Steven A.; Clemons, Paul A.; Munoz, Benito; Wagner, Bridget K.; Shamji, Alykhan F.; Koehler, Angela N.; Schenone, Monica; Burgin, Alex B.; Schreiber, Stuart L.; Greulich, Heidi; Meyerson, Matthew] Broad Inst Harvard & MIT, Cambridge, MA USA.
[de Waal, Luc; Choi, Peter S.; Greulich, Heidi; Meyerson, Matthew] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Koehler, Angela N.] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Greulich, Heidi] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Meyerson, Matthew] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Greulich, H; Meyerson, M (reprint author), Broad Inst Harvard & MIT, Cambridge, MA USA.; Greulich, H; Meyerson, M (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Greulich, H (reprint author), Harvard Univ, Sch Med, Dept Med, Boston, MA USA.; Meyerson, M (reprint author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
EM heidig@broadinstitute.org; matthew_meyerson@dfci.harvard.edu
FU US National Cancer Institute (NCI) [1R35CA197568]; American Cancer
Society Research Professorship; Doctors Cancer Foundation; Friends of
Dana-Farber Cancer Institute; US National Institutes of Health's
Molecular Libraries Program Center Network (MLPCN) [3U54HG005032-05S1];
NCI's Cancer Target Discovery and Development (CTD2) Network
[U01CA176152]
FX This work was supported in part by the US National Cancer Institute
(NCI) Grant (grant number 1R35CA197568, awarded to M.M.), the American
Cancer Society Research Professorship (awarded to M.M.), the Doctors
Cancer Foundation (awarded to H.G.), the Friends of Dana-Farber Cancer
Institute (awarded to H.G.), and the US National Institutes of Health's
Molecular Libraries Program Center Network (MLPCN) (grant number
3U54HG005032-05S1, awarded to H.G., M.M. and S.L.S.). The cancer
cell-line profiling studies were supported in part by the NCI's Cancer
Target Discovery and Development (CTD2) Network (grant number
U01CA176152, awarded to S.L.S.). We thank A. Bhatt, H. Gannon, J. Jung,
T. Sharifnia and all members of the Meyerson laboratory for their advice
and helpful discussions. S.L.S. is an Investigator of the Howard Hughes
Medical Institute.
NR 52
TC 5
Z9 5
U1 5
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1552-4450
EI 1552-4469
J9 NAT CHEM BIOL
JI Nat. Chem. Biol.
PD FEB
PY 2016
VL 12
IS 2
BP 102
EP +
DI 10.1038/NCHEMBIO.1984
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DC6GG
UT WOS:000369317300012
PM 26656089
ER
PT J
AU Rees, MG
Seashore-Ludlow, B
Cheah, JH
Adams, DJ
Price, EV
Gill, S
Javaid, S
Coletti, ME
Jones, VL
Bodycombe, NE
Soule, CK
Alexander, B
Li, A
Montgomery, P
Kotz, JD
Hon, CSY
Munoz, B
Liefeld, T
Dancik, V
Haber, DA
Clish, CB
Bittker, JA
Palmer, M
Wagner, BK
Clemons, PA
Shamji, AF
Schreiber, SL
AF Rees, Matthew G.
Seashore-Ludlow, Brinton
Cheah, Jaime H.
Adams, Drew J.
Price, Edmund V.
Gill, Shubhroz
Javaid, Sarah
Coletti, Matthew E.
Jones, Victor L.
Bodycombe, Nicole E.
Soule, Christian K.
Alexander, Benjamin
Li, Ava
Montgomery, Philip
Kotz, Joanne D.
Hon, C. Suk-Yee
Munoz, Benito
Liefeld, Ted
Dancik, Vlado
Haber, Daniel A.
Clish, Clary B.
Bittker, Joshua A.
Palmer, Michelle
Wagner, Bridget K.
Clemons, Paul A.
Shamji, Alykhan F.
Schreiber, Stuart L.
TI Correlating chemical sensitivity and basal gene expression reveals
mechanism of action
SO NATURE CHEMICAL BIOLOGY
LA English
DT Article
ID ANTICANCER DRUG-SENSITIVITY; SMALL MOLECULES; CANCER-CELLS;
IDENTIFICATION; INHIBITORS; DISCOVERY; TARGET; METABOLISM; PROFILES;
RESISTANCE
AB Changes in cellular gene expression in response to small-molecule or genetic perturbations have yielded signatures that can connect unknown mechanisms of action (MoA) to ones previously established. We hypothesized that differential basal gene expression could be correlated with patterns of small-molecule sensitivity across many cell lines to illuminate the actions of compounds whose MoA are unknown. To test this idea, we correlated the sensitivity patterns of 481 compounds with similar to 19,000 basal transcript levels across 823 different human cancer cell lines and identified selective outlier transcripts. This process yielded many novel mechanistic insights, including the identification of activation mechanisms, cellular transporters and direct protein targets. We found that ML239, originally identified in a phenotypic screen for selective cytotoxicity in breast cancer stem-like cells, most likely acts through activation of fatty acid desaturase 2 (FADS2). These data and analytical tools are available to the research community through the Cancer Therapeutics Response Portal.
C1 [Rees, Matthew G.; Seashore-Ludlow, Brinton; Cheah, Jaime H.; Adams, Drew J.; Price, Edmund V.; Gill, Shubhroz; Coletti, Matthew E.; Jones, Victor L.; Bodycombe, Nicole E.; Soule, Christian K.; Alexander, Benjamin; Li, Ava; Montgomery, Philip; Kotz, Joanne D.; Hon, C. Suk-Yee; Munoz, Benito; Liefeld, Ted; Dancik, Vlado; Clish, Clary B.; Bittker, Joshua A.; Palmer, Michelle; Wagner, Bridget K.; Clemons, Paul A.; Shamji, Alykhan F.; Schreiber, Stuart L.] Broad Inst, Cambridge, MA USA.
[Javaid, Sarah; Haber, Daniel A.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA.
[Seashore-Ludlow, Brinton] Karolinska Inst, Chem Biol Consortium Sweden, Div Translat Med & Chem Biol, Sci Life Lab Stockholm,Dept Med Biochem & Biophys, Solna, Sweden.
[Cheah, Jaime H.; Soule, Christian K.] MIT, Koch Inst Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Adams, Drew J.] Case Western Reserve Univ, Sch Med, Dept Genet & Genome Sci, Cleveland, OH 44106 USA.
[Price, Edmund V.] Novartis Inst Biomed Res, Emeryville, CA USA.
[Bodycombe, Nicole E.] Pfizer, Cambridge, MA USA.
[Liefeld, Ted] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.
[Palmer, Michelle] ImmunoGen, Waltham, MA USA.
RP Clemons, PA; Shamji, AF; Schreiber, SL (reprint author), Broad Inst, Cambridge, MA USA.
OI Seashore-Ludlow, Brinton/0000-0001-8658-5967
FU US National Cancer Institute's Cancer Target Discovery and Development
(CTD2) Network [U01CA176152]
FX This work was supported by the US National Cancer Institute's Cancer
Target Discovery and Development (CTD2) Network (grant number
U01CA176152, awarded to S.L.S.). We acknowledge the following colleagues
and centers for contributing compounds and for valuable critique: Boston
University, J. Bradner, P. Brown, C. Chen, J. Clardy, CNIO (Spanish
National Cancer Research Center), E.J. Corey, the Drug Synthesis and
Chemistry Branch (Developmental Therapeutics Program, Division of Cancer
Treatment and Diagnosis, National Cancer Institute), Eutropics, J.
Gutterman, E. Holson, Karyopharm, M. Meyerson, A. Myers, J. Porco, J.
Qi, Sanford-Burnham, M. Serrano-Wu, M. Shair, B. Stockwell, L. Walensky,
X. Wang and D. Zaharevitz. We thank A. Deik for conducting lipid
profiling measurements; S. Chattopadhay, J. Law, G. Schaefer, M.
Stewart, V. Viswanathan and other members of the Schreiber laboratory
for advice and helpful discussions; S. Wang for helping curate the
Informer Set; K. Emmith, J. Aseidu and the CSofT informatics group for
development and support of cell-line and data-tracking software; A.
Vrcic and the Broad Compound Management team for handling the Informer
Set; J. Boehm, A. Tsherniak, A. Aguirre and the Broad Cancer Program for
training and advice; the Broad Biological Samples Platform for providing
CCLs; and L. Garraway and the Broad-Novartis Cancer Cell Line
Encyclopedia (CCLE) team. S.L.S. is an Investigator of the Howard Hughes
Medical Institute.
NR 49
TC 20
Z9 20
U1 11
U2 17
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1552-4450
EI 1552-4469
J9 NAT CHEM BIOL
JI Nat. Chem. Biol.
PD FEB
PY 2016
VL 12
IS 2
BP 109
EP +
DI 10.1038/NCHEMBIO.1986
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DC6GG
UT WOS:000369317300014
PM 26656090
ER
PT J
AU Zhang, XY
Choi, PS
Francis, JM
Imielinski, M
Watanabe, H
Cherniack, AD
Meyers, M
AF Zhang, Xiaoyang
Choi, Peter S.
Francis, Joshua M.
Imielinski, Marcin
Watanabe, Hideo
Cherniack, Andrew D.
Meyers, Matthew
TI Identification of focally amplified lineage-specific super-enhancers in
human epithelial cancers
SO NATURE GENETICS
LA English
DT Article
ID COPY-NUMBER ALTERATION; B-CELL LINE; LUNG ADENOCARCINOMA;
GENE-EXPRESSION; TRANSCRIPTION FACTORS; HUMAN GENOME; C-MYC; SIGNATURES;
LEUKEMIA; TRANSFORMATION
AB Whole-genome analysis approaches are identifying recurrent cancer-associated somatic alterations in noncoding DNA regions. We combined somatic copy number analysis of 12 tumor types with tissue-specific epigenetic profiling to identify significant regions of focal amplification harboring super-enhancers. Copy number gains of noncoding regions harboring super-enhancers near KLF5, USP12, PARD6B and MYC are associated with overexpression of these cancer-related genes. We show that two distinct focal amplifications of super-enhancers 3' to MYC in lung adenocarcinoma (MYC-LASE) and endometrial carcinoma (MYC-ECSE) are physically associated with the MYC promoter and correlate with MYC overexpression. CRISPR/Cas9-mediated repression or deletion of a constituent enhancer within the MYC-LASE region led to significant reductions in the expression of MYC and its target genes and to the impairment of anchorage independent and clonogenic growth, consistent with an oncogenic function. Our results suggest that genomic amplification of super-enhancers represents a common mechanism to activate cancer driver genes in multiple cancer types.
C1 [Zhang, Xiaoyang; Choi, Peter S.; Francis, Joshua M.; Imielinski, Marcin; Meyers, Matthew] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Zhang, Xiaoyang; Choi, Peter S.; Francis, Joshua M.; Imielinski, Marcin; Cherniack, Andrew D.; Meyers, Matthew] Broad Inst Harvard & MIT, Canc Program, Cambridge, MA USA.
[Imielinski, Marcin] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA USA.
[Watanabe, Hideo] Icahn Sch Med Mt Sinai, Dept Med, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA.
[Watanabe, Hideo] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.
[Meyers, Matthew] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Meyers, Matthew] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
RP Meyers, M (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Meyers, M (reprint author), Broad Inst Harvard & MIT, Canc Program, Cambridge, MA USA.; Meyers, M (reprint author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.; Meyers, M (reprint author), Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
EM matthew_meyerson@dfci.harvard.edu
FU US Department of Defense [W81XWH-12-1-0269]; National Cancer Institute
[1R35CA197568, 1F32CA180662]; American Cancer Society; Lung Cancer
Research Foundation; American Association for Cancer Research-John and
Elizabeth Leonard Family Foundation; International Association for the
Study of Lung Cancer
FX We thank G. Ha and other members of the Meyerson laboratory for
discussions. We acknowledge support from US Department of Defense grant
W81XWH-12-1-0269 (KM.), National Cancer Institute grant 1R35CA197568
(KM.) and the American Cancer Society Research Professorship (KM.). X.Z.
is supported by the Lung Cancer Research Foundation and the American
Association for Cancer Research-John and Elizabeth Leonard Family
Foundation Basic Cancer Research Fellowship. P.S.C. is supported by a
fellowship from the International Association for the Study of Lung
Cancer and National Cancer Institute grant 1F32CA180662.
NR 49
TC 28
Z9 29
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD FEB
PY 2016
VL 48
IS 2
BP 176
EP 182
DI 10.1038/ng.3470
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA DC2JV
UT WOS:000369043900015
PM 26656844
ER
PT J
AU Bailey, JNC
Loomis, SJ
Kang, JH
Allingham, RR
Gharahkhani, P
Khor, CC
Burdon, KP
Aschard, H
Chasman, DI
Igo, RP
Hysi, PG
Glastonbury, CA
Ashley-Koch, A
Brilliant, M
Brown, AA
Budenz, DL
Buil, A
Cheng, CY
Choi, H
Christen, WG
Curhan, G
De Vivo, I
Fingert, JH
Foster, PJ
Fuchs, C
Gaasterland, D
Gaasterland, T
Hewitt, AW
Hu, F
Hunter, DJ
Khawaja, AP
Lee, RK
Li, Z
Lichter, PR
Mackey, DA
McGuffin, P
Mitchell, P
Moroi, SE
Perera, SA
Pepper, KW
Qi, QB
Realini, T
Richards, JE
Ridker, PM
Rimm, E
Ritch, R
Ritchie, M
Schuman, JS
Scott, WK
Singh, K
Sit, AJ
Song, YE
Tamimi, RM
Topouzis, F
Viswanathan, AC
Verma, SS
Vollrath, D
Wang, JJ
Weisschuh, N
Wissinger, B
Wollstein, G
Wong, TY
Yaspan, BL
Zack, DJ
Zhang, K
Weinreb, RN
Pericak-Vance, MA
Small, K
Hammond, CJ
Aung, T
Liu, YT
Vithana, EN
MacGregor, S
Craig, JE
Kraftl, P
Howell, G
Hauser, MA
Pasguale, LR
Haines, JL
Wiggs, JL
AF Bailey, Jessica N. Cooke
Loomis, Stephanie J.
Kang, Jae H.
Allingham, R. Rand
Gharahkhani, Puya
Khor, Chiea Chuen
Burdon, Kathryn P.
Aschard, Hugues
Chasman, Daniel I.
Igo, Robert P., Jr.
Hysi, Pirro G.
Glastonbury, Craig A.
Ashley-Koch, Allison
Brilliant, Murray
Brown, Andrew A.
Budenz, Donald L.
Buil, Alfonso
Cheng, Ching-Yu
Choi, Hyon
Christen, William G.
Curhan, Gary
De Vivo, Immaculata
Fingert, John H.
Foster, Paul J.
Fuchs, Charles
Gaasterland, Douglas
Gaasterland, Terry
Hewitt, Alex W.
Hu, Frank
Hunter, David J.
Khawaja, Anthony P.
Lee, Richard K.
Li, Zheng
Lichter, Paul R.
Mackey, David A.
McGuffin, Peter
Mitchell, Paul
Moroi, Sayoko E.
Perera, Shamira A.
Pepper, Keating W.
Qi, Qibin
Realini, Tony
Richards, Julia E.
Ridker, Paul M.
Rimm, Eric
Ritch, Robert
Ritchie, Marylyn
Schuman, Joel S.
Scott, William K.
Singh, Kuldev
Sit, Arthur J.
Song, Yeunjoo E.
Tamimi, Rulla M.
Topouzis, Fotis
Viswanathan, Ananth C.
Verma, Shefali Setia
Vollrath, Douglas
Wang, Jie Jin
Weisschuh, Nicole
Wissinger, Bernd
Wollstein, Gadi
Wong, Tien Y.
Yaspan, Brian L.
Zack, Donald J.
Zhang, Kang
Weinreb, Robert N.
Pericak-Vance, Margaret A.
Small, Kerrin
Hammond, Christopher J.
Aung, Tin
Liu, Yutao
Vithana, Eranga N.
MacGregor, Stuart
Craig, Jamie E.
Kraftl, Peter
Howell, Gareth
Hauser, Michael A.
Pasguale, Louis R.
Haines, Jonathan L.
Wiggs, Janey L.
CA EPIC Norfolk Eye Study
ANZRAG Consortium
TI Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as
susceptibility loci for primary open-angle glaucoma
SO NATURE GENETICS
LA English
DT Article
ID COMMON VARIANTS; INTRAOCULAR-PRESSURE; GENOTYPE IMPUTATION;
METAANALYSIS; STRESS; NUMBER; DYSFUNCTION; PREVALENCE; ANNOTATION;
MUTATIONS
AB Primary open-angle glaucoma (POAG) is a leading cause of blindness worldwide. To identify new susceptibility loci, we performed meta-analysis on genome-wide association study (GWAS) results from eight independent studies from the United States (3,853 cases and 33,480 controls) and investigated the most significantly associated SNPs in two Australian studies (1,252 cases and 2,592 controls), three European studies (875 cases and 4,107 controls) and a Singaporean Chinese study (1,037 cases and 2,543 controls). A meta-analysis of the top SNPs identified three new associated loci: rs35934224[T] in TXNRD2 (odds ratio (OR) = 0.78, P = 4.05 x 10(-11)) encoding a mitochondrial protein required for redox homeostasis; rs7137828[T] in ATXN2 (OR = 1.17, P = 8.73 x 10(-10)); and rs2745572[A] upstream of FOXC1 (OR = 1.17, P = 1.76 x 10(-10)). Using RT-PCR and immunohistochemistry, we show TXNRD2 and ATXN2 expression in retinal ganglion cells and the optic nerve head. These results identify new pathways underlying POAG susceptibility and suggest new targets for preventative therapies.
C1 [Bailey, Jessica N. Cooke; Igo, Robert P., Jr.; Song, Yeunjoo E.; Haines, Jonathan L.] Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Inst Computat Biol, Cleveland, OH 44106 USA.
[Loomis, Stephanie J.; Pasguale, Louis R.; Wiggs, Janey L.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Kang, Jae H.; Curhan, Gary; De Vivo, Immaculata; Fuchs, Charles; Rimm, Eric; Tamimi, Rulla M.; Pasguale, Louis R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA.
[Allingham, R. Rand; Hauser, Michael A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
[Gharahkhani, Puya; MacGregor, Stuart] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.
[Khor, Chiea Chuen; Li, Zheng] Genome Inst Singapore, Div Human Genet, Singapore, Singapore.
[Khor, Chiea Chuen; Cheng, Ching-Yu; Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
[Burdon, Kathryn P.; Mackey, David A.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia.
[Burdon, Kathryn P.; Craig, Jamie E.] Flinders Univ S Australia, Dept Ophthalmol, Adelaide, SA 5001, Australia.
[Aschard, Hugues; Hu, Frank; Hunter, David J.; Rimm, Eric; Kraftl, Peter] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Chasman, Daniel I.; Christen, William G.; Ridker, Paul M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02115 USA.
[Hysi, Pirro G.; Glastonbury, Craig A.; Small, Kerrin; Hammond, Christopher J.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.
[Ashley-Koch, Allison; Hauser, Michael A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
[Brilliant, Murray] Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, WI USA.
[Brown, Andrew A.; Buil, Alfonso] Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland.
[Budenz, Donald L.] Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC USA.
[Cheng, Ching-Yu; Perera, Shamira A.; Wong, Tien Y.; Aung, Tin; Vithana, Eranga N.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
[Cheng, Ching-Yu; Aung, Tin; Vithana, Eranga N.] Duke Nat Univ Singapore Grad Med Sch, Eye Acad Clin Program, Singapore, Singapore.
[Choi, Hyon] Boston Univ, Sch Med, Sect Rheumatol & Clin Epidemiol Unit, Boston, MA 02118 USA.
[Curhan, Gary] Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA.
[Fingert, John H.] Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA.
[Fingert, John H.] Univ Iowa, Coll Med, Dept Anat & Cell Biol, Iowa City, IA USA.
[Foster, Paul J.; Viswanathan, Ananth C.] Moorfields Eye Hosp, Biomed Res Ctr, Nat Inst Hlth Res, London, England.
[Foster, Paul J.] UCL, Dept Ophthalmol, London, England.
[Fuchs, Charles] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
[Gaasterland, Douglas] Eye Doctors Washington, Chevy Chase, MD USA.
[Gaasterland, Terry] Univ Calif San Diego, Scripps Genome Ctr, San Diego, CA 92103 USA.
[Hewitt, Alex W.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
[Hewitt, Alex W.] Royal Victorian Eye & Ear Hosp, Dept Ophthalmol, Melbourne, Vic 3002, Australia.
[Hu, Frank; Rimm, Eric] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Hunter, David J.; Kraftl, Peter] Harvard Univ, Sch Publ Hlth, Program Genet Epidemiol & Stat Genet, 665 Huntington Ave, Boston, MA 02115 USA.
[Khawaja, Anthony P.] Univ Cambridge, Sch Clin Med, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England.
[Lee, Richard K.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
[Lichter, Paul R.; Moroi, Sayoko E.; Richards, Julia E.] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
[Mackey, David A.] Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Visual Sci, Perth, WA 6009, Australia.
[McGuffin, Peter] Kings Coll London, Inst Psychiat, Med Res Council Social Genet & Dev Psychiat Res C, London, England.
[Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Ctr Vis Res, Westmead, NSW 2145, Australia.
[Perera, Shamira A.] Duke Natl Univ Singapore Grad Med Sch, Singapore, Singapore.
[Pepper, Keating W.; Howell, Gareth] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.
[Qi, Qibin] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Realini, Tony] West Virginia Univ Eye Inst, Dept Ophthalmol, Morgantown, WV USA.
[Richards, Julia E.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Ritch, Robert] New York Eye & Ear Infirm Mt Sinai, Dept Ophthalmol, Einhorn Clin Res Ctr, New York, NY USA.
[Ritchie, Marylyn; Verma, Shefali Setia] Penn State Univ, Ctr Syst Genom, University Pk, PA 16802 USA.
[Schuman, Joel S.; Wollstein, Gadi] Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA 15260 USA.
[Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, Inst Human Genom, Miami, FL 33136 USA.
[Singh, Kuldev] Stanford Univ, Sch Med, Dept Ophthalmol, Palo Alto, CA 94304 USA.
[Sit, Arthur J.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
[Topouzis, Fotis] Aristotle Univ Thessaloniki, AHEPA Hosp, Sch Med, Dept Ophthalmol, GR-54006 Thessaloniki, Greece.
[Vollrath, Douglas] Stanford Univ, Sch Med, Dept Genet, Palo Alto, CA 94304 USA.
[Weisschuh, Nicole; Wissinger, Bernd] Univ Tubingen, Ctr Ophthalmol, Inst Ophthalmic Res, Tubingen, Germany.
[Yaspan, Brian L.] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA.
[Zack, Donald J.] Johns Hopkins Univ Hosp, Wilmer Eye Inst, Baltimore, MD USA.
[Zhang, Kang; Weinreb, Robert N.] Univ Calif San Diego, Shiley Eye Inst, Hamilton Glaucoma Ctr, San Diego, CA 92103 USA.
[Liu, Yutao] Georgia Regents Univ, Dept Cell Biol & Anat, Augusta, GA USA.
[Liu, Yutao] Georgia Regents Univ, James & Jean Culver Vis Discovery Inst, Augusta, GA USA.
RP Wiggs, JL (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
EM janey_wiggs@meei.harvard.edu
RI Hewitt, Alex/D-1936-2013; Macgregor, Stuart/C-6442-2009; Mitchell,
Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014; Burdon,
Kathryn/A-5026-2009;
OI Ashley-Koch, Allison/0000-0001-5409-9155; Hammond,
Christopher/0000-0002-3227-2620; Mackey, David/0000-0001-7914-4709;
Gharahkhani, Puya/0000-0002-4203-5952; Hewitt, Alex/0000-0002-5123-5999;
Brown, Andrew/0000-0002-8087-3033; Macgregor,
Stuart/0000-0001-6731-8142; Perera, Shamira/0000-0002-1404-5096; Small,
Kerrin/0000-0003-4566-0005; Wang, Jie Jin/0000-0001-9491-4898; Burdon,
Kathryn/0000-0001-8217-1249; Li , Zheng/0000-0002-7060-2213; Buil,
Alfonso/0000-0002-3097-1014; Cooke Bailey, Jessica/0000-0002-4001-8702
FU US National Institutes of Health/National Eye Institute (NIH/NEI)
[R01EY022305]; UK Medical Research Council [G1000143]; Cancer Research
UK [C864/A14136]; NHMRC; Centre for Clinical Research Excellence in
Translational Clinical Research in Eye Diseases; Wellcome Trust, UK;
National Institute for Health Research (NIHR); Fight for Sight Early
Career Investigator Award; Biomedical Research Council (BMRC) grant in
Singapore [BMRC 10/1/35/19/675]; Singapore National Research Foundation
[NMRC/TCR/008-SERI/2013]; Royal Australian and New Zealand College of
Ophthalmology (RANZCO) Eye Foundation; National Health and Medical
Research Council (NHMRC) of Australia [535074, 1031362, 1023911,
1021105]
FX NEIGHBORHOOD data collection and analysis are supported by US National
Institutes of Health/National Eye Institute (NIH/NEI) grant R01EY022305
(J.L.W.). Support for recruitment in ANZRAG (Australian and New Zealand
Registry of Advanced Glaucoma) was provided by the Royal Australian and
New Zealand College of Ophthalmology (RANZCO) Eye Foundation and by the
National Health and Medical Research Council (NHMRC) of Australia
(535074, 1031362, 1023911 and 1021105). EPIC-Norfolk infrastructure and
core functions are supported by grants from the UK Medical Research
Council (G1000143) and Cancer Research UK (C864/A14136). BMES (Blue
Mountains Eye Study) was supported by the NHMRC, the Centre for Clinical
Research Excellence in Translational Clinical Research in Eye Diseases,
NHMRC Senior Research Fellowships and the Wellcome Trust, UK. Collection
and genotyping for the South London Case-Control cohort (UK) were
supported by a National Institute for Health Research (NIHR) Senior
Research Fellowship (C.J.H.), and analysis was supported by a Fight for
Sight Early Career Investigator Award (P.J.H.). The Singapore study
(E.N.V., T.A. and C.C.K.) was supported by a Biomedical Research Council
(BMRC) grant in Singapore, reference BMRC 10/1/35/19/675. This research
was also partly supported by a grant (NMRC/TCR/008-SERI/2013) from the
Singapore National Research Foundation under its Translational and
Clinical Research Flagship Programme and administered by the Singapore
Ministry of Health's National Medical Research Council. Additional
acknowledgment and funding details are in the Supplementary Note.
NR 47
TC 23
Z9 23
U1 2
U2 12
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD FEB
PY 2016
VL 48
IS 2
BP 189
EP 194
DI 10.1038/ng.3482
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA DC2JV
UT WOS:000369043900017
PM 26752265
ER
PT J
AU Kim, KH
Roberts, CWM
AF Kim, Kimberly H.
Roberts, Charles W. M.
TI Targeting EZH2 in cancer
SO NATURE MEDICINE
LA English
DT Review
ID POLYCOMB-REPRESSIVE COMPLEX; HISTONE METHYLTRANSFERASE EZH2; GROUP
PROTEIN EZH2; EMBRYONIC STEM-CELLS; ACUTE LYMPHOBLASTIC-LEUKEMIA;
CHROMATIN REMODELING GENES; NERVE SHEATH TUMORS; SOMATIC MUTATIONS;
PROSTATE-CANCER; BREAST-CANCER
AB Recent genomic studies have resulted in an emerging understanding of the role of chromatin regulators in the development of cancer. EZH2, a histone methyl transferase subunit of a Polycomb repressor complex, is recurrently mutated in several forms of cancer and is highly expressed in numerous others. Notably, both gain-of-function and loss-of-function mutations occur in cancers but are associated with distinct cancer types. Here we review the spectrum of EZH2-associated mutations, discuss the mechanisms underlying EZH2 function, and synthesize a unifying perspective that the promotion of cancer arises from disruption of the role of EZH2 as a master regulator of transcription. We further discuss EZH2 inhibitors that are now showing early signs of promise in clinical trials and also additional strategies to combat roles of EZH2 in cancer.
C1 [Kim, Kimberly H.; Roberts, Charles W. M.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Kim, Kimberly H.; Roberts, Charles W. M.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
[Kim, Kimberly H.; Roberts, Charles W. M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Kim, Kimberly H.; Roberts, Charles W. M.] Broad Inst Harvard, Boston, MA USA.
[Kim, Kimberly H.; Roberts, Charles W. M.] MIT, Boston, MA USA.
[Roberts, Charles W. M.] St Jude Childrens Res Hosp, Ctr Comprehens Canc, 332 N Lauderdale St, Memphis, TN 38105 USA.
[Roberts, Charles W. M.] St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.
RP Roberts, CWM (reprint author), St Jude Childrens Res Hosp, Ctr Comprehens Canc, 332 N Lauderdale St, Memphis, TN 38105 USA.; Roberts, CWM (reprint author), St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.
EM Charles.Roberts@stjude.org
FU National Cancer Center; US National Cancer Institute [R01CA172152,
R01CA113794]; Garrett B. Smith Foundation; Cure AT/RT Now foundation;
Avalanna Fund; Miles for Mary
FX K.H.K. was supported by an award from the National Cancer Center.
C.W.M.R. was supported by US National Cancer Institute grants
R01CA172152 and R01CA113794. The Garrett B. Smith Foundation, the Cure
AT/RT Now foundation, The Avalanna Fund and Miles for Mary provided
additional support.
NR 122
TC 55
Z9 57
U1 21
U2 46
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD FEB
PY 2016
VL 22
IS 2
BP 128
EP 134
DI 10.1038/nm.4036
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA DC8JX
UT WOS:000369466800005
PM 26845405
ER
PT J
AU Cloonan, SM
Glass, K
Laucho-Contreras, ME
Bhashyam, AR
Cervo, M
Pabon, MA
Konrad, C
Polverino, F
Siempos, II
Perez, E
Mizumura, K
Ghosh, MC
Parameswaran, H
Williams, NC
Rooney, KT
Chen, ZH
Goldklang, MP
Yuan, GC
Moore, SC
Demeo, DL
Rouault, TA
D'Armiento, JM
Schon, EA
Manfredi, G
Quackenbush, J
Mahmood, A
Silverman, EK
Owen, CA
Choi, AMK
AF Cloonan, Suzanne M.
Glass, Kimberly
Laucho-Contreras, Maria E.
Bhashyam, Abhiram R.
Cervo, Morgan
Pabon, Maria A.
Konrad, Csaba
Polverino, Francesca
Siempos, Ilias I.
Perez, Elizabeth
Mizumura, Kenji
Ghosh, Manik C.
Parameswaran, Harikrishnan
Williams, Niamh C.
Rooney, Kristen T.
Chen, Zhi-Hua
Goldklang, Monica P.
Yuan, Guo-Cheng
Moore, Stephen C.
Demeo, Dawn L.
Rouault, Tracey A.
D'Armiento, Jeanine M.
Schon, Eric A.
Manfredi, Giovanni
Quackenbush, John
Mahmood, Ashfaq
Silverman, Edwin K.
Owen, Caroline A.
Choi, Augustine M. K.
TI Mitochondrial iron chelation ameliorates cigarette smoke-induced
bronchitis and emphysema in mice
SO NATURE MEDICINE
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; CYTOCHROME-C-OXIDASE; GENOME-WIDE
ASSOCIATION; GENE-EXPRESSION; REGULATORY PROTEIN-2; TARGETED DELETION;
LUNG-CANCER; COPD; DEFICIENCY; ANEMIA
AB Chronic obstructive pulmonary disease (COPD) is linked to both cigarette smoking and genetic determinants. We have previously identified iron-responsive element binding protein 2 (IRP2) as an important COPD susceptibility gene and have shown that IRP2 protein is increased in the lungs of individuals with COPD. Here we demonstrate that mice deficient in Irp2 were protected from cigarette smoke (CS)-induced experimental COPD. By integrating RNA immunoprecipitation followed by sequencing (RIP-seq), RNA sequencing (RNA-seq), and gene expression and functional enrichment clustering analysis, we identified Irp2 as a regulator of mitochondrial function in the lungs of mice. Irp2 increased mitochondrial iron loading and levels of cytochrome c oxidase (COX), which led to mitochondrial dysfunction and subsequent experimental COPD. Frataxin-deficient mice, which had higher mitochondria! iron loading, showed impaired airway mucociliary clearance (MCC) and higher pulmonary inflammation at baseline, whereas mice deficient in the synthesis of cytochrome c oxidase, which have reduced COX, were protected from CS-induced pulmonary inflammation and impairment of MCC. Mice treated with a mitochondria! iron chelator or mice fed a low-iron diet were protected from CS-induced COPD. Mitochondrial iron chelation also alleviated CS-induced impairment of MCC, CS-induced pulmonary inflammation and CS-associated lung injury in mice with established COPD, suggesting a critical functional role and potential therapeutic intervention for the mitochondrial-iron axis in COPD.
C1 [Cloonan, Suzanne M.; Pabon, Maria A.; Siempos, Ilias I.; Perez, Elizabeth; Mizumura, Kenji; Williams, Niamh C.; Rooney, Kristen T.; Choi, Augustine M. K.] New York Presbyterian Hosp, Weill Cornell Med Coll, Joan & Sanford I Weill Dept Med, New York, NY USA.
[Cloonan, Suzanne M.; Laucho-Contreras, Maria E.; Bhashyam, Abhiram R.; Polverino, Francesca; Mizumura, Kenji; Chen, Zhi-Hua; Demeo, Dawn L.; Silverman, Edwin K.; Owen, Caroline A.; Choi, Augustine M. K.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
[Glass, Kimberly; Yuan, Guo-Cheng; Quackenbush, John] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Glass, Kimberly; Yuan, Guo-Cheng; Quackenbush, John] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Glass, Kimberly; Demeo, Dawn L.; Quackenbush, John; Silverman, Edwin K.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Cervo, Morgan; Moore, Stephen C.; Mahmood, Ashfaq] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Konrad, Csaba; Manfredi, Giovanni] Weill Cornell Med Coll, Brain & Mind Res Inst, New York, NY USA.
[Polverino, Francesca; Owen, Caroline A.] Lovelace Resp Res Inst, Albuquerque, NM USA.
[Polverino, Francesca] Univ Parma, Dept Pulm, I-43100 Parma, Italy.
[Siempos, Ilias I.] Univ Athens, Sch Med, Evangelismos Hosp, Dept Crit Care Med & Pulm Serv 1, Athens, Greece.
[Ghosh, Manik C.; Rouault, Tracey A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
[Parameswaran, Harikrishnan] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
[Chen, Zhi-Hua] Zhejiang Univ, Sch Med, Dept Resp & Crit Care Med, Hosp 2, Hangzhou, Zhejiang, Peoples R China.
[Goldklang, Monica P.; D'Armiento, Jeanine M.] Columbia Univ, Dept Anesthesiol, New York, NY USA.
[Goldklang, Monica P.; D'Armiento, Jeanine M.] Columbia Univ, Dept Med, New York, NY USA.
[D'Armiento, Jeanine M.] Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY USA.
[Schon, Eric A.] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA.
[Schon, Eric A.] Columbia Univ, Med Ctr, Dept Genet & Dev, New York, NY USA.
RP Choi, AMK (reprint author), New York Presbyterian Hosp, Weill Cornell Med Coll, Joan & Sanford I Weill Dept Med, New York, NY USA.; Choi, AMK (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
EM amc2056@med.cornell.edu
RI Polverino, Francesca/F-3816-2017;
OI Polverino, Francesca/0000-0001-9686-5698; Rooney, Kristen
T/0000-0002-7495-1437
FU US National Institutes of Health (NIH) [P01-HL114501, R01-HL055330,
R01-HL079904, R01-A1111475-01, R01-HL86814, R21-HL111835, HL122513,
R01-HL086936, P01-HD080642]; NIH-National Heart, Lung and Blood
Institute [K99-HL125899]; American Lung Association Biomedical Research
[RG-348928]; Flight Attendants Medical Research Institute (FAMRI)
clinical innovator award; clinical innovator FAMRI [CIA 123046]; FAMRI
Young Clinical Scientist a [YFEL141004, YFEL103236]; US Department of
Defense [W911F-15-1-0169]; NIH [P01-HL114501, P01-HL105339,
R01-HL111759, R21-ES025379-01, R01-GM088999]; Brigham and Women's
Hospital-Lovelace Respiratory Research institute Research Consortium;
intramural research program of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development, NIH; Muscular Dystrophy
Association; J. Willard and Alice S. Marriott Foundation
FX The authors thank J.S. Moon, H.C. Lam, K. Taylor and B. Ding for
technical assistance. The authors also acknowledge S. Chan (Harvard
Medical School) for the cyto-GRX2 and mito-GRX2 plasmids, Y. Hua
(Columbia University) for the breeding of the Sco2ki/ki and
Sco2ki/ko mice and J. Connelly (ApoPharma Inc.) for providing
Ferriprox. The authors also thank R. Rubio for assistance with RNA-seq,
Y. Shao for assistance with the microarray study and M. Ericsson for
assistance with transmission electron microscopy. The authors also
acknowledge discussion and input from S.W. Ryter, C.A. MacRae and P.Y.
Sips. This work was supported by US National Institutes of Health (NIH)
grants P01-HL114501 (A.M.K.C.), R01-HL055330 (A.M.K.C.), R01-HL079904
(A.M.K.C.), R01-A1111475-01 (C.A.O.), R01-HL86814 (C.A.O.), R21-HL111835
(C.A.O.), HL122513 (H.P.), R01-HL086936 (to J.M.D'A.) and P01-HD080642
(Project 2 to E.A.S.), NIH-National Heart, Lung and Blood Institute
grant K99-HL125899 (S.M.C.), American Lung Association Biomedical
Research grant RG-348928 (S.M.C.), a Flight Attendants Medical Research
Institute (FAMRI) clinical innovator award (A.M.K.C.), clinical
innovator FAMRI grant CIA#123046 (C.A.O.), FAMRI Young Clinical
Scientist awards YFEL141004 (F.P.) and YFEL103236 (M.P.G.), and US
Department of Defense grant W911F-15-1-0169 (E.A.S.). S.M.C., A.M.K.C.,
J.Q. and E.K.S. were also supported by NIH grant P01-HL105339 (to
E.K.S.). K.G. was supported by NIH grant R01-HL111759 (to J.Q., G.C.Y.
and E.K.S.). C.A.O. was also supported by NIH grants R21-ES025379-01 (to
A. Fedulov), P01-HL105339 (to E.K.S.) and P01-HL114501 (to A.M.K.C.) and
by Brigham and Women's Hospital-Lovelace Respiratory Research institute
Research Consortium grants. G.M. and C.K. were supported by NIH grant
R01-GM088999 (to G.M.). M.C.G. and T.A.R. acknowledge support from the
intramural research program of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development, NIH. Additional support
was provided by the Muscular Dystrophy Association (E.A.S.) and the J.
Willard and Alice S. Marriott Foundation (E.A.S.).
NR 60
TC 9
Z9 9
U1 2
U2 12
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD FEB
PY 2016
VL 22
IS 2
BP 163
EP 174
DI 10.1038/nm.4021
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA DC8JX
UT WOS:000369466800010
PM 26752519
ER
PT J
AU Dotiwala, F
Mulik, S
Polidoro, RB
Ansara, JA
Burleigh, BA
Walchs, M
Gazzinelli, RT
Lieberman, J
AF Dotiwala, Farokh
Mulik, Sachin
Polidoro, Rafael B.
Ansara, James A.
Burleigh, Barbara A.
Walchs, Michael
Gazzinelli, Ricardo T.
Lieberman, Judy
TI Killer lymphocytes use granulysin, perforin and granzymes to kill
intracellular parasites
SO NATURE MEDICINE
LA English
DT Article
ID PROGRAMMED CELL-DEATH; CD8(+) T-CELLS; TRYPANOSOMA-CRUZI;
IMMUNE-RESPONSE; MICE; GLUTATHIONE; PEROXIDASE; LESSONS; DISEASE
AB Protozoan infections are a serious global health problem(1,2). Natural killer (NK) cells and cytolytic T lymphocytes (CTLs) eliminate pathogen-infected cells by releasing cytolytic granule contents granzyme (Gzm) proteases and the pore-forming perforin (PFN)-into the infected cell(3). However, these cytotoxic molecules do not kill intracellular parasites. CD8(+) CTLs protect against parasite infections in mice primarily by secreting interferon (IFN)-gamma(4-10). However, human, but not rodent, cytotoxic granules contain the antimicrobial peptide granulysin (GNLY), which selectively destroys cholesterol poor microbial membranes(11-14), and GNLY, PFN and Gzms rapidly kill intracellular bacteria(15). Here we show that GNLY delivers Gzms into three protozoan parasites (Trypanosoma cruzi, Toxoplasma gondii and Leishmania major), in which the Gzms generate superoxide and inactivate oxidative defense enzymes to kill the parasite. PFN delivers GNLY and Gzms into infected cells, and GNLY then delivers Gzms to the intracellular parasites. Killer cell-mediated parasite death, which we term 'microbe-programmed cell death' or 'microptosis', is caspase independent but resembles mammalian apoptosis, causing mitochondria! swelling, transmembrane potential dissipation, membrane blebbing, phosphatidylserine exposure, DNA damage and chromatin condensation. GNLY-transgenic mice are protected against infection by T. cruzi and T. gondii, and survive infections that are lethal to wild-type mice. Thus, GNLY-, PFN- and Gzm-mediated elimination of intracellular protozoan parasites is an unappreciated immune defense mechanism.
C1 [Dotiwala, Farokh; Mulik, Sachin; Polidoro, Rafael B.; Ansara, James A.; Lieberman, Judy] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
[Dotiwala, Farokh; Mulik, Sachin; Polidoro, Rafael B.; Lieberman, Judy] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Polidoro, Rafael B.; Gazzinelli, Ricardo T.] Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
[Burleigh, Barbara A.; Gazzinelli, Ricardo T.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.
[Walchs, Michael] Univ Fribourg, Dept Med, CH-1700 Fribourg, Switzerland.
[Gazzinelli, Ricardo T.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA.
RP Dotiwala, F; Lieberman, J (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.; Dotiwala, F; Lieberman, J (reprint author), Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.; Gazzinelli, RT (reprint author), Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.; Gazzinelli, RT (reprint author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.; Gazzinelli, RT (reprint author), Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA.
EM farokh.dotiwala@childrens.harvard.edu; ricardo.gazzinelli@umassmed.edu;
jbdy.lieberman@childrens.harvard.edu
RI Polidoro, Rafael/A-6385-2016
OI Polidoro, Rafael/0000-0003-2982-0072
FU US National Institutes of Health [T32HL066987]; Coordenacao de
Aperfeicoamento de Pessoal de Ensino Superior (CAPES); David Rockefeller
Center for Latin American Studies at Harvard University; Conselho
Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Brazilian
National Institute of Science and Technology for Vaccines
[CNPq/Fapemig/MS 573547/2008-4]
FX This work was supported by the US National Institutes of Health grant
T32HL066987 (F.D.), a Scholar Fellowship from Coordenacao de
Aperfeicoamento de Pessoal de Ensino Superior (CAPES) and the David
Rockefeller Center for Latin American Studies at Harvard University
(R.T.G.), a Science Without Borders Scholar Fellowship from Conselho
Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) (R.B.P.) and
the Brazilian National Institute of Science and Technology for Vaccines
grant CNPq/Fapemig/MS 573547/2008-4 (R.T.G.). We thank S. Wilkinson
(Queen Mary University, London) and J. Kelly (London School of Hygiene
and Tropical Medicine) for T. cruzi overexpression plasmids, K. Okuda
(University of Massachusetts Medical School) for L. major, K. Engelberg
and M.J. Gubbels (Boston College) for T gondii, and M. Ericsson and R.
Bronson (Harvard Medical School) for technical support.
NR 20
TC 7
Z9 7
U1 4
U2 13
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD FEB
PY 2016
VL 22
IS 2
BP 210
EP 216
DI 10.1038/nm.4023
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA DC8JX
UT WOS:000369466800015
PM 26752517
ER
PT J
AU Morrell, NW
Bloch, DB
ten Dijke, P
Goumans, MJTH
Hata, A
Smith, J
Yu, PB
Bloch, KD
AF Morrell, Nicholas W.
Bloch, Donald B.
ten Dijke, Peter
Goumans, Marie-Jose T. H.
Hata, Akiko
Smith, Jim
Yu, Paul B.
Bloch, Kenneth D.
TI Targeting BMP signalling in cardiovascular disease and anaemia
SO NATURE REVIEWS CARDIOLOGY
LA English
DT Review
ID BONE MORPHOGENETIC PROTEIN; HEREDITARY HEMORRHAGIC TELANGIECTASIA;
PULMONARY ARTERIAL-HYPERTENSION; SMOOTH-MUSCLE-CELLS; PLURIPOTENT
STEM-CELLS; BLOOD-VESSEL FORMATION; TRANSFORMING GROWTH FACTOR-BETA(1);
PATHOLOGICAL CARDIAC-HYPERTROPHY; SUPPRESSES TUMOR-GROWTH; RECEPTOR-LIKE
KINASE-1
AB Bone morphogenetic proteins (BMPs) and their receptors, known to be essential regulators of embryonic patterning and organogenesis, are also critical for the regulation of cardiovascular structure and function. In addition to their contributions to syndromic disorders including heart and vascular development, BMP signalling is increasingly recognized for its influence on endocrine-like functions in postnatal cardiovascular and metabolic homeostasis. In this Review, we discuss several critical and novel aspects of BMP signalling in cardiovascular health and disease, which highlight the cell-specific and context-specific nature of BMP signalling. Based on advancing knowledge of the physiological roles and regulation of BMP signalling, we indicate opportunities for therapeutic intervention in a range of cardiovascular conditions including atherosclerosis and pulmonary arterial hypertension, as well as for anaemia of inflammation. Depending on the context and the repertoire of ligands and receptors involved in specific disease processes, the selective inhibition or enhancement of signalling via particular BMP ligands (such as in atherosclerosis and pulmonary arterial hypertension, respectively) might be beneficial. The development of selective small molecule antagonists of BMP receptors, and the identification of ligands selective for BMP receptor complexes expressed in the vasculature provide the most immediate opportunities for new therapies.
C1 [Morrell, Nicholas W.] Univ Cambridge, Sch Clin Med, Addenbrookes Hosp, Dept Med, Hills Road, Cambridge CB2 0QQ, England.
[Bloch, Donald B.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
[Bloch, Donald B.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[ten Dijke, Peter; Goumans, Marie-Jose T. H.] Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands.
[ten Dijke, Peter; Goumans, Marie-Jose T. H.] Leiden Univ, Med Ctr, Canc Genom Ctr Netherlands, NL-2300 RA Leiden, Netherlands.
[Hata, Akiko] Univ Calif, Cardiovasc Res Inst, Davis, CA USA.
[Smith, Jim] MRC Natl Inst Med Res, London, England.
[Yu, Paul B.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Bloch, Kenneth D.] Anaesthesia Ctr Crit Care Res, Dept Anaesthesia Crit Care & Pain, Oxford, MS USA.
RP Morrell, NW (reprint author), Univ Cambridge, Sch Clin Med, Addenbrookes Hosp, Dept Med, Hills Road, Cambridge CB2 0QQ, England.
EM nwm23@cam.ac.uk
OI Yu, Paul/0000-0003-2145-4944
FU British Heart Foundation [RG/13/4/30107]; Medical Research Council
[G0800784, G1000847, MC_U117597140, MR/K020919/1]; NHLBI NIH HHS [K08
HL079943]; NIAMS NIH HHS [R01 AR057374]; NIDDK NIH HHS [R01 DK082971]
NR 214
TC 10
Z9 13
U1 1
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5002
EI 1759-5010
J9 NAT REV CARDIOL
JI Nat. Rev. Cardiol.
PD FEB
PY 2016
VL 13
IS 2
BP 106
EP 120
DI 10.1038/nrcardio.2015.156
PG 15
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DC6JH
UT WOS:000369325600011
PM 26461965
ER
PT J
AU Alhamud, A
Taylor, PA
van der Kouwe, AJW
Meintjes, EM
AF Alhamud, A.
Taylor, Paul A.
van der Kouwe, Andre J. W.
Meintjes, Ernesta M.
TI Real-time measurement and correction of both B0 changes and subject
motion in diffusion tensor imaging using a double volumetric navigated
(DvNav) sequence
SO NEUROIMAGE
LA English
DT Article
DE Diffusion tensor imaging (DTI); Zero-order shim (frequency); The
first-order shim (linear gradients); Navigated diffusion sequence
(vNav); Double volumetric navigators (DvNav); B0 correction
ID NORMAL BRAIN MATURATION; STATIC MAGNETIC-FIELD; ECHO-PLANAR IMAGES;
INDUCED DISTORTION; FRACTIONAL ANISOTROPY; ARTIFACT REDUCTION;
SPIN-ECHO; MRI; SPECTROSCOPY; CHILDHOOD
AB Diffusion tensor imaging (DTI) requires a set of diffusion weighted measurements in order to acquire enough information to characterize local structure. The MRI scanner automatically performs a shimming process by acquiring a field map before the start of a DTI scan. Changes in B0, which can occur throughout the DTI acquisition due to several factors (including heating of the iron shim coils or subject motion), cause significant signal distortions that result in warped diffusion tensor (DT) parameter estimates.
In this work we introduce a novel technique to simultaneously measure, report and correct in real time subject motion and changes in B0 field homogeneity, both in and through the imaging plane. This is achieved using double volumetric navigators (DvNav), i.e. a pair of 3D EPI acquisitions, interleaved with the DTI pulse sequence. Changes in the B0 field are evaluated in terms of zero-order (frequency) and first-order (linear gradients) shim. The ability of the DvNav to accurately estimate the shim parameters was first validated in a water phantom. Two healthy subjects were scanned both in the presence and absence of motion using standard, motion corrected (single navigator, vNav), and DvNav DTI sequences. The difference in performance between the proposed 3D EPI field maps and the standard 3D gradient echo field maps of the MRI scanner was also evaluated in a phantom and two healthy subjects. The DvNav sequence was shown to accurately measure and correct changes in B0 following manual adjustments of the scanner's central frequency and the linear shim gradients. Compared to other methods, the DvNav produced DTI results that showed greater spatial overlap with anatomical references, particularly in scans with subject motion. This is largely due to the ability of the DvNav system to correct shim changes and subject motion between each volume acquisition, thus reducing shear distortion. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Alhamud, A.; Taylor, Paul A.; Meintjes, Ernesta M.] Univ Cape Town, Dept Human Biol, MRC UCT Med Imaging Res Unit, ZA-7700 Rondebosch, South Africa.
[Taylor, Paul A.] AIMS, Muizenberg, South Africa.
[van der Kouwe, Andre J. W.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[van der Kouwe, Andre J. W.] Harvard Univ, Sch Med, Dept Radiol, Brookline, MA USA.
RP Alhamud, A (reprint author), Univ Cape Town, Dept Human Biol, MRC UCT Med Imaging Res Unit, ZA-7700 Rondebosch, South Africa.
EM alkk1973@gmail.com
FU NIAAA NIH HHS [R21 AA017410]; NICHD NIH HHS [R01 HD071664]; NIMH NIH HHS
[R21 MH096559]
NR 58
TC 2
Z9 2
U1 4
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD FEB 1
PY 2016
VL 126
BP 60
EP 71
DI 10.1016/j.neuroimage.2015.11.022
PG 12
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA DC5VX
UT WOS:000369289800006
PM 26584865
ER
PT J
AU Whiteman, AS
Young, DE
Budson, AE
Stern, CE
Schon, K
AF Whiteman, Andrew S.
Young, Daniel E.
Budson, Andrew E.
Stern, Chantal E.
Schon, Karin
TI Entorhinal volume, aerobic fitness, and recognition memory in healthy
young adults: A voxel-based morphometry study
SO NEUROIMAGE
LA English
DT Article
DE Medial temporal lobes; Hippocampus; Recognition memory; Cardiovascular
fitness; Neurotrophins
ID MILD COGNITIVE IMPAIRMENT; MEDIAL TEMPORAL-LOBE; RAT CEREBRAL-CORTEX;
GRAY-MATTER VOLUME; HIPPOCAMPAL VOLUME; DENTATE GYRUS; ENVIRONMENTAL
ENRICHMENT; PHYSICAL-ACTIVITY; MESSENGER-RNA; CARDIORESPIRATORY FITNESS
AB Converging evidence supports the hypothesis effects of aerobic exercise and environmental enrichment are beneficial for cognition, in particular for hippocampus-supported learning and memory. Recent work in humans suggests that exercise training induces changes in hippocampal volume, but it is not known if aerobic exercise and fitness also impact the entorhinal cortex. In animal models, aerobic exercise increases expression of growth factors, including brain derived neurotrophic factor (BDNF). This exercise-enhanced expression of growth hormones may boost synaptic plasticity, and neuronal survival and differentiation, potentially supporting function and structure in brain areas including but not limited to the hippocampus. Here, using voxel based morphometry and a standard graded treadmill test to determine cardio-respiratory fitness (Bruce protocol; VO2 max), we examined if entorhinal and hippocampal volumes were associated with cardio-respiratory fitness in healthy young adults (N = 33). In addition, we examined if volumes were modulated by recognition memory performance and by serum BDNF, a putative marker of synaptic plasticity. Our results show a positive association between volume in right entorhinal cortex and cardio-respiratory fitness. In addition, average gray matter volume in the entorhinal cortex, bilaterally, was positively associated with memory performance. These data extend prior work on the cerebral effects of aerobic exercise and fitness to the entorhinal cortex in healthy young adults thus providing compelling evidence for a relationship between aerobic fitness and structure of the medial temporal lobe memory system. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Whiteman, Andrew S.; Stern, Chantal E.; Schon, Karin] Boston Univ, Dept Psychol & Brain Sci, 2 Cummington Mall, Boston, MA 02215 USA.
[Whiteman, Andrew S.; Stern, Chantal E.; Schon, Karin] Boston Univ, Ctr Memory & Brain, 2 Cummington Mall, Boston, MA 02215 USA.
[Young, Daniel E.] Univ Massachusetts, Coll Nursing & Hlth Sci, Exercise & Hlth Sci Program, 100 Morrissey Blvd, Boston, MA 02125 USA.
[Budson, Andrew E.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA.
[Schon, Karin] Boston Univ, Sch Med, Dept Anat & Neurobiol, 72 East Concord St,L-1004, Boston, MA 02215 USA.
[Schon, Karin] Boston Univ, Sch Med, Ctr Biomed Imaging, 650 Albany St, Boston, MA 02215 USA.
[Budson, Andrew E.] VA Boston Healthcare Syst, 150 South Huntington St, Boston, MA 02130 USA.
RP Schon, K (reprint author), Boston Univ, Sch Med, Dept Anat & Neurobiol, 72 East Concord St,L-1004, Boston, MA 02215 USA.
EM asw221@bu.edu; daniel.young@umb.edu; abudson@bu.edu; chantal@bu.edu;
kschon@bu.edu
RI Meijer, Anna/K-5118-2016;
OI Schon, Karin/0000-0003-2963-8449
FU Pathway to Independence Award [NIH K99AG036845, NIH R00AG036845]; Boston
University Clinical and Translational Science Institute (CTSI)
[UL1-TR000157]; Boston University Center for Biomedical Imaging (CBI);
Boston University Undergraduate Research Opportunities Program
FX This work was supported by a Pathway to Independence Award to K.S. (NIH
K99AG036845 and NIH R00AG036845), the Boston University Clinical and
Translational Science Institute (CTSI; UL1-TR000157), the Boston
University Center for Biomedical Imaging (CBI), and a Student Research
Award from the Boston University Undergraduate Research Opportunities
Program to A.S.W. We would like to thank Drs. Xuemei He and Tai Chen for
performing and overseeing the BDNF ELISAs, respectively, and the staff
of the CTSI General Clinical Research Unit (GCRU) and of the CBI for
their support. In addition, we would like to thank Dr. Neil Kowall for
serving as the study physician for the GCRU, and Ms. Rachel Nauer for
assistance with preparation of figures.
NR 90
TC 4
Z9 4
U1 4
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD FEB 1
PY 2016
VL 126
BP 229
EP 238
DI 10.1016/j.neuroimage.2015.11.049
PG 10
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA DC5VX
UT WOS:000369289800021
PM 26631814
ER
PT J
AU Schorge, JO
AF Schorge, John O.
TI Personalized Therapy in Action Evolving From a Series of One-Hit Wonders
to a Paradigm With Staying Power
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Editorial Material
ID CANCER
C1 [Schorge, John O.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Obstet & Gynecol Serv, Boston, MA USA.
RP Schorge, JO (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Obstet & Gynecol Serv, Boston, MA USA.
EM jschorge@partners.org
NR 6
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7844
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD FEB
PY 2016
VL 127
IS 2
BP 202
EP 203
DI 10.1097/AOG.0000000000001278
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DC5IS
UT WOS:000369255300003
PM 26942343
ER
PT J
AU Collins, L
Ellis, M
Pritchard, EWJ
Jenkins, C
Hoeritzauer, I
Farquhar, A
Laverty, O
Murray, V
Nelson, BD
AF Collins, Lisa
Ellis, Matthew
Pritchard, Edward W. J.
Jenkins, Christopher
Hoeritzauer, Ingrid
Farquhar, Adam
Laverty, Orla
Murray, Vincent
Nelson, Brett D.
TI Child-headed households in Rakai District, Uganda: a mixed-methods study
SO PAEDIATRICS AND INTERNATIONAL CHILD HEALTH
LA English
DT Article
DE Child-headed families; Uganda; HIV/AIDS
ID COMMUNITY; AFRICA
AB Objective: An important but neglected consequence of the AIDS pandemic that continues across sub-Saharan Africa is the phenomenon of child-headed households (CHH). This study aims to describe the challenges to health and well-being for young people living in child-headed households.
Methods: A mixed-methods research approach linked common themes using qualitative and quantitative instruments to provide a broad picture of the location and challenges of CHH in Kabira, Kyotera and Kamuganja in the Rakai District of southern Uganda. Local knowledge was used to locate CHH.
Results: 163 children living in 40 CHH were traced: 42.5% of the household heads were double orphans caring for younger siblings, and 43% were also caring for chronically ill or disabled grandparents who were economically unproductive and largely dependent on the eldest child for survival. It was found that those heading households were more likely not to attend school than children living at home with a parent. Their immediate needs ranged from food and shelter to health-care and education. Fear was a major theme: 38% of those interviewed reported fear of 'violence'. Children as young as 13 were responsible for navigating through complex decision-making processes from everyday basic necessities to decisions on the health care of younger siblings and grandparents.
Conclusion: Children and young people living in CHH are a largely invisible and highly vulnerable population. Clear, officially accepted definitions of CHH are a first step in recognising this vulnerable group for whom safeguards will be necessary as social work develops in lower-and middle-income countries (LMICs). The precise numbers of CHH are unknown and further examination of this undocumented group is needed.
C1 [Collins, Lisa; Ellis, Matthew; Pritchard, Edward W. J.] Univ Bristol, Sch Med, Bristol BS8 1TH, Avon, England.
[Collins, Lisa; Nelson, Brett D.] Harvard Humanitarian Initiat, Boston, MA USA.
[Ellis, Matthew] Univ Bristol, Sch Social & Community Med, Ctr Child & Adolescent Hlth, Bristol BS8 1TH, Avon, England.
[Jenkins, Christopher; Hoeritzauer, Ingrid; Laverty, Orla] Natl Hlth Serv, London, England.
[Jenkins, Christopher] Univ Nottingham, Nottingham NG7 2RD, England.
[Farquhar, Adam; Murray, Vincent] Queens Univ Belfast, Belfast, Antrim, North Ireland.
[Nelson, Brett D.] Massachusetts Gen Hosp, Dept Pediat, Div Global Hlth, Boston, MA 02114 USA.
RP Collins, L (reprint author), Manor Hall,Lower Clifton Hill, Bristol BS8 1BU, Avon, England.
EM lisabridgetcollins@gmail.com
OI Jenkins, Chris/0000-0003-3514-3581; Nelson, Brett/0000-0002-5049-1798
NR 23
TC 1
Z9 1
U1 1
U2 4
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 2046-9047
EI 2046-9055
J9 PAEDIATR INT CHILD H
JI Paediatr. Int. Child Health
PD FEB
PY 2016
VL 36
IS 1
BP 58
EP 63
DI 10.1179/2046905514Y.0000000152
PG 6
WC Pediatrics
SC Pediatrics
GA DC9JW
UT WOS:000369538800011
PM 26825224
ER
PT J
AU Akhbari, M
Shamsollahi, MB
Jutten, C
Armoundas, AA
Sayadi, O
AF Akhbari, Mahsa
Shamsollahi, Mohammad B.
Jutten, Christian
Armoundas, Antonis A.
Sayadi, Omid
TI ECG denoising and fiducial point extraction using an extended Kalman
filtering framework with linear and nonlinear phase observations
SO PHYSIOLOGICAL MEASUREMENT
LA English
DT Article
DE electrocardiogram (ECG); extended Kalman filter (EKF); fiducial point
extraction; denoising; dynamic time warping (DTW)
ID HIDDEN MARKOV-MODELS; T-WAVE DELINEATION; DYNAMICAL MODEL; GIBBS
SAMPLER; SIGNALS; ALGORITHMS; DATABASE
AB In this paper we propose an efficient method for denoising and extracting fiducial point (FP) of ECG signals. The method is based on a nonlinear dynamic model which uses Gaussian functions to model ECG waveforms. For estimating the model parameters, we use an extended Kalman filter (EKF). In this framework called EKF25, all the parameters of Gaussian functions as well as the ECG waveforms (P-wave, QRS complex and T-wave) in the ECG dynamical model, are considered as state variables. In this paper, the dynamic time warping method is used to estimate the nonlinear ECG phase observation. We compare this new approach with linear phase observation models. Using linear and nonlinear EKF25 for ECG denoising and nonlinear EKF25 for fiducial point extraction and ECG interval analysis are the main contributions of this paper. Performance comparison with other EKF-based techniques shows that the proposed method results in higher output SNR with an average SNR improvement of 12 dB for an input SNR of -8 dB. To evaluate the FP extraction performance, we compare the proposed method with a method based on partially collapsed Gibbs sampler and an established EKF-based method. The mean absolute error and the root mean square error of all FPs, across all databases are 14 ms and 22 ms, respectively, for our proposed method, with an advantage when using a nonlinear phase observation. These errors are significantly smaller than errors obtained with other methods. For ECG interval analysis, with an absolute mean error and a root mean square error of about 22 ms and 29 ms, the proposed method achieves better accuracy and smaller variability with respect to other methods.
C1 [Akhbari, Mahsa; Shamsollahi, Mohammad B.] Sharif Univ Technol, Dept Elect Engn, Biomed Signal & Image Proc Lab BiSIPL, Tehran, Iran.
[Akhbari, Mahsa; Jutten, Christian] CNRS, Dept Images & Signals, GIPSA Lab, F-75700 Paris, France.
[Akhbari, Mahsa; Jutten, Christian] Univ Grenoble Alpes, St Martin Dheres, France.
[Armoundas, Antonis A.; Sayadi, Omid] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.
RP Akhbari, M; Shamsollahi, MB (reprint author), Sharif Univ Technol, Dept Elect Engn, Biomed Signal & Image Proc Lab BiSIPL, Tehran, Iran.; Akhbari, M; Jutten, C (reprint author), CNRS, Dept Images & Signals, GIPSA Lab, F-75700 Paris, France.; Akhbari, M; Jutten, C (reprint author), Univ Grenoble Alpes, St Martin Dheres, France.; Armoundas, AA; Sayadi, O (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.
EM mahsa_akhbari@yahoo.com; mbshams@sharif.edu;
christian.jutten@gipsa-lab.grenoble-inp.fr; aarmoundas@partners.org;
sayadi.omid@mgh.harvard.edu
FU French Embassy; [ERC-2012-AdG-320684-CHESS]
FX This work has been partly supported by the PhD scholarship of French
Embassy and the European project ERC-2012-AdG-320684-CHESS.
NR 47
TC 4
Z9 4
U1 4
U2 11
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0967-3334
EI 1361-6579
J9 PHYSIOL MEAS
JI Physiol. Meas.
PD FEB
PY 2016
VL 37
IS 2
BP 203
EP 226
DI 10.1088/0967-3334/37/2/203
PG 24
WC Biophysics; Engineering, Biomedical; Physiology
SC Biophysics; Engineering; Physiology
GA DC6WC
UT WOS:000369359300003
PM 26767425
ER
PT J
AU Sheu, EG
Channick, R
Gee, DW
AF Sheu, Eric G.
Channick, Richard
Gee, Denise W.
TI Improvement in severe pulmonary hypertension in obese patients after
laparoscopic gastric bypass or sleeve gastrectomy
SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
LA English
DT Article
DE Bariatric; Obesity; Pulmonary (lungs); Cardio; Clinical
papers/trials/research
ID BARIATRIC SURGERY; ARTERIAL-HYPERTENSION; OUTCOMES
AB Case reports have suggested that bariatric surgery improves pulmonary hypertension. We performed a retrospective, case-control study to evaluate the safety and efficacy of bariatric surgery in obese patients with severe pulmonary hypertension.
Morbidly obese patients followed in a specialty pulmonary hypertension clinic who underwent laparoscopic gastric bypass or sleeve gastrectomy between 2008 and 2013 (n = 10) were compared to a BMI-matched cohort managed with maximal medical therapy (n = 10). Patients with advanced malignancy, prior heart/lung transplantation, and pulmonary hypertension from thromboembolism were excluded. Primary outcomes assessed were changes in use of pulmonary vasodilatory and diuretic medications, need for home oxygen therapy, and mean pulmonary arterial pressures. Secondary outcomes measured were excess body weight loss, perioperative mortality and morbidity, and hospital length of stay.
More patients who underwent bariatric surgery experienced improvements in pulmonary arterial pressures (75 vs. 0 %, p = 0.02), reduction in or discontinuation of pulmonary vasodilatory therapy (67 vs. 0 %, p = 0.01), and decreased diuretic requirements (86 vs. 13 %, p = 0.01) than the control cohort. Seventy-five percent of patients previously on home oxygen discontinued therapy after surgery, while oxygen requirements increased in 50 % of the control cohort. Excess body weight loss was greater in the surgical group (EWL 68 vs. 19 %, p < 0.001). Seven significant complications in five patients occurred in the first postoperative year, but there were no mortalities. Mean inpatient length of stay was 5 days.
Laparoscopic gastric bypass and sleeve gastrectomy in obese patients improves pulmonary hypertension in the short term.
C1 [Sheu, Eric G.] Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.
[Channick, Richard] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Gee, Denise W.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Sheu, Eric G.; Channick, Richard; Gee, Denise W.] Harvard Univ, Sch Med, Boston, MA USA.
RP Sheu, EG (reprint author), Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.; Sheu, EG (reprint author), Harvard Univ, Sch Med, Boston, MA USA.
EM esheu@partners.org
NR 12
TC 3
Z9 3
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-2794
EI 1432-2218
J9 SURG ENDOSC
JI Surg. Endosc.
PD FEB
PY 2016
VL 30
IS 2
BP 633
EP 637
DI 10.1007/s00464-015-4251-5
PG 5
WC Surgery
SC Surgery
GA DC6NE
UT WOS:000369335900031
PM 26091991
ER
PT J
AU Vergallo, R
Aguirre, AD
Abtahian, F
Minami, Y
Soeda, T
Chatzizisis, YS
Croce, K
Jang, IK
AF Vergallo, Rocco
Aguirre, Aaron D.
Abtahian, Farhad
Minami, Yoshiyasu
Soeda, Tsunenari
Chatzizisis, Yiannis S.
Croce, Kevin
Jang, Ik-Kyung
TI Recurrent myocardial infarctions and premature coronary atherosclerosis
in a 23-year-old man with antiphospholipid syndrome
SO THROMBOSIS AND HAEMOSTASIS
LA English
DT Editorial Material
C1 [Vergallo, Rocco; Abtahian, Farhad; Minami, Yoshiyasu; Soeda, Tsunenari; Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Aguirre, Aaron D.; Chatzizisis, Yiannis S.; Croce, Kevin] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA.
[Jang, Ik-Kyung] Kyung Hee Univ, Div Cardiol, Seoul, South Korea.
RP Jang, IK (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St,GRB 800, Boston, MA 02114 USA.
EM ijang@mgh.harvard.edu
NR 8
TC 0
Z9 0
U1 0
U2 3
PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN
PI STUTTGART
PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY
SN 0340-6245
J9 THROMB HAEMOSTASIS
JI Thromb. Haemost.
PD FEB
PY 2016
VL 115
IS 2
BP 237
EP 239
DI 10.1160/TH15-05-0412
PG 3
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA DC7WP
UT WOS:000369431700003
PM 26423215
ER
PT J
AU Chen, YF
Sadow, PM
Suh, H
Lee, KE
Choi, JY
Suh, YJ
Wang, TS
Lubitz, CC
AF Chen, Yufei
Sadow, Peter M.
Suh, Hyunsuk
Lee, Kyu Eun
Choi, June Young
Suh, Yong Joon
Wang, Tracy S.
Lubitz, Carrie C.
TI BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid
Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data
Analysis, and Meta-Analysis
SO THYROID
LA English
DT Article
ID BRAF V600E MUTATION; UNITED-STATES; FOLLOW-UP; INCREASING INCIDENCE;
PROGNOSTIC-FACTORS; CANCER; CARCINOMA; ASSOCIATION; OUTCOMES; RISK
AB Background: Given the increasing incidence of papillary thyroid carcinoma despite stable disease-specific mortality rates, the potential for the disease to reoccur is a key outcome to predict. The BRAF(V600E) mutation has been associated with recurrent disease in larger tumors. However, its correlation in papillary thyroid microcarcinoma (PTMC) is not clear in individual series. Methods: The MEDLINE, EMBASE, Web of Science, and Cochrane databases were searched for studies including patients with PTMC undergoing initial surgical treatment. Studies with at least two years of follow-up, BRAF genotyping (the comparator), and recurrence as an outcome were included, as were unpublished primary data on 485 patients from two institutions. The metameter analyzed was odds ratio (OR) for recurrence between patients with BRAF(V600E) versus BRAF wild type (BRAFwt). Results: The initial search identified 431 references. After screening of the abstracts for inclusion, 44 manuscripts were reviewed in full by two independent reviewers. Four published studies and primary data from two institutional cohorts were included in the final analysis. A meta-analysis of 2247 PTMC patients revealed that patients with a BRAF(V600E) mutation had a higher likelihood for recurrence (odds ratio 2.09 [confidence interval 1.31-3.33], p=0.002). Conclusions: This meta-analysis shows that BRAF mutational status correlates with recurrence of PTMCs, highlighting the potential utility of genotyping in preoperative and postoperative planning. BRAF mutation may be helpful in risk-stratifying patients with PTMC for surgical management versus observation.
C1 [Chen, Yufei; Lubitz, Carrie C.] Massachusetts Gen Hosp, Dept Surg, 55 Fruit St,GRB 425, Boston, MA 02114 USA.
[Sadow, Peter M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Suh, Hyunsuk] Mt Sinai Med Ctr, Dept Surg, Box 1259, New York, NY 10029 USA.
[Lee, Kyu Eun; Choi, June Young; Suh, Yong Joon] Seoul Natl Univ Hosp, Dept Surg, Seoul 110744, South Korea.
[Lee, Kyu Eun; Choi, June Young; Suh, Yong Joon] Coll Med, Seoul, South Korea.
[Wang, Tracy S.] Med Coll Wisconsin, Dept Surg, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA.
[Lubitz, Carrie C.] Inst Technol Assessment, Boston, MA USA.
RP Chen, YF (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St,GRB 425, Boston, MA 02114 USA.
EM ychen49@partners.org
NR 43
TC 5
Z9 7
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
EI 1557-9077
J9 THYROID
JI Thyroid
PD FEB 1
PY 2016
VL 26
IS 2
BP 248
EP 255
DI 10.1089/thy.2015.0391
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DC8YO
UT WOS:000369506700009
PM 26671072
ER
PT J
AU Kitahara, CM
McCullough, ML
Franceschi, S
Rinaldi, S
Wolk, A
Neta, G
Adami, HO
Anderson, K
Andreotti, G
Freeman, LEB
Bernstein, L
Buring, JE
Clavel-Chapelon, F
De Roo, LA
Gao, YT
Gaziano, JM
Giles, GG
Hakansson, N
Horn-Ross, PL
Kirsh, VA
Linet, MS
Maclnnis, RJ
Orsini, N
Park, Y
Patel, AV
Purdue, MP
Riboli, E
Robien, K
Rohan, T
Sandler, DP
Schairer, C
Schneider, AB
Sesso, HD
Shu, XO
Singh, PN
van den Brandt, PA
Ward, E
Weiderpass, E
White, E
Xiang, YB
Zeleniuch-Jacquotte, A
Zheng, W
Hartge, P
de Gonzalez, AB
AF Kitahara, Cari M.
McCullough, Marjorie L.
Franceschi, Silvia
Rinaldi, Sabina
Wolk, Alicja
Neta, Gila
Adami, Hans Olov
Anderson, Kristin
Andreotti, Gabriella
Freeman, Laura E. Beane
Bernstein, Leslie
Buring, Julie E.
Clavel-Chapelon, Francoise
De Roo, Lisa A.
Gao, Yu-Tang
Gaziano, J. Michael
Giles, Graham G.
Hakansson, Niclas
Horn-Ross, Pamela L.
Kirsh, Vicki A.
Linet, Martha S.
Maclnnis, Robert J.
Orsini, Nicola
Park, Yikyung
Patel, Alpa V.
Purdue, Mark P.
Riboli, Elio
Robien, Kimberly
Rohan, Thomas
Sandler, Dale P.
Schairer, Catherine
Schneider, Arthur B.
Sesso, Howard D.
Shu, Xiao-Ou
Singh, Pramil N.
van den Brandt, Piet A.
Ward, Elizabeth
Weiderpass, Elisabete
White, Emily
Xiang, Yong-Bing
Zeleniuch-Jacquotte, Anne
Zheng, Wei
Hartge, Patricia
de Gonzalez, Amy Berrington
TI Anthropometric Factors and Thyroid Cancer Risk by Histological Subtype:
Pooled Analysis of 22 Prospective Studies
SO THYROID
LA English
DT Article
ID BASE-LINE CHARACTERISTICS; BODY-MASS INDEX; NIH-AARP DIET;
UNITED-STATES; BREAST-CANCER; LARGE COHORT; POSTMENOPAUSAL WOMEN;
PHYSICAL-ACTIVITY; FAT DISTRIBUTION; LIFE-STYLE
AB Background: Greater height and body mass index (BMI) have been associated with an increased risk of thyroid cancer, particularly papillary carcinoma, the most common and least aggressive subtype. Few studies have evaluated these associations in relation to other, more aggressive histologic types or thyroid cancer-specific mortality. Methods: This large pooled analysis of 22 prospective studies (833,176 men and 1,260,871 women) investigated thyroid cancer incidence associated with greater height, BMI at baseline and young adulthood, and adulthood BMI gain (difference between young-adult and baseline BMI), overall and separately by sex and histological subtype using multivariable Cox proportional hazards regression models. Associations with thyroid cancer mortality were investigated in a subset of cohorts (578,922 men and 774,373 women) that contributed cause of death information. Results: During follow-up, 2996 incident thyroid cancers and 104 thyroid cancer deaths were identified. All anthropometric factors were positively associated with thyroid cancer incidence: hazard ratios (HR) [confidence intervals (CIs)] for height (per 5cm)=1.07 [1.04-1.10], BMI (per 5kg/m(2))=1.06 [1.02-1.10], waist circumference (per 5cm)=1.03 [1.01-1.05], young-adult BMI (per 5kg/m(2))=1.13 [1.02-1.25], and adulthood BMI gain (per 5kg/m(2))=1.07 [1.00-1.15]. Associations for baseline BMI and waist circumference were attenuated after mutual adjustment. Baseline BMI was more strongly associated with risk in men compared with women (p=0.04). Positive associations were observed for papillary, follicular, and anaplastic, but not medullary, thyroid carcinomas. Similar, but stronger, associations were observed for thyroid cancer mortality. Conclusion: The results suggest that greater height and excess adiposity throughout adulthood are associated with higher incidence of most major types of thyroid cancer, including the least common but most aggressive form, anaplastic carcinoma, and higher thyroid cancer mortality. Potential underlying biological mechanisms should be explored in future studies.
C1 [Kitahara, Cari M.; Andreotti, Gabriella; Freeman, Laura E. Beane; Linet, Martha S.; Schairer, Catherine; Hartge, Patricia; de Gonzalez, Amy Berrington] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.
[McCullough, Marjorie L.; Patel, Alpa V.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
[Franceschi, Silvia; Rinaldi, Sabina] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.
[Wolk, Alicja; Hakansson, Niclas; Orsini, Nicola] Karolinska Inst, Inst Environm Med, Div Nutr Epidemiol, S-10401 Stockholm, Sweden.
[Neta, Gila] NCI, Div Canc Control & Populat Sci, Rockville, MD USA.
[Adami, Hans Olov] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Adami, Hans Olov; Buring, Julie E.; Sesso, Howard D.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Anderson, Kristin] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Anderson, Kristin] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA.
[Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Div Canc Etiol, Duarte, CA 91010 USA.
[Buring, Julie E.; Gaziano, J. Michael; Sesso, Howard D.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA.
[Clavel-Chapelon, Francoise] Ctr Res Epidemiol & Populat Hlth CESP, INSERM, U1018, Villejuif, France.
[Clavel-Chapelon, Francoise] France Paris South Univ, INSERM, UMRS 1018, Team 9, Villejuif, France.
[De Roo, Lisa A.] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway.
[De Roo, Lisa A.; Sandler, Dale P.] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA.
[Gao, Yu-Tang] Shanghai Jiao Tong Univ, Sch Med, Dept Epidemiol, Shanghai Canc Inst,Renji Hosp, Shanghai, Peoples R China.
[Gaziano, J. Michael; Sesso, Howard D.] Brigham & Womens Hosp, Div Aging, 75 Francis St, Boston, MA 02115 USA.
[Gaziano, J. Michael] Massachusetts Vet Epidemiol Res & Informat Ctr, Geriatric Res Educ & Clin Ctr, VA Boston Healthcare Syst, Boston, MA USA.
[Giles, Graham G.; Maclnnis, Robert J.] Canc Epidemiol Ctr, Canc Council Victoria, Melbourne, Vic, Australia.
[Giles, Graham G.; Maclnnis, Robert J.] Univ Melbourne, Ctr Biostat & Epidemiol, Melbourne Sch Populat & Global Hlth, Carlton, Vic 3053, Australia.
[Horn-Ross, Pamela L.] Canc Prevent Inst Calif, Fremont, CA USA.
[Kirsh, Vicki A.] Canc Care Ontario, Prevent & Canc Control, Toronto, ON, Canada.
[Kirsh, Vicki A.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
[Park, Yikyung] Washington Univ, Div Publ Hlth Sci, Sch Med, St Louis, MO USA.
[Purdue, Mark P.] Ontario Inst Canc Res, Toronto, ON, Canada.
[Riboli, Elio] Univ London Imperial Coll Sci Technol & Med, Imperial Sch Publ Hlth, London, England.
[Robien, Kimberly] George Washington Univ, Milken Inst Sch Publ Hlth, Dept Exercise & Nutr Sci, Washington, DC USA.
[Rohan, Thomas] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Schneider, Arthur B.] Univ Illinois, Sect Endocrinol Diabet & Metab, Chicago, IL USA.
[Shu, Xiao-Ou] Vanderbilt Univ, Sch Med, Vanderbilt Epidemiol Ctr, Vanderbilt Ingram Canc Ctr,Div Epidemiol,Dept Med, Nashville, TN 37212 USA.
[Singh, Pramil N.] Loma Linda Univ, Sch Publ Hlth, Ctr Hlth Res, Loma Linda, CA 92350 USA.
[van den Brandt, Piet A.] Maastricht Univ, Dept Epidemiol, GROW Sch Oncol & Dev Biol, NL-6200 MD Maastricht, Netherlands.
[Ward, Elizabeth] Amer Canc Soc, Intramural Res, Atlanta, GA 30329 USA.
[Weiderpass, Elisabete] Univ Tromso, Dept Community Med, Fac Hlth Sci, Arctic Univ Norway, Tromso, Norway.
[Weiderpass, Elisabete] Canc Registry Norway, Inst Populat Based Canc Res, Dept Res, Oslo, Norway.
[Weiderpass, Elisabete] Folkalsan Res Ctr, Genet Epidemiol Grp, Helsinki, Finland.
[White, Emily] Fred Hutchinson Canc Res Ctr, Publ Hlth Serv Div, 1124 Columbia St, Seattle, WA 98104 USA.
[White, Emily] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Zeleniuch-Jacquotte, Anne] NYU, Sch Med, Div Epidemiol, Dept Populat Hlth, New York, NY USA.
[Zeleniuch-Jacquotte, Anne] NYU, Sch Med, Inst Canc, New York, NY USA.
RP Kitahara, CM (reprint author), Div Canc Epidemiol & Genet, 9609 Med Ctr Dr,Rm 7E 536, Bethesda, MD 20892 USA.
EM kitaharac@mail.nih.gov
RI Purdue, Mark/C-9228-2016; Weiderpass, Elisabete/M-4029-2016; CLAVEL,
Christine/P-6333-2016; Zheng, Wei/O-3351-2013; Beane Freeman,
Laura/C-4468-2015; Kitahara, Cari/R-8267-2016;
OI Purdue, Mark/0000-0003-1177-3108; Zeleniuch-Jacquotte,
Anne/0000-0001-9350-1303; Weiderpass, Elisabete/0000-0003-2237-0128;
Zheng, Wei/0000-0003-1226-070X; Beane Freeman,
Laura/0000-0003-1294-4124; Robien, Kim/0000-0002-2120-2280; Sandler,
Dale/0000-0002-6776-0018
FU Swedish Research Council; Swedish Cancer Foundation; Karolinska
Institutet, Stockholm, Sweden; American Cancer Society; National Cancer
Institute [R01 CA77398, R01 CA39742, CA-34933, CA-40360, CA-097193, R37
CA070867, UM1 CA182910, R01 CA082729, UM1 CA173640, K05-CA154337];
California Department of Public Health (CDPH) [103885]; NCI's SEER
program [HHSN261201000140C, HHSN261201000035C, HHSN261201000034C];
Centers for Disease Control and Prevention's (CDCP) National Program of
Cancer Registries [U58DP003862-01]; World Cancer Research Fund
[2009/92]; European Commission (DG-SANCO); International Agency for
Research on Cancer; Danish Cancer Society, Denmark; Ligue Contre le
Cancer, France; Institut Gustave Roussy, France; Mutuelle Generale de
l'Education Nationale, France; Institut National de la Sante et de la
Recherche Medicale, France; Deutsche Krebshilfe, Germany; Deutsches
Krebsforschungszentrum; Federal Ministry of Education and Research,
Germany; Hellenic Health Foundation, Greece; Italian Association for
Research on Cancer; National Research Council, Italy; Dutch Ministry of
Public Health, Welfare and Sports, the Netherlands; Netherlands Cancer
Registry, the Netherlands; LK Research Funds, the Netherlands; Dutch
Prevention Funds, the Netherlands; Dutch ZON (Zorg Onderzoek Nederland),
the Netherlands; World Cancer Research Fund, London, UK; Statistics
Netherlands, the Netherlands; European Research Council, Norway; Health
Research Fund; Regional Government of Andalucia [6236]; Regional
Government of Asturias [6236]; Regional Government of Basque Country
[6236]; Regional Government of Murcia [6236]; Navarra, ISCIII RETIC,
Spain [RD06/0020/0091]; Swedish Cancer Society, Sweden; Swedish
Scientific Council, Sweden; Regional Government of Skane; Vasterbotten,
Sweden; Cancer Research United Kingdom; Medical Research Council, United
Kingdom; Stroke Association, United Kingdom; British Heart Foundation,
United Kingdom; Department of Health, Food Standards Agency, United
Kingdom; Wellcome Trust; French National Cancer Institute (L'Institut
National du Cancer; INCA) [2009-139]; Ligue contre le Cancer (France);
Institut Gustave Roussy (France); Mutuelle Generale de l'Education
Nationale (France); Institut National de la Sante et de la Recherche
Medicale (INSERM) (France); German Cancer Aid; German Cancer Research
Center (DKFZ); German Federal Ministry of Education and Research; Danish
Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of
Health (RTICC) [DR06/0020/0091]; regional government from Asturias;
regional government from Andalucia; regional government from Murcia;
regional government from Navarra; regional government from Vasco
Country; Catalan Institute of Oncology of Spain; Cancer Research UK;
Medical Research Council, UK; Stroke Association, UK; British Heart
Foundation; Department of Health, UK; Food Standards Agency, UK;
Wellcome Trust, UK; Hellenic Health Foundation; Compagnia San Paolo,
Italy; Dutch Ministry of Public Health, Welfare and Sports; Dutch
Ministry of Health; Dutch Prevention Funds; LK Research Funds; Dutch ZON
(Zorg Onderzoek Nederland); World Cancer Research Fund (WCRF);
Statistics Netherlands (The Netherlands); Swedish Cancer Society;
Swedish Scientific Council; Regional Government of Skane, Sweden;
Nordforsk-Centre of Excellence programme; National Health and Medical
Research Council of Australia [209057, 251533]; National Heart, Lung,
and Blood Institute [HL-26490, HL-34595]; National Institutes of Health,
Bethesda, MD; NIH, National Institute of Environmental Health Sciences
[ZO1-ES-044005]; Office of Dietary Supplements [K05-CA154337]
FX COSM and SMC: These cohorts are supported by the Swedish Research
Council, the Swedish Cancer Foundation, and by Strategic Funds from
Karolinska Institutet, Stockholm, Sweden.; CPS-II: The American Cancer
Society funds the creation, maintenance, and updating of the Cancer
Prevention Study-II (CPS-II) cohort.; CTS: The CTS is supported by grant
R01 CA77398 from the National Cancer Institute. The collection of cancer
incidence data used in the CTS is supported by the California Department
of Public Health (CDPH) as part of the state-wide cancer reporting
program mandated by California Health and Safety Code Section 103885;
the NCI's SEER program under contract HHSN261201000140C awarded to the
Cancer Prevention Institute of California, contract HHSN261201000035C
awarded to the University of Southern California, and contract
HHSN261201000034C awarded to the Public Health Institute; and the
Centers for Disease Control and Prevention's (CDCP) National Program of
Cancer Registries, under agreement U58DP003862-01 awarded to the CDPH.
The ideas and opinions expressed herein are those of the author(s) and
endorsement by the CDPH, NCI, and CDCP or their contractors and
subcontractors is not intended nor should be inferred.; EPIC: The
authors are grateful to the support of the World Cancer Research Fund
(2009/92). The coordination of EPIC is financially supported by the
European Commission (DG-SANCO) and the International Agency for Research
on Cancer. The national cohorts are supported by Danish Cancer Society,
Denmark; Ligue Contre le Cancer, France; Institut Gustave Roussy,
France; Mutuelle Generale de l'Education Nationale, France; Institut
National de la Sante et de la Recherche Medicale, France; Deutsche
Krebshilfe, Germany, Deutsches Krebsforschungszentrum and Federal
Ministry of Education and Research, Germany; Hellenic Health Foundation,
Greece; Italian Association for Research on Cancer; National Research
Council, Italy; Dutch Ministry of Public Health, Welfare and Sports, the
Netherlands; Netherlands Cancer Registry, the Netherlands; LK Research
Funds, the Netherlands; Dutch Prevention Funds, the Netherlands; Dutch
ZON (Zorg Onderzoek Nederland), the Netherlands; World Cancer Research
Fund, London, UK; Statistics Netherlands, the Netherlands; European
Research Council, Norway; Health Research Fund, Regional Governments of
Andalucia, Asturias, Basque Country, Murcia (project no. 6236) and
Navarra, ISCIII RETIC (RD06/0020/0091), Spain; Swedish Cancer Society,
Sweden; Swedish Scientific Council, Sweden; Regional Government of Skane
and Vasterbotten, Sweden; Cancer Research United Kingdom; Medical
Research Council, United Kingdom; Stroke Association, United Kingdom,
British Heart Foundation, United Kingdom; Department of Health, Food
Standards Agency, United Kingdom; and Wellcome Trust; United Kingdom. We
thank Bertrand Hemon for his precious help with the EPIC database. The
principle investigators and funders corresponding to each of the EPIC
centers that contributed cases were Kim Overvad, Anne Tjonneland
(Denmark); Francoise Clavel-Chapelon (France); Heiner Boeing, Rudolf
Kaaks (Germany); Antonia Trichopoulou (Greece); Vittorio Krogh, Domenico
Palli, Paolo Vineis, Salvatore Panico, Rosario Tumino (Italy); Eiliv
Lund (Norway); Antonio Agudo, Maria Jose Sanchez, J. Ramon Quiros,
Carmen Navarro, Aurelio Barricarte, Miren Dorronsoro (Spain); Mattias
Johansson, Jonas Manjer (Sweden); H. Bas Bueno-de-Mesquita, Petra H.
Peeters (The Netherlands); Timothy Key, Nick Wareham (UK); The
coordination of European Prospective Investigation into Cancer and
Nutrition is financially supported by the European Commission (DG-SANCO)
and the International Agency for Research on Cancer.; The national
cohorts are supported by the French National Cancer Institute
(L'Institut National du Cancer; INCA); Grant Number: 2009-139; Ligue
contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de
l'Education Nationale, Institut National de la Sante et de la Recherche
Medicale (INSERM) (France); German Cancer Aid; German Cancer Research
Center (DKFZ); German Federal Ministry of Education and Research; Danish
Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of
Health (RTICC (DR06/0020/0091); the participating regional governments
from Asturias, Andalucia, Murcia, Navarra and Vasco Country and the
Catalan Institute of Oncology of Spain; Cancer Research UK; Medical
Research Council, UK; the Stroke Association, UK; British Heart
Foundation; Department of Health, UK; Food Standards Agency, UK; the
Wellcome Trust, UK; the Hellenic Health Foundation; Italian Association
for Research on Cancer; Compagnia San Paolo, Italy; Dutch Ministry of
Public Health, Welfare and Sports; Dutch Ministry of Health; Dutch
Prevention Funds; LK Research Funds; Dutch ZON (Zorg Onderzoek
Nederland); World Cancer Research Fund (WCRF); Statistics Netherlands
(The Netherlands); Swedish Cancer Society; Swedish Scientific Council;
Regional Government of Skane, Sweden; Nordforsk-Centre of Excellence
programme.; IWHS: The authors thank the study participants. IWHS is
funded by a grant from the National Cancer Institute (R01 CA39742).;
Melbourne Collaborative Cohort Study: This study was made possible by
the contribution of many people, including the original investigators
and the diligent team who recruited the participants and who continue
working on follow-up. We would also like to express our gratitude to the
many thousands of Melbourne residents who continue to participate in the
study. This work was supported by infrastructure from Cancer Council
Victoria and grants from the National Health and Medical Research
Council of Australia 209057 and 251533.; PHS: This study is supported by
grants from the National Cancer Institute (CA-34933, CA-40360, and
CA-097193) and from the National Heart, Lung, and Blood Institute
(HL-26490 and HL-34595), National Institutes of Health, Bethesda, MD.;
The Sister Study is supported by the Intramural Research Program of the
NIH, National Institute of Environmental Health Sciences
(ZO1-ES-044005). Support for data collection and study and data
management are provided by Social & Scientific Systems, Inc., and
Westat, Inc., Durham, NC. Aimee D'Aloisio, Sandra Halverson, Dan Scharf,
and David Shore helped prepare the data for this analysis.; The SWHS and
SMHS are supported in part by research grants from the National Cancer
Institute (R37 CA070867, UM1 CA182910, R01 CA082729, and UM1 CA173640).
The authors thank participants and research staff members of the studies
for their contribution.; USRT: The authors thank the study participants
and Jerry Reid of the American Registry of Radiologic Technologists for
their continued support of this study; Diane Kampa and Allison Iwan of
the University of Minnesota for study management and data collection;
and Jeremy Miller at Information Management Services, Inc., for
biomedical computing support.; VITAL: Emily White was supported by the
grant K05-CA154337 (National Cancer Institute and Office of Dietary
Supplements).
NR 63
TC 3
Z9 3
U1 2
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
EI 1557-9077
J9 THYROID
JI Thyroid
PD FEB 1
PY 2016
VL 26
IS 2
BP 306
EP 318
DI 10.1089/thy.2015.0319
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DC8YO
UT WOS:000369506700016
PM 26756356
ER
PT J
AU Charness, ME
Riley, EP
Sowell, ER
AF Charness, Michael E.
Riley, Edward P.
Sowell, Elizabeth R.
TI Drinking During Pregnancy and the Developinc Brain: Is Any Amount Safe?
SO TRENDS IN COGNITIVE SCIENCES
LA English
DT Editorial Material
ID ALCOHOL SPECTRUM DISORDERS; EXPOSURE; MODERATE; MOTHERS
C1 [Charness, Michael E.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.
[Charness, Michael E.] Harvard Univ, Sch Med, Dept Neurol, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.
[Charness, Michael E.] Boston Univ, Sch Med, Dept Neurol, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.
[Riley, Edward P.] San Diego State Univ, Ctr Behav Teratol, 6330 Alvarado Court, San Diego, CA 92120 USA.
[Sowell, Elizabeth R.] Univ So Calif, Keck Sch Med, Inst Dev Mind, Childrens Hosp Los Angeles,Dev Cognit Neuroimagin, Los Angeles, CA 90027 USA.
[Sowell, Elizabeth R.] Univ So Calif, Keck Sch Med, Inst Dev Mind, Childrens Hosp Los Angeles,Dept Pediat, Los Angeles, CA 90027 USA.
RP Charness, ME (reprint author), Harvard Univ, Sch Med, VA Boston Healthcare Syst, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.; Charness, ME (reprint author), Harvard Univ, Sch Med, Dept Neurol, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.; Charness, ME (reprint author), Boston Univ, Sch Med, Dept Neurol, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.; Sowell, ER (reprint author), Univ So Calif, Keck Sch Med, Inst Dev Mind, Childrens Hosp Los Angeles,Dev Cognit Neuroimagin, Los Angeles, CA 90027 USA.; Sowell, ER (reprint author), Univ So Calif, Keck Sch Med, Inst Dev Mind, Childrens Hosp Los Angeles,Dept Pediat, Los Angeles, CA 90027 USA.
EM mcharness@hms.harvard.edu
FU NIAAA [AA12974, AA014811, AA017122]; VA Merit Review [5101BX002374]
FX The work of the authors is supported by NIAAA grants AA12974, AA014811,
AA017122, and VA Merit Review 5101BX002374.
NR 15
TC 2
Z9 2
U1 1
U2 8
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1364-6613
J9 TRENDS COGN SCI
JI TRENDS COGN. SCI.
PD FEB
PY 2016
VL 20
IS 2
BP 80
EP 82
DI 10.1016/j.tics.2015.09.011
PG 3
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA DC8MJ
UT WOS:000369473400004
PM 26801950
ER
PT J
AU Chanes, L
Barrett, LF
AF Chanes, Lorena
Barrett, Lisa Feldman
TI Redefining the Role of Limbic Areas in Cortical Processing
SO TRENDS IN COGNITIVE SCIENCES
LA English
DT Review
ID SUPERIOR TEMPORAL SULCUS; OLD-WORLD MONKEY; RHESUS-MONKEY; HUMAN BRAIN;
PREFRONTAL CORTEX; CORTICOCORTICAL CONNECTIONS; PIRIFORM CORTEX;
RESTING-STATE; INTEROCEPTIVE INFERENCE; FUNCTIONAL NETWORKS
AB There is increasing evidence that the brain actively constructs action and perception using past experience. In this paper, we propose that the direction of information flow along gradients of laminar differentiation provides important insight on the role of limbic cortices in cortical processing. Cortical limbic areas, with a simple laminar structure (e.g., no or rudimentary layer IV), send 'feedback' projections to lower level better laminated areas. We propose that this 'feedback' functions as predictions that drive processing throughout the cerebral cortex. This hypothesis has the potential to provide a unifying framework for an increasing number of proposals that use predictive coding to explain a myriad of neural processes and disorders, and has important implications for hypotheses about consciousness.
C1 [Chanes, Lorena; Barrett, Lisa Feldman] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA.
[Chanes, Lorena; Barrett, Lisa Feldman] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA.
[Chanes, Lorena; Barrett, Lisa Feldman] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
RP Barrett, LF (reprint author), Northeastern Univ, Dept Psychol, Boston, MA 02115 USA.; Barrett, LF (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA.; Barrett, LF (reprint author), Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
EM l.barrett@neu.edu
FU US National Institute on Aging grant [R01AG030311]; US National
Institute of Child Health and Human Development grant [R21 HD076164]; US
Army Research Institute for the Behavioral and Social Sciences
[W5J9CQ1200049, W5J9CQ1100046]; Fyssen Foundation
FX The authors thank M.A. Garcia-Cabezas for helpful discussions,
thoughtful feedback on earlier versions of this manuscript, and
preparation of Figure I in Box 2. We also thank T. Cleland for guidance
on predictive coding account of olfactory and gustatory systems. This
work was supported by a US National Institute on Aging grant
(R01AG030311), a US National Institute of Child Health and Human
Development grant (R21 HD076164), and contracts from the US Army
Research Institute for the Behavioral and Social Sciences (contracts
W5J9CQ1200049 and W5J9CQ1100046) to L.F.B., as well as a Fyssen
Foundation postdoctoral fellowship to L.C.
NR 112
TC 12
Z9 12
U1 5
U2 9
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1364-6613
J9 TRENDS COGN SCI
JI TRENDS COGN. SCI.
PD FEB
PY 2016
VL 20
IS 2
BP 96
EP 106
DI 10.1016/j.tics.2015.11.005
PG 11
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA DC8MJ
UT WOS:000369473400008
PM 26704857
ER
PT J
AU Mao, Y
Hedgire, SS
Liao, G
Lv, FJ
Li, YM
Li, Q
Wang, ZW
AF Mao, Yun
Hedgire, Sandeep S.
Liao, Gang
Lv, Fajin
Li, Yongmei
Li, Qi
Wang, Ziwei
TI Topographic distribution and characteristics of normal gastric regional
lymph nodes on diffusion-weighted magnetic resonance imaging
SO ACTA RADIOLOGICA
LA English
DT Article
DE Gastric cancer; lymph node; magnetic resonance imaging (MRI);
diffusion-weighted imaging (DWI); apparent diffusion coefficient (ADC)
ID MULTIDETECTOR ROW CT; CERVICAL-CANCER; METASTASES; DISCRIMINATION;
COEFFICIENT; CARCINOMA
AB Background: Current lack of recognition of normal gastric regional lymph nodes (GRLNs) and inherent defect of morphological imaging limit the accuracy of preoperative nodal (N) staging of gastric cancer.
Purpose: To map the distribution of normal GRLNs and evaluating the characteristics of GRLNs with diffusion-weighted imaging (DWI) in healthy population.
Material and Methods: Forty-nine enrolled healthy volunteers were divided into two age groups and underwent conventional magnetic resonance imaging (MRI) and DWI examinations. The characteristics of GRLNs in 14 regional stations, including short axis diameter (SD), short-to-long axis diameter ratio (SLR), signal-to-noise ratio (SNR), contrast- to-noise ratio (CNR), and apparent diffusion coefficient (ADC), were recorded and compared between age groups and among different stations.
Results: The normal GRLNs were mainly distributed in station 7 in both age groups, followed by stations 3, 8, and 9. The SLR was lower in the young group than in the old group (P=0.034) while SD, SNR, CNR, and ADC were significantly higher in the young group compared to the old group, P=0.045, 0.041, 0.037, and 0.042, respectively. SD was different among stations in both age groups (P=0.002, 0.001), especially bigger in station 8, and the SNRs and CNRs of stations 8 and 9 were relatively high in the old group (P=0.031, 0.035), while there was no difference in ADC value.
Conclusion: Better understanding of the appearances of normal GRLNs on conventional MRI and DWI may help to build more appropriate imaging criteria for GRLN assessment in gastric cancer.
C1 [Mao, Yun; Liao, Gang; Lv, Fajin; Li, Yongmei; Li, Qi; Wang, Ziwei] Chongqing Med Univ, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China.
[Hedgire, Sandeep S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Abdominal Imaging & Intervent, Boston, MA USA.
RP Wang, ZW (reprint author), Chongqing Med Univ, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China.
EM maoyun1979@163.com
NR 23
TC 0
Z9 0
U1 2
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0284-1851
EI 1600-0455
J9 ACTA RADIOL
JI Acta Radiol.
PD FEB
PY 2016
VL 57
IS 2
BP 152
EP 161
DI 10.1177/0284185115574736
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DC0LT
UT WOS:000368909500006
PM 25735622
ER
PT J
AU Sidani, JE
Shensa, A
Shiffman, S
Switzer, GE
Primack, BA
AF Sidani, Jaime E.
Shensa, Ariel
Shiffman, Saul
Switzer, Galen E.
Primack, Brian A.
TI Behavioral associations with waterpipe tobacco smoking dependence among
US young adults
SO ADDICTION
LA English
DT Article
DE Addiction; dependence; hookah; measurement; scale; tobacco; waterpipe
ID HOOKAH SMOKING; UNITED-STATES; UNIVERSITY-STUDENTS; CIGARETTE-SMOKING;
NICOTINE EXPOSURE; PUFF TOPOGRAPHY; SMOKERS; PREVALENCE; ATTITUDES;
ADDICTION
AB Background and AimsWaterpipe tobacco smoking (WTS) is increasingly prevalent in the United States, especially among young adults. We aimed to (1) adapt items from established dependence measures into a WTS dependence scale for US young adults (the US Waterpipe Dependence Scale), (2) determine the factor structure of the items and (3) assess associations between scale values and behavioral use characteristics known to be linked to dependence.
DesignCross-sectional survey.
SettingUnited States.
ParticipantsA total of 436 past-year waterpipe tobacco users ages 18-30years selected at random from a national probability-based panel.
MeasurementsParticipants responded to six tobacco dependence items adapted for WTS in US populations. Behavioral use characteristics included factors such as frequency of use and age of initiation.
FindingsPrincipal components analysis yielded an unambiguous one-factor solution. Approximately half (52.9%) of past-year waterpipe tobacco users received a score of 0, indicating that none of the six WTS dependence items were endorsed. Approximately one-quarter (25.4%) endorsed one dependence item and 22.7% endorsed two or more items. Higher WTS dependence scores were associated significantly with all five behavioral use characteristics. For example, compared with those who endorsed no dependence items, those who endorsed two or more had an adjusted odds ratio (AOR) of 3.90 [95% confidence interval (CI)=1.56-9.78] for having had earlier age of initiation and an AOR of 32.75 (95% CI=9.76-109.86) for more frequent WTS sessions.
ConclusionsScores on a six-item waterpipe tobacco smoking dependence scale (the US Waterpipe Dependence Scale) correlate with measures that would be expected to be related to dependence, such as amount used and age of initiation.
C1 [Sidani, Jaime E.; Shensa, Ariel; Primack, Brian A.] Univ Pittsburgh, Sch Med, Dept Med, UPMCMontefiore Hosp,Div Gen Internal Med, Pittsburgh, PA 15213 USA.
[Sidani, Jaime E.; Shensa, Ariel; Primack, Brian A.] Univ Pittsburgh, Ctr Res Media Technol & Hlth, Pittsburgh, PA USA.
[Shiffman, Saul] Pinney Associates, Pittsburgh, PA USA.
[Switzer, Galen E.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Switzer, Galen E.] Univ Pittsburgh, Dept Psychiat Med, Pittsburgh, PA USA.
[Switzer, Galen E.] Univ Pittsburgh, Dept Clin, Pittsburgh, PA USA.
[Switzer, Galen E.] Univ Pittsburgh, Dept Translat Sci, Pittsburgh, PA USA.
[Primack, Brian A.] Univ Pittsburgh, Dept Pediat, Sch Med, Div Adolescent Med, 3420 Fifth Ave, Pittsburgh, PA 15260 USA.
RP Sidani, JE (reprint author), Ctr Res Media Technol & Hlth, 230 McKee Pl Suite 600, Pittsburgh, PA 15213 USA.
EM sidanije@upmc.edu
FU National Cancer Institute at the National Institutes of Health
[R01-CA140150]; Steven Manners Memorial Fund at the University of
Pittsburgh Center for Social and Urban Research
FX This work was supported by the National Cancer Institute at the National
Institutes of Health (R01-CA140150) and the Steven Manners Memorial Fund
at the University of Pittsburgh Center for Social and Urban Research,
both awarded to B.A.P. The funding agencies had no role in the design
and conduct of the study; collection, management, analysis and
interpretation of the data; and preparation, review or approval of the
manuscript.
NR 44
TC 3
Z9 3
U1 1
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
PD FEB
PY 2016
VL 111
IS 2
BP 351
EP 359
DI 10.1111/add.13163
PG 9
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA DC0XE
UT WOS:000368940500020
PM 26417942
ER
PT J
AU Pursnani, A
Celeng, C
Schlett, CL
Maythofer, T
Zakroysky, P
Lee, H
Ferencik, M
Fleg, JL
Bamberg, F
Wiviott, SD
Truong, QA
Udelson, JE
Nagurney, JT
Hoffmann, U
AF Pursnani, Amit
Celeng, Csilla
Schlett, Christopher L.
Maythofer, Thomas
Zakroysky, Pearl
Lee, Hang
Ferencik, Maros
Fleg, Jerome L.
Bamberg, Fabian
Wiviott, Stephen D.
Truong, Quynh A.
Udelson, James E.
Nagurney, John T.
Hoffmann, Udo
TI Use of Coronary Computed Tomographic Angiography Findings to Modify
Statin and Aspirin Prescription in Patients With Acute Chest Pain
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID INTERNATIONAL MULTICENTER REGISTRY; ARTERY-DISEASE; PROGNOSTIC VALUE; CT
ANGIOGRAPHY; EMERGENCY-DEPARTMENT; SYMPTOMATIC PATIENTS;
CLINICAL-OUTCOMES; RISK-FACTORS; ATHEROSCLEROSIS; METAANALYSIS
AB Coronary CT angiography (CCTA) is used in patients with low-intermediate chest pain presenting to the emergency department for its reliability in excluding acute coronary syndrome (ACS). However, its influence on medication modification in this setting is unclear. We sought to determine whether knowledge of CCTA-based coronary artery disease (CAD) was associated with change in statin and aspirin prescription. We used the CCTA arm of the Rule Out Myocardial Infarction using Computed Angiographic Tomography II multicenter, randomized control trial (R-II) and comparison cohort from the observational Rule Out Myocardial Infarction using Computed Angiographic Tomography I cohort (R-I). In R-II, subjects were randomly assigned to CCTA to guide decision making, whereas in R-I patients underwent CCTA with results blinded to caregivers and managed according to standard care. Our final cohort consisted of 277 subjects from R-I and 370 from R-II. ACS rate was similar (6.9% vs 6.2% respectively, p = 0.75). For subjects with CCTA-detected obstructive CAD without ACS, initiation of statin was significantly greater after disclosure of CCTA results (0% in R-I vs 20% in R-II, p = 0.009). Conversely, for subjects without CCTA-detected. CAD, aspirin prescription was lower with disclosure of CCTA results (16% in R-I vs 4.8% in R-II, p = 0.001). However, only 68% of subjects in R-II with obstructive CAD were discharged on statin and 65% on aspirin. In conclusion, physician knowledge of CCTA results leads to improved alignment of aspirin and statin with the presence and severity of CAD although still many patients with CCTA-detected CAD are not discharged on aspirin or statin. Our findings suggest opportunity for practice improvement when CCTA is performed in the emergency department. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Pursnani, Amit; Celeng, Csilla; Maythofer, Thomas; Ferencik, Maros; Truong, Quynh A.; Hoffmann, Udo] Harvard Univ, Sch Med, Dept Radiol, Div Cardiol,Cardiac Magnet Resonance Positron Emi, Boston, MA 02115 USA.
[Nagurney, John T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Emergency Med, Boston, MA USA.
[Schlett, Christopher L.] Univ Heidelberg Hosp, Dept Diagnost & Intervent Radiol, Heidelberg, Germany.
[Zakroysky, Pearl; Lee, Hang] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Biostat Ctr, Boston, MA USA.
[Fleg, Jerome L.] NHLBI, Div Cardiovasc Sci, Bldg 10, Bethesda, MD 20892 USA.
[Bamberg, Fabian] Univ Munich, Klinikum Grosshadern, Dept Clin Radiol, D-80539 Munich, Germany.
[Wiviott, Stephen D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA.
[Udelson, James E.] Tufts Med Ctr, Div Cardiol, Boston, MA USA.
[Udelson, James E.] Tufts Med Ctr, Ctr Cardiovasc, Boston, MA USA.
RP Pursnani, A (reprint author), Harvard Univ, Sch Med, Dept Radiol, Div Cardiol,Cardiac Magnet Resonance Positron Emi, Boston, MA 02115 USA.
EM amit.pursnani@gmail.com
FU National Institutes of Health/ National Heart Lung Blood Institute
(Bethesda, Maryland) [U01HL092040, U01HL092022, 5K24HL113128]
FX The study was supported by the grants U01HL092040, U01HL092022 and
5K24HL113128 from National Institutes of Health/ National Heart Lung
Blood Institute (Bethesda, Maryland).
NR 16
TC 2
Z9 2
U1 2
U2 5
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD FEB 1
PY 2016
VL 117
IS 3
BP 319
EP 324
DI 10.1016/j.amjcard.2015.10.052
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DC4ME
UT WOS:000369194200001
PM 26762723
ER
PT J
AU Gao, L
Lee, S
Kim, CJ
Minami, Y
Ong, DS
Soeda, T
Lowe, H
Choi, SY
Lerman, A
Lee, J
Lee, H
Uemura, S
Yu, B
Jang, IK
AF Gao, Lei
Lee, Stephen
Kim, Chong-Jin
Minami, Yoshiyasu
Ong, Daniel S.
Soeda, Tsunenari
Lowe, Harry
Choi, So-Yeon
Lerman, Amir
Lee, Jay
Lee, Hang
Uemura, Shim
Yu, Bo
Jang, Ik-Kyung
TI Incidence and Morphological Predictors of Intrastent Coronary Thrombus
After Drug-Eluting Stent Implantation (from a Multicenter Registry)
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; BARE-METAL STENTS; SIROLIMUS; MECHANISMS;
PATHOLOGY; HUMANS
AB The mechanisms responsible for late and very late stent thrombosis remain incompletely understood. This study aimed to evaluate the incidence and morphologic predictors of intrastent thrombus in patients after drug-eluting stent (DES) implantation using optical coherence tomography (OCT). A total of 208 patients with 262 DES who underwent follow-up OCT examination >6 months after DES implantation were included. The detailed vascular morphology including characteristics of neointima was analyzed. Thrombus was identified in 24 patients (11.5%) 11 months after DES implantation. Minimal lumen cross-sectional area was significantly smaller in the thrombus group than in the nonthrombus group (2.9 +/- 1.7 vs 4.6 +/- 2.0 mm(2); p <0.001). No difference was found in the frequency of uncovered or malapposed struts between the 2 groups. Thin-cap fibroatheroma (20.6% vs 0.1%; p <0.001) and heterogeneous neointima (22.2% vs 9.0%; p = 0.001) were more frequently detected in the thrombus group compared to the nonthrombus group. Second-generation DES showed lower incidence of thrombus, uncovered struts, and extrastent lumen compared with first-generation DES. In conclusion, the present OCT study revealed that smaller lumen cross-sectional area and neointimal morphology are important factors associated with intrastent "thrombus. Second-generation DES demonstrated improved arterial healing and a lower incidence of intrastent thrombus compared with first-generation DES. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Gao, Lei; Minami, Yoshiyasu; Ong, Daniel S.; Lee, Jay; Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Lee, Hang] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Biostat Ctr, Boston, MA USA.
[Lee, Stephen] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.
[Jang, Ik-Kyung] Kyung Hee Univ, Div Cardiol, Seoul, South Korea.
[Soeda, Tsunenari] Nara Med Univ, Dept Med 1, Nara, Japan.
[Lowe, Harry] Concord Repatriat Gen Hosp, Dept Cardiol, Sydney, NSW, Australia.
[Choi, So-Yeon] Ajou Univ Hosp, Dept Cardiol, Suwon, South Korea.
[Lerman, Amir] Mayo Coll Med, Div Cardiovasc Dis, Rochester, MN USA.
[Lerman, Amir] Mayo Coll Med, Dept Internal Med, Rochester, MN USA.
[Uemura, Shim] Kawasaki Med Univ, Cardiovasc Med Dept, Kurashiki, Okayama, Japan.
[Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Key Lab Myocardial Ischemia,Chinese Minist Educ, Harbin, Peoples R China.
RP Jang, IK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.; Jang, IK (reprint author), Kyung Hee Univ, Div Cardiol, Seoul, South Korea.; Yu, B (reprint author), Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Key Lab Myocardial Ischemia,Chinese Minist Educ, Harbin, Peoples R China.
EM yubodr@163.com; IJANG@mgh.harvard.edu
FU Boston Scientific Corp.; Medtronic; St. Jude Medical
FX Dr. Jang reports receiving a research grant and honorarium from St. Jude
Medical and research grant from Boston Scientific Corp. and Medtronic.
NR 22
TC 1
Z9 1
U1 2
U2 2
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD FEB 1
PY 2016
VL 117
IS 3
BP 369
EP 375
DI 10.1016/j.amjcard.2015.10.055
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DC4ME
UT WOS:000369194200009
PM 26705880
ER
PT J
AU Akabane, H
Sullivan, RJ
AF Akabane, Hugo
Sullivan, Ryan J.
TI The Future of Molecular Analysis in Melanoma: Diagnostics to Direct
Molecularly Targeted Therapy
SO AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
LA English
DT Article
ID BRAF V600E MUTATION; POLYMERASE-CHAIN-REACTION; BREAST-TUMOR CELLS;
METASTATIC MELANOMA; UVEAL MELANOMA; MEK INHIBITION;
ACQUIRED-RESISTANCE; CUTANEOUS MELANOMA; MALIGNANT-MELANOMA;
PERIPHERAL-BLOOD
AB Melanoma is a malignancy of pigment-producing cells that is driven by a variety of genetic mutations and aberrations. In most cases, this leads to upregulation of the mitogen-activated protein kinase (MAPK) pathway through activating mutations of upstream mediators of the pathway including BRAF and NRAS. With the advent of effective MAPK pathway inhibitors, including the US FDA-approved BRAF inhibitors vemurafenib and dabrafenib and MEK inhibitor trametinib, molecular analysis has become an integral part of the care of patients with metastatic melanoma. In this article, the key molecular targets and strategies to inhibit these targets therapeutically are presented, and the techniques of identifying these targets, in both tissue and blood, are discussed.
C1 [Akabane, Hugo] Metrowest Med Ctr, Dept Med, Framingham, MA USA.
[Sullivan, Ryan J.] Massachusetts Gen Hosp, Ctr Canc, Ctr Melanoma, 55 Fruit St, Boston, MA 02114 USA.
RP Sullivan, RJ (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Melanoma, 55 Fruit St, Boston, MA 02114 USA.
EM rsullivan7@mgh.harvard.edu
NR 106
TC 1
Z9 1
U1 0
U2 6
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1175-0561
EI 1179-1888
J9 AM J CLIN DERMATOL
JI Am. J. Clin. Dermatol.
PD FEB
PY 2016
VL 17
IS 1
BP 1
EP 10
DI 10.1007/s40257-015-0159-z
PG 10
WC Dermatology
SC Dermatology
GA DC1PJ
UT WOS:000368988100001
PM 26518880
ER
PT J
AU Shenoy, ES
Lee, H
Cotter, JA
Ware, W
Kelbaugh, D
Weil, E
Walensky, RP
Hooper, DC
AF Shenoy, Erica S.
Lee, Hang
Cotter, Jessica A.
Ware, Winston
Kelbaugh, Douglas
Weil, Eric
Walensky, Rochelle P.
Hooper, David C.
TI Impact of rapid screening for discontinuation of methicillin-resistant
Staphylococcus aureus contact precautions
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE Contact precautions; Costs; Implementation; MRSA
ID HEALTH-CARE SETTINGS; XPERT MRSA ASSAY; HOSPITAL DISCHARGE;
UNITED-STATES; COLONIZATION; CARRIAGE; DURATION; INFECTIONS; PREVALENCE;
DEPRESSION
AB Background: A history of methicillin-resistant Staphylococcus aureus (MRSA) is a determinant of inpatient bed assignment.
Methods: We assessed outcomes associated with rapid testing and discontinuation of MRSA contact precautions (CP) in a prospective cohort study of polymerase chain reaction (PCR)-based screening in the Emergency Department (ED) of Massachusetts General Hospital. Eligible patients had a history of MRSA and were assessed and enrolled if documented off antibiotics with activity against MRSA and screened for nasal colonization (subject visit). PCR-negative subjects had CP discontinued; the primary outcome was CP discontinuation. We identified semiprivate rooms in which a bed was vacant owing to the CP status of the study subject, calculated the hours of vacancy, and compared idle bed-hours by PCR results. Program costs were compared with predicted revenue.
Results: There were 2864 eligible patients, and 648 (22.6%) subject visits were enrolled. Of these, 65.1% (422/648) were PCR-negative and had CP discontinued. PCR-negative subjects had fewer idle bed-hours compared with PCR-positive subjects (28.6 +/- 25.2 vs 75.3 +/- 70.5; P <. 001). The expected revenues from occupied idle beds and averted CP costs ranged from $214,160 to $268,340, and exceeded the program costs.
Conclusion: A program of targeted PCR-based screening for clearance of MRSA colonization resulted in expected revenues and decreased CP costs that outweighed programmatic costs. Copyright (c) 2016 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Shenoy, Erica S.; Walensky, Rochelle P.; Hooper, David C.] Harvard Univ, Sch Med, Boston, MA USA.
[Shenoy, Erica S.; Walensky, Rochelle P.; Hooper, David C.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
[Shenoy, Erica S.; Cotter, Jessica A.; Hooper, David C.] Massachusetts Gen Hosp, Infect Control Unit, 55 Fruit St,Bulfinch 334, Boston, MA 02114 USA.
[Shenoy, Erica S.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA.
[Lee, Hang] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA.
[Ware, Winston] Massachusetts Gen Hosp, Clin Care Management Unit, Boston, MA 02114 USA.
[Kelbaugh, Douglas] Massachusetts Gen Hosp, Partners Informat Syst, Boston, MA 02114 USA.
[Kelbaugh, Douglas; Weil, Eric] Massachusetts Gen Phys Org, Boston, MA USA.
[Weil, Eric; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA.
RP Shenoy, ES; Hooper, DC (reprint author), Massachusetts Gen Hosp, Infect Control Unit, 55 Fruit St,Bulfinch 334, Boston, MA 02114 USA.; Hooper, DC (reprint author), Massachusetts Gen Hosp, 55 Fruit St,GRJ 504, Boston, MA 02114 USA.
EM eshenoy@partners.org; dhooper@mgh.harvard.edu
FU National Center for Research Resources [KL2 RR025757-03]; Harvard
Catalyst \ The Harvard Clinical and Translational Science Center
[UL1TR001102]; National Center for Research Resources; National Center
for Advancing Translational Sciences, National Institutes of Health;
Harvard University and its affiliated academic healthcare centers;
National Institute of Allergy and Infectious Diseases, National
Institutes of Health [K01AI110524]; Center for Integration of Medicine
and Innovative Technology CIMIT under U.S. Army Medical Research
Acquisition Activity CoopsAgreement (CIMIT) [12-1082]; Departmental
Funds from the MGH Infection Control Unit
FX This work was supported by KL2 RR025757-03 (National Center for Research
Resources), UL1TR001102 (Harvard Catalyst vertical bar The Harvard
Clinical and Translational Science Center; National Center for Research
Resources and the National Center for Advancing Translational Sciences,
National Institutes of Health; with financial contributions from Harvard
University and its affiliated academic healthcare centers), K01AI110524
(National Institute of Allergy and Infectious Diseases, National
Institutes of Health), Center for Integration of Medicine and Innovative
Technology CIMIT under U.S. Army Medical Research Acquisition Activity
CoopsAgreement (CIMIT No. 12-1082), and Departmental Funds from the MGH
Infection Control Unit. The funders did not contribute to the design or
conduct of the study; in the collection, management, analysis or
interpretation of the data; preparation, review, or approval of the
manuscript; or the decision to submit the manuscript for publication.
The content of the manuscript is solely the responsibility of the
authors and does not necessarily represent the official views of any
funders.
NR 25
TC 1
Z9 1
U1 2
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
EI 1527-3296
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD FEB 1
PY 2016
VL 44
IS 2
BP 215
EP 221
DI 10.1016/j.ajic.2015.08.019
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DB8NF
UT WOS:000368772700019
PM 26440593
ER
PT J
AU Al-Maawali, A
Barry, BJ
Rajab, A
El-Quessny, M
Seman, A
Coury, SN
Barkovich, AJ
Yang, E
Walsh, CA
Mochida, GH
Stoler, JM
AF Al-Maawali, Almundher
Barry, Brenda J.
Rajab, Anna
El-Quessny, Malak
Seman, Ann
Coury, Stephanie Newton
Barkovich, A. James
Yang, Edward
Walsh, Christopher A.
Mochida, Ganeshwaran H.
Stoler, Joan M.
TI Novel loss-of-function variants in DIAPH1 associated with syndromic
microcephaly, blindness, and early onset seizures
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE DIAPH1; microcephaly; blindness; seizures; intellectual disability;
deafness
ID MIGRATION; MUTATION
AB Exome sequencing identified homozygous loss-of-function variants in DIAPH1 (c.2769delT; p.F923fs and c.3145C>T; p.R1049X) in four affected individuals from two unrelated consanguineous families. The affected individuals in our report were diagnosed with postnatal microcephaly, early-onset epilepsy, severe vision impairment, and pulmonary symptoms including bronchiectasis and recurrent respiratory infections. A heterozygous DIAPH1 mutation was originally reported in one family with autosomal dominant deafness. Recently, however, a homozygous nonsense DIAPH1 mutation (c.2332C4T; p.Q778X) was reported in five siblings in a single family affected by microcephaly, blindness, early onset seizures, developmental delay, and bronchiectasis. The role of DIAPH1 was supported using parametric linkage analysis, RNA and protein studies in their patients' cell lines and further studies in human neural progenitors cells and a diap1 knockout mouse. In this report, the proband was initially brought to medical attention for profound metopic synostosis. Additional concerns arose when his head circumference did not increase after surgical release at 5 months of age and he was diagnosed with microcephaly and epilepsy at 6 months of age. Clinical exome analysis identified a homozygous DIAPH1 mutation. Another homozygous DIAPH1 mutation was identified in the research exome analysis of a second family with three siblings presenting with a similar phenotype. Importantly, no hearing impairment is reported in the homozygous affected individuals or in the heterozygous carrier parents in any of the families demonstrating the autosomal recessive microcephaly phenotype. These additional families provide further evidence of the likely causal relationship between DIAPH1 mutations and a neurodevelopmental disorder. (c) 2015 Wiley Periodicals, Inc.
C1 [Al-Maawali, Almundher; Barry, Brenda J.; El-Quessny, Malak; Seman, Ann; Coury, Stephanie Newton; Walsh, Christopher A.; Mochida, Ganeshwaran H.; Stoler, Joan M.] Boston Childrens Hosp, Div Genet & Genom, Dept Med, 300 Longwood Ave,Hunnewell 536, Boston, MA 02115 USA.
[Al-Maawali, Almundher; Barry, Brenda J.; El-Quessny, Malak; Walsh, Christopher A.; Mochida, Ganeshwaran H.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA.
[Al-Maawali, Almundher; Barry, Brenda J.; Walsh, Christopher A.] Boston Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Al-Maawali, Almundher] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Genet, Muscat, Oman.
[Rajab, Anna] Minist Hlth, Directorate Gen Hlth Affairs, Natl Genet Ctr, Muscat, Oman.
[Barkovich, A. James] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Yang, Edward] Boston Childrens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Yang, Edward] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Walsh, Christopher A.; Mochida, Ganeshwaran H.; Stoler, Joan M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Walsh, Christopher A.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Walsh, Christopher A.] Harvard Univ, Program Biol & Biomed Sci, Sch Med, Boston, MA USA.
[Mochida, Ganeshwaran H.] Massachusetts Gen Hosp, Dept Neurol, Pediat Neurol Unit, Boston, MA 02114 USA.
RP Mochida, GH; Stoler, JM (reprint author), Boston Childrens Hosp, Div Genet & Genom, Dept Med, 300 Longwood Ave,Hunnewell 536, Boston, MA 02115 USA.; Mochida, GH (reprint author), Boston Childrens Hosp, Div Genet & Genom, Dept Med, 300 Longwood Ave,CLS 15070-1,Mail Stop BCH3150, Boston, MA 02115 USA.
EM Ganesh.Mochida@childrens.harvard.edu; Joan.Stoler@childrens.harvard.edu
FU NINDS [R01 NS 35129]
FX Grant sponsor: NINDS; Grant number: R01 NS 35129.
NR 7
TC 2
Z9 3
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD FEB
PY 2016
VL 170
IS 2
BP 435
EP 440
DI 10.1002/ajmg.a.37422
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA DB9BR
UT WOS:000368811500019
PM 26463574
ER
PT J
AU Hirsch, JA
Harvey, HB
Barr, RM
Donovan, WD
Duszak, R
Nicola, GN
Schaefer, PW
Manchikanti, L
AF Hirsch, J. A.
Harvey, H. B.
Barr, R. M.
Donovan, W. D.
Duszak, R., Jr.
Nicola, G. N.
Schaefer, P. W.
Manchikanti, L.
TI Sustainable Growth Rate Repealed, MACRA Revealed: Historical Context and
Analysis of Recent Changes in Medicare Physician Payment Methodologies
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article
ID HEALTH-CARE; NEUROINTERVENTIONALISTS; PRIMER
C1 [Hirsch, J. A.; Harvey, H. B.; Schaefer, P. W.] Massachusetts Gen Hosp, Dept Radiol, 175 Cambridge St,Suite 200, Boston, MA 02114 USA.
[Hirsch, J. A.; Harvey, H. B.; Schaefer, P. W.] Harvard Univ, Sch Med, Boston, MA USA.
[Barr, R. M.] Mecklenburg Radiol Associates PA, Charlotte, NC USA.
[Donovan, W. D.] Norwich Diagnost Imaging Associates, Norwich, CT USA.
[Duszak, R., Jr.] Emory Univ, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA.
[Duszak, R., Jr.] Harvey L Neiman Hlth Policy Inst, Reston, VA USA.
[Nicola, G. N.] Hackensack Univ Med Ctr, Hackensack, NJ USA.
[Manchikanti, L.] Pain Management Ctr Paducah, Paducah, KY USA.
[Manchikanti, L.] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40292 USA.
RP Harvey, HB (reprint author), Massachusetts Gen Hosp, Dept Radiol, 175 Cambridge St,Suite 200, Boston, MA 02114 USA.; Harvey, HB (reprint author), Harvard Univ, Sch Med, Boston, MA USA.
EM hbharvey@partners.org
RI Duszak, Richard/L-1811-2016
OI Duszak, Richard/0000-0003-0425-3008
NR 20
TC 8
Z9 8
U1 4
U2 7
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD FEB
PY 2016
VL 37
IS 2
BP 210
EP 214
DI 10.3174/ajnr.A4522
PG 5
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA DC3HU
UT WOS:000369111200010
PM 26585253
ER
PT J
AU Heit, JJ
Pastena, GT
Nogueira, RG
Yoo, AJ
Leslie-Mazwi, TM
Hirsch, JA
Rabinov, JD
AF Heit, J. J.
Pastena, G. T.
Nogueira, R. G.
Yoo, A. J.
Leslie-Mazwi, T. M.
Hirsch, J. A.
Rabinov, J. D.
TI Cerebral Angiography for Evaluation of Patients with CT
Angiogram-Negative Subarachnoid Hemorrhage: An 11-Year Experience
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article
ID DIGITAL-SUBTRACTION-ANGIOGRAPHY; 3D ROTATIONAL ANGIOGRAPHY; INTRACRANIAL
ANEURYSMS; CATHETER ANGIOGRAPHY; COMPUTED-TOMOGRAPHY;
REPEAT-ANGIOGRAPHY; INITIAL ANGIOGRAPHY; DIAGNOSTIC YIELD; MANAGEMENT;
ETIOLOGY
AB BACKGROUND AND PURPOSE: CT angiography is increasingly used to evaluate patients with nontraumatic subarachnoid hemorrhage given its high sensitivity for aneurysms. We investigated the yield of digital subtraction angiography among patients with SAH or intraventricular hemorrhage and a negative CTA.
MATERIALS AND METHODS: An 11-year, single-center retrospective review of all consecutive patients with CTA-negative SAH was performed. Noncontrast head CT, CTA, DSA, and MR imaging studies were reviewed by 2 experienced interventional neuroradiologists and 1 neuroradiologist.
RESULTS: Two hundred thirty patients (mean age, 54 years; 51% male) with CTA-negative SAH were identified. The pattern of SAH was diffuse (40%), perimesencephalic (31%), sulcal (31%), isolated IVH (6%), or identified by xanthochromia (7%). Initial DSA yield was 13%, including vasculitis/vasculopathy (7%), aneurysm (5%), arteriovenous malformation (0.5%), and dural arteriovenous fistula (0.5%). An additional 6 aneurysms/pseudoaneurysms (4%) were identified by follow-up DSA, and a single cavernous malformation (0.4%) was identified by MRI. No cause of hemorrhage was identified in any patient presenting with isolated intraventricular hemorrhage or xanthochromia. Diffuse SAH was due to aneurysm rupture (17%); perimesencephalic SAH was due to aneurysm rupture (3%) or vasculitis/vasculopathy (1.5%); and sulcal SAH was due to vasculitis/vasculopathy (32%), arteriovenous malformation (3%), or dural arteriovenous fistula (3%).
CONCLUSIONS: DSA identifies vascular pathology in 13% of patients with CTA-negative SAH. Aneurysms or pseudoaneurysms are identified in an additional 4% of patients by repeat DSA following an initially negative DSA. All patients with CT-negative SAH should be considered for DSA. The pattern of SAH may suggest the cause of hemorrhage, and aneurysms should specifically be sought with diffuse or perimesencephalic SAH.
C1 [Heit, J. J.] Stanford Univ Hosp, Dept Radiol, Intervent Neuroradiol Div, Stanford, CA 94305 USA.
[Pastena, G. T.] Albany Med Ctr, Dept Radiol, Albany, NY USA.
[Nogueira, R. G.] Emory Univ, Dept Neurol, Sch Med, Marcus Stroke & Neurosci Ctr, Atlanta, GA 30322 USA.
[Nogueira, R. G.] Emory Univ, Dept Neurosurg, Sch Med, Marcus Stroke & Neurosci Ctr, Atlanta, GA 30322 USA.
[Nogueira, R. G.] Emory Univ, Dept Radiol, Sch Med, Marcus Stroke & Neurosci Ctr, Atlanta, GA 30322 USA.
[Leslie-Mazwi, T. M.; Hirsch, J. A.; Rabinov, J. D.] Massachusetts Gen Hosp, Dept Neuroradiol & Intervent Neuroradiol, Boston, MA 02114 USA.
[Yoo, A. J.] Texas Stroke Inst, Plano, TX USA.
RP Rabinov, JD (reprint author), Massachusetts Gen Hosp, Intervent Neuroradiol, Gray 241,55 Fruit St, Boston, MA 02114 USA.
EM jrabinov@partners.org
NR 42
TC 3
Z9 3
U1 2
U2 4
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD FEB
PY 2016
VL 37
IS 2
BP 297
EP 304
DI 10.3174/ajnr.A4503
PG 8
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA DC3HU
UT WOS:000369111200025
PM 26338924
ER
PT J
AU Murphy, K
Oaklander, AL
Elias, G
Kathuria, S
Long, DM
AF Murphy, K.
Oaklander, A. L.
Elias, G.
Kathuria, S.
Long, D. M.
TI Treatment of 213 Patients with Symptomatic Tarlov Cysts by CT-Guided
Percutaneous Injection of Fibrin Sealant
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article
ID NERVE-ROOT CYSTS; SACRAL PERINEURIAL CYSTS; TECHNICAL CASE-REPORT;
MENINGEAL CYSTS; CLINICAL-SIGNIFICANCE; MICROSURGICAL TREATMENT;
CEREBROSPINAL-FLUID; GLUE THERAPY; PATHOGENESIS; SPINE
AB This cohort study assesses outcomes in patients who underwent CT-guided aspiration and injection of sacral Tarlov cysts at Johns Hopkins Hospital from 2003-2013. A total of 289 cysts were treated in 213 consecutive patients, with 83% followed for 3-6 years. One year postprocedure, excellent results were obtained in 104 patients (54.2% of patients followed), and good or satisfactory results were obtained in 53 patients (27.6%).
BACKGROUND AND PURPOSE: There has been a steady progression of case reports and a small surgical series that report successful surgical treatment of Tarlov cysts with concomitant relief of patients' symptoms and improvement in their neurological dysfunction, yet patients are still told that these lesions are asymptomatic by physicians. The purpose of this study was to analyze the efficacy and safety of intervention in 213 consecutive patients with symptomatic Tarlov cysts treated by CT-guided 2-needle cyst aspiration and fibrin sealing.
MATERIALS AND METHODS: This study was designed to assess outcomes in patients who underwent CT-guided aspiration and injection of 1 sacral Tarlov cyst at Johns Hopkins Hospital between 2003 and 2013. In all, 289 cysts were treated in 213 consecutive patients. All these patients were followed for at least 6 months, 90% were followed for 1 year, and 83% were followed for 3-6 years. The aspiration-injection procedure used 2 needles and was performed with the patients under local anesthesia and intravenous anesthesia. In the fibrin-injection stage of the procedure, a commercially available fibrin sealant was injected into the cyst through the deep needle (Tisseel VH).
RESULTS: One year postprocedure, excellent results were obtained in 104 patients (54.2% of patients followed), and good or satisfactory results were obtained in 53 patients (27.6%). Thus, 157 patients (81.8%) in all were initially satisfied with the outcome of treatment. At 3-6 years postprocedure, 74.0% of patients followed were satisfied with treatment. There were no clinically significant complications.
CONCLUSIONS: The aspiration-injection technique described herein constitutes a safe and efficacious treatment option that holds promise for relieving cyst-related symptoms in many patients with very little risk.
C1 [Murphy, K.; Elias, G.] Univ Toronto, Dept Radiol, Toronto, ON M5S 1A1, Canada.
[Oaklander, A. L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA.
[Oaklander, A. L.] Harvard Univ, Massachusetts Gen Hosp, Dept Pathol Neuropathol, Sch Med, Boston, MA USA.
[Kathuria, S.] Johns Hopkins Univ Hosp, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA.
[Long, D. M.] Neurosci Consults, Lutherville Timonium, MD USA.
RP Murphy, K (reprint author), Toronto Western Hosp, Dept Radiol, Room 3 Mc 424,399 Bathurst St, Toronto, ON M5T 2S8, Canada.
EM Kieran.murphy@uhn.ca
FU US Public Health Service (NIH) [K24NS9892]
FX This work was supported in part by research grants from the US Public
Health Service (NIH K24NS9892).
NR 44
TC 3
Z9 3
U1 1
U2 4
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD FEB
PY 2016
VL 37
IS 2
BP 373
EP 379
DI 10.3174/ajnr.A4517
PG 7
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA DC3HU
UT WOS:000369111200037
PM 26405086
ER
PT J
AU Serrano-Pozo, A
Betensky, RA
Frosch, MP
Hyman, BT
AF Serrano-Pozo, Alberto
Betensky, Rebecca A.
Frosch, Matthew P.
Hyman, Bradley T.
TI Plaque-Associated Local Toxicity Increases over the Clinical Course of
Alzheimer Disease
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID A-BETA PLAQUES; AMYLOID-BETA; MOUSE MODEL; APOLIPOPROTEIN-E;
NEUROFIBRILLARY TANGLES; NATIONAL INSTITUTE; APOE GENOTYPE;
NEUROPATHOLOGIC ASSESSMENT; COGNITIVE IMPAIRMENT; NEURITE TRAJECTORIES
AB Amyloid (senile) plaques, one of the two pathologic hallmarks of Alzheimer disease (AD), are associated with dystrophic neurites and gial responses, both astrocytic and microglial.;Although plaque burden remains relatively stable through the clinical course of AD, whether these features of local plaque toxicity continue to worsen over the course of the disease is unclear. We performed an unbiased plaque-centered quantification of SMI312(+) dystrophic neurites, GFAP(+) reactive astrocytes, and IBA1(+) and CD68(+) activated microglia in randomly selected dense-core (Thioflavin-S+) plaques from the temporal neocortex of 40 AD subjects with a symptom duration ranging from 4 to 20 years, and nine nondemented control subjects with dense-core plaques. Dystrophic neurites (Kendall tau = 0.34, P = 0.001), reactive astrocytes (Kendall tau = 0.30, P = 0.003), and CD68(+) (Kendall tau = 0.48, P < 0.0001), but not IBA1 microglia (Kendall tau = 0.045, P = 0.655), exhibited a significant positive correlation with symptom duration. When excluding control subjects, only the positive association between CD68+ microglia and symptom duration remained significant (Kendall tau = 0.39, P = 0.0003). The presence of the APOE epsilon 4 allele did not affect these results. We conclude that plaques exert an increasing toxicity in the surrounding neuropil over the clinical course of AD, thereby potentially contributing to cognitive decline.
C1 [Serrano-Pozo, Alberto; Betensky, Rebecca A.; Frosch, Matthew P.; Hyman, Bradley T.] Massachusetts Gen Hosp, Massachusetts Alzheimer Dis Res Ctr, Charlestown, MA USA.
[Serrano-Pozo, Alberto; Hyman, Bradley T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Betensky, Rebecca A.] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA.
[Frosch, Matthew P.] Massachusetts Gen Hosp, CS Kubik Lab Neuropathol, Boston, MA 02114 USA.
[Serrano-Pozo, Alberto] Univ Iowa Hosp & Clin, Dept Neurol, Iowa City, IA 52242 USA.
[Betensky, Rebecca A.] Harvard Univ, Dept Biostat, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
RP Hyman, BT (reprint author), Massachusetts Alzheimer Dis Res Ctr, 16th St,Bldg 114, Charlestown, MA 02129 USA.
EM bhyman@mgh.harvard.edu
OI SERRANO-POZO, ALBERTO/0000-0003-0899-7530
FU NIH grant [P50AG05134]; Fondo de Investigaciones Sanitarias-Instituto de
Salud Carlos III of the Spanish former Ministerio de Ciencia e
Innovacion grant [CM06/00161]; Fundacion Alfonso Martin-Escudero
(Madrid, Spain)
FX The Massachusetts Alzheimer Disease Research Center is supported by NIH
grant P50AG05134 (R.A.B., M.P.F., and B.T.H.). A.S.-P. was supported by
nonoverlapping fellowships from the Fondo de Investigaciones
Sanitarias-Instituto de Salud Carlos III of the Spanish former
Ministerio de Ciencia e Innovacion grant CM06/00161 and the Fundacion
Alfonso Martin-Escudero (Madrid, Spain).
NR 74
TC 3
Z9 3
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD FEB
PY 2016
VL 186
IS 2
BP 375
EP 384
DI 10.1016/j.ajpath.2015.10.010
PG 10
WC Pathology
SC Pathology
GA DC1IL
UT WOS:000368969900015
PM 26687817
ER
PT J
AU Dupre, TV
Doll, MA
Shah, PP
Sharp, CN
Kiefer, A
Scherzer, MT
Saurabh, K
Saforo, D
Siow, D
Casson, L
Arteel, GE
Jenson, AB
Megyesi, J
Schnellmann, RG
Beverly, LJ
Siskind, LJ
AF Dupre, Tess V.
Doll, Mark A.
Shah, Parag P.
Sharp, Cierra N.
Kiefer, Alex
Scherzer, Michael T.
Saurabh, Kumar
Saforo, Doug
Siow, Deanna
Casson, Lavona
Arteel, Gavin E.
Jenson, Alfred Bennett
Megyesi, Judit
Schnellmann, Rick G.
Beverly, Levi J.
Siskind, Leah J.
TI Suramin protects from cisplatin-induced acute kidney injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE cisplatin; acute kidney injury; suramin; renoprotective strategies
ID ACUTE-RENAL-FAILURE; EPITHELIAL-CELLS; PROXIMAL TUBULE; ER STRESS;
NEPHROTOXICITY; RECEPTORS; APOPTOSIS; FIBROSIS; LIVER; MICE
AB Cisplatin, a commonly used cancer chemotherapeutic, has a dose-limiting side effect of nephrotoxicity. Approximately 30% of patients administered cisplatin suffer from kidney injury, and there are limited treatment options for the treatment of cisplatin-induced kidney injury. Suramin, which is Federal Drug Administration-approved for the treatment of trypanosomiasis, improves kidney function after various forms of kidney injury in rodent models. We hypothesized that suramin would attenuate cisplatin-induced kidney injury. Suramin treatment before cisplatin administration reduced cisplatin-induced decreases in kidney function and injury. Furthermore, suramin attenuated cisplatin-induced expression of inflammatory cytokines and chemokines, endoplasmic reticulum stress, and apoptosis in the kidney cortex. Treatment of mice with suramin 24 h after cisplatin also improved kidney function, suggesting that the mechanism of protection is not by inhibition of tubular cisplatin uptake or its metabolism to nephrotoxic species. If suramin is to be used in the context of cancer, then it cannot prevent cisplatin-induced cytotoxicity of cancer cells. Suramin did not alter the dose-response curve of cisplatin in lung adenocarcinoma cells in vitro. In addition, suramin pretreatment of mice harboring lung adenocarcinomas did not alter the initial cytotoxic effects of cisplatin (DNA damage and apoptosis) on tumor cells. These results provide evidence that suramin has potential as a renoprotective agent for the treatment/prevention of cisplatin-induced acute kidney injury and justify future long-term preclinical studies using cotreatment of suramin and cisplatin in mouse models of cancer.
C1 [Dupre, Tess V.; Doll, Mark A.; Sharp, Cierra N.; Saforo, Doug; Siow, Deanna; Arteel, Gavin E.; Beverly, Levi J.; Siskind, Leah J.] Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA.
[Shah, Parag P.; Kiefer, Alex; Scherzer, Michael T.; Saurabh, Kumar; Casson, Lavona; Beverly, Levi J.] Univ Louisville, Dept Med, Louisville, KY 40292 USA.
[Jenson, Alfred Bennett; Beverly, Levi J.; Siskind, Leah J.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA.
[Megyesi, Judit] Univ Arkansas Med Sci, Dept Internal Med, Div Nephrol, Little Rock, AR 72205 USA.
[Megyesi, Judit] Cent Arkansas & Vet Healthcare Syst, Little Rock, AR USA.
[Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
[Schnellmann, Rick G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Siskind, LJ (reprint author), Univ Louisville, Dept Pharmacol & Toxicol, James Graham Brown Canc Ctr, 505 S Hancock St,CTRB 204, Louisville, KY 40202 USA.
EM leah.siskind@louisville.edu
FU National Institutes of Health (NIH) Grant [R01-DK-093462]; NIH
[R01-GM-084147, UL1-RR-029882]; Small Business Innovation Research/Small
Business Technology Transfer Grant [ES-023767]; Biomedical Laboratory
Research and Development Program of the Department of Veterans Affairs
Grant [1BX000851]; South Carolina Clinical and Translational Research
Institute, with an academic home at the Medical University of South
Carolina
FX This work was supported by National Institutes of Health (NIH) Grant
R01-DK-093462 (to L. J. Siskind). This work was also supported by NIH
Grants R01-GM-084147 (to R. G. Schnellmann), Grant UL1-RR-029882 (to R.
G. Schnellmann), and Small Business Innovation Research/Small Business
Technology Transfer Grant ES-023767 (to R. G. Schnellmann), Biomedical
Laboratory Research and Development Program of the Department of
Veterans Affairs Grant 1BX000851 (to R. G. Schnellmann), and the South
Carolina Clinical and Translational Research Institute, with an academic
home at the Medical University of South Carolina (to R. G. Schnellmann).
NR 46
TC 1
Z9 1
U1 2
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
EI 1522-1466
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD FEB 1
PY 2016
VL 310
IS 3
BP F248
EP F258
DI 10.1152/ajprenal.00433.2015
PG 11
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA DC2TU
UT WOS:000369070400007
PM 26661653
ER
PT J
AU Navarro-Millan, I
Yang, S
DuVall, SL
Chen, L
Baddley, J
Cannon, GW
Delzell, ES
Zhang, J
Safford, MM
Patkar, NM
Mikuls, TR
Singh, JA
Curtis, JR
AF Navarro-Millan, Iris
Yang, Shuo
DuVall, Scott L.
Chen, Lang
Baddley, John
Cannon, Grant W.
Delzell, Elizabeth S.
Zhang, Jie
Safford, Monika M.
Patkar, Nivedita M.
Mikuls, Ted R.
Singh, Jasvinder A.
Curtis, Jeffrey R.
TI Association of hyperlipidaemia, inflammation and serological status and
coronary heart disease among patients with rheumatoid arthritis: data
from the National Veterans Health Administration
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR RISK-FACTORS; C-REACTIVE
PROTEIN; FOLLOW-UP; MORTALITY; POLYARTHRITIS; EVENTS; COHORT;
VALIDATION; DATABASES
AB Objective To examine the association of serum lipids, inflammation and seropositivity on coronary heart disease (CHD) and stroke in patients with rheumatoid arthritis (RA).
Methods The incidence of hospitalised myocardial infarction (MI) or stroke was calculated in a cohort of patients with RA receiving care within the national Veterans Health Administration from 1998 to 2011. Cox proportional hazard models were used to examine the association between these outcomes and low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as time-varying variables, divided into quintiles.
Results There were 37 568 patients with RA in the cohort with mean age of 63 years (SD 12.1); 90% were men. There was a no clear association between LDL-C and CHD/stroke. Compared with lower HDL-C (<34 mg/dL), higher HDL-C (>= 54 mg/dL) was inversely associated with MI (hazard ratio (HR)=0.68, 95% CI 0.55 to 0.85) and stroke (HR=0.69, 95% CI 0.50 to 0.96). Higher CRP >2.17 mg/dL (vs CRP <0.26 mg/dL) was associated with increased risk (HR=2.43, 95% CI 1.77 to 3.33) for MI and 2.02 (95% CI 1.32 to 3.08) for stroke. ESR >47 mm/h compared with <8 mm/h had an HR 1.87 (95% CI 1.39 to 2.52) for MI and 2.00 (95% CI 1.26 to 3.18) for stroke. The association between MI was significant for RA seropositivity (HR=1.23, 95% CI 1.03 to 1.48).
Conclusions In this predominantly older male RA cohort, there was no clear association between LDL-C and CHD, whereas higher HDL-C was inversely associated with MI and stroke. CRP and ESR were similarly associated with increase MI risk and stroke, reflecting the prominent role of inflammation in CHD risk in RA.
C1 [Navarro-Millan, Iris; Yang, Shuo; Chen, Lang; Baddley, John; Singh, Jasvinder A.; Curtis, Jeffrey R.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Navarro-Millan, Iris; Yang, Shuo; Chen, Lang; Baddley, John; Delzell, Elizabeth S.; Zhang, Jie; Safford, Monika M.; Patkar, Nivedita M.; Singh, Jasvinder A.; Curtis, Jeffrey R.] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, 510 20th St S,Fac Off Tower 802D, Birmingham, AL 35294 USA.
[DuVall, Scott L.; Cannon, Grant W.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA.
[DuVall, Scott L.; Cannon, Grant W.] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Mikuls, Ted R.] Omaha VA, Omaha, NE USA.
[Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA.
RP Curtis, JR (reprint author), Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, 510 20th St S,Fac Off Tower 802D, Birmingham, AL 35294 USA.
EM jcurtis@uab.edu
FU Agency for Healthcare Research and Quality (AHRQ) [R01HS018517]; NIH [AR
053351, R01 AR062376-S1]; Arthritis Foundation [5561]
FX This work was supported by the Agency for Healthcare Research and
Quality (AHRQ) (R01HS018517). Dr Curtis receives support from the NIH
(AR 053351). Dr Navarro-Millan received support from the Arthritis
Foundation (5561) and NIH (R01 AR062376-S1).
NR 37
TC 6
Z9 7
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD FEB
PY 2016
VL 75
IS 2
BP 341
EP 347
DI 10.1136/annrheumdis-2013-204987
PG 7
WC Rheumatology
SC Rheumatology
GA DC1CZ
UT WOS:000368955700004
PM 25609412
ER
PT J
AU Linsenmeyer, K
Strymish, J
Weir, S
Berg, G
Brecher, S
Gupta, K
AF Linsenmeyer, Katherine
Strymish, Judith
Weir, Susan
Berg, Gretchen
Brecher, Stephen
Gupta, Kalpana
TI Activity of Fosfomycin against
Extended-Spectrum-beta-Lactamase-Producing Uropathogens in Patients in
the Community and Hospitalized Patients
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; INCREASING PREVALENCE;
ENTEROBACTERIACEAE; EXPERIENCE; RESISTANCE
AB Few oral antibiotics exist for the empirical treatment of extended-spectrum beta-lactamase (ESBL) urinary tract infections (UTI). In this study, we sought to determine the activity of fosfomycin against ESBL-producing uropathogens from patients at 3 Veterans Affairs (VA) facilities between 2010 and 2013. Among the ESBL uropathogens, 19.9% were fosfomycin resistant. Klebsiella species were more likely than Escherichia coli to be resistant (46% versus 4%; P < 0.001). Fosfomycin remains active against a majority of the ESBL uropathogens, although resistance among Klebsiella spp. was higher than that in previous reports.
C1 [Linsenmeyer, Katherine; Strymish, Judith; Weir, Susan; Berg, Gretchen; Brecher, Stephen; Gupta, Kalpana] VA Boston Healthcare Syst, West Roxbury, MA USA.
[Linsenmeyer, Katherine; Weir, Susan; Berg, Gretchen; Brecher, Stephen; Gupta, Kalpana] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Strymish, Judith] Harvard Univ, Sch Med, Boston, MA USA.
[Gupta, Kalpana] Natl Ctr Occupat Hlth & Infect Control, Gainesville, FL USA.
RP Linsenmeyer, K (reprint author), VA Boston Healthcare Syst, West Roxbury, MA USA.; Linsenmeyer, K (reprint author), Boston Univ, Sch Med, Boston, MA 02118 USA.
EM katherine.linsenmeyer@bmc.org
NR 18
TC 3
Z9 3
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD FEB
PY 2016
VL 60
IS 2
BP 1134
EP 1136
DI 10.1128/AAC.02614-15
PG 3
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA DC3ZR
UT WOS:000369159800049
PM 26596940
ER
PT J
AU Silverstein, M
Kistin, C
Bair-Merritt, M
Wiltsey-Stirman, S
Feinberg, E
Diaz-Linhart, Y
Sandler, J
Chen, N
Cabral, H
AF Silverstein, Michael
Kistin, Caroline
Bair-Merritt, Megan
Wiltsey-Stirman, Shannon
Feinberg, Emily
Diaz-Linhart, Yaminette
Sandler, Jenna
Chen, Ning
Cabral, Howard
TI Avoidance as an obstacle to preventing depression among urban women at
high risk for violent trauma
SO ARCHIVES OF WOMENS MENTAL HEALTH
LA English
DT Article
DE Maternal depression; PTSD; Avoidance; Prevention
ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; DOMESTIC
VIOLENCE; PTSD SYMPTOMS; MENTAL-HEALTH; PRIMARY-CARE; SELF-REPORT;
IMPACT; OUTCOMES; COMORBIDITY
AB The impact of depression interventions is often attenuated in women who have experienced trauma. We explored whether psychological avoidance could explain this phenomenon. We synthesized two pilot randomized trials of problem-solving education (PSE) among a total of 93 urban mothers. Outcomes included depressive symptoms and perceived stress. Mothers with avoidant coping styles experienced an average 1.25 episodes of moderately severe depressive symptoms over 3 months of follow-up, compared to 0.40 episodes among those with non-avoidant coping (adjusted incident rate ratio [aIRR] 2.18; 95 % CI 1.06, 4.48). PSE tended to perform better among mothers with non-avoidant coping. Among mothers with non-avoidant coping, PSE mothers experienced an average 0.24 episodes, compared to 0.58 episodes among non-avoidant controls (aIRR 0.27; 95 % CI 0.05, 1.34). Among mothers with avoidant coping, PSE mothers experienced an average 1.26 episodes, compared to 1.20 episodes among avoidant controls (aIRR 0.76; 95 % CI 0.44, 1.33). This trend toward differential impact persisted when avoidance was measured as a problem-solving style and among traumatized mothers with and without avoidant PTSD symptoms. Further research is warranted to explore the hypothesis that psychological avoidance could explain why certain depression treatment and prevention strategies break down in the presence of trauma.
C1 [Silverstein, Michael; Kistin, Caroline; Bair-Merritt, Megan; Feinberg, Emily] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA.
[Silverstein, Michael; Kistin, Caroline; Bair-Merritt, Megan; Diaz-Linhart, Yaminette; Sandler, Jenna; Chen, Ning] Boston Med Ctr, Dept Pediat, Vose Hall 3,One Boston Med Ctr Pl, Boston, MA 02118 USA.
[Wiltsey-Stirman, Shannon] Boston Vet Adm Hosp, Dept Vet Affairs, Natl Ctr PTSD, Boston, MA USA.
[Wiltsey-Stirman, Shannon] Boston Univ, Dept Psychiat, Sch Med, Boston, MA 02118 USA.
[Feinberg, Emily] Boston Univ, Dept Community Hlth Sci, Sch Publ Hlth, Boston, MA 02118 USA.
[Cabral, Howard] Boston Univ, Dept Biostat, Sch Publ Hlth, Boston, MA 02118 USA.
RP Silverstein, M (reprint author), Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA.; Silverstein, M (reprint author), Boston Med Ctr, Dept Pediat, Vose Hall 3,One Boston Med Ctr Pl, Boston, MA 02118 USA.
EM michael.silverstein@bmc.org
OI Wiltsey Stirman, Shannon/0000-0001-9917-5078
FU NICHD R03 award [R03HD058075]; NICHD K24 award [K24HD081057]
FX This work was funded by an NICHD R03 award (R03HD058075, PI
Silverstein); Dr. Silverstein is currently supported in part by an NICHD
K24 award (K24HD081057). We thank Barry Zuckerman for his advice in
conceptualizing this work.
NR 37
TC 0
Z9 0
U1 3
U2 5
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 1434-1816
EI 1435-1102
J9 ARCH WOMEN MENT HLTH
JI Arch. Womens Ment. Health
PD FEB
PY 2016
VL 19
IS 1
BP 63
EP 70
DI 10.1007/s00737-015-0521-4
PG 8
WC Psychiatry
SC Psychiatry
GA DC1XU
UT WOS:000369012400009
PM 25833808
ER
PT J
AU Ward, MM
Deodhar, A
Akl, EA
Lui, A
Ermann, J
Gensler, LS
Smith, JA
Borenstein, D
Hiratzka, J
Weiss, PF
Inman, RD
Majithia, V
Haroon, N
Maksymowych, WP
Joyce, J
Clark, BM
Colbert, RA
Figgie, MP
Hallegua, DS
Prete, PE
Rosenbaum, JT
Stebulis, JA
Van Den Bosch, F
Yu, DTY
Miller, AS
Reveille, JD
Caplan, L
AF Ward, Michael M.
Deodhar, Atul
Akl, Elie A.
Lui, Andrew
Ermann, Joerg
Gensler, Lianne S.
Smith, Judith A.
Borenstein, David
Hiratzka, Jayme
Weiss, Pamela F.
Inman, Robert D.
Majithia, Vikas
Haroon, Nigil
Maksymowych, Walter P.
Joyce, Janet
Clark, Bruce M.
Colbert, Robert A.
Figgie, Mark P.
Hallegua, David S.
Prete, Pamela E.
Rosenbaum, James T.
Stebulis, Judith A.
Van Den Bosch, Filip
Yu, David T. Y.
Miller, Amy S.
Reveille, John D.
Caplan, Liron
TI American College of Rheumatology/Spondylitis Association of
America/Spondyloarthritis Research and Treatment Network 2015
Recommendations for the Treatment of Ankylosing Spondylitis and
Nonradiographic Axial Spondyloarthritis
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; CLASSIFICATION CRITERIA;
PSORIATIC-ARTHRITIS; MANAGEMENT; EFFICACY; SAFETY; INJECTIONS; THERAPY;
DRUGS; GRADE
AB ObjectiveTo provide evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA).
MethodsA core group led the development of the recommendations, starting with the treatment questions. A literature review group conducted systematic literature reviews of studies that addressed 57 specific treatment questions, based on searches conducted in OVID Medline (1946-2014), PubMed (1966-2014), and the Cochrane Library. We assessed the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. A separate voting group reviewed the evidence and voted on recommendations for each question using the GRADE framework.
ResultsIn patients with active AS, the strong recommendations included use of nonsteroidal antiinflammatory drugs (NSAIDs), use of tumor necrosis factor inhibitors (TNFi) when activity persists despite NSAID treatment, not to use systemic glucocorticoids, use of physical therapy, and use of hip arthroplasty for patients with advanced hip arthritis. Among the conditional recommendations was that no particular TNFi was preferred except in patients with concomitant inflammatory bowel disease or recurrent iritis, in whom TNFi monoclonal antibodies should be used. In patients with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi. Other recommendations for patients with nonradiographic axial SpA were based on indirect evidence and were the same as for patients with AS.
ConclusionThese recommendations provide guidance for the management of common clinical questions in AS and nonradiographic axial SpA. Additional research on optimal medication management over time, disease monitoring, and preventive care is needed to help establish best practices in these areas.
C1 [Ward, Michael M.; Colbert, Robert A.] NIAMSD, NIH, Bldg 10 CRC,Room 4-1339,10 Ctr Dr, Bethesda, MD 20892 USA.
[Deodhar, Atul; Hiratzka, Jayme; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Akl, Elie A.] Amer Univ Beirut, Beirut, Lebanon.
[Akl, Elie A.] McMaster Univ, Hamilton, ON, Canada.
[Lui, Andrew; Gensler, Lianne S.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Ermann, Joerg] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Smith, Judith A.] Univ Wisconsin, Madison, WI 53706 USA.
[Borenstein, David] Arthrit & Rheumatism Assoc, Washington, DC USA.
[Weiss, Pamela F.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Weiss, Pamela F.] Univ Penn, Philadelphia, PA 19104 USA.
[Inman, Robert D.; Haroon, Nigil] Univ Toronto, Toronto, ON, Canada.
[Majithia, Vikas] Univ Mississippi, Med Ctr, Jackson, MS USA.
[Maksymowych, Walter P.] Univ Alberta, Edmonton, AB, Canada.
[Joyce, Janet; Miller, Amy S.] Amer Coll Rheumatol, 60 Execut Pk S,Suite 150, Atlanta, GA 30329 USA.
[Clark, Bruce M.] RPT, Vancouver, BC, Canada.
[Figgie, Mark P.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA.
[Hallegua, David S.] Cedars Sinai Med Ctr, Beverly Hills, CA USA.
[Prete, Pamela E.] VA Long Beach Med Ctr, Long Beach, CA USA.
[Prete, Pamela E.] Univ Calif Irvine, Irvine, CA USA.
[Rosenbaum, James T.] Legacy Devers Eye Inst, Portland, OR USA.
[Stebulis, Judith A.] Univ Massachusetts, Worcester, MA 01605 USA.
[Van Den Bosch, Filip] Univ Ghent, B-9000 Ghent, Belgium.
[Yu, David T. Y.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
[Caplan, Liron] Denver VA Med Ctr, Denver, CO USA.
[Caplan, Liron] Univ Colorado, Aurora, CO USA.
RP Ward, MM (reprint author), NIAMSD, NIH, Bldg 10 CRC,Room 4-1339,10 Ctr Dr, Bethesda, MD 20892 USA.
EM wardm1@mail.nih.gov
FU American College of Rheumatology; Spondylitis Association of America
FX This work was supported by the American College of Rheumatology and the
Spondylitis Association of America. We thank our patient representative
for adding valuable perspectives. We thank Laurie Savage and Charlotte
Howard of the Spondylitis Association of America for their partnership
on this project. We thank Regina Parker for administrative assistance
and Tamara Rader, who with Janet Joyce, developed and reviewed the
literature search strategies. We appreciate the contributions of Drs.
Robert Hart, Siba Raychaudhuri, and James Witter to the literature
review.
NR 29
TC 3
Z9 3
U1 2
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
EI 2151-4658
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD FEB
PY 2016
VL 68
IS 2
BP 151
EP 166
DI 10.1002/acr.22708
PG 16
WC Rheumatology
SC Rheumatology
GA DB9RT
UT WOS:000368855100001
PM 26401907
ER
PT J
AU Schoenfeld, SR
Choi, HK
Sayre, EC
Avina-Zubieta, JA
AF Schoenfeld, Sara R.
Choi, Hyon K.
Sayre, Eric C.
Avina-Zubieta, J. Antonio
TI Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic
Sclerosis: A General Population-Based Study
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID RHEUMATOID-ARTHRITIS; ADMINISTRATIVE DATA; VASCULAR-DISEASE; VEIN
THROMBOSIS; THROMBOEMBOLISM; SCLERODERMA; EVENTS; INFLAMMATION;
INVOLVEMENT; FIBROSIS
AB ObjectiveTo determine the risk of venous thromboembolism (VTE) (pulmonary embolism [PE] and deep vein thrombosis [DVT]) in individuals with incident systemic sclerosis (SSc; scleroderma) in the general population.
MethodsUsing a population database that includes all residents of British Columbia, Canada, we conducted a cohort study of all patients with incident SSc and up to 10 age-, sex-, and entry time-matched individuals from the general population. We compared incidence rates of PE, DVT, and VTE between the 2 groups according to SSc disease duration. We calculated hazard ratios (HRs), adjusting for confounders.
ResultsAmong 1,245 individuals with SSc (83% female, mean age 56 years), the incidence rates of PE, DVT, and VTE were 3.47, 3.48, and 6.56 per 1,000 person-years, respectively, whereas the corresponding rates were 0.78, 0.76, and 1.37 per 1,000 person-years among 12,670 non-SSc individuals. Compared with non-SSc individuals, the multivariable HRs among SSc patients were 3.73 (95% confidence interval [95% CI] 1.98-7.04), 2.96 (95% CI 1.54-5.69), and 3.47 (95% CI 2.14-5.64) for PE, DVT, and VTE, respectively. The age-, sex-, and entry time-matched HRs for PE, DVT, and VTE were highest during the first year after SSc diagnosis (32.77 [95% CI 6.60-162.75], 8.50 [95% CI 3.13-23.04], and 12.03 [95% CI 5.27-27.45], respectively).
ConclusionThese findings provide population-based evidence that SSc patients are at a substantially increased risk of VTE, especially within the first year after SSc diagnosis. Increased monitoring for this potentially fatal outcome and its modifiable risk factors is warranted in this patient population.
C1 [Schoenfeld, Sara R.; Choi, Hyon K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Schoenfeld, Sara R.; Choi, Hyon K.] Harvard Univ, Sch Med, Boston, MA USA.
[Choi, Hyon K.; Sayre, Eric C.; Avina-Zubieta, J. Antonio] Arthrit Res Canada, Vancouver, BC, Canada.
[Avina-Zubieta, J. Antonio] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
RP Avina-Zubieta, JA (reprint author), 5591 3 Rd, Richmond, BC V6X 2C7, Canada.
EM azubieta@arthritisresearch.ca
FU Canadian Arthritis Network; Arthritis Society of Canada; British
Columbia Lupus Society [10-SRP-IJD-01]; Canadian Institutes for Health
Research [MOP 125960, THC 135235]
FX Supported by the Canadian Arthritis Network, the Arthritis Society of
Canada, the British Columbia Lupus Society (grant 10-SRP-IJD-01), and
the Canadian Institutes for Health Research (grants MOP 125960 and THC
135235).
NR 51
TC 2
Z9 2
U1 2
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
EI 2151-4658
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD FEB
PY 2016
VL 68
IS 2
BP 246
EP 253
DI 10.1002/acr.22673
PG 8
WC Rheumatology
SC Rheumatology
GA DB9RT
UT WOS:000368855100011
PM 26212772
ER
PT J
AU Ward, MM
Deodhar, A
Akl, EA
Lui, A
Ermann, J
Gensler, LS
Smith, JA
Borenstein, D
Hiratzka, J
Weiss, PF
Inman, RD
Majithia, V
Haroon, N
Maksymowych, WP
Joyce, J
Clark, BM
Colbert, RA
Figgie, MP
Hallegua, DS
Prete, PE
Rosenbaum, JT
Stebulis, JA
van den Bosch, F
Yu, DTY
Miller, AS
Reveille, JD
Caplan, L
AF Ward, Michael M.
Deodhar, Atul
Akl, Elie A.
Lui, Andrew
Ermann, Joerg
Gensler, Lianne S.
Smith, Judith A.
Borenstein, David
Hiratzka, Jayme
Weiss, Pamela F.
Inman, Robert D.
Majithia, Vikas
Haroon, Nigil
Maksymowych, Walter P.
Joyce, Janet
Clark, Bruce M.
Colbert, Robert A.
Figgie, Mark P.
Hallegua, David S.
Prete, Pamela E.
Rosenbaum, James T.
Stebulis, Judith A.
van den Bosch, Filip
Yu, David T. Y.
Miller, Amy S.
Reveille, John D.
Caplan, Liron
TI American College of Rheumatology/Spondylitis Association of
America/Spondyloarthritis Research and Treatment Network 2015
Recommendations for the Treatment of Ankylosing Spondylitis and
Nonradiographic Axial Spondyloarthritis
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; CLASSIFICATION CRITERIA;
PSORIATIC-ARTHRITIS; MANAGEMENT; EFFICACY; SAFETY; INJECTIONS; THERAPY;
DRUGS; GRADE
AB Objective. To provide evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA).
Methods. A core group led the development of the recommendations, starting with the treatment questions. A literature review group conducted systematic literature reviews of studies that addressed 57 specific treatment questions, based on searches conducted in OVID Medline (1946-2014), PubMed (1966-2014), and the Cochrane Library. We assessed the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. A separate voting group reviewed the evidence and voted on recommendations for each question using the GRADE framework.
Results. In patients with active AS, the strong recommendations included use of nonsteroidal antiinflammatory drugs (NSAIDs), use of tumor necrosis factor inhibitors (TNFi) when activity persists despite NSAID treatment, not to use systemic glucocorticoids, use of physical therapy, and use of hip arthroplasty for patients with advanced hip arthritis. Among the conditional recommendations was that no particular TNFi was preferred except in patients with concomitant inflammatory bowel disease or recurrent iritis, in whom TNFi monoclonal antibodies should be used. In patients with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi. Other recommendations for patients with nonradiographic axial SpA were based on indirect evidence and were the same as for patients with AS.
Conclusion. These recommendations provide guidance for the management of common clinical questions in AS and nonradiographic axial SpA. Additional research on optimal medication management over time, disease monitoring, and preventive care is needed to help establish best practices in these areas.
C1 [Ward, Michael M.; Colbert, Robert A.] NIAMSD, NIH, Bldg 10 CRC,Room 4-1339,10 Ctr Dr, Bethesda, MD 20892 USA.
[Deodhar, Atul; Hiratzka, Jayme; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Akl, Elie A.] Amer Univ Beirut, Beirut, Lebanon.
[Akl, Elie A.] McMaster Univ, Hamilton, ON, Canada.
[Lui, Andrew; Gensler, Lianne S.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Ermann, Joerg] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Smith, Judith A.] Univ Wisconsin, Madison, WI 53706 USA.
[Borenstein, David] Arthrit & Rheumatism Associates, Washington, DC USA.
[Weiss, Pamela F.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Weiss, Pamela F.] Univ Penn, Philadelphia, PA 19104 USA.
[Inman, Robert D.; Haroon, Nigil] Univ Toronto, Toronto, ON, Canada.
[Majithia, Vikas] Univ Mississippi, Med Ctr, Jackson, MS USA.
[Maksymowych, Walter P.] Univ Alberta, Edmonton, AB, Canada.
[Joyce, Janet; Miller, Amy S.] Amer Coll Rheumatol, 60 Execut Pk S,Suite 150, Atlanta, GA 30329 USA.
[Clark, Bruce M.] RPT, Vancouver, BC, Canada.
[Figgie, Mark P.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA.
[Hallegua, David S.] Cedars Sinai Med Ctr, Beverly Hills, CA USA.
[Prete, Pamela E.] VA Long Beach Med Ctr, Long Beach, CA USA.
[Prete, Pamela E.] Univ Calif Irvine, Irvine, CA USA.
[Rosenbaum, James T.] Legacy Devers Eye Inst, Portland, OR USA.
[Stebulis, Judith A.] Univ Massachusetts, Worcester, MA 01605 USA.
[van den Bosch, Filip] Univ Ghent, B-9000 Ghent, Belgium.
[Yu, David T. Y.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
[Caplan, Liron] Denver VA Med Ctr, Denver, CO USA.
[Caplan, Liron] Univ Colorado, Aurora, CO USA.
RP Ward, MM (reprint author), NIAMSD, NIH, Bldg 10 CRC,Room 4-1339,10 Ctr Dr, Bethesda, MD 20892 USA.
EM wardm1@mail.nih.gov
FU Intramural Research Program of the National Institute of Arthritis and
Musculoskeletal and Skin Diseases, NIH; Abbott; Amgen; Pfizer; Novartis;
AbbVie; UCB; Johnson Johnson; Celgene; Iroko; Janssen; Amgen/Pfizer;
GlaxoSmithKline; Janssen/Johnson & Johnson/Centocor/Ortho Biotech
Products; Janssen Biotech; Augurex; Bristol-Myers Squibb; Medtronic;
Ethicon; Q-Med AB; Centocor; IDEC; Xoma; Roche; Isis; Pharmacia; La
Jolla Pharma; Genentech; Proctor Gamble; Genelabs; MedImmune; Human
Genome Sciences; Array Biopharma; Cipher; Regeneron; Lux Biosciences;
Elan; Allergan; Santen; Teva; Sanofi; Janssen/Johnson Johnson
FX Drs. Ward and Colbert's work was supported by the Intramural Research
Program of the National Institute of Arthritis and Musculoskeletal and
Skin Diseases, NIH.; Dr. Deodhar has received consulting fees, speaking
fees, and/or honoraria from Abbott, Amgen, Pfizer, and Novartis (less
than $10,000 each) and from AbbVie and UCB (more than $10,000 each), and
research grants from Novartis, UCB, Johnson & Johnson, and Amgen. Dr.
Ermann has received honoraria from AbbVie (less than $10,000) for
Advisory Board service. Dr. Gensler has received consulting fees,
speaking fees, and/or honoraria from AbbVie, UCB, and Amgen (less than
$10,000 each) and research grants from Celgene and AbbVie. Dr.
Borenstein has received consulting fees, speaking fees, and/or honoraria
from Iroko and Abbott (less than $10,000 each) and honoraria from
Clinical Care Options (more than $10,000). Dr. Inman has received
consulting fees, speaking fees, and/or honoraria from AbbVie, Abbott,
Janssen, Amgen/Pfizer, UCB, Novartis, and Celgene (less than $10,000
each). Dr. Majithia has received consulting fees, speaking fees, and/or
honoraria from GlaxoSmithKline (less than $10,000). Dr. Haroon has
received consulting fees, speaking fees, and/or honoraria from AbbVie,
Abbott, Amgen, Janssen/Johnson & Johnson/Centocor/Ortho Biotech
Products, Janssen Biotech, Celgene, UCB, and Pfizer (less than $10,000
each). Dr. Maksymowych has received consulting fees, speaking fees,
and/or honoraria from AbbVie, UCB, Pfizer, Amgen, Janssen, and Augurex
(less than $10,000 each) and receives licensing fees and royalties from
Augurex for the 14-3-3 biomarker. Mr. Clark has received consulting
fees, speaking fees, and/or honoraria from AbbVie, Abbott, Amgen,
Janssen, and Bristol-Myers Squibb (less than $10,000 each). Dr. Figgie
has received consulting fees, speaking fees, and/or honoraria from
Medtronic and Ethicon (less than $10,000 each). Dr. Hallegua has
received consulting fees, speaking fees, and/or honoraria from AbbVie,
Q-Med AB, UCB, Bristol-Myers Squibb, Centocor, Amgen, IDEC, Xoma,
Novartis, Roche, Isis, Pharmacia, La Jolla Pharma, Genentech, Proctor &
Gamble, Genelabs, MedImmune, Human Genome Sciences, Array Biopharma, and
Cipher (less than $10,000 each). Dr. Prete has received consulting fees,
speaking fees, and/or honoraria from Abbott (less than $10,000). Dr.
Rosenbaum has received consulting fees, speaking fees, and/or honoraria
from UCB, Regeneron, Xoma, Lux Biosciences, Elan, Allergan, Santen,
Teva, Novartis, Sanofi, AbbVie, Amgen, Bristol-Myers Squibb, Celgene,
and Genentech (less than $10,000 each) and is a contributor to UpToDate.
Dr. van den Bosch has received consulting fees, speaking fees, and/or
honoraria from AbbVie, Bristol-Myers Squibb, Celgene, Janssen/Johnson &
Johnson, Pfizer, and UCB (less than $10,000 each). Dr. Reveille has
received consulting fees, speaking fees, and/or honoraria from Abbott
and UCB (less than $10,000 each).
NR 29
TC 24
Z9 27
U1 3
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD FEB
PY 2016
VL 68
IS 2
BP 282
EP 298
DI 10.1002/art.39298
PG 17
WC Rheumatology
SC Rheumatology
GA DC0XY
UT WOS:000368942500005
PM 26401991
ER
PT J
AU Baker, JF
Ibrahim, S
Billig, E
Michaud, K
Caplan, L
Cannon, GW
Stokes, A
Majithia, V
Mikuls, TR
AF Baker, Joshua F.
Ibrahim, Said
Billig, Erica
Michaud, Kaleb
Caplan, Liron
Cannon, Grant W.
Stokes, Andrew
Majithia, Vikas
Mikuls, Ted R.
TI Weight loss, the obesity paradox in rheumatoid arthritis: is it a
paradox? Comment on the article by Baker et al Reply
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Letter
ID OLDER-ADULTS
C1 [Baker, Joshua F.; Ibrahim, Said] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Baker, Joshua F.; Ibrahim, Said; Billig, Erica] Univ Penn, Philadelphia, PA 19104 USA.
[Michaud, Kaleb; Mikuls, Ted R.] Nebraska Western Iowa VA Med Ctr, Omaha, NE USA.
[Michaud, Kaleb; Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Michaud, Kaleb] Natl Data Bank Rheumat Dis, Wichita, KS USA.
[Caplan, Liron] Denver VA Med Ctr, Denver, CO USA.
[Cannon, Grant W.] Salt Lake City VA Med Ctr, Salt Lake City, UT USA.
[Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA.
[Stokes, Andrew] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Majithia, Vikas] GV Sonny Montgomery VA Med Ctr, Jackson, MS USA.
[Majithia, Vikas] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA.
RP Baker, JF (reprint author), Philadelphia VA Med Ctr, Philadelphia, PA USA.
FU CSRD VA [IK2 CX000955]
NR 4
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD FEB
PY 2016
VL 68
IS 2
BP 553
EP 554
PG 2
WC Rheumatology
SC Rheumatology
GA DC0XY
UT WOS:000368942500035
PM 26555220
ER
PT J
AU de Velasco, G
Bermas, B
Choueiri, TK
AF de Velasco, Guillermo
Bermas, Boonie
Choueiri, Toni K.
TI Clinical Images: Autoimmune arthropathy and uveitis as complications of
programmed death 1 inhibitor treatment
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Editorial Material
ID CELLS; TH17
C1 [de Velasco, Guillermo; Choueiri, Toni K.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bermas, Boonie] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
RP de Velasco, G (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 3
TC 10
Z9 10
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD FEB
PY 2016
VL 68
IS 2
BP 556
EP 556
DI 10.1002/art.39406
PG 1
WC Rheumatology
SC Rheumatology
GA DC0XY
UT WOS:000368942500038
PM 26314277
ER
PT J
AU Schorderet, P
AF Schorderet, Patrick
TI NEAT: a framework for building fully automated NGS pipelines and
analyses
SO BMC BIOINFORMATICS
LA English
DT Article
DE Bioinformatics; Genomics; High throughput sequencing; RNAseq; ChIPseq;
NGS pipelines
ID INTEGRATIVE GENOMICS VIEWER; SEQUENCING DATA; BROWSER; UCSC; SEQ;
VISUALIZATION; DISCOVERY; ALIGNMENT; GALAXY; TOOLS
AB Background: The analysis of next generation sequencing (NGS) has become a standard task for many laboratories in the life sciences. Though there exists several tools to support users in the manipulation of such datasets on various levels, few are built on the basis of vertical integration. Here, we present the NExt generation Analysis Toolbox (NEAT) that allows non-expert users including wet-lab scientists to comprehensively build, run and analyze NGS data through double-clickable executables without the need of any programming experience.
Results: In comparison to many publicly available tools including Galaxy, NEAT provides three main advantages: (1) Through the development of double-clickable executables, NEAT is efficient (completes within <24 hours), easy to implement and intuitive; (2) Storage space, maximum number of job submissions, wall time and cluster-specific parameters can be customized as NEAT is run on the institution's cluster; (3) NEAT allows users to visualize and summarize NGS data rapidly and efficiently using various built-in exploratory data analysis tools including metagenomic and differentially expressed gene analysis.
To simplify the control of the workflow, NEAT projects are built around a unique and centralized file containing sample names, replicates, conditions, antibodies, alignment-, filtering-and peak calling parameters as well as cluster-specific paths and settings. Moreover, the small-sized files produced by NEAT allow users to easily manipulate, consolidate and share datasets from different users and institutions.
Conclusions: NEAT provides biologists and bioinformaticians with a robust, efficient and comprehensive tool for the analysis of massive NGS datasets. Frameworks such as NEAT not only allow novice users to overcome the increasing number of technical hurdles due to the complexity of manipulating large datasets, but provide more advance users with tools that ensure high reproducibility standards in the NGS era. NEAT is publically available at https://github.com/pschorderet/NEAT.
C1 [Schorderet, Patrick] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Schorderet, Patrick] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
RP Schorderet, P (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.; Schorderet, P (reprint author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
EM patrick.schorderet@molbio.mgh.harvard.edu
FU Advanced Swiss National Foundation Fellowship [P300P3_158516]; National
Institute of General Medical Sciences (US) [R37 GM48405-21]
FX PS is supported by an Advanced Swiss National Foundation Fellowship
(P300P3_158516) and is supported in part through the National Institute
of General Medical Sciences (US) grant R37 GM48405-21 awarded to Robert
E Kingston. I would like to acknowledge the Kingston Lab members for
stimulating discussions, feedback and testing; particularly Alan
Rodrigues, Sharon Marr, Aaron Plys, Ozlem Yildirim, Ruslan Sadreyev and
Bob Kingston for critical reading during the preparation of the
manuscript.
NR 27
TC 0
Z9 0
U1 2
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD FEB 1
PY 2016
VL 17
AR 53
DI 10.1186/s12859-016-0902-3
PG 9
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
GA DC2MK
UT WOS:000369050600001
PM 26830846
ER
PT J
AU Saeed, H
Mantagos, IS
Chodosh, J
AF Saeed, Hajirah
Mantagos, Iason S.
Chodosh, James
TI Complications of Stevens-Johnson syndrome beyond the eye and skin
SO BURNS
LA English
DT Review
DE Stevens-Johnson syndrome; Toxic epidermal necrolysis
ID TOXIC EPIDERMAL NECROLYSIS; AMNIOTIC MEMBRANE TRANSPLANTATION;
OF-THE-LITERATURE; BRONCHIOLITIS OBLITERANS; ERYTHEMA MULTIFORME;
ESOPHAGEAL STRICTURE; PULMONARY COMPLICATIONS; VAGINAL STENOSIS; LYELL
SYNDROME; BILE-DUCTS
AB Introduction: Ocular and cutaneous disease are common chronic sequelae of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and have been well described in the literature. Long-term complications affecting other organ systems have not been so well described. The purpose of this review article is to highlight non-ocular and non-cutaneous chronic complications of SJS/TEN.
Methods: The PubMed database was searched for the keywords "Stevens-Johnson syndrome'' and "toxic epidermal necrolysis'' through September 1, 2014. Relevant articles were then reviewed in full.
Results: 138 articles in the English language were found that described chronic sequelae of SJS/TEN. Our search revealed six affected organ systems other than the eyes and integument, with chronic sequelae from SJS/TEN: respiratory, gastrointestinal/hepatic, oral, otorhinolaryngologic, gynecologic/genitourinary, and renal. Complications involving these organs systems appeared likely to reduce the quality of life for SJS/TEN survivors.
Discussion: SJS/TEN is a multi-organ disease requiring multidisciplinary care from a variety of specialists. Affected patients have complex hospital stays, and their quality of life may be severely impacted by multiple long-term complications. We believe that preventative care in the acute setting might limit the development and progression of many of the sequelae described above. (C) 2015 Elsevier Ltd and ISBI. All rights reserved.
C1 [Saeed, Hajirah; Chodosh, James] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
[Mantagos, Iason S.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Ophthalmol, 300 Longwood Ave, Boston, MA 02115 USA.
RP Chodosh, J (reprint author), 243 Charles St, Boston, MA 02114 USA.
EM Hajirah_Saeed@meei.harvard.edu; Jason.Mantagos@childrens.harvard.edu;
James_Chodosh@meei.harvard.edu
OI Mantagos, Iason/0000-0002-3510-5465
FU Research to Prevent Blindness, New York, NY
FX This work was supported in part by an unrestricted grant to the
Department of Ophthalmology, Harvard Medical School, by Research to
Prevent Blindness, New York, NY. We would like to acknowledge Louise
Collins of the Howe Library at Massachusetts Eye and Ear Infirmary for
her help in searching for and obtaining articles of interest.
NR 102
TC 2
Z9 3
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0305-4179
EI 1879-1409
J9 BURNS
JI Burns
PD FEB
PY 2016
VL 42
IS 1
BP 20
EP 27
DI 10.1016/j.burns.2015.03.012
PG 8
WC Critical Care Medicine; Dermatology; Surgery
SC General & Internal Medicine; Dermatology; Surgery
GA DB9MP
UT WOS:000368840600004
PM 25865527
ER
PT J
AU Sircar, M
Bhatia, A
Munshi, M
AF Sircar, Mousumi
Bhatia, Ashmeet
Munshi, Medha
TI Review of Hypoglycemia in the Older Adult: Clinical Implications and
Management
SO CANADIAN JOURNAL OF DIABETES
LA English
DT Review
DE diabetes; geriatric; hypoglycemia; older adult; patient safety
ID TYPE-2 DIABETES-MELLITUS; ELDERLY-PATIENTS; COGNITIVE IMPAIRMENT;
GLYCEMIC CONTROL; GLUCOSE CONTROL; WORKING PARTY; PEOPLE EDWPOP; RISK;
INSULIN; SULFONYLUREAS
AB The aging of the population is a worldwide phenomenon. The prevalence of diabetes rises with increasing age, so the personal and financial costs of diabetes in the aging population have become significant burdens. In 2012, 104 billion (59%) of the estimated $176 billion in United States healthcare expenditures attributable to diabetes were utilized by patients older than 65 years of age [American Diabetes Association (1)]. With improvement in diabetes management and better glycemic control in the general population, there is an increase in the prevalence of hypoglycemia, which is the complication of the treatment of diabetes. Older adults with diabetes have a higher risk for hypoglycemia due to altered adaptive physiologic responses to low glucose levels. These patients also have comorbidities, such as cognitive and functional loss, that interfere with prompt identification and/or appropriate treatment of hypoglycemia. Older adults who suffer from hypoglycemia also have increased risk for falls, fall-related fractures, seizures and comas and exacerbation of chronic conditions, such as cognitive dysfunction and cardiac events. Thus, hypoglycemia in the older adult must be proactively avoided to decrease significant morbidity and mortality. Education of the patients and caregivers is important in prevention and treatment of hypoglycemia. In this article, we discuss the important aspects and unique challenges pertaining to hypoglycemia in older population. We also highlight the risks, consequences and prevention and management strategies for hypoglycemia that can be used by healthcare providers caring for older populations. (C) 2015 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.
C1 [Sircar, Mousumi; Bhatia, Ashmeet; Munshi, Medha] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Munshi, Medha] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Sircar, Mousumi; Bhatia, Ashmeet; Munshi, Medha] Harvard Univ, Sch Med, Boston, MA USA.
RP Munshi, M (reprint author), 110 Francis St,LMOB 1B, Boston, MA 02215 USA.
EM mmunshi@bidmc.harvard.edu
NR 46
TC 1
Z9 1
U1 4
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1499-2671
J9 CAN J DIABETES
JI Can. J. Diabetes
PD FEB
PY 2016
VL 40
IS 1
BP 66
EP 72
DI 10.1016/j.jcjd.2015.10.004
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DC4DQ
UT WOS:000369170800013
PM 26752195
ER
PT J
AU Santiago-Walker, A
Gagnon, R
Mazumdar, J
Casey, M
Long, GV
Schadendorf, D
Flaherty, K
Kefford, R
Hauschild, A
Hwu, P
Haney, P
O'Hagan, A
Carver, J
Goodman, V
Legos, J
Martin, AM
AF Santiago-Walker, Ademi
Gagnon, Robert
Mazumdar, Jolly
Casey, Michelle
Long, Georgina V.
Schadendorf, Dirk
Flaherty, Keith
Kefford, Richard
Hauschild, Axel
Hwu, Patrick
Haney, Patricia
O'Hagan, Anne
Carver, Jennifer
Goodman, Vicki
Legos, Jeffrey
Martin, Anne-Marie
TI Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor
and Association with Clinical Outcome across Four BRAFi and MEKi
Clinical Trials
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID DOSE-ESCALATION TRIAL; METASTATIC MELANOMA; NUCLEIC-ACIDS; OPEN-LABEL;
PHASE-II; CANCER; DABRAFENIB; PLASMA; SERUM; MULTICENTER
AB Purpose: Tumor-derived circulating cell-free DNA (cfDNA) is a potential alternative source from which to derive tumor mutation status. cfDNA data from four clinical studies of the BRAF inhibitor (BRAFi) dabrafenib or the MEK inhibitor (MEKi) trametinib were analyzed to determine the association between BRAF mutation status in cfDNA and tumor tissue, and the association of BRAF cfDNA mutation status with baseline factors and clinical outcome.
Experimental Design: Patients with BRAF V600 mutation-positive melanoma were enrolled in each study after central confirmation of BRAF status in tumor using a PCR-based assay. BRAF mutation status in cfDNA from patient plasma collected at baseline, 732 of 836 (88%) enrolled patients in total, was determined.
Results: BRAF mutations were detectable in cfDNA in 76% and 81% of patients with BRAF V600E/V600K-positive tumors, respectively. Patients negative for BRAF mutations in cfDNA had longer progression-free survival (PFS) and overall survival in each of the four studies, compared with patients with detectable cfDNA BRAF mutations. The presence of BRAF-mutant cfDNA was an independent prognostic factor for PFS after multivariate adjustment for baseline factors in three of four studies. Patients negative for BRAF mutation-positive cfDNA in plasma had higher response rates to dabrafenib and trametinib.
Conclusions: BRAF mutations in cfDNA are detectable in >75% of late-stage melanoma patients with BRAF mutation-positive tumors. The lack of circulating, BRAF mutation-positive cfDNA is clinically significant for metastatic melanoma patients, and may be a prognostic marker for better disease outcome. (C) 2015 AACR.
C1 [Santiago-Walker, Ademi; Gagnon, Robert; Mazumdar, Jolly; Casey, Michelle; Haney, Patricia; O'Hagan, Anne; Carver, Jennifer; Goodman, Vicki; Legos, Jeffrey; Martin, Anne-Marie] GlaxoSmithKline, Collegeville, PA 19426 USA.
[Long, Georgina V.; Kefford, Richard] Melanoma Inst Australia, Dept Med Oncol, Sydney, NSW, Australia.
[Long, Georgina V.; Kefford, Richard] Univ Sydney, Sydney, NSW, Australia.
[Schadendorf, Dirk] Univ Hosp Essen, Dept Dermatol, Essen, Germany.
[Flaherty, Keith] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Kefford, Richard] Westmead Hosp, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia.
[Hauschild, Axel] Univ Hosp Schleswig Holstein, Dept Dermatol, Holstein, Germany.
[Hwu, Patrick] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA.
[Santiago-Walker, Ademi; O'Hagan, Anne] Janssen, 1400 McKean Rd, Spring House, PA USA.
[Gagnon, Robert; Carver, Jennifer; Legos, Jeffrey] Novartis Pharmaceut, 1 Hlth Plaza, E Hanover, NJ USA.
[Casey, Michelle; Haney, Patricia] Pfizer, 500 Arcola Rd, Collegeville, PA USA.
[Goodman, Vicki] Bristol Myers Squibb, 3551 Lawrenceville Princeton, Lawrence Township, NJ USA.
[Martin, Anne-Marie] Adaptimmune LLC, Univ City Sci Ctr, 3711 Market St,8th Floor, Philadelphia, PA USA.
RP Gagnon, R (reprint author), Novartis Pharmaceut, 151 S Warner Rd, Collegeville, PA 19426 USA.
EM Robert.Gagnon@novartis.com
FU GlaxoSmithKline [NCT01153763, NCT01227889, NCT01266967, NCT01245062]
FX This study (NCT01153763, NCT01227889, NCT01266967, and NCT01245062) was
funded by GlaxoSmithKline.
NR 30
TC 11
Z9 12
U1 1
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 1
PY 2016
VL 22
IS 3
BP 567
EP 574
DI 10.1158/1078-0432.CCR-15-0321
PG 8
WC Oncology
SC Oncology
GA DC2XY
UT WOS:000369083300008
PM 26446943
ER
PT J
AU Huang, RY
Rahman, R
Ballman, KV
Felten, SJ
Anderson, SK
Ellingson, BM
Nayak, L
Lee, EQ
Abrey, LE
Galanis, E
Reardon, DA
Pope, WB
Cloughesy, TF
Wen, PY
AF Huang, Raymond Y.
Rahman, Rifaquat
Ballman, Karla V.
Felten, Sara J.
Anderson, S. Keith
Ellingson, Benjamin M.
Nayak, Lakshmi
Lee, Eudocia Q.
Abrey, Lauren E.
Galanis, Evanthia
Reardon, David A.
Pope, Whitney B.
Cloughesy, Timothy F.
Wen, Patrick Y.
TI The Impact of T2/FLAIR Evaluation per RANO Criteria on Response
Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PROGRESSION-FREE SURVIVAL; HIGH-GRADE GLIOMAS; PHASE-II TRIAL;
END-POINT; ANTIANGIOGENIC THERAPY; MALIGNANT GLIOMA; PLUS IRINOTECAN;
TEMOZOLOMIDE; MULTIFORME
AB Purpose: The RANO criteria have not been assessed using outcome data from prospective trials. We examined the radiologic data of patients with recurrent glioblastoma from the randomized phase II trial (AVF3708g) to determine the effect of including T2/FLAIR evaluation as per RANO criteria on measurements of objective response rates (ORRs) and progression-free survival (PFS) compared with assessment based on contrast enhancement (Macdonald criteria).
Experimental Design: The ORRs and median PFS were determined using the RANO criteria and compared with those obtained using the Macdonald criteria. Landmark analyses were performed at 2, 4, and 6 months, and Cox proportional hazard models were used to determine the associations between OR and progression with subsequent survival.
Results: The ORRs were 0.331 [95% confidence interval (CI), 0.260-0.409] and 0.393 (95% CI, 0.317-0.472) by RANO and Macdonald criteria, respectively (P < 0.0001). The median PFS was 4.6 months (95% CI, 4.1-5.5) using RANO criteria, compared with 6.4 months ( 95% CI, 5.5-7.1) as determined by Macdonald criteria (P = 0.01). At 2-, 4-, and 6-month landmarks, both OR status and PFS determined by either RANO or Macdonald criteria were predictive of overall survival [OS; hazard ratios for 4- month landmark (ORHR = 1.93, P = 0.0012; PFS HR, 4.23, P < 0.0001)].
Conclusions: The inclusion of T2/FLAIR assessment resulted in statistically significant differences in median PFS and ORRs compared with assessment of solely enhancing tumor (Macdonald criteria), although OR and PFS determined by both RANO and Macdonald criteria correlated with OS. (C) 2015 AACR.
C1 [Huang, Raymond Y.] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.
[Huang, Raymond Y.; Rahman, Rifaquat; Nayak, Lakshmi; Lee, Eudocia Q.; Reardon, David A.; Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA.
[Ballman, Karla V.; Felten, Sara J.; Anderson, S. Keith; Pope, Whitney B.] Mayo Clin, Div Biomed Stat & Informat, Dept Hlth Sci Res, Rochester, MN USA.
[Ellingson, Benjamin M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA.
[Ellingson, Benjamin M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Abrey, Lauren E.] F Hoffmann Roche Ltd, Div Pharmaceut, Prod Dev Oncol, Basel, Switzerland.
[Galanis, Evanthia] Mayo Clin, Dept Oncol, Div Med Oncol, Rochester, MN USA.
[Cloughesy, Timothy F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
RP Huang, RY (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
EM ryhuang@partners.org
FU ARRS/ASNR scholar award
FX Dr. R.Y. Huang was supported by ARRS/ASNR scholar award (foundation
grant).
NR 24
TC 3
Z9 3
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 1
PY 2016
VL 22
IS 3
BP 575
EP 581
DI 10.1158/1078-0432.CCR-14-3040
PG 7
WC Oncology
SC Oncology
GA DC2XY
UT WOS:000369083300009
PM 26490307
ER
PT J
AU Lu, DH
Sinnott, JA
Valdimarsdottir, U
Fang, F
Gerke, T
Tyekucheva, S
Fiorentino, M
Lambe, M
Sesso, HD
Sweeney, CJ
Wilson, KM
Giovannucci, EL
Loda, M
Mucci, LA
Fall, K
AF Lu, Donghao
Sinnott, Jennifer A.
Valdimarsdottir, Unnur
Fang, Fang
Gerke, Travis
Tyekucheva, Svitlana
Fiorentino, Michelangelo
Lambe, Mats
Sesso, Howard D.
Sweeney, Christopher J.
Wilson, Kathryn M.
Giovannucci, Edward L.
Loda, Massimo
Mucci, Lorelei A.
Fall, Katja
TI Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate
Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID BETA-BLOCKERS; EXPRESSION; RECEPTOR; SURVIVAL; GROWTH; CELLS; MEN;
ASSOCIATION; PROGRESSION; MECHANISMS
AB Purpose: Recent data suggest that neuroendocrine signaling may influence progression in some cancers. We aimed to determine whether genes within the five major stress-related signaling pathways are differentially expressed in tumor tissue when comparing prostate cancer patients with lethal and non-lethal disease.
Experimental Design: We measured mRNA expression of 51 selected genes involved in predetermined stress-related signaling pathways (adrenergic, glucocorticoid, dopaminergic, serotoninergic, and muscarinic systems) in tumor tissue and normal prostate tissue collected from prostate cancer patients in the Physicians' Health Study (n = 150; n = 82 with normal) and the Health Professionals Follow-Up Study (n = 254; n = 120 with normal). We assessed differences in pathway expression in relation to prostate cancer lethality as the primary outcome and to biomarkers as secondary outcomes.
Results: Differential mRNA expression of genes within the adrenergic (P = 0.001), glucocorticoid (P < 0.0001), serotoninergic (P = 0.0019), and muscarinic (P = 0.0045) pathways in tumor tissue was associated with the risk of lethality. The adrenergic pathway was also statistically significant (P = 0.001) when comparing against differential expression of genes not involved in the pathways. In adjacent normal prostate tissue, none of the pathways was clearly differentially expressed between lethal and nonlethal prostate cancer. The glucocorticoid and adrenergic pathways were associated with cell proliferation, while the glucocorticoid pathway was additionally associated with angiogenesis and perineural invasion.
Conclusions: Our study suggests that stress-related signaling pathways, particularly the adrenergic and glucocorticoid, may be dysregulated in the tumors of men whose prostate cancer proves to be lethal, and motivates further investigation of these pathways in functional studies. (C)2015 AACR.
C1 [Lu, Donghao; Valdimarsdottir, Unnur; Fang, Fang; Lambe, Mats] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Sinnott, Jennifer A.] Ohio State Univ, Dept Stat, 1958 Neil Ave, Columbus, OH 43210 USA.
[Sinnott, Jennifer A.; Valdimarsdottir, Unnur; Gerke, Travis; Fiorentino, Michelangelo; Sesso, Howard D.; Wilson, Kathryn M.; Giovannucci, Edward L.; Mucci, Lorelei A.; Fall, Katja] Harvard Univ, Dept Epidemiol, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
[Valdimarsdottir, Unnur; Wilson, Kathryn M.] Univ Iceland, Sch Hlth Sci, Ctr Publ Hlth Sci, Fac Med, Reykjavik, Iceland.
[Gerke, Travis] Univ Florida, Coll Med, Dept Epidemiol, Gainesville, FL USA.
[Gerke, Travis] Univ Florida, Coll Publ Hlth & Hlth Profess, Gainesville, FL USA.
[Tyekucheva, Svitlana] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Fiorentino, Michelangelo; Loda, Massimo] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA.
[Fiorentino, Michelangelo] St Orsola Marcello Malpighi Hosp, Addarii Inst, Pathol Unit, Bologna, Italy.
[Lambe, Mats] Univ Uppsala Hosp, Reg Canc Ctr, Uppsala, Sweden.
[Sesso, Howard D.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA.
[Sesso, Howard D.; Giovannucci, Edward L.; Loda, Massimo; Mucci, Lorelei A.] Harvard Univ, Sch Med, Boston, MA USA.
[Sesso, Howard D.] Brigham & Womens Hosp, Dept Med, Div Aging, 75 Francis St, Boston, MA 02115 USA.
[Sweeney, Christopher J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Giovannucci, Edward L.; Mucci, Lorelei A.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
[Loda, Massimo] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
[Fall, Katja] Univ Orebro, Clin Epidemiol & Biostat, Fac Med & Hlth, SE-70182 Orebro, Sweden.
RP Sinnott, JA (reprint author), Ohio State Univ, Dept Stat, 1958 Neil Ave, Columbus, OH 43210 USA.; Lu, DH (reprint author), Karolinska Inst, Nobels Vag 12A,Box 281, S-17177 Stockholm, Sweden.
EM DONGHAO.LU@KI.SE; jsinnott@stat.osu.edu
FU Partial Financing of New Doctoral Student (KID) from the Karolinska
Institutet; NIH [T32GM074897, T32 CA09001, CA136578, CA090381]; A. David
Mazzone Career Development Award; Svenska Sallskapet for Medicinsk
Forskning; Cancerfonden [CAN 2013/650]; Strategic funding from Orebro
University; Prostate Cancer Foundation; [CA34944]; [CA40360];
[CA097193]; [HL26490]; [HL34595]; [CA133891]; [CA141298];
[P01CA055075]
FX The Physicians' Health Study was supported by grants CA34944, CA40360,
CA097193, HL26490, and HL34595. The Health Professionals Follow-up Study
was supported by grants CA133891, CA141298, and P01CA055075. This work
was supported by Partial Financing of New Doctoral Student (KID) from
the Karolinska Institutet (to D. Lu); by the NIH grants T32GM074897, T32
CA09001 (to J.A. Sinnott), CA136578 and CA090381 (to L.A. Mucci); by the
A. David Mazzone Career Development Award (JAS); by Svenska Sallskapet
for Medicinsk Forskning (to F. Fang); by Cancerfonden (CAN 2013/650) and
Strategic funding from Orebro University (to K. Fall), and the Prostate
Cancer Foundation (to L.A. Mucci).
NR 38
TC 0
Z9 0
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 1
PY 2016
VL 22
IS 3
BP 765
EP 772
DI 10.1158/1078-0432.CCR-15-0101
PG 8
WC Oncology
SC Oncology
GA DC2XY
UT WOS:000369083300026
PM 26490316
ER
PT J
AU Christensen, KD
Vassy, JL
Jamal, L
Lehmann, LS
Slashinski, MJ
Perry, DL
Robinson, JO
Blumenthal-Barby, J
Feuerman, LZ
Murray, MF
Green, RC
McGuire, AL
AF Christensen, K. D.
Vassy, J. L.
Jamal, L.
Lehmann, L. S.
Slashinski, M. J.
Perry, D. L.
Robinson, J. O.
Blumenthal-Barby, J.
Feuerman, L. Z.
Murray, M. F.
Green, R. C.
McGuire, A. L.
CA MedSeq Project Team
TI Are physicians prepared for whole genome sequencing? a qualitative
analysis
SO CLINICAL GENETICS
LA English
DT Article
DE genetic literacy; physicians; preparedness; qualitative research;
self-efficacy; whole genome sequencing
ID GENETICS SERVICES; MEDSEQ PROJECT; CLINICAL CARE; MEDICINE;
PERSPECTIVES; INTEGRATION; EDUCATION; DELIVERY; OUTCOMES; SOCIETY
AB Although the integration of whole genome sequencing (WGS) into standard medical practice is rapidly becoming feasible, physicians may be unprepared to use it. Primary care physicians (PCPs) and cardiologists enrolled in a randomized clinical trial of WGS received genomics education before completing semi-structured interviews. Themes about preparedness were identified in transcripts through team-based consensus-coding. Data from 11 PCPs and 9 cardiologists suggested that physicians enrolled in the trial primarily to prepare themselves for widespread use of WGS in the future. PCPs were concerned about their general genomic knowledge, while cardiologists were concerned about how to interpret specific types of results and secondary findings. Both cohorts anticipated preparing extensively before disclosing results to patients by using educational resources with which they were already familiar, and both cohorts anticipated making referrals to genetics specialists as needed. A lack of laboratory guidance, time pressures, and a lack of standards contributed to feeling unprepared. Physicians had specialty-specific concerns about their preparedness to use WGS. Findings identify specific policy changes that could help physicians feel more prepared, and highlight how providers of all types will need to become familiar with interpreting WGS results.
C1 [Christensen, K. D.; Vassy, J. L.; Lehmann, L. S.; Perry, D. L.; Green, R. C.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.
[Christensen, K. D.; Vassy, J. L.; Lehmann, L. S.; Perry, D. L.; Green, R. C.] Harvard Univ, Sch Med, EC Alumnae Bldg,Suite 301,41 Ave Louis Pasteur, Boston, MA 02115 USA.
[Vassy, J. L.] VA Boston Healthcare Syst, Sect Gen Internal Med, Boston, MA USA.
[Jamal, L.; Robinson, J. O.; Blumenthal-Barby, J.; Feuerman, L. Z.; McGuire, A. L.] Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA.
[Slashinski, M. J.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA.
[Murray, M. F.] Geisinger Hlth Syst, Genom Med Inst, Danville, PA USA.
[Green, R. C.] Brigham & Womens Hosp, Partners Personalized Med, 75 Francis St, Boston, MA 02115 USA.
RP Christensen, KD (reprint author), Harvard Univ, Sch Med, EC Alumnae Bldg,Suite 301,41 Ave Louis Pasteur, Boston, MA 02115 USA.; Christensen, KD (reprint author), Brigham & Womens Hosp, EC Alumnae Bldg,Suite 301,41 Ave Louis Pasteur, Boston, MA 02115 USA.
EM kchristensen@genetics.med.harvard.edu
FU NHGRI [U01HG006500]; National Institutes of Health (NIH) [U19HD077671,
F32HG006993, KL2TR001100]
FX This study is a Clinical Sequencing Exploratory Research (CSER) program
project supported by NHGRI U01HG006500. This work was also supported by
the National Institutes of Health (NIH) grants U19HD077671, F32HG006993,
and KL2TR001100). The authors thank the members and participants of the
MedSeq Project for their important contributions. The authors thank 5AM
Solutions, Inc. (Rockville, MD) for their help in customizing the
workflow of the 'My Family Health Portrait' web tool for this study.
NR 43
TC 8
Z9 8
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9163
EI 1399-0004
J9 CLIN GENET
JI Clin. Genet.
PD FEB
PY 2016
VL 89
IS 2
BP 228
EP 234
DI 10.1111/cge.12626
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA DB8ZY
UT WOS:000368806900014
PM 26080898
ER
PT J
AU Heyne, TF
Robinban, NH
Lin, AE
AF Heyne, T. F.
Robinban, N. H.
Lin, A. E.
TI Sixteenth-century German woodcut of a male infant with possible
disorganization
SO CLINICAL GENETICS
LA English
DT Editorial Material
DE art; congenital; disorganization; German; history; malformation; woodcut
ID MOUSE MUTANT DISORGANIZATION; POSSIBLE HUMAN HOMOLOG; HUMANS; MICE
AB History has preserved a beautiful 16th century woodcut print, which depicts an infant with several malformations. The German inscription describes the infant's hypotonia and ectopic growths, and the image itself shows a child with an ectopic accessory third lower limb, a large papilla, and an omphalocele-like growth. The case' bears striking similarity to reported human cases of the disorganization (Ds) syndrome. This article describes the woodcut, describes Ds, and then explains how the image may represent the earliest depiction of Ds in history.
C1 [Heyne, T. F.] Massachusetts Gen Hosp, Harvard Internal Med & Pediat Residency Program, Boston, MA 02114 USA.
[Robinban, N. H.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA.
[Robinban, N. H.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA.
[Robinban, N. H.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.
[Lin, A. E.] Mass Gen Hosp Children, Med Genet Unit, Boston, MA USA.
RP Heyne, TF (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Internal Med & Pediat, 175 Cambridge St,5th Floor, Boston, MA 02114 USA.
EM theyne@partners.org
NR 12
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9163
EI 1399-0004
J9 CLIN GENET
JI Clin. Genet.
PD FEB
PY 2016
VL 89
IS 2
BP 269
EP 271
DI 10.1111/cge.12643
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA DB8ZY
UT WOS:000368806900020
PM 26183129
ER
PT J
AU Hashoul-Andary, R
Assayag-Nitzan, Y
Yuval, K
Aderka, IM
Litz, B
Bernstein, A
AF Hashoul-Andary, Raneen
Assayag-Nitzan, Yaara
Yuval, Kim
Aderka, Idan M.
Litz, Brett
Bernstein, Amit
TI A Longitudinal Study of Emotional Distress Intolerance and
Psychopathology Following Exposure to a Potentially Traumatic Event in a
Community Sample
SO COGNITIVE THERAPY AND RESEARCH
LA English
DT Article
DE Anxiety Sensitivity; Distress Tolerance; Trauma; PTSD; Psychopathology;
Structural Equation Modeling
ID POSTTRAUMATIC-STRESS-DISORDER; PTSD SYMPTOM SEVERITY; NATIONAL
COMORBIDITY SURVEY; SELF-REPORT MEASURE; ANXIETY SENSITIVITY; PANIC
DISORDER; INTEROCEPTIVE EXPOSURE; PSYCHIATRIC-DISORDERS; INCREMENTAL
VALIDITY; STRUCTURAL MODELS
AB This study focused on better understanding the association between anxiety sensitivity (AS), distress tolerance (DT), and psychopathology, including posttraumatic stress, depression, panic and suicidality, in the aftermath of a potentially traumatizing event. A community-based sample of 151 adults exposed to the Mount Carmel Forest Fire Disaster were assessed within 30-days of exposure (T1) and then at 3- (T2) and 6-month (T3) follow-up intervals. At T1, AS, DT, and psychopathology symptoms loaded on a single common latent factor reflecting Emotional Avoidance and Distress; whereas by T2 AS-DT and psychopathology symptoms diverged into distinct latent variables-Emotional Distress Intolerance and Distress Post-Trauma, respectively. Levels of Emotional Distress and Avoidance at T1 predicted levels of Emotional Distress Intolerance as well as Distress Post-Trauma at T2. Finally, levels of Emotional Intolerance at T2 predicted levels of Distress Post-Trauma at T3 above and beyond the strong stability effects of Distress Post-Trauma over time. Findings are discussed with respect to their theoretical and clinical implications for understanding and promoting resilience to, and recovery following, exposure to potentially traumatic events.
C1 [Hashoul-Andary, Raneen; Assayag-Nitzan, Yaara; Yuval, Kim; Aderka, Idan M.; Bernstein, Amit] Univ Haifa, Dept Psychol, IL-31905 Haifa, Israel.
[Litz, Brett] VA Boston Healthcare Syst, Boston, MA USA.
[Litz, Brett] Boston Univ, Boston, MA 02215 USA.
RP Bernstein, A (reprint author), Univ Haifa, Dept Psychol, IL-31905 Haifa, Israel.
EM abernstein@psy.haifa.ac.il
FU Israeli Science Foundation (ISF); Israeli Council for Higher Education
Yigal Alon Fellowship; European Union FP-7 Marie Curie Fellowship
International Reintegration Grant; Psychology Beyond Borders Mission
Award; Rothschild-Caesarea Foundation
FX Dr. Bernstein recognizes the funding support from the Israeli Science
Foundation (ISF), Israeli Council for Higher Education Yigal Alon
Fellowship, the European Union FP-7 Marie Curie Fellowship International
Reintegration Grant, Psychology Beyond Borders Mission Award, and the
Rothschild-Caesarea Foundation. We thank Dr. Barbara M. Byrne for her
kind assistance with the SEM analyses in AMOS.
NR 100
TC 0
Z9 0
U1 5
U2 16
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0147-5916
EI 1573-2819
J9 COGNITIVE THER RES
JI Cogn. Ther. Res.
PD FEB
PY 2016
VL 40
IS 1
BP 1
EP 13
DI 10.1007/s10608-015-9730-4
PG 13
WC Psychology, Clinical
SC Psychology
GA DC1VP
UT WOS:000369006100001
ER
PT J
AU Riddle, MA
Maher, BS
Wang, Y
Grados, M
Bienvenu, OJ
Goes, FS
Cullen, B
Murphy, DL
Rauch, SL
Greenberg, BD
Knowles, JA
McCracken, JT
Pinto, A
Piacentini, J
Pauls, DL
Rasmussen, SA
Shugart, YY
Nestadt, G
Samuels, J
AF Riddle, Mark A.
Maher, Brion S.
Wang, Ying
Grados, Marco
Bienvenu, O. Joseph
Goes, Fernando S.
Cullen, Bernadette
Murphy, Dennis L.
Rauch, Scott L.
Greenberg, Benjamin D.
Knowles, James A.
McCracken, James T.
Pinto, Anthony
Piacentini, John
Pauls, David L.
Rasmussen, Steven A.
Shugart, Yin Yao
Nestadt, Gerald
Samuels, Jack
TI OBSESSIVE-COMPULSIVE PERSONALITY DISORDER: EVIDENCE FOR TWO DIMENSIONS
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE obsessive-compulsive disorder; personality disorder; genetic; assessment
and diagnosis; hoarding
ID OCD COLLABORATIVE GENETICS; GENOTYPING ERRORS; COMMUNITY SAMPLE; DSM-IV;
PREVALENCE; IDENTIFICATION; ASSOCIATION; RATIONALE; FAMILY
AB BackgroundTo determine possible dimensions that underlie obsessive-compulsive personality disorder (OCPD) and to investigate their clinical correlates, familiality, and genetic linkage.
MethodsParticipants were selected from 844 adults assessed with the Structured Instrument for the Diagnosis of DSM-IV Personality Disorders (SIDP) in the OCD Collaborative Genetics Study (OCGS) that targeted families with obsessive-compulsive disorder (OCD) affected sibling pairs. We conducted an exploratory factor analysis, which included the eight SIDP-derived DSM-IV OCPD traits and the indecision trait from the DSM-III, assessed clinical correlates, and estimated sib-sib correlations to evaluate familiality of the factors. Using MERLIN and MINX, we performed genome-wide quantitative trait locus (QTL) linkage analysis to test for allele sharing among individuals.
ResultsTwo factors were identified: Factor 1: order/control (perfectionism, excessive devotion to work, overconscientiousness, reluctance to delegate, and rigidity); and Factor 2: hoarding/indecision (inability to discard and indecisiveness). Factor 1 score was associated with poor insight, whereas Factor 2 score was associated with task incompletion. A significant sib-sib correlation was found for Factor 2 (rICC = .354, P < .0001) but not Factor 1 (rICC = .129, P = .084). The linkage findings were different for the two factors. When Factor 2 was analyzed as a quantitative trait, a strong signal was detected on chromosome 10 at marker d10s1221: KAC LOD = 2.83, P = .0002; and marker d10s1225: KAC LOD = 1.35, P = .006.
ConclusionsThe results indicate two factors of OCPD, order/control and hoarding/indecision. The hoarding/indecision factor is familial and shows modest linkage to a region on chromosome 10.
C1 [Riddle, Mark A.; Wang, Ying; Grados, Marco; Bienvenu, O. Joseph; Goes, Fernando S.; Cullen, Bernadette; Nestadt, Gerald; Samuels, Jack] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, 550 N Broadway,Suite 203, Baltimore, MD 21205 USA.
[Maher, Brion S.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, 550 N Broadway,Suite 203, Baltimore, MD 21205 USA.
[Murphy, Dennis L.] NIMH, Clin Sci Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Rauch, Scott L.] Harvard Univ, Sch Med, Dept Psychiat, McLean Hosp, Boston, MA 02115 USA.
[Greenberg, Benjamin D.; Rasmussen, Steven A.] Butler Hosp, Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI 02906 USA.
[Knowles, James A.] Univ So Calif, Sch Med, Dept Psychiat, Los Angeles, CA USA.
[McCracken, James T.; Piacentini, John] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Pinto, Anthony] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Psychiat, New York, NY 10032 USA.
[Pauls, David L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Psychiat & Neurodev Genet Unit, Boston, MA USA.
[Shugart, Yin Yao] NIMH, Unit Stat Genom, Div Intramural Res, NIH, Bethesda, MD 20892 USA.
RP Riddle, MA (reprint author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, 550 N Broadway,Suite 203, Baltimore, MD 21205 USA.; Riddle, MA (reprint author), Johns Hopkins Univ, Sch Med, 550 N Broadway,Suite 203, Baltimore, MD 21205 USA.
EM mriddle1@jhmi.edu
RI Pinto, Anthony/D-2718-2017;
OI Pinto, Anthony/0000-0002-6078-7242; Samuels, Jack/0000-0002-6715-7905
FU National Institute of Mental Health; NIH; NARSAD; Seaside Therapeutics;
Roche; Shire; Dart Neuroscience [R01MH50214, MH071507, MH079489,
MH079487, MH079488, MH079494]
FX Contract grant sponsor: National Institute of Mental Health; Contract
grant sponsor: NIH; Contract grant sponsor: NARSAD; Contract grant
sponsor: Seaside Therapeutics; Contract grant sponsor: Roche; Contract
grant sponsor: Shire Contract grant sponsor: Dart Neuroscience; Contract
grant numbers: R01MH50214, MH071507, MH079489, MH079487, MH079488, and
MH079494.
NR 42
TC 1
Z9 1
U1 6
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
EI 1520-6394
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD FEB
PY 2016
VL 33
IS 2
BP 128
EP 135
DI 10.1002/da.22452
PG 8
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA DC2SE
UT WOS:000369065800004
PM 26594839
ER
PT J
AU Boes, AD
Caruso, P
Duhaime, AC
Fischl, B
AF Boes, Aaron D.
Caruso, Paul
Duhaime, Ann-Christine
Fischl, Bruce
TI FreeSurfer is useful for early detection of Rasmussen's encephalitis
prior to obvious atrophy
SO DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
LA English
DT Editorial Material
C1 [Boes, Aaron D.] Harvard Univ, Sch Med, Dept Neurol, Berenson Allen Ctr Noninvas Brain Stimulat,Div Co, Boston, MA 02114 USA.
[Boes, Aaron D.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Boes, Aaron D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Neurol, Boston, MA 02114 USA.
[Caruso, Paul; Fischl, Bruce] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA.
[Duhaime, Ann-Christine] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Neurosurg, Boston, MA 02114 USA.
[Fischl, Bruce] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Fischl, Bruce] MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
RP Boes, AD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Neurol, Boston, MA 02114 USA.
EM aboes@partners.org
FU NINDS NIH HHS [R25 NS065743, 5R25NS065743-05]
NR 2
TC 0
Z9 0
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0012-1622
EI 1469-8749
J9 DEV MED CHILD NEUROL
JI Dev. Med. Child Neurol.
PD FEB
PY 2016
VL 58
IS 2
BP 209
EP 210
DI 10.1111/dmcn.12847
PG 2
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA DC1MV
UT WOS:000368981300027
PM 26174006
ER
PT J
AU Jaffa, MA
Luttrell, D
Schmaier, AH
Klein, RL
Lopes-Virella, M
Luttrell, LM
Jaffa, AA
AF Jaffa, Miran A.
Luttrell, Deirdre
Schmaier, Alvin H.
Klein, Richard L.
Lopes-Virella, Maria
Luttrell, Louis M.
Jaffa, Ayad A.
CA DCC EDIC Res Grp
TI Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness
in Type 1 Diabetes
SO DIABETES
LA English
DT Article
ID KALLIKREIN-KININ SYSTEM; VASCULAR SMOOTH-MUSCLE; MACROVASCULAR
COMPLICATIONS; CONTACT ACTIVATION; ENDOTHELIAL-CELLS;
PROLYLCARBOXYPEPTIDASE; INFLAMMATION; NEPHROPATHY; PROGRESSION;
MECHANISM
AB The hypothesis that plasma prekallikrein (PK) is a risk factor for the development of vascular complications was assessed in a study using the Diabetes Control and Complications Trial (DCCT)/Epidemiology and Diabetes Interventions and Complications (EDIC) cohort of subjects with type 1 diabetes. The circulating levels of plasma PK activity were measured in the plasma of 636 subjects with type 1 diabetes (EDIC years 3-5). Common and internal carotid intima-media thickness (IMT) were measured by B-mode ultrasonography in EDIC years 1 and 6. Plasma PK levels were positively and significantly associated with BMI, hemoglobin A(1c), systolic blood pressure, total cholesterol, LDL cholesterol, and triglycerides but not with age, sex, duration of diabetes, or HDL cholesterol. Univariate and multivariable statistical models after controlling for other risk factors consistently demonstrated a positive association between plasma PK and progression of internal carotid IMT. Multivariate analysis using a general linear model showed plasma PK to be significantly associated with progression of both internal and combined IMT (Wilks Lambda P value of 0.005). In addition, the mean internal carotid IMT levels were higher in subjects with plasma PK levels in the highest 10th percentile compared with subjects with plasma PK levels in the lower 10th percentile (P = 0.048). These novel findings implicate plasma PK as a risk factor for vascular disease in type 1 diabetes.
C1 [Jaffa, Miran A.] Amer Univ Beirut, Fac Hlth Sci, Epidemiol & Populat Hlth Dept, Beirut, Lebanon.
[Luttrell, Deirdre; Klein, Richard L.; Lopes-Virella, Maria; Luttrell, Louis M.; Jaffa, Ayad A.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Schmaier, Alvin H.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA.
[Klein, Richard L.] Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC 29403 USA.
[Jaffa, Ayad A.] Amer Univ Beirut, Dept Biochem & Mol Genet, Fac Med, Beirut, Lebanon.
RP Jaffa, AA (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.; Jaffa, AA (reprint author), Amer Univ Beirut, Dept Biochem & Mol Genet, Fac Med, Beirut, Lebanon.
EM aj24@aub.edu.lb
FU National Institutes for Health [HL-052779, HL-055782, HL-077192,
HL-087986]; Division of Diabetes, Endocrinology, and Metabolic Diseases,
National Institute for Diabetes and Digestive and Kidney Diseases,
National Institutes of Health
FX This work was supported by National Institutes for Health research
grants HL-052779 (to A.H.S.), HL-055782 (to M.L.-V.), and HL-077192 and
HL-087986 (to A.A.J.). The DCCT/EDIC was sponsored through research
contracts from the Division of Diabetes, Endocrinology, and Metabolic
Diseases, National Institute for Diabetes and Digestive and Kidney
Diseases, National Institutes of Health.
NR 24
TC 1
Z9 1
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD FEB
PY 2016
VL 65
IS 2
BP 498
EP 502
DI 10.2337/db15-0930
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DC1HS
UT WOS:000368968000020
PM 26603531
ER
PT J
AU Hivert, MF
Christophi, CA
Franks, PW
Jablonski, KA
Ehrmann, DA
Kahn, SE
Horton, ES
Pollin, TI
Mather, KJ
Perreault, L
Barrett-Connor, E
Knowler, WC
Florez, JC
AF Hivert, Marie-France
Christophi, Costas A.
Franks, Paul W.
Jablonski, Kathleen A.
Ehrmann, David A.
Kahn, Steven E.
Horton, Edward S.
Pollin, Toni I.
Mather, Kieren J.
Perreault, Leigh
Barrett-Connor, Elizabeth
Knowler, William C.
Florez, Jose C.
CA Diabetes Prevention Program Res
TI Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of
the Genetic Burden of Established Insulin Resistance Variants in
Diabetes Prevention Program Participants
SO DIABETES
LA English
DT Article
ID BETA-CELL DYSFUNCTION; RELATIVE CONTRIBUTIONS; GLUCOSE-TOLERANCE;
GLYCEMIC TRAITS; INTERVENTION; HOMEOSTASIS; SECRETION
AB Large genome-wide association studies of glycemic traits have identified genetics variants that are associated with insulin resistance (IR) in the general population. It is unknown whether people with genetic enrichment for these IR variants respond differently to interventions that aim to improve insulin sensitivity. We built a genetic risk score (GRS) based on 17 established IR variants and effect sizes (weighted IR-GRS) in 2,713 participants of the Diabetes Prevention Program (DPP) with genetic consent. We tested associations between the weighted IR-GRS and insulin sensitivity index (ISI) at baseline in all participants, and with change in ISI over 1 year of follow-up in the DPP intervention (metformin and lifestyle) and control (placebo) arms. All models were adjusted for age, sex, ethnicity, and waist circumference at baseline (plus baseline ISI for 1-year ISI change models). A higher IR-GRS was associated with lower baseline ISI (beta= -0.754 [SE = 0.229] log-ISI per unit, P = 0.001 in fully adjusted models). There was no differential effect of treatment for the association between the IR-GRS on the change in ISI; higher IR-GRS was associated with an attenuation in ISI improvement over 1 year (beta = -0.520 [SE = 0.233], P = 0.03 in fully adjusted models; all treatment arms). Lifestyle intervention and metformin treatment improved the ISI, regardless of the genetic burden of IR variants.
C1 [Hivert, Marie-France] Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA 02115 USA.
[Hivert, Marie-France; Florez, Jose C.] Massachusetts Gen Hosp, Dept Med, Diabet Res Ctr, Diabet Unit, Boston, MA 02114 USA.
[Hivert, Marie-France] Univ Sherbrooke, Dept Med, Sherbrooke, PQ J1K 2R1, Canada.
[Christophi, Costas A.; Jablonski, Kathleen A.] George Washington Univ, Ctr Biostat, Rockville, MD USA.
[Franks, Paul W.] Lund Univ, Dept Clin Sci, Ctr Diabet, Genet & Mol Epidemiol Unit, Malmo, Sweden.
[Franks, Paul W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
[Franks, Paul W.] Umea Univ, Dept Publ Hlth & Clin Med, Div Med, Umea, Sweden.
[Ehrmann, David A.] Univ Chicago, Sch Med, Dept Med, Chicago, IL 60637 USA.
[Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA.
[Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA.
[Horton, Edward S.] Joslin Diabet Ctr, Sect Clin Behav & Outcomes Res, Boston, MA 02215 USA.
[Horton, Edward S.; Florez, Jose C.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Pollin, Toni I.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.
[Pollin, Toni I.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA.
[Pollin, Toni I.] Univ Maryland, Sch Med, Program Personalized & Genom Med, Baltimore, MD 21201 USA.
[Mather, Kieren J.] Indiana Univ Sch Med, Dept Med, Div Endocrinol, Indianapolis, IN 46202 USA.
[Perreault, Leigh] Univ Colorado, Dept Med, Div Endocrinol Metab & Diabet, Anschutz Med Campus, Aurora, CO USA.
[Barrett-Connor, Elizabeth] Univ Calif San Diego, Dept Family Med & Publ Hlth, Div Epidemiol, La Jolla, CA 92093 USA.
[Knowler, William C.] NIDDK, Diabet Epidemiol & Clin Res Sect, Phoenix, AZ USA.
[Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Florez, Jose C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
RP Florez, JC (reprint author), Massachusetts Gen Hosp, Dept Med, Diabet Res Ctr, Diabet Unit, Boston, MA 02114 USA.; Florez, JC (reprint author), Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.; Florez, JC (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.; Florez, JC (reprint author), Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
EM dppmail@bsc.gwu.edu
OI Kahn, Steven/0000-0001-7307-9002
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
of the National Institutes of Health [DK-48489]; NIDDK; Indian Health
Service; National Institute of Child Health and Human Development;
National Institute on Aging; National Eye Institute; National Heart,
Lung, and Blood Institute; Office of Research on Women's Health;
National Institute on Minority Health and Health Disparities; Centers
for Disease Control and Prevention; American Diabetes Association
FX During the DPPOS, the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) of the National Institutes of Health provided
funding (grant DK-48489) to the clinical centers and the Coordinating
Center for the design and conduct of the study, and The collection,
management, analysis, and interpretation of the data. The Southwestern
American Indian Centers were supported directly by the NIDDK, including
its Intramural Research Program and the Indian Health Service. The
General Clinical Research Center Program, National Center for Research
Resources, and the Department of Veterans Affairs supported data
collection at many of the clinical centers. Funding was also provided by
the National Institute of Child Health and Human Development; the
National Institute on Aging; the National Eye Institute; the National
Heart, Lung, and Blood Institute; the Office of Research on Women's
Health; the National Institute on Minority Health and Health
Disparities; the Centers for Disease Control and Prevention; and the
American Diabetes Association. Lipha (Merck-Sante) provided medication,
and LifeScan, Inc. donated materials during the DPP and DPPOS.
NR 20
TC 4
Z9 4
U1 2
U2 4
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD FEB
PY 2016
VL 65
IS 2
BP 520
EP 526
DI 10.2337/db15-0950
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DC1HS
UT WOS:000368968000023
PM 26525880
ER
PT J
AU Kaunitz, JD
AF Kaunitz, Jonathan D.
TI The Doppler Effect: A Century from Red Shift to Red Spot
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Editorial Material
ID BLOOD-FLOW; ULTRASOUND
C1 [Kaunitz, Jonathan D.] VA Greater Los Angeles Healthcare Syst, Bldg 114-217E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
[Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Bldg 114-217E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
RP Kaunitz, JD (reprint author), VA Greater Los Angeles Healthcare Syst, Bldg 114-217E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.; Kaunitz, JD (reprint author), Univ Calif Los Angeles, Sch Med, Bldg 114-217E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jake@ucla.edu
FU BLRD VA [I01 BX001245]; Intramural VA [VA999999]; NIDDK NIH HHS [R01
DK054221]
NR 12
TC 0
Z9 0
U1 1
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD FEB
PY 2016
VL 61
IS 2
BP 340
EP 341
DI 10.1007/s10620-015-3998-9
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DC1XR
UT WOS:000369012100006
PM 26745970
ER
PT J
AU Sahora, K
Crippa, S
Zamboni, G
Ferrone, C
Warshaw, AL
Lillemoe, K
Mino-Kenudson, M
Falconi, M
Fernandez-del Castillo, C
AF Sahora, K.
Crippa, S.
Zamboni, G.
Ferrone, C.
Warshaw, A. L.
Lillemoe, K.
Mino-Kenudson, M.
Falconi, M.
Fernandez-del Castillo, C.
TI Intraductal papillary mucinous neoplasms of the pancreas with concurrent
pancreatic and periampullary neoplasms
SO EJSO
LA English
DT Article
DE Pancreas; Intraductal papillary mucinous noeplasm; Concurrent neoplasm;
Pancreatic cancer
ID TERM-FOLLOW-UP; BRANCH-DUCT; CARCINOMA; CONSENSUS; CONCOMITANT;
PREDICTORS; RESECTION; TUMOR; IPMN; ADENOCARCINOMAS
AB Background: Intraductal papillary mucinous neoplasms (IPMN) have been reported to be associated with concurrent, distinct pancreatic ductal adenocarcinoma (con-PDAC) in about 8% (range, 4-10%) of resected branch duct (BD) lesions. In addition, other pancreatic and ampullary tumors are occasionally diagnosed with IPMN in patients undergoing pancreatic surgery. The objective of this study is to describe the prevalence, clinicopathologic characteristics and prognosis of IPMN with concurrent pancreatic and ampullary neoplasms, especially con-PDAC.
Methods: The combined databases of pancreatic resections from the Massachusetts General Hospital and the Negrar Hospital, Italy, were analyzed for patients who had been diagnosed with IPMN and concurrent pancreatic or ampullary neoplasms.
Results: 2762 patients underwent pancreatic surgery from January 2000 to December 2012. Sixteen percent (n = 441) had pathologically confirmed IPMN and 11% of these (n = 50) had a different distinct synchronous pancreatic neoplasm. The majority of these, 62%, were con-PDAC, followed by neuroendocrine neoplasms (10%) and ampullary carcinoma (10%). Less frequently, mucinous (6%) as well as serous cystic neoplasms (6%), adenosquamous carcinoma (4%) and distal bile duct cancer (2%) were diagnosed. Among all patients with synchronous neoplasms, 66% harbored BD-IPMN, 28% combined IPMN and 6% main duct IPMN. Abdominal pain and/or jaundice were the leading symptoms in half of patients.
Conclusion: IPMN, mainly BD-IPMN, are associated with con-PDAC in about 7% of patients and account for 62% of all concurrent pancreatic/ampullary neoplasms. Other synchronous neoplasms may be found sporadically with IPMN without a suspected association. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Sahora, K.; Ferrone, C.; Warshaw, A. L.; Lillemoe, K.; Fernandez-del Castillo, C.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Sahora, K.; Ferrone, C.; Warshaw, A. L.; Lillemoe, K.; Mino-Kenudson, M.; Fernandez-del Castillo, C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Crippa, S.; Falconi, M.] Osped Sacro Cuore Don Calabria, Dept Surg, Negrar, VR, Italy.
[Crippa, S.; Zamboni, G.; Falconi, M.] Osped Sacro Cuore Don Calabria, Dept Pathol, Negrar, VR, Italy.
[Crippa, S.; Falconi, M.] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Div Pancreat Surg, Milan, Italy.
RP Fernandez-del Castillo, C (reprint author), Harvard Univ, Massachusetts Gen Hosp, Wang Ambulatory Care Ctr, Dept Surg,Med Sch, 460,15 Parkman St, Boston, MA 02114 USA.
EM cfernandez@partners.org
OI Zamboni, Giuseppe/0000-0001-7428-4673; Falconi,
Massimo/0000-0001-9654-7243
NR 40
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0748-7983
EI 1532-2157
J9 EJSO-EUR J SURG ONC
JI EJSO
PD FEB
PY 2016
VL 42
IS 2
BP 197
EP 204
DI 10.1016/j.ejso.2015.10.014
PG 8
WC Oncology; Surgery
SC Oncology; Surgery
GA DC1GP
UT WOS:000368965100006
PM 26687069
ER
PT J
AU Flinn, IW
Bartlett, NL
Blum, KA
Ardeshna, KM
LaCasce, AS
Flowers, CR
Shustov, AR
Thress, KS
Mitchell, P
Zheng, F
Skolnik, JM
Friedberg, JW
AF Flinn, Ian W.
Bartlett, Nancy L.
Blum, Kristie A.
Ardeshna, Kirit M.
LaCasce, Ann S.
Flowers, Christopher R.
Shustov, Andrei R.
Thress, Kenneth S.
Mitchell, Patrick
Zheng, Fred
Skolnik, Jeffrey M.
Friedberg, Jonathan W.
TI A phase II trial to evaluate the efficacy of fostamatinib in patients
with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE DLBCL; Syk inhibitor; B-cell receptor; Phase II; Clinical trial
ID GENE-EXPRESSION; MALIGNANT-LYMPHOMA; CHEMOTHERAPY; THERAPY; RITUXIMAB;
SURVIVAL; RECEPTOR; SUBTYPES; CHOP; SYK
AB Purpose: To assess the safety and efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Experimental design: Relapsed or refractory DLBCL patients originally received the oral spleen tyrosine kinase inhibitor, fostamatinib in a two-arm, randomised, double-blinded manner at either 100 mg twice a day (BID) or 200 mg BID until disease progression or unacceptable toxicity. The primary objective was to assess the overall response rate (ORR). Preliminary analysis showed limited efficacy and all subsequent patients were treated at 200 mg BID. Previously randomised patients were unblinded and given the opportunity to receive 200 mg BID.
Results: Sixty-eight patients were treated (47 at 200 mg BID, 21 at 100 mg BID). Cell of origin analysis showed 58% germinal B-cell (GCB) origin, 30% activated B-cell (ABC) origin and 12% with an intermediate cell of origin signature. The most common treatment-related adverse events of all patients were diarrhoea (21% total, 6% grade 3/4), nausea (19% total, 3% grade 3/4), and, fatigue (18% total, 9% grade 3/4). The ORR rate was 3% across both arms and clinical benefit (>= stable disease) was achieved for 13% of all patients. The cell of origin for patients with clinical benefit was GCB (4 patients), intermediate (4 patients) or unknown (1 patient). None of the patients with clinical benefit had ABC genotype.
Conclusions: While fostamatinib was generally well tolerated in this patient population, efficacy at these doses and schedule was poor. Unlike data with other B-cell antigen receptor pathway inhibitors, responses were not observed in the ABC genotype. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Flinn, Ian W.] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA.
[Bartlett, Nancy L.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA.
[Blum, Kristie A.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Ardeshna, Kirit M.] UCL, Sarah Cannon Res Inst United Kingdom, London, England.
[LaCasce, Ann S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Flowers, Christopher R.] Winship Canc Inst, Atlanta, GA USA.
[Shustov, Andrei R.] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
[Thress, Kenneth S.; Mitchell, Patrick] AstraZeneca, Waltham, MA USA.
[Zheng, Fred; Skolnik, Jeffrey M.] AstraZeneca, Wilmington, DE USA.
[Friedberg, Jonathan W.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
[Zheng, Fred] GlaxoSmithKline, Brentford, England.
[Skolnik, Jeffrey M.] TetraL Pharmaceut, Malvern, PA USA.
RP Flinn, IW (reprint author), Sarah Cannon Res Inst, 250 25th Ave North, Nashville, TN 37203 USA.
EM iflinn@tnonc.com
RI Flowers, Christopher/F-1953-2010
OI Flowers, Christopher/0000-0002-9524-3990
NR 32
TC 6
Z9 7
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD FEB
PY 2016
VL 54
BP 11
EP 17
DI 10.1016/j.ejca.2015.10.005
PG 7
WC Oncology
SC Oncology
GA DC3WQ
UT WOS:000369150000002
PM 26707592
ER
PT J
AU Wong, JC
Linn, KA
Shinohara, RT
Mateen, FJ
AF Wong, J. C.
Linn, K. A.
Shinohara, R. T.
Mateen, F. J.
TI Traumatic brain injury in Africa in 2050: a modeling study
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE acute brain injury; adolescent; adult; epidemiology
ID KENYA
AB Background and purposeOur aim was to provide estimates of traumatic brain injury (TBI) in 2050 for the African population by region, sex and age strata.
MethodsA literature search was performed in October 2014 in PubMed for population-based studies of TBI in different geographical locations. Articles were selected from Kenya (model 1), New Zealand (model 2) and the USA (model 3). In model 1, rates of road traffic injury in Kenya were used to estimate TBI rates in the African continent. Models 2 and 3 used existing TBI incidence estimates from other locations to estimate the burden of TBI for Africa in 2050. The 2050 African population, as projected by the United Nations, was used as a base population.
ResultsBased on rates from model 1, the estimated total TBI count in Africa in 2050 is 5.98 0.03 million, with the highest count in eastern (2.04 +/- 0.01 million) and lowest count in southern (0.15 +/- 0.00 million) Africa. A higher TBI count is predicted by models 2 (14.25 +/- 0.75 million) and 3 (10.40 +/- 0.02 million). Estimated TBI count is highest for males aged 15-34 (5.47 +/- 0.55 million in model 2 and 3.21 +/- 0.13 million in model 3).
ConclusionsProjected estimates of TBI in Africa are high, with a burden of anywhere between approximately 6 and 14 million new cases in 2050. This emphasizes the importance of developing accurate surveillance systems of TBI at a population level and public health measures to mitigate the risk and burden of TBI.
C1 [Wong, J. C.; Mateen, F. J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Wong, J. C.; Mateen, F. J.] Harvard Univ, Sch Med, Boston, MA USA.
[Wong, J. C.] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.
[Linn, K. A.; Shinohara, R. T.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
RP Mateen, FJ (reprint author), Massachusetts Gen Hosp, Neurol Clin Res Inst, Dept Neurol, 165 Cambridge St,627, Boston, MA 02114 USA.
EM fmateen@partners.org
NR 16
TC 1
Z9 1
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD FEB
PY 2016
VL 23
IS 2
BP 382
EP 386
DI 10.1111/ene.12877
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DB8WE
UT WOS:000368797100034
PM 26435298
ER
PT J
AU Kimball, AB
AF Kimball, Alexa B.
TI New insights into diagnosis of HS & classifications
SO EXPERIMENTAL DERMATOLOGY
LA English
DT Meeting Abstract
CT Joint CHSF/HSF/EHSF Pre-WCD Hidradenitis Suppurativa Symposium
CY JUN 06, 2015
CL Vancouver, CANADA
SP CHSF, HSF, EHSF
C1 [Kimball, Alexa B.] Harvard Univ, Sch Med, Boston, MA USA.
[Kimball, Alexa B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0906-6705
EI 1600-0625
J9 EXP DERMATOL
JI Exp. Dermatol.
PD FEB
PY 2016
VL 25
SU 1
MA 3
BP 7
EP 7
PG 1
WC Dermatology
SC Dermatology
GA DB9OR
UT WOS:000368846400005
ER
PT J
AU Schoenfeld, P
Dominitz, JA
AF Schoenfeld, Philip
Dominitz, Jason A.
TI No Polyp Left Behind: Defining Bowel Preparation Adequacy to Avoid
Missed Polyps
SO GASTROENTEROLOGY
LA English
DT Editorial Material
ID SOCIETY-TASK-FORCE; ADENOMA DETECTION RATE; AVERAGE-RISK PATIENTS;
COLORECTAL-CANCER; PREPARATION SCALE; COLONOSCOPY; RECOMMENDATIONS;
IMPACT; SURVEILLANCE; CLEANLINESS
C1 [Schoenfeld, Philip] Univ Michigan, Sch Med, Ann Arbor Vet Hlth Care Syst, Ann Arbor, MI USA.
[Dominitz, Jason A.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Schoenfeld, P (reprint author), Univ Michigan, Sch Med, Med, Room 111-D,2215 Fuller Rd, Ann Arbor, MI USA.
NR 23
TC 0
Z9 0
U1 1
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD FEB
PY 2016
VL 150
IS 2
BP 303
EP 306
DI 10.1053/j.gastro.2015.12.024
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DB6MU
UT WOS:000368629900010
PM 26713765
ER
PT J
AU Su, F
Yu, L
Berry, K
Liou, IW
Landis, CS
Rayhill, SC
Reyes, JD
Ioannou, GN
AF Su, Feng
Yu, Lei
Berry, Kristin
Liou, Iris W.
Landis, Charles S.
Rayhill, Stephen C.
Reyes, Jorge D.
Ioannou, George N.
TI Aging of Liver Transplant Registrants and Recipients: Trends and Impact
on Waitlist Outcomes, Post-Transplantation Outcomes, and
Transplant-Related Survival Benefit
SO GASTROENTEROLOGY
LA English
DT Article
DE Waitlist Outcomes; Post-Transplantation Outcomes; Transplant-Related
Survival Benefit
ID C VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; UNITED-STATES;
WAITING-LIST; NONALCOHOLIC STEATOHEPATITIS; CANDIDATES; MORTALITY;
OLDER; AGE; DISEASE
AB BACKGROUND & AIMS: Epidemiologic factors have generated increased demand for liver transplantation among older patients. We aimed to describe trends in age among liver transplant registrants and recipients and the effect of age on waitlist and post-transplantation outcomes and on transplant-related survival benefit. METHODS: We obtained data from the United Network for Organ Sharing on adults who were listed for liver transplantation (N = 122,606) or underwent liver transplantation (N = 60,820) from 2002 to 2014 in the United States. Competing risks analysis was used to model waitlist outcomes and Cox proportional hazards analysis to model post-transplantation survival. These models were also used to estimate 5-year transplant-related survival benefit for different age groups, calculated as the difference between waitlist and post-transplantation life expectancy. RESULTS: Between 2002 and 2014, the mean age of liver transplant registrants increased from 51.2 to 55.7 years, with a more prominent increase in hepatitis C virus-positive (50.9 - 57.9 years) than hepatitis C virus-negative (51.3 - 54.3 years) registrants. The proportion of registrants aged >= 60 years increased from 19% to 41%. In hepatitis C virus-negative patients, aging trends were driven by increasing proportions of patients with hepatocellular carcinoma or nonalcoholic steatohepatitis. Among transplant registrants, increasing age was associated with increasing mortality before transplantation and decreasing likelihood of transplantation. Among transplant recipients, increasing age was associated with increasing post-transplantation mortality. There was little difference in 5-year transplant-related survival benefit between different age groups who had the same Model for EndStage Liver Disease score. CONCLUSIONS: Dramatic aging of liver transplant registrants and recipients occurred from 2002 to 2014, driven by aging of the hepatitis C virus - positive cohort and increased prevalence of nonalcoholic steatohepatitis and hepatocellular carcinoma. Increasing age does not affect transplant-related survival benefit substantially because age diminishes both post-transplantation survival and waitlist survival approximately equally.
C1 [Su, Feng] Univ Washington, Dept Med, Div Internal Med, Seattle, WA USA.
[Yu, Lei; Liou, Iris W.; Landis, Charles S.; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA.
[Yu, Lei; Liou, Iris W.; Landis, Charles S.; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA.
[Berry, Kristin] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA.
[Rayhill, Stephen C.; Reyes, Jorge D.] Univ Washington, Dept Surg, Div Transplant Surg, Seattle, WA 98195 USA.
RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol, S-111 Gastro 1660 S Columbian Way, Seattle, WA 98108 USA.
EM georgei@medicine.washington.edu
FU Research and Development, Veterans Affairs Puget Sound Healthcare
System; Health Resources and Services Administration [231-00-0115]
FX This study was funded byResearch and Development, Veterans Affairs Puget
Sound Healthcare System. This work was supported in part by Health
Resources and Services Administration contract 231-00-0115.
NR 42
TC 4
Z9 4
U1 3
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD FEB
PY 2016
VL 150
IS 2
BP 441
EP +
DI 10.1053/j.gastro.2015.10.043
PG 19
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DB6MU
UT WOS:000368629900031
PM 26522262
ER
PT J
AU Berry, K
Ioannou, GN
AF Berry, Kristin
Ioannou, George N.
TI Estimation of Liver Transplant Related Survival Benefit: the Devil Is in
The Details Reply
SO GASTROENTEROLOGY
LA English
DT Letter
ID HEPATOCELLULAR-CARCINOMA
C1 [Berry, Kristin; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA.
[Ioannou, George N.] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA USA.
RP Berry, K (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD FEB
PY 2016
VL 150
IS 2
BP 535
EP 537
DI 10.1053/j.gastro.2015.12.030
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DB6MU
UT WOS:000368629900042
PM 26718174
ER
PT J
AU Schneider, JL
Davis, J
Kauffman, TL
Reiss, JA
McGinley, C
Arnold, K
Zepp, J
Gilmore, M
Muessig, KR
Syngal, S
Acheson, L
Wiesner, GL
Peterson, SK
Goddard, KAB
AF Schneider, Jennifer L.
Davis, James
Kauffman, Tia L.
Reiss, Jacob A.
McGinley, Cheryl
Arnold, Kathleen
Zepp, Jamilyn
Gilmore, Marian
Muessig, Kristin R.
Syngal, Sapna
Acheson, Louise
Wiesner, Georgia L.
Peterson, Susan K.
Goddard, Katrina A. B.
TI Stakeholder perspectives on implementing a universal Lynch syndrome
screening program: a qualitative study of early barriers and
facilitators
SO GENETICS IN MEDICINE
LA English
DT Article
DE implementation factors; stakeholder interviews; universal Lynch syndrome
screening
ID NONPOLYPOSIS COLORECTAL-CANCER; GENETIC TESTING STRATEGIES;
MICROSATELLITE INSTABILITY; REDUCING MORBIDITY; COST-EFFECTIVENESS;
MUTATIONS; IMMUNOHISTOCHEMISTRY; FEASIBILITY; MORTALITY; TUMORS
AB Purpose: Evidence-based guidelines recommend that all newly diagnosed colon cancer be screened for Lynch syndrome (LS), but best practices for implementing universal tumor screening have not been extensively studied. We interviewed a range of stakeholders in an integrated health-care system to identify initial factors that might promote or hinder the successful implementation of a universal LS screening program.
Methods: We conducted interviews with health-plan leaders, managers, and staff. Interviews were audio-recorded and transcribed. Thematic analysis began with a grounded approach and was also guided by the Practical Robust Implementation and Sustainability Model (PRISM).
Results: We completed 14 interviews with leaders/managers and staff representing involved clinical and health-plan departments. Although stakeholders supported the concept of universal screening, they identified several internal (organizational) and external (environment) factors that promote or hinder implementation. Facilitating factors included perceived benefits of screening for patients and organization, collaboration between departments, and availability of organizational resources. Barriers were also identified, including: lack of awareness of guidelines, lack of guideline clarity, staffing and program "ownership" concerns, and cost uncertainties. Analysis also revealed nine important infrastructure-type considerations for successful implementation.
Conclusion: We found that clinical, laboratory, and administrative departments supported universal tumor screening for LS. Requirements for successful implementation may include interdepartmental collaboration and communication, patient and provider/staff education, and significant infrastructure and resource support related to laboratory processing and systems for electronic ordering and tracking.
C1 [Schneider, Jennifer L.; Davis, James; Kauffman, Tia L.; Reiss, Jacob A.; McGinley, Cheryl; Arnold, Kathleen; Muessig, Kristin R.; Goddard, Katrina A. B.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA.
[Zepp, Jamilyn; Gilmore, Marian] Kaiser Permanente Northwest, Northwest Permanente, Portland, OR USA.
[Syngal, Sapna] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Acheson, Louise] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA.
[Wiesner, Georgia L.] Vanderbilt Ingram Canc Ctr, Vanderbilt Hereditary Canc Program, Nashville, TN USA.
[Peterson, Susan K.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
RP Schneider, JL (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA.
EM Jennifer.L.Schneider@kpchr.org
FU National Institute of Health [5R01CA140377]
FX This work was supported through a grant by the National Institute of
Health: 5R01CA140377 (K.A.B.G.). The authors thank Jill Pope for
editorial support and Robin Daily and Elizabeth Sheeley for
administrative assistance.
NR 34
TC 1
Z9 1
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
EI 1530-0366
J9 GENET MED
JI Genet. Med.
PD FEB
PY 2016
VL 18
IS 2
BP 152
EP 161
DI 10.1038/gim.2015.43
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA DC4EQ
UT WOS:000369173600008
PM 25880440
ER
PT J
AU Koyfman, SA
Cooper, JS
Beitler, JJ
Busse, PM
Jones, CU
McDonald, MW
Quon, H
Ridge, JA
Saba, NF
Salama, JK
Siddiqui, F
Smith, RV
Worden, F
Yao, M
Yom, SS
AF Koyfman, Shlomo A.
Cooper, Jay S.
Beitler, Jonathan J.
Busse, Paul M.
Jones, Christopher U.
McDonald, Mark W.
Quon, Harry
Ridge, John A.
Saba, Nabil F.
Salama, Joseph K.
Siddiqui, Farzan
Smith, Richard V.
Worden, Francis
Yao, Min
Yom, Sue S.
TI ACR Appropriateness Criteria((R)) Aggressive Nonmelanomatous Skin Cancer
of the Head and Neck
SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND
NECK
LA English
DT Article
DE Appropriateness Criteria; nonmelanomatous skin cancer; head neck; high
risk; radiotherapy
ID SQUAMOUS-CELL CARCINOMA; ORGAN TRANSPLANT RECIPIENTS; ADVANCED
BASAL-CELL; X-RAY THERAPY; PERINEURAL INVASION; CUTANEOUS HEAD;
PHASE-II; RADIOTHERAPY; FACE; CHEMOTHERAPY
AB BackgroundAggressive nonmelanomatous skin cancer (NMSC) of the head and neck presents an increasingly common therapeutic challenge for which prospective clinical trials are lacking.
MethodsThe American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
ResultsThe American College of Radiology Expert Panel on Radiation Oncology - Head and Neck Cancer developed consensus recommendations for guiding management of aggressive NMSC.
ConclusionMultidisciplinary assessment is vital to guiding the ideal use of surgery, radiation, and systemic therapy in this disease. (c) 2016 Wiley Periodicals, Inc. Head Neck38: 175-182, 2016
C1 [Koyfman, Shlomo A.] Cleveland Clin, Cleveland, OH 44106 USA.
[Cooper, Jay S.] Maimonides Canc Ctr, Brooklyn, NY USA.
[Beitler, Jonathan J.] Emory Univ, Sch Med, Atlanta, GA USA.
[Busse, Paul M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Jones, Christopher U.] Radiol Associates Sacramento, Sacramento, CA USA.
[McDonald, Mark W.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
[Quon, Harry] Johns Hopkins Univ, Baltimore, MD USA.
[Ridge, John A.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
[Saba, Nabil F.] Emory Univ, Atlanta, GA 30322 USA.
[Salama, Joseph K.] Duke Univ, Durham, NC USA.
[Siddiqui, Farzan] Henry Ford Hlth Syst, Detroit, MI USA.
[Smith, Richard V.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA.
[Worden, Francis] Univ Michigan, Ann Arbor, MI 48109 USA.
[Yao, Min] Univ Hosp, Case Med Ctr, Cleveland, OH USA.
[Yom, Sue S.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Koyfman, SA (reprint author), Cleveland Clin Fdn, Dept Radiat Oncol, 9500 Euclid Ave,Desk T28, Cleveland, OH 44195 USA.
EM Koyfmas@ccf.org
NR 37
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1043-3074
EI 1097-0347
J9 HEAD NECK-J SCI SPEC
JI Head Neck-J. Sci. Spec. Head Neck
PD FEB
PY 2016
VL 38
IS 2
BP 175
EP 182
DI 10.1002/hed.24171
PG 8
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA DB7ZB
UT WOS:000368735100009
PM 26791005
ER
PT J
AU Varvares, MA
Walker, RJ
AF Varvares, Mark A.
Walker, Ronald J.
TI Letter to the editor regarding: Management of invasive
well-differentiated thyroid cancer: An American Head and Neck Society
Consensus Statement
SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND
NECK
LA English
DT Letter
C1 [Varvares, Mark A.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Cambridge, MA 02138 USA.
[Varvares, Mark A.; Walker, Ronald J.] St Louis Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63103 USA.
RP Varvares, MA (reprint author), Massachusetts Eye & Ear Infirm, Dept Otorhinolaryngol Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA.
EM Mark_Varvares@meei.harvard.edu
NR 3
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1043-3074
EI 1097-0347
J9 HEAD NECK-J SCI SPEC
JI Head Neck-J. Sci. Spec. Head Neck
PD FEB
PY 2016
VL 38
IS 2
BP 328
EP 329
DI 10.1002/hed.24288
PG 2
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA DB7ZB
UT WOS:000368735100032
PM 26667782
ER
PT J
AU Mebazaa, A
Tolppanen, H
Mueller, C
Lassus, J
DiSomma, S
Baksyte, G
Cecconi, M
Choi, DJ
Solal, AC
Christ, M
Masip, J
Arrigo, M
Nouira, S
Ojji, D
Peacock, F
Richards, M
Sato, N
Sliwa, K
Spinar, J
Thiele, H
Yilmaz, MB
Januzzi, J
AF Mebazaa, A.
Tolppanen, H.
Mueller, C.
Lassus, J.
DiSomma, S.
Baksyte, G.
Cecconi, M.
Choi, D. J.
Solal, A. Cohen
Christ, M.
Masip, J.
Arrigo, M.
Nouira, S.
Ojji, D.
Peacock, F.
Richards, M.
Sato, N.
Sliwa, K.
Spinar, J.
Thiele, H.
Yilmaz, M. B.
Januzzi, J.
TI Acute heart failure and cardiogenic shock: a multidisciplinary practical
guidance
SO INTENSIVE CARE MEDICINE
LA English
DT Review
DE Heart failure; Cardiogenic shock; Emergency; Treatment
ID ACUTE MYOCARDIAL-INFARCTION; COLLEGE-OF-CARDIOLOGY; NATRIURETIC PEPTIDE
LEVELS; RIGHT-VENTRICULAR FAILURE; INTENSIVE-CARE MEDICINE; 2013
ACCF/AHA GUIDELINE; ASSOCIATION TASK-FORCE; PULMONARY-EDEMA;
EUROPEAN-SOCIETY; NONINVASIVE VENTILATION
AB Purpose: Acute heart failure (AHF) causes high burden of mortality, morbidity, and repeated hospitalizations worldwide. This guidance paper describes the tailored treatment approaches of different clinical scenarios of AHF and CS, focusing on the needs of professionals working in intensive care settings.
Results: Tissue congestion and hypoperfusion are the two leading mechanisms of end-organ injury and dysfunction, which are associated with worse outcome in AHF. Diagnosis of AHF is based on clinical assessment, measurement of natriuretic peptides, and imaging modalities. Simultaneously, emphasis should be given in rapidly identifying the underlying trigger of AHF and assessing severity of AHF, as well as in recognizing end-organ injuries. Early initiation of effective treatment is associated with superior outcomes. Oxygen, diuretics, and vasodilators are the key therapies for the initial treatment of AHF. In case of respiratory distress, non-invasive ventilation with pressure support should be promptly started. In patients with severe forms of AHF with cardiogenic shock (CS), inotropes are recommended to achieve hemodynamic stability and restore tissue perfusion. In refractory CS, when hemodynamic stabilization is not achieved, the use of mechanical support with assist devices should be considered early, before the development of irreversible end-organ injuries.
Conclusion: A multidisciplinary approach along the entire patient journey from pre-hospital care to hospital discharge is needed to ensure early recognition, risk stratification, and the benefit of available therapies. Medical management should be planned according to the underlying mechanisms of various clinical scenarios of AHF.
C1 [Mebazaa, A.; Tolppanen, H.; Solal, A. Cohen; Arrigo, M.] INSERM, U942, Paris, France.
[Mebazaa, A.; Solal, A. Cohen] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France.
[Mebazaa, A.] Hop Lariboisiere, AP HP, Dept Anesthesia & Crit Care, F-75475 Paris, France.
[Tolppanen, H.; Lassus, J.] Univ Helsinki, Cent Hosp, Heart & Lung Ctr, Helsinki, Finland.
[Mueller, C.] Univ Basel Hosp, Dept Cardiol, CH-4031 Basel, Switzerland.
[Mueller, C.] Univ Basel Hosp, Cardiovasc Res Inst Basel, CH-4031 Basel, Switzerland.
[DiSomma, S.] Univ Roma La Sapienza, St Andrea Hosp, Dept Med Sci & Translat Med, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
[Baksyte, G.] Kaunas Univ Med, Dept Cardiol, Kaunas, Lithuania.
[Cecconi, M.] St Georges Hosp & Med Sch, Anaesthesia & Intens Care, London SW17 0QT, England.
[Choi, D. J.] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, South Korea.
[Solal, A. Cohen] Hop Lariboisiere, AP HP, Dept Cardiol, F-75475 Paris, France.
[Christ, M.] Paracelsus Med Univ, Dept Emergency & Intens Care Med, Nurnberg, Germany.
[Masip, J.] Univ Barcelona, Consorci Sanitari Integral, Dept Intens Care Med, Barcelona, Spain.
[Nouira, S.] Fattouma Bourguiba Univ Hosp, Emergency Dept, Monastir, Tunisia.
[Nouira, S.] Fattouma Bourguiba Univ Hosp, Res Unit UR06SP21, Monastir, Tunisia.
[Ojji, D.] Univ Abuja, Teaching Hosp, Dept Med, Cardiol Unit, Gwagwalada, Abuja, Nigeria.
[Peacock, F.] Baylor Coll Med, Dept Emergency Med, Boston, MA USA.
[Richards, M.] Christchurch Hosp, Christchurch Cardioendocrine Res Grp, Christchurch, New Zealand.
[Sato, N.] Nippon Med Sch, Musashi Kosugi Hosp, Internal Med Cardiol & Intens Care Unit, Kawasaki, Kanagawa, Japan.
[Sliwa, K.] Univ Cape Town, Hatter Inst Cardiovasc Res Africa, Fac Hlth Sci, ZA-7925 Cape Town, South Africa.
[Sliwa, K.] Univ Cape Town, IIDMM, ZA-7925 Cape Town, South Africa.
[Spinar, J.] Univ Hosp Brno, Int Clin Res Ctr, Dept Cardiovasc Dis, Brno, Czech Republic.
[Thiele, H.] Univ Hosp Schleswig Holstein, Univ Heart Ctr Luebeck, Med Clin Cardiol Angiol Intens Care Med 2, Lubeck, Germany.
[Yilmaz, M. B.] Cumhuriyet Univ, Sch Med, Dept Cardiol, Sivas, Turkey.
[Januzzi, J.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Mebazaa, A (reprint author), Hop Lariboisiere, AP HP, Dept Anesthesia & Crit Care, F-75475 Paris, France.
EM alexandre.mebazaa@aphp.fr
RI Cecconi, Maurizio/A-6241-2012;
OI Cecconi, Maurizio/0000-0002-4376-6538; Nouira, Semir/0000-0002-0137-5491
FU Research Council of Lithuania [MIP-049/2015]
FX The work of G. Baksyte was supported by the grant MIP-049/2015 from the
Research Council of Lithuania.
NR 94
TC 10
Z9 10
U1 2
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD FEB
PY 2016
VL 42
IS 2
BP 147
EP 163
DI 10.1007/s00134-015-4041-5
PG 17
WC Critical Care Medicine
SC General & Internal Medicine
GA DB7UM
UT WOS:000368722000002
PM 26370690
ER
PT J
AU Ehrmann, S
Roche-Campo, F
Bodet-Contentin, L
Razazi, K
Dugernier, J
Trenado-Alvarez, J
Donzeau, A
Vermeulen, F
Thevoz, D
Papanikolaou, M
Edelson, A
Yoshido, HL
Piquilloud, L
Lakhal, K
Lopes, C
Vicent, C
Desachy, A
Apiou-Sbirlea, G
Isabey, D
Brochard, L
AF Ehrmann, Stephan
Roche-Campo, Ferran
Bodet-Contentin, Laetitia
Razazi, Keyvan
Dugernier, Jonathan
Trenado-Alvarez, Josep
Donzeau, Alexis
Vermeulen, Francois
Thevoz, David
Papanikolaou, Metaxia
Edelson, Antoine
Leon Yoshido, Hector
Piquilloud, Lise
Lakhal, Karim
Lopes, Carlos
Vicent, Carlos
Desachy, Arnaud
Apiou-Sbirlea, Gabriela
Isabey, Daniel
Brochard, Laurent
CA Reva Res Network
AT ICU Study Grp
TI Aerosol therapy in intensive and intermediate care units: prospective
observation of 2808 critically ill patients
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Administration, inhalation [MeSH]; Metered dose inhalers [MeSH];
Nebulizers and vaporizers [MeSH]; Bronchodilator agents [MeSH];
Anti-bacterial agents [MeSH]; Respiration, artificial [MeSH]
ID VENTILATOR-ASSOCIATED PNEUMONIA; RECEIVING MECHANICAL VENTILATION;
CYSTIC-FIBROSIS; DELIVERY; NEBULIZATION; ANTIBIOTICS; INHALATION;
EFFICIENCY; EVOLUTION; AMIKACIN
AB Purpose: Unlike in the outpatient setting, delivery of aerosols to critically ill patients may be considered complex, particularly in ventilated patients, and benefits remain to be proven. Many factors influence aerosol delivery and recommendations exist, but little is known about knowledge translation into clinical practice.
Method: Two-week cross-sectional study to assess the prevalence of aerosol therapy in 81 intensive and intermediate care units in 22 countries. All aerosols delivered to patients breathing spontaneously, ventilated invasively or noninvasively (NIV) were recorded, and drugs, devices, ventilator settings, circuit set-up, humidification and side effects were noted.
Result: A total of 9714 aerosols were administered to 678 of the 2808 admitted patients (24 %, CI95 22-26 %), whereas only 271 patients (10 %) were taking inhaled medication before admission. There were large variations among centers, from 0 to 57 %. Among intubated patients 22 % (n = 262) received aerosols, and 50 % (n = 149) of patients undergoing NIV, predominantly (75 %) inbetween NIV sessions. Bronchodilators (n = 7960) and corticosteroids (n = 1233) were the most frequently delivered drugs (88 % overall), predominantly but not exclusively (49 %) administered to patients with chronic airway disease. An anti-infectious drug was aerosolized 509 times (5 % of all aerosols) for nosocomial infections. Jet-nebulizers were the most frequently used device (56 %), followed by metered dose inhalers (23 %). Only 106 (< 1 %) mild side effects were observed, despite frequent suboptimal set-ups such as an external gas supply of jet nebulizers for intubated patients.
Conclusion:Aerosol therapy concerns every fourth critically ill patient and one-fifth of ventilated patients.
C1 [Ehrmann, Stephan; Apiou-Sbirlea, Gabriela; Isabey, Daniel] Univ Paris Est, INSERM, UMR 955, Creteil, France.
[Ehrmann, Stephan; Apiou-Sbirlea, Gabriela; Isabey, Daniel] Univ Paris Est, CNRS, ERL 7240, Equipe Biomecan Cellulaire & Resp, Creteil, France.
[Ehrmann, Stephan; Bodet-Contentin, Laetitia] CHR Univ Tours, Reanimat Polyvalente, F-37044 Tours 9, France.
[Ehrmann, Stephan] Univ Tours, Fac Med, INSERM, Ctr Etud Pathol Resp,UMR 1100,Aerosoltherapie & B, Tours, France.
[Roche-Campo, Ferran] Hosp Verge Cinta, Med Intens, Tarragona, Spain.
[Bodet-Contentin, Laetitia] Univ Paris 05, Sorbonne Paris Cite, Hop Cochin, AP HP,Reanimat Med, Paris, France.
[Bodet-Contentin, Laetitia] Univ Paris 05, Sorbonne Paris Cite, Fac Med, Paris, France.
[Razazi, Keyvan] GHU Henri Mondor, AP HP, DHU A TVB, Serv Reanimat Med,Grp Rech CARMAS, Creteil, France.
[Dugernier, Jonathan] Clin Univ St Luc, Intens Care Unit, B-1200 Brussels, Belgium.
[Trenado-Alvarez, Josep] Univ Barcelona, Hosp Univ Mutua Terrassa, Serv Med Intens, Barcelona, Spain.
[Donzeau, Alexis; Piquilloud, Lise] Ctr Hosp Reg Univ Angers, Reanimat Med & Med Hyperbare, Angers, France.
[Vermeulen, Francois] Hop Univ Geneve, Dept Intens Care, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva, Switzerland.
[Thevoz, David; Piquilloud, Lise] CHU Vaudois, Med Intens Adulte, CH-1011 Lausanne, Switzerland.
[Thevoz, David; Piquilloud, Lise] CHU Vaudois, Ctr Brules, CH-1011 Lausanne, Switzerland.
[Papanikolaou, Metaxia] Hippocrateion Gen Hosp Athens, Intens Care Unit, Athens, Greece.
[Edelson, Antoine] Ctr Hosp Taaone, Reanimat, Pirae, Fr Polynesia.
[Leon Yoshido, Hector] Hosp Nacl Edgardo Rebagliati Martins Essalud, Med Intens, Lima, Peru.
[Lakhal, Karim] Ctr Hosp Reg Univ Nantes, Hop Laennec, Serv Anesthesie Reanimat, Reanimat Chirurg Polyvalente, F-44093 Nantes, France.
[Lopes, Carlos] CHLN, Hosp Santa Maria, UCIR Pulmonol, Lisbon, Portugal.
[Vicent, Carlos] Hosp Lluis Alcanyis, Intens Care Unit, Valencia, Spain.
[Desachy, Arnaud] Ctr Hosp Angouleme, Serv Reanimat, Angouleme, France.
[Apiou-Sbirlea, Gabriela] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Dermatol,Wellman Ctr Photomed, Boston, MA USA.
[Brochard, Laurent] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, 30 Bond St, Toronto, ON M5B 1W8, Canada.
[Brochard, Laurent] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada.
RP Ehrmann, S (reprint author), CHR Univ Tours, Reanimat Polyvalente, F-37044 Tours 9, France.
EM stephanehrmann@gmail.com
OI Curiel-Balsera, Emilio/0000-0002-9932-5053; Ehrmann,
Stephan/0000-0001-6221-4467; Lopez-Herce, Jesus/0000-0001-6105-9178
FU Agence Nationale de la Recherche [ANR-2010 BLAN 1119 05]
FX The authors acknowledge receipt of grant ANR-2010 BLAN 1119 05 from
Agence Nationale de la Recherche. Beyond the investigators listed below,
the authors sincerely thank all physicians, nursing and research staff
who participated in the study.
NR 36
TC 4
Z9 4
U1 2
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD FEB
PY 2016
VL 42
IS 2
BP 192
EP 201
DI 10.1007/s00134-015-4114-5
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA DB7UM
UT WOS:000368722000006
PM 26602786
ER
PT J
AU Paul, S
Song, PI
Ogbechie, OA
Sugai, DY
Morley, KW
Schalock, PC
Kroshinsky, D
AF Paul, Suchismita
Song, Philip I.
Ogbechie, Oluwatobi A.
Sugai, Daniel Y.
Morley, Keith W.
Schalock, Peter C.
Kroshinsky, Daniela
TI Vesiculobullous and hemorrhagic erythema migrans: uncommon variants of a
common disease
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Article
ID LYME-DISEASE; BORRELIOSIS
AB BackgroundThe diagnosis of Lyme disease relies on the accurate diagnosis of erythema chronicum migrans (ECM) because serologic tests, culture, and polymerase chain reactions are often inaccurate. Although ECM is classically associated with a targetoid rash, there are many variants of this lesion. These variants of ECM are often initially diagnosed as cellulitis or spider bite reactions and treated with oral antibiotics. Inappropriate treatment further delays the diagnosis of Lyme disease, leading to late complications.
MethodsWe present four cases of vesiculobullous and hemorrhagic ECM, a less common variant of ECM.
ResultsAll four patients had a history of exposure to wooded areas in Massachusetts during the summer months. In these patients, ECM presented with central vesicles and bullae with hemorrhage, crusting, and in some cases necrosis. Serologic testing was positive in three of the four cases at presentation. In one case, microscopic examination of a skin biopsy showed epidermal spongiosis with parakeratosis, focal necrosis, papillary dermal edema, erythrocyte extravasation, and a superficial and deep perivascular lymphocytic infiltrate with neutrophils and eosinophils of the dermis. No fungal organisms or bacteria were identified. All four patients were treated with doxycycline with complete resolution of symptoms.
ConclusionsIt is important to recognize the vesiculobullous and hemorrhagic variants of ECM in order to minimize the provision of inappropriate antibiotic treatment for other diagnoses. Early diagnosis of ECM and the initiation of appropriate antibiotics may prevent late complications of Lyme disease.
C1 [Paul, Suchismita; Ogbechie, Oluwatobi A.; Schalock, Peter C.; Kroshinsky, Daniela] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Song, Philip I.; Sugai, Daniel Y.; Morley, Keith W.; Schalock, Peter C.; Kroshinsky, Daniela] Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Schalock, PC (reprint author), Massachusetts Gen Hosp, Dept Dermatol, 55 Fruit St,BAR622, Boston, MA 02114 USA.
EM schalock.prof@gmail.com
NR 12
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0011-9059
EI 1365-4632
J9 INT J DERMATOL
JI Int. J. Dermatol.
PD FEB
PY 2016
VL 55
IS 2
BP E79
EP E82
DI 10.1111/ijd.12927
PG 4
WC Dermatology
SC Dermatology
GA DC0XW
UT WOS:000368942300005
PM 26498075
ER
PT J
AU Solus, JF
Murphy, GF
Kraft, S
AF Solus, Jason F.
Murphy, George F.
Kraft, Stefan
TI Cutaneous Squamous Cell Carcinomas of the Lower Extremities Show
Distinct Clinical and Pathologic Features
SO INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE squamous cell carcinoma; actinic keratosis; skin neoplasms; stem cells
ID NONMELANOMA SKIN-CANCER; ACTINIC KERATOSIS; STEM-CELLS; RECOGNIZED
NEOPLASM; NOTCH-1 EXPRESSION; CYTOKERATIN 15; P53 MUTATIONS;
UNITED-STATES; LESIONS; HEAD
AB Cutaneous squamous cell carcinomas mainly affect older, predominantly male patients. Most are due to chronic ultraviolet exposure, and associated with actinic keratoses. On the lower extremities, they occur more commonly in women. However, data on these tumors as a distinct group are scarce. We evaluated 61 squamous cell carcinomas of the lower extremities. Overall, 69% of patients were female. Mean age was 75 years. More than 90% of tumors were well differentiated, 3% showed perineural invasion, and none lymphovascular invasion. In all, 63.9% showed evidence of severe chronic sun damage. Associated actinic keratoses were identified in only 13% of cases. By contrast, 80% were associated with distinctive basal epidermal proliferations with a retiform growth pattern. These proliferations were evaluated immunohistochemically for keratinocyte stem cell markers, p53 and Notch1 in 15 cases. All cases were positive for cytokeratin 14, p53, and Notch1 (with variable intensity in the latter 2), and predominantly negative for cytokeratin 19. Interestingly, basal retiform proliferations were positive for cytokeratin 15 in 66% of cases. Fifteen head and neck squamous cell carcinomas were evaluated in comparison. Those lacked associated basal retiform proliferations except in 1 case. In contrast, 87% were associated with actinic keratoses and 100% with severe chronic sun damage. Actinic keratoses associated with head and neck tumors showed cytokeratin 15 staining only in 7% of cases (P = .003 compared with cytokeratin 15 in basal retiform proliferations associated with leg carcinomas). These findings support the hypothesis that lower extremity squamous cell carcinomas are distinct and may exhibit a pathogenesis less reliant on actinic damage.
C1 [Solus, Jason F.; Kraft, Stefan] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Solus, Jason F.] Washington Univ, Sch Med, St Louis, MO USA.
[Murphy, George F.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
RP Kraft, S (reprint author), Massachusetts Gen Hosp, Pathol Serv, 55 Fruit St, Boston, MA 02114 USA.
EM skraft@mgh.harvard.edu
NR 38
TC 2
Z9 2
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1066-8969
EI 1940-2465
J9 INT J SURG PATHOL
JI Int. J. Surg. Pathol.
PD FEB
PY 2016
VL 24
IS 1
BP 29
EP 36
DI 10.1177/1066896915599058
PG 8
WC Pathology; Surgery
SC Pathology; Surgery
GA DC0VU
UT WOS:000368936800004
PM 26261102
ER
PT J
AU Knapp, AA
Blumenthal, H
Mischel, ER
Badour, CL
Leen-Feldner, EW
AF Knapp, Ashley A.
Blumenthal, Heidemarie
Mischel, Emily R.
Badour, Christal L.
Leen-Feldner, Ellen W.
TI Anxiety Sensitivity and Its Factors in Relation to Generalized Anxiety
Disorder among Adolescents
SO JOURNAL OF ABNORMAL CHILD PSYCHOLOGY
LA English
DT Article
DE Anxiety sensitivity; Worry; Generalized anxiety disorder; Adolescents
ID REVISED CHILD ANXIETY; DSM-IV ANXIETY; EMOTIONAL DISORDERS; DEPRESSION
SCALE; UNIFIED PROTOCOL; NEGATIVE AFFECT; PANIC-ATTACKS; SYMPTOMS;
INDEX; WORRY
AB Anxiety psychopathology, one of the most prevalent classes of disorder among youth, is linked to detrimental outcomes. Accordingly, identifying factors that influence vulnerability to anxiety disorders is important. One promising factor, given emerging evidence for its transdiagnostic nature, is anxiety sensitivity (AS); however, relatively little is known about the linkage between AS and indicators of generalized anxiety disorder (GAD), particularly among youth. The aim of the current investigation was to address this gap in the literature using a community-based sample of adolescents aged 10-17 years (n = 165; M (age) = 14.49 years, SD = 2.26). Results indicated global AS and the AS-physical concerns dimension were significantly associated with worry, generalized anxiety symptoms, and GAD diagnosis assessed via a structured clinical interview, above and beyond key theoretically-relevant covariates. These findings add to a growing body of work underscoring the relevance of AS for multiple types of anxiety-related disorders among youth.
C1 [Knapp, Ashley A.; Mischel, Emily R.; Leen-Feldner, Ellen W.] Univ Arkansas, Dept Psychol Sci, 216 Mem Hall, Fayetteville, AR 72701 USA.
[Blumenthal, Heidemarie] Univ N Texas, Dept Psychol, 155 Union Circle 311280, Denton, TX 76203 USA.
[Badour, Christal L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,MSC 861,2nd Fl IOP South Bldg, Charleston, SC 29425 USA.
[Badour, Christal L.] Ralph H Johnson VA Med Ctr, Dept Psychiat, 109 Bee St, Charleston, SC 29401 USA.
RP Knapp, AA (reprint author), Univ Arkansas, Dept Psychol Sci, 216 Mem Hall, Fayetteville, AR 72701 USA.
EM aaknapp@uark.edu
NR 70
TC 2
Z9 2
U1 6
U2 17
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0091-0627
EI 1573-2835
J9 J ABNORM CHILD PSYCH
JI J. Abnorm. Child Psychol.
PD FEB
PY 2016
VL 44
IS 2
BP 233
EP 244
DI 10.1007/s10802-015-9991-0
PG 12
WC Psychology, Clinical; Psychology, Developmental
SC Psychology
GA DC1ZF
UT WOS:000369016300003
PM 25724327
ER
PT J
AU Walter, ND
Miller, MA
Vasquez, J
Weiner, M
Chapman, A
Engle, M
Higgins, M
Quinones, AM
Rosselli, V
Canono, E
Yoon, C
Cattamanchi, A
Davis, JL
Phang, T
Stearman, RS
Datta, G
Garcia, BJ
Daley, CL
Strong, M
Kechris, K
Fingerlin, TE
Reves, R
Geraci, MW
AF Walter, Nicholas D.
Miller, Mikaela A.
Vasquez, Joshua
Weiner, Marc
Chapman, Adam
Engle, Melissa
Higgins, Michael
Quinones, Amy M.
Rosselli, Vanessa
Canono, Elizabeth
Yoon, Christina
Cattamanchi, Adithya
Davis, J. Lucian
Phang, Tzu
Stearman, Robert S.
Datta, Gargi
Garcia, Benjamin J.
Daley, Charles L.
Strong, Michael
Kechris, Katerina
Fingerlin, Tasha E.
Reves, Randall
Geraci, Mark W.
TI Blood Transcriptional Biomarkers for Active Tuberculosis among Patients
in the United States: a Case-Control Study with Systematic
Cross-Classifier Evaluation
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID SIGNATURES; EXPRESSION; MEDICINE; AFRICA
AB Blood transcriptional signatures are promising for tuberculosis (TB) diagnosis but have not been evaluated among U.S. patients. To be used clinically, transcriptional classifiers need reproducible accuracy in diverse populations that vary in genetic composition, disease spectrum and severity, and comorbidities. In a prospective case-control study, we identified novel transcriptional classifiers for active TB among U.S. patients and systematically compared their accuracy to classifiers from published studies. Blood samples from HIV-uninfected U.S. adults with active TB, pneumonia, or latent TB infection underwent whole-transcriptome microarray. We used support vector machines to classify disease state based on transcriptional patterns. We externally validated our classifiers using data from sub-Saharan African cohorts and evaluated previously published transcriptional classifiers in our population. Our classifier distinguishing active TB from pneumonia had an area under the concentration-time curve (AUC) of 96.5% (95.4% to 97.6%) among U.S. patients, but the AUC was lower (90.6% [89.6% to 91.7%]) in HIV-uninfected Sub-Saharan Africans. Previously published comparable classifiers had AUC values of 90.0% (87.7% to 92.3%) and 82.9% (80.8% to 85.1%) when tested in U.S. patients. Our classifier distinguishing active TB from latent TB had AUC values of 95.9% (95.2% to 96.6%) among U.S. patients and 95.3% (94.7% to 96.0%) among Sub-Saharan Africans. Previously published comparable classifiers had AUC values of 98.0% (97.4% to 98.7%) and 94.8% (92.9% to 96.8%) when tested in U.S. patients. Blood transcriptional classifiers accurately detected active TB among U.S. adults. The accuracy of classifiers for active TB versus that of other diseases decreased when tested in new populations with different disease controls, suggesting additional studies are required to enhance generalizability. Classifiers that distinguish active TB from latent TB are accurate and generalizable across populations and can be explored as screening assays.
C1 [Walter, Nicholas D.] Vet Adm Med Ctr, Pulm Sect, Denver, CO 80220 USA.
[Walter, Nicholas D.; Chapman, Adam; Phang, Tzu; Stearman, Robert S.; Geraci, Mark W.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO USA.
[Walter, Nicholas D.; Miller, Mikaela A.; Rosselli, Vanessa; Kechris, Katerina; Fingerlin, Tasha E.; Reves, Randall] Univ Colorado Denver, Colorado Sch Publ Hlth, Aurora, CO USA.
[Vasquez, Joshua; Yoon, Christina; Cattamanchi, Adithya; Davis, J. Lucian] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA.
[Weiner, Marc; Engle, Melissa] Vet Adm Med Ctr, Dept Med, San Antonio, TX USA.
[Higgins, Michael; Reves, Randall] Denver Metro TB Control Program, Denver, CO USA.
[Quinones, Amy M.] Denver Hlth Med Ctr, Denver, CO USA.
[Canono, Elizabeth] Natl Jewish Hlth, Clin Translat Res Ctr, Denver, CO USA.
[Datta, Gargi; Garcia, Benjamin J.; Strong, Michael] Natl Jewish Hlth, Ctr Genes Environm & Hlth, Denver, CO USA.
[Daley, Charles L.] Natl Jewish Hlth, Div Mycobacterial & Resp Infect, Denver, CO USA.
[Davis, J. Lucian] Yale Univ, Sch Publ Hlth, Epidemiol Microbial Dis, New Haven, CT USA.
[Stearman, Robert S.] Indiana Univ, Dept Med, Indianapolis, IN USA.
[Fingerlin, Tasha E.] Natl Jewish Hlth, Ctr Genes Environm & Hlth, Denver, CO USA.
[Geraci, Mark W.] Indiana Univ, Dept Med, Indianapolis, IN USA.
RP Walter, ND (reprint author), Vet Adm Med Ctr, Pulm Sect, Denver, CO 80220 USA.; Walter, ND (reprint author), Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO USA.; Walter, ND (reprint author), Univ Colorado Denver, Colorado Sch Publ Hlth, Aurora, CO USA.
EM nicholas.walter@ucdenver.edu
OI Garcia, Benjamin/0000-0001-5524-6946
FU Veteran's Administration Career Development Award Colorado Clinical and
Translational Sciences Institute, Mucosal and Vaccine Research Colorado
[CDA 1IK2CX000914-01A1]; University of Colorado Denver Division of
Pulmonary Sciences and Critical Care Medicine
FX The Veteran's Administration Career Development Award (CDA
1IK2CX000914-01A1) Colorado Clinical and Translational Sciences
Institute, Mucosal and Vaccine Research Colorado and the University of
Colorado Denver Division of Pulmonary Sciences and Critical Care
Medicine provided funding.
NR 24
TC 2
Z9 2
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD FEB
PY 2016
VL 54
IS 2
BP 274
EP 282
DI 10.1128/JCM.01990-15
PG 9
WC Microbiology
SC Microbiology
GA DC3YD
UT WOS:000369155100006
PM 26582831
ER
PT J
AU Zhang, Y
Jenkins, AJ
Basu, A
Stoner, JA
Lopes-Virella, MF
Klein, RL
Lyons, TJ
AF Zhang, Ying
Jenkins, Alicia J.
Basu, Arpita
Stoner, Julie A.
Lopes-Virella, Maria F.
Klein, Richard L.
Lyons, Timothy J.
CA DCCT EDIC Res Grp
TI Associations between intensive diabetes therapy and NMR-determined
lipoprotein subclass profiles in type 1 diabetes
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE intensive diabetes treatment; dyslipidemia; atherosclerosis; clinical
trial; high density lipoprotein; low density lipoprotein; nuclear
magnetic resonance
ID MAGNETIC-RESONANCE-SPECTROSCOPY; CORONARY-ARTERY-DISEASE; INTIMA-MEDIA
THICKNESS; COMPLICATIONS TRIAL; HEART-DISEASE; CARDIOVASCULAR-DISEASE;
DCCT/EDIC COHORT; FOLLOW-UP; CAROTID ATHEROSCLEROSIS; PARTICLE
CONCENTRATIONS
AB Our objective is to define differences in circulating lipoprotein subclasses between intensive versus conventional management of type 1 diabetes during the randomization phase of the Diabetes Control and Complications Trial (DCCT). NMR-determined lipoprotein subclass profiles (NMR-LSPs), which estimate molar subclass concentrations and mean particle diameters, were determined in 1,294 DCCT subjects after a median of 5 years (interquartile range: 4-6 years) of randomization to intensive or conventional diabetes management. In cross-sectional analyses, we compared standard lipids and NMR-LSPs between treatment groups. Standard total, LDL, and HDL cholesterol levels were similar between randomization groups, while triglyceride levels were lower in the intensively treated group. NMR-LSPs showed that intensive therapy was associated with larger LDL diameter (20.7 vs. 20.6 nm, P = 0.01) and lower levels of small LDL (median: 465 vs. 552 nmol/l, P = 0.007), total IDL/LDL (mean: 1,000 vs. 1,053 nmol/l, P = 0.01), and small HDL (mean: 17.3 vs. 18.6 mu mol/l, P < 0.0001), the latter accounting for reduced total HDL (mean: 33.8 vs. 34.8 mu mol/l, P = 0.01). In conclusion, intensive diabetes therapy was associated with potentially favorable changes in LDL and HDL subclasses in sera. Further research will determine whether these changes contribute to the beneficial effects of intensive diabetes management on vascular complications.
C1 [Zhang, Ying; Stoner, Julie A.] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA.
[Lyons, Timothy J.] Univ Oklahoma, Hlth Sci Ctr, Sect Endocrinol & Diabet, Oklahoma City, OK USA.
[Jenkins, Alicia J.] Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Sydney, NSW 2006, Australia.
[Jenkins, Alicia J.; Lyons, Timothy J.] Queens Univ Belfast, Ctr Med Expt, Belfast BT7 1NN, Antrim, North Ireland.
[Basu, Arpita] Oklahoma State Univ, Dept Nutr Sci, Stillwater, OK 74078 USA.
[Lopes-Virella, Maria F.; Klein, Richard L.] Med Univ S Carolina, Div Endocrinol, Charleston, SC 29425 USA.
[Lopes-Virella, Maria F.; Klein, Richard L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Lyons, TJ (reprint author), Univ Oklahoma, Hlth Sci Ctr, Sect Endocrinol & Diabet, Oklahoma City, OK USA.; Lyons, TJ (reprint author), Queens Univ Belfast, Ctr Med Expt, Belfast BT7 1NN, Antrim, North Ireland.
EM t.lyons@qub.ac.uk
FU National Institutes of Health [R01DK080043]; American Diabetes
Association [7-12-CT-46]; Division of Diabetes, Endocrinology, and
Metabolic Diseases of the National Institute of Diabetes and Digestive
and Kidney Diseases; National Eye Institute, the National Institute of
Neurologic Disorders and Stroke, the General Clinical Research Centers
Program; National Eye Institute, the National Institute of Neurologic
Disorders and Stroke, Clinical Translational Science Center Program
FX This project was supported by grants from the National Institutes of
Health (R01DK080043) and the American Diabetes Association (7-12-CT-46).
DCCT/EDIC has been supported by U01 Cooperative Agreement grants
(1982-1993, 2011-2016) and contracts (1982-2011) from the Division of
Diabetes, Endocrinology, and Metabolic Diseases of the National
Institute of Diabetes and Digestive and Kidney Diseases, and through
support by the National Eye Institute, the National Institute of
Neurologic Disorders and Stroke, the General Clinical Research Centers
Program (1993-2007), and Clinical Translational Science Center Program
(2006-present). The authors have no relevant conflicts of interest to
disclose. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National
Institutes of Health.
NR 52
TC 2
Z9 2
U1 1
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD FEB
PY 2016
VL 57
IS 2
BP 310
EP 317
DI 10.1194/jlr.P060657
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DC3AN
UT WOS:000369091600014
PM 26658239
ER
PT J
AU Jeong, SY
Jeon, R
Choi, YK
Jung, JE
Liang, A
Xing, CH
Wang, XY
Lo, EH
Song, YS
AF Jeong, Si-Yeon
Jeon, Raok
Choi, Yoon Kyung
Jung, Joo Eun
Liang, Anna
Xing, Changhong
Wang, Xiaoying
Lo, Eng H.
Song, Yun Seon
TI Activation of microglial Toll-like receptor 3 promotes neuronal survival
against cerebral ischemia
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE cerebral ischemia; interleukin-6; microglia; neuroprotection; oxygen
glucose deprivation; Toll-like receptor 3
ID HUMAN ASTROCYTES; IN-VITRO; INJURY; EXPRESSION; BRAIN; PHAGOCYTOSIS;
MECHANISMS; PROTECTS; ACID
AB Emerging experimental evidence suggests that activation of Toll-like receptor 3 (TLR3) by its agonist polyinosinic polycytidylic acid (poly-ICLC) protects neurons against cerebral ischemia, but the underlying mechanisms remain largely unknown. In the brain, TLR3 is mostly expressed in glial cells. Therefore, we assess the hypothesis that TLR3 activation in microglia is required for neuroprotection against ischemia. After transient focal cerebral ischemia, microglia/macrophages (MMs) demonstrate a significant reduction in TLR3 and its downstream cytokine interleukin 6 (IL-6). Subsequently, activation of TLR3 by poly-ICLC restored TLR3 expression and decreased infarction. To further investigate these mechanisms, we turned to a primary cell culture system. Consistent with the invivo findings, oxygen-glucose deprivation (OGD) significantly reduced TLR3 and IL-6 mRNA expression in microglia, but poly-ICLC significantly rescued TLR3 and IL-6 expression. Importantly, conditioned media from OGD-treated microglia increased neuronal death after OGD. In contrast, the conditioned media from microglia treated with poly-ICLC after OGD significantly protected against OGD-induced neuron death. Taken together, our findings provide proof-of-concept that activation of TLR3 in microglia may promote neuron survival after ischemia.
C1 [Jeong, Si-Yeon; Jeon, Raok; Song, Yun Seon] Sookmyung Womens Univ, Coll Pharm, Seoul, South Korea.
[Choi, Yoon Kyung; Jung, Joo Eun; Liang, Anna; Xing, Changhong; Wang, Xiaoying; Lo, Eng H.; Song, Yun Seon] Harvard Univ, Neuroprotect Res Lab, Dept Radiol, Massachusetts Gen Hosp,Med Sch, Charlestown, MA 02129 USA.
[Choi, Yoon Kyung; Jung, Joo Eun; Liang, Anna; Xing, Changhong; Wang, Xiaoying; Lo, Eng H.; Song, Yun Seon] Harvard Univ, Neuroprotect Res Lab, Dept Neurol, Massachusetts Gen Hosp,Med Sch, Charlestown, MA 02129 USA.
RP Lo, EH; Song, YS (reprint author), Harvard Univ, Neuroprotect Res Lab, Dept Radiol, Massachusetts Gen Hosp,Med Sch, Charlestown, MA 02129 USA.; Lo, EH; Song, YS (reprint author), Harvard Univ, Neuroprotect Res Lab, Dept Neurol, Massachusetts Gen Hosp,Med Sch, Charlestown, MA 02129 USA.
EM lo@helix.mgh.edu; yssong@sookmyung.ac.kr
FU National Research Foundation of Korea [2010-00894]; Medical Research
Center Program through the National Research Foundation of Korea (NRF) -
Korea Government (MSIP) [2011-0030074]
FX The authors declare no conflict of interest. This work was supported by
the National Research Foundation of Korea (grant # 2010-00894) and the
Medical Research Center Program (No. 2011-0030074) through the National
Research Foundation of Korea (NRF) grant funded by the Korea Government
(MSIP) to Y.S.S.
NR 18
TC 1
Z9 1
U1 3
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD FEB
PY 2016
VL 136
IS 4
BP 851
EP 858
DI 10.1111/jnc.13441
PG 8
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA DC3UU
UT WOS:000369145200017
ER
PT J
AU Ramachandran, M
Retarekar, R
Raghavan, ML
Berkowitz, B
Dickerhoff, B
Correa, T
Lin, S
Johnson, K
Hasan, D
Ogilvy, C
Rosenwasser, R
Torner, J
Bogason, E
Stapleton, CJ
Harbaugh, RE
AF Ramachandran, Manasi
Retarekar, Rohini
Raghavan, Madhavan L.
Berkowitz, Benjamin
Dickerhoff, Benjamin
Correa, Tatiana
Lin, Steve
Johnson, Kevin
Hasan, David
Ogilvy, Christopher
Rosenwasser, Robert
Torner, James
Bogason, Einar
Stapleton, Christopher J.
Harbaugh, Robert E.
TI Assessment of image-derived risk factors for natural course of
unruptured cerebral aneurysms
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE aneurysm; quantified aneurysm shape; subarachnoid hemorrhage; aneurysm
growth; vascular disorders
ID WALL SHEAR-STRESS; INTRACRANIAL ANEURYSMS; RUPTURE RISK; CT ANGIOGRAPHY;
HEMODYNAMICS; RECONSTRUCTION; HISTORY; ARTERY; SHAPE; SIZE
AB OBJECTIVE The goal of this prospective longitudinal study was to test whether image-derived metrics can differentiate unruptured aneurysms that will become unstable (grow and/or rupture) from those that will remain stable.
METHODS One hundred seventy-eight patients harboring 198 unruptured cerebral aneurysms for whom clinical observation and follow-up with imaging surveillance was recommended at 4 clinical centers were prospectively recruited into this study. Imaging data (predominantly CT angiography) at initial presentation was recorded. Computational geometry was used to estimate numerous metrics of aneurysm morphology that described the size and shape of the aneurysm. The nonlinear, finite element method was used to estimate uniform pressure-induced peak wall tension. Computational fluid dynamics was used to estimate blood flow metrics. The median follow-up period was 645 days. Longitudinal outcome data on these aneurysm patients-whether their aneurysms grew or ruptured (the unstable group) or remained unchanged (the stable group)-was documented based on follow-up at 4 years after the beginning of recruitment.
RESULTS Twenty aneurysms (10.1%) grew, but none ruptured. One hundred forty-nine aneurysms (75.3%) remained stable and 29 (14.6%) were lost to follow-up. None of the metrics-including aneurysm size, nonsphericity index, peak wall tension, and low shear stress area-differentiated the stable from unstable groups with statistical significance.
CONCLUSIONS The findings in this highly selected group do not support the hypothesis that image-derived metrics can predict aneurysm growth in patients who have been selected for observation and imaging surveillance. If aneurysm shape is a significant determinant of invasive versus expectant management, selection bias is a key limitation of this study.
C1 [Ramachandran, Manasi; Retarekar, Rohini; Raghavan, Madhavan L.; Berkowitz, Benjamin; Dickerhoff, Benjamin; Correa, Tatiana; Lin, Steve] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA.
[Johnson, Kevin; Hasan, David] Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
[Torner, James] Univ Iowa, Dept Epidemiol, Iowa City, IA USA.
[Ogilvy, Christopher] Beth Israel Deaconess Med Ctr, Dept Surg, Div Neurosurg, 330 Brookline Ave, Boston, MA 02215 USA.
[Stapleton, Christopher J.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Rosenwasser, Robert] Jefferson Univ Hosp, Dept Neurosurg, Philadelphia, PA USA.
[Bogason, Einar; Harbaugh, Robert E.] Penn State Univ, Dept Neurosurg, Hershey, PA USA.
[Harbaugh, Robert E.] Penn State Univ, Dept Engn Sci & Mech, State Coll, PA USA.
RP Harbaugh, RE (reprint author), Penn State Milton S Hershey Med Ctr, Dept Neurosurg, 30 Hope Dr, Hershey, PA 17033 USA.
EM reh1@mac.com
FU National Heart Lung and Blood Institute [R01HL083475]
FX This study was funded by National Heart Lung and Blood Institute grant
no. R01HL083475, "Assessment of intracranial aneurysm shape as an
indicator of rupture risk." The work described in this manuscript is
based on Ph.D. dissertations by the co-lead authors,
Ramachandran24 and Retarekar.27 We are grateful to
Deborah Hoffman, study clinical coordinator at Penn State Milton S.
Hershey Medical Center, for collection and organization of clinical
data. We are grateful to the Vascular Modeling ToolKit (VMTK) developer
and user community for assistance with image processing.
NR 37
TC 2
Z9 2
U1 1
U2 2
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
EI 1933-0693
J9 J NEUROSURG
JI J. Neurosurg.
PD FEB
PY 2016
VL 124
IS 2
BP 288
EP 295
DI 10.3171/2015.2.JNS142265
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA DB9VR
UT WOS:000368866300003
PM 26381246
ER
PT J
AU Barker, FG
AF Barker, Fred G., II
TI Randomized clinical trials and neurosurgery
SO JOURNAL OF NEUROSURGERY
LA English
DT Editorial Material
ID GLIOBLASTOMA-MULTIFORME; PARKINSONS-DISEASE; RADIATION-THERAPY; CNS
2007; SURVIVAL; SURGERY; QUALITY; INTERVENTION; ADHERENCE; JOURNALS
C1 [Barker, Fred G., II] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
RP Barker, FG (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
NR 56
TC 2
Z9 2
U1 0
U2 1
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
EI 1933-0693
J9 J NEUROSURG
JI J. Neurosurg.
PD FEB
PY 2016
VL 124
IS 2
BP 552
EP 556
DI 10.3171/2015.2.JNS142960
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA DB9VR
UT WOS:000368866300039
PM 26315008
ER
PT J
AU Kepler, CK
Vaccaro, AR
Chen, E
Patel, AA
Ahn, H
Nassr, A
Shaffrey, CI
Harrop, J
Schroeder, GD
Agarwala, A
Dvorak, MF
Fourney, DR
Wood, KB
Traynelis, VC
Yoon, ST
Fehlings, MG
Aarabi, B
AF Kepler, Christopher K.
Vaccaro, Alexander R.
Chen, Eric
Patel, Alpesh A.
Ahn, Henry
Nassr, Ahmad
Shaffrey, Christopher I.
Harrop, James
Schroeder, Gregory D.
Agarwala, Amit
Dvorak, Marcel F.
Fourney, Daryl R.
Wood, Kirkham B.
Traynelis, Vincent C.
Yoon, S. Tim
Fehlings, Michael G.
Aarabi, Bizhan
TI Treatment of isolated cervical facet fractures: a systematic review
SO JOURNAL OF NEUROSURGERY-SPINE
LA English
DT Review
DE systematic reviews; unilateral facet fracture; bilateral facet fracture;
surgical reduction; closed reduction; cervical; trauma
ID ANTERIOR FUSION; SPINE; DISLOCATIONS; SUBLUXATION; PATTERNS; INJURY
AB OBJECTIVE In this clinically based systematic review of cervical facet fractures, the authors' aim was to determine the optimal clinical care for patients with isolated fractures of the cervical facets through a systematic review.
METHODS A systematic review of nonoperative and operative treatment methods of cervical facet fractures was performed. Reduction and stabilization treatments were compared, and analysis of postoperative outcomes was performed. MEDLINE and Scopus databases were used. This work was supported through support received from the Association for Collaborative Spine Research and AOSpine North America.
RESULTS Eleven studies with 368 patients met the inclusion criteria. Forty-six patients had bilateral isolated cervical facet fractures and 322 had unilateral isolated cervical facet fractures. Closed reduction was successful in 56.4% (39 patients) and 63.8% (94 patients) of patients using a halo vest and Gardner-Wells tongs, respectively. Comparatively, open reduction was successful in 94.9% of patients (successful reduction of open to closed reduction OR 12.8 [95% CI 6.1-26.9], p < 0.0001); 183 patients underwent internal fixation, with an 87.2% success rate in maintaining anatomical alignment. When comparing the success of patients who underwent anterior versus posterior procedures, anterior approaches showed a 90.5% rate of maintenance of reduction, compared with a 75.6% rate for the posterior approach (anterior vs posterior OR 3.1 [95% CI 1.0-9.4], p = 0.05).
CONCLUSIONS In comparison with nonoperative treatments, operative treatments provided a more successful outcome in terms of failure of treatment to maintain reduction for patients with cervical facet fractures. Operative treatment appears to provide superior results to the nonoperative treatments assessed.
C1 [Kepler, Christopher K.; Vaccaro, Alexander R.; Schroeder, Gregory D.] Rothman Inst, Dept Orthopaed Surg, Philadelphia, PA USA.
[Kepler, Christopher K.; Vaccaro, Alexander R.; Schroeder, Gregory D.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA.
[Chen, Eric; Harrop, James] Thomas Jefferson Univ Hosp, Dept Neurosurg, Philadelphia, PA 19107 USA.
[Patel, Alpesh A.] NW Mem Hosp, Dept Orthopaed Surg, Chicago, IL 60611 USA.
[Ahn, Henry] Univ Toronto, Dept Orthopaed Surg, Toronto, ON M5S 1A1, Canada.
[Fehlings, Michael G.] Univ Toronto, Dept Neurosurg, Toronto, ON M5S 1A1, Canada.
[Nassr, Ahmad] Mayo Clin, Dept Orthopaed Surg, Rochester, MN USA.
[Shaffrey, Christopher I.] Univ Virginia, Dept Neurosurg, Charlottesville, VA USA.
[Agarwala, Amit] Panorama Orthoped & Spine Ctr, Denver, CO USA.
[Dvorak, Marcel F.] Univ British Columbia, Dept Orthopaed Surg, Vancouver, BC V5Z 1M9, Canada.
[Fourney, Daryl R.] Univ Saskatchewan, Dept Neurosurg, Saskatoon, SK, Canada.
[Wood, Kirkham B.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
[Traynelis, Vincent C.] Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA.
[Yoon, S. Tim] Emory Univ, Dept Orthopaed Surg, Atlanta, GA 30322 USA.
[Aarabi, Bizhan] Univ Maryland, Dept Neurosurg, Baltimore, MD 21201 USA.
RP Schroeder, GD (reprint author), 925 Chesnut St,5th Fl, Philadelphia, PA 19107 USA.
EM gregdschroeder@gmail.com
FU Medtronic; Springer; AOSpine; CSRS; OREF; NACTN; NIH; Department of
Defense; AO; NREF; UVa; Asubio Pharmaceuticals; Canadian Institute of
Health Research; Rick Hansen Foundation; Saskatchewan Health Research
Foundation; Royal University Hospital; Globus Medical; K2M; Synthes;
Globus
FX The authors report that AOSpine and the Association for Collaborative
Spine Research provided resources to help with this paper. The authors
report the following. Dr Schroeder: funding from Medtronic for travel to
meetings. Dr. Kepler: consultant for Healthgrades. Dr. Vaccaro:
consultant for Medtronic, Stryker Spine, Globus, Stout Medical, Gerson
Lehrman Group, Guidepoint Global, Medacorp, Innovative Surgical Design,
and Orthobullets; expert testimony for Ellipse; service on scientific
advisory board/board of directors/service on committees for innovative
surgical design for Spinicity, AOSpine, and Association of Collaborative
Spine Research; royalties from Thieme, Jaypee, Elsevier, Taylor Francis,
Aesculap, Globus, Medtronic, Stryker, and Biomet Spine; institutional
support from Cerapedics; owns stock in Spine Medica, Computational
Biodynamics, Progressive Spinal Technologies, Spinology, Small Bone
Innovations, Cross Current, In Vivo, Flagship Surgical, Advanced Spinal
Intellectual Properties, Cytonics, Bonovo Orthopaedics, Electrocore,
Gamma Spine, Location Based Intelligence, FlowPharma, R.S.I.,
Replication Medica, Globus, Stout Medical, Rothman Institute and Related
Properties, Innovative Surgical Design, Spinicity; and Paradigm Spine.
Dr. Patel: consultant for Biomet, DePuy (A Johnson & Johnson Company),
Stryker, Zimmer, GE Healthcare Nocimed, Amedica, Ulrich, and Relievant;
direct stock ownership in Amedica, Trinity Orthopaedics, Cytonics,
Nocimed, and Vital 5; IP royalties from Amedica and Ulrich Medical USA;
publishing royalties, financial or material support from Springer; board
or committee member AAOS, American College of Surgeons, American
Orthopaedic Association, AOSpine North America, Cervical Spine Research
Society, Indo-American Spine Alliance, Lumbar Spine Research Society,
and North American Spine Society; and editorial or governing board of
Journal of the American Academy of Orthopaedic Surgeons, Surgical
Neurology International, and Wolters Kluwer Health Lippincott Williams &
Wilkins. Dr. Nassr: grants from AOSpine, CSRS, and OREF; and fellowship
support from AOSpine. Dr. Harrop: consultant for DePuy and Bioventus;
grants from NACTN; and fellowship Support from AOSpine NA. Dr. Shaffrey:
consultant for Biomet, Globus, Medtronic, NuVasive, and Stryker; stock
ownership in NuVasive; patent holder with Biomet, Medtronic, and
NuVasive; royalties from Biomet and Medtronic; grants from NIH,
Department of Defense, AO, NREF, and NACTN; fellowship support: NREF,
AO, and UVa; non study-related support form ISSG and DePuy Synthes. Dr.
Agarawala: consultant for Medtronic. Dr. Fourney: research support from
Asubio Pharmaceuticals; grants from Canadian Institute of Health
Research, Rick Hansen Foundation, Saskatchewan Health Research
Foundation, Royal University Hospital, and AOSpine, and fellowship
support from AOSpine. Dr. Wood: stock ownership in TranS1; other
financial or material support from Globus Medical and OREF; research
support from K2M; editorial or governing board of Spine and Spinal
Deformity; and fellowship support form Synthes. Dr. Traynelis:
consultant for, royalties from, patent holder with, and research support
from Medtronic; grants from NIH; and fellowship support from Globus.
Dr.; Yoon: consultant for Meditech Advisors, and Stryker; and
intellectual property royalties from Stryker and Meditech; stock
ownership in Alphatec Spine, Meditech Advisors, Medyssey, and Phygen;
editorial or governing board for American Journal of Orthopedics,
Journal of Bone and Joint Surgery American, Journal of Orthopaedic
Research, The Spine Journal, Spine; and board or committee member of
International Society for the Study of the Lumbar Spine.
NR 12
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 1547-5654
EI 1547-5646
J9 J NEUROSURG-SPINE
JI J. Neurosurg.-Spine
PD FEB
PY 2016
VL 24
IS 2
BP 347
EP 354
DI 10.3171/2015.6.SPINE141260
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA DB9VO
UT WOS:000368866000022
ER
PT J
AU Karnezis, AN
Wang, YM
Ramos, P
Hendricks, WPD
Oliva, E
D'Angelo, E
Prat, J
Nucci, MR
Nielsen, TO
Chow, C
Leung, S
Kommoss, F
Kommoss, S
Silva, A
Ronnett, BM
Rabban, JT
Bowtell, DD
Weissman, BE
Trent, JM
Gilks, CB
Huntsman, DG
AF Karnezis, Anthony N.
Wang, Yemin
Ramos, Pilar
Hendricks, William P. D.
Oliva, Esther
D'Angelo, Emanuela
Prat, Jaime
Nucci, Marisa R.
Nielsen, Torsten O.
Chow, Christine
Leung, Samuel
Kommoss, Friedrich
Kommoss, Stefan
Silva, Annacarolina
Ronnett, Brigitte M.
Rabban, Joseph T.
Bowtell, David D.
Weissman, Bernard E.
Trent, Jeffrey M.
Gilks, C. Blake
Huntsman, David G.
TI Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is
highly sensitive and specific for small cell carcinoma of the ovary,
hypercalcaemic type
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE small cell carcinoma; hypercalcaemic type; rhabdoid tumour;
SMARCA4/BRG1; SMARCA2/BRM; SMARCB1/INI1; SWI/SNF; HDAC inhibitor;
trichostatin A; epigenetic silencing
ID NEUROENDOCRINE CARCINOMA; CANCER GENOMICS; CD44 EXPRESSION;
DOWN-REGULATION; BRM EXPRESSION; RHABDOID TUMOR; CYCLE ARREST;
LUNG-CANCER; HIGH-GRADE; BRG-1
AB Small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) is a lethal and sometimes familial ovarian tumour of young women and children. We and others recently discovered that over 90% of SCCOHTs harbour inactivating mutations in the chromatin remodelling gene SMARCA4 with concomitant loss of its encoded protein SMARCA4 (BRG1), one of two mutually exclusive ATPases of the SWI/SNF chromatin remodelling complex. To determine the specificity of SMARCA4 loss for SCCOHT, we examined the expression of SMARCA4 by immunohistochemistry in more than 3000 primary gynaecological tumours. Among ovarian tumours, it was only absent in clear cell carcinoma (15 of 360, 4%). In the uterus, it was absent in endometrial stromal sarcomas (4 of 52, 8%) and high-grade endometrioid carcinomas (2 of 338, 1%). Recent studies have shown that SMARCA2 (BRM), the other mutually exclusive ATPase of the SWI/SNF complex, is necessary for survival of tumour cells lacking SMARCA4. Therefore, we examined SMARCA2 expression and discovered that all SMARCA4-negative SCCOHTs also lacked SMARCA2 protein by IHC, including the SCCOHT cell lines BIN67 and SCCOHT1. Among ovarian tumours, the SMARCA4/SMARCA2 dual loss phenotype appears completely specific for SCCOHT. SMARCA2 loss was not due to mutation but rather from an absence of mRNA expression, which was restored by treatment with the histone deacetylase inhibitor trichostatin A. Re-expression of SMARCA4 or SMARCA2 inhibited the growth of BIN67 and SCCOHT1 cell lines. Our results indicate that SMARCA4 loss, either alone or with SMARCA2, is highly sensitive and specific for SCCOHT and that restoration of either SWI/SNF ATPase can inhibit the growth of SCCOHT cell lines. (c) 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
C1 [Karnezis, Anthony N.; Wang, Yemin; Nielsen, Torsten O.; Gilks, C. Blake; Huntsman, David G.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.
[Ramos, Pilar; Hendricks, William P. D.; Trent, Jeffrey M.] Translat Genom Res Inst TGen, Div Integrated Canc Genom, Phoenix, AZ USA.
[Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[D'Angelo, Emanuela; Prat, Jaime] Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Dept Pathol, Barcelona, Spain.
[Nucci, Marisa R.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
[Chow, Christine; Leung, Samuel; Huntsman, David G.] Univ British Columbia, Vancouver Gen Hosp, Genet Pathol Evaluat Ctr, Vancouver, BC V5Z 1M9, Canada.
[Kommoss, Friedrich] Synlab MVZ Pathol, Mannheim, Germany.
[Kommoss, Stefan] Univ Hosp Tuebingen, Dept Obstet & Gynecol, Tubingen, Germany.
[Silva, Annacarolina] Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA USA.
[Ronnett, Brigitte M.] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA.
[Rabban, Joseph T.] Univ Calif San Francisco, Dept Anat Pathol, San Francisco, CA 94143 USA.
[Bowtell, David D.] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia.
[Weissman, Bernard E.] Univ N Carolina, Dept Pathol & Lab Med, Lineberger Canc Ctr, Chapel Hill, NC USA.
[Huntsman, David G.] British Columbia Canc Res Ctr, Dept Mol Oncol, Vancouver, BC V5Z 1L3, Canada.
RP Huntsman, DG (reprint author), British Columbia Canc Agcy, Res Ctr, Dept Mol Oncol, 3427-600 West 10th Ave, Vancouver, BC V5Z 4E6, Canada.; Gilks, CB (reprint author), Vancouver Gen Hosp, Dept Pathol & Lab Med, Room 1250,First Floor JPPN,910 West 10th Ave, Vancouver, BC V5Z 1M9, Canada.
EM Blake.Gilks@vch.ca; dhuntsma@bccancer.bc.ca
RI Bowtell, David/H-1007-2016; D'Angelo, Emanuela/J-3417-2012; Prat,
Jaime/G-4679-2011;
OI Bowtell, David/0000-0001-9089-7525; Silva,
Annacarolina/0000-0002-0067-0288
FU National Institutes of Health [R01 CA195670-01]; Terry Fox Research
Initiative New Frontiers Program in Cancer [1021]; Canadian Cancer
Society Research Initiative; Terry Fox Foundation Strategic Health
Research Training Program in Cancer Research at Canadian Institutes of
Health Research; Anne Rita Monahan Foundation; Marsha Rivkin Center for
Ovarian Cancer Research; Ovarian Cancer Alliance of Arizona; Small Cell
Ovarian Cancer Foundation
FX We thank the SCCOHT families and patients for their important
contributions to TGen's institutional review board-approved study. We
thank Drs Ralf Hass and Barbara Vanderhyden for kindly providing
SCCOHT-1 and BIN67 cells, respectively. Viable frozen SCCOHT tumour
cells used to establish patient-derived xenografts were obtained from
Molecular Response (San Diego, CA, USA). This study was supported by
grants from the National Institutes of Health (R01 CA195670-01; BEW,
JMT, and DGH), the Terry Fox Research Initiative New Frontiers Program
in Cancer (grant 1021; DGH), the Canadian Cancer Society Research
Initiative (DGH and YW), the Terry Fox Foundation Strategic Health
Research Training Program in Cancer Research at Canadian Institutes of
Health Research (ANK), the Anne Rita Monahan Foundation (PR), the Marsha
Rivkin Center for Ovarian Cancer Research, the Ovarian Cancer Alliance
of Arizona, the Small Cell Ovarian Cancer Foundation, and philanthropic
support to the TGen Foundation.
NR 44
TC 18
Z9 18
U1 3
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD FEB
PY 2016
VL 238
IS 3
BP 389
EP 400
DI 10.1002/path.4633
PG 12
WC Oncology; Pathology
SC Oncology; Pathology
GA DC1QA
UT WOS:000368990000005
PM 26356327
ER
PT J
AU Vanderberg, RH
Farkas, AH
Miller, E
Sucato, GS
Akers, AY
Borrero, SB
AF Vanderberg, Rachel H.
Farkas, Amy H.
Miller, Elizabeth
Sucato, Gina S.
Akers, Aletha Y.
Borrero, Sonya B.
TI Racial and/or Ethnic Differences in Formal Sex Education and Sex
Education by Parents among Young Women in the United States
SO JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY
LA English
DT Article
DE Contraception; Disparities; Parents; Race; Sex education
ID REPRODUCTIVE HEALTH COMMUNICATION; UNINTENDED PREGNANCY; ADOLESCENT
WOMEN; DISPARITIES; PERSPECTIVES; KNOWLEDGE; ATTITUDES
AB Study Objective: We sought to investigate the associations between race and/or ethnicity and young women's formal sex education and sex education by parents.
Design, Setting, and Participants: Cross-sectional analysis of a nationally representative sample of 1768 women aged 15-24 years who participated in the 2011-2013 National Survey of Family Growth.
Interventions and Main Outcome Measures: We assessed 6 main outcomes: participants' report of: (1) any formal sex education; (2) formal contraceptive education; (3) formal sexually transmitted infection (STI) education; (4) any sex education by parents; (5) contraceptive education by parents; and (6) STI education by parents. The primary independent variable was self-reported race and/or ethnicity.
Results: Nearly all of participants (95%) reported any formal sex education, 68% reported formal contraceptive education, and 92% reported formal STI education. Seventy-five percent of participants reported not having any sex education by parents and only 61% and 56% reported contraceptive and STI education by parents, respectively. US-born Hispanic women were more likely than white women to report STI education by parents (adjusted odds ratio = 1.87; 95% confidence interval, 1.17-2.99). No other significant racial and/or ethnic differences in sex education were found.
Conclusion: There are few racial and/or ethnic differences in formal sex education and sex education by parents among young women.
C1 [Vanderberg, Rachel H.; Farkas, Amy H.; Borrero, Sonya B.] Univ Pittsburgh, Med Ctr, Div Gen Internal Med, Pittsburgh, PA USA.
[Miller, Elizabeth; Sucato, Gina S.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Div Adolescent & Young Adult Med,Dept Pediat, Pittsburgh, PA 15213 USA.
[Akers, Aletha Y.] Childrens Hosp Philadelphia, Craig Dalsimer Div Adolescent Med, Philadelphia, PA 19104 USA.
[Borrero, Sonya B.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Borrero, SB (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA.
EM borrerosp@upmc.edu
FU NIH [UL1-TR-000005]; Eunice Kennedy Shriver National Institute of Child
Health and Human Development [1R21HD068736-01A1]
FX The authors thank Dan Winger, at the Clinical and Translation Science
Institute, University of Pittsburgh, supported by NIH Grant
UL1-TR-000005, for his assistance with statistical analysis. This work
was also supported by Dr. Sonya Borrero's Grant 1R21HD068736-01A1 from
the Eunice Kennedy Shriver National Institute of Child Health and Human
Development.
NR 24
TC 0
Z9 0
U1 4
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-3188
EI 1873-4332
J9 J PEDIATR ADOL GYNEC
JI J. Pediatr Adolesc. Gynecol.
PD FEB
PY 2016
VL 29
IS 1
BP 69
EP 73
DI 10.1016/j.jpag.2015.06.011
PG 5
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA DC1IS
UT WOS:000368970600014
PM 26143556
ER
PT J
AU Rhee, EP
AF Rhee, Eugene P.
TI NADPH Oxidase 4 at the Nexus of Diabetes, Reactive Oxygen Species, and
Renal Metabolism
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Editorial Material
ID NAD(P)H OXIDASE; KIDNEY; NEPHROPATHY; NOX4; EXPRESSION; INHIBITOR;
FUMARATE; GLUCOSE
C1 [Rhee, Eugene P.] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA.
RP Rhee, EP (reprint author), Thier Bldg,50 Blossom St,Thier 1051, Boston, MA 02114 USA.
EM eprhee@partners.org
FU NIDDK NIH HHS [K08-DK090142, K08 DK090142]
NR 20
TC 1
Z9 1
U1 2
U2 10
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD FEB
PY 2016
VL 27
IS 2
BP 337
EP 339
DI 10.1681/ASN.2015060698
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA DC1DS
UT WOS:000368957600002
PM 26203117
ER
PT J
AU Rosales, IA
Collins, AB
do Carmo, PAS
Tolkoff-Rubin, N
Smith, RN
Colvin, RB
AF Rosales, Ivy A.
Collins, A. Bernard
do Carmo, Paula Alves S.
Tolkoff-Rubin, Nina
Smith, R. Neal
Colvin, Robert B.
TI Immune Complex Tubulointerstitial Nephritis Due to Autoantibodies to the
Proximal Tubule Brush Border
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID BASEMENT-MEMBRANE; INTERSTITIAL NEPHRITIS; HEYMANN NEPHRITIS; LUPUS
NEPHRITIS; ANTIBODIES; DEPOSITS; NEPHROPATHY; ANTIGENS; DISEASE; INJURY
AB Immune complex tubulointerstitial nephritis due to antibodies to brush border antigens of the proximal tubule has been demonstrated experimentally and rarely in humans. Our patient developed ESRD and early recurrence after transplantation. IgG and C3 deposits were conspicuous in the tubular basement membrane of proximal tubules, corresponding to deposits observed by electron microscopy. Rare subepithelial deposits were found in the glomeruli. The patient had no evidence of SLE and had normal complement levels. Serum samples from the patient reacted with the brush border of normal human kidney, in contrast with the negative results with 20 control serum samples. Preliminary characterization of the brush border target antigen excluded megalin, CD10, and maltase. We postulate that antibodies to brush border antigens cause direct epithelial injury, accumulate in the tubular basement membrane, and elicit an interstitial inflammatory response.
C1 [Rosales, Ivy A.; Collins, A. Bernard; Smith, R. Neal; Colvin, Robert B.] Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Thier 831A, Boston, MA 02114 USA.
[Tolkoff-Rubin, Nina] Massachusetts Gen Hosp, Renal Transplantat Program, Div Nephrol, Boston, MA 02114 USA.
[do Carmo, Paula Alves S.] Ctr Especializado Anat Patol, Belo Horizonte, MG, Brazil.
RP Rosales, IA (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Thier 831A, Boston, MA 02114 USA.
EM irosales@mgh.harvard.edu
FU International Society of Nephrology Fellowship Grant
FX This work was made possible through an International Society of
Nephrology Fellowship Grant to I.A.R.
NR 16
TC 1
Z9 1
U1 0
U2 4
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD FEB
PY 2016
VL 27
IS 2
BP 380
EP 384
DI 10.1681/ASN.2015030334
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA DC1DS
UT WOS:000368957600008
PM 26334028
ER
PT J
AU van Ballegooijen, AJ
Rhee, EP
Elmariah, S
de Boer, IH
Kestenbaum, B
AF van Ballegooijen, Adriana J.
Rhee, Eugene P.
Elmariah, Sammy
de Boer, Ian H.
Kestenbaum, Bryan
TI Renal Clearance of Mineral Metabolism Biomarkers
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; MOLECULAR-WEIGHT
PROTEINS; PARATHYROID-HORMONE; HALF-LIFE; FGF-23; CATABOLISM; DISORDERS;
TRANSPORT; FRAGMENT
AB CKD leads to disturbances in multiple interrelated hormones that regulate bone and mineral metabolism. The renal handling of mineral metabolism hormones in humans is incompletely understood. We determined the single-pass renal clearance of parathyroid hormone, fibroblast growth factor 23, vitamin D metabolites, and phosphate from paired blood samples collected from the abdominal aorta and renal vein in 17 participants undergoing simultaneous right and left heart catheterization and estimated associations of eGFR with the renal elimination of metabolites. The mean age +/- SD of the study population was 71.4 +/- 10.0 years and 11 participants (65%) were male. We found a relatively large mean +/- SD single-pass renal extraction of parathyroid hormone (44.2%+/- 10.3%) that exceeded the extraction of creatinine (22.1%+/- 7.9%). The proportionate renal extraction of parathyroid hormone correlated with eGFR. The renal extraction of fibroblast growth factor 23 was, on average, lower than that of parathyroid hormone with greater variability across individuals (17.1%+/- 19.5%). There were no differences in the mean concentrations of vitamin D metabolites across the renal vein and artery. In summary, we demonstrate substantial single-pass renal extraction of parathyroid hormone at a rate that exceeds glomerular filtration. Impaired renal clearance of parathyroid hormone may contribute to secondary hyperparathyroidism in CKD.
C1 [van Ballegooijen, Adriana J.; de Boer, Ian H.; Kestenbaum, Bryan] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA.
[Rhee, Eugene P.] Massachusetts Gen Hosp, Nephrol Div, Boston, MA 02114 USA.
[Rhee, Eugene P.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Elmariah, Sammy] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Elmariah, Sammy] Harvard Clin Res Inst, Boston, MA USA.
RP van Ballegooijen, AJ (reprint author), Kidney Res Inst, Box 35906, Seattle, WA USA.
EM hvb2@uw.edu
FU Niels Stensen Fellowship; Extramural Grant Program by Satellite
Healthcare; NIH [K08-DK090142, R01-DK099199]
FX This research was supported by the Niels Stensen Fellowship 2014, the
Extramural Grant Program by Satellite Healthcare, and NIH grants
K08-DK090142 and R01-DK099199.
NR 21
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD FEB
PY 2016
VL 27
IS 2
BP 392
EP 397
DI 10.1681/ASN.2014121253
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA DC1DS
UT WOS:000368957600010
PM 26047790
ER
PT J
AU Deo, R
Shou, HC
Soliman, EZ
Yang, W
Arkin, JM
Zhang, XM
Townsend, RR
Go, AS
Shlipak, MG
Feldman, HI
AF Deo, Rajat
Shou, Haochang
Soliman, Elsayed Z.
Yang, Wei
Arkin, Joshua M.
Zhang, Xiaoming
Townsend, Raymond R.
Go, Alan S.
Shlipak, Michael G.
Feldman, Harold I.
TI Electrocardiographic Measures and Prediction of Cardiovascular and
Noncardiovascular Death in CKD
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID HEART-ASSOCIATION ELECTROCARDIOGRAPHY; OF-CARDIOLOGY-FOUNDATION;
LEFT-VENTRICULAR HYPERTROPHY; SUDDEN CARDIAC DEATH; SERVICES TASK-FORCE;
ARRHYTHMIAS COMMITTEE; SCIENTIFIC STATEMENT; CLINICAL CARDIOLOGY;
RHYTHM-SOCIETY; AHA/ACCF/HRS RECOMMENDATIONS
AB Limited studies have assessed the resting 12-lead electrocardiogram (ECG) as a screening test in intermediate risk populations. We evaluated whether a panel of common ECG parameters are independent predictors of mortality risk in a prospective cohort of participants with CKD. The Chronic Renal Insufficiency Cohort (CRIC) study enrolled 3939 participants with eGFR<70 ml/min per 1.73 m(2) from June 2003 to September 2008. Over a median follow-up of 7.5 years, 750 participants died. After adjudicating the initial 497 deaths, we identified 256 cardiovascular and 241 noncardiovascular deaths. ECG metrics were independent risk markers for cardiovascular death (hazard ratio, 95% confidence interval): PR interval >= 200 ms (1.62, 1.19-2.19); QRS interval 100-119 ms (1.64, 1.20-2.25) and >= 120 ms (1.75, 1.17-2.62); corrected QT (QTc) interval >= 450 ms in men or >= 460 ms in women (1.72, 1.19-2.49); and heart rate 60-90 beats per minute (1.21, 0.89-1.63) and >= 90 beats per minute (2.35, 1.03-5.33). Most ECG measures were stronger markers of risk for cardiovascular death than for all-cause mortality or noncardiovascular death. Adding these intervals to a comprehensive model of cardiorenal risk factors increased the C-statistic for cardiovascular death from 0.77 to 0.81 (P<0.001). Furthermore, adding ECG metrics to the model adjusted for standard risk factors resulted in a net reclassification of 12.1% (95% confidence interval 8.1%-16.0%). These data suggest common ECG metrics are independent risk factors for cardiovascular death and enhance the ability to predict death events in a population with CKD.
C1 [Deo, Rajat; Arkin, Joshua M.] Univ Penn, Cardiac Electrophysiol Sect, Div Cardiovasc Med, Dept Med,Perelman Sch Med, Philadelphia, PA 19104 USA.
[Shou, Haochang; Yang, Wei; Zhang, Xiaoming; Feldman, Harold I.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Shou, Haochang; Yang, Wei; Zhang, Xiaoming; Feldman, Harold I.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Soliman, Elsayed Z.] Wake Forest Univ, Bowman Gray Sch Med, Epidemiol Cardiol Res Ctr EPICARE, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA.
[Soliman, Elsayed Z.] Wake Forest Univ, Sch Med, Dept Internal Med, Cardiol Sect, Winston Salem, NC 27109 USA.
[Townsend, Raymond R.; Feldman, Harold I.] Univ Penn, Renal Electrolyte & Hypertens Div, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Go, Alan S.] Stanford Univ, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA.
[Go, Alan S.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol Biostat & Med, San Francisco, CA 94143 USA.
[Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA USA.
RP Deo, R (reprint author), 3400 Spruce St,9 Founders Cardiol, Philadelphia, PA 19146 USA.
EM Rajat.Deo@uphs.upenn.edu
FU National Institutes of Health (NIH) [K23-DK089118]; National Institute
of Diabetes and Digestive and Kidney Diseases [U01-DK060990,
U01-DK060984, U01-DK061022, U01-DK061021, U01-DK061028, U01-DK060980,
U01-DK060963, U01-DK060902]; Perelman School of Medicine at the
University of Pennsylvania Clinical and Translational Science Award NIH/
National Center for Advancing Translational Sciences (NCATS)
[UL1-TR000003]; Johns Hopkins University [UL1-TR000424]; University of
Maryland [M01-RR16500]; Clinical and Translational Science Collaborative
of Cleveland from the NCATS component of the NIH and NIH roadmap for
Medical Research [UL1-TR000439]; Michigan Institute for Clinical and
Health Research Grant [UL1-TR000433]; University of Illinois at Chicago
CTSA Grant [UL1-RR029879]; Tulane University Translational Research in
Hypertension and Renal Biology Grant [P30-GM103337]; Kaiser Permanente
NIH/NCRR UCSF-CTSI Grant [UL1-RR024131]
FX We appreciate the support of the other CRIC Study Investigators
including Lawrence J. Appel, Jiang He, John W. Kusek, James P. Lash,
Akinlolu Ojo, and Mahboob Rahman. The CRIC ancillary study was supported
by the National Institutes of Health (NIH) grant K23-DK089118 (to R.D.).
The CRIC study is supported by cooperative agreement project grants from
the National Institute of Diabetes and Digestive and Kidney Diseases
(U01-DK060990, U01-DK060984, U01-DK061022, U01-DK061021, U01-DK061028,
U01-DK060980, U01-DK060963, and U01-DK060902).; In addition, this work
was supported in part by the Perelman School of Medicine at the
University of Pennsylvania Clinical and Translational Science Award NIH/
National Center for Advancing Translational Sciences (NCATS) Grant
UL1-TR000003, Johns Hopkins University Grant UL1-TR000424, University of
Maryland GCRC Grant M01-RR16500, Clinical and Translational Science
Collaborative of Cleveland Grant UL1-TR000439 from the NCATS component
of the NIH and NIH roadmap for Medical Research, Michigan Institute for
Clinical and Health Research Grant UL1-TR000433, University of Illinois
at Chicago CTSA Grant UL1-RR029879, Tulane University Translational
Research in Hypertension and Renal Biology Grant P30-GM103337, and
Kaiser Permanente NIH/NCRR UCSF-CTSI Grant UL1-RR024131.
NR 33
TC 4
Z9 4
U1 0
U2 3
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD FEB
PY 2016
VL 27
IS 2
BP 559
EP 569
DI 10.1681/ASN.2014101045
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA DC1DS
UT WOS:000368957600025
PM 26160896
ER
PT J
AU Sundt, TM
AF Sundt, Thoralf M.
TI Decisions, decisions: Chocolate, vanilla, or something else?
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Editorial Material
C1 [Sundt, Thoralf M.] Massachusetts Gen Hosp, Div Cardiac Surg, 55 Fruit St, Boston, MA 02114 USA.
[Sundt, Thoralf M.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
RP Sundt, TM (reprint author), Massachusetts Gen Hosp, Div Cardiac Surg, 55 Fruit St, Boston, MA 02114 USA.
EM tsundt@mgh.harvard.edu
NR 4
TC 0
Z9 0
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD FEB
PY 2016
VL 151
IS 2
BP 339
EP 340
DI 10.1016/j.jtcvs.2015.10.103
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA DB8ZR
UT WOS:000368806200028
PM 26651964
ER
PT J
AU Garcia, JP
Rajagopal, K
AF Garcia, Jose P.
Rajagopal, Keshava
TI Ex vivo lung perfusion: Theme and variation
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Editorial Material
C1 [Garcia, Jose P.] Massachusetts Gen Hosp, Div Cardiac Surg, 55 Fruit St,Cox Bldg 642, Boston, MA 02114 USA.
[Rajagopal, Keshava] Texas Med Ctr, Mem Hermann Hosp, Ctr Adv Heart Failure, Dept Cardiovasc Surg, Houston, TX USA.
RP Garcia, JP (reprint author), Massachusetts Gen Hosp, Div Cardiac Surg, 55 Fruit St,Cox Bldg 642, Boston, MA 02114 USA.
EM jgarcia@partners.org
NR 7
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD FEB
PY 2016
VL 151
IS 2
BP 576
EP 577
DI 10.1016/j.jtcvs.2015.06.055
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA DB8ZR
UT WOS:000368806200075
PM 26232315
ER
PT J
AU Kinloch, NN
MacMillan, DR
Le, AQ
Cotton, LA
Bangsberg, DR
Buchbinder, S
Carrington, M
Fuchs, J
Harrigan, PR
Koblin, B
Kushel, M
Markowitz, M
Mayer, K
Milloy, MJ
Schechter, MT
Wagner, T
Walker, BD
Carlson, JM
Poon, AFY
Brumme, ZL
AF Kinloch, Natalie N.
MacMillan, Daniel R.
Le, Anh Q.
Cotton, Laura A.
Bangsberg, David R.
Buchbinder, Susan
Carrington, Mary
Fuchs, Jonathan
Harrigan, P. Richard
Koblin, Beryl
Kushel, Margot
Markowitz, Martin
Mayer, Kenneth
Milloy, M. J.
Schechter, Martin T.
Wagner, Theresa
Walker, Bruce D.
Carlson, Jonathan M.
Poon, Art F. Y.
Brumme, Zabrina L.
TI Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during
the North American Epidemic
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; T-LYMPHOCYTE ESCAPE; SAN-FRANCISCO;
CLASS-I; VANCOUVER LYMPHADENOPATHY; CELL RESPONSES; PHYLOGENETIC
ANALYSIS; DISEASE PROGRESSION; HOMOSEXUAL-MEN; VIRAL-LOAD
AB Human leukocyte antigen (HLA) class I-associated polymorphisms in HIV-1 that persist upon transmission to HLA-mismatched hosts may spread in the population as the epidemic progresses. Transmission of HIV-1 sequences containing such adaptations may undermine cellular immune responses to the incoming virus in future hosts. Building upon previous work, we investigated the extent of HLA-associated polymorphism accumulation in HIV-1 polymerase (Pol) through comparative analysis of linked HIV-1/HLA class I genotypes sampled during historic (1979 to 1989; n = 338) and modern (2001 to 2011; n = 278) eras from across North America (Vancouver, BC, Canada; Boston, MA; New York, NY; and San Francisco, CA). Phylogenies inferred from historic and modern HIV-1 Pol sequences were star-like in shape, with an inferred most recent common ancestor (epidemic founder virus) sequence nearly identical to the modern North American subtype B consensus sequence. Nevertheless, modern HIV-1 Pol sequences exhibited roughly 2-fold-higher patristic (tip-to-tip) genetic distances than historic sequences, with HLA pressures likely driving ongoing diversification. Moreover, the frequencies of published HLA-associated polymorphisms in individuals lacking the selecting HLA class I allele was on average similar to 2.5-fold higher in the modern than in the historic era, supporting their spread in circulation, though some remained stable in frequency during this time. Notably, polymorphisms restricted by protective HLA alleles appear to be spreading to a greater relative extent than others, though these increases are generally of modest absolute magnitude. However, despite evidence of polymorphism spread, North American hosts generally remain at relatively low risk of acquiring an HIV-1 polymerase sequence substantially preadapted to their HLA profiles, even in the present era.
C1 [Kinloch, Natalie N.; MacMillan, Daniel R.; Le, Anh Q.; Cotton, Laura A.; Poon, Art F. Y.; Brumme, Zabrina L.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada.
[Bangsberg, David R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Bangsberg, David R.; Mayer, Kenneth] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Buchbinder, Susan; Fuchs, Jonathan; Wagner, Theresa] San Francisco Dept Publ Hlth, San Francisco, CA USA.
[Buchbinder, Susan; Fuchs, Jonathan; Kushel, Margot] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Carrington, Mary] Frederick Natl Lab Canc Res, Leidos Biomed Res Inc, Canc & Inflammat Program, Expt Immunol Lab, Frederick, MD USA.
[Carrington, Mary; Walker, Bruce D.] Ragon Inst Massachusetts Gen Hosp MIT & Harvard U, Cambridge, MA USA.
[Harrigan, P. Richard; Milloy, M. J.; Poon, Art F. Y.; Brumme, Zabrina L.] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada.
[Harrigan, P. Richard; Milloy, M. J.; Schechter, Martin T.; Poon, Art F. Y.] Univ British Columbia, Fac Med, Vancouver, BC, Canada.
[Koblin, Beryl] New York Blood Ctr, New York, NY 10021 USA.
[Markowitz, Martin] Aaron Diamond AIDS Res Ctr, New York, NY USA.
[Mayer, Kenneth] Fenway Community Hlth, Boston, MA USA.
[Carlson, Jonathan M.] Microsoft Res, Seattle, WA USA.
RP Brumme, ZL (reprint author), Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada.; Brumme, ZL (reprint author), British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada.
EM zbrumme@sfu.ca
FU Frederick National Laboratory for Cancer Research [HHSN261200800001E];
Intramural Research Program of the NIH, Frederick National Laboratory
for Cancer Research; Gouvernement du Canada \ Canadian Institutes of
Health Research (CIHR) [MOP-93536, HOP-115700]; Michael Smith Foundation
for Health Research (MSFHR)
FX Frederick National Laboratory for Cancer Research provided funding to
Mary Carrington under grant number HHSN261200800001E. Intramural
Research Program of the NIH, Frederick National Laboratory for Cancer
Research provided funding to Mary Carrington. Gouvernement du Canada
vertical bar Canadian Institutes of Health Research (CIHR) provided
funding to Natalie N. Kinloch, Anh Q. Le, Art F. Y. Poon, Zabrina L.
Brumme. Michael Smith Foundation for Health Research (MSFHR) provided
funding to Art F. Y. Poon and Zabrina L. Brumme. Gouvernement du Canada
vertical bar Canadian Institutes of Health Research (CIHR) provided
funding to Zabrina L. Brumme under grant number MOP-93536. Gouvernement
du Canada vertical bar Canadian Institutes of Health Research (CIHR)
provided funding to Art F. Y. Poon and Zabrina L. Brumme under grant
number HOP-115700.
NR 81
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD FEB
PY 2016
VL 90
IS 3
BP 1244
EP 1258
DI 10.1128/JVI.02353-15
PG 15
WC Virology
SC Virology
GA DC3WW
UT WOS:000369150800008
ER
PT J
AU Kearney, MF
Wiegand, A
Shao, W
Coffin, JM
Mellors, JW
Lederman, M
Gandhi, RT
Keele, BF
Li, JZ
AF Kearney, Mary F.
Wiegand, Ann
Shao, Wei
Coffin, John M.
Mellors, John W.
Lederman, Michael
Gandhi, Rajesh T.
Keele, Brandon F.
Li, Jonathan Z.
TI Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses
That Are Transcriptionally Active before Stopping of Antiretroviral
Therapy
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID SEQUENTIAL 3-DRUG REGIMENS; INFECTED-CELLS; TREATMENT INTERRUPTION;
REVERSE-TRANSCRIPTASE; CONTROLLED-TRIAL; INITIAL THERAPY; REPLICATION;
RESERVOIR; DISCONTINUATION; PROLIFERATION
AB Understanding the origin of HIV variants during viral rebound may provide insight into the composition of the HIV reservoir and has implications for the design of curative interventions. HIV single-genome sequences were obtained from 10 AIDS Clinical Trials Group participants who underwent analytic antiretroviral therapy (ART) interruption (ATI). Rebounding variants were compared with those in pre-ART plasma in all 10 participants and with on-ART peripheral blood mononuclear cell (PBMC)-associated DNA and RNA (CA-RNA) in 7/10 participants. The highest viral diversities were found in the DNA and CA-RNA populations. In 3 of 7 participants, we detected multiple, identical DNA and CA-RNA sequences during suppression on ART that exactly matched plasma HIV sequences. Hypermutated DNA and CA-RNA were detected in four participants, contributing to diversities in these compartments that were higher than in the pre-ART and post-ATI plasma. Shifts in the viral rebound populations could be detected in some participants over the 2- to 3-month observation period. These findings suggest that a source of initial rebound viremia could be populations of infected cells that clonally expanded prior to and/or during ART, some of which were already expressing HIV RNA before treatment was interrupted. These clonally expanding populations of HIV-infected cells may represent an important target for strategies aimed at achieving reservoir reduction and sustained virologic remission.
C1 [Kearney, Mary F.; Wiegand, Ann] NCI, HIV Dynam & Replicat Program, Frederick, MD 21701 USA.
[Shao, Wei; Keele, Brandon F.] Leidos Biomed Res Inc, Frederick Natl Labs Canc Res, Frederick, MD USA.
[Coffin, John M.] Tufts Univ, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.
[Mellors, John W.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Lederman, Michael] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Gandhi, Rajesh T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Li, Jonathan Z.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
RP Keele, BF (reprint author), Leidos Biomed Res Inc, Frederick Natl Labs Canc Res, Frederick, MD USA.; Li, JZ (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
EM kearneym@ncifcrf.gov; jli@bwh.harvard.edu
FU National Institutes of Health (NIH) [AI100699, U01AI068636,
UM1AI106701]; Leidos Biomedical Research, Inc. [12XS547, 13SX110]; NIH
[HHSN261200800001E]; National Cancer Institute; AIDS Targeted Antiviral
Program Award; FM Kirby Foundation
FX This work was supported by National Institutes of Health (NIH) grants
AI100699 (to J.Z.L.), U01AI068636 (to the AIDS Clinical Trials Group),
and UM1AI106701 (to the Pittsburgh Virology Specialty Laboratory), and
by Leidos Biomedical Research, Inc. (subcontract 12XS547 to J.W.M. and
13SX110 to J.M.C. through the National Cancer Institute), and by
intramural NIH funding, including the National Cancer Institute, the
AIDS Targeted Antiviral Program Award to M.F.K., and NIH Contract No.
HHSN261200800001E. J.M.C. was a Research Professor of the American
Cancer Society, with support from the FM Kirby Foundation. The content
is solely the responsibility of the authors and does not necessarily
represent the official views of the National Cancer Institute or the
National Institutes of Health.
NR 33
TC 9
Z9 9
U1 2
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD FEB
PY 2016
VL 90
IS 3
BP 1369
EP 1376
DI 10.1128/JVI.02139-15
PG 8
WC Virology
SC Virology
GA DC3WW
UT WOS:000369150800018
PM 26581989
ER
PT J
AU Lee, WS
Richard, J
Lichtfuss, M
Smith, AB
Park, J
Courter, JR
Melillo, BN
Sodroski, JG
Kaufmann, DE
Finzi, A
Parsons, MS
Kent, SJ
AF Lee, Wen Shi
Richard, Jonathan
Lichtfuss, Marit
Smith, Amos B., III
Park, Jongwoo
Courter, Joel R.
Melillo, Bruno N.
Sodroski, Joseph G.
Kaufmann, Daniel E.
Finzi, Andres
Parsons, Matthew S.
Kent, Stephen J.
TI Antibody-Dependent Cellular Cytotoxicity against Reactivated
HIV-1-Infected Cells
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; LATENTLY INFECTED-CELLS; VACCINE EFFICACY
TRIAL; CD4(+) T-CELLS; NK CELLS; MEDIATED CYTOTOXICITY; HIV-1 GP120;
DISEASE PROGRESSION; IN-VITRO; EX-VIVO
AB Lifelong antiretroviral therapy (ART) for HIV-1 does not diminish the established latent reservoir. A possible cure approach is to reactivate the quiescent genome from latency and utilize immune responses to eliminate cells harboring reactivated HIV-1. It is not known whether antibodies within HIV-1-infected individuals can recognize and eliminate cells reactivated from latency through antibody-dependent cellular cytotoxicity (ADCC). We found that reactivation of HIV-1 expression in the latently infected ACH-2 cell line elicited antibody-mediated NK cell activation but did not result in antibody-mediated killing. The lack of CD4 expression on these HIV-1 envelope (Env)-expressing cells likely resulted in poor recognition of CD4-induced antibody epitopes on Env. To examine this further, cultured primary CD4(+) T cells from HIV-1(+) subjects were used as targets for ADCC. These ex vivo-expanded primary cells were modestly susceptible to ADCC mediated by autologous or heterologous HIV-1(+) serum antibodies. Importantly, ADCC mediated against these primary cells could be enhanced following incubation with a CD4-mimetic compound (JP-III-48) that exposes CD4-induced antibody epitopes on Env. Our studies suggest that with sufficient reactivation and expression of appropriate Env epitopes, primary HIV-1-infected cells can be targets for ADCC mediated by autologous serum antibodies and innate effector cells. The results of this study suggest that further investigation into the potential of ADCC to eliminate reactivated latently infected cells is warranted.
C1 [Lee, Wen Shi; Lichtfuss, Marit; Parsons, Matthew S.; Kent, Stephen J.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia.
[Richard, Jonathan; Kaufmann, Daniel E.; Finzi, Andres] CHUM, Ctr Rech, Montreal, PQ, Canada.
[Richard, Jonathan; Finzi, Andres] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada.
[Smith, Amos B., III; Park, Jongwoo; Courter, Joel R.; Melillo, Bruno N.] Univ Penn, Sch Arts & Sci, Dept Chem, Philadelphia, PA 19104 USA.
[Sodroski, Joseph G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & Virol, 44 Binney St, Boston, MA 02115 USA.
[Sodroski, Joseph G.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, 44 Binney St, Boston, MA 02115 USA.
[Sodroski, Joseph G.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 44 Binney St, Boston, MA 02115 USA.
[Kaufmann, Daniel E.] MIT & Harvard, Massachusetts Gen Hosp, Ragon Inst, Cambridge, MA USA.
[Kaufmann, Daniel E.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada.
[Kaufmann, Daniel E.] Scripps Res Inst, Ctr HIV AIDS Vaccine Immunol & Immunogen Discover, La Jolla, CA 92037 USA.
[Finzi, Andres] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.
[Kent, Stephen J.] Monash Univ, Melbourne Sexual Hlth Ctr, Cent Clin Sch, Clayton, Vic 3800, Australia.
[Kent, Stephen J.] Monash Univ, Dept Infect Dis, Clayton, Vic 3800, Australia.
[Kent, Stephen J.] Univ Melbourne, ARC Ctr Excellence Convergent Bionano Sci & Techn, Melbourne, Vic 3010, Australia.
RP Kent, SJ (reprint author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia.; Finzi, A (reprint author), CHUM, Ctr Rech, Montreal, PQ, Canada.; Finzi, A (reprint author), Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada.; Finzi, A (reprint author), McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.; Kent, SJ (reprint author), Monash Univ, Melbourne Sexual Hlth Ctr, Cent Clin Sch, Clayton, Vic 3800, Australia.; Kent, SJ (reprint author), Monash Univ, Dept Infect Dis, Clayton, Vic 3800, Australia.
EM andres.finzi@umontreal.ca; skent@unimelb.edu.au
OI Kent, Stephen/0000-0002-8539-4891
FU Australia NHMRC [1052979, 10471832]; Australia-India Strategic Research
Fund; Canada Foundation for Innovation Program Leader; Canadian
Institutes for Health Research (CIHR) [119334, 134117]; Establishment of
Young Scientist [26702]; FRQS AIDS and Infectious Diseases Network; NIH
[AI100645, AI100663, GM56550]; Center for HIV/AIDS Vaccine Immunology
and Immunogen Design (CHAVI-ID); National Institutes of Health [RO1
HL-092565]; Canada Research Chair on Retroviral Entry; CIHR Fellowship
Awards; Research Scholar Career Award from the Quebec Health Research
Fund (FQRS)
FX This work was supported by Australia NHMRC awards 1052979 and 10471832,
an Australia-India Strategic Research Fund award, a Canada Foundation
for Innovation Program Leader grant, Canadian Institutes for Health
Research (CIHR) operating grants 119334 and 134117, Establishment of
Young Scientist grant 26702 to A.F., the FRQS AIDS and Infectious
Diseases Network, NIH grants AI100645, AI100663, and GM56550, and Center
for HIV/AIDS Vaccine Immunology and Immunogen Design (CHAVI-ID) and
National Institutes of Health grant RO1 HL-092565. A.F. is a recipient
of a Canada Research Chair on Retroviral Entry. J.R. and M.S.P. are
recipients of CIHR Fellowship Awards. D.E.K. is supported by a Research
Scholar Career Award from the Quebec Health Research Fund (FQRS). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 54
TC 4
Z9 4
U1 3
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD FEB
PY 2016
VL 90
IS 4
BP 2021
EP 2030
DI 10.1128/JVI.02717-15
PG 10
WC Virology
SC Virology
GA DC3XL
UT WOS:000369152700028
PM 26656700
ER
PT J
AU Patti, ME
Goldfine, AB
AF Patti, Mary-Elizabeth
Goldfine, Allison B.
TI The rollercoaster of post-bariatric hypoglycaemia
SO LANCET DIABETES & ENDOCRINOLOGY
LA English
DT Editorial Material
ID GASTRIC BYPASS-SURGERY; SLEEVE GASTRECTOMY; MIXED MEAL; NEUROGLYCOPENIA;
SYMPTOMS; RISK
C1 [Patti, Mary-Elizabeth; Goldfine, Allison B.] Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.
[Patti, Mary-Elizabeth; Goldfine, Allison B.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Patti, ME (reprint author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.; Patti, ME (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.
EM mary.elizabeth.patti@joslin.harvard.edu
NR 14
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2213-8587
J9 LANCET DIABETES ENDO
JI Lancet Diabetes Endocrinol.
PD FEB
PY 2016
VL 4
IS 2
BP 94
EP 96
DI 10.1016/S2213-8587(15)00460-X
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DB7OL
UT WOS:000368705000010
PM 26701701
ER
PT J
AU Shanbhogue, VV
Mitchell, DM
Rosen, CJ
Bouxsein, ML
AF Shanbhogue, Vikram V.
Mitchell, Deborah M.
Rosen, Clifford J.
Bouxsein, Mary L.
TI Type 2 diabetes and the skeleton: new insights into sweet bones
SO LANCET DIABETES & ENDOCRINOLOGY
LA English
DT Review
ID DEPENDENT INSULINOTROPIC PEPTIDE; PREVALENT VERTEBRAL DEFORMITIES;
RANDOMIZED CLINICAL-TRIALS; ISLET AMYLOID POLYPEPTIDE; COLLAGEN
CROSS-LINKING; FORMATION IN-VIVO; MINERAL DENSITY; FRACTURE RISK;
POSTMENOPAUSAL WOMEN; BODY-COMPOSITION
AB Substantial evidence shows that skeletal fragility should be considered among the complications associated with type 2 diabetes. Individuals with type 2 diabetes have increased fracture risk, despite normal bone mineral density (BMD) and high BMI-factors that are generally protective against fractures. The mechanisms underlying skeletal fragility in diabetes are not completely understood, but are multifactorial and likely include effects of obesity, hyperglycaemia, oxidative stress, and accumulation of advanced glycation end products, leading to altered bone metabolism, structure, and strength. Clinicians should be aware that BMD measurements underestimate fracture risk in people with type 2 diabetes, and that new treatments for diabetes, with neutral or positive effects on skeletal health, might play a part in the management of diabetes in those at high risk of fracture. Data for the optimum management of osteoporosis in patients with type 2 diabetes are scarce, but in the absence of evidence to the contrary, physicians should follow guidelines established for postmenopausal osteoporosis.
C1 [Shanbhogue, Vikram V.] Univ Southern Denmark, Odense Univ Hosp, Dept Endocrinol, Odense, Denmark.
[Shanbhogue, Vikram V.] Univ Southern Denmark, Inst Clin Res, Odense, Denmark.
[Mitchell, Deborah M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Rosen, Clifford J.] Maine Med Ctr, Res Inst, Ctr Clin & Translat Res, Scarborough, ME USA.
[Bouxsein, Mary L.] Beth Israel Deaconess Med Ctr, Ctr Adv Orthopaed Studies, Boston, MA 02215 USA.
[Bouxsein, Mary L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Bouxsein, ML (reprint author), Beth Israel Deaconess Med Ctr, Ctr Adv Orthopaed Studies, Boston, MA 02215 USA.
EM mbouxsei@bidmc.harvard.edu
FU Danish PhD School of Endocrinology; National Institute of Diabetes and
Digestive and Kidney Diseases of the National Institutes of Health
[R24DK092759, P30DK057521]
FX We acknowledge funding support from The Danish PhD School of
Endocrinology and the National Institute of Diabetes and Digestive and
Kidney Diseases of the National Institutes of Health under award numbers
R24DK092759 and P30DK057521. The content is solely the responsibility of
the authors and does not necessarily represent the official views of the
National Institutes of Health.
NR 137
TC 15
Z9 16
U1 3
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2213-8587
J9 LANCET DIABETES ENDO
JI Lancet Diabetes Endocrinol.
PD FEB
PY 2016
VL 4
IS 2
BP 159
EP 173
DI 10.1016/S2213-8587(15)00283-1
PG 15
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DB7OL
UT WOS:000368705000027
PM 26365605
ER
PT J
AU Gray, ST
Sadow, PM
Lin, DT
Sedaghat, AR
AF Gray, Stacey T.
Sadow, Peter M.
Lin, Derrick T.
Sedaghat, Ahmad R.
TI Endoscopic sinus surgery for chronic rhinosinusitis in patients
previously treated for sinonasal malignancy
SO LARYNGOSCOPE
LA English
DT Article
DE Chronic rhinosinusitis; endoscopic sinus surgery; complications;
sinonasal malignancy
ID NASOPHARYNGEAL CARCINOMA PATIENTS; SINGLE-INSTITUTION-EXPERIENCE;
PARA-NASAL SINUSES; PARANASAL SINUSES; SKULL BASE; CRANIOFACIAL
RESECTION; RADIATION-THERAPY; COMPLICATIONS; CANCER; EPIDEMIOLOGY
AB Objectives/HypothesisPatients with a history of sinonasal malignancy can develop chronic rhinosinusitis (CRS) as a consequence of their oncologic treatment. Some patients will fail medical management and require endoscopic sinus surgery (ESS). This study reviews the use of ESS in the management of CRS in patients previously treated for sinonasal malignancy.
Study DesignRetrospective review.
MethodsAll patients with a history of sinonasal malignancy who developed CRS and underwent ESS were reviewed. Preoperative and postoperative imaging and symptoms were collected. Major complications (bleeding, orbital injury, and cerebrospinal fluid leak) and minor complications (adhesion formation) and postoperative healing were reviewed.
ResultsEighteen patients were identified. All patients presented with symptoms of CRS and sinonasal crusting. Additionally, five patients presented with recurrent facial cellulitis, and six patients had mucoceles. No major complications were encountered. Postoperatively, all patients reported a subjective improvement in their sinonasal symptoms. Comparison of pre- and post-ESS imaging revealed a significant improvement in Lund-Mackay scores after ESS (P<0.001) from 12.8 (range 5-22) to 7 (range). Despite symptomatic improvement, all patients continued to have nasal crusting. All patients who initially presented with recurrent facial cellulitis had no further episodes after ESS. None of the endoscopically drained mucoceles recurred.
ConclusionFor patients previously treated for sinonasal malignancy with refractory CRS, ESS appears to be a safe and effective treatment option. ESS in these patients results in subjective improvement in sinonasal symptoms as well as objective improvement in radiographic CRS disease burden, although sinonasal crusting will likely not resolve.
Level of Evidence4. Laryngoscope, 126:304-315, 2016
C1 [Gray, Stacey T.; Lin, Derrick T.; Sedaghat, Ahmad R.] Harvard Univ, Sch Med, Dept Otolaryngol, Massachusetts Eye & Ear Infirm,Massachusetts Gen, Boston, MA 02115 USA.
[Gray, Stacey T.; Lin, Derrick T.; Sedaghat, Ahmad R.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Gray, ST (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM stacey_gray@meei.harvard.edu
NR 62
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD FEB
PY 2016
VL 126
IS 2
BP 304
EP 315
DI 10.1002/lary.25435
PG 12
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA DC1SX
UT WOS:000368998200010
PM 26309057
ER
PT J
AU Meier, JC
Remenschneider, AK
Gray, ST
Holbrook, EH
Gliklich, RE
Metson, R
AF Meier, Josh C.
Remenschneider, Aaron K.
Gray, Stacey T.
Holbrook, Eric H.
Gliklich, Richard E.
Metson, Ralph
TI The impact of surgical trainee participation on sinus surgery outcomes
SO LARYNGOSCOPE
LA English
DT Article
DE Quality of life; allergy; rhinology; outcomes; cost-effectiveness; adult
rhinology
ID QUALITY-IMPROVEMENT-PROGRAM; RESIDENT INVOLVEMENT; CHRONIC
RHINOSINUSITIS; ACS-NSQIP; COMPLICATION RATES; CLINICAL-OUTCOMES;
AMERICAN-COLLEGE; HEALTH STATES; EDUCATION; MORBIDITY
AB Objectives/HypothesisTo determine the effect of otolaryngology trainee participation on clinical outcomes in patients who undergo endoscopic sinus surgery (ESS) for chronic rhinosinusitis.
Study DesignSecondary analysis of prospectively collected data.
MethodsPatients enrolled in a sinus surgery outcomes study between May 2011 and March 2013 were stratified into two groupsthose who were operated on by an attending alone and those operated on by an attending with a trainee present (resident, fellow, or both). Patients completed quality of life (QOL) surveys including the Chronic Sinusitis Survey (CSS), 22-item Sino-Nasal Outcome Test (SNOT-22), and EuroQol 5-dimension survey preoperatively and 1 year postoperatively. Operative time, estimated blood loss (EBL), complication rates, and survey scores were compared between groups.
ResultsThe study population consisted of 452 patients. The attending alone (n=119) and trainee (n=333) groups were statistically comparable in terms of patient demographics, disease severity, and extent of surgery. Mean operative time was significantly shorter in the attending-alone group (80.0 vs. 90.6 minutes, P<.01). Mean EBL (105 mL attending vs. 117 mL trainee, P=.39) and complication rates (3.3% attending vs. 0.6% trainee, P=.07) were similar between groups. Observed changes in QOL measures following ESS were comparable between groups, although absolute improvement in the SNOT-22 scores (19.0 attending vs. 24.5 trainee, P=.05) did show a trend toward greater improvement in the trainee group.
ConclusionsTrainee participation in ESS is associated with prolongation in surgical time; however, such participation was not found to adversely affect patient safety or clinical outcomes.
Level of Evidence2b Laryngoscope, 126:316-321, 2016
C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
RP Meier, JC (reprint author), 9770 S McCarran Blvd, Reno, NV 89523 USA.
EM meier_josh@yahoo.com
FU Board Committee on Quality at the Massachusetts Eye and Ear Infirmary,
Boston, Massachusetts
FX This work was supported by a funding grant from the Board Committee on
Quality at the Massachusetts Eye and Ear Infirmary, Boston,
Massachusetts.
NR 39
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD FEB
PY 2016
VL 126
IS 2
BP 316
EP 321
DI 10.1002/lary.25504
PG 6
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA DC1SX
UT WOS:000368998200011
PM 26360316
ER
PT J
AU Gin, JL
Kranke, D
Saia, R
Dobalian, A
AF Gin, June L.
Kranke, Derrick
Saia, Rebecca
Dobalian, Aram
TI Disaster Preparedness in Homeless Residential Organizations in Los
Angeles County: Identifying Needs, Assessing Gaps
SO NATURAL HAZARDS REVIEW
LA English
DT Article
DE Disasters; Residential organizations; Disaster planning; Preparedness;
Homeless persons; Emergency management; Vulnerable populations
ID HEALTH-CARE; COMMUNITY
AB Community-based organizations (CBOs) are essential to supporting homeless populations during disasters, yet little is known about their preparedness and ability to support their vulnerable clients. This qualitative study evaluated the perceptions of Los Angeles nonprofit homeless residential service providers regarding the likely impacts of a disaster on their clients and operations, the barriers they face in disaster planning, and their suggested solutions to facilitate preparedness within their sector. Twelve semistructured interviews were conducted with executive staff and emergency planners from six organizations serving people experiencing homelessness. Respondents reported significant barriers to both postdisaster services and collaboration with emergency management. They indicated both a need for and interest in technical assistance and training to develop their disaster capabilities. These concerns suggest that a multisector effort, including homeless-service organizations, their funders, and emergency managers, is needed to strengthen the resilience of safety-net CBOs serving homeless populations. This work is made available under the terms of the Creative Commons Attribution 4.0 International license, http://creativecommons. org/licenses/by/4.0/.
C1 [Gin, June L.; Kranke, Derrick; Saia, Rebecca; Dobalian, Aram] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, 16111 Plummer St,MS 152, North Hills, CA 91343 USA.
[Dobalian, Aram] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA.
[Dobalian, Aram] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
RP Gin, JL (reprint author), US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, 16111 Plummer St,MS 152, North Hills, CA 91343 USA.
EM June.Gin@va.gov; Derrick.Kranke@va.gov; Rebecca.Saia@va.gov;
Aram.Dobalian@va.gov
NR 46
TC 0
Z9 0
U1 5
U2 8
PU ASCE-AMER SOC CIVIL ENGINEERS
PI RESTON
PA 1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA
SN 1527-6988
EI 1527-6996
J9 NAT HAZARDS REV
JI Nat. Hazards Rev.
PD FEB
PY 2016
VL 17
IS 1
AR 04015022
DI 10.1061/(ASCE)NH.1527-6996.0000208
PG 8
WC Engineering, Civil; Environmental Studies; Geosciences,
Multidisciplinary; Meteorology & Atmospheric Sciences; Water Resources
SC Engineering; Environmental Sciences & Ecology; Geology; Meteorology &
Atmospheric Sciences; Water Resources
GA DB9LK
UT WOS:000368837300016
ER
PT J
AU Weaver, GC
Villar, RF
Kanekiyo, M
Nabel, GJ
Mascola, JR
Lingwood, D
AF Weaver, Grant C.
Villar, Rina F.
Kanekiyo, Masaru
Nabel, Gary J.
Mascola, John R.
Lingwood, Daniel
TI In vitro reconstitution of B cell receptor-antigen interactions to
evaluate potential vaccine candidates
SO NATURE PROTOCOLS
LA English
DT Article
ID NEUTRALIZING ANTIBODIES; HEMAGGLUTININ-STEM; INFLUENZA ANTIBODIES;
MEMORY; RECOGNITION; EXPRESSION; MATURATION; IMMUNOGEN; RESPONSES;
BINDING
AB Predicting immune responses before vaccination is challenging because of the complexity of the governing parameters. Nevertheless, recent work has shown that B cell receptor (BCR)-antigen engagement in vitro can prove a powerful means of informing the design of antibody-based vaccines. We have developed this principle into a two-phased immunogen evaluation pipeline to rank-order vaccine candidates. In phase 1, recombinant antigens are screened for reactivity to the germline precursors that produce the antibody responses of interest. To both mimic the architecture of initial antigen engagement and facilitate rapid immunogen screening, these antibodies are expressed as membrane-anchored IgM (mIgM) in 293F indicator cells. In phase 2, the binding hits are multimerized by nanoparticle or proteoliposome display, and they are evaluated for BCRCR triggering in an engineered B cell line displaying the IgM sequences of interest. Key developments that complement existing methodology in this area include the following: (i) introduction of a high-throughput screening step before evaluation of more time-intensive BCRCR-triggering analyses; (ii) generalizable multivalent antigen-display platforms needed for BCRCR activation; and (iii) engineered use of a human B cell line that does not display endogenous antibody, but only ectopically expressed BCRCR sequences of interest. Through this pipeline, the capacity to initiate favorable antibody responses is evaluated. The entire protocol can be completed within 2.5 months.
C1 [Weaver, Grant C.; Villar, Rina F.; Lingwood, Daniel] MIT, Massachusetts Gen Hosp, Ragon Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Weaver, Grant C.; Villar, Rina F.; Lingwood, Daniel] Harvard Univ, Cambridge, MA 02138 USA.
[Kanekiyo, Masaru; Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Nabel, Gary J.] Sanofi, Cambridge, MA USA.
RP Lingwood, D (reprint author), MIT, Massachusetts Gen Hosp, Ragon Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Lingwood, D (reprint author), Harvard Univ, Cambridge, MA 02138 USA.
EM dlingwood@mgh.harvard.edu
FU Harvard University Center for AIDS Research (CFAR) grant [P30 AI060354];
Broad-Ragon ENDHIV Catalytic grant; William F. Milton Fund; Gilead
Sciences Research Scholars Program in HIV
FX The authors thank members of the Lingwood laboratory for critical
reading of the manuscript, S. Perfetto (Vaccine Research Center,
National Institutes of Health (NIH)) for flow cytometry advice, and J.
Boyington and J. Whittle (Vaccine Research Center, NIH) for key
discussions. This work was supported by the following awards to D.L.: a
Harvard University Center for AIDS Research (CFAR) grant (P30 AI060354);
a Broad-Ragon ENDHIV Catalytic grant; the William F. Milton Fund; and
the Gilead Sciences Research Scholars Program in HIV.
NR 48
TC 1
Z9 1
U1 6
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
EI 1750-2799
J9 NAT PROTOC
JI Nat. Protoc.
PD FEB
PY 2016
VL 11
IS 2
BP 193
EP 213
DI 10.1038/nprot.2016.009
PG 21
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA DC2YK
UT WOS:000369084500001
PM 26741406
ER
PT J
AU Buchbinder, EI
Hodi, FS
AF Buchbinder, Elizabeth I.
Hodi, F. Stephen
TI Immune-checkpoint blockade - durable cancer control
SO NATURE REVIEWS CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID UNTREATED MELANOMA; CTLA-4 BLOCKADE; IPILIMUMAB; NIVOLUMAB
C1 [Buchbinder, Elizabeth I.; Hodi, F. Stephen] Dana Farber Canc Inst, Dept Med Oncol, Melanoma Dis Ctr, 450 Brookline Ave, Boston, MA 02215 USA.
RP Hodi, FS (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Melanoma Dis Ctr, 450 Brookline Ave, Boston, MA 02215 USA.
EM stephen_hodi@dfci.harvard.edu
NR 10
TC 7
Z9 7
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4774
EI 1759-4782
J9 NAT REV CLIN ONCOL
JI Nat. Rev. Clin. Oncol.
PD FEB
PY 2016
VL 13
IS 2
BP 77
EP 78
DI 10.1038/nrclinonc.2015.237
PG 2
WC Oncology
SC Oncology
GA DC2GD
UT WOS:000369034300006
PM 26787285
ER
PT J
AU Weir, GC
AF Weir, Gordon C.
TI Understanding secretion, ageing and death in beta cells
SO NATURE REVIEWS ENDOCRINOLOGY
LA English
DT Editorial Material
AB The pancreatic islets of Langerhans have been intensively investigated for many years, largely because of their central role in the pathogenesis of type 1 and type 2 diabetes mellitus. Notable advances in 2015 related to glucose-stimulated insulin secretion in beta cells, beta-cell death and the rote of epigenetics in beta-cell heterogeneity.
C1 [Weir, Gordon C.] Joslin Diabet Ctr, Sect Islet Cell & Regenerat Biol, 1 Joslin Pl, Boston, MA 02215 USA.
RP Weir, GC (reprint author), Joslin Diabet Ctr, Sect Islet Cell & Regenerat Biol, 1 Joslin Pl, Boston, MA 02215 USA.
EM gordon.weir@joslin.harvard.edu
NR 5
TC 0
Z9 0
U1 4
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5029
EI 1759-5037
J9 NAT REV ENDOCRINOL
JI Nat. Rev. Endocrinol.
PD FEB
PY 2016
VL 12
IS 2
BP 72
EP 74
DI 10.1038/nrendo.2015.236
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DC3JM
UT WOS:000369115600005
PM 26729035
ER
PT J
AU Lo, WK
Goldberg, HJ
Burakoff, R
Feldman, N
Chan, WW
AF Lo, W. -K.
Goldberg, H. J.
Burakoff, R.
Feldman, N.
Chan, W. W.
TI Increased proximal acid reflux is associated with early readmission
following lung transplantation
SO NEUROGASTROENTEROLOGY AND MOTILITY
LA English
DT Article
DE acid reflux; GERD; impedance; lung transplant; post-transplant;
readmission
ID GASTROESOPHAGEAL-REFLUX; ALLOGRAFT INJURY; NORMAL VALUES; ASPIRATION;
IMPEDANCE; DISEASE; BRONCHIOLITIS; REJECTION; THERAPY
AB Background Gastroesophageal reflux disease has been associated with poor outcomes following lung transplantation. However, the association between pretransplant reflux and post-transplant readmission, an indicator of early clinical outcome, has not been previously assessed. Methods This was a retrospective cohort study of lung transplant recipients undergoing pretransplant multichannel intraluminal impedance and pH (MII-pH) study off acid suppression at a tertiary care center since 2007. Subjects with pretransplant fundoplication were excluded. Time to readmission was defined as duration from post-transplant discharge to next hospital admission for any reason. Subgroup analysis was performed to exclude elective readmissions. Time-to-event analysis was performed using Cox proportional hazards model, with appropriate censoring. Key Results Forty-three subjects (60% men, mean age: 57, median follow-up: 1.7 years) met inclusion criteria for the study. Patient demographics and pretransplant cardiopulmonary function were similar between readmission cohorts. Time to all-cause readmission was associated with increased distal acid episodes (HR: 3.15, p = 0.04) and proximal acid episodes (HR: 3.61, p = 0.008) on impedance, increased acid exposure on pH (HR: 2.22, p = 0.04), and elevated Demeester score (HR: 2.26, p = 0.03). When elective readmissions were excluded, early readmission remained significantly associated with increased proximal acid reflux episodes (HR: 2.49, p = 0.04). All findings were confirmed on Kaplan-Meier analysis. Conclusions & Inferences Elevated proximal acid reflux on pretransplant MII-pH testing was associated with early readmission following lung transplantation, even after excluding elective readmissions. Exposure to severe acid reflux has measurable effects on early postoperative outcomes such as readmission, and aggressive early antireflux therapy should be considered.
C1 [Lo, W. -K.; Burakoff, R.; Feldman, N.; Chan, W. W.] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, 75 Francis St, Boston, MA 02115 USA.
[Lo, W. -K.] VA Boston Healthcare Syst, Dept Gastroenterol, Boston, MA USA.
[Lo, W. -K.; Goldberg, H. J.; Burakoff, R.; Chan, W. W.] Harvard Univ, Sch Med, Boston, MA USA.
[Goldberg, H. J.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.
RP Chan, WW (reprint author), Brigham & Womens Hosp, Div Gastroenterol, 75 Francis St, Boston, MA 02115 USA.
EM wwchan@partners.org
NR 21
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1350-1925
EI 1365-2982
J9 NEUROGASTROENT MOTIL
JI Neurogastroenterol. Motil.
PD FEB
PY 2016
VL 28
IS 2
BP 251
EP 259
DI 10.1111/nmo.12720
PG 9
WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences
SC Gastroenterology & Hepatology; Neurosciences & Neurology
GA DB9EB
UT WOS:000368818100011
PM 26568193
ER
PT J
AU Dijkink, S
Fuentes, E
Quraishi, SA
Cropano, C
Kaafarani, HMA
Lee, J
King, DR
DeMoya, M
Fagenholz, P
Butler, K
Velmahos, G
Yeh, DD
AF Dijkink, Suzan
Fuentes, Eva
Quraishi, Sadeq A.
Cropano, Catrina
Kaafarani, Haytham M. A.
Lee, Jarone
King, David R.
DeMoya, Marc
Fagenholz, Peter
Butler, Kathryn
Velmahos, George
Yeh, Daniel Dante
TI Nutrition in the Surgical Intensive Care Unit: The Cost of Starting Low
and Ramping Up Rates
SO NUTRITION IN CLINICAL PRACTICE
LA English
DT Article
DE caloric deficit; feeding protocols; enteral nutrition; nutritional
support; critical illness; intensive care units; clinical protocols
ID CRITICALLY-ILL PATIENTS; PROTEIN-ENERGY PROVISION; ENTERAL NUTRITION;
CALORIC-INTAKE; CLINICAL-OUTCOMES; RANDOMIZED-TRIAL; DELIVERY;
INFECTIONS; MORTALITY; PROTOCOL
AB Background: Calorie/protein deficit in the surgical intensive care unit (SICU) is associated with worse clinical outcomes. It is customary to initiate enteral nutrition (EN) at a low rate and increase to goal (RAMP-UP). Increasing evidence suggests that RAMP-UP may contribute to iatrogenic malnutrition. We sought to determine what proportion of total SICU calorie/protein deficit is attributable to RAMP-UP. Materials and Methods: This is a retrospective study of a prospectively collected registry of adult patients (N = 109) receiving at least 72 hours of EN in the SICU according to the RAMP-UP protocol (July 2012-June 2014). Subjects receiving only trophic feeds or with interrupted EN during RAMP-UP were excluded. Deficits were defined as the amount of prescribed calories/protein minus the actual amount received. RAMP-UP deficit was defined as the deficit between EN initiation and arrival at goal rate. Data included demographics, nutritional prescription/delivery, and outcomes. Results: EN was started at a median of 34.0 hours (interquartile range [IQR], 16.5-53.5) after ICU admission, with a mean duration of 8.7 +/- 4.3 days. The median total caloric deficit was 2185 kcal (249-4730), with 900 kcal (551-1562) attributable to RAMP-UP (41%). The protein deficit was 98.5 g (27.5-250.4), with 51.9 g (20.6-83.3) caused by RAMP-UP (53%). Conclusions: In SICU patients initiating EN, the RAMP-UP period accounted for 41% and 53% of the overall caloric and protein deficits, respectively. Starting EN immediately at goal rate may eliminate a significant proportion of macronutrient deficit in the SICU.
C1 [Dijkink, Suzan; Fuentes, Eva; Cropano, Catrina; Kaafarani, Haytham M. A.; Lee, Jarone; King, David R.; DeMoya, Marc; Fagenholz, Peter; Butler, Kathryn; Velmahos, George; Yeh, Daniel Dante] Massachusetts Gen Hosp, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.
[Quraishi, Sadeq A.] Massachusetts Gen Hosp, Dept Anesthesiol, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.
RP Dijkink, S (reprint author), Massachusetts Gen Hosp, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.
EM s.dijkink@lumc.nl
FU Nestle
FX Dr Daniel D. Yeh received a research grant from Nestle. The goal of this
grant was to support research by Dr Yeh in general and not this research
project specifically. Also no products of Nestle were discussed or
alluded in this article, and Nestle had no influence on the results
published.
NR 26
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0884-5336
EI 1941-2452
J9 NUTR CLIN PRACT
JI Nutr. Clin. Pract.
PD FEB
PY 2016
VL 31
IS 1
BP 86
EP 90
DI 10.1177/0884533615621047
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DC2LN
UT WOS:000369048300011
PM 26673198
ER
PT J
AU Therkelsen, KE
Pedley, A
Rosenquist, KJ
Hoffmann, U
Massaro, JM
Murabito, JM
Fox, CS
AF Therkelsen, Kate E.
Pedley, Alison
Rosenquist, Klara J.
Hoffmann, Udo
Massaro, Joseph M.
Murabito, Joanne M.
Fox, Caroline S.
TI Adipose tissue attenuation as a marker of adipose tissue quality:
Associations with six-year changes in body weight
SO OBESITY
LA English
DT Article
DE epidemiology; adipose tissue; population studies; obesity
ID COMPUTED TOMOGRAPHIC ATTENUATION; INSULIN SENSITIVITY; ABDOMINAL FAT;
OBESE INDIVIDUALS; CONTROLLED-TRIAL; RISK-FACTORS; FRAMINGHAM; EXERCISE;
HEART; DIET
AB ObjectiveWeight gain is associated with fat volume increases, but associations with fat quality are less well characterized The associations of weight change with visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) volume and attenuation were investigated.
MethodsComputed tomography abdominal scans were acquired on a Framingham Heart Study subset (N=836; 40.2% women; mean age 45.7years), a mean of 6.1years apart. Fat attenuation estimated fat quality.
ResultsMean weight change was +2.0 (SD 6.8; IQR -0.7, 5.0)kg in women and +2.7 (SD 6.0; IQR -0.5, 5.4)kg in men. Per 2.5kg weight increase in women, VAT volume increased 126cm(3) (95% CI, 112-140, p<0.0001), SAT volume increased 258cm(3) (95% CI, 239-278, p<0.0001), and fat attenuation decreased (i.e., fat quality worsened) in VAT and SAT (p<0.0001). Increasing VAT volume was associated with decreasing fat attenuation even after accounting for weight change. Relative to weight-stable women (n=129), women who lost >2.5kg (n=58) had smaller SAT attenuation decreases (p<0.0001). Similar patterns were seen in men.
ConclusionsWeight gain was associated with decreases in fat attenuation independent of VAT and SAT volume changes. These findings highlighted the associations of weight gain and worsening fat attenuation, suggesting fat attenuation may be dynamic.
C1 [Therkelsen, Kate E.; Pedley, Alison; Fox, Caroline S.] NHLBI, Div Intramural Res, Framingham, MA USA.
[Therkelsen, Kate E.; Pedley, Alison; Fox, Caroline S.] NHLBI, Ctr Populat Studies, Framingham, MA USA.
[Therkelsen, Kate E.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Rosenquist, Klara J.] North Shore Phys Grp, Dept Endocrinol, Peabody, MA USA.
[Hoffmann, Udo] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Hoffmann, Udo; Fox, Caroline S.] Harvard Univ, Sch Med, Boston, MA USA.
[Massaro, Joseph M.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Murabito, Joanne M.] Boston Univ, Sch Med, Gen Internal Med Sect, Boston, MA 02118 USA.
[Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol & Metab, 75 Francis St, Boston, MA 02115 USA.
RP Fox, CS (reprint author), NHLBI, Div Intramural Res, Framingham, MA USA.; Fox, CS (reprint author), NHLBI, Ctr Populat Studies, Framingham, MA USA.; Fox, CS (reprint author), Harvard Univ, Sch Med, Boston, MA USA.; Fox, CS (reprint author), Brigham & Womens Hosp, Div Endocrinol & Metab, 75 Francis St, Boston, MA 02115 USA.
EM foxca@nhlbi.nih.gov
FU [N01-HC-25195]
FX The Framingham Heart Study of the National Heart, Lung, and Blood
Institute is supported by contract N01-HC-25195.
NR 30
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD FEB
PY 2016
VL 24
IS 2
BP 499
EP 505
DI 10.1002/oby.21337
PG 7
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA DC3SQ
UT WOS:000369139500032
PM 26694629
ER
PT J
AU Guo, FJ
Garvey, WT
AF Guo, Fangjian
Garvey, W. Timothy
TI Cardiometabolic disease risk in metabolically healthy and unhealthy
obesity: Stability of metabolic health status in adults
SO OBESITY
LA English
DT Article
ID BODY-MASS INDEX; TREATMENT PANEL-III; CARDIOVASCULAR-DISEASE;
INSULIN-RESISTANCE; MYOCARDIAL-INFARCTION; NORMAL-WEIGHT; IMPACT; WOMEN;
POPULATION; OVERWEIGHT
AB ObjectiveTo assess the stability of metabolic status and body mass index (BMI) status and their relative contribution to risk of diabetes, cardiovascular events, and mortality.
MethodsA total of 14,685 participants from the Atherosclerosis Risk in Communities Study and 4,990 from the Coronary Artery Risk Development in Young Adults Study were included. People with healthy obesity (HO) are defined as those meeting all three indices of blood pressure, blood glucose, and blood lipids. People with unhealthy obesity crossed the risk threshold for all three criteria.
ResultsIn both healthy and unhealthy subgroups, risks for coronary heart disease (CHD), stroke, and mortality were comparable among BMI status during a mean 18.7-year follow-up. When compared with HO, hazard ratios were increased for diabetes (5.56, 95% confidence interval [CI] 4.12-7.48), CHD (5.60, 95% CI 3.14-9.98), stroke (4.84, 95% CI 2.13-10.97), and mortality (2.6, 95% CI 1.88-3.61) in people with unhealthy obesity. BMI only moderately increased the risks for diabetes among healthy subjects. In the Coronary Artery Risk Development in Young Adults Study over 20 years, 17.5% of lean subjects and 67.3% of overweight subjects at baseline developed obesity during follow-up. Despite rising BMI, metabolic status remained relatively stable.
ConclusionsMetabolic status is relatively stable despite rising BMI. HO had lower risks for diabetes, CHD, stroke, and mortality than unhealthy subjects but increased diabetes risks than healthy lean people. Cardiometabolic risk factors confer much higher risk than obesity per se.
C1 [Guo, Fangjian] Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA.
[Guo, Fangjian] Univ Texas Med Branch, Ctr Interdisciplinary Res Womens Hlth, Galveston, TX 77555 USA.
[Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr GRECC, Birmingham, AL USA.
RP Guo, FJ (reprint author), Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA.; Guo, FJ (reprint author), Univ Texas Med Branch, Ctr Interdisciplinary Res Womens Hlth, Galveston, TX 77555 USA.; Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.; Garvey, WT (reprint author), Birmingham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr GRECC, Birmingham, AL USA.
EM faguo@utmb.edu; garveyt@uab.edu
OI Guo, Fangjian/0000-0003-3729-2724
FU Eunice Kennedy Shriver National Institute of Child Health & Human
Development (NICHD) at the National Institutes of Health (NIH)
[T32HD055163]; U.S. Department of Veterans Affairs, National Institutes
of Health [DK-038765, DK-083562]; University of Alabama at Birmingham
Diabetes Research Center [P60-DK079626]
FX Dr. Guo is currently a postdoctoral fellow supported by an institutional
training grant (National Research Service Award T32HD055163) from the
Eunice Kennedy Shriver National Institute of Child Health & Human
Development (NICHD) at the National Institutes of Health (NIH). This
study is supported by the Merit Review program of the U.S. Department of
Veterans Affairs, National Institutes of Health (DK-038765 and
DK-083562), and the University of Alabama at Birmingham Diabetes
Research Center (P60-DK079626).
NR 34
TC 9
Z9 9
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD FEB
PY 2016
VL 24
IS 2
BP 516
EP 525
DI 10.1002/oby.21344
PG 10
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA DC3SQ
UT WOS:000369139500034
PM 26719125
ER
PT J
AU Yagi, Y
Riedlinger, G
Xu, X
Nakamura, A
Levy, B
Iafrate, AJ
Mino-Kenudson, M
Klepeis, VE
AF Yagi, Yukako
Riedlinger, Gregory
Xu, Xun
Nakamura, Akira
Levy, Bruce
Iafrate, A. John
Mino-Kenudson, Mari
Klepeis, Veronica E.
TI Development of a database system and image viewer to assist in the
correlation of histopathologic features and digital image analysis with
clinical and molecular genetic information
SO PATHOLOGY INTERNATIONAL
LA English
DT Review
DE database management system; genetic information; lung adenocarcinoma;
image analysis; histopathology
ID REARRANGED LUNG ADENOCARCINOMAS; EGFR MUTATIONS; PATHOLOGY
AB Pathologists are required to integrate data from multiple sources when making a diagnosis. Furthermore, whole slide imaging (WSI) and next generation sequencing will escalate data size and complexity. Development of well-designed databases that can allow efficient navigation between multiple data types is necessary for both clinical and research purposes. We developed and evaluated an interactive, web-based database that integrates clinical, histologic, immunohistochemical and genetic information to aid in pathologic diagnosis and interpretation with nine lung adenocarcinoma cases. To minimize sectioning artifacts, representative blocks were serially sectioned using automated tissue sectioning (Kurabo Industries, Osaka Japan) and selected slides were stained by multiple techniques, (hematoxylin and eosin [H&E], immunohistochemistry [IHC] or fluorescence in situ hybridization [FISH]). Slides were digitized by WSI scanners. An interactive relational database was designed based on a list of proposed fields covering a variety of clinical, pathologic and molecular parameters. By focusing on the three main tasks of 1.) efficient management of textual information, 2.) effective viewing of all varieties of stained whole slide images (WSI), and 3.) assistance in evaluating WSI with computer-aided diagnosis, this database prototype shows great promise for multi-modality research and diagnosis.
C1 [Yagi, Yukako; Riedlinger, Gregory; Levy, Bruce; Iafrate, A. John; Mino-Kenudson, Mari; Klepeis, Veronica E.] Harvard Univ, Sch Med, 101 Merrimac St,Suite 820, Boston, MA 02114 USA.
[Yagi, Yukako; Riedlinger, Gregory; Levy, Bruce; Iafrate, A. John; Mino-Kenudson, Mari; Klepeis, Veronica E.] Massachusetts Gen Hosp, 101 Merrimac St,Suite 820, Boston, MA 02114 USA.
[Xu, Xun; Nakamura, Akira] Sony Elect Inc, San Jose, CA USA.
[Riedlinger, Gregory] Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA.
[Levy, Bruce] Univ Illinois, Chicago, IL USA.
RP Yagi, Y (reprint author), Harvard Univ, Sch Med, 101 Merrimac St,Suite 820, Boston, MA 02114 USA.; Yagi, Y (reprint author), Massachusetts Gen Hosp, 101 Merrimac St,Suite 820, Boston, MA 02114 USA.
EM yyagi@mgh.harvard.edu
FU Sony Corporation, Tokyo, Japan
FX This project was supported by Sony Corporation, Tokyo, Japan.
NR 21
TC 1
Z9 1
U1 3
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1320-5463
EI 1440-1827
J9 PATHOL INT
JI Pathol. Int.
PD FEB
PY 2016
VL 66
IS 2
BP 63
EP 74
DI 10.1111/pin.12382
PG 12
WC Pathology
SC Pathology
GA DC3VG
UT WOS:000369146400002
PM 26778830
ER
PT J
AU Korppi, M
Kivisto, J
Koponen, P
Lehtinen, P
Remes, S
Piippo-Savolainen, E
Piedra, PA
Espinola, JA
Camargo, CA
Jartti, T
AF Korppi, Matti
Kivisto, Juho
Koponen, Petri
Lehtinen, Pasi
Remes, Sami
Piippo-Savolainen, Eija
Piedra, Pedro A.
Espinola, Janice A.
Camargo, Carlos A., Jr.
Jartti, Tuomas
TI ABSENCE OF BORDETELLA PERTUSSIS AMONG INFANTS HOSPITALIZED FOR
BRONCHIOLITIS IN FINLAND, 2008-2010
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE Bordetella pertussis; bronchiolitis; infant; polymerase chain reaction;
respiratory syncytial virus
ID LENGTH-OF-STAY; CHILDREN; ETIOLOGY; SEASON
AB In 169 Finnish infants hospitalized for bronchiolitis at age <6 months in 2008-2010, nasopharyngeal aspirates were tested by polymerase chain reaction for Bordetella pertussis and 16 viruses. Respiratory viruses were detected in 89% (71% with respiratory syncytial virus), but no infant had B. pertussis. The latter finding may reflect a positive effect from the broadening of the Finnish pertussis vaccination program in 2005.
C1 [Korppi, Matti; Kivisto, Juho; Koponen, Petri] Tampere Univ, Ctr Child Hlth Res, FIN-33101 Tampere, Finland.
[Korppi, Matti; Kivisto, Juho; Koponen, Petri] Tampere Univ Hosp, Tampere, Finland.
[Lehtinen, Pasi; Jartti, Tuomas] Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland.
[Remes, Sami; Piippo-Savolainen, Eija] Kuopio Univ Hosp, Dept Pediat, SF-70210 Kuopio, Finland.
[Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
[Piedra, Pedro A.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
[Espinola, Janice A.; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
RP Korppi, M (reprint author), Tampere Univ, Ctr Child Hlth Res, FIN-33101 Tampere, Finland.; Korppi, M (reprint author), 33014 Tampere Univ, Univ Hosp, Tampere, Finland.
EM matti.korppi@uta.fi
FU Academy of Finland, Helsinki, Finland [132595, 114034]; Finnish Medical
Foundation, Helsinki, Finland
FX T.J. was supported by the Academy of Finland (grant numbers 132595 and
114034) and the Finnish Medical Foundation, both in Helsinki, Finland.
The other authors have no conflicts of interest to disclose.
NR 11
TC 0
Z9 0
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD FEB
PY 2016
VL 35
IS 2
BP 219
EP 221
DI 10.1097/INF.0000000000000973
PG 3
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA DB7WL
UT WOS:000368727500022
PM 26551447
ER
PT J
AU Golier, JA
Caramanica, K
Michaelides, AC
Makotkine, I
Schmeidler, J
Harvey, PD
Yehuda, R
AF Golier, Julia A.
Caramanica, Kimberly
Michaelides, Andreas C.
Makotkine, Iouri
Schmeidler, James
Harvey, Philip D.
Yehuda, Rachel
TI A randomized, double-blind, placebo-controlled, crossover trial of
mifepristone in Gulf War veterans with chronic multisymptom illness
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Gulf War; Mifepristone; CMI; Dexamethasone; ACTH; Cortisol; Verbal
learning
ID POSTTRAUMATIC-STRESS-DISORDER; OPEN-LABEL TRIAL; PSYCHOTIC DEPRESSION;
COGNITIVE DYSFUNCTION; ALZHEIMERS-DISEASE; HIPPOCAMPAL; MEMORY;
DEXAMETHASONE; NEUROGENESIS; RU-486
AB No pharmacological treatments have been demonstrated to effectively treat chronic multisymptom illness (CMI) in Gulf War veterans (GWV). This study assessed the effect of the glucocorticoid receptor antagonist mifepristone in GWV with CMI. A randomized, double-blind, cross-over trial of mifepristone, with two six-week treatment phases separated by a one-month washout period, was conducted at a Veterans Affairs (VA) hospital between 2008 and 2011. Participants were randomized to receive either 200 mg of mifepristone per day or matched placebo first. The primary clinical outcome measure was change in self-reported physical health. Neurocognitive functioning and self-reported measures of depression, PTSD, and fatigue were secondary outcomes. Sixty-five participants enrolled, of whom 36 were randomized and 32 (mean age, 49.1 (7.2) years) completed the study. Physical and mental health status and neurocognitive functioning were poor at baseline. Mifepristone treatment was not associated with improvement in self-reported physical health (p = 0.838) or in other self-reported measures of mental health. Mifepristone treatment was significantly associated with improvements in verbal learning (p = 0.008, d = 0.508), in the absence of improvement in other cognitive measures (working memory (p = 0.914), visual learning (p = 0.643) and a global composite measure (p = 0.937). Baseline morning cortisol levels and lysozyme IC50-DEX, a measure of peripheral glucocorticoid sensitivity, displayed a significant relationship with endpoint verbal learning scores (p = 0.012 and p = 0.007, respectively). The magnitude of cortisol change during treatment mediated the improvement in verbal learning.
This study was negative for the primary and secondary clinical outcomes. However, the data suggest a moderate dose of mifepristone may have circumscribed cognitive-enhancing effects in CMI. Further study is warranted to determine whether and through which mechanisms mifepristone treatment can yield clinically meaningful improvement in cognitive function in CMI or other neuropsychiatric conditions associated with HPA axis dysregulation. (C) Published by Elsevier Ltd.
C1 [Golier, Julia A.; Caramanica, Kimberly; Michaelides, Andreas C.; Makotkine, Iouri; Yehuda, Rachel] James J Peters VA Med Ctr, OOMH 526,130 West Kingsbridge Rd, Bronx, NY 10468 USA.
[Golier, Julia A.; Makotkine, Iouri; Schmeidler, James; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, 1428 Madison Ave, New York, NY 10029 USA.
[Harvey, Philip D.] Univ Miami, Miller Sch Med, 1600 NW 10th Ave 1140, Miami, FL 33136 USA.
RP Golier, JA (reprint author), James J Peters VA Med Ctr, OOMH 526,130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM julia.golier@va.gov
FU Department of Defense (DoD)
FX This study is registered with ClinicalTrials.gov (NCT00691067) and was
solely funded by the Department of Defense (DoD). The DoD did not
influence any aspects of the study design or manuscript preparation. The
authors declare no conflicts of interests. The authors also acknowledge
the assistance of Ahmed El-Razi, B.A. in the revising of the manuscript.
NR 44
TC 2
Z9 2
U1 4
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD FEB
PY 2016
VL 64
BP 22
EP 30
DI 10.1016/j.psyneuen.2015.11.001
PG 9
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DB9WF
UT WOS:000368867700003
PM 26600007
ER
PT J
AU Kline, CE
Reboussin, DM
Foster, GD
Rice, TB
Strotmeyer, ES
Jakicic, JM
Millman, RP
Pi-Sunyer, X
Newman, AB
Wadden, TA
Zammit, G
Kuna, ST
AF Kline, Christopher E.
Reboussin, David M.
Foster, Gary D.
Rice, Thomas B.
Strotmeyer, Elsa S.
Jakicic, John M.
Millman, Richard P.
Pi-Sunyer, Xavier
Newman, Anne B.
Wadden, Thomas A.
Zammit, Gary
Kuna, Samuel T.
CA Look AHEAD Res Grp
TI The Effect of Changes in Cardiorespiratory Fitness and Weight on
Obstructive Sleep Apnea Severity in Overweight Adults with Type 2
Diabetes
SO SLEEP
LA English
DT Article
DE apnea-hypopnea index; cardiorespiratory fitness; obstructive sleep
apnea; physical activity; weight loss
ID LIFE-STYLE INTERVENTION; CARDIOVASCULAR-DISEASE RISK; RANDOMIZED
CONTROLLED-TRIAL; POSITIVE AIRWAY PRESSURE; HEART-RATE RECOVERY;
ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; OBESE-PATIENTS; FOLLOW-UP;
METABOLIC SYNDROME
AB Study Objectives: To examine the effect of changes in cardiorespiratory fitness on obstructive sleep apnea (OSA) severity prior to and following adjustment for changes in weight over the course of a 4-y weight loss intervention.
Methods: As secondary analyses of a randomized controlled trial, 263 overweight/obese adults with type 2 diabetes and OSA participated in an intensive lifestyle intervention or education control condition. Measures of OSA severity, cardiorespiratory fitness, and body weight were obtained at baseline, year 1, and year 4. Change in the apnea-hypopnea index (AHI) served as the primary outcome. The percentage change in fitness (submaximal metabolic equivalents [METs]) and change in weight (kg) were the primary independent variables. Primary analyses collapsed intervention conditions with statistical adjustment for treatment group and baseline METs, weight, and AHI among other relevant covariates.
Results: At baseline, greater METs were associated with lower AHI (B [SE] = -1.48 [0.71], P = 0.038), but this relationship no longer existed (B [SE] = -0.24 [0.73], P = 0.75) after adjustment for weight (B [SE] = 0.31 [0.07], P < 0.0001). Fitness significantly increased at year 1 (+16.53 +/- 28.71% relative to baseline), but returned to near-baseline levels by year 4 (+1.81 +/- 24.48%). In mixed-model analyses of AHI change over time without consideration of weight change, increased fitness at year 1 (B [SE] = -0.15 [0.04], P < 0.0001), but not at year 4 (B [SE] = 0.04 [0.05], P = 0.48), was associated with AHI reduction. However, with weight change in the model, greater weight loss was associated with AHI reduction at years 1 and 4 (B [SE] = 0.81 [0.16] and 0.60 [0.16], both P < 0.0001), rendering the association between fitness and AHI change at year 1 nonsignificant (B [SE] = -0.04 [0.04], P = 0.31).
Conclusions: Among overweight/obese adults with type 2 diabetes, fitness change did not influence OSA severity change when weight change was taken into account.
C1 [Kline, Christopher E.; Rice, Thomas B.; Strotmeyer, Elsa S.; Jakicic, John M.; Newman, Anne B.] Univ Pittsburgh, Pittsburgh, PA USA.
[Reboussin, David M.] Wake Forest Univ, Winston Salem, NC 27109 USA.
[Foster, Gary D.] Temple Univ, Philadelphia, PA 19122 USA.
[Foster, Gary D.] Weight Watchers Int, New York, NY USA.
[Millman, Richard P.] Brown Univ, Providence, RI 02912 USA.
[Pi-Sunyer, Xavier] Columbia Univ, New York, NY USA.
[Wadden, Thomas A.; Kuna, Samuel T.] Univ Penn, Philadelphia, PA 19104 USA.
[Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Kline, CE (reprint author), Univ Pittsburgh, Dept Hlth & Phys Act, 32 Oak Hill Court,Room 227, Pittsburgh, PA 15261 USA.
EM chriskline@pitt.edu
RI Newman, Anne B./C-6408-2013;
OI Newman, Anne B./0000-0002-0106-1150; Strotmeyer,
Elsa/0000-0002-4093-6036
FU Abbott; Abbvie; Actelion; Ancile; Apnex; Arena; Aptalis; Astra-Zeneca;
Aventis; Banyu; Biomarin; BMS; Catalyst; Celgene; Cephalon; CHDI;
Edgemont; Elan; Epix; Eisai; Elminda; Evotec; Forest; Fresca; Galderma;
Genentech; Gilead; Glaxo Smith Kline; H. Lundbeck A/S; Janssen; Jazz;
Johnson Johnson; King; Merck and Co.; National Institutes of Health
(NIH); Neurim; Neurocrine Biosciences; Naurex; Neurogen; Novo Nordisk;
Organon; Orphan Medical; Otsuka; Pfizer; Predix; Respironics; Roxane;
Saladax; Sanofi-Aventis; Sanofi-Synthelabo; Schering-Plough; Sepracor;
Sunovion; Shire; Somaxon; Takeda; Takeda Pharmaceuticals North America;
Targacept; Teva; Thymon; Transcept; UCB; USWorldmeds; Pharma;
Ultragenyx; Vanda; Wyeth-Ayerst Research; Orexigen; Nutrisystem; Weight
Watchers; Jawbone; [HL070301]; [DK60426]; [DK56992]; [DK057135];
[HL118318]
FX This was not an industry supported study. Financial support was provided
by HL070301, DK60426, DK56992, DK057135, HL118318. Dr. Zammit is a
consultant for Acorda, Actelion, Alexza, Arena, Aventis, Biovail,
Boehringer-Ingelheim, Cephalon, Elan, Eli Lilly, Evotec, Forest, Glaxo
Smith Kline, Jazz, King Pharmaceuticals, Ligand, McNeil, Merck,
Neurocrine Biosciences, Organon, Pfizer, Purdue, Renovis,
Sanofi-Aventis, Select Comfort, Sepracor, Shire, Somnus, Takeda
Pharmaceuticals, Vela, and Wyeth; has grant support from Abbott, Abbvie,
Actelion, Ancile, Apnex, Arena, Aptalis, Astra-Zeneca, Aventis, Banyu,
Biomarin, BMS, Catalyst, Celgene, Cephalon, CHDI, Edgemont, Elan, Epix,
Eisai, Elminda, Evotec, Forest, Fresca, Galderma, Genentech, Gilead,
Glaxo Smith Kline, Gilead, H. Lundbeck A/S, Janssen, Jazz, Johnson &
Johnson, King, Merck and Co., National Institutes of Health (NIH),
Neurim, Neurocrine Biosciences, Naurex, Neurim, Neurogen, Novo Nordisk,
Organon, Orphan Medical, Otsuka, Pfizer, Predix, Respironics, Roxane,
Saladax, Sanofi-Aventis, Sanofi-Synthelabo, Schering-Plough, Sepracor,
Sunovion, Shire, Somaxon, Takeda, Takeda Pharmaceuticals North America,
Targacept, Teva, Thymon, Transcept, UCB, USWorldmeds, Pharma,
Ultragenyx, Predix, Vanda, and Wyeth-Ayerst Research; and has received
honoraria from King Pharmaceuticals, McNeil, Merck, Neurocrine
Biosciences, Sanofi-Aventis, Sanofi-Synthelabo, Sepracor, Takeda
Pharmaceuticals, Vela Pharmaceuticals, and Wyeth-Ayerst Research. Dr.
Wadden serves on Scientific Advisory Boards for Orexigen, Novo Nordisk,
Nutrisystem, and Weight Watchers and has received grant support, on
behalf of the University of Pennsylvania, from Orexigen, Novo Nordisk,
Nutrisystem, and Weight Watchers. Dr. Jakicic is a member of Weight
Watchers International Scientific Advisory Board and has served as the
Principal Investigator on a research grant received from Jawbone that
was awarded to the University of Pittsburgh. Dr. Foster is the Chief
Scientific Officer for Weight Watchers International. The other authors
have indicated no financial conflicts of interest. The work was
performed at: Brown University, Providence, RI; St. Luke's-Roosevelt
Hospital/Clinilabs, New York, NY; Temple University, Philadelphia, PA;
University of Pennsylvania, Philadelphia, PA; and University of
Pittsburgh, Pittsburgh, PA.
NR 62
TC 1
Z9 1
U1 2
U2 9
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
EI 1550-9109
J9 SLEEP
JI Sleep
PD FEB 1
PY 2016
VL 39
IS 2
BP 317
EP 325
DI 10.5665/sleep.5436
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DC0WH
UT WOS:000368938100008
PM 26446118
ER
PT J
AU Ioannou, GN
AF Ioannou, George N.
TI The Role of Cholesterol in the Pathogenesis of NASH
SO TRENDS IN ENDOCRINOLOGY AND METABOLISM
LA English
DT Review
ID FATTY LIVER-DISEASE; HEPATIC STELLATE CELLS; LOW-DENSITY-LIPOPROTEIN;
ENDOPLASMIC-RETICULUM STRESS; NONALCOHOLIC STEATOHEPATITIS; LIPID
DROPLETS; INSULIN-RESISTANCE; OXIDIZED LDL; HEPATOCELLULAR-CARCINOMA;
CARDIOVASCULAR-DISEASE
AB Lipotoxicity drives the development of progressive hepatic inflammation and fibrosis in a subgroup of patients with nonalcoholic fatty liver disease (NAFLD), causing nonalcoholic steatohepatitis (NASH) and even progression to cirrhosis and hepatocellular carcinoma (HCC). While the underlying molecular mechanisms responsible for the development of inflammation and fibrosis that characterize progressive NASH remain unclear, emerging evidence now suggests that hepatic free cholesterol (FC) is a major lipotoxic molecule critical in the development of experimental and human NASH. In this review, we examine the effects of excess FC in hepatocytes, Kupffer cells (KCs), and hepatic stellate cells (HSCs), and the subcellular mechanisms by which excess FC can induce cellular toxicity or proinflammatory and profibrotic effects in these cells.
C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA.
[Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA.
[Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA.
RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA.; Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA.; Ioannou, GN (reprint author), Univ Washington, Seattle, WA 98195 USA.
EM georgei@medicine.washington.edu
NR 99
TC 8
Z9 9
U1 7
U2 11
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1043-2760
J9 TRENDS ENDOCRIN MET
JI Trends Endocrinol. Metab.
PD FEB
PY 2016
VL 27
IS 2
BP 84
EP 95
DI 10.1016/j.tem.2015.11.008
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DC1DE
UT WOS:000368956200003
PM 26703097
ER
PT J
AU Kramer, H
Rosas, SE
Matsushita, K
AF Kramer, Holly
Rosas, Sylvia E.
Matsushita, Kunihiro
TI Beef Tea, Vitality, Creatinine, and the Estimated GFR
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Editorial Material
ID GLOMERULAR-FILTRATION-RATE; CYSTATIN-C; KIDNEY-FUNCTION; SERUM; RISK;
POPULATION
C1 [Kramer, Holly] Loyola Univ Chicago, Maywood, IL 60153 USA.
[Rosas, Sylvia E.] Harvard Univ, Joslin Diabet Ctr, Boston, MA 02115 USA.
[Matsushita, Kunihiro] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Kramer, H (reprint author), Loyola Univ Chicago, Dept Publ Hlth Sci, 2160 First Ave, Maywood, IL 60153 USA.
EM hkramer@luc.edu
NR 15
TC 0
Z9 0
U1 1
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
EI 1523-6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD FEB
PY 2016
VL 67
IS 2
BP 169
EP 172
DI 10.1053/j.ajkd.2015.11.001
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA DB3NQ
UT WOS:000368418800005
PM 26802326
ER
PT J
AU Boyce, R
Mitton, J
Chu, J
Finn, K
AF Boyce, Ross
Mitton, Julian
Chu, Jacqueline
Finn, Kathleen
TI South Sudan to Martha's Vineyard: Malaria
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID HUMAN BABESIOSIS; UNITED-STATES; SURVEILLANCE
C1 [Boyce, Ross; Mitton, Julian; Finn, Kathleen] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Chu, Jacqueline] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Boyce, R (reprint author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St,GB 740, Boston, MA 02114 USA.
EM roboyce@gmail.com
OI Boyce, Ross/0000-0002-9489-6324
NR 9
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
EI 1555-7162
J9 AM J MED
JI Am. J. Med.
PD FEB
PY 2016
VL 129
IS 2
BP 163
EP 166
DI 10.1016/j.amjmed.2015.08.030
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA DB2MG
UT WOS:000368342300032
PM 26394268
ER
PT J
AU Waks, JW
Steinhaus, DA
Shvilkin, A
Kramer, DB
AF Waks, Jonathan W.
Steinhaus, Daniel A.
Shvilkin, Alexei
Kramer, Daniel B.
TI Post-pacemaker T-wave Inversions: Cardiac Memory
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID ABNORMALITIES
C1 Harvard Univ, Sch Med, Harvard Thorndike Electrophys Inst, Boston, MA USA.
Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Arrhythmia Serv,Div Cardiovasc Med,Dept Med, Boston, MA 02215 USA.
RP Kramer, DB (reprint author), Beth Israel Deaconess Med Ctr, 185 Pilgrim Rd,Baker 4, Boston, MA 02215 USA.
EM dkramer@bidmc.harvard.edu
OI Shvilkin, Alexei/0000-0003-3662-9938
FU NIA NIH HHS [K23 AG045963, K23AG045963]
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
EI 1555-7162
J9 AM J MED
JI Am. J. Med.
PD FEB
PY 2016
VL 129
IS 2
BP 170
EP 172
DI 10.1016/j.amjmed.2015.09.001
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA DB2MG
UT WOS:000368342300034
PM 26440583
ER
PT J
AU Kearney, DJ
Simpson, TL
Malte, CA
Felleman, B
Martinez, ME
Hunt, SC
AF Kearney, David J.
Simpson, Tracy L.
Malte, Carol A.
Felleman, Benjamin
Martinez, Michelle E.
Hunt, Stephen C.
TI Mindfulness-based Stress Reduction in Addition to Usual Care Is
Associated with Improvements in Pain, Fatigue, and Cognitive Failures
Among Veterans with Gulf War Illness
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Complementary and alternative medicine; Gulf War illness; Mindfulness;
Veterans
ID QUALITY-OF-LIFE; HEALTH-STATUS; THEORETICAL CONSIDERATIONS; ALTERNATIVE
MEDICINE; PHYSICAL SYMPTOMS; FOLLOW-UP; THERAPY; QUESTIONNAIRE;
DEPRESSION; DISORDER
AB BACKGROUND: Many Gulf War I veterans report ongoing negative health consequences. The constellation of pain, fatigue, and concentration/memory disturbances is referred to as "Gulf War illness." Prior research suggests that mindfulness-based stress reduction may be beneficial for these symptoms, but mindfulness-based stress reduction has not been studied for veterans with Gulf War illness. The objective of this trial was to conduct a pilot study of mindfulness-based stress reduction for veterans with Gulf War illness.
METHODS: Veterans (N = 55) with Gulf War illness were randomly assigned to treatment as usual plus mindfulness-based stress reduction or treatment as usual only. Mindfulness-based stress reduction was delivered in 8 weekly 2.5-hour sessions plus a single 7-hour weekend session. Pain, fatigue, and cognitive failures were the primary outcomes, assessed at baseline, after mindfulness-based stress reduction, and 6 months follow-up. Secondary outcomes included symptoms of posttraumatic stress disorder and depression.
RESULTS: In intention-to-treat analyses, at 6-month follow-up, veterans randomized to mindfulness-based stress reduction plus treatment as usual reported greater reductions in pain (f = 0.33; P = .049), fatigue (f = 0.32; P = .027), and cognitive failures (f = 0.40; P < .001). Depressive symptoms showed a greater decline after mindfulness-based stress reduction (f = 0.22; P = .050) and at 6 months (f = 0.27; P = .031) relative to treatment as usual only. Veterans with posttraumatic stress disorder at baseline randomized to mindfulness-based stress reduction plus treatment as usual experienced significantly greater reductions in symptoms of posttraumatic stress disorder after mindfulness-based stress reduction (f = 0.44; P = .005) but not at 6 months follow-up (f = 0.31; P = .082).
CONCLUSIONS: Mindfulness-based stress reduction in addition to treatment as usual is associated with significant improvements in self-reported symptoms of Gulf War illness, including pain, fatigue, cognitive failures, and depression. Published by Elsevier Inc.
C1 [Kearney, David J.; Hunt, Stephen C.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
[Kearney, David J.; Hunt, Stephen C.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Simpson, Tracy L.; Malte, Carol A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Substance Abuse Treatment & Educ C, Seattle, WA USA.
[Simpson, Tracy L.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Felleman, Benjamin; Martinez, Michelle E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Kearney, DJ (reprint author), Seattle VAMC 111GI,1660 S Columbian Way, Seattle, WA 98108 USA.
EM david.kearney@va.gov
FU VA Office of Research and Development [5I01CX000313-02]
FX This trial was funded by a grant from the VA Office of Research and
Development (5I01CX000313-02).
NR 70
TC 1
Z9 1
U1 6
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
EI 1555-7162
J9 AM J MED
JI Am. J. Med.
PD FEB
PY 2016
VL 129
IS 2
BP 204
EP 214
DI 10.1016/j.amjmed.2015.09.015
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA DB2MG
UT WOS:000368342300039
PM 26519614
ER
PT J
AU Matioc, AA
AF Matioc, Adrian A.
TI An Anesthesiologist's Perspective on the History of Basic Airway
Management The "Preanesthetic" Era-1700 to 1846
SO ANESTHESIOLOGY
LA English
DT Article
ID RESUSCITATION
AB Basic airway management modern history starts in the early 18th century in the context of resuscitation of the apparently dead. History saw the rise and fall of the mouth-to-mouth and then of the instrumental positive-pressure ventilation generated by bellows. Pulmonary ventilation had a secondary role to external and internal organ stimulation in resuscitation of the apparently dead. Airway access for the extraglottic technique was to the victim's nose. The bellows-to-nose technique was the basic airway management technique applicable by both medical and nonmedical personnel. Although the techniques had been described at the time, very few physicians practiced glottic (intubation) and subglottic (tracheotomy) techniques. Before the anesthetic era, positive-pressure ventilation was discredited and replaced by manual negative-pressure techniques. In the middle of the 19th century, physicians who would soon administer anesthetic gases were unfamiliar with the positive-pressure ventilation concept.
C1 [Matioc, Adrian A.] Univ Wisconsin, Dept Anesthesiol, Sch Med & Publ Hlth, Madison, WI USA.
[Matioc, Adrian A.] William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room A8030, Madison, WI 53705 USA.
RP Matioc, AA (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room A8030, Madison, WI 53705 USA.
EM aamatioc@wisc.edu
FU Paul M. Wood Fellowship at the Wood Library-Museum of Anesthesiology,
Schaumburg, Illinois
FX Support was provided by departmental sources and by a 2013 Paul M. Wood
Fellowship at the Wood Library-Museum of Anesthesiology, Schaumburg,
Illinois, awarded in the author name for this topic.
NR 61
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD FEB
PY 2016
VL 124
IS 2
BP 301
EP 311
DI 10.1097/ALN.0000000000000955
PG 11
WC Anesthesiology
SC Anesthesiology
GA DB5FP
UT WOS:000368540300008
PM 26580835
ER
PT J
AU Ladha, KS
Patorno, E
Liu, J
Bateman, BT
AF Ladha, Karim S.
Patorno, Elisabetta
Liu, Jun
Bateman, Brian T.
TI Impact of Perioperative Epidural Placement on Postdischarge Opioid Use
in Patients Undergoing Abdominal Surgery
SO ANESTHESIOLOGY
LA English
DT Article
ID TERM POSTTHORACOTOMY PAIN; PREVENTIVE ANALGESIA; POSTSURGICAL PAIN;
RISK-FACTORS; COHORT; METAANALYSIS; ANESTHESIA; MANAGEMENT; SCORE
AB Background: Opioids play a crucial role in providing analgesia throughout the perioperative period; however, patients may become persistent users of these medications months after surgery. Epidurals have been posited to prevent the development of persistent pain, but there are little data on the effect of epidurals on persistent opioid use.
Methods: This study was conducted using a claims database of a large, nationwide commercial health insurer. Opioid-naive patients who underwent open abdominal surgery from January 2004 to December 2013 were included in the study. Propensity scores for epidural placement were calculated accounting for demographic characteristics, resource utilization, and comorbid conditions (including medical, psychiatric, and pain conditions). Time-to-event analysis was used with the primary outcome defined as 30 days without filling an opioid prescription after discharge. In addition, total morphine equivalents dispensed within 90 days of discharge were also calculated for each patient.
Results: A total of 6,432 patients were included in the final propensity score-matched cohort. The Cox proportional hazards ratio was 0.96 (95% CI, 0.91 to 1.01; P = 0.0910) for the relation between epidural placement and time till a 30-day gap without filling an opioid prescription. There was no difference in the total morphine equivalents dispensed within 90 days of discharge between the groups (P = 0.7670).
Conclusions: Epidural placement was not protective against persistent opioid use in a large cohort of opioid-naive patients undergoing abdominal surgery. This finding does not detract from the other potential benefits of epidural placement. More research is needed to understand the mechanism of persistent opioid use after surgery and its prevention.
C1 [Ladha, Karim S.; Bateman, Brian T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesiol Crit Care & Pain Med, Boston, MA USA.
[Ladha, Karim S.] Toronto Gen Hosp, Dept Anesthesia, Toronto, ON, Canada.
[Ladha, Karim S.] Univ Toronto, Toronto, ON, Canada.
[Patorno, Elisabetta; Liu, Jun; Bateman, Brian T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, Boston, MA 02115 USA.
RP Ladha, KS (reprint author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.
EM karim.ladha@post.harvard.edu
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development of the National Institutes of Health (Bethesda, Maryland)
[K08HD075831]
FX Dr. Bateman is supported by the Eunice Kennedy Shriver National
Institute of Child Health and Human Development of the National
Institutes of Health (Bethesda, Maryland) under award number
K08HD075831. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National
Institutes of Health.
NR 28
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD FEB
PY 2016
VL 124
IS 2
BP 396
EP 403
DI 10.1097/ALN.0000000000000952
PG 8
WC Anesthesiology
SC Anesthesiology
GA DB5FP
UT WOS:000368540300017
PM 26575145
ER
PT J
AU Lee, SM
Takemoto, S
Wallace, AW
AF Lee, Susan M.
Takemoto, Steven
Wallace, Arthur W.
TI Early Postoperative Withholding Angiotensin Receptor Blockers and 30-day
Mortality after Noncardiac Surgery Reply
SO ANESTHESIOLOGY
LA English
DT Letter
ID SYSTEMS
C1 [Lee, Susan M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
RP Lee, SM (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
EM susan.lee5@va.gov
NR 5
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD FEB
PY 2016
VL 124
IS 2
BP 513
EP 514
DI 10.1097/ALN.0000000000000965
PG 2
WC Anesthesiology
SC Anesthesiology
GA DB5FP
UT WOS:000368540300032
PM 26785436
ER
PT J
AU Lee, CH
Verma, P
Lee, J
Klaustermeyer, WB
AF Lee, Christina H.
Verma, Prashant
Lee, Joyce
Klaustermeyer, William B.
TI Cost analysis of asthma maintenance medications in a veteran population
SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
LA English
DT Letter
C1 [Lee, Christina H.; Verma, Prashant; Lee, Joyce; Klaustermeyer, William B.] Univ Calif Los Angeles, Dept Med, Div Allergy & Immunol, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA.
RP Klaustermeyer, WB (reprint author), Univ Calif Los Angeles, Dept Med, Div Allergy & Immunol, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA.
EM william.klaustermeyer@va.gov
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1081-1206
EI 1534-4436
J9 ANN ALLERG ASTHMA IM
JI Ann. Allergy Asthma Immunol.
PD FEB
PY 2016
VL 116
IS 2
BP 165
EP 166
PG 3
WC Allergy; Immunology
SC Allergy; Immunology
GA DB5SD
UT WOS:000368573000016
PM 26702545
ER
PT J
AU Cairns, J
Ingle, J
Dudenkov, T
Kalari, K
Buzdar, A
Kubo, M
Robson, M
Ellis, M
Goss, P
Shepherd, L
Weinshilboum, R
Wang, L
AF Cairns, J.
Ingle, J.
Dudenkov, T.
Kalari, K.
Buzdar, A.
Kubo, M.
Robson, M.
Ellis, M.
Goss, P.
Shepherd, L.
Weinshilboum, R.
Wang, L.
TI AROMATASE INHIBITOR-INDUCED HORMONE LEVEL CHANGE ASSOCIATED WITH CSMD1
SNP AND ANDROSTENEDIONE-DEPENDENT VARIATION IN AROMATASE EXPRESSION.
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
CT Annual Meeting of the
American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT)
CY MAR 08-12, 2016
CL San Diego, CA
SP Amer Soc Clin Pharmacol & Therapeut
C1 [Cairns, J.; Ingle, J.; Dudenkov, T.; Kalari, K.; Weinshilboum, R.; Wang, L.] Mayo Clin, Rochester, MN USA.
[Buzdar, A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Kubo, M.] RIKEN Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan.
[Robson, M.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
[Ellis, M.] Baylor Canc Ctr, Houston, TX USA.
[Goss, P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Shepherd, L.] NCIC Clin Trials Grp, Kingston, ON, Canada.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 2016
VL 99
SU 1
MA PII-038
BP S84
EP S85
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DB7JZ
UT WOS:000368692600303
ER
PT J
AU Gomeni, R
Bressolle, F
Spencer, TJ
Faraone, SV
AF Gomeni, R.
Bressolle, F.
Spencer, T. J.
Faraone, S. V.
TI USE OF A CLINICAL RESPONSE INDEX DERIVED FROM A PK/PD MODEL TO ESTIMATE
THE OPTIMAL IN VIVO RELEASE RATE OF EXTENDED RELEASE FORMULATIONS OF
MPH.
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
CT Annual Meeting of the
American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT)
CY MAR 08-12, 2016
CL San Diego, CA
SP Amer Soc Clin Pharmacol & Therapeut
C1 [Gomeni, R.; Bressolle, F.] Pharmacometrica, La Fouillade, France.
[Spencer, T. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Faraone, S. V.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 2016
VL 99
SU 1
MA E-004
BP S22
EP S22
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DB7JZ
UT WOS:000368692600066
ER
PT J
AU Gomeni, R
Bressolle, F
Spencer, TJ
Faraone, SV
AF Gomeni, R.
Bressolle, F.
Spencer, T. J.
Faraone, S. V.
TI OPTIMAL STUDY DESIGN TO EVALUATE THE CLINICAL RESPONSE OF EXTENDED
RELEASE FORMULATIONS OF METHYLPHENIDATE (MPH)IN A PEDIATRIC POPULATION.
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
CT Annual Meeting of the
American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT)
CY MAR 08-12, 2016
CL San Diego, CA
SP Amer Soc Clin Pharmacol & Therapeut
C1 [Gomeni, R.; Bressolle, F.] Pharmacometrica, La Fouillade, France.
[Spencer, T. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Faraone, S. V.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 2016
VL 99
SU 1
MA E-005
BP S22
EP S22
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DB7JZ
UT WOS:000368692600067
ER
PT J
AU Gomeni, R
Bressolle, F
Spencer, TJ
Faraone, SV
AF Gomeni, R.
Bressolle, F.
Spencer, T. J.
Faraone, S. V.
TI META-ANALYTIC APPROACH TO EVALUATE ALTERNATIVE MODELS FOR CHARACTERIZING
THE PK PROFILES OF EXTENDED RELEASE FORMULATIONS OF MPH.
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
CT Annual Meeting of the
American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT)
CY MAR 08-12, 2016
CL San Diego, CA
SP Amer Soc Clin Pharmacol & Therapeut
C1 [Gomeni, R.; Bressolle, F.] Pharmacometrica, La Fouillade, France.
[Spencer, T. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Faraone, S. V.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 2016
VL 99
SU 1
MA E-003
BP S21
EP S21
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DB7JZ
UT WOS:000368692600065
ER
PT J
AU Morrissey, K
Vora, B
Zhu, R
Apt, D
Olivero, A
Ware, J
Mueller, L
Cloughesy, T
Gerstner, E
Rodon, J
Wen, P
Salphati, L
AF Morrissey, K.
Vora, B.
Zhu, R.
Apt, D.
Olivero, A.
Ware, J.
Mueller, L.
Cloughesy, T.
Gerstner, E.
Rodon, J.
Wen, P.
Salphati, L.
TI CLINICAL PHARMACOKINETICS AND BRAIN PENETRATION OF GDC-0084, AN ORAL
PI3K/mTOR INHIBITOR, IN PATIENTS WITH HIGH-GRADE GLIOMA.
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
CT Annual Meeting of the
American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT)
CY MAR 08-12, 2016
CL San Diego, CA
SP Amer Soc Clin Pharmacol & Therapeut
C1 [Morrissey, K.; Vora, B.; Zhu, R.; Apt, D.; Olivero, A.; Ware, J.; Mueller, L.; Salphati, L.] Genentech Inc, San Francisco, CA 94080 USA.
[Cloughesy, T.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Gerstner, E.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Rodon, J.] Vall dHebron Inst Oncol, Barcelona, Spain.
[Wen, P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 2016
VL 99
SU 1
MA PII-045
BP S86
EP S87
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DB7JZ
UT WOS:000368692600310
ER
PT J
AU Pirrone, M
Fisher, D
Chipman, D
Imber, DAE
Corona, J
Mietto, C
Kacmarek, RM
Berra, L
AF Pirrone, Massimiliano
Fisher, Daniel
Chipman, Daniel
Imber, David A. E.
Corona, Javier
Mietto, Cristina
Kacmarek, Robert M.
Berra, Lorenzo
TI Recruitment Maneuvers and Positive End-Expiratory Pressure Titration in
Morbidly Obese ICU Patients
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE lung compliance; mechanical ventilation; obesity; positive
end-expiratory pressure; pulmonary gas exchange; respiratory mechanics
ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; BODY-MASS INDEX;
MECHANICAL VENTILATION; NITROGEN WASHOUT/WASHIN; ANESTHESIA; TOMOGRAPHY;
PARALYSIS; VOLUME; PEEP
AB Objective: The approach to applying positive end-expiratory pressure in morbidly obese patients is not well defined. These patients frequently require prolonged mechanical ventilation, increasing the risk for failed liberation from ventilatory support. We hypothesized that lung recruitment maneuvers and titration of positive end-expiratory pressure were both necessary to improve lung volumes and the elastic properties of the lungs, leading to improved gas exchange.
Design: Prospective, crossover, nonrandomized interventional study.
Setting: Medical and surgical ICUs at Massachusetts General Hospital.
Patients: Critically ill, mechanically ventilated morbidly obese (body mass index > 35 kg/m(2)) patients (n = 14).
Interventions: This study evaluated two methods of titrating positive end-expiratory pressure; both trials were done utilizing positive end-expiratory pressure titration and recruitment maneuvers while measuring hemodynamics and respiratory mechanics. Measurements were obtained at the baseline positive end-expiratory pressure set by the clinicians, at zero positive end-expiratory pressure, at best positive end-expiratory pressure identified through esophageal pressure measurement before and after a recruitment maneuver, and at best positive end-expiratory pressure identified through a best decremental positive end-expiratory pressure trial.
Measurements and Main Results: The average body mass index was 50.7 16.0 kg/m(2). The two methods of evaluating positive end-expiratory pressure identified similar optimal positive end-expiratory pressure levels (20.7 +/- 4.0 vs 21.3 +/- 3.8 cm H2O; p = 0.40). End-expiratory pressure titration increased end-expiratory lung volumes (11 +/- 7 mL/kg; p < 0.01) and oxygenation (86 +/- 50 torr; p < 0.01) and decreased lung elastance (5 +/- 5 cm H2O/L; p < 0.01). Recruitment maneuvers followed by titrated positive end-expiratory pressure were effective at increasing end-expiratory lung volumes while decreasing end-inspiratory transpulmonary pressure, suggesting an improved distribution of lung aeration and reduction of overdistension. The positive end-expiratory pressure levels set by the clinicians (11.6 +/- 2.9 cm H2O) were associated with lower lung volumes, worse elastic properties of the lung, and lower oxygenation.
Conclusions: Commonly used positive end-expiratory pressure by clinicians is inadequate for optimal mechanical ventilation of morbidly obese patients. A recruitment maneuver followed by end-expiratory pressure titration was found to significantly improve lung volumes, respiratory system elastance, and oxygenation.
C1 [Pirrone, Massimiliano; Imber, David A. E.; Corona, Javier; Mietto, Cristina; Kacmarek, Robert M.; Berra, Lorenzo] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Pirrone, Massimiliano; Mietto, Cristina] Univ Milan, Dipartimento Anestesiol Terapia Intens & Sci Derm, Milan, Italy.
[Fisher, Daniel; Chipman, Daniel; Kacmarek, Robert M.] Massachusetts Gen Hosp, Resp Care Serv, Boston, MA 02114 USA.
[Corona, Javier] Univ Complutense Madrid, Fac Med, Madrid, Spain.
RP Berra, L (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
EM lberra@partners.org
FU Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts
General Hospital; Department of Anesthesia; Hollister; Covidien; Venner
Medical; National Institutes of Health [T32]; Endoclear; LLC
FX Supported, in part, by the Department of Anesthesia, Critical Care and
Pain Medicine, Massachusetts General Hospital.; Dr. Pirrone's
institution received grant support from the Department of Anesthesia to
cover study-related expenses. Mr. Fisher received educational grant from
Hollister. Dr. Kacmarek has received grants from Covidien and Venner
Medical. He consulted for Covidien on mechanical ventilators. His
institution received grant support (research grants from Venner Medical
and Covidien). Dr. Berra received support for travel from E-motion
(visit to the laboratory located in Tel Aviv, Israel). He and his
institution received grant support from the National Institutes of
Health (T32 training grant). His institution received grant support from
Endoclear, LLC (Endoclear, LLC supported research-related expenses and
provided devices for a study on endotracheal tube cleaning devices). The
remaining authors have disclosed that they do not have any potential
conflicts of interest.
NR 34
TC 6
Z9 7
U1 5
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD FEB
PY 2016
VL 44
IS 2
BP 300
EP 307
DI 10.1097/CCM.0000000000001387
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA DB4SO
UT WOS:000368503700008
PM 26584196
ER
PT J
AU Taylor, BE
McClave, SA
Martindale, RG
Warren, MM
Johnson, DR
Braunschweig, C
McCarthy, MS
Davanos, E
Rice, TW
Cresci, GA
Gervasio, JM
Sacks, GS
Roberts, PR
Compher, C
AF Taylor, Beth E.
McClave, Stephen A.
Martindale, Robert G.
Warren, Malissa M.
Johnson, Debbie R.
Braunschweig, Carol
McCarthy, Mary S.
Davanos, Evangelia
Rice, Todd W.
Cresci, Gail A.
Gervasio, Jane M.
Sacks, Gordon S.
Roberts, Pamela R.
Compher, Charlene
CA Soc Critical Care Med
Amer Soc Parenteral Enteral Nutr
TI Guidelines for the Provision and Assessment of Nutrition Support Therapy
in the Adult Critically Ill Patient: Society of Critical Care Medicine
(SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN)
SO CRITICAL CARE MEDICINE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; SEVERE ACUTE-PANCREATITIS; RESTING
ENERGY-EXPENDITURE; MECHANICALLY VENTILATED PATIENTS; GAMMA-LINOLENIC
ACID; INFLAMMATORY RESPONSE SYNDROME; INTENSIVE INSULIN THERAPY;
PLACEBO-CONTROLLED TRIAL; MILD ACUTE-PANCREATITIS; TRAUMATIC
BRAIN-INJURY
C1 [Taylor, Beth E.] Barnes Jewish Hosp, St Louis, MO 63110 USA.
[McClave, Stephen A.] Univ Louisville, Dept Med, Louisville, KY 40292 USA.
[Martindale, Robert G.] Oregon Hlth & Sci Univ, Div Gen Surg, Portland, OR 97201 USA.
[Warren, Malissa M.] Portland VA Med Ctr, Portland, OR USA.
[Johnson, Debbie R.] UW Hlth Univ, Wisconsin Hosp & Clin, Wound Skin Ost, Madison, WI USA.
[Braunschweig, Carol] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL USA.
[Braunschweig, Carol] Univ Illinois, Div Epidemiol & Biostat, Chicago, IL USA.
[McCarthy, Mary S.] Madigan Healthcare Syst, Ctr Nursing Sci & Clin Inquiry, Tacoma, WA USA.
[Davanos, Evangelia] Brooklyn Hosp Ctr, Nutr Support, Brooklyn, NY USA.
[Rice, Todd W.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Med, Nashville, TN 37212 USA.
[Cresci, Gail A.] Inst Digest Dis, Gastroenterol & Pathobiol, Cleveland, OH USA.
[Gervasio, Jane M.] Butler Univ, Coll Pharm & Hlth Sci, Pharm Practice, Indianapolis, IN 46208 USA.
[Sacks, Gordon S.] Auburn Univ, Dept Pharm Practice, Harrison Sch Pharm, Auburn, AL 36849 USA.
[Roberts, Pamela R.] Univ Oklahoma, Hlth Sci Ctr, Dept Anesthesiol, Oklahoma City, OK 73190 USA.
[Compher, Charlene] Univ Penn, Sch Nursing, Nutr Sci, Philadelphia, PA 19104 USA.
RP Taylor, BE (reprint author), Barnes Jewish Hosp, St Louis, MO 63110 USA.
EM bet1217@bjc.org
FU Metagenics; Kabi USA, LLC; A.S.P.E.N. Rhoads Research Foundation - Board
of Advisors; Fresenius Kabi USA, LLC; March of Dimes Foundation
FX Dr. Taylor disclosed serving as an A.S.P.E.N. committee member and DNS
past chair. Dr. McClave disclosed other relationships with Nestle
(consulting), Abbott (Speaker), Metagenics (consulting), Covidien
(consultant), and A.S.P.E.N. Dr. Martindale disclosed other
relationships with Davol, LifeCell, and Metagenics (consultant) and
received funding from Metagenics (research grant recipient). Dr. Warren
disclosed serving as Co-chair for the Veterans Health Administration
Dietary Supplement Committee and as a Chair for the Dietitians in
Nutrition Support webinar planning committee. Dr. Braunschweig disclosed
serving as the A.S.P.E.N. editor for clinical guidelines. Dr. McCarthy
disclosed serving as an A.S.P.E.N. Committee Member for Research
Committee and Abstract Review Committee, A.S.P.E.N. Nursing Section
Member, and SCCM Nursing Section Member. Dr. Davanos disclosed other
relationships with Baxter Healthcare (Medical Science Liaison and
employee) and NY/LISPEN chapter (President Elect). Dr. Cresci disclosed
other relatiosnhips with Metagenics, Advocare, and Covidien. She
received funding from Metagenics (research grant, speaker) and served as
a research committee member for A.S.P.E.N. and DNS (Chair - symposium
planning committee). Dr. Rice disclosed other relationships with Avisa,
LLC (Consultant) and GSK (DSMB). Dr. Roberts disclosed other
relationships as ASA Committee Member (critical care) and as an
A.S.P.E.N. Committee member (abstract reviews). Dr. Gervasio disclosed
serving as an A.S.P.E.N. committee member. Dr. Sacks disclosed other
relationships with Kabi USA, LLC (research grant recipient) and
A.S.P.E.N. (President and member of Board of Directors, A.S.P.E.N.
Rhoads Research Foundation - Board of Advisors); received funding
(Research grant recipient, related to parenteral nutrition); and
received funding from Fresenius Kabi USA, LLC (research grant
recipient). Dr. Rice served as expert witness. Dr. Compher received
funding from the March of Dimes Foundation (Research grant recipient)
and disclosed other relationships with A.S.P.E.N. (Board of directors
and President elect). Dr. Johnson disclosed that she does not have any
potential conflicts of interest.
NR 484
TC 21
Z9 27
U1 22
U2 36
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD FEB
PY 2016
VL 44
IS 2
BP 390
EP 438
DI 10.1097/CCM.0000000000001525
PG 49
WC Critical Care Medicine
SC General & Internal Medicine
GA DB4SO
UT WOS:000368503700020
PM 26771786
ER
PT J
AU Leiter, LA
Teoh, H
Mosenzon, O
Cahn, A
Hirshberg, B
Stahre, CAM
Hoekstra, JBL
Alvarsson, M
Im, K
Scirica, BM
Bhatt, DL
Raz, I
AF Leiter, L. A.
Teoh, H.
Mosenzon, O.
Cahn, A.
Hirshberg, B.
Stahre, C. A. M.
Hoekstra, J. B. L.
Alvarsson, M.
Im, K.
Scirica, B. M.
Bhatt, D. L.
Raz, I.
TI Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial
SO DIABETES OBESITY & METABOLISM
LA English
DT Article
DE antihyperglycemic agents; cancer; saxagliptin
ID RISK; METAANALYSIS; METFORMIN; PEOPLE
AB The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 trial randomized trial of 16 492 patients (placebo, n = 8212; saxagliptin, n = 8280) treated and followed for a median of 2.1 years afforded an opportunity to explore whether there was any association with cancer reported as a serious adverse event. At least one cancer event was reported by 688 patients (4.1%): 362 (4.3%) and 326 (3.8%) in the placebo and saxagliptin arms, respectively (p = 0.13). There were 59 (0.6%) deaths adjudicated as malignancy deaths with placebo and 53 (0.6%) with saxagliptin. Stratification by gender, age, race and ethnicity, diabetes duration, baseline glycated haemoglobin and pharmacotherapy did not show any clinically meaningful differences between the two study arms. The overall number of cancer events and malignancy-associated mortality rates were generally balanced between the placebo and saxagliptin groups, suggesting a null relationship with saxagliptin use over the median follow-up of 2.1 years. Multivariable modelling showed that male gender, dyslipidaemia and current smoking were independent predictors of cancer. These randomized data with adequate numbers of cancer cases are reassuring but limited, by the short follow-up in a trial not designed to test this hypothesis.
C1 [Leiter, L. A.; Teoh, H.] Univ Toronto, Div Endocrinol & Metab, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON, Canada.
[Teoh, H.] Li Ka Shing Knowledge Inst, Div Cardiac Surg, Toronto, ON, Canada.
[Teoh, H.] St Michaels Hosp, Keenan Res Ctr Biomed Sci, 30 Bond St, Toronto, ON M5B 1W8, Canada.
[Mosenzon, O.; Cahn, A.; Raz, I.] Hadassah Hebrew Univ, Med Ctr, Diabetes Unit, Div Internal Med, Jerusalem, Israel.
[Hirshberg, B.] AstraZeneca, Wilmington, DE USA.
[Stahre, C. A. M.] AstraZeneca, Molndal, Sweden.
[Hoekstra, J. B. L.] Univ Amsterdam, Internal Med, Amsterdam, Netherlands.
[Alvarsson, M.] Karolinska Inst Solna, Mol Med & Surg, Endocrinol Metab & Diabet, Stockholm, Sweden.
[Im, K.; Scirica, B. M.; Bhatt, D. L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Cardiovasc Div, Boston, MA 02115 USA.
RP Leiter, LA (reprint author), St Michaels Hosp Med Ctr, 61 Queen St East,6121Q, Toronto, ON M5C 2T2, Canada.
EM leiterl@smh.ca
FU AstraZeneca; Bristol-Myers Squibb
FX The Executive Committee comprises Eugene Braunwald (Study Chair), Deepak
L. Bhatt (Co-Principal Investigator), Itamar Raz (Co-Principal
Investigator), Jaime A. Davidson, Robert Frederich (non-voting), Boaz
Hirshberg (non-voting), Ph. Gabriel Steg. The SAVOR-TIMI 53 RCT was
sponsored by AstraZeneca and Bristol-Myers Squibb and designed by the
TIMI Study Group and Hadassah Medical Organization in conjunction with
the sponsors, who provided monitoring support and provided the
saxagliptin used. The authors gratefully acknowledge the efforts of the
SAVOR-TIMI 53 patients, investigators, research coordinators and
committee members. A complete list of the participating investigators
and the Consolidated Standards of Reporting Trials (CONSORT) statement
have been published [5].
NR 16
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8902
EI 1463-1326
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
PD FEB
PY 2016
VL 18
IS 2
BP 186
EP 190
DI 10.1111/dom.12582
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DB6LK
UT WOS:000368626300009
PM 26443993
ER
PT J
AU Laffel, L
AF Laffel, Lori
TI Improved Accuracy of Continuous Glucose Monitoring Systems in Pediatric
Patients with Diabetes Mellitus: Results from Two Studies
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
ID EXCHANGE CLINIC REGISTRY; AUGMENTED PUMP THERAPY; CHILDREN AGED 4;
GLYCEMIC CONTROL; BLOOD-GLUCOSE; FOLLOW-UP; STAR 3; TYPE-1; TRIAL; YOUTH
AB Objective: This study was designed to evaluate accuracy, performance, and safety of the Dexcom (San Diego, CA) G4((R)) Platinum continuous glucose monitoring (CGM) system (G4P) compared with the Dexcom G4 Platinum with Software 505 algorithm (SW505) when used as adjunctive management to blood glucose (BG) monitoring over a 7-day period in youth, 2-17 years of age, with diabetes. Research Design and Methods: Youth wore either one or two sensors placed on the abdomen or upper buttocks for 7 days, calibrating the device twice daily with a uniform BG meter. Participants had one in-clinic session on Day 1, 4, or 7, during which fingerstick BG measurements (self-monitoring of blood glucose [SMBG]) were obtained every 305min for comparison with CGM, and in youth 6-17 years of age, reference YSI glucose measurements were obtained from arterialized venous blood collected every 155min for comparison with CGM. The sensor was removed by the participant/family after 7 days. Results: In comparison of 2,922 temporally paired points of CGM with the reference YSI measurement for G4P and 2,262 paired points for SW505, the mean absolute relative difference (MARD) was 17% for G4P versus 10% for SW505 (P<0.0001). In comparison of 16,318 temporally paired points of CGM with SMBG for G4P and 4,264 paired points for SW505, MARD was 15% for G4P versus 13% for SW505 (P<0.0001). Similarly, error grid analyses indicated superior performance with SW505 compared with G4P in comparison of CGM with YSI and CGM with SMBG results, with greater percentages of SW505 results falling within error grid Zone A or the combined Zones A plus B. There were no serious adverse events or device-related serious adverse events for either the G4P or the SW505, and there was no sensor breakoff. Conclusions: The updated algorithm offers substantial improvements in accuracy and performance in pediatric patients with diabetes. Use of CGM with improved performance has potential to increase glucose time in range and improve glycemic outcomes for youth.
C1 [Laffel, Lori] Harvard Univ, Sch Med, Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Boston, MA 02115 USA.
[Laffel, Lori] Harvard Univ, Sch Med, Joslin Diabet Ctr, Genet & Epidemiol Sect, Boston, MA 02115 USA.
RP Laffel, L (reprint author), Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Genet & Epidemiol Sect, One Joslin Pl, Boston, MA 02215 USA.
EM Lori.Laffel@Joslin.Harvard.Edu
FU Dexcom
FX I would like to thank the participating sites, study staff, and the
patients, acknowledging the site physicians and the bio-statistician
from Dexcom: Andrew Ahmann, MD, Portland, OR; Timothy Bailey, MD,
Clinical Research, Advanced Metabolic Care and Research Institute,
Escondido, CA; Bruce Buckingham, MD, Stanford University School of
Medicine, Palo Alto, CA; Peter Chase, MD, Pediatrics, Barbara Davis
Center for Diabetes, Denver, CO; Mark Daniels, MD, Children's Hospital
of Orange County, Orange, CA; David Liljenquist, MD, Diabetes and
Osteoporosis Center, Rocky Mountain, Idaho Falls, ID; Eva Tsalikian, MD,
UIHC Department of Pediatrics, University of Iowa, Iowa City, IA; and
Katherine Nakamura, PhD, Dexcom, San Diego, CA. The clinical studies
were funded by Dexcom.
NR 39
TC 3
Z9 3
U1 3
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
EI 1557-8593
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD FEB 1
PY 2016
VL 18
SU 2
BP 23
EP 33
DI 10.1089/dia.2015.0380
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DB6DF
UT WOS:000368602900002
PM 26784126
ER
PT J
AU Bailey, WM
Mazur, A
McCotter, C
Woodard, PK
Rosenthal, L
Johnson, W
Mela, T
AF Bailey, William M.
Mazur, Alexander
McCotter, Craig
Woodard, Pamela K.
Rosenthal, Lawrence
Johnson, Whitney
Mela, Theofanie
CA ProMRI Study Investigators
TI Clinical safety of the ProMRI pacemaker system in patients subjected to
thoracic spine and cardiac 1.5-T magnetic resonance imaging scanning
conditions
SO HEART RHYTHM
LA English
DT Article
DE Bradycardia pacing; Clinical trial; ENTOVIS; Magnetic resonance imaging;
Pacemaker; Safety; ProMRI
ID IMPLANTABLE-CARDIOVERTER-DEFIBRILLATORS; DEVICES; PERFORMANCE; IMPACT;
HEART; TESLA; LEAD
AB BACKGROD Permanent cardiac pacemakers have historically been considered a contraindication to magnetic resonance imaging (MRI).
OBJECTIVE The purpose of the ProMRI Phase B Study, a multicenter, prospective, single-arm, nonrandomized study, was to evaluate the clinical safety of the Biotronik ProMRI pacemaker system in patients undergoing thoracic spine and cardiac MRI.
METHODS The ProMRI Phase B study enrolled 245 patients with stable baseline pacing indices implanted with an Entovis pacemaker (DR-T or SR-T) and Setrox 53-cm and/or 60-cm lead(s). Device interrogation was performed at enrollment, pre- and post-MRI scan, and 1 and 3 months post-MRI. End-points were (1) freedom from MRI- and pacing system-related serious adverse device effects through 1 month post-MRI; (2) freedom from atrial and ventricular MRI-induced pacing threshold increase (>0.5 V); and (3) freedom from P-and R-wave amplitude attenuation (<50%), or P wave <1.5 mV, or R wave <5.0 mV at 1 month post-MRI.
RESULTS In total, 216 patients completed the MRI and 1-month post-MRI follow-up. One adverse event possibly related to the implanted system and the MRI procedure occurred, resulting in a serious adverse device effect-free rate of 99.6% (220/221; P < .0001. Freedom from atrial and ventricular pacing threshold increase was 1000/0 (194/194, P < .001) and 1000/0 (206/206, P < .001) respectively. Freedom from P-and R-wave amplitude attenuation was 98.2% (167/170, P < .001) and 1000/0 (188/188, P < .001) respectively.
CONCLUSION The results of the ProMRI Phase B study demonstrate the clinical safety and efficacy of the ProMRI pacemaker system in patients subjected to thoracic spine and cardiac MRI conditions.
C1 [Bailey, William M.] Louisiana Heart Rhythm Specialists, Lafayette, LA 70503 USA.
[Bailey, William M.] Lafayette Gen Med Ctr, Lafayette, LA USA.
[Mazur, Alexander] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.
[McCotter, Craig] Upstate Cardiol, Greenville, SC USA.
[Woodard, Pamela K.] Washington Univ, Sch Med, St Louis, MO USA.
[Rosenthal, Lawrence] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Johnson, Whitney] Biotronik Inc, Lake Oswego, OR USA.
[Mela, Theofanie] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Bailey, WM (reprint author), Louisiana Heart Rhythm Specialists, 913 South Coll Rd,Suite 103, Lafayette, LA 70503 USA.
EM wbailey@heartrhythmmd.com
OI McCotter, Craig/0000-0002-4366-2181
FU Biotronik; Biotronik Inc (Berlin); Biotronik Inc (Germany); Biotronik
Inc (Lake Oswego OR)
FX Dr. Bailey is a trial investigator; has received research support and
speaking honoraria from Biotronik; and has served as a consultant for
Biotronik. Dr. Mazur is a trial investigator and has received research
support from Biotronik. Dr. McCotter is a trial investigator and has
received research support from Biotronik. Dr. Woodard participated as a
consultant to Biotronik for this trial. Ms. Johnson is an employee of
Biotronik. Dr. Rosenthal is a trial investigator and has received
research support from Biotronik. Dr. Mela is a trial investigator and
has received research support from Biotronik. Biotronik Inc (Berlin,
Germany; and Lake Oswego OR) provided funding for the trial and is the
manufacturer of the pacemaker systems used in the trial.
ClinicalTrials.gov Identifier: NCT02009696.
NR 25
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
EI 1556-3871
J9 HEART RHYTHM
JI Heart Rhythm
PD FEB
PY 2016
VL 13
IS 2
BP 464
EP 471
DI 10.1016/j.hrthm.2015.09.021
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DB2PM
UT WOS:000368351500022
PM 26409098
ER
PT J
AU Wilkoff, BL
Fauchier, L
Stiles, MK
Morillo, CA
Al-Khatib, SM
Almendral, J
Aguinaga, L
Berger, RD
Cuesta, A
Daubert, JP
Dubner, S
Ellenbogen, KA
Estes, NAM
Fenelon, G
Garcia, FC
Gasparini, M
Haines, DE
Healey, JS
Hurtwitz, JL
Keegan, R
Kolb, C
Kuck, KH
Marinskis, G
Martinelli, M
McGuire, M
Molina, LG
Okumura, K
Proclemer, A
Russo, AM
Singh, JP
Swerdlow, CD
Teo, WS
Uribe, W
Viskin, S
Wang, CC
Zhang, S
AF Wilkoff, Bruce L.
Fauchier, Laurent
Stiles, Martin K.
Morillo, Carlos A.
Al-Khatib, Sana M.
Almendral, Jesus
Aguinaga, Luis
Berger, Ronald D.
Cuesta, Alejandro
Daubert, James P.
Dubner, Sergio
Ellenbogen, Kenneth A.
Estes, N. A. Mark, III
Fenelon, Guilherme
Garcia, Fermin C.
Gasparini, Maurizio
Haines, David E.
Healey, Jeff S.
Hurtwitz, Jodie L.
Keegan, Roberto
Kolb, Christof
Kuck, Karl-Heinz
Marinskis, Germanas
Martinelli, Martino
McGuire, Mark
Molina, Luis G.
Okumura, Ken
Proclemer, Alessandro
Russo, Andrea M.
Singh, Jagmeet P.
Swerdlow, Charles D.
Teo, Wee Siong
Uribe, William
Viskin, Sami
Wang, Chun-Chieh
Zhang, Shu
TI 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal
implantable cardioverter-defibrillator programming and testing
SO HEART RHYTHM
LA English
DT Article
DE Implantable cardioverter-defibrillator; Bradycardia mode and rate;
Tachycardia detection; Tachycardia therapy; Defibrillation testing;
Programming
ID CARDIAC-RESYNCHRONIZATION THERAPY; QUALITY-OF-LIFE; FAST
VENTRICULAR-TACHYCARDIA; SICK-SINUS SYNDROME; CLINICAL-PRACTICE
GUIDELINES; DUAL-CHAMBER DEFIBRILLATORS; REDUCE INAPPROPRIATE SHOCKS;
PRIMARY PREVENTION PATIENTS; RATE-RESPONSIVE PACEMAKERS; LONG-DETECTION
INTERVAL
C1 [Wilkoff, Bruce L.] Cleveland Clin, Cleveland, OH 44106 USA.
[Fauchier, Laurent] CHU Trousseau, Tours, France.
[Stiles, Martin K.] Waikato Hosp, Hamilton, New Zealand.
[Morillo, Carlos A.] McMaster Univ, Dept Med, Div Cardiol, Populat Hlth Res Inst, Hamilton, ON, Canada.
[Al-Khatib, Sana M.; Daubert, James P.] Duke Univ, Med Ctr, Durham, NC USA.
[Almendral, Jesus] Univ CEU San Pablo, Grp HM Hosp, Madrid, Spain.
[Aguinaga, Luis] Ctr Privado Cardiol, San Miguel De Tucuman, Argentina.
[Berger, Ronald D.] Johns Hopkins Univ, Baltimore, MD USA.
[Cuesta, Alejandro] Inst Cardiol Infantil, Serv Arritmias, Montevideo, Uruguay.
[Dubner, Sergio] Clin & Maternidad Suizo Argentina & De Los Arcos, Buenos Aires, DF, Argentina.
[Ellenbogen, Kenneth A.] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA.
[Estes, N. A. Mark, III] Tufts Univ New England Med Ctr, Boston, MA 02111 USA.
[Fenelon, Guilherme] Univ Fed Sao Paulo, Sao Paulo, Brazil.
[Garcia, Fermin C.] Hosp Univ Penn, Philadelphia, PA 19104 USA.
[Gasparini, Maurizio] Humanitas Res Hosp, Milan, Italy.
[Haines, David E.] William Beaumont Hosp, Div Cardiol, Royal Oak, MI 48072 USA.
[Hurtwitz, Jodie L.] North Texas Heart Ctr, Dallas, TX USA.
[Keegan, Roberto] Hosp Privado Sur, Bahia Blanca, Buenos Aires, Argentina.
[Kolb, Christof] Deutsch Herzzentrum Munich, Munich, Germany.
[Kuck, Karl-Heinz] Allgemeines Krankenhaus St Georg, Hamburg, Germany.
[Marinskis, Germanas] Vilnius State Univ, Clin Cardiac & Vasc Dis, Vilnius, Lithuania.
[Martinelli, Martino] Univ Sao Paulo, Inst Coracao, Sao Paulo, Brazil.
[McGuire, Mark] Royal Prince Alfred Hosp, Sydney, NSW, Australia.
[Molina, Luis G.] Mexicos Natl Univ, Mexicos Gen Hosp, Mexico City, DF, Mexico.
[Okumura, Ken] Hirosaki Univ, Grad Sch Med, Hirosaki, Aomori, Japan.
[Proclemer, Alessandro] Azienda Osped Univ S Maria della Misericordia Udi, Udine, Italy.
[Russo, Andrea M.] Cooper Univ Hosp, Camden, NJ USA.
[Singh, Jagmeet P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Swerdlow, Charles D.] Cedars Sinai Med Ctr, Beverly Hills, CA USA.
[Teo, Wee Siong] Natl Heart Ctr Singapore, Singapore, Singapore.
[Uribe, William] CES Cardiol, Medellin, Colombia.
[Uribe, William] Ctr Especializados San Vicente Fdn, Medellin, Colombia.
[Uribe, William] CES Cardiol, Rionegro, Colombia.
[Uribe, William] Ctr Especializados San Vicente Fdn, Rionegro, Colombia.
[Viskin, Sami] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel.
[Viskin, Sami] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel.
[Wang, Chun-Chieh] Chang Gung Mem Hosp, Taipei 10591, Taiwan.
[Zhang, Shu] Natl Ctr Cardiovasc Dis, Beijing, Peoples R China.
[Zhang, Shu] Peking Union Med Coll, Beijing Fu Wai Hosp, Beijing 100021, Peoples R China.
[Zhang, Shu] China Acad Med Sci, Beijing, Peoples R China.
RP Wilkoff, BL (reprint author), Cleveland Clin, Cleveland, OH 44106 USA.
NR 220
TC 18
Z9 18
U1 4
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
EI 1556-3871
J9 HEART RHYTHM
JI Heart Rhythm
PD FEB
PY 2016
VL 13
IS 2
BP E50
EP E86
DI 10.1016/j.hrthm.2015.11.018
PG 37
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DB2PM
UT WOS:000368351500002
PM 26607062
ER
PT J
AU Post, RM
Altshuler, LL
Kupka, R
McElroy, SL
Frye, MA
Rowe, M
Grunze, H
Suppes, T
Keck, PE
Leverich, GS
Nolen, WA
AF Post, Robert M.
Altshuler, Lori L.
Kupka, Ralph
McElroy, Susan L.
Frye, Mark A.
Rowe, Michael
Grunze, Heinz
Suppes, Trisha
Keck, Paul E.
Leverich, Gabriele S.
Nolen, Willem A.
TI More illness in offspring of bipolar patients from the US compared to
Europe
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Review
DE Depression; Substance abuse; Anxiety disorder; Family history; Suicide
attempt
ID UNITED-STATES; EARLY-ONSET; N-ACETYLCYSTEINE; EARLY AGE; DISORDER; RISK;
TRIAL; ADOLESCENTS; GENERATIONS; STRATEGIES
AB Background: Evidence suggests that patients with bipolar disorder from the United States have an earlier age of onset and a more difficult course of illness than those from Germany and the Netherlands. These characteristics were related to a greater family burden of psychiatric illness and the experience of more psychosocial adversity in childhood. We hypothesized that this greater illness burden would extend to the offspring of the US patients.
Methods: 968 outpatients (average age 41) with bipolar illness gave informed consent for participation in a treatment outcome network and filled out a detailed questionnaire about their illness and family history of illness, including whether their offspring had a diagnosis of depression, bipolar disorder, alcohol or substance abuse, suicide attempt or "other" illness. Of those with children, 356 were from the US and 132 were from Europe.
Results: Compared to the Europeans, offspring of patients from the US had significantly (p < 0.001) more depression, bipolar disorder, drug abuse, and "other" illnesses. The number of illnesses in the offspring was related to the bipolar parent being from the US, having had childhood adversity, more than 20 prior episodes, and more parental psychiatric illness.
Conclusions: While the findings are limited by their basis on self report, the distribution of the percentages in the US offspring are similar to those of Axelson et al. (2015) who used direct interviews. The higher burden of illness in the offspring and their in direct progenitors from the US compared to Europe warrant new attempts at better treatment and prevention. (c) 2016 The Authors. Published by Elsevier B.V.
C1 [Post, Robert M.; Rowe, Michael; Leverich, Gabriele S.] Bipolar Collaborat Network, Bethesda, MD 20814 USA.
[Post, Robert M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA.
[Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, West Los Angeles Healthcare Ctr, Dept Psychiat, Los Angeles, CA USA.
[Kupka, Ralph; Keck, Paul E.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA.
[McElroy, Susan L.; Keck, Paul E.] Lindner Ctr HOPE, Mason, OH USA.
[McElroy, Susan L.] Univ Cincinnati, Coll Med, Biol Psychiat Program, Cincinnati, OH USA.
[Frye, Mark A.] Mayo Clin, Dept Psychiat, Rochester, MI USA.
[Grunze, Heinz] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
[Suppes, Trisha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA.
[Suppes, Trisha] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Nolen, Willem A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.
[Altshuler, Lori L.] UCLA Mood Disorders Res Program, Mood Disorders Res, Los Angeles, CA USA.
RP Post, RM (reprint author), Bipolar Collaborat Network, Bethesda, MD 20814 USA.
EM Robert.post@speakeasy.net
OI Grunze, Heinz/0000-0003-4712-8979
NR 44
TC 6
Z9 6
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
EI 1573-2517
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD FEB
PY 2016
VL 191
BP 180
EP 186
DI 10.1016/j.jad.2015.11.038
PG 7
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DB1FL
UT WOS:000368253400025
PM 26655863
ER
PT J
AU Kim, K
Hong, JP
Cho, MJ
Fava, M
Mischoulon, D
Lee, DW
Heo, JY
Jeon, HJ
AF Kim, Kiwon
Hong, Jin Pyo
Cho, Maeng Je
Fava, Maurizio
Mischoulon, David
Lee, Dong-Woo
Heo, Jung-Yoon
Jeon, Hong Jin
TI Loss of sexual interest and premenstrual mood change in women with
postpartum versus non-postpartum depression: A nationwide community
sample of Korean adults
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Loss of sexual interest; Loss of confidence; Loss of pleasure;
Premenstrual mood change; Postpartum depression
ID ASTERISK-D-CHILD; PERINATAL DEPRESSION; POSTNATAL DEPRESSION;
MENSTRUAL-CYCLE; SELF-HARM; SUICIDAL IDEATION; MENTAL-DISORDERS;
PREGNANCY; PREVALENCE; PERIOD
AB Background: Postpartum depression (PPD) is a type of clinical depression that can affect women after childbirth. Few previous studies have explored the association of depressive and physical symptoms among women with PPD in a nationwide community study.
Method: A total of 18,807 adults, randomly selected, completed a face-to-face interview using the Korean version of Composite International Diagnostic Interview (K-CIDI) (response rate 80.2%). PPD was defined as a major depressive episode that began within 4 weeks after delivery.
Results: Of 679 female subjects with major depressive disorder (MDD), 14.0% (n=95) experienced PPD. Subjects with PPD were significantly more likely to have higher income, education, and reside in an urban area, compared to those with non-PPD. No significant differences were found in number of children. Multiple logistic regression revealed that the loss of sexual interest was the only symptom among 23 depressive symptoms that was significantly associated with depressive episodes among individuals with PPD (AOR= 1.91, 95% Cl 1.01-3.60) when compared with non-PPD. Loss of sexual interest was also significantly associated with the subjects with lifetime PPD regardless of depressive episode (AOR= 1.93, 95% Cl 1.12-3.31). Conversely, loss of confidence and loss of pleasure were less frequent in subjects with PPD. Premenstrual mood change (x(2)=5.57, p=0.0036) and comorbid alcohol use disorder (X-2 =5.11, p=0.031) showed a valid association with PPD.
Conclusions: Loss of sexual interest and premenstrual mood change were associated with women with PPD, whereas those with non-PPD were not, thereby suggesting the possible link between sexual hormones and PPD. (c) 2015 Elsevier BY. All rights reserved.
C1 [Kim, Kiwon; Hong, Jin Pyo; Heo, Jung-Yoon; Jeon, Hong Jin] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Psychiat,Depress Ctr, Seoul 135710, South Korea.
[Cho, Maeng Je] Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul, South Korea.
[Fava, Maurizio; Mischoulon, David; Jeon, Hong Jin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA USA.
[Lee, Dong-Woo] Inje Univ, Coll Med, Sanggye Paik Hosp, Dept Psychiat, Seoul, South Korea.
[Jeon, Hong Jin] Sungkyunkwan Univ, SAIHST, Dept Hlth Sci & Technol, Seoul 135710, South Korea.
[Jeon, Hong Jin] Sungkyunkwan Univ, SAIHST, Dept Med Device Management & Res, Seoul 135710, South Korea.
[Jeon, Hong Jin] Sungkyunkwan Univ, SAIHST, Dept Clin Res Design & Evaluat, Seoul 135710, South Korea.
RP Jeon, HJ (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Psychiat,Depress Ctr, 81 Irwon Ro, Seoul 135710, South Korea.
EM jeonhj@skku.edu
FU Korean Ministry of Health Welfare; Basic Science Research Program
through National Research Foundation of Korea (NRF) - Ministry of
Education, Science and Technology [2011-0013064]; Samsung Medical Center
Clinical Research Development Program (CRDP) [SMO1131461]
FX The authors wish to express their gratitude to 12 local investigators
and 160 interviewers. This study was supported by the Korean Ministry of
Health & Welfare. This research was also supported by the Basic Science
Research Program through the National Research Foundation of Korea (NRF)
funded by the Ministry of Education, Science and Technology (No.
2011-0013064) (PI: Hong Jin Jeon, MD, Ph.D.). This study was also
supported by the Samsung Medical Center Clinical Research Development
Program (CRDP) Grant SMO1131461 (PI: Hong Jin Jeon, MD, Ph.D.). The
authors thank the Samsung Statistical Support Team, Chief Dr. Seon-Woo
Kim and Dr. Keumhee Cho for statistical support. These funding sources
were not involved in the creation of the study protocol, data analysis,
or in writing the manuscript.
NR 77
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
EI 1573-2517
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD FEB
PY 2016
VL 191
BP 222
EP 229
DI 10.1016/j.jad.2015.11.050
PG 8
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DB1FL
UT WOS:000368253400029
PM 26682491
ER
PT J
AU Vanmarcke, S
Van der Hallen, R
Evers, K
Noens, I
Steyaert, J
Wagemans, J
AF Vanmarcke, Steven
Van der Hallen, Ruth
Evers, Kris
Noens, Ilse
Steyaert, Jean
Wagemans, Johan
TI Ultra-Rapid Categorization of Meaningful Real-Life Scenes in Adults With
and Without ASD
SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS
LA English
DT Article
DE Autism spectrum disorder; Vision research; Ultra-rapid categorization;
Theory of mind; Reverse hierarchy theory
ID AUTISM SPECTRUM DISORDERS; HIGH-FUNCTIONING AUTISM; VISUAL
CATEGORIZATION; SOCIAL-PERCEPTION; IMPLICIT THEORY; WEAK COHERENCE;
MIND; OBJECTS; CHILDREN; TASK
AB In comparison to typically developing (TD) individuals, people with autism spectrum disorder (ASD) appear to be worse in the fast extraction of the global meaning of a situation or picture. Ultra-rapid categorization [paradigm developed by Thorpe et al. (Nature 381:520-522, 1996)] involves such global information processing. We therefore tested a group of adults with and without ASD, without intellectual disability, on a set of ultra-rapid categorization tasks. Individuals with ASD performed equally well as TD individuals except when the task required the categorization of social interactions. These results argue against a general deficit in ultra-rapid gist perception in people with ASD, while suggesting a more specific problem with the fast processing of information about social relations.
C1 [Vanmarcke, Steven; Van der Hallen, Ruth; Evers, Kris; Wagemans, Johan] Univ Leuven KU Leuven, Dept Brain & Cognit, Expt Psychol Lab, B-3000 Louvain, Belgium.
[Van der Hallen, Ruth; Evers, Kris; Steyaert, Jean] UPC KU Leuven, Dept Child Psychiat, Louvain, Belgium.
[Vanmarcke, Steven; Van der Hallen, Ruth; Evers, Kris; Noens, Ilse; Steyaert, Jean; Wagemans, Johan] Katholieke Univ Leuven, Leuven Autism Res LAuRes, Louvain, Belgium.
[Noens, Ilse] Katholieke Univ Leuven, Parenting & Special Educ Res Unit, Louvain, Belgium.
[Noens, Ilse] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
RP Vanmarcke, S (reprint author), Univ Leuven KU Leuven, Dept Brain & Cognit, Expt Psychol Lab, B-3000 Louvain, Belgium.; Vanmarcke, S (reprint author), Katholieke Univ Leuven, Leuven Autism Res LAuRes, Louvain, Belgium.
EM steven.vanmarcke@ppw.kuleuven.be
FU Flemish Government [METH/08/02]; Research Foundation-Flanders (FWO)
FX This work was supported by the Research Foundation-Flanders (FWO) to
Steven Vanmarcke and long-term structural funding by the Flemish
Government (METH/08/02) to Johan Wagemans. The authors would like to
thank Nadege Mace, Michelle Fabre-Thorpe and Simon Thorpe for providing
us with their stimulus material used in previous papers (e.g., Mace et
al. 2009). A substantial subset of these images was used in the
animal/vehicle task. We also thank Maarten Demeyer and Bart Machilsen
for their help with programming in PsychoPy, Thomas Schouteden for his
assistance with data collection and all participants for their time and
contribution to this research.
NR 95
TC 3
Z9 3
U1 6
U2 13
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0162-3257
EI 1573-3432
J9 J AUTISM DEV DISORD
JI J. Autism Dev. Disord.
PD FEB
PY 2016
VL 46
IS 2
SI SI
BP 450
EP 466
DI 10.1007/s10803-015-2583-6
PG 17
WC Psychology, Developmental
SC Psychology
GA DB7HP
UT WOS:000368685700009
PM 26349920
ER
PT J
AU Halbert, CH
Melvin, C
Briggs, V
Delmoor, E
Rice, LJ
Lynch, C
Jefferson, M
Johnson, JC
AF Halbert, Chanita Hughes
Melvin, Cathy
Briggs, Vanessa
Delmoor, Ernestine
Rice, LaShanta J.
Lynch, Cheryl
Jefferson, Melanie
Johnson, Jerry C.
TI Neighborhood Satisfaction and Colorectal Cancer Screening in a Community
Sample of African Americans
SO JOURNAL OF COMMUNITY HEALTH
LA English
DT Article
DE Neighborhood satisfaction; Social determinants; Colorectal cancer
screening; African Americans
ID HEALTH; COLONOSCOPY; VALIDATION; VEGETABLES; KNOWLEDGE; COLLEGE; ACCESS;
FRUITS; WOMEN
AB Social determinants are important to cancer screening among African Americans. To evaluate the association between social determinants (e.g., psychological characteristics, perceived social environment, cultural beliefs such as present temporal orientation) and colorectal cancer (CRC) screening among African Americans. African American adults (n = 262) ages 50-75 completed a telephone interview. Multivariate logistic regression analysis was used to identify factors having significant independent associations with CRC screening. Only 57 % of respondents reported having CRC screening. The likelihood of screening increased with greater neighborhood satisfaction (OR = 1.38, 95 % CI = 1.01, 1.90, p = 0.04), older age (OR = 1.75, 95 % CI = 1.24, 2.48, p = 0.002), greater self-efficacy (OR = 2.73, 95 % CI = 1.40, 5.35, p = 0.003), and health care provider communication (OR = 10.78, 95 % CI = 4.85, 29.94, p = 0.0001). Community resources are important precursors to CRC screening and outcomes among African Americans. In addition to addressing psychological factors and patient-provider communication, efforts to ensure the availability of quality health care facilities that provide CRC screening in the neighborhoods where African Americans live are needed.
C1 [Halbert, Chanita Hughes; Rice, LaShanta J.; Jefferson, Melanie] Med Univ S Carolina, Dept Psychiat & Behav Sci, Ctr Populat Hlth & Outcomes, 68 President St,Suite BE103, Charleston, SC 29425 USA.
[Halbert, Chanita Hughes] Ralph H Johnson Vet Adm Med Ctr, 68 President St,Suite BE103, Charleston, SC 29425 USA.
[Melvin, Cathy] Med Univ S Carolina, Hollings Canc Ctr, 68 President St,Suite BE103, Charleston, SC 29425 USA.
[Melvin, Cathy] Med Univ S Carolina, Dept Publ Hlth Sci, 68 President St,Suite BE103, Charleston, SC 29425 USA.
[Briggs, Vanessa] Public Hlth Management Corp, Hlth Promot Serv, 260 South Broad St, Philadelphia, PA 19102 USA.
[Delmoor, Ernestine] Natl Black Leadership Initiat Canc, Philadelphia Chapter, 1415 N Broad St,Suite 221B, Philadelphia, PA 19122 USA.
[Lynch, Cheryl] Med Univ S Carolina, Div Gen Internal Med, Dept Med, 135 Rutledge Ave, Charleston, SC 29425 USA.
[Lynch, Cheryl] Ralph H Johnson Vet Adm Med Ctr, 135 Rutledge Ave, Charleston, SC 29425 USA.
[Johnson, Jerry C.] Univ Penn, Dept Med, Div Geriatr, 3615 Chestnut St, Philadelphia, PA 19104 USA.
RP Halbert, CH (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Ctr Populat Hlth & Outcomes, 68 President St,Suite BE103, Charleston, SC 29425 USA.; Halbert, CH (reprint author), Ralph H Johnson Vet Adm Med Ctr, 68 President St,Suite BE103, Charleston, SC 29425 USA.
EM hughesha@musc.edu
FU National Cancer Institute [R01CA100254]; National Institute on Minority
Health and Health Disparities Grant [R24MD001594]
FX This research was supported by National Cancer Institute Grant No.
R01CA100254 and National Institute on Minority Health and Health
Disparities Grant No. R24MD001594. We would like to Benita Weathers, MPH
for project management, Aliya Collier, BA for data management, Stacey
Brown, MSW for data collection and administration, and Brenda Bryant, BA
for community outreach and relations. We are very appreciative to all of
the women and men who participated in this research.
NR 35
TC 1
Z9 1
U1 2
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0094-5145
EI 1573-3610
J9 J COMMUN HEALTH
JI J. Community Health
PD FEB
PY 2016
VL 41
IS 1
BP 38
EP 45
DI 10.1007/s10900-015-0062-9
PG 8
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA DB6PY
UT WOS:000368638400006
PM 26184107
ER
PT J
AU Jha, A
Lin, L
Savoia, E
AF Jha, Ayan
Lin, Leesa
Savoia, Elena
TI The Use of Social Media by State Health Departments in the US: Analyzing
Health Communication Through Facebook
SO JOURNAL OF COMMUNITY HEALTH
LA English
DT Article
DE Social media; Health communication; State Health Department; Facebook;
CDC
ID INFORMATION; ADOPTION
AB The use of social media as a powerful health communication tool is an area of current research interest. Our objective was to describe use of Facebook by State Health Departments (SHDs) in US, and their relationship with CDC's Behavioral Risk Factor Surveillance System (BRFSS) data. Facebook pages of 34 SHDs were studied over a 200 day period, coding 2597 posts into 19 broad health communication categories. Mean number of Facebook posts per SHD was 76.4 (range 34-133); most frequent topic areas included healthy living (12 %), communicable diseases (9 %), vaccines and immunization (7 %), emergency preparedness and response (7 %), infant and child health (5 %), smoking and tobacco use (5 %), and miscellaneous (32 %). Through web-based interactive graphics (Google motion charts), we contrasted Facebook posts with CDC's BRFSS data on adult nutrition and physical activity, vaccination, smoking, adolescent health and road traffic accidents. Our research finds an apparent disconnect between content provided on Facebook by SHDs and the health conditions that affect their populations. Acknowledging the severe limitations in funding and human resources faced by the SHDs, our research attempts to present the factual situation in embracing a vastly popular social media platform for health communication. We believe there is a need for research exploring methods to balance the demands and resources.
C1 [Jha, Ayan] CAMC, CAMC Hlth Educ & Res Inst, 3211 Maccorkle Ave SE, Charleston, WV 25304 USA.
[Lin, Leesa] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
[Lin, Leesa] Harvard Univ, TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA.
[Lin, Leesa; Savoia, Elena] Harvard Univ, TH Chan Sch Publ Hlth, Div Policy Translat & Leadership Dev, Boston, MA 02115 USA.
[Savoia, Elena] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
RP Jha, A (reprint author), CAMC, CAMC Hlth Educ & Res Inst, 3211 Maccorkle Ave SE, Charleston, WV 25304 USA.
EM ayanjha@mail.harvard.edu
FU U.S. Centers for Disease Control and Prevention (CDC) [1U90TP000417-05,
5PO1TP000307-05]
FX We acknowledge funding support from the U.S. Centers for Disease Control
and Prevention (CDC) cooperative agreement numbers: 1U90TP000417-05
(Preparedness and Emergency Response Learning Center) and
5PO1TP000307-05 (Preparedness and Emergency Response Research Center)
Supplement. The content of this publication as well as the views and
discussions expressed in this paper are solely those of the authors and
do not necessarily represent the views of any partner organizations, the
CDC or the U.S. Department of Health and Human Services nor does mention
of trade names, commercial practices, or organizations imply endorsement
by the U.S. Government.
NR 18
TC 2
Z9 2
U1 11
U2 30
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0094-5145
EI 1573-3610
J9 J COMMUN HEALTH
JI J. Community Health
PD FEB
PY 2016
VL 41
IS 1
BP 174
EP 179
DI 10.1007/s10900-015-0083-4
PG 6
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA DB6PY
UT WOS:000368638400023
PM 26318742
ER
PT J
AU Muluke, M
Gold, T
Kiefhaber, K
Al-Sahli, A
Celenti, R
Jiang, H
Cremers, S
Van Dyke, T
Schulze-Spate, U
AF Muluke, M.
Gold, T.
Kiefhaber, K.
Al-Sahli, A.
Celenti, R.
Jiang, H.
Cremers, S.
Van Dyke, T.
Schulze-Spaete, U.
TI Diet-Induced Obesity and Its Differential Impact on Periodontal Bone
Loss
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE palmitic acid; oleic acid; high-fat diet; bone metabolism; inflammation;
osteoclast
ID NECROSIS-FACTOR-ALPHA; PORPHYROMONAS-GINGIVALIS; PALMITIC ACID;
MEDITERRANEAN DIET; FATTY-ACIDS; OLEIC-ACID; IN-VIVO; DISEASE;
INFLAMMATION; TISSUE
AB Obesity is associated with abnormal lipid metabolism and impaired bone homeostasis. The aim of our study was to investigate the impact of specific elevated fatty acid (FA) levels on alveolar bone loss in a Porphyromonas gingivalis-induced model of periodontal disease and to analyze underlying cellular mechanisms in bone-resorbing osteoclasts and bone-forming osteoblasts in mice. Four-week-old male C57BL/6 mice were randomly divided in groups and subjected to a palmitic acid (PA)- or oleic acid (OA)-enriched high-fat diet (HFD) (20% of calories from FA) or a normal caloric diet (C group) (10% of calories from FA) for 16 wk. Starting at week 10, mice were infected orally with P. gingivalis (W50) or placebo to induce alveolar bone loss. Animals were sacrificed, and percentage fat, serum inflammation (tumor necrosis factor [TNF]-alpha), and bone metabolism (osteocalcin [OC], carboxy-terminal collagen crosslinks [CTX], and N-terminal propeptides of type I procollagen [P1NP]) markers were measured. Osteoblasts and osteoclasts were cultured in the presence of elevated PA or OA levels and exposed to P. gingivalis. Animals on FA-enriched diets weighed significantly more compared with animals on a normal caloric diet (P < 0.05). Both obese groups had similar percentages of fat (P = nonsignificant); however, alveolar bone loss was significantly greater in animals that were on the PA-enriched HFD (P < 0.05). TNF-alpha levels were highest in the PA group (P < 0.001) and increased in all groups in response to P. gingivalis inoculation (P < 0.01), whereas bone remodeling markers OC, CTX, and P1NP were lowest in the PA group (P < 0.001) and highest in the C group. Bacterial challenge decreased bone metabolism markers in all groups (P < 0.01). Further, osteoclasts showed an augmented inflammatory response to P. gingivalis in the presence of hyperlipidemic PA levels as opposed to OA cultures, which responded similarly to controls. These findings indicate that the specific FA profile of diet rather than weight gain and obesity alone modulates bone metabolism and can therefore influence alveolar bone loss.
C1 [Muluke, M.; Gold, T.; Kiefhaber, K.; Al-Sahli, A.; Celenti, R.; Schulze-Spaete, U.] Columbia Univ, Coll Dent Med, Div Periodont, 630 W 168th St,PH7C-200C, New York, NY 10032 USA.
[Muluke, M.; Gold, T.; Kiefhaber, K.] Columbia Univ, Inst Human Nutr, 630 W 168th St,PH7C-200C, New York, NY 10032 USA.
[Jiang, H.; Cremers, S.] Columbia Univ, Med Ctr, Irving Inst Clin & Translat Res, 630 W 168th St,PH7C-200C, New York, NY 10032 USA.
[Van Dyke, T.] Forsyth Inst, Boston, MA USA.
RP Schulze-Spate, U (reprint author), Columbia Univ, Coll Dent Med, Div Periodont, 630 W 168th St,PH7C-200C, New York, NY 10032 USA.; Schulze-Spate, U (reprint author), Columbia Univ, Coll Dent Med, 630 W 168th St,PH7C-200C, New York, NY 10032 USA.
EM us2141@cumc.columbia.edu
FU National Institute of Dental and Craniofacial Research, National Center
for Advancing Translational Sciences [K08DE018968, UL1 TR000040]
FX This study was supported by National Institute of Dental and
Craniofacial Research K08DE018968, UL1 TR000040, National Center for
Advancing Translational Sciences. The authors declare no potential
conflicts of interest with respect to the authorship and/or publication
of this article.
NR 40
TC 2
Z9 2
U1 1
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-0345
EI 1544-0591
J9 J DENT RES
JI J. Dent. Res.
PD FEB
PY 2016
VL 95
IS 2
BP 223
EP 229
DI 10.1177/0022034515609882
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA DB4TY
UT WOS:000368507500013
PM 26450512
ER
PT J
AU AlJaroudi, WA
Hage, FG
AF AlJaroudi, Wael A.
Hage, Fadi G.
TI Review of cardiovascular literature
SO JOURNAL OF NUCLEAR CARDIOLOGY
LA English
DT Editorial Material
C1 [AlJaroudi, Wael A.] Clemenceau Med Ctr, Div Cardiovasc Med, Beirut, Lebanon.
[Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA.
[Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA.
RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA.
EM fadihage@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-3581
EI 1532-6551
J9 J NUCL CARDIOL
JI J. Nucl. Cardiol.
PD FEB
PY 2016
VL 23
IS 1
BP 8
EP 10
DI 10.1007/s12350-015-0343-9
PG 3
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA DB6CQ
UT WOS:000368601300004
PM 26626784
ER
PT J
AU Iskandrian, AE
Roth, CP
Hage, FG
AF Iskandrian, Ami E.
Roth, Christopher P.
Hage, Fadi G.
TI Serial imaging and outcome prediction
SO JOURNAL OF NUCLEAR CARDIOLOGY
LA English
DT Editorial Material
ID CORONARY-ARTERY-DISEASE; LEFT-VENTRICULAR PERFUSION;
MYOCARDIAL-PERFUSION; QUANTITATIVE-ANALYSIS; ASYMPTOMATIC PATIENTS;
TRIAL; ISCHEMIA; ADENOSINE; NUCLEAR; SPECT
C1 [Iskandrian, Ami E.; Roth, Christopher P.; Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, 318 LHRB,1900 Univ BLVD, Birmingham, AL 35294 USA.
[Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA.
RP Iskandrian, AE (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, 318 LHRB,1900 Univ BLVD, Birmingham, AL 35294 USA.
EM aiskand@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
NR 21
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-3581
EI 1532-6551
J9 J NUCL CARDIOL
JI J. Nucl. Cardiol.
PD FEB
PY 2016
VL 23
IS 1
BP 117
EP 121
DI 10.1007/s12350-015-0312-3
PG 5
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA DB6CQ
UT WOS:000368601300019
PM 26514576
ER
PT J
AU AlJaroudi, WA
Hage, FG
AF AlJaroudi, Wael A.
Hage, Fadi G.
TI Review of cardiovascular imaging in the journal of nuclear cardiology in
2015. Part 1 of 2: Plaque imaging, positron emission tomography,
computed tomography, and magnetic resonance
SO JOURNAL OF NUCLEAR CARDIOLOGY
LA English
DT Review
DE Vulnerable atherosclerotic plaque; myocardial perfusion imaging: PET;
fluorodeoxyglucose (FDG); computed tomography (CT); magnetic resonance
imaging
ID CORONARY-ARTERY-DISEASE; SCREENING ASYMPTOMATIC PATIENTS;
MYOCARDIAL-ISCHEMIA; CARDIAC AMYLOIDOSIS; HIV-INFECTION; MR-IMPACT; PET;
ATHEROSCLEROSIS; INFLAMMATION; TRIAL
AB In 2015, many original articles pertaining to cardiovascular imaging with impressive quality were published in the Journal of Nuclear Cardiology. In a set of 2 articles, we provide an overview of these contributions to facilitate for the interested reader a quick review of the advancements that occurred in the field over this year. In this first article, we focus on arterial plaque imaging, cardiac positron emission tomography, computed tomography, and magnetic resonance imaging.
C1 [AlJaroudi, Wael A.] Clemenceau Med Ctr, Cardiovasc Imaging, Div Cardiovasc Med, Beirut, Lebanon.
[Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 314,1720 2nd AVE S, Birmingham, AL 35294 USA.
[Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA.
RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 314,1720 2nd AVE S, Birmingham, AL 35294 USA.
EM fadihage@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
NR 43
TC 1
Z9 1
U1 2
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-3581
EI 1532-6551
J9 J NUCL CARDIOL
JI J. Nucl. Cardiol.
PD FEB
PY 2016
VL 23
IS 1
BP 122
EP 130
DI 10.1007/s12350-015-0319-9
PG 9
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA DB6CQ
UT WOS:000368601300020
PM 26542991
ER
PT J
AU Steverson, D
Tian, L
Fu, YC
Zhang, W
Ma, E
Garvey, WT
AF Steverson, Dennis, Jr.
Tian, Ling
Fu, Yuchang
Zhang, Wei
Ma, Elizabeth
Garvey, William Timothy
TI Tribbles Homolog 3 Promotes Foam Cell Formation Associated with
Decreased Proinflammatory Cytokine Production in Macrophages: Evidence
for Reciprocal Regulation of Cholesterol Uptake and Inflammation
SO METABOLIC SYNDROME AND RELATED DISORDERS
LA English
DT Article
ID LOW-DENSITY-LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES;
CARDIOVASCULAR-DISEASE; NLRP3 INFLAMMASOMES; INSULIN-RESISTANCE;
METABOLIC SYNDROME; DEFICIENT MICE; ATHEROSCLEROSIS; PLAQUES; TRB3
AB Background: Insulin resistance is central in the pathophysiology of cardiometabolic disease; however, common mechanisms that explain the parallel development of both type 2 diabetes and atherosclerosis have not been elucidated. We have previously shown that tribbles homolog 3 (TRB3) can exert a chronic pathophysiological role in promoting insulin resistance and also has an acute physiological role to alternatively regulate glucose uptake in fat and muscle during short-term fasting and nutrient excess. Since TRB3 is expressed in human atherosclerotic plaques, we explored its role in foam cell formation to assess its potential contribution to atherogenesis. Methods: We have used human THP-1 monocytes, which transition to lipid-laden macrophage foam cells when exposed to oxidized low-density lipoprotein (ox-LDL). Results: We first observed that TRB3 was upregulated by more than twofold (P<0.01) within 24hr of treatment with ox-LDL. To determine whether TRB3 actively participated in foam cell formation, we overexpressed TRB3 in THP-1 monocytes and found that this led to a 1.5-fold increase in cholesterol accumulation after 48hr (P<0.01), compared with controls. At the same time, TRB3 overexpression suppressed inflammation in macrophages as evidenced by reduced expression and secretion of tumor necrosis factor alpha (TNF-) and interleukin-1 beta (IL-1) (both P<0.01). Conclusions: (1) TRB3 is upregulated in macrophages upon treatment with ox-LDL; (2) TRB3 promotes lipid accumulation and suppresses cytokine expression; and (3) inflammation and foam cell formation can be reciprocally regulated, and TRB3 orients the macrophage to assume a more primary role for lipid accumulation while maintaining a secondary role as an inflammatory immune cell.
C1 [Steverson, Dennis, Jr.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Steverson, Dennis, Jr.; Tian, Ling; Fu, Yuchang; Zhang, Wei; Ma, Elizabeth; Garvey, William Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Garvey, William Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Steverson, D (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, 1675 Univ Blvd, Birmingham, AL 35294 USA.
EM dsteversonjr@gmail.com
FU National Institutes of Health [DK-038765, DK-083562]; Merit Review
program of the Department of Veterans Affairs
FX This work was supported by grants from the National Institutes of Health
(DK-038765, DK-083562) and by the Merit Review program of the Department
of Veterans Affairs. The authors also acknowledge support from core
facilities of the UAB Diabetes Research Center (P30 DK079626).
NR 39
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-4196
EI 1557-8518
J9 METAB SYNDR RELAT D
JI Metab. Syndr. Relat. Disord.
PD FEB 1
PY 2016
VL 14
IS 1
BP 7
EP 15
DI 10.1089/met.2015.0037
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DB4XT
UT WOS:000368517600003
PM 26584255
ER
PT J
AU Ensan, S
Li, A
Besla, R
Degousee, N
Cosme, J
Roufaiel, M
Shikatani, EA
El-Maldizil, M
Williams, JW
Robins, L
Li, C
Lewis, B
Yun, TJ
Lees, JS
Wieghofer, P
Khattar, R
Farrokhil, K
Byrne, J
Ouzounian, M
Zavitz, CCJ
Levy, GA
Bauer, CMT
Libby, P
Husain, M
Swirski, FK
Cheong, C
Prinz, M
Hilgendorf, I
Randolph, GJ
Epelman, S
Gramolini, AO
Cybulksky, MI
Rubin, BB
Robbins, CS
AF Ensan, Sherine
Li, Angela
Besla, Rickvinder
Degousee, Norbert
Cosme, Jake
Roufaiel, Mark
Shikatani, Eric A.
El-Maldizil, Mahmoud
Williams, Jesse W.
Robins, Lauren
Li, Cedric
Lewis, Bonnie
Yun, Tae Jin
Lees, Jun Seong
Wieghofer, Peter
Khattar, Ramzi
Farrokhil, Kaveh
Byrne, John
Ouzounian, Maral
Zavitz, Caleb C. J.
Levy, Gary A.
Bauer, Carla M. T.
Libby, Peter
Husain, Mansoor
Swirski, Filip K.
Cheong, Cheolho
Prinz, Marco
Hilgendorf, Ingo
Randolph, Gwendalyn J.
Epelman, Slava
Gramolini, Anthony O.
Cybulksky, Myron I.
Rubin, Barry B.
Robbins, Clinton S.
TI Self-renewing resident arterial macrophages arise from embryonic
CX3CR1(+) precursors and circulating monocytes immediately after birth
SO NATURE IMMUNOLOGY
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; DENDRITIC CELLS; YOLK-SAC; CHEMOKINE
FRACTALKINE; COMMITTED PROGENITORS; CARDIAC MACROPHAGES; TISSUE
MACROPHAGES; FETAL MONOCYTES; STEADY-STATE; ADULT LIFE
AB Resident macrophages densely populate the normal arterial wall, yet their origins and the mechanisms that sustain them are poorly understood. Here we use gene-expression profiling to show that arterial macrophages constitute a distinct population among macrophages. Using multiple fate-mapping approaches, we show that arterial macrophages arise embryonically from CX3CR1(+) precursors and postnatally from bone marrow derived monocytes that colonize the tissue immediately after birth. In adulthood, proliferation (rather than monocyte recruitment) sustains arterial macrophages in the steady state and after severe depletion following sepsis. After infection, arterial macrophages return rapidly to functional homeostasis. Finally, survival of resident arterial macrophages depends on a CX3CR1-CX3CL1 axis within the vascular niche.
C1 [Ensan, Sherine; Li, Angela; El-Maldizil, Mahmoud; Farrokhil, Kaveh; Epelman, Slava; Robbins, Clinton S.] Univ Toronto, Dept Immunol, Toronto, ON, Canada.
[Besla, Rickvinder; Shikatani, Eric A.; Husain, Mansoor; Cybulksky, Myron I.; Robbins, Clinton S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
[Degousee, Norbert; Cosme, Jake; Roufaiel, Mark; Robins, Lauren; Li, Cedric; Lewis, Bonnie; Khattar, Ramzi; Ouzounian, Maral; Zavitz, Caleb C. J.; Levy, Gary A.; Husain, Mansoor; Epelman, Slava; Gramolini, Anthony O.; Cybulksky, Myron I.; Rubin, Barry B.; Robbins, Clinton S.] Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada.
[Williams, Jesse W.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
[Yun, Tae Jin; Lees, Jun Seong] Inst Rech Clin Montreal, Lab Cellular Physiol & Immunol, Montreal, PQ H2W 1R7, Canada.
[Yun, Tae Jin; Lees, Jun Seong] Univ Freiburg, Inst Neuropathol, Hugstetter Str 55, D-79106 Freiburg, Germany.
[Wieghofer, Peter] Univ Freiburg, Fac Biol, Hugstetter Str 55, D-79106 Freiburg, Germany.
[Bauer, Carla M. T.] Hoffmann La Roche Inc, pRED, Pharma Res & Early Dev, DTA Inflammat, 340 Kingsland St, Nutley, NJ 07110 USA.
[Libby, Peter] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[Swirski, Filip K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA USA.
[Prinz, Marco] Univ Freiburg, Inst Neuropathol, Hugstetter Str 55, D-79106 Freiburg, Germany.
[Prinz, Marco] Univ Freiburg, BIOSS Ctr Biol Signaling Studies, Hugstetter Str 55, D-79106 Freiburg, Germany.
[Hilgendorf, Ingo] Univ Freiburg, Dept Cardiol & Angiol 1, Hugstetter Str 55, D-79106 Freiburg, Germany.
[Gramolini, Anthony O.] Univ Toronto, Dept Physiol, Toronto, ON, Canada.
[Byrne, John; Ouzounian, Maral; Husain, Mansoor; Epelman, Slava; Gramolini, Anthony O.; Cybulksky, Myron I.; Rubin, Barry B.; Robbins, Clinton S.] Univ Hlth Network, Peter Munk Cardiac Ctr, Toronto, ON, Canada.
RP Robbins, CS (reprint author), Univ Toronto, Dept Immunol, Toronto, ON, Canada.; Robbins, CS (reprint author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.; Robbins, CS (reprint author), Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada.
EM clint.robbins@utoronto.ca
OI Williams, Jesse/0000-0003-3815-0891
FU Canadian Institutes of Health Research (CIHR) [MSH136670]; CIHR
[MOP133390]; Ontario Lung Association/Pfizer Award; Peter Munk Chair in
Aortic Disease Research; Ontario Graduate Scholarship
FX We acknowledge the administrative assistance of B. Bali. Supported by a
Canadian Institutes of Health Research (CIHR) New Investigator Award
(MSH136670), a CIHR operating grant (MOP133390), an Ontario Lung
Association/Pfizer Award and the Peter Munk Chair in Aortic Disease
Research (C.S.R.) and an Ontario Graduate Scholarship (S.E.).
NR 45
TC 25
Z9 27
U1 2
U2 15
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
EI 1529-2916
J9 NAT IMMUNOL
JI Nat. Immunol.
PD FEB
PY 2016
VL 17
IS 2
BP 159
EP 168
DI 10.1038/ni.3343
PG 10
WC Immunology
SC Immunology
GA DB5RO
UT WOS:000368571500009
PM 26642357
ER
PT J
AU Khanna, AR
Coumans, JV
AF Khanna, Arjun R.
Coumans, Jean-Valery
TI Spontaneous Improvement of Chiari I Malformation and Syringomyelia in a
Patient With Cystic Fibrosis: Case Report
SO NEUROSURGERY
LA English
DT Article
DE Chiari I malformation; Cystic fibrosis; Syringomyelia; Syrinx; Tonsillar
herniation
ID OF-THE-LITERATURE; SPONTANEOUS RESOLUTION; PRESSURE; SYRINX;
PATHOGENESIS
AB BACKGROUND AND IMPORTANCE:Syringomyelia is highly associated with Chiari I malformation, but the pathophysiologic mechanism of syrinx formation and its relation to downward cerebellar tonsillar displacement remains elusive. Cough, Valsalva maneuver, and other physiological strains transiently exacerbate the clinical symptoms of these conditions, exert profound effects on the flow dynamics across the craniospinal junction, and are thought to play an important role in the pathogenesis of syringomyelia.CLINICAL PRESENTATION:We report the case of a patient with cystic fibrosis who presented during an exacerbation of bronchiectasis and was found to have a Chiari I malformation with associated syringomyelia. Eight months later, when the patient had returned to baseline pulmonary status, repeat imaging showed interval improvement in both the size of the syrinx and descent of cerebellar tonsils.CONCLUSION:This rare case of spontaneous improvement of syringomyelia and Chiari I malformation attributable to relief from chronic cough offers interesting insight into the mechanism of these disorders.ABBREVIATIONS:FEV1, forced expiratory volume in 1 secondFVC, forced vital capacity
C1 [Khanna, Arjun R.; Coumans, Jean-Valery] Massachusetts Gen Hosp, Dept Neurosurg, 15 Parkman St, Boston, MA 02114 USA.
RP Coumans, JV (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, 15 Parkman St, Boston, MA 02114 USA.
EM jcoumans@partners.org
NR 26
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-396X
J9 NEUROSURGERY
JI Neurosurgery
PD FEB
PY 2016
VL 78
IS 2
BP E305
EP E308
DI 10.1227/NEU.0000000000000980
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA DB6BP
UT WOS:000368598400001
PM 26308731
ER
PT J
AU Patel, AV
Lane, AM
Morrison, MA
Trofimov, AV
Shih, HA
Gragoudas, ES
Kim, IK
AF Patel, Avni V.
Lane, Anne Marie
Morrison, Margaux A.
Trofimov, Alexei V.
Shih, Helen A.
Gragoudas, Evangelos S.
Kim, Ivana K.
TI Visual Outcomes after Proton Beam Irradiation for Choroidal Melanomas
Involving the Fovea
SO OPHTHALMOLOGY
LA English
DT Article
ID UVEAL MELANOMAS; RADIATION MACULOPATHY; RADIOTHERAPY; THERAPY; TRIAL
AB Purpose: To report visual outcomes in patients undergoing proton beam irradiation of tumors located within 1 disc diameter of the fovea.
Design: Retrospective review.
Participants: Patients with choroidal melanoma involving the fovea treated with proton beam therapy between 1975 and 2009.
Methods: Three hundred fifty-one patients with choroidal melanomas located 1 disc diameter (DD) or less from the fovea and more than 1 DD away from the optic nerve were included in this study. In a subgroup of 203 of the patients with small and medium choroidal melanomas, the effect of a reduced dose of radiation, 50 Gy (relative biological effectiveness [RBE]) versus 70 Gy (RBE), on visual outcomes was analyzed. The Kaplan-Meier method and Cox regression analysis were performed to calculate cumulative rates of vision loss and to assess risk factors for vision loss, respectively.
Main Outcome Measures: Visual acuity and radiation complications, which included radiation maculopathy, papillopathy, retinal detachment, and rubeosis, were assessed.
Results: Three hundred fifty-one patients were included in this study with a mean follow-up time of 68.7 months. More than one-third of patients (35.5%) retained 20/200 or better vision 5 years after proton beam irradiation. For those patients with a baseline visual acuity of 20/40 or better, 16.2% of patients retained this level of vision 5 years after proton beam irradiation. Tumor height less than 5 mm and baseline visual acuity 20/40 or better were associated significantly with a better visual outcome (P < 0.001). More than two-thirds (70.4%) of patients receiving 50 Gy (RBE) and nearly half (45.1%) of patients receiving 70 Gy (RBE) retained 20/200 or better vision 5 years after treatment, but this difference was not significant. Approximately 20% of patients with these smaller macular tumors retained 20/40 vision or better 5 years after irradiation.
Conclusions: The results of this retrospective analysis demonstrate that despite receiving a full dose of radiation to the fovea, many patients with choroidal melanoma with foveal involvement maintain useful vision. A radiation dose reduction from 70 to 50 Gy (RBE) did not seem to increase the proportion of patients who retain usable vision. (C) 2016 by the American Academy of Ophthalmology.
C1 [Patel, Avni V.; Lane, Anne Marie; Gragoudas, Evangelos S.; Kim, Ivana K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Morrison, Margaux A.] Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
[Trofimov, Alexei V.; Shih, Helen A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
RP Kim, IK (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM ivana_kim@meei.harvard.edu
FU Grimshaw-Gudewicz Charitable Foundation (Fall River, MA)
FX Supported by the Grimshaw-Gudewicz Charitable Foundation (Fall River,
MA).
NR 17
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2016
VL 123
IS 2
BP 369
EP 377
DI 10.1016/j.ophtha.2015.09.031
PG 9
WC Ophthalmology
SC Ophthalmology
GA DB2TK
UT WOS:000368362200030
PM 26545316
ER
PT J
AU Bell, RC
Yager, PH
Clark, ME
Roumiantsev, S
Venancio, HL
Chipman, DW
Kacmarek, RM
Noviski, NN
AF Bell, Rebecca C.
Yager, Phoebe H.
Clark, Maureen E.
Roumiantsev, Serguei
Venancio, Heather L.
Chipman, Daniel W.
Kacmarek, Robert M.
Noviski, Natan N.
TI Telemedicine Versus Face-to-Face Evaluations by Respiratory Therapists
of Mechanically Ventilated Neonates and Children: A Pilot Study
SO RESPIRATORY CARE
LA English
DT Article
DE telemedicine; pediatrics; intensive care; physical examination;
reliability of results
ID INTENSIVE-CARE-UNIT; ICU TELEMEDICINE; OUTCOMES; PROGRAM
AB BACKGROUND: Mechanical ventilation is one of the most important therapeutic interventions in neonatal and pediatric ICUs. Telemedicine has been shown to reliably extend pediatric intensivist expertise to facilities where expertise is limited. If reliable, telemedicine may extend the reach of pediatric respiratory therapists (RTs) to facilities where expertise does not exist or free up existing RT resources for important face-to-face activities in facilities where expertise is limited. The aim of this study was to determine how well respiratory assessments for ventilated neonates and children correlated when performed simultaneously by 2 RTs face-to-face and via telemedicine. METHODS: We conducted a pilot study including 40 assessments by 16 RTs on 11 subjects (5 neonatal ICU; 6 pediatric ICU). Anonymously completed intake forms by 2 different RTs concurrently assessing 14 ventilator-derived and patient-based respiratory variables were used to determine correlations. RESULTS: Forty paired assessments were performed. Median telemedicine assessment time was 8 min. The Pearson correlation coefficient (r) was used to determine agreement between continuous data, and the Cohen kappa statistics were used for binary variables. Pressure control, PEEP, breathing frequency, and F-IO2 perfectly correlated (r = 1, all P < .001) as did the presence of a CO2 monitor and need for increased ventilatory support (kappa = 1). The Pearson correlation coefficient for V-T, minute ventilation, mean airway pressure, and oxygen saturation ranged from 0.84 to 0.97 (all P<.001). kappa = 0.41 (95% CI 0.02-0.80) for patient-triggered breaths, and kappa = 0.57 (95% CI 0.19-0.94) for breathing frequency higher than set frequency. kappa = -0.25 (95% CI -0.46 to -0.04) for need for suctioning. CONCLUSIONS: Telemedicine technology was acceptable to RTs. Telemedicine evaluations highly correlated with face-to-face for 10 of 14 aspects of standard bedside respiratory assessment. Poor correlation was noted for more complex, patient-generated parameters, highlighting the importance of further investigation incorporating a virtual stethoscope.
C1 [Bell, Rebecca C.] Univ Vermont, Childrens Hosp, Div Inpatient & Crit Care Pediat, Burlington, VT 05405 USA.
[Yager, Phoebe H.; Clark, Maureen E.; Noviski, Natan N.] Massachusetts Gen Hosp, Dept Pediat, Div Pediat Crit Care, Boston, MA 02114 USA.
[Roumiantsev, Serguei] Massachusetts Gen Hosp, Dept Pediat, Div Neonatol & Newborn Med, Boston, MA 02114 USA.
[Venancio, Heather L.; Chipman, Daniel W.; Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA.
RP Noviski, NN (reprint author), 175 Cambridge St,CPZS 5, Boston, MA 02114 USA.
EM nnoviski@partners.org
FU Department of Pediatrics, Massachusetts General Hospital, Boston,
Massachusetts; Covidien; Venner Medical
FX This work was supported by the Department of Pediatrics, Massachusetts
General Hospital, Boston, Massachusetts. Dr Kacmarek consults for Orange
Medical and has received research grants from Covidien and Venner
Medical. Drs Bell, Yager, Roumiantsev, Noviski, Ms Clark, Ms Venancio
and Mr Chipman have disclosed no conflicts of interest.
NR 26
TC 0
Z9 0
U1 1
U2 5
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD FEB
PY 2016
VL 61
IS 2
BP 149
EP 154
DI 10.4187/respcare.04080
PG 6
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA DB3LZ
UT WOS:000368414400005
PM 26647456
ER
PT J
AU Nezolosky, MD
Dinh, KT
Muralidhar, V
Mahal, BA
Chen, YW
Beard, CJ
Choueiri, TK
Martin, NE
Sweeney, CJ
Trinh, QD
Nguyen, PL
AF Nezolosky, Michelle D.
Dinh, Kathryn T.
Muralidhar, Vinayak
Mahal, Brandon A.
Chen, Yu-Wei
Beard, Clair J.
Choueiri, Toni K.
Martin, Neil E.
Sweeney, Christopher J.
Quoc-Dien Trinh
Nguyen, Paul L.
TI Significant increase in prostatectomy and decrease in radiation for
clinical T3 prostate cancer from 1998 to 2012
SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
LA English
DT Article
DE Prostate cancer; Prostatectomy; Radiation therapy; Clinical T3 disease;
Treatment patterns
ID SEMINAL-VESICLE INVASION; RADICAL PROSTATECTOMY; ADJUVANT RADIOTHERAPY;
SINGLE-INSTITUTION; SURVIVAL; OUTCOMES; TRIAL; MEN; RECURRENCE;
ADENOCARCINOMA
AB Purpose: We aimed to describe changes in treatment patterns for clinical T3 prostate cancer (PCa) from 1998 to 2012, specifically investigating what factors influence receipt of prostatectomy or radiation.
Materials and methods: Using the Surveillance, Epidemiology, and End Results database, we studied 11,604 men with clinical T3NOMO PCa from 1998 to 2012, with treatment categorized as radiation, radical prostatectomy (RP), or no curative therapy. We calculated rate of treatment type by year of diagnosis to investigate trends in treatment patterns, further stratifying by clinical T3a, defined as unilateral and bilateral extracapsular extension (n = 3,842), vs. T3b (defined as extension to seminal vesicles (n = 3,665). Finally, a multivariable logistic regression analysis measured association of demographic and clinical variables with type of treatment received for years 2010 to 2011.
Results: Rates of prostatectomy increased significantly from 1998 to 2012 (12.5% vs. 44.4%), radiation decreased significantly (55.8% vs. 38.4%), and receipt of no treatment also decreased (31.7% vs. 17.2%, all P < 0.001). These trends were similar for clinical T3a and T3b. Rates of prostatectomy surpassed radiation by 2008 in clinical T3a, reaching 49.8% vs. 37.1%, respectively, in 2012 (P = 0.002), and were statistically similar to radiation in 2012 for clinical T3b, reaching 41.6% vs. 42.1% (P = 0.92). Multivariable logistic regression analysis demonstrated that patients were less likely to receive prostatectomy than radiation if biopsy Gleason scores of 8 to 10 (adjusted odds ratio [AOR] = 0.41, 0.32-0.53), higher initial prostate-specific antigen (AOR = 0.97, 0.97-0.98), and older age (AOR = 0.92, 0.90-0.03, all P < 0.01). The likelihood of RP was similar among cT3b vs. cT3a (AOR = 0.95, 0.71-1.26, P = 0.74).
Conclusions: Since 1998, there has been a significant increase in the use of RP for clinical T3 PCa and a significant decrease in the use of radiation such that in 2012, the use of prostatectomy exceeded the use of radiation. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Nezolosky, Michelle D.; Beard, Clair J.; Martin, Neil E.; Nguyen, Paul L.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Nezolosky, Michelle D.; Beard, Clair J.; Martin, Neil E.; Nguyen, Paul L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Dinh, Kathryn T.; Muralidhar, Vinayak; Beard, Clair J.; Choueiri, Toni K.; Martin, Neil E.; Sweeney, Christopher J.; Quoc-Dien Trinh; Nguyen, Paul L.] Harvard Univ, Sch Med, Boston, MA USA.
[Mahal, Brandon A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Internal Med, Boston, MA 02115 USA.
[Chen, Yu-Wei] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
[Choueiri, Toni K.; Sweeney, Christopher J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Choueiri, Toni K.; Sweeney, Christopher J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Quoc-Dien Trinh] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Urol, Boston, MA 02115 USA.
RP Nguyen, PL (reprint author), Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
EM pnguyen@LROC.harvard.edu
FU Fitz's Cancer Warriors; Prostate Cancer Foundation; Campbell Family in
Honor of Joan Campbell; anonymous family foundation
FX This work is supported financially by Fitz's Cancer Warriors, David and
Cynthia Chapin, the Prostate Cancer Foundation, Hugh Simons in honor of
Frank and Anne Simons, Scott Forbes and Gina Ventre, The Campbell Family
in Honor of Joan Campbell, and a grant from an anonymous family
foundation. All listed authors were involved in the design, data
analysis, and manuscript preparation, and all authors approved the final
version of this paper. Paul L. Nguyen has consulted for Medivation and
GenomeDX.
NR 38
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1078-1439
EI 1873-2496
J9 UROL ONCOL-SEMIN ORI
JI Urol. Oncol.-Semin. Orig. Investig.
PD FEB
PY 2016
VL 34
IS 2
AR 57.e22
DI 10.1016/j.urolonc.2015.09.002
PG 8
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA DB2HN
UT WOS:000368329000009
ER
PT J
AU Gupta, P
Tang, XY
Rettiganti, M
Lauer, C
Kacmarek, RM
Rice, TB
Markovitz, BP
Wetzel, RC
AF Gupta, Punkaj
Tang, Xinyu
Rettiganti, Mallikarjuna
Lauer, Casey
Kacmarek, Robert M.
Rice, Tom B.
Markovitz, Barry P.
Wetzel, Randall C.
TI Association of house staff training with mortality in children with
critical illness
SO ACTA PAEDIATRICA
LA English
DT Article
DE Children; Critical illness; Fellowship; Intensive care; Mortality
ID PEDIATRIC INTENSIVE-CARE; RESIDENT INVOLVEMENT; OUTCOMES; UNITS; COSTS;
SURGERY; TESTS; TIMES
AB Aim: To evaluate the association of house staff training with mortality in children with critical illness.
Methods: Patients <18 years of age in the Virtual PICU Systems (VPS, LLC) Database (2009-2013) were included. The study population was divided in two study groups: hospitals with residency programme only and hospitals with both residency and fellowship programme. Control group constituted hospitals with no residency or fellowship programme. The primary study outcome was mortality before intensive care unit (ICU) discharge. Multivariable logistic regression models were fitted to evaluate association of training programmes with ICU mortality.
Results: A total of 336 335 patients from 108 centres were included. Case-mix of patients among the hospitals with training programmes was complex; patients cared for in the hospitals with training programmes had greater severity of illness, had higher resource utilisation and had higher overall admission risk of death compared to patients cared for in the control hospitals. Despite caring for more complex and sicker patients, the hospitals with training programmes were associated with lower odds of ICU mortality.
Conclusion: Our study establishes that ICU care provided in hospitals with training programmes is associated with improved adjusted survival rates among the Virtual PICU database hospitals in the United States.
C1 [Gupta, Punkaj] Univ Arkansas Med Sci, Dept Pediat, Div Pediat Cardiol, Little Rock, AR 72223 USA.
[Tang, Xinyu; Rettiganti, Mallikarjuna] Univ Arkansas Med Sci, Dept Pediat, Biostat Sect, Little Rock, AR 72223 USA.
[Lauer, Casey; Rice, Tom B.; Markovitz, Barry P.; Wetzel, Randall C.] Virtual PICU Syst LLC, Los Angeles, CA USA.
[Kacmarek, Robert M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
[Rice, Tom B.] Med Coll Wisconsin, Dept Pediat, Div Pediat Crit Care, Milwaukee, WI 53226 USA.
[Markovitz, Barry P.; Wetzel, Randall C.] USC, Childrens Hosp Los Angeles, Keck Sch Med, Div Crit Care Med,Dept Pediat & Anesthesiol, Los Angeles, CA USA.
RP Gupta, P (reprint author), Univ Arkansas Med Sci, Arkansas Childrens Hosp, Coll Med, Div Pediat Cardiol,Dept Pediat, 1 Childrens Way,Slot 512-3, Little Rock, AR 72223 USA.
EM pgupta2@uams.edu
NR 20
TC 3
Z9 3
U1 2
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0803-5253
EI 1651-2227
J9 ACTA PAEDIATR
JI Acta Paediatr.
PD FEB
PY 2016
VL 105
IS 2
BP E60
EP E66
DI 10.1111/apa.13223
PG 7
WC Pediatrics
SC Pediatrics
GA DA6NK
UT WOS:000367921500003
PM 26399703
ER
PT J
AU McElroy, SL
Kemp, DE
Friedman, ES
Reilly-Harrington, NA
Sylvia, LG
Calabrese, JR
Rabideau, DJ
Ketter, TA
Thase, ME
Singh, V
Tohen, M
Bowden, CL
Bernstein, EE
Brody, BD
Deckersbach, T
Kocsis, JH
Kinrys, G
Bobo, WV
Kamali, M
McInnis, MG
Leon, AC
Faraone, S
Nierenberg, AA
Shelton, RC
AF McElroy, S. L.
Kemp, D. E.
Friedman, E. S.
Reilly-Harrington, N. A.
Sylvia, L. G.
Calabrese, J. R.
Rabideau, D. J.
Ketter, T. A.
Thase, M. E.
Singh, V.
Tohen, M.
Bowden, C. L.
Bernstein, E. E.
Brody, B. D.
Deckersbach, T.
Kocsis, J. H.
Kinrys, G.
Bobo, W. V.
Kamali, M.
McInnis, M. G.
Leon, A. C.
Faraone, S.
Nierenberg, A. A.
Shelton, R. C.
TI Obesity, but not metabolic syndrome, negatively affects outcome in
bipolar disorder
SO ACTA PSYCHIATRICA SCANDINAVICA
LA English
DT Article
DE bipolar disorder; obesity; metabolic syndrome; outcome
ID BODY-MASS INDEX; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; I-DISORDER;
1ST-EPISODE MANIA; LONG-TERM; MEDICAL BURDEN; SYMPTOMS SCALE; REGIONAL
GRAY; DSM-IV; OVERWEIGHT
AB Objective: Examine the effects of obesity and metabolic syndrome on outcome in bipolar disorder.
Method: The Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic Mood Stabilizer for Bipolar Disorder (Bipolar CHOICE) study randomized 482 participants with bipolar disorder in a 6-month trial comparing lithium- and quetiapine-based treatment. Baseline variables were compared between groups with and without obesity, with and without abdominal obesity, and with and without metabolic syndrome respectively. The effects of baseline obesity, abdominal obesity, and metabolic syndrome on outcomes were examined using mixed effects linear regression models.
Results: At baseline, 44.4% of participants had obesity, 48.0% had abdominal obesity, and 27.3% had metabolic syndrome; neither obesity, nor abdominal obesity, nor metabolic syndrome were associated with increased global severity, mood symptoms, or suicidality, or with poorer functioning or life satisfaction. Treatment groups did not differ on prevalence of obesity, abdominal obesity, or metabolic syndrome. By contrast, among the entire cohort, obesity was associated with less global improvement and less improvement in total mood and depressive symptoms, suicidality, functioning, and life satisfaction after 6 months of treatment. Abdominal obesity was associated with similar findings. Metabolic syndrome had no effect on outcome.
Conclusion: Obesity and abdominal obesity, but not metabolic syndrome, were associated with less improvement after 6 months of lithium-or quetiapine-based treatment.
C1 [McElroy, S. L.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA.
[McElroy, S. L.] Lindner Ctr HOPE, Mason, OH USA.
[Kemp, D. E.; Calabrese, J. R.] Case Western Reserve Univ, Dept Psychiat, Cleveland, OH 44106 USA.
[Friedman, E. S.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA.
[Reilly-Harrington, N. A.; Sylvia, L. G.; Bernstein, E. E.; Deckersbach, T.; Kinrys, G.; Nierenberg, A. A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Reilly-Harrington, N. A.; Sylvia, L. G.; Deckersbach, T.; Kinrys, G.; Nierenberg, A. A.] Harvard Univ, Sch Med, Boston, MA USA.
[Rabideau, D. J.] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA.
[Ketter, T. A.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA USA.
[Thase, M. E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Singh, V.; Bowden, C. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Tohen, M.] Univ New Mexico, Dept Psychiat, Hlth Sci Ctr, Albuquerque, NM 87131 USA.
[Brody, B. D.; Kocsis, J. H.; Leon, A. C.] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA.
[Bobo, W. V.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA.
[Kamali, M.; McInnis, M. G.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
[Faraone, S.] SUNY Upstate Med Univ, Dept Psychiat & Neurosci & Physiol, Syracuse, NY 13210 USA.
[Shelton, R. C.] Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL USA.
RP McElroy, SL (reprint author), Lindner Ctr HOPE, Mason, OH USA.
EM susan.mcelroy@lindnercenter.org
OI Faraone, Stephen/0000-0002-9217-3982
FU AHRQ [R01 HS019371-01]
FX This study was funded by AHRQ Grant R01 HS019371-01.
NR 55
TC 2
Z9 2
U1 4
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-690X
EI 1600-0447
J9 ACTA PSYCHIAT SCAND
JI Acta Psychiatr. Scand.
PD FEB
PY 2016
VL 133
IS 2
BP 144
EP 153
DI 10.1111/acps.12460
PG 10
WC Psychiatry
SC Psychiatry
GA DA7SE
UT WOS:000368003600006
ER
PT J
AU Stricker, NH
Salat, DH
Kuhn, TP
Foley, JM
Price, JS
Westlye, LT
Esterman, MS
McGlinchey, RE
Milberg, WP
Leritz, EC
AF Stricker, Nikki H.
Salat, David H.
Kuhn, Taylor P.
Foley, Jessica M.
Price, Jenessa S.
Westlye, Lars T.
Esterman, Michael S.
McGlinchey, Regina E.
Milberg, William P.
Leritz, Elizabeth C.
TI Mild Cognitive Impairment is Associated With White Matter Integrity
Changes in Late-Myelinating Regions Within the Corpus Callosum
SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS
LA English
DT Article
DE diffusion tensor imaging; magnetic resonance imaging; mild cognitive
impairment; corpus callosum; Alzheimer's disease
ID ALZHEIMERS-DISEASE; HUMAN BRAIN; TRACT INTEGRITY; DIFFUSION ANISOTROPY;
FIBER TRACTOGRAPHY; NERVE-FIBERS; LIFE-SPAN; AGE; MRI; DEMENTIA
AB Degenerative brain changes in Alzheimer's disease may occur in reverse order of normal brain development based on the retrogenesis model. This study tested whether evidence of reverse myelination was observed in mild cognitive impairment (MCI) using a data-driven analytic approach based on life span developmental data. Whole-brain high-resolution diffusion tensor imaging scans were obtained for 31 patients with MCI and 79 demographically matched healthy older adults. Comparisons across corpus callosum (CC) regions of interest (ROIs) showed decreased fractional anisotropy (FA) in the body but not in the genu or splenium; early-, middle-, and late-myelinating ROIs restricted to the CC revealed decreased FA in late- but not early- or middle-myelinating ROIs. Voxelwise group differences revealed areas of lower FA in MCI, but whole-brain differences were equally distributed across early-, middle-, and late-myelinating regions. Overall, results within the CC support the retrogenesis model, although caution is needed when generalizing these results beyond the CC.
C1 [Stricker, Nikki H.; Kuhn, Taylor P.; Foley, Jessica M.] VA Boston Healthcare Syst, Psychol Serv, Boston, MA USA.
[Stricker, Nikki H.; Esterman, Michael S.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Salat, David H.; Esterman, Michael S.; Leritz, Elizabeth C.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA USA.
[Salat, David H.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Salat, David H.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Foley, Jessica M.; Price, Jenessa S.; McGlinchey, Regina E.; Milberg, William P.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Price, Jenessa S.] McLean Hosp, Belmont, MA 02178 USA.
[Westlye, Lars T.] Univ Oslo, Norwegian Ctr Mental Disorder Res NORMENT, KG Jebsen Ctr Psychosis Res, Div Mental Hlth & Addict,Oslo Univ Hosp, Oslo, Norway.
[Westlye, Lars T.] Univ Oslo, Inst Clin Med, Oslo, Norway.
[Westlye, Lars T.] Univ Oslo, Dept Psychol, Oslo, Norway.
[McGlinchey, Regina E.; Milberg, William P.] VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA.
[Leritz, Elizabeth C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Stricker, NH (reprint author), VA Boston Med Ctr, 116B,150 S Huntington Ave, Jamaica Plain, MA 02130 USA.
EM nikki.stricker@va.gov
RI McGlinchey, Regina/R-1971-2016;
OI Westlye, Lars T./0000-0001-8644-956X
FU Department of Veterans Affairs; Veterans Health Administration; VISN 1
Career Development Award; Gilbert Foundation/AFAR; Medical Research
Service VA Merit Review Awards; Veterans Affairs Clinical Science R&D
Career Development Award [1IK2CX000706-01A2]; National Institute of
Neurologic Disorders and Stroke [K23NS062148]; National Institute of
Nursing Research [R01NR010827]; National Institute on Aging [P60AG08812,
P01AG004390]; Research Council of Norway [204966/F20]; National
Institute on Drug Abuse [2T32DA015036]
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
supported by the Department of Veterans Affairs, Veterans Health
Administration, VISN 1 Career Development Award, and the Gilbert
Foundation/AFAR. This work was also supported by the Medical Research
Service VA Merit Review Awards, Veterans Affairs Clinical Science R&D
Career Development Award (1IK2CX000706-01A2), the National Institute of
Neurologic Disorders and Stroke (grant number K23NS062148); the National
Institute of Nursing Research (grant number R01NR010827), the National
Institute on Aging (grant numbers P60AG08812, P01AG004390); the Research
Council of Norway (204966/F20), and by the National Institute on Drug
Abuse (2T32DA015036).
NR 74
TC 3
Z9 3
U1 2
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-3175
EI 1938-2731
J9 AM J ALZHEIMERS DIS
JI Am. J. Alzheimers Dis. Other Dement.
PD FEB
PY 2016
VL 31
IS 1
BP 68
EP 75
DI 10.1177/1533317515578257
PG 8
WC Geriatrics & Gerontology; Clinical Neurology
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA DB0CG
UT WOS:000368175600008
PM 25904759
ER
PT J
AU Foley, JM
Salat, DH
Stricker, NH
McGlinchey, RE
Milberg, WP
Grande, LJ
Leritz, EC
AF Foley, Jessica M.
Salat, David H.
Stricker, Nikki H.
McGlinchey, Regina E.
Milberg, William P.
Grande, Laura J.
Leritz, Elizabeth C.
TI Glucose Dysregulation Interacts With APOE-epsilon 4 to Potentiate
Temporoparietal Cortical Thinning
SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS
LA English
DT Article
DE APOE-epsilon 4; cortical thickness; aging; Alzheimer's disease;
neuroimaging; diabetes
ID APOLIPOPROTEIN-E EPSILON-4; MILD COGNITIVE IMPAIRMENT; TENSOR-BASED
MORPHOMETRY; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; WHITE-MATTER
LESIONS; ALZHEIMERS-DISEASE; RISK-FACTORS; HIPPOCAMPAL ATROPHY;
DIABETES-MELLITUS
AB We examined the interactive effects of apolipoprotein 4 (APOE-epsilon 4), a risk factor for Alzheimer's disease (AD), and diabetes risk on cortical thickness among 107 healthy elderly participants; in particular, participants included 27 APOE-epsilon 4+ and 80 APOE-epsilon 4- controls using T1-weighted structural magnetic resonance imaging. Regions of interests included select frontal, temporal, and parietal cortical regions. Among APOE-epsilon 4, glucose abnormalities independently predicted reduced cortical thickness among temporoparietal regions but failed to predict changes for noncarriers. However, among noncarriers, age independently predicted reduced cortical thickness among temporoparietal and frontal regions. Diabetes risk is particularly important for the integrity of cortical gray matter in APOE-epsilon 4 and demonstrates a pattern of thinning that is expected in preclinical AD. However, in the absence of this genetic factor, age confers risk for reduced cortical thickness among regions of expected compromise. This study supports aggressive management of cerebrovascular factors and earlier preclinical detection of AD among individuals presenting with genetic and metabolic risks.
C1 [Foley, Jessica M.; Salat, David H.; Stricker, Nikki H.; McGlinchey, Regina E.; Milberg, William P.; Grande, Laura J.; Leritz, Elizabeth C.] VA Boston Healthcare Syst, Dept Psychiat, Boston, MA USA.
[Foley, Jessica M.; Salat, David H.; McGlinchey, Regina E.; Milberg, William P.; Leritz, Elizabeth C.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Foley, Jessica M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA.
[Salat, David H.; Milberg, William P.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Stricker, Nikki H.; Grande, Laura J.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
RP Foley, JM (reprint author), Univ Calif San Francisco, Med Ctr, Dept Neurol, 1500 Owens St, San Francisco, CA 94158 USA.
EM jessica.foley@ucsf.edu
RI McGlinchey, Regina/R-1971-2016
FU National Institute of Neurologic Disorders and Stroke [K23NS062148,
R01NS086882]; National Institute of Nursing Research [R01NS086882,
R01NR010827]; National Institute on Aging [P60AG08812, P01AG004390];
American Psychological Association Division 40; Rosalind and Arthur
Gilbert Foundation/AFAR New Investigator Award in Alzheimer's Disease;
Medical Research Service VA Merit Review Awards
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
supported by the National Institute of Neurologic Disorders and Stroke
(K23NS062148 and R01NS086882), the National Institute of Nursing
Research (R01NR010827 and R01NS086882), the National Institute on Aging
(P60AG08812 and P01AG004390), American Psychological Association
Division 40, The Rosalind and Arthur Gilbert Foundation/AFAR New
Investigator Award in Alzheimer's Disease, and by Medical Research
Service VA Merit Review Awards to William Milberg and Regina McGlinchey.
NR 73
TC 0
Z9 0
U1 1
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-3175
EI 1938-2731
J9 AM J ALZHEIMERS DIS
JI Am. J. Alzheimers Dis. Other Dement.
PD FEB
PY 2016
VL 31
IS 1
BP 76
EP 86
DI 10.1177/1533317515587084
PG 11
WC Geriatrics & Gerontology; Clinical Neurology
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA DB0CG
UT WOS:000368175600009
PM 26006791
ER
PT J
AU Iezzoni, LI
Kurtz, SG
Rao, SR
AF Iezzoni, Lisa I.
Kurtz, Stephen G.
Rao, Sowmya R.
TI Trends in Pap Testing Over Time for Women With and Without Chronic
Disability
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID PREVENTIVE SERVICES; PHYSICAL-DISABILITIES; MOBILITY IMPAIRMENTS;
HEALTH-CARE; BREAST; RECEIPT; ACCESS; LEVEL
AB Introduction: Data from 20 years ago-shortly after passage of the Americans with Disabilities Act -showed that women with significant mobility disability had 40% lower Pap test rates than other women.
Methods: To examine whether disability disparities in Pap test rates have diminished over time, this study analyzed National Health Interview Survey responses from selected years between 1998 and 2010 from women aged 21-65 years without histories of cervical cancer or hysterectomy. Seven chronic disability types were identified using self-reported functional impairments or participation limitations. Self-reported Pap testing within the previous 3 years was studied. Bivariable analyses and multivariable logistic regression analyses controlling for sociodemographic variables were conducted in 2014.
Results: Rates of all chronic disability types increased over time. Pap test rates remained relatively constant over time for all women, holding around 84%-87%. Bivariable analyses found statistically significantly lower rates of Pap testing for women with disability compared with nondisabled women. Multivariable analyses failed to find consistent evidence of lower Pap test rates among women across disability types compared with nondisabled women. In 2010, the AOR for reporting Pap testing for women noting the most severe movement difficulty compared with nondisabled women was 0.35 (95% CI = 0.15, 0.79). However, the AOR for this disability type varied over time.
Conclusions: Little has changed over time in Pap test rates for all women. Women with certain disabilities continue to experience disparities compared with nondisabled women in receipt of this important screening test. (C) 2016 American Journal of Preventive Medicine
C1 [Iezzoni, Lisa I.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Iezzoni, Lisa I.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Kurtz, Stephen G.; Rao, Sowmya R.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Rao, Sowmya R.] Bedford Vet Affairs Med Ctr, CHOIR, Bedford, MA USA.
RP Iezzoni, LI (reprint author), Massachusetts Gen Hosp, Mongan Inst Hlth Policy, 50 Staniford St,Room 901B, Boston, MA 02114 USA.
EM liezzoni@mgh.harvard.edu
FU National Cancer Institute [5 R01 CA160286-02]
FX This work was funded by the National Cancer Institute, 5 R01
CA160286-02.
NR 32
TC 1
Z9 1
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD FEB
PY 2016
VL 50
IS 2
BP 210
EP 219
DI 10.1016/j.amepre.2015.06.031
PG 10
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA DB1DG
UT WOS:000368247600014
PM 26372417
ER
PT J
AU McGrath, JM
Fisher, V
Krejci-Manwaring, J
AF McGrath, John M.
Fisher, Valerie
Krejci-Manwaring, Jennifer
TI Skin Cancer Warnings and the Need for New Preventive Campaigns A Pilot
Study
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Editorial Material
ID PREVALENCE
C1 [McGrath, John M.] Trinity Univ, Dept Human Commun, San Antonio, TX 78212 USA.
[McGrath, John M.; Krejci-Manwaring, Jennifer] Audie L Murphy Vet Hosp, San Antonio, TX USA.
[Fisher, Valerie; Krejci-Manwaring, Jennifer] Univ Texas Hlth Sci Ctr San Antonio, Div Dermatol & Cutaneous Surg, San Antonio, TX 78229 USA.
RP McGrath, JM (reprint author), Trinity Univ, Dept Human Commun, One Trinity Pl, San Antonio, TX 78212 USA.
EM jmcgrath@trinity.edu
NR 10
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD FEB
PY 2016
VL 50
IS 2
BP E62
EP E63
DI 10.1016/j.amepre.2015.10.009
PG 2
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA DB1DG
UT WOS:000368247600004
PM 26657182
ER
PT J
AU Acosta, DC
Loehrer, A
Chang, DC
AF Acosta, D. C.
Loehrer, A.
Chang, D. C.
TI Nativity Status Negatively Impacts Quality of Breast Cancer Care for
Latinos in the U.S
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Acosta, D. C.; Loehrer, A.; Chang, D. C.] Massachusetts Gen Hosp, Codman Ctr Clin Effectiveness Surg, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA P21
BP S52
EP S52
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000126
ER
PT J
AU Berger, ER
Kinnier, CV
Minami, CA
Winchester, DP
Yang, AD
Bilimoria, K
AF Berger, E. R.
Kinnier, C. V.
Minami, C. A.
Winchester, D. P.
Yang, A. D.
Bilimoria, K.
TI Hospital Level Adjusted Sentinel Lymph Node Positivity Rates in Breast
Cancer
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Berger, E. R.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA.
[Minami, C. A.; Yang, A. D.; Bilimoria, K.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Chicago, IL 60611 USA.
[Kinnier, C. V.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Winchester, D. P.] Northshore Univ HealthSyst, Dept Surg, Evanston, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA P1
BP S47
EP S47
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000108
ER
PT J
AU Chan, CH
Liesenfeld, L
Ferreiro-Neira, I
Cusack, JC
AF Chan, C. H.
Liesenfeld, L.
Ferreiro-Neira, I.
Cusack, J. C.
TI Detecting Peritoneal Surface Malignancies with Cathepsin-Based
Fluorescent Imaging System
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Chan, C. H.; Liesenfeld, L.; Ferreiro-Neira, I.; Cusack, J. C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA P127
BP S88
EP S88
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000231
ER
PT J
AU Cintolo-Gonzalez, JA
Hammond, M
Frederick, D
Lawrence, N
Piris, A
Flaherty, K
Wargo, J
Cooper, Z
Hoang, M
Kwong, L
Boland, G
AF Cintolo-Gonzalez, J. A.
Hammond, M.
Frederick, D.
Lawrence, N.
Piris, A.
Flaherty, K.
Wargo, J.
Cooper, Z.
Hoang, M.
Kwong, L.
Boland, G.
TI Predicting Response to BRAF-Targeted Therapy Using an Immune Signature
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Cintolo-Gonzalez, J. A.; Hammond, M.; Frederick, D.; Lawrence, N.; Flaherty, K.; Hoang, M.; Boland, G.] Massachusetts Gen Hosp, Surg, Boston, MA 02114 USA.
[Piris, A.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Wargo, J.; Cooper, Z.; Kwong, L.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA P239
BP S123
EP S123
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000334
ER
PT J
AU Datta, J
Cintolo-Gonzalez, JA
Ellingsworth, C
Xu, S
Lowenfeld, L
Berk, E
Somasundaram, R
Czerniecki, BJ
AF Datta, J.
Cintolo-Gonzalez, J. A.
Ellingsworth, C.
Xu, S.
Lowenfeld, L.
Berk, E.
Somasundaram, R.
Czerniecki, B. J.
TI A Novel Dendritic Cell Vaccine Targeting Mutated BRAF Overcomes
Vemurafenib Resistance and Synergistically Improves Survival in
BRAF-Mutant Murine Melanoma
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Datta, J.; Xu, S.; Lowenfeld, L.; Berk, E.; Czerniecki, B. J.] Univ Penn, Surg, Philadelphia, PA 19104 USA.
[Ellingsworth, C.; Somasundaram, R.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.
[Cintolo-Gonzalez, J. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA 66
BP S31
EP S31
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000067
ER
PT J
AU Epstein, J
Kozak, G
Fong, Z
Jiang, W
Lavu, H
Ferrone, CR
Lillemoe, K
Yeo, C
Fernandez-del Castillo, C
Winter, J
AF Epstein, J.
Kozak, G.
Fong, Z.
Jiang, W.
Lavu, H.
Ferrone, C. R.
Lillemoe, K.
Yeo, C.
Fernandez-del Castillo, C.
Winter, J.
TI Lymphovascular Invasion: An Underappreciated Prognostic Factor in
Pancreatic Cancer
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Epstein, J.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.
[Kozak, G.; Lavu, H.; Yeo, C.; Winter, J.] Thomas Jefferson Univ Hosp, Dept Surg, Philadelphia, PA 19107 USA.
[Fong, Z.; Ferrone, C. R.; Lillemoe, K.; Fernandez-del Castillo, C.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Jiang, W.] Thomas Jefferson Univ Hosp, Dept Pathol, Philadelphia, PA 19107 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA P385
BP S172
EP S172
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000477
ER
PT J
AU Fong, Z
Mehtsun, W
Lillemoe, K
Warshaw, A
Fernandez-del Castillo, C
Chang, DC
Ferrone, CR
AF Fong, Z.
Mehtsun, W.
Lillemoe, K.
Warshaw, A.
Fernandez-del Castillo, C.
Chang, D. C.
Ferrone, C. R.
TI The Role of Staging Laparoscopy in Patients with Pancreatic
Adenocarcinoma: Withstanding the Test of Time?
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Fong, Z.; Mehtsun, W.; Lillemoe, K.; Warshaw, A.; Fernandez-del Castillo, C.; Chang, D. C.; Ferrone, C. R.] Massachusetts Gen Hosp, Surg, Natick, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA P384
BP S171
EP S172
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000476
ER
PT J
AU Loehrer, A
Chang, DC
Song, Z
Hutter, MM
Mullen, JT
AF Loehrer, A.
Chang, D. C.
Song, Z.
Hutter, M. M.
Mullen, J. T.
TI Impact of Insurance Expansion on Access to Colorectal Cancer Care
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Loehrer, A.; Chang, D. C.; Song, Z.; Hutter, M. M.; Mullen, J. T.] Massachusetts Gen Hosp, Surg, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA 37
BP S20
EP S20
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000038
ER
PT J
AU Mehtsun, W
Fong, Z
Del Castillo, CF
Hemingway, K
Lillemoe, K
Warshaw, A
Chang, DC
Ferrone, CR
AF Mehtsun, W.
Fong, Z.
Del Castillo, C. Fernandez
Hemingway, K.
Lillemoe, K.
Warshaw, A.
Chang, D. C.
Ferrone, C. R.
TI Indeterminate Nodules in Pancreatic Adenocarcinoma: Are CT Scans of the
Chest Necessary?
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Mehtsun, W.; Fong, Z.; Del Castillo, C. Fernandez; Hemingway, K.; Lillemoe, K.; Warshaw, A.; Chang, D. C.; Ferrone, C. R.] Massachusetts Gen Hosp, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA P377
BP S169
EP S169
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000469
ER
PT J
AU Nurudeen, S
Chun, Y
Guo, H
Barry, W
Coopey, SB
Garber, JE
Dominici, LS
AF Nurudeen, S.
Chun, Y.
Guo, H.
Barry, W.
Coopey, S. B.
Garber, J. E.
Dominici, L. S.
TI Patient Experience with Breast Reconstruction Following Bilateral
Mastectomy in BRCA Mutation Carriers
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Dominici, L. S.] Dana Farber Brigham & Womens Canc Ctr, Surg Oncol, Boston, MA USA.
[Nurudeen, S.; Chun, Y.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Guo, H.; Barry, W.; Garber, J. E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Coopey, S. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA P81
BP S72
EP S73
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000185
ER
PT J
AU Plichta, JK
Coopey, SB
Queiroz, PD
Specht, MC
Smith, BL
Gadd, MA
Mazzola, E
Parmigiani, G
Garber, JE
Guidi, AJ
Roche, CA
Hughes, KS
AF Plichta, J. K.
Coopey, S. B.
Queiroz, P. De Moura
Specht, M. C.
Smith, B. L.
Gadd, M. A.
Mazzola, E.
Parmigiani, G.
Garber, J. E.
Guidi, A. J.
Roche, C. A.
Hughes, K. S.
TI The Utility of Screening MRI for Women Diagnosed with Atypical Breast
Lesions
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Plichta, J. K.; Coopey, S. B.; Queiroz, P. De Moura; Specht, M. C.; Smith, B. L.; Gadd, M. A.; Roche, C. A.; Hughes, K. S.] Massachusetts Gen Hosp, Surg, Boston, MA 02114 USA.
[Mazzola, E.; Parmigiani, G.; Garber, J. E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Guidi, A. J.] Newton Wellesley Hosp, Newton, MA USA.
RI Plichta, Jennifer/L-5450-2016
OI Plichta, Jennifer/0000-0002-7411-0558
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA P77
BP S71
EP S71
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000181
ER
PT J
AU Smalley, R
Collura, C
Miller, C
Berger, D
Tanabe, K
Ferrone, CR
AF Smalley, R.
Collura, C.
Miller, C.
Berger, D.
Tanabe, K.
Ferrone, C. R.
TI With Modern Chemotherapy Prognostic Models Underestimate Which Patients
May Benefit from Hepatic Resection for Colorectal Liver Metastases
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Smalley, R.; Miller, C.] Harvard Univ, Sch Med, Boston, MA USA.
[Collura, C.; Berger, D.; Tanabe, K.; Ferrone, C. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA P180
BP S102
EP S102
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000277
ER
PT J
AU Williams, R
Sich, N
Wang, J
Pezzi, C
Clancy, T
Ashley, S
Swanson, R
AF Williams, R.
Sich, N.
Wang, J.
Pezzi, C.
Clancy, T.
Ashley, S.
Swanson, R.
TI Palliative Pancreaticoduodenectomy for Metastatic Pancreatic
Adenocarcinoma is Associated with Excessive Postoperative Mortality
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Williams, R.; Wang, J.; Clancy, T.; Ashley, S.; Swanson, R.] Dana Farber Partners Canc Care, Surg Oncol, Boston, MA USA.
[Sich, N.; Pezzi, C.] Abington Jefferson Hlth, Abington, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA P370
BP S167
EP S167
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000463
ER
PT J
AU Williams, R
Sich, N
Clancy, T
Wang, J
Pezzi, C
Ashley, S
Swanson, R
AF Williams, R.
Sich, N.
Clancy, T.
Wang, J.
Pezzi, C.
Ashley, S.
Swanson, R.
TI Pancreaticoduodenectomy for Metastatic Pancreatic Neuroendocrine Tumor
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Williams, R.; Clancy, T.; Wang, J.; Ashley, S.; Swanson, R.] Dana Farber Partners Canc Care, Surg Oncol, Boston, MA USA.
[Sich, N.; Pezzi, C.] Abington Jefferson Hlth, Abington, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA P367
BP S166
EP S167
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000460
ER
PT J
AU Wong, SM
Freedman, RA
Sagara, Y
Aydogan, F
Barry, WT
Golshan, M
AF Wong, S. M.
Freedman, R. A.
Sagara, Y.
Aydogan, F.
Barry, W. T.
Golshan, M.
TI Contralateral Prophylactic Mastectomy: Becoming the New Norm Despite a
Paucity of Evidence Indicating Survival Benefit?
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology
CY MAR 02-05, 2016
CL Boston, MA
SP Soc Surg Oncol
C1 [Wong, S. M.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Freedman, R. A.; Barry, W. T.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sagara, Y.; Aydogan, F.; Golshan, M.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2016
VL 23
SU 1
MA P9
BP S48
EP S49
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA DB0FW
UT WOS:000368185000114
ER
PT J
AU Holmes, DR
Nishimura, RA
Grover, FL
Brindis, RG
Carroll, JD
Edwards, FH
Peterson, ED
Rumsfeld, JS
Shahian, DM
Thourani, VH
Tuzcu, EM
Vemulapalli, S
Hewitt, K
Michaels, J
Fitzgerald, S
Mack, MJ
AF Holmes, David R., Jr.
Nishimura, Rick A.
Grover, Frederick L.
Brindis, Ralph G.
Carroll, John D.
Edwards, Fred H.
Peterson, Eric D.
Rumsfeld, John S.
Shahian, David M.
Thourani, Vinod H.
Tuzcu, E. Murat
Vemulapalli, Sreekanth
Hewitt, Kathleen
Michaels, Joan
Fitzgerald, Susan
Mack, Michael J.
CA STS ACC TVT Registry
TI Annual Outcomes With Transcatheter Valve Therapy: From the STS/ACC TVT
Registry
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID CITY CARDIOMYOPATHY QUESTIONNAIRE; END-POINT DEFINITIONS; VASCULAR
COMPLICATIONS; UNITED-STATES; HEALTH-STATUS; IMPLANTATION; REPLACEMENT;
SURVEILLANCE; PACEMAKER; INFRASTRUCTURE
AB Background. The Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry has been a joint initiative of the STS and the ACC in concert with multiple stake-holders. The TVT Registry has important information regarding patient selection, delivery of care, science, education, and research in the field of structural valvular heart disease.
Objectives. This report provides an overview on current U.S. TVT practice and trends. The emphasis is on demographics, in-hospital procedural characteristics, and outcomes of patients having transcatheter aortic valve replacement (TAVR) performed at 348 U.S. centers.
Methods. The TVT Registry captured 26,414 TAVR procedures as of December 31, 2014. Temporal trends between 2012 and 2013 versus 2014 were compared.
Results. Comparison of the 2 time periods reveals that TAVR patients remain elderly (mean age 82 years), with multiple comorbidities, reflected by a high mean STS predicted risk of mortality (STS PROM) for surgical valve replacement (8.34%), were highly symptomatic (New York Heart Association functional class III/IV in 82.5%), frail (slow 5-m walk test in 81.6%), and have poor self-reported health status (median baseline Kansas City Cardiomyopathy Questionnaire score of 39.1). Procedure performance is changing, with an increased use of moderate sedation (from 1.6% to 5.1%) and increase in femoral access using percutaneous techniques (66.8% in 2014). Vascular complication rates are decreasing (from 5.6% to 4.2%), whereas site-reported stroke rates remain stable at 2.2%.
Conclusions. The TVT Registry provides important information on characteristics and outcomes of TAVR in contemporary U.S. clinical practice. It can be used to identify trends in practice and opportunities for quality improvement. (C) 2016 by The Society of Thoracic Surgeons and the American College of Cardiology Foundation
C1 [Holmes, David R., Jr.] Mayo Clin, Rochester, MN 55905 USA.
Univ Colorado, Denver, CO 80202 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ Florida, Jacksonville, FL USA.
Duke Univ, Med Ctr, Durham, NC USA.
Denver VA Med Ctr, Denver, CO USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Emory Univ, Atlanta, GA 30322 USA.
Cleveland Clin, Cleveland, OH 44106 USA.
Amer Coll Cardiol, Washington, DC USA.
Baylor Scott & White Hlth, Plano, TX USA.
RP Holmes, DR (reprint author), Mayo Clin, 200 First St Southwest, Rochester, MN 55905 USA.
EM holmes.david@mayo.edu
FU Edwards Lifesciences; Abbott Vascular; Direct Flow; Janssen; Eli Lily;
Boehringer Ingelheim; Bayer; AstraZeneca; Boston Scientific; Philips
Medical Systems
FX A current list of STS/ACC TVT Registry participating hospitals can be
found at
https://www.ncdr.com/TVT/Private/Resources/ParticipantDirectory.aspx. Dr
Grover has served as a consultant to Somalution; and is the vice chair
of the STS/ACC/TVT Registry Steering Committee. Dr Brindis is a senior
medical officer for the National Cardiovascular Data Registry. Dr
Carroll has served as an investigator in research trials sponsored by
Edwards Lifesciences, Abbott Vascular, and Direct Flow. Dr Peterson has
received grants from Janssen and Eli Lily; has received personal fees
from Janssen, Eli Lilly, Boehringer Ingelheim, Bayer, and AstraZeneca;
and has received consulting support from Merck and Sanofi. Dr Rumsfeld
is chief science officer for the National Cardiovascular Data Registry.
Dr Thourani is an advisor for Edwards Lifesciences; and conducts
research for Edwards Lifesciences and Medtronic. Dr Vemulapalli has
received research grant support from Boston Scientific; has received
funding for travels from Abbott Vascular; and received payment for
travel from Philips Medical Systems. Dr Mack is a member of the
Executive Committee of the PARTNER Trial, sponsored by Edwards
Lifesciences. All other authors have reported that they have no
relationships relevant to the contents of this paper to disclose. Raj
Makkar, MD, served as Guest Editor for this paper.
NR 22
TC 6
Z9 6
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD FEB
PY 2016
VL 101
IS 2
BP 789
EP 800
DI 10.1016/j.athoracsur.2015.10.049
PG 12
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA DB0HR
UT WOS:000368189700092
PM 27175453
ER
PT J
AU Banks, WA
Dohi, K
Hansen, K
Thompson, HJ
AF Banks, William A.
Dohi, Kenji
Hansen, Kim
Thompson, Hilaire J.
TI Assessing blood granulocyte colony-stimulating factor as a potential
biomarker of acute traumatic brain injury in mice and humans
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
DE G-CSF; Traumatic brain injury; Biomarker; Neuroinflammation; Blood brain
barrier
ID INTRACEREBROVENTRICULAR INJECTION; SEVERITY SCORE; RATS;
INTERLEUKIN-1-BETA; CYTOKINES; BARRIER; IMMUNE; MODEL; CARE
AB Previous work has found that serum G-CSF was acutely elevated in mice 24 h but not one week after controlled cortical impact (CCI). The purpose of this study was to investigate whether blood G-CSF correlates with the elevated brain cytokines in mice after CCI and also if it correlates with traumatic brain injury (TBI) in humans. Here, we found in mice undergoing CCI, a procedure that induces direct injury to the brain, that serum G-CSF correlated directly or indirectly with several brain cytokines, indicating it is a useful marker for the neuroinflammation of TBI. A pilot study in humans (phase I, n = 19) confirmed that plasma G-CSF is acutely elevated on day I (p < 0.001) of TBI and has returned to baseline by one week. In a second human sample (phase II) (n = 80), we found plasma G-CSF peaks about 12 h after arriving in the emergency department (41.6 +/ 5.4 pg/ml). Aging was weakly associated (p < 0.05) with a less robust elevation in serum G-CSF, but there was no difference with gender. ISS, a measure of total severity of injury, correlated with the degree of elevation in serum G-CSF (r = .419; p < 0.05), but severity of head injury (via AIS) did not. The latter may have been because of the statistically narrow range of head injuries among our cases and the high number of cases diagnosed with closed head injury (a non-codable diagnosis). In conclusion, plasma G-CSF may be a useful biomarker of TBI, correlating with neuroinflammation in the animal model and in the human studies with time since injury and total severity of injury. As such, it may be useful in determining whether TBI has occurred within the last 24 h. Published by Elsevier Inc.
C1 [Banks, William A.; Dohi, Kenji; Hansen, Kim; Thompson, Hilaire J.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Banks, William A.; Dohi, Kenji; Hansen, Kim] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA.
[Dohi, Kenji] Jikei Univ, Sch Med, Dept Emergency Med, Tokyo, Japan.
[Thompson, Hilaire J.] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA.
[Thompson, Hilaire J.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA.
RP Banks, WA (reprint author), VAPSHCS, Rm 1-810A,1660 S Columbian Way, Seattle, WA 98108 USA.
EM wabanks1@uw.edu; kdoppy@jikei.ac.jp; nesnah@u.washington.edu;
hilairet@uw.edu
FU National Institutes of Health, National Center for Research Resources
[KL2RR025015]; National Institute of Neurologic Diseases and Stroke
[R01NS077913]; Department of Veterans Affairs; National Institute on
Aging [R01AG029839, R01AG046619]
FX Supported by grants from the National Institutes of Health, National
Center for Research Resources KL2RR025015 (HT), the National Institute
of Neurologic Diseases and Stroke R01NS077913 (HT), the Department of
Veterans Affairs (WAB), and the National Institute on Aging R01AG029839
(WAB) and R01AG046619 (WAB).
NR 30
TC 1
Z9 1
U1 2
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
EI 1090-2139
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD FEB
PY 2016
VL 52
BP 81
EP 87
DI 10.1016/j.bbi.2015.10.002
PG 7
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA DB2DB
UT WOS:000368317400011
PM 26441136
ER
PT J
AU Ring, D
Jawa, A
Cannada, L
AF Ring, David
Jawa, Andrew
Cannada, Lisa
TI Clinical Faceoff: Are Distal-third Diaphyseal Humerus Fractures Best
Treated Nonoperatively?
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Editorial Material
C1 [Ring, David] Massachusetts Gen Hosp, Dept Orthopaed Surg, Hand & Upper Extrem Serv, Boston, MA 02114 USA.
[Jawa, Andrew] Boston Univ, Dept Orthopaed, Boston, MA 02215 USA.
[Cannada, Lisa] St Louis Univ, Dept Orthopaed Surg, St Louis, MO 63103 USA.
RP Ring, D (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Hand & Upper Extrem Serv, 55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
NR 4
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
EI 1528-1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD FEB
PY 2016
VL 474
IS 2
BP 310
EP 314
DI 10.1007/s11999-015-4636-8
PG 5
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DA7YQ
UT WOS:000368021900007
PM 26584799
ER
PT J
AU Healy, WL
Iorio, R
Clair, AJ
Pellegrini, VD
Della Valle, CJ
Berend, KR
AF Healy, William L.
Iorio, Richard
Clair, Andrew J.
Pellegrini, Vincent D.
Della Valle, Craig J.
Berend, Keith R.
TI Complications of Total Hip Arthroplasty: Standardized List, Definitions,
and Stratification Developed by The Hip Society
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID KNEE ARTHROPLASTY; CLASSIFICATION
AB Reporting of complications after total hip arthroplasty (THA) is not standardized, and it is done inconsistently across various studies on the topic. Advantages of standardizing complications include improved patient safety and outcomes and better reporting in comparative studies.
The purpose of this project was to develop a standardized list of complications and adverse events associated with THA, develop standardized definitions for each complication, and stratify the complications. A further purpose was to validate these standardized THA complications.
The Hip Society THA Complications Workgroup proposed a list of THA complications, definitions for each complication, and a stratification scheme for the complications. The stratification system was developed from a previously validated grading system for complications of hip preservation surgery. The proposed complications, definitions, and stratification were validated with an expert opinion survey of members of The Hip Society, a case study evaluation, and analysis of a large administrative hospital system database with a focus on readmissions.
One hundred five clinical members (100%) of The Hip Society responded to the THA complications survey. Initially, 21 THA complications were proposed. The validation process reduced the 21 proposed complications to 19 THA complications with definitions and stratification that were endorsed by The Hip Society (bleeding, wound complication, thromboembolic disease, neural deficit, vascular injury, dislocation/instability, periprosthetic fracture, abductor muscle disruption, deep periprosthetic joint infection, heterotopic ossification, bearing surface wear, osteolysis, implant loosening, cup-liner dissociation, implant fracture, reoperation, revision, readmission, death).
Acceptance and use of these standardized, stratified, and validated THA complications and adverse events could advance reporting of outcomes of THA and improve assessment of THA by clinical investigators.
Level V, therapeutic study.
C1 [Healy, William L.] Newton Wellesley Hosp, Kaplan Joint Ctr, Newton, MA 02462 USA.
[Healy, William L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Iorio, Richard; Clair, Andrew J.] NYU, Langone Med Ctr, New York, NY USA.
[Pellegrini, Vincent D.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Della Valle, Craig J.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Berend, Keith R.] Joint Implant Surgeons, New Albany, OH USA.
RP Healy, WL (reprint author), Newton Wellesley Hosp, Kaplan Joint Ctr, 2014 Washington St, Newton, MA 02462 USA.
EM whealy@partners.org
OI Iorio, Richard/0000-0001-8083-8687
NR 10
TC 2
Z9 2
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
EI 1528-1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD FEB
PY 2016
VL 474
IS 2
BP 357
EP 364
DI 10.1007/s11999-015-4341-7
PG 8
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DA7YQ
UT WOS:000368021900015
PM 26040966
ER
PT J
AU Huddleston, JI
Tetreault, MW
Yu, M
Bedair, H
Hansen, VJ
Choi, HR
Goodman, SB
Sporer, SM
Della Valle, CJ
AF Huddleston, James I., III
Tetreault, Matthew W.
Yu, Michael
Bedair, Hany
Hansen, Viktor J.
Choi, Ho-Rim
Goodman, Stuart B.
Sporer, Scott M.
Della Valle, Craig J.
TI Is There a Benefit to Modularity in 'Simpler' Femoral Revisions?
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID TOTAL HIP-ARTHROPLASTY; POROUS-COATED STEMS; FOLLOW-UP; KNEE
ARTHROPLASTY; BONE INGROWTH; COMPONENTS
AB Modular revision femoral components allow the surgeon to make more precise intraoperative adjustments in anteversion and sizing, which may afford lower dislocation rates and improved osseointegration, but may not offer distinct advantages when compared with less expensive monoblock revision stems.
We compared modular and monoblock femoral components for revision of Paprosky Type I to IIIA femoral defects to determine (1) survivorship of the stems; and (2) complications denoted as intraoperative fracture, dislocation, or failure of osseointegration.
Between 2004 and 2010, participating surgeons at three centers revised 416 total hip arthroplasties (THAs) with Paprosky Type I to IIIA femoral defects. Of those with minimum 2-year followup (343 THAs, mean followup 51 +/- 13 months), 150 (44%) were treated with modular stems and 193 (56%) were treated with monoblock, cylindrical, fully porous-coated stems. During this time, modular stems were generally chosen when there was remodeling of the proximal femur into retroversion and/or larger canal diameters (usually > 18 mm). A total of 27 patients died (6%) with stems intact before 2 years, 46 THAs (13%) were lost to followup before 2 years for reasons other than death, and there was no differential loss to followup between the study groups. The modular stems included 101 with a cylindrical distal geometry (67%) and 49 with a tapered geometry (33%). Mean age (64 versus 68 years), percentage of women (53% versus 47%), and body mass index (31 versus 30 kg/m(2)) were not different between the two cohorts, whereas there was trend toward a slightly greater case complexity in the modular group (55% versus 65% Type 3a femoral defects, p = 0.06). Kaplan-Meier survivorship was calculated for the endpoint of aseptic revision. Proportions of complications in each cohort (dislocation, intraoperative fracture, and failure of osseointegration) were compared.
Femoral component rerevision for any reason (including infection) was greater (OR, 2.01; 95% CI, 1.63-2.57; p = 0.03) in the monoblock group (27 of 193 [14%]) compared with the modular cohort (10 of 150 [7%]). Femoral component survival free from aseptic rerevision was greater in the modular group with 91% survival (95% CI, 89%-95%) at 9 years compared with 86% survival (95% CI, 83%-88%) for the monoblock group in the same timeframe. There was no difference in the proportion of mechanically relevant aseptic complications (30 of 193 [16%] in the monoblock group versus 34 of 150 [23%] in the modular group, p = 0.10; OR, 1.47; 95% CI, 0.86-2.53). There were more intraoperative fractures in the modular group (17 of 150 [11%] versus nine of 193 [5%]; OR, 2.2; 95% CI, 1.68-2.73; p = 0.02). There were no differences in the proportions of dislocation (13 of 193 [7%] monoblock versus 14 of 150 [9%] modular; OR, 0.96; 95% CI, 0.67-1.16; p = 0.48) or failure of osseointegration (eight of 193 [4%] monoblock versus three of 150 [2%] modular; OR, 1.92; 95% CI, 0.88-2.84; p = 0.19) between the two groups with the number of hips available for study.
Although rerevisions were less common in patients treated with modular stems, aseptic complications such as intraoperative fractures were more common in that group, and the sample was too small to evaluate corrosion-related or fatigue concerns associated with modularity. We cannot therefore conclude from this that one design is superior to the other. Larger studies and pooled analyses will need to be performed to answer this question, but we believe modularity should be avoided in more straightforward cases if possible.
Level III, therapeutic study.
C1 [Huddleston, James I., III; Yu, Michael; Goodman, Stuart B.] Stanford Univ, Sch Med, Dept Orthopaed Surg, Stanford, CA 94305 USA.
[Tetreault, Matthew W.; Sporer, Scott M.; Della Valle, Craig J.] Rush Univ, Med Ctr, Dept Orthopaed Surg, Chicago, IL 60612 USA.
[Bedair, Hany; Hansen, Viktor J.; Choi, Ho-Rim] Massachusetts Gen Hosp, Dept Orthopaed Surg, Harris Orthoped Lab, Boston, MA 02114 USA.
[Huddleston, James I., III] Stanford Med Outpatient Ctr, Dept Orthopaed Surg, Redwood City, CA 94063 USA.
RP Huddleston, JI (reprint author), Stanford Med Outpatient Ctr, Dept Orthopaed Surg, 450 Broadway St,MC 6342, Redwood City, CA 94063 USA.
EM jhuddleston@stanford.edu
OI Tetreault, Matthew/0000-0003-3584-9285
NR 20
TC 2
Z9 2
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
EI 1528-1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD FEB
PY 2016
VL 474
IS 2
BP 415
EP 420
DI 10.1007/s11999-015-4474-8
PG 6
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DA7YQ
UT WOS:000368021900025
PM 26245164
ER
PT J
AU Menendez, ME
Ring, D
AF Menendez, Mariano E.
Ring, David
TI Emergency Department Visits After Hand Surgery Are Common and Usually
Related to Pain or Wound Issues
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID ACUTE-CARE; ADMINISTRATIVE DATA; ORTHOPEDIC-SURGERY; COMORBIDITY INDEX;
DISCHARGE; READMISSION; ICD-9-CM
AB As payment models shift toward a focus on value and reimbursement becomes increasingly tied to quality and patient experience, minimizing unexpected acute health needs has become a priority for both policymakers and clinical leaders. Despite recent emphasis on emergency department (ED) visits as a quality measure in surgery, little is known about the role of the ED in the early postoperative period after hand surgery.
The purpose of this study was to determine the rates, reasons, and factors associated with ED visits within 30 days of elective outpatient hand surgery.
Using our institutional database for 2009 through 2013, we assessed ED visit rates for 2332 patients undergoing carpal tunnel or trigger finger release. Medical records were manually reviewed to ascertain the primary reason for the ED visit. Multivariable logistic regression modeling was used to identify factors independently associated with ED use.
A total of 67 patients (3%) experienced at least one ED visit within 30 days of hand surgery (carpal tunnel: 3%; trigger finger: 3%). Most visits (66%) occurred within the first 2 weeks of surgery, and 31% led to hospitalization. The most common reasons for ED visits were pain (18%) and wound issues (16%). Unmarried and medically infirm patients were more likely to visit the ED.
ED visits after hand surgery are common, often related to the procedure, and potentially responsive to quality improvement initiatives. Targeted efforts to educate patients about pain management, wound care, and the expected course of recovery before surgery, together with close postoperative contact (eg, routine phone calls, facsimile correspondence by email, or secure messaging) may limit visits to the ED.
Level IV, prognostic study.
C1 [Menendez, Mariano E.; Ring, David] Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand & Upper Extrem Serv, Dept Orthopaed Surg, Boston, MA 02114 USA.
RP Menendez, ME (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand & Upper Extrem Serv, Dept Orthopaed Surg, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM marianofurrer@gmail.com
NR 20
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
EI 1528-1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD FEB
PY 2016
VL 474
IS 2
BP 551
EP 556
DI 10.1007/s11999-015-4489-1
PG 6
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DA7YQ
UT WOS:000368021900046
PM 26245167
ER
PT J
AU Claessen, FMAP
Braun, Y
van Leeuwen, WF
Dyer, GS
van den Bekerom, MPJ
Ring, D
AF Claessen, Femke M. A. P.
Braun, Yvonne
van Leeuwen, Wouter F.
Dyer, George S.
van den Bekerom, Michel P. J.
Ring, David
TI What Factors are Associated With a Surgical Site Infection After
Operative Treatment of an Elbow Fracture?
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID PERIPROSTHETIC JOINT INFECTION; PROXIMAL HUMERAL FRACTURES;
RISK-FACTORS; SMOKING-CESSATION; ORTHOPEDIC PATIENTS; TIBIA FRACTURES;
SHAFT FRACTURES; COMPLICATIONS; SURGERY; PREVENTION
AB Surgical site infections are one of the more common major complications of elbow fracture surgery and can contribute to other adverse outcomes, prolonged hospital stays, and increased healthcare costs.
We asked: (1) What are the factors associated with a surgical site infection after elbow fracture surgery? (2) When taking the subset of closed elbow fractures only, what are the factors associated with a surgical site infection? (3) What are the common organisms isolated from an elbow infection after open treatment?
One thousand three hundred twenty adult patients underwent surgery for an elbow fracture between January 2002 and July 2014 and were included in our study. Forty-eight of 1320 patients (4%) had a surgical site infection develop. Thirty-four of 1113 patients with a closed fracture (3%) had a surgical site infection develop.
For all elbow fractures, use of plate and screw fixation (adjusted odds ratio [OR]= 2.2; 95% CI, 1.0-4.5; p = 0.041) and use of external fixation before surgery (adjusted OR = 4.7; 95% CI, 1.1-21; p = 0.035) were associated with higher infection rates. When subset analysis was performed for closed fractures, only smoking (adjusted OR = 2.2; 95% CI, 1.1-4.5; p = 0.023) was associated with higher infection rates. Staphylococcus aureus was the most common bacteria cultured (59%).
The only modifiable risk factor for a surgical site infection after open reduction and internal fixation was cigarette smoking. Plate fixation and temporary external fixation are likely surrogates for more complex injuries, therefore no recommendations should be inferred from this association. Surgeons should counsel patients who smoke.
Level IV, prognostic study.
C1 [Claessen, Femke M. A. P.; Braun, Yvonne; van Leeuwen, Wouter F.; Ring, David] Massachusetts Gen Hosp, Hand Surg, Boston, MA 02114 USA.
[Dyer, George S.] Brigham Womens Hosp, Upper Extrem Div, Dept Orthopaed Surg, Boston, MA USA.
[van den Bekerom, Michel P. J.] Onze Lieve Vrouw Hosp, Shoulder & Elbow Unit, Amsterdam, Netherlands.
[Ring, David] Harvard Univ, Sch Med, Orthopaed Surg, Boston, MA 02115 USA.
[Ring, David] Massachusetts Gen Hosp, Orthopaed Surg, Yawkey Ctr, Boston, MA 02114 USA.
RP Ring, D (reprint author), Massachusetts Gen Hosp, Orthopaed Surg, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@mgh.harvard.edu
FU Skeletal Dynamics (Miami, FL, USA); Biomet (Warsaw, IN, USA); Acumed
(Hillsboro, OR, USA)
FX One of the authors certifies that he (DR), or a member of his or her
immediate family, has or may receive payments or benefits, during the
study period, an amount of USD 10,000-USD 100,000 from Skeletal Dynamics
(Miami, FL, USA); an amount of less than USD 10,000 from Biomet (Warsaw,
IN, USA); and an amount of less than USD 10,000 from Acumed (Hillsboro,
OR, USA) outside the submitted work.
NR 35
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
EI 1528-1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD FEB
PY 2016
VL 474
IS 2
BP 562
EP 570
DI 10.1007/s11999-015-4523-3
PG 9
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA DA7YQ
UT WOS:000368021900048
PM 26304043
ER
PT J
AU Garvey, KC
Telo, GH
Needleman, JS
Forbes, P
Finkelstein, JA
Laffel, LM
AF Garvey, Katharine C.
Telo, Gabriela H.
Needleman, Joseph S.
Forbes, Peter
Finkelstein, Jonathan A.
Laffel, Lori M.
TI Health Care Transition in Young Adults With Type 1 Diabetes:
Perspectives of Adult Endocrinologists in the US
SO DIABETES CARE
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; EMERGING ADULTS; ADOLESCENTS; YOUTH;
SERVICES; MELLITUS; GASTROENTEROLOGISTS; PREVALENCE; BARRIERS; SYSTEMS
AB Objective Young adults with type 1 diabetes transitioning from pediatric to adult care are at risk for adverse outcomes. Our objective was to describe experiences, resources, and barriers reported by a national sample of adult endocrinologists receiving and caring for young adults with type 1 diabetes.
RESEARCH DESIGN AND METHODS We fielded an electronic survey to adult endocrinologists with a valid e-mail address identified through the American Medical Association Physician Masterfile.
RESULTS We received responses from 536 of 4,214 endocrinologists (response rate 13%); 418 surveys met the eligibility criteria. Respondents (57% male, 79% Caucasian) represented 47 states; 64% had been practicing > 10 years and 42% worked at an academic center. Only 36% of respondents reported often/always reviewing pediatric records and 11% reported receiving summaries for transitioning young adults with type 1 diabetes, although > 70% felt that these activities were important for patient care. While most respondents reported easy access to diabetes educators (94%) and dietitians (95%), fewer (42%) reported access to mental health professionals, especially in nonacademic settings. Controlling for practice setting and experience, endocrinologists without easy access to mental health professionals were more likely to report barriers to diabetes management for young adults with depression (odds ratio [OR] 5.3; 95% CI 3.4, 8.2), substance abuse (OR 3.5; 95% CI 2.2, 5.6), and eating disorders (OR 2.5; 95% CI 1.6, 3.8).
CONCLUSIONS Our findings underscore the need for enhanced information transfer between pediatric and adult providers and increased mental health referral access for young adults with diabetes post-transition.
C1 [Garvey, Katharine C.; Laffel, Lori M.] Boston Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA.
[Telo, Gabriela H.; Needleman, Joseph S.; Laffel, Lori M.] Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Boston, MA 02215 USA.
[Forbes, Peter] Boston Childrens Hosp, Clin Res Program, Boston, MA USA.
[Finkelstein, Jonathan A.] Boston Childrens Hosp, Div Gen Pediat, Boston, MA USA.
[Finkelstein, Jonathan A.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA.
RP Garvey, KC (reprint author), Boston Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA.
EM katharine.garvey@childrens.harvard.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
[K12DK094721, K23DK102655, P30DK036836]; National Institute of Child
Health and Human Development [K24HD060786]; William Randolph Hearst
Foundation; Harvard Catalyst \ The Harvard Clinical and Translational
Science Center (National Center for Research Resources and the National
Center for Advancing Translational Sciences, National Institutes of
Health) [UL1 TR001102]; Harvard University and its affiliated academic
health care centers
FX This work was supported by the National Institute of Diabetes and
Digestive and Kidney Diseases (K12DK094721, K23DK102655, and
P30DK036836), the National Institute of Child Health and Human
Development (K24HD060786), and the William Randolph Hearst Foundation.
This work was conducted with support from Harvard Catalyst vertical bar
The Harvard Clinical and Translational Science Center (National Center
for Research Resources and the National Center for Advancing
Translational Sciences, National Institutes of Health Award UL1
TR001102) and financial contributions from Harvard University and its
affiliated academic health care centers.
NR 41
TC 2
Z9 2
U1 5
U2 13
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD FEB
PY 2016
VL 39
IS 2
BP 190
EP 197
DI 10.2337/dc15-1775
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DB4XF
UT WOS:000368516200010
PM 26681724
ER
PT J
AU Munshi, MN
Florez, H
Huang, ES
Kalyani, RR
Mupanomunda, M
Pandya, N
Swift, CS
Taveira, TH
Haas, LB
AF Munshi, Medha N.
Florez, Hermes
Huang, Elbert S.
Kalyani, Rita R.
Mupanomunda, Maria
Pandya, Naushira
Swift, Carrie S.
Taveira, Tracey H.
Haas, Linda B.
TI Management of Diabetes in Longterm Care and Skilled Nursing Facilities:
A Position Statement of the American Diabetes Association
SO DIABETES CARE
LA English
DT Article
ID HOME RESIDENTS; OLDER PATIENTS; GLYCEMIC CONTROL; PALLIATIVE CARE;
HYPOGLYCEMIA; MELLITUS; PREVALENCE; PHYSICIANS; RISK; TRANSITIONS
AB Diabetes is more common in older adults, has a high prevalence in long-term care (LTC) facilities, and is associated with significant disease burden and higher cost. The heterogeneity of this population with regard to comorbidities and overall health status is critical to establishing personalized goals and treatments for diabetes. The risk of hypoglycemia is the most important factor in determining glycemic goals due to the catastrophic consequences in this population. Simplified treatment regimens are preferred, and the sole use of sliding scale insulin (SSI) should be avoided. This position statement provides a classification system for older adults in LTC settings, describes how diabetes goals and management should be tailored based on comorbidities, delineates key issues to consider when using glucose-lowering agents in this population, and provides recommendations on how to replace SSI in LTC facilities. As these patients transition from one setting to another, or from one provider to another, their risk for adverse events increases. Strategies are presented to reduce these risks and ensure safe transitions. This article addresses diabetes management at end of life and in those receiving palliative and hospice care. The integration of diabetes management into LTC facilities is important and requires an interprofessional team approach. To facilitate this approach, acceptance by administrative personnel is needed, as are protocols and possibly system changes. It is important for clinicians to understand the characteristics, challenges, and barriers related to the older population living in LTC facilities as well as the proper functioning of the facilities themselves. Once these challenges are identified, individualized approaches can be designed to improve diabetes management while lowering the risk of hypoglycemia and ultimately improving quality of life.
C1 [Munshi, Medha N.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
[Munshi, Medha N.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
[Florez, Hermes] Miami Vet Affairs Healthcare Syst, Ctr Geriatr Res Educ & Clin, Miami, FL USA.
[Florez, Hermes] Univ Miami, Miami, FL USA.
[Huang, Elbert S.] Univ Chicago, Gen Internal Med Sect, Chicago, IL 60637 USA.
[Kalyani, Rita R.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Mupanomunda, Maria] Amer Diabet Assoc, Alexandria, VA USA.
[Pandya, Naushira] Nova SE Univ, Coll Osteopath Med, Dept Geriatr, Ft Lauderdale, FL 33314 USA.
[Swift, Carrie S.] Kadlec Reg Med Ctr, Richland, WA USA.
[Taveira, Tracey H.] Univ Rhode Isl, Coll Pharm, Providence, RI 02908 USA.
RP Munshi, MN (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
EM mmunshi@bidmc.harvard.edu
FU Midcareer Investigator Award in Patient-Oriented Research [K24
DK105340]; Chicago Center for Diabetes Translation Research [P30
DK092949]; National Institute of Diabetes and Digestive and Kidney
Diseases [K23-DK093583]; Health Resources and Services Administration
(HRSA) of the U.S. Department of Health and Human Services (HHS)
[UB4HP19211]; [R01 HS018542]
FX E.S.H. is supported in part through the following grants: Midcareer
Investigator Award in Patient-Oriented Research (K24 DK105340), the
Chicago Center for Diabetes Translation Research (P30 DK092949), and a
project grant (R01 HS018542). R.R.K. is supported in part by a grant
fromthe National Institute of Diabetes and Digestive and Kidney Diseases
(K23-DK093583). N.P. is supported by the Health Resources and Services
Administration (HRSA) of the U.S. Department of Health and Human
Services (HHS) under grant number UB4HP19211 "Geriatric Education
Centers."
NR 57
TC 9
Z9 9
U1 1
U2 6
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD FEB
PY 2016
VL 39
IS 2
BP 308
EP 318
DI 10.2337/dc15-2512
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DB4XF
UT WOS:000368516200025
PM 26798150
ER
PT J
AU Ganda, OP
AF Ganda, Om P.
TI Fasting Until Noon Triggers Increased Postprandial Hyperglycemia and
Impaired Insulin Response After Lunch and Dinner in Individuals With
Type 2 Diabetes: A Randomized Clinical Trial. Diabetes Care
2015;38:1820-1826
SO DIABETES CARE
LA English
DT Editorial Material
ID GLUCOSE
C1 [Ganda, Om P.] Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Ganda, OP (reprint author), Joslin Diabet Ctr, Boston, MA 02215 USA.
EM om.ganda@joslin.harvard.edu
NR 7
TC 0
Z9 0
U1 3
U2 4
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD FEB
PY 2016
VL 39
IS 2
BP E28
EP E28
DI 10.2337/dc15-2362
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DB4XF
UT WOS:000368516200007
PM 26798157
ER
PT J
AU Takx, RAP
MacNabb, MH
Emami, H
Abdelbaky, A
Singh, P
Lavender, ZR
di Carli, M
Taqueti, V
Foster, C
Mann, J
Comley, RA
Weber, CIK
Tawakol, A
AF Takx, Richard A. P.
MacNabb, Megan H.
Emami, Hamed
Abdelbaky, Amr
Singh, Parmanand
Lavender, Zachary R.
di Carli, Marcelo
Taqueti, Viviany
Foster, Courtney
Mann, Jessica
Comley, Robert A.
Weber, Chek Ing Kiu
Tawakol, Ahmed
TI Increased arterial inflammation in individuals with stage 3 chronic
kidney disease
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Article
DE Atherosclerosis; Chronic kidney disease; FDGPET/CT; Inflammation
ID POSITRON-EMISSION-TOMOGRAPHY; ATHEROSCLEROTIC PLAQUE INFLAMMATION;
RENAL-DISEASE; VASCULAR CALCIFICATION; CARDIOVASCULAR EVENTS;
FLUORODEOXYGLUCOSE; THERAPY; RISK; PET; QUANTIFICATION
AB Purpose While it is well known that patients with chronic kidney disease (CKD) are at increased risk for the development and progression of atherosclerosis, it is not known whether arterial inflammation is increased in mild CKD. The aim of this study was to compare arterial inflammation using F-18-FDG PET/CT in patients with CKD and in matched controls.
Methods This restrospective study included 128 patients undergoing FDG PET/CT imaging for clinical indications, comprising 64 patients with stage 3 CKD and 64 control patients matched by age, gender, and cancer history. CKD was defined according to guidelines using a calculated glomerular filtration rate (eGFR). Arterial inflammation was measured in the ascending aorta as FDG uptake on PET. Background FDG uptake (venous, subcutaneous fat and muscle) were recorded. Coronary artery calcification (CAC) was assessed using the CT images. The impact of CKD on arterial inflammation and CAC was then assessed.
Results Arterial inflammation was higher in patients with CKD than in matched controls (standardized uptake value, SUV: 2.41 +/- 0.49 vs. 2.16 +/- 0.43; p=0.002). Arterial SUV correlated inversely with eGFR (r=-0.299, p=0.001). Venous SUV was also significantly elevated in patients with CKD, while subcutaneous fat and muscle tissue SUVs did not differ between groups. Moreover, arterial SUV remained significantly elevated in patients with CKD compared to controls after correcting for muscle and fat background, and also remained significant after adjusting for clinical risk factors. Further, CKD was associated with arterial inflammation (SUV) independent of the presence of subclinical atherosclerosis (CAC).
Conclusion Moderate CKD is associated with increased arterial inflammation beyond that of controls. Further, the increased arterial inflammation is independent of presence of subclinical atherosclerosis. Current risk stratification tools may underestimate the presence of atherosclerosis in patients with CKD and thereby the risk of cardiovascular events.
C1 [Takx, Richard A. P.; MacNabb, Megan H.; Emami, Hamed; Abdelbaky, Amr; Singh, Parmanand; Lavender, Zachary R.; Tawakol, Ahmed] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA.
[Takx, Richard A. P.; MacNabb, Megan H.; Emami, Hamed; Abdelbaky, Amr; Singh, Parmanand; Lavender, Zachary R.; di Carli, Marcelo; Taqueti, Viviany; Foster, Courtney; Tawakol, Ahmed] Harvard Univ, Sch Med, Boston, MA USA.
[Tawakol, Ahmed] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Takx, Richard A. P.] Univ Med Ctr Utrecht, Dept Radiol, Utrecht, Netherlands.
[di Carli, Marcelo; Taqueti, Viviany; Foster, Courtney] Brigham & Womens Hosp, Dept Med, Div Radiol, Boston, MA 02115 USA.
[Mann, Jessica; Comley, Robert A.; Weber, Chek Ing Kiu] F Hoffmann La Roche Ltd, Basel, Switzerland.
[Tawakol, Ahmed] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Singh, Parmanand] New York Presbyterian Hosp, Div Cardiol, Weill Cornell Med Coll, New York, NY USA.
RP Tawakol, A (reprint author), Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA.
EM atawakol@partners.org
FU F. Hoffmann-La Roche Ltd., Switzerland
FX F. Hoffmann-La Roche Ltd., Switzerland
NR 29
TC 0
Z9 0
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619-7070
EI 1619-7089
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD FEB
PY 2016
VL 43
IS 2
BP 333
EP 339
DI 10.1007/s00259-015-3203-6
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DA6MF
UT WOS:000367918200017
ER
PT J
AU Digumarthy, SR
Kovacina, B
Otrakji, A
Lanuti, M
Shepard, JAO
Sharma, A
AF Digumarthy, Subba R.
Kovacina, Bojan
Otrakji, Alexi
Lanuti, Michael
Shepard, Jo-Anne O.
Sharma, Amita
TI Percutaneous CT guided lung biopsy in patients with pulmonary
hypertension: Assessment of complications
SO EUROPEAN JOURNAL OF RADIOLOGY
LA English
DT Article
DE CT; Biopsy; Pulmonary hypertension; Chest; Lung nodules
ID TRANSTHORACIC NEEDLE-BIOPSY; OF-THE-LITERATURE;
DOPPLER-ECHOCARDIOGRAPHY; VASCULAR-RESISTANCE; SYSTOLIC PRESSURE;
ASPIRATION BIOPSY; PNEUMOTHORAX RATE; NODULES; GUIDELINES; HEMORRHAGE
AB Purpose: To assess the complications of CT-guided percutaneous transthoracic needle aspiration and/or core biopsy (PTNAB) of lung nodules in patients with pulmonary arterial hypertension (PHTN).
Method and materials: We analyzed PTNAB of 74 lung lesions (mean size: 3.6+/-2.1 cm) in 74 patients (M: F 38:36; age 68+/-15 years) with documented PHTN on cardiac ultrasound. 39 patients with lung lesions (M: F 24:15; age 65+/-14) who underwent PTNAB in the same period with right ventricle systolic pressure (RVSP) <35 mmHg were selected as controls. Pulmonary arterial pressures were estimated on cardiac ultrasounds by using the tricuspid regurgitation jet method. Two thoracic radiologists reviewed the medical records and PTNAB images on a PACS station and documented nodule size, location, distance traversed in lung, technical success and complications.
Results: Fine needle aspirates were obtained in all and core biopsy in 23% (17174) of the nodules. 61% (45174) of the nodules were in the middle and 39% (29174) were in the outer third of lung. PHTN was mild, moderate and severe in 84% (62174), 13% (10174) and 3% (2174) of the patients. Biopsy was complicated by hemorrhage in 26% (19174), moderate hemoptysis in 1.3% (1174), pneumothorax in 17% (12174), chest tube in 1.3% (1174) and hemothorax in 1.3% (1174) of the patients. The complications rate in control group was similar, hemorrhage in 33% (19139) (p= 0.6), moderate hemoptysis in 5% (2139) (p= 0.3), pneumothorax in 28% (11139)(p= 0.2), chest tube in (0139)(p= 0.3), and hemothorax in 3% (1139) of the patients (p = 0.7).
Conclusion: Percutaneous needle biopsy of lung lesions in patients with mild to moderate PHTN can be performed without significant increase in complications. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Digumarthy, Subba R.; Otrakji, Alexi; Shepard, Jo-Anne O.; Sharma, Amita] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Thorac Imaging,Dept Radiol, Boston, MA 02114 USA.
[Lanuti, Michael] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA.
[Kovacina, Bojan] McGill Univ, Montreal Gen Hosp, Dept Radiol, Montreal, PQ H3G 1A4, Canada.
RP Digumarthy, SR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Thorac Imaging,Dept Radiol, 55 Fruit St,Founders 213, Boston, MA 02114 USA.
EM sdigumarthy@mgh.harvard.edu
NR 29
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0720-048X
EI 1872-7727
J9 EUR J RADIOL
JI Eur. J. Radiol.
PD FEB
PY 2016
VL 85
IS 2
BP 466
EP 471
DI 10.1016/j.ejrad.2015.12.007
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DB1NW
UT WOS:000368276000018
PM 26781153
ER
PT J
AU Pfarr, N
Sinn, HP
Klauschen, F
Flechtenmacher, C
Bockmayr, M
Ridinger, K
von Winterfeld, M
Warth, A
Lorenz, K
Budczies, J
Penzel, R
Lennerz, JK
Endris, V
Weichert, W
Stenzinger, A
AF Pfarr, Nicole
Sinn, Hans-Peter
Klauschen, Frederick
Flechtenmacher, Christa
Bockmayr, Michael
Ridinger, Kathrin
von Winterfeld, Moritz
Warth, Arne
Lorenz, Katja
Budczies, Jan
Penzel, Roland
Lennerz, Jochen K.
Endris, Volker
Weichert, Wilko
Stenzinger, Albrecht
TI Mutations in Genes Encoding PI3K-AKT and MAPK Signaling Define
Anogenital Papillary Hidradenoma
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID MAMMARY-LIKE GLANDS; HUMAN-PAPILLOMAVIRUS; VULVA; PAPILLIFERUM; TUMORS;
DISEASE; ADENOCARCINOMA; CARCINOMA; BIOLOGY; LESIONS
AB Papillary hidradenoma (a.k.a. hidradenoma papilliferum) is a benign tumor of the anogenital region that almost exclusively arises in middle-aged Caucasian women. These tumors may recur and rare cases of malignant development have been reported. The genetic basis of papillary hidradenoma is currently unknown. Hence, we employed targeted high-coverage next generation sequencing interrogating 50 cancer-related genes and conventional Sanger sequencing to investigate the mutational landscape in a cohort of 15 cases. Additionally, we analyzed the HPV status of these tumors. Thirteen cases (87%) harbored mutations in cancer-related genes. Recurrent mutations in PIK3CA and AKT1 were present in 10 of the cases (67%). One PIK3CA mutated case had a concomitant STK11 mutation. Three cases harbored mutually exclusive mutations in BRAF, APC and ERBB4. The remaining two cases showed no mutations. None of the cases harbored DNA of human papilloma virus. Our results also provide evidence that -just as BRAF V600E mutations in hyperplastic polyps and benign nevi- a mutated driver gene does not imply malignant behavior per se but may set the basis for malignant transformation. The latter point may explain why rare cases of papillary hidradenoma have been reported to take a malignant course. Lastly, our genetic data may suggest treatment avenues beyond conventional surgery for some of these tumors. (C) 2015 Wiley Periodicals, Inc.
C1 [Pfarr, Nicole; Weichert, Wilko] TUM, Inst Pathol, D-81675 Munich, Germany.
[Sinn, Hans-Peter; Flechtenmacher, Christa; Ridinger, Kathrin; Warth, Arne; Lorenz, Katja; Penzel, Roland; Endris, Volker; Weichert, Wilko; Stenzinger, Albrecht] Univ Heidelberg Hosp, Inst Pathol, D-69120 Heidelberg, Germany.
[Klauschen, Frederick; Bockmayr, Michael; von Winterfeld, Moritz; Budczies, Jan] Charite, Inst Pathol, D-10117 Berlin, Germany.
[Lennerz, Jochen K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol,CID, Boston, MA 02114 USA.
[Weichert, Wilko; Stenzinger, Albrecht] Natl Ctr Tumor Dis NCT, Heidelberg, Germany.
[Weichert, Wilko] German Canc Consortium DKTK, Heidelberg, Germany.
[Stenzinger, Albrecht] Heidelberg Sch Oncol NCT HSO, Natl Ctr Tumor Dis, Heidelberg, Germany.
RP Stenzinger, A (reprint author), Univ Heidelberg Hosp, Inst Pathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany.
EM albrecht.stenzinger@med.uni-heidelberg.de
FU National Center for Tumor Diseases (Heidelberg, Germany)
FX The authors thank the staff of the tissue bank of the National Center
for Tumor Diseases (Heidelberg, Germany) for their support and help with
tissue handling. Further, they acknowledge excellent technical
assistance of Angelika Bruntgens, Angelika Bonisch, and Waltraud
Schmitz.
NR 33
TC 4
Z9 5
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-2257
EI 1098-2264
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD FEB
PY 2016
VL 55
IS 2
BP 113
EP 119
DI 10.1002/gcc.22315
PG 7
WC Oncology; Genetics & Heredity
SC Oncology; Genetics & Heredity
GA DB1HR
UT WOS:000368259600001
PM 26493284
ER
PT J
AU Lu, C
Winkelman, M
Wong, SS
AF Lu, Catherine
Winkelman, Megan
Wong, Shane Shucheng
TI Tablet-based education to reduce depression-related stigma
SO HEALTH EDUCATION JOURNAL
LA English
DT Article
DE Depression literacy; multimedia application; psychoeducation; stigma
ID MENTAL-ILLNESS; HEALTH LITERACY; SELF-STIGMA; CARE
AB Objectives: This study investigated the efficacy of a tablet-based multimedia education application, the Project Not Alone Depression Module, in improving depression literacy and reducing depression stigma among a community-based mental health clinic population.
Methods: A total of 93 participants completed either a tablet-based multimedia education or a print education module containing the same content on depression. Primary outcomes were changes in depression literacy as measured by a knowledge quiz and stigma as measured by the Depression Stigma Scale administered before and after the education intervention. Secondary outcomes included participant preference, ease of use, and likeliness to discuss topic with a physician.
Results: In comparison to print education, tablet-based multimedia education significantly increased depression-related knowledge and reduced depression stigma (p < .05). Among all participants, a reduction in the personal stigma score was correlated with an increase in knowledge score (p < .05). Participants preferred the tablet-based module to a human health educator (p < .05).
Conclusion: With advantages of scalability, user preference, and efficacy in improving depression literacy and stigma, tablet-based multimedia education has the potential to improve the health outcomes of mental health clinic populations. Although the study findings are limited by small sample size and lack of randomisation, the results are encouraging for future research and development in tablet-based multimedia patient education.
C1 [Lu, Catherine; Winkelman, Megan; Wong, Shane Shucheng] Stanford Univ, Stanford, CA 94305 USA.
[Wong, Shane Shucheng] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Wong, SS (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 55 Parkman St,WACC 812, Boston, MA 02114 USA.
EM swong20@partners.org
FU Dalai Llama Fellows Program
FX This research received funding support from the Dalai Llama Fellows
Program.
NR 17
TC 0
Z9 0
U1 3
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0017-8969
EI 1748-8176
J9 HEALTH EDUC J
JI Health Educ. J.
PD FEB
PY 2016
VL 75
IS 1
BP 84
EP 93
DI 10.1177/0017896914568434
PG 10
WC Education & Educational Research; Public, Environmental & Occupational
Health
SC Education & Educational Research; Public, Environmental & Occupational
Health
GA DB1TF
UT WOS:000368291200008
ER
PT J
AU Cajaiba, MM
Khanna, G
Smith, EA
Gellert, L
Chi, YY
Mullen, EA
Hill, DA
Geller, JI
Dome, JS
Perlman, EJ
AF Cajaiba, Mariana M.
Khanna, Geetika
Smith, Ethan A.
Gellert, Lan
Chi, Yueh-Yun
Mullen, Elizabeth A.
Hill, Dana A.
Geller, James I.
Dome, Jeffrey S.
Perlman, Elizabeth J.
TI Pediatric cystic nephromas: distinctive features and frequent DICER1
mutations
SO HUMAN PATHOLOGY
LA English
DT Article
DE Cystic nephromas; DICER1; Pediatric renal tumors; Renal development;
Renal cystic lesions
ID STROMAL TUMOR; PLEUROPULMONARY BLASTOMA; MULTILOCULAR CYST; KIDNEY
AB Cystic nephromas (CNs) are uncommon benign renal neoplasms that present with a bimodal age distribution, affecting either infants/young children or adult females. Although differences between these age groups have been suggested, large studies of pediatric CN have not been conducted. As a result, the nomenclature and diagnostic criteria for these lesions remain controversial. In addition, the morphological overlap seen between CN and cystic partially differentiated nephroblastoma (CPDN) can result in diagnostic dilemmas. This study reviews the morphologic and radiographic features of 44 pediatric CN prospectively enrolled on a Children's Oncology Group protocol from 2007 to 2013. Although the typical multicystic architecture with thin septa described in adult CN was present in all of our pediatric cases, differences were also identified. We report distinctive features that add to the morphological spectrum of CN in children. Of the 44 cases, 16 had been previously analyzed and reported for DICER1 mutation, and either loss of function or missense mutations or both were identified in 15 of 16. In contrast, we analyzed 10 cases of adult CN, and all were negative for DICER/mutations; similarly, 6 CPDNs previously analyzed and reported were negative for DICER1 mutations. Therefore, the clinical, morphological, and genetic differences between pediatric and adult CN, as well as between CN and CPDN, suggest that these 3 lesions represent distinct entities. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Cajaiba, Mariana M.; Perlman, Elizabeth J.] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pathol & Lab Med, Chicago, IL 60611 USA.
[Cajaiba, Mariana M.; Perlman, Elizabeth J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Khanna, Geetika] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA.
[Smith, Ethan A.] Univ Michigan Hlth Syst, Dept Radiol, Ann Arbor, MI 48109 USA.
[Gellert, Lan] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA.
[Chi, Yueh-Yun] Univ Florida, Dept Biostat, Gainesville, FL 32611 USA.
[Mullen, Elizabeth A.] Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Hill, Dana A.] Childrens Natl Med Ctr, Dept Pathol, Washington, DC 20010 USA.
[Geller, James I.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Pediat Oncol, Cincinnati, OH 45229 USA.
[Dome, Jeffrey S.] Childrens Natl Med Ctr, Div Pediat Oncol, Washington, DC 20010 USA.
RP Cajaiba, MM (reprint author), Ann & Robert H Lurie Childrens Hosp Chicago, 225 East Chicago Ave,Room 08-413, Chicago, IL 60642 USA.
EM mcajaiba@luriechildrens.org
FU National Institutes of Health to the Children's Oncology Group
[U10CA180886, U10CA180899, U10CA098543]
FX This study was supported by grants from the National Institutes of
Health to the Children's Oncology Group (U10CA180886, U10CA180899, and
U10CA098543).
NR 24
TC 1
Z9 1
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD FEB
PY 2016
VL 48
BP 81
EP 87
DI 10.1016/j.humpath.2015.08.022
PG 7
WC Pathology
SC Pathology
GA DB2DT
UT WOS:000368319200012
PM 26772403
ER
PT J
AU Gupta, RK
Xie, BH
Patton, KT
Lisovsky, M
Burks, E
Behrman, SW
Klimstra, D
Deshpande, V
AF Gupta, Rajib K.
Xie, Bill H.
Patton, Kurt T.
Lisovsky, Mikhail
Burks, Eric
Behrman, Stephen W.
Klimstra, David
Deshpande, Vikram
TI Follicular pancreatitis: a distinct form of chronic pancreatitis-an
additional mimic of pancreatic neoplasms
SO HUMAN PATHOLOGY
LA English
DT Article
DE Follicular pancreatitis; Autoimmune pancreatitis; IgG4; Pancreatitis;
Lymphoma
ID LOCALIZED LYMPHOID HYPERPLASIA; AUTOIMMUNE PANCREATITIS; IGG4-RELATED
DISEASE; PSEUDOLYMPHOMA; CANCER
AB Follicular pancreatitis is a recently described variant of chronic pancreatitis characterized clinically by the formation of a discrete pancreatic mass and histologically by the presence of florid lymphoid aggregates with reactive germinal centers. Our aim was to study the clinical and histologic features of follicular pancreatitis, as well as to critically examine potential overlap with autoimmune pancreatitis Immunohistochemistry for Bcl-2, CD21, k and lambda light chains as well as IgG4 and IgG were performed. We found a total of 6 patients (male-female ratio, 2:1; mean age, 57 years) who fulfilled the diagnosis of follicular pancreatitis in our institutions. Four had an incidental diagnosis, while two presented with abdominal pain, fatigue, and elevated liver enzymes. On imaging, 3 patients had a discrete solid mass, whereas 2 cases showed a dilated main pancreatic duct, mimicking an intraductal pancreatic mucinous neoplasm on imaging. One patient had a lesion in the intra-pancreatin portion of the common bile duct. On histopathology, all cases showed numerous lymphoid follicles with Bcl-2-negative germinal centers either in a periductal or in a more diffuse (periductal and intra-parenchymal) fashion, but without attendant storiform fibrosis, obliterative phlebitis, or granulocytic epithelial lesions. IgG4-to-IgG ratio was <40% in 5 cases. A comparison cohort revealed germinal centers in 25% of type 1 autoimmune pancreatitis and 2% of type 2 autoimmune pancreatitis cases, but none were periductal in location. In conclusion, follicular pancreatitis, an under-recognized mimic of pancreatic neoplasms is characterized by intrapancreatic lymphoid follicles with reactive germinal centers. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Gupta, Rajib K.] Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN 38163 USA.
[Xie, Bill H.; Patton, Kurt T.] Trumbull Labs, Pathol Grp Midsouth, Germantown, TN 38138 USA.
[Xie, Bill H.; Patton, Kurt T.] Baptist Mem Hosp, Dept Pathol, Memphis, TN 38120 USA.
[Lisovsky, Mikhail] Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA.
[Lisovsky, Mikhail] Geisel Sch Med Dartmouth, Lebanon, NH USA.
[Burks, Eric] Lahey Hosp, Dept Pathol, Burlington, MA 01805 USA.
[Behrman, Stephen W.] Univ Tennessee, Hlth Sci Ctr, Dept Surg, Div Surg Oncol, Memphis, TN 38163 USA.
[Behrman, Stephen W.] Baptist Mem Hosp, Dept Surg, Memphis, TN 38120 USA.
[Klimstra, David] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA.
[Klimstra, David] Mem Hosp Canc & Allied Dis, New York, NY 10065 USA.
[Deshpande, Vikram] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Deshpande, Vikram] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Deshpande, V (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
EM rajibgupta2011@gmail.com; hbup@yahoo.com; kurt_patton@yahoo.com;
mikhail.lisovslcy@hitchcock.org; eric.burks@lahey.org;
sbehrman@uthsc.edu; klimstrd@mskcc.org
FU NCI NIH HHS [P30 CA008748]
NR 15
TC 2
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD FEB
PY 2016
VL 48
BP 154
EP 162
DI 10.1016/j.humpath.2015.09.017
PG 9
WC Pathology
SC Pathology
GA DB2DT
UT WOS:000368319200022
PM 26563969
ER
PT J
AU Seltman, HJ
Mitchell, S
Sweet, RA
AF Seltman, Howard J.
Mitchell, Shaina
Sweet, Robert A.
TI A Bayesian model of psychosis symptom trajectory in Alzheimer's disease
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Alzheimer's disease; cognitive impairment; neuropsychiatric symptoms
ID LAST 2 DECADES; CARDIOVASCULAR HEALTH; COGNITIVE IMPAIRMENT; DIAGNOSIS
AB ObjectivePsychosis, like other neuropsychiatric symptoms of dementia, has many features that make predictive modeling of its onset difficult. For example, psychosis onset is associated with both the absolute degree of cognitive impairment and the rate of cognitive decline. Moreover, psychotic symptoms, while more likely than not to persist over time within individuals, may remit and recur. To facilitate predictive modeling of psychosis for personalized clinical decision making, including evaluating the role of risk genes in its onset, we have developed a novel Bayesian model of the dual trajectories of cognition and psychosis symptoms.
MethodsCognition was modeled as a four-parameter logistic curve with random effects for all four parameters and possible covariates for the rate and time of fall. Psychosis was modeled as a continuous-time hidden Markov model with a latent never-psychotic class and states for pre-psychotic, actively psychotic and remitted psychosis. Covariates can affect the probability of being in the never-psychotic class. Covariates and the level of cognition can affect the transition rates for the hidden Markov model.
ResultsThe model characteristics were confirmed using simulated data. Results from 434 AD patients show that a decline in cognition is associated with an increased rate of transition to the psychotic state.
ConclusionsThe model allows declining cognition as an input for psychosis prediction, while incorporating the full uncertainty of the interpolated cognition values. The techniques used can be used in future genetic studies of AD and are generalizable to the study of other neuropsychiatric symptoms in dementia. Copyright (c) 2015 John Wiley & Sons, Ltd.
C1 [Seltman, Howard J.] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA.
[Mitchell, Shaina] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA.
[Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA.
[Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA.
RP Seltman, HJ (reprint author), Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA.
EM hseltman@stat.cmu.edu
FU National Institutes of Health [AG 027224]
FX This work was supported in part by the National Institutes of Health
grant AG 027224. The content is solely the responsibility of the authors
and does not necessarily represent the official views of the National
Institute of Mental Health, the National Institutes of Health, the
Department of Veterans Affairs, or the United States Government.
NR 19
TC 1
Z9 1
U1 4
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-6230
EI 1099-1166
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD FEB
PY 2016
VL 31
IS 2
BP 204
EP 210
DI 10.1002/gps.4326
PG 7
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA DA8BU
UT WOS:000368030100013
PM 26216660
ER
PT J
AU Inverso, G
Chuang, SK
Kaban, LB
AF Inverso, Gino
Chuang, Sung-Kiang
Kaban, Leonard B.
TI Oral and Maxillofacial Surgery Foundation Research and Fellowship
Awards: A 26-Year Review at Massachusetts General Hospital and Harvard
School of Dental Medicine
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID CAREER
AB Purpose: The purpose of this study was to review outcomes of the Oral and Maxillofacial Surgery (OMS) Foundation's funding awards to members of the OMS department at Massachusetts General Hospital (MGH) in terms of projects completed, abstracts presented, peer-reviewed publications, and career trajectories of recipients.
Materials and Methods: Datawere collected from MGH and OMS Foundation records and interviews with award recipients. Primary outcome variables included 1) number of awards and award types, 2) funding amount, 3) project completion, 4) number of presented abstracts, 5) conversion from abstracts to publications, 6) number of peer-reviewed publications, 7) career trajectories of awardees, and 8) additional extramural funding.
Results: Eleven Student Research Training Awards provided $135,000 for 39 projects conducted by 37 students. Of these, 34 (87.2%) were completed. There were 30 student abstracts presented, 21 peer-reviewed publications, and a publication conversion rate of 58.8%. Faculty research awards comprised $1,510,970 for 22 research projects by 12 faculty members and two research fellows. Of the 22 funded projects, 21 (95.5%) were completed. There were 110 faculty and research fellow abstracts presented and 113 peer-reviewed publications, for a publication conversion rate of 93.8%. In the student group, 17 of 37 (45.9%) are enrolled in or are applying for OMS residencies. Of the 10 students who have completed OMS training, 3 (30%) are in full-time academic positions. Of the 12 faculty recipients, 9 (75%) remain in OMS academic practice. During this time period, the department received $9.9 million of extramural foundation or National Institutes of Health funding directly or indirectly related to the OMS Foundation grants.
Conclusions: The results of this study indicate that 90.2% of projects funded by the OMS Foundation have been completed. Most projects resulted in abstracts and publications in peer-reviewed journals. These grants encouraged students to pursue OMS careers and aided OMS faculty in developing their research programs. (C) 2016 American Association of Oral and Maxillofacial Surgeons
C1 [Kaban, Leonard B.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
[Inverso, Gino] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA.
RP Kaban, LB (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
EM Kaban.Leonard@mgh.harvard.edu
FU Department of Oral and Maxillofacial Surgery Education and Research
Fund; Harvard Medical School Enrichment Fund
FX This project was supported by the Department of Oral and Maxillofacial
Surgery Education and Research Fund and the Harvard Medical School
Enrichment Fund.
NR 6
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-2391
EI 1531-5053
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD FEB
PY 2016
VL 74
IS 2
BP 234
EP 238
DI 10.1016/j.joms.2015.08.012
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA DB1KG
UT WOS:000368266500005
PM 26343762
ER
PT J
AU McClave, SA
Taylor, BE
Martindale, RG
Warren, MM
Johnson, DR
Braunschweig, C
McCarthy, MS
Davanos, E
Rice, TW
Cresci, GA
Gervasio, JM
Sacks, GS
Roberts, PR
Compher, C
AF McClave, Stephen A.
Taylor, Beth E.
Martindale, Robert G.
Warren, Malissa M.
Johnson, Debbie R.
Braunschweig, Carol
McCarthy, Mary S.
Davanos, Evangelia
Rice, Todd W.
Cresci, Gail A.
Gervasio, Jane M.
Sacks, Gordon S.
Roberts, Pamela R.
Compher, Charlene
CA Soc Critical Care Med
Amer Soc Parenteral Enteral Nutr
TI Guidelines for the Provision and Assessment of Nutrition Support Therapy
in the Adult Critically Ill Patient: Society of Critical Care Medicine
(SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN)
SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
LA English
DT Article
DE nutrition; critical care; intensive care unit; enteral; parenteral;
evidence-based medicine; Grading of Recommendations, Assessment,
Development, and Evaluation criteria; guidelines
ID RANDOMIZED CONTROLLED-TRIAL; SEVERE ACUTE-PANCREATITIS; RESTING
ENERGY-EXPENDITURE; MECHANICALLY VENTILATED PATIENTS; GAMMA-LINOLENIC
ACID; INFLAMMATORY RESPONSE SYNDROME; INTENSIVE INSULIN THERAPY;
PLACEBO-CONTROLLED TRIAL; MILD ACUTE-PANCREATITIS; TRAUMATIC
BRAIN-INJURY
C1 [McClave, Stephen A.] Univ Louisville, Dept Med, Louisville, KY 40292 USA.
[Taylor, Beth E.] Barnes Jewish Hosp, St Louis, MO 63110 USA.
[Martindale, Robert G.] Oregon Hlth & Sci Univ, Div Gen Surg, Portland, OR 97201 USA.
[Warren, Malissa M.] Portland VA Med Ctr, Portland, OR USA.
[Johnson, Debbie R.] Univ Wisconsin Hosp & Clin, UW Hlth, Wound Skin Ost, Madison, WI 53792 USA.
[Braunschweig, Carol] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL USA.
[Braunschweig, Carol] Univ Illinois, Div Epidemiol & Biostat, Chicago, IL USA.
[McCarthy, Mary S.] Madigan Healthcare Syst, Ctr Nursing Sci & Clin Inquiry, Tacoma, WA USA.
[Davanos, Evangelia] Brooklyn Hosp Ctr, Nutr Support, Brooklyn, NY USA.
[Rice, Todd W.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Med, Nashville, TN 37235 USA.
[Cresci, Gail A.] Inst Digest Dis, Gastroenterol & Pathobiol, Cleveland, OH USA.
[Gervasio, Jane M.] Butler Univ, Coll Pharm & Hlth Sci, Indianapolis, IN 46208 USA.
[Sacks, Gordon S.] Auburn Univ, Harrison Sch Pharm, Dept Pharm Practice, Auburn, AL 36849 USA.
[Roberts, Pamela R.] Res John A Moffitt Endowed Chair, Dept Anesthesiol, Div Chief Crit Care Med, Oklahoma City, OK USA.
[Compher, Charlene] Univ Penn, Sch Nursing, Nutr Sci, Philadelphia, PA 19104 USA.
RP Compher, C (reprint author), Univ Penn, Sch Nursing, Nutr Sci, Philadelphia, PA 19104 USA.
EM stephen.mcclave@louisville.edu; compherc@nursing.upenn.edu
FU Metagenics; Fresenius Kabi USA, LLC; March of Dimes Foundation
FX Dr Taylor disclosed serving as an A.S.P.E.N. committee member and
Dietitians in Nutrition Support past chair. Dr McClave disclosed other
relationships with Nestle (consulting), Abbott (speaker), Metagenics
(consulting), Covidien (consultant), and A.S.P.E.N. Dr Martindale
disclosed other relationships with Davol, LifeCell, and Metagenics
(consultant) and received funding from Metagenics (research grant
recipient). Dr Warren disclosed serving as cochair for the Veterans
Health Administration Dietary Supplement Committee and as a chair for
the Dietitians in Nutrition Support Webinar Planning Committee. Dr
Johnson disclosed that she does not have any potential conflicts of
interest. Dr Braunschweig disclosed serving as the A.S.P.E.N. editor for
clinical guidelines. Dr McCarthy disclosed serving as an A.S.P.E.N.
committee member for the Research Committee and the Abstract Review
Committee, an A.S.P.E.N. Nursing Section member, and a SCCM Nursing
Section member. Dr Davanos disclosed other relationships with Baxter
Healthcare (medical science liaison and employee) and NY/LISPEN chapter
(president-elect). Dr Rice disclosed other relationships with Avisa, LLC
(consultant) and GSK (Data and Safety Monitoring Board) and served as an
expert witness. Dr Cresci disclosed other relationships with Metagenics,
Advocare, and Covidien; received funding from Metagenics (research
grant, speaker); and served as a Research Committee member for
A.S.P.E.N. and Dietitians in Nutrition Support (chair of the Symposium
Planning Committee). Dr Gervasio disclosed serving as an A.S.P.E.N.
committee member. Dr Sacks disclosed other relationships with Fresenius
Kabi USA, LLC (research grant recipient) and A.S.P.E.N. (president and
member of Board of Directors, A.S.P.E.N. Rhoads Research
Foundation-Board of Advisors). Dr Roberts disclosed other relationships
as an American Society of Anesthesiologists committee member (critical
care) and as an A.S.P.E.N. committee member (abstract reviews). Dr
Compher received funding from the March of Dimes Foundation (research
grant recipient) and disclosed other relationships with A.S.P.E.N.
(Board of Directors and president-elect).
NR 481
TC 63
Z9 81
U1 19
U2 39
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0148-6071
EI 1941-2444
J9 JPEN-PARENTER ENTER
JI J. Parenter. Enter. Nutr.
PD FEB
PY 2016
VL 40
IS 2
BP 159
EP 211
DI 10.1177/0148607115621863
PG 53
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DB1TS
UT WOS:000368292500002
PM 26773077
ER
PT J
AU Bergamaschi, CC
Santamaria, MP
Berto, LA
Cogo-Muller, K
Motta, RHL
Salum, EA
Nociti, FH
Goodson, JM
Groppo, FC
AF Bergamaschi, C. C.
Santamaria, M. P.
Berto, L. A.
Cogo-Mueller, K.
Motta, R. H. L.
Salum, E. A.
Nociti Junior, F. H.
Goodson, J. M.
Groppo, F. C.
TI Full mouth periodontal debridement with or without adjunctive
metronidazole gel in smoking patients with chronic periodontitis: A
pilot study
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE adjunctive periodontal therapy; metronidazole; periodontitis; smoking
ID PROFESSIONAL PLAQUE REMOVAL; ULTRASONIC DEBRIDEMENT; SYSTEMIC
METRONIDAZOLE; CIGARETTE-SMOKING; AGGRESSIVE PERIODONTITIS; SUBGINGIVAL
MICROFLORA; BRAZILIAN POPULATION; THERAPY; SMOKERS; AMOXICILLIN
AB Background and ObjectiveThe evidence of effectiveness of metronidazole (Mtz) as an adjunct therapy to periodontal procedure in the treatment of patients with chronic periodontitis is not conclusive. The aim of this study was to compare the effect of Mtz (delivered locally as a gel or systemically as a tablet) as an adjunctive therapy with full mouth periodontal debridement (1h of ultrasonic calculus/plaque removal) in smokers with chronic periodontitis.
Material and MethodsThis pilot study involved 30 smokers with at least six teeth with a clinical attachment loss of 5mm and probing pocket depth (PPD) of 5mm. They were randomly assigned into one of three groups (n=10): (i) 3g daily of placebo gel applied topically (using a dental tray with the gel overnight) + periodontal debridement; (ii) 3g daily of a 15% Mtz benzoate gel applied topically (using a dental tray with the gel overnight) + periodontal debridement; and (iii) a daily single dose of 750mg Mtz (Flagyl((R))) + periodontal debridement. Clinical parameters (visible plaque index, gingival bleeding index [GBI], relative attachment level and PPD) and quantitative analysis (by real-time polymerase chain reaction) of Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis and Tannerella forsythia were assessed at baseline and at 1, 3 and 6mo after periodontal debridement.
ResultsThere was no statistically significant difference in the average GBI and visible plaque index values at baseline between the groups (p0.05). There was no significant difference between groups in all parameters evaluated (p0.05). Significant reductions in GBI at 3 and 6mo were observed in all groups (p<0.05). Significant reductions in both PPD and relative attachment level at 1, 3 and 6mo were observed in all groups (p<0.05). Significant reductions in bacterial levels at 7 and 30d were observed in all groups (p<0.05).
ConclusionAdjunctive use of Mtz (gel or tablet) to periodontal debridement had similar clinical and microbiological improvement compared to treatment with placebo + periodontal debridement in smokers with chronic periodontitis up to 6mo post-treatment. Further studies are necessary to confirm the clinical relevance of these findings.
C1 [Bergamaschi, C. C.] Univ Sorocaba, Dept Pharmaceut Sci, BR-18023000 Sorocaba, SP, Brazil.
[Santamaria, M. P.] State Univ Sao Paulo, Coll Dent, Div Periodont, Sao Jose Dos Campos, Brazil.
[Berto, L. A.; Groppo, F. C.] Univ Estadual Campinas, Dent Sch Piracicaba, Dept Pharmacol Anesthesiol & Therapeut, Piracicaba, Brazil.
[Cogo-Mueller, K.] Univ Santo Amaro, Dept Dent, Sao Paulo, Brazil.
[Motta, R. H. L.] Sao Leopoldo Mandic Dent Sch, Dept Pharmacol Anesthesiol & Therapeut, Campinas, SP, Brazil.
[Salum, E. A.; Nociti Junior, F. H.] Univ Estadual Campinas, Dent Sch Piracicaba, Dept Prosthodont & Periodontol, Piracicaba, Brazil.
[Goodson, J. M.] Forsyth Inst, Dept Clin Res, Boston, MA USA.
RP Bergamaschi, CC (reprint author), Univ Sorocaba, Rodovia Raposo Tavares Km 92-5, BR-18023000 Sorocaba, SP, Brazil.
EM cristiane.motta@prof.uniso.br
RI Berto, Luciana/L-1488-2014; santamaria, mauro/P-1263-2014; Cogo-Muller,
Karina /H-2365-2012
OI Cogo-Muller, Karina /0000-0002-9048-8702
FU FAPESP [06/01492-0, 06/0898-9]
FX The authors thank FAPESP for the scholarship and financial support for
this research (FAPESP # 06/01492-0 and 06/0898-9) and Prof. Jorge
Valerio for assistance in manuscript.
NR 48
TC 1
Z9 1
U1 2
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3484
EI 1600-0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD FEB
PY 2016
VL 51
IS 1
BP 50
EP 59
DI 10.1111/jre.12278
PG 10
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA DA6XG
UT WOS:000367948400005
PM 25900347
ER
PT J
AU Janssen, SJ
van Dijke, M
Lozano-Calderon, SA
Ready, JE
Raskin, KA
Ferrone, ML
Hornicek, FJ
Schwab, JH
AF Janssen, Stein J.
van Dijke, Maarten
Lozano-Calderon, Santiago A.
Ready, John E.
Raskin, Kevin A.
Ferrone, Marco L.
Hornicek, Francis J.
Schwab, Joseph H.
TI Complications after surgery for metastatic humeral lesions
SO JOURNAL OF SHOULDER AND ELBOW SURGERY
LA English
DT Article
DE Humerus; operative; surgery metastases; carcinoma; myeloma; lymphoma
ID RENAL-CELL CARCINOMA; OPERATIVE TREATMENT; SURVIVAL; FRACTURES;
PROGNOSTICATION; DISEASE
AB Background: Knowledge of surgical outcome and its predictors helps inform patients and aids in surgical decision-making. We aimed to assess the outcome-reoperation and systemic complication rate-of surgery for humeral metastases, myeloma, or lymphoma. Our null hypothesis was that there are no factors associated with these outcomes.
Methods: We included 295 consecutive patients in this retrospective study: 134 (45%) proximal, 131 (44%) diaphyseal, and 30 (10%) distal impending or pathologic fractures. Proximal lesions were treated by intramedullary nailing (43%, n = 57), prosthesis (34%, n = 46), plate-screw fixation (22%, n = 30), and a combination (n = 1). Diaphyseal lesions were treated by intramedullary nailing (69%, n = 91), plate-screw fixation (30%, n = 39), and a combination (n = 1). Distal lesions were treated by platescrew fixation (97%, n = 29) and intramedullary nailing (3.3%, n = 1).
Results: We found 25 (8.5%) reoperations, and 17 (5.8%) patients had 18 systemic complications: pneumonia (3.7%, n = 11), pulmonary embolism(1.3%, n = 4), sepsis (0.68%, n = 2), and fat embolism(0.34%, n = 1). No factors were independently associated with reoperation. Logistic regression analysis demonstrated that favorable cancer status (i.e., a higher modified Bauer score: odds ratio, 0.48; 95% confidence interval, 0.29-0.80; P =.005) was independently associated with a decreased systemic complication rate.
Conclusion: Poor cancer status was an independent predictor of postoperative systemic complications. This could help inform the patient and anticipate postoperative problems. (C) 2016 Journal of Shoulder and Elbow Surgery Board of Trustees.
C1 [Janssen, Stein J.; van Dijke, Maarten; Lozano-Calderon, Santiago A.; Raskin, Kevin A.; Hornicek, Francis J.; Schwab, Joseph H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Orthopaed Oncol Serv, Boston, MA USA.
[Ready, John E.; Ferrone, Marco L.] Brigham & Womens Hosp, Orthopaed Oncol Serv, Dept Orthopaed Surg, Boston, MA 02115 USA.
RP Janssen, SJ (reprint author), Massachusetts Gen Hosp, Room 3-946,Yawkey Bldg,55 Fruit St, Boston, MA 02114 USA.
EM steinjanssen@gmail.com
FU Anna Foundation; Michael van Vloten Foundation; De Drie Lichten
Foundation; KWF Kankerbestrijding
FX Stein J. Janssen has received research funding from Anna Foundation,
Michael van Vloten Foundation, De Drie Lichten Foundation, and KWF
Kankerbestrijding.
NR 24
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1058-2746
J9 J SHOULDER ELB SURG
JI J. Shoulder Elbow Surg.
PD FEB
PY 2016
VL 25
IS 2
BP 207
EP 215
DI 10.1016/j.jse.2015.08.009
PG 9
WC Orthopedics; Sport Sciences; Surgery
SC Orthopedics; Sport Sciences; Surgery
GA DB0YL
UT WOS:000368234400010
PM 26547526
ER
PT J
AU ter Meulen, DP
Janssen, SJ
Hageman, MGJS
Ring, DC
AF ter Meulen, Dirk P.
Janssen, Stein J.
Hageman, Michiel G. J. S.
Ring, David C.
TI Quantitative three-dimensional computed tomography analysis of glenoid
fracture patterns according to the AO/OTA classification
SO JOURNAL OF SHOULDER AND ELBOW SURGERY
LA English
DT Article
DE Glenoid; fracture; three-dimensional; quantitative; surface area;
classification
ID SCAPULAR FRACTURES; CORONOID FRACTURES
AB Hypothesis/Background: This study measures the characteristics of glenoid fractures to determine if the AO Foundation and Orthopaedic Trauma Association (AO/OTA) classification captures the most common fracture patterns. The primary null hypothesis was that surface area and degree of fragmentation do not differ among the different fracture types. Secondarily, we tested if there was a relationship between high- vs. low-energy trauma and fracture classification.
Methods: Three-dimensional models were created for a consecutive series of 53 fractures. The fracture classifications, the number of fragments, and the fragmented articular surface area were related to the type of injury. The difference of articular surface size and number of fragments among classification groups was analyzed with the Kruskal-Wallis test.
Results: There is a significant difference in fractured articular surface area among classification groups. Compared with transverse and multifragmented fractures, both anterior and posterior fractures involved significantly less of the articular surface area. High-energy trauma is associated with transverse and multifragmented fractures in 93% of the cases. It is associated with a greater number of fracture fragments and fracture of a larger percentage of the glenoid surface area, with a mean fractured surface of 60% for high-energy fractures and 25% for low-energy injuries.
Discussion/Conclusion: Quantitative 3-dimensional CT analysis confirms that the current AO/OTA classification adequately characterizes and discriminates glenoid fracture patterns. The classification groups are related to the fragmented articular surface area and the number of fragments. Also, the mechanism of injury is related to the classification group, which supports the clinical relevance of the classification. (C) 2016 Journal of Shoulder and Elbow Surgery Board of Trustees.
C1 [ter Meulen, Dirk P.; Janssen, Stein J.; Hageman, Michiel G. J. S.; Ring, David C.] Massachusetts Gen Hosp, Hand & Upper Extrem Serv, Boston, MA 02114 USA.
RP Ring, DC (reprint author), Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
OI Ring, David/0000-0002-6506-4879
FU Skeletal Dynamics; Biomet
FX David C. Ring has received study-specific grants from Skeletal Dynamics
and Biomet. He is a consultant for Wright Medical, Skeletal Dynamics,
and Acumed. He receives honoraria from AO North America and AO
International. He receives royalties from Wright Medical, Biomet, and
Skeletal Dynamics. He has stock options in Illuminos.
NR 14
TC 1
Z9 1
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1058-2746
J9 J SHOULDER ELB SURG
JI J. Shoulder Elbow Surg.
PD FEB
PY 2016
VL 25
IS 2
BP 269
EP 275
DI 10.1016/j.jse.2015.07.022
PG 7
WC Orthopedics; Sport Sciences; Surgery
SC Orthopedics; Sport Sciences; Surgery
GA DB0YL
UT WOS:000368234400018
PM 26456425
ER
PT J
AU Wofford, J
Fenves, AZ
Jackson, JM
Kimball, AB
Menter, A
AF Wofford, Jay
Fenves, Andrew Z.
Jackson, J. Mark
Kimball, Alexa B.
Menter, Alan
TI Genetic causes of nephrocutaneous disease
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE autoimmune; dermatology; genetic; genodermatoses; inflammatory;
nephrocutaneous; nephrology
ID BECKWITH-WIEDEMANN-SYNDROME; TUBEROUS SCLEROSIS COMPLEX; NAIL-PATELLA
SYNDROME; HIPPEL-LINDAU-DISEASE; HOGG-DUBE-SYNDROME; POLYCYSTIC
KIDNEY-DISEASE; RENAL-CELL CANCER; FABRY-DISEASE; DIAGNOSTIC-CRITERIA;
NEUROFIBROMATOSIS TYPE-1
AB There are a significant number of diseases and treatment considerations of considerable importance relating to the skin and renal systems. This emphasizes the need for dermatologists in practice or in clinical training to be aware of these associations. Part I of this 2-part continuing medical education article reviews the genetic syndromes with both renal and cutaneous involvement that are most important for the dermatologist to be able to identify, manage, and appropriately refer to nephrology colleagues. Part II reviews the inflammatory syndromes with relevant renal manifestations and therapeutic agents commonly used by dermatologists that have drug-induced effects on or require close consideration of renal function. In addition, we will likewise review therapeutic agents commonly used by nephrologists that have drug-induced effects on the skin that dermatologists are likely to encounter in clinical practice. In both parts of this continuing medical education article, we discuss diagnosis, management, and appropriate referral to our nephrology colleagues in the context of each nephrocutaneous association. There are a significant number of dermatoses associated with renal abnormalities and disease, emphasizing the need for dermatologists to be keenly aware of their presence in order to avoid overlooking important skin conditions with potentially devastating renal complications. This review discusses important nephrocutaneous disease associations with recommendations for the appropriate urgency of referral to nephrology colleagues for diagnosis, surveillance, and early management of potential renal sequelae.
C1 [Wofford, Jay; Menter, Alan] Baylor Univ, Med Ctr, Dept Dermatol, Dallas, TX USA.
[Fenves, Andrew Z.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Kimball, Alexa B.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Jackson, J. Mark] Univ Louisville, Dept Dermatol, Louisville, KY 40292 USA.
RP Menter, A (reprint author), Texas Dermatol Associates, 3900 Junius St,Ste 145, Dallas, TX 75246 USA.
EM amderm@gmail.com
NR 83
TC 2
Z9 2
U1 1
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD FEB
PY 2016
VL 74
IS 2
BP 231
EP 244
DI 10.1016/j.jaad.2015.05.039
PG 14
WC Dermatology
SC Dermatology
GA DB1MP
UT WOS:000368272600009
PM 26775773
ER
PT J
AU Pascoe, VL
Fenves, AZ
Wofford, J
Jackson, JM
Menter, A
Kimball, AB
AF Pascoe, Vanessa L.
Fenves, Andrew Z.
Wofford, Jay
Jackson, J. Mark
Menter, Alan
Kimball, Alexandra Boer
TI Inflammatory and medication-related nephrocutaneous associations
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE antihypertensive medication; autoimmune; dermatology; genetic;
genodermatoses; immunosuppression; inflammatory; medication side
effects; nephrocutaneous; nephrology; renal transplantation
ID CUTANEOUS LUPUS-ERYTHEMATOSUS; CALCIUM-CHANNEL BLOCKERS; ORGAN
TRANSPLANT RECIPIENTS; STEVENS-JOHNSON SYNDROME; LOW-DOSE METHOTREXATE;
TOXIC EPIDERMAL NECROLYSIS; HENOCH-SCHONLEIN PURPURA; OF-THE-LITERATURE;
CONVERTING ENZYME-INHIBITORS; HYDRALAZINE-INDUCED LUPUS
AB There are a significant number of dermatoses associated with renal abnormalities and disease, and dermatologists need to be keenly aware of their presence in order to avoid overlooking important skin conditions with potentially devastating renal complications. This review discusses important nephrocutaneous disease associations and recommendations for the appropriate urgency of referral to nephrology colleagues for diagnosis, surveillance, and early management of potential renal sequelae. Part II of this 2-part continuing medical education article addresses inflammatory and medication-related nephrocutaneous associations.
C1 [Pascoe, Vanessa L.; Fenves, Andrew Z.; Kimball, Alexandra Boer] Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Pascoe, Vanessa L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Wofford, Jay; Menter, Alan] Baylor Univ, Med Ctr, Dallas, TX USA.
[Jackson, J. Mark] Univ Louisville, Div Dermatol, Louisville, KY 40292 USA.
RP Kimball, AB (reprint author), Massachusetts Gen Hosp, Dept Dermatol, Clin Unit Res Trials & Outcomes Skin, 50 Staniford St,Ste 240, Boston, MA 02114 USA.
EM harvardskinstudies@partners.org
NR 401
TC 1
Z9 1
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD FEB
PY 2016
VL 74
IS 2
BP 247
EP 270
DI 10.1016/j.jaad.2015.05.042
PG 24
WC Dermatology
SC Dermatology
GA DB1MP
UT WOS:000368272600010
PM 26775774
ER
PT J
AU Sonpavde, G
Pond, GR
Rosenberg, JE
Bajorin, DF
Choueiri, TK
Necchi, A
Di Lorenzo, G
Bellmunt, J
AF Sonpavde, Guru
Pond, Gregory R.
Rosenberg, Jonathan E.
Bajorin, Dean F.
Choueiri, Toni K.
Necchi, Andrea
Di Lorenzo, Giuseppe
Bellmunt, Joaquim
TI Improved 5-Factor Prognostic Classification of Patients Receiving
Salvage Systemic Therapy for Advanced Urothelial Carcinoma
SO JOURNAL OF UROLOGY
LA English
DT Article
DE urinary tract; urothelium; carcinoma; albumins; prognosis
ID CISPLATIN-BASED CHEMOTHERAPY; TRANSITIONAL-CELL CARCINOMA;
BLADDER-CANCER PATIENTS; PHASE-II; TRIAL DESIGN; PREDICTING SURVIVAL;
SOLID TUMORS; SINGLE GROUP; SCORE GPS; PACLITAXEL
AB Purpose: Prognostic factors in patients receiving salvage systemic therapy for advanced urothelial carcinoma include performance status, liver metastasis, hemoglobin and time since chemotherapy. We investigated the impact of albumin, and neutrophil, lymphocyte and platelet counts.
Materials and Methods: Patient level data from 10 phase II trials were used. Cox proportional hazards regression was applied to evaluate associations with overall survival. An optimal regression model was constructed using forward stepwise selection and risk groups were defined using the number of adverse factors. Trial was a stratification factor. External validation was done in a separate data set of 5 salvage phase II trials.
Results: Discovery data were obtained on 708 patients. After adjustment for the 4 known factors a platelet count of the upper limit of normal or greater and albumin less than the lower limit of normal were significant poor prognostic factors. Only the addition of albumin was externally validated. For 0 or 1, 2 and 3 or greater risk factors median overall survival was 8.9, 6.4 and 4.5 months in 207, 171 and 113 patients in the discovery data set of 491, and 10.6, 10.0 and 7.0 months in 73, 47 and 47 patients, respectively, in the validation data set of 167. By adding albumin the c-index improved from 0.610 to 0.639 in the discovery set and from 0.616 to 0.646 in the validation set.
Conclusions: Albumin was externally validated as a prognostic factor for overall survival after accounting for time from prior chemotherapy, hemoglobin, performance status and liver metastasis status in patients receiving salvage systemic therapy for advanced urothelial carcinoma. The discovery of molecular prognostic factors is a priority to further enhance this new preferred 5-factor clinical prognostic model.
C1 [Sonpavde, Guru] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
[Pond, Gregory R.] McMaster Univ, Hamilton, ON, Canada.
[Rosenberg, Jonathan E.; Bajorin, Dean F.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Choueiri, Toni K.; Bellmunt, Joaquim] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Choueiri, Toni K.; Bellmunt, Joaquim] Harvard Univ, Sch Med, Boston, MA USA.
[Necchi, Andrea] Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
[Di Lorenzo, Giuseppe] Univ Naples Federico II, Naples, Italy.
RP Sonpavde, G (reprint author), Univ Alabama Birmingham, Ctr Comprehens Canc, 1720 2nd Ave South,NP2540B, Birmingham, AL 35294 USA.
EM gsonpavde@uabmc.edu
OI Rosenberg, Jonathan/0000-0003-2637-4249; Necchi,
Andrea/0000-0002-3007-2756
FU NCI NIH HHS [P30 CA008748]
NR 30
TC 10
Z9 10
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD FEB
PY 2016
VL 195
IS 2
BP 277
EP 282
DI 10.1016/j.juro.2015.07.111
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA DA8KZ
UT WOS:000368054800011
PM 26292040
ER
PT J
AU Newcomb, LF
Thompson, IM
Boyer, HD
Brooks, JD
Carroll, PR
Cooperberg, MR
Dash, A
Ellis, WJ
Fazli, L
Feng, ZD
Gleave, ME
Kunju, P
Lance, RS
McKenney, JK
Meng, MV
Nicolas, MM
Sanda, MG
Simko, J
So, A
Tretiakova, MS
Troyer, DA
True, LD
Vakar-Lopez, F
Virgin, J
Wagner, AA
Wei, JT
Zheng, YY
Nelson, PS
Lin, DW
AF Newcomb, Lisa F.
Thompson, Ian M., Jr.
Boyer, Hilary D.
Brooks, James D.
Carroll, Peter R.
Cooperberg, Matthew R.
Dash, Atreya
Ellis, William J.
Fazli, Ladan
Feng, Ziding
Gleave, Martin E.
Kunju, Priya
Lance, Raymond S.
McKenney, Jesse K.
Meng, Maxwell V.
Nicolas, Marlo M.
Sanda, Martin G.
Simko, Jeffry
So, Alan
Tretiakova, Maria S.
Troyer, Dean A.
True, Lawrence D.
Vakar-Lopez, Funda
Virgin, Jeff
Wagner, Andrew A.
Wei, John T.
Zheng, Yingye
Nelson, Peter S.
Lin, Daniel W.
CA Canary PASS Investigators
TI Outcomes of Active Surveillance for Clinically Localized Prostate Cancer
in the Prospective, Multi-Institutional Canary PASS Cohort
SO JOURNAL OF UROLOGY
LA English
DT Article
DE prostatic neoplasms; prospective studies; watchful waiting
ID RADICAL PROSTATECTOMY; RISK-ASSESSMENT; DISEASE RECURRENCE; PREDICTION;
ANTIGEN; TRENDS; VALIDATION; MANAGEMENT; PATHOLOGY; MEN
AB Purpose: Active surveillance represents a strategy to address the overtreatment of prostate cancer, yet uncertainty regarding individual patient outcomes remains a concern. We evaluated outcomes in a prospective multicenter study of active surveillance.
Materials and Methods: We studied 905 men in the prospective Canary PASS enrolled between 2008 and 2013. We collected clinical data at study entry and at prespecified intervals, and determined associations with adverse reclassification, defined as increased Gleason grade or greater cancer volume on followup biopsy. We also evaluated the relationships of clinical parameters with pathology findings in participants who underwent surgery after a period of active surveillance.
Results: At a median followup of 28 months 24% of participants experienced adverse reclassification, of whom 53% underwent treatment while 31% continued on active surveillance. Overall 19% of participants received treatment, 68% with adverse reclassification, while 32% opted for treatment without disease reclassification. In multivariate Cox proportional hazards modeling the percent of biopsy cores with cancer, body mass index and prostate specific antigen density were associated with adverse reclassification (p = 0.01, 0.04, 0.04, respectively). Of 103 participants subsequently treated with radical prostatectomy 34% had adverse pathology, defined as primary pattern 4-5 or nonorgan confined disease, including 2 with positive lymph nodes, with no significant relationship between risk category at diagnosis and findings at surgery (p = 0.76).
Conclusions: Most men remain on active surveillance at 5 years without adverse reclassification or adverse pathology at surgery. However, clinical factors had only a modest association with disease reclassification, supporting the need for approaches that improve the prediction of this outcome.
C1 [Newcomb, Lisa F.; Boyer, Hilary D.; Feng, Ziding; Zheng, Yingye; Nelson, Peter S.; Lin, Daniel W.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Newcomb, Lisa F.; Ellis, William J.; Tretiakova, Maria S.; True, Lawrence D.; Vakar-Lopez, Funda; Lin, Daniel W.] Univ Washington, Seattle, WA 98195 USA.
[Dash, Atreya; Virgin, Jeff; Lin, Daniel W.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Brooks, James D.] Stanford Univ, Stanford, CA 94305 USA.
[Carroll, Peter R.; Cooperberg, Matthew R.; Meng, Maxwell V.; Simko, Jeffry] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Fazli, Ladan; Gleave, Martin E.; So, Alan] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Thompson, Ian M., Jr.; Nicolas, Marlo M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Sanda, Martin G.; Wagner, Andrew A.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Lance, Raymond S.; Troyer, Dean A.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA.
[McKenney, Jesse K.] Cleveland Clin, Cleveland, OH 44106 USA.
[Kunju, Priya; Wei, John T.] Univ Michigan, Ann Arbor, MI 48109 USA.
RP Lin, DW (reprint author), Univ Washington, Dept Urol, 1959 NE Pacific St,Box 356510, Seattle, WA 98195 USA.
EM dlin@uw.edu
FU Canary Foundation; National Cancer Institute at the National Institutes
of Health Early Detection Research Network [U01 CA086402]; National
Institutes of Health [P30 CA054174]; National Institutes of Health
(Pacific Northwest Prostate Cancer SPORE) [P50 CA097186]
FX Supported by the Canary Foundation; the National Cancer Institute at the
National Institutes of Health Early Detection Research Network (Grant
U01 CA086402); and the National Institutes of Health (Grant P30
CA054174, and the Pacific Northwest Prostate Cancer SPORE P50 CA097186).
NR 27
TC 15
Z9 15
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD FEB
PY 2016
VL 195
IS 2
BP 313
EP 320
DI 10.1016/j.juro.2015.08.087
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA DA8KZ
UT WOS:000368054800023
PM 26327354
ER
PT J
AU Gelpi-Hammerschmidt, F
Tinay, I
Allard, CB
Su, LM
Preston, MA
Trinh, QD
Kibel, AS
Wang, Y
Chung, BI
Chang, SL
AF Gelpi-Hammerschmidt, Francisco
Tinay, Ilker
Allard, Christopher B.
Su, Li-Ming
Preston, Mark A.
Quoc-Dien Trinh
Kibel, Adam S.
Wang, Ye
Chung, Benjamin I.
Chang, Steven L.
TI The Contemporary Incidence and Sequelae of Rhabdomyolysis Following
Extirpative Renal Surgery: A Population Based Analysis
SO JOURNAL OF UROLOGY
LA English
DT Article
DE rhabdomyolysis; kidney; surgical procedures; operative; population
groups
ID SURGICAL-PROCEDURES; BARIATRIC SURGERY; FLANK POSITION; UNITED-STATES;
RISK-FACTORS; COMPLICATIONS; FAILURE; CLASSIFICATION; NEPHRECTOMY; COSTS
AB Purpose: We evaluate the contemporary incidence and consequences of postoperative rhabdomyolysis after extirpative renal surgery.
Materials and Methods: We conducted a population based, retrospective cohort study of patients who underwent extirpative renal surgery with a diagnosis of a renal mass or renal cell carcinoma in the United States between 2004 and 2013. Regression analysis was performed to evaluate 90-day mortality (Clavien grade V), nonfatal major complications (Clavien grade III-IV), hospital readmission rates, direct costs and length of stay.
Results: The final weighted cohort included 310,880 open, 174,283 laparoscopic and 69,880 robotic extirpative renal surgery cases during the 10-year study period, with 745 (0.001%) experiencing postoperative rhabdomyolysis. The presence of postoperative rhabdomyolysis led to a significantly higher incidence of 90-day nonfatal major complications (34.7% vs 7.3%, p < 0.05) and higher 90-day mortality (4.4% vs 1.02%, p < 0.05). Length of stay was twice as long for patients with postoperative rhabdomyolysis (incidence risk ratio 1.83, 95% CI 1.56e2.15, p < 0.001). The robotic approach was associated with a higher likelihood of postoperative rhabdomyolysis (vs laparoscopic approach, OR 2.43, p < 0.05). Adjusted 90-day median direct hospital costs were USD 7,515 higher for patients with postoperative rhabdomyolysis (p < 0.001). Our model revealed that the combination of obesity and prolonged surgery (more than 5 hours) was associated with a higher likelihood of postoperative rhabdomyolysis developing.
Conclusions: Our study confirms that postoperative rhabdomyolysis is an uncommon complication among patients undergoing extirpative renal surgery, but has a potentially detrimental impact on surgical morbidity, mortality and costs. Male gender, comorbidities, obesity, prolonged surgery (more than 5 hours) and a robotic approach appear to place patients at higher risk for postoperative rhabdomyolysis.
C1 [Gelpi-Hammerschmidt, Francisco; Tinay, Ilker; Allard, Christopher B.; Preston, Mark A.; Quoc-Dien Trinh; Kibel, Adam S.; Chang, Steven L.] Brigham & Womens Hosp, Div Urol, Boston, MA 02115 USA.
[Quoc-Dien Trinh; Wang, Ye; Chang, Steven L.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA.
[Gelpi-Hammerschmidt, Francisco; Allard, Christopher B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA USA.
[Tinay, Ilker] Marmara Univ, Sch Med, Dept Urol, Istanbul, Turkey.
[Su, Li-Ming] Univ Florida, Coll Med, Dept Urol, Gainesville, FL USA.
[Chung, Benjamin I.] Stanford Univ, Med Ctr, Dept Urol, Stanford, CA 94305 USA.
RP Tinay, I (reprint author), Brigham & Womens Hosp, Div Urol, 45 Francis St, Boston, MA 02115 USA.
EM itinay@partners.org
FU Society of Urological Surgery in Turkey Scholarship Program; Kidney
Cancer SPORE Career Development Award [5P50CA101942-09]
FX Supported by the Society of Urological Surgery in Turkey Scholarship
Program.; Supported by a Kidney Cancer SPORE Career Development Award
(5P50CA101942-09).
NR 29
TC 3
Z9 3
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD FEB
PY 2016
VL 195
IS 2
BP 399
EP 405
DI 10.1016/j.juro.2015.08.084
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA DA8KZ
UT WOS:000368054800052
PM 26321407
ER
PT J
AU Rosand, J
Mitchell, BD
Ay, H
de Bakker, PIW
Gwinn, K
Kittner, SJ
Lindgren, A
Meschia, JF
Pulit, SL
Sudlow, CLM
Thijs, V
Woo, D
Worrall, BB
Arnett, DK
Benavente, O
Cole, JW
Dichgans, M
Grewal, RP
Jern, C
Conde, JJ
Johnson, JA
Kittner, SJ
Lee, JM
Levi, C
Lindgren, A
Markus, HS
Melander, O
Meschia, JF
Rexrode, K
Rosand, J
Rothwell, PM
Rundek, T
Sacco, RL
Schmidt, R
Sharma, P
Slowik, A
Sudlow, CLM
Thijs, V
Wasssertheil-Smoller, S
Woo, D
Worrall, BB
AF Rosand, Jonathan
Mitchell, Braxton D.
Ay, Hakan
de Bakker, Paul I. W.
Gwinn, Katrina
Kittner, Steven J.
Lindgren, Arne
Meschia, James F.
Pulit, Sara L.
Sudlow, Cathie L. M.
Thijs, Vincent
Woo, Daniel
Worrall, Bradford B.
Arnett, Donna K.
Benavente, Oscar
Cole, John W.
Dichgans, Martin
Grewal, Raji P.
Jern, Christina
Conde, Jordi Jimenez
Johnson, Julie A.
Kittner, Steven J.
Lee, Jin-Moo
Levi, Christopher
Lindgren, Arne
Markus, Hugh S.
Melander, Olle
Meschia, James F.
Rexrode, Kathryn
Rosand, Jonathan
Rothwell, Peter M.
Rundek, Tatjana
Sacco, Ralph L.
Schmidt, Reinhold
Sharma, Pankaj
Slowik, Agnieszka
Sudlow, Cathie L. M.
Thijs, Vincent
Wasssertheil-Smoller, Sylvia
Woo, Daniel
Worrall, Bradford B.
CA NINDS Stroke Genetics Network SiGN
ISGC
TI Loci associated with ischaemic stroke and its subtypes (SiGN): a
genome-wide association study
SO LANCET NEUROLOGY
LA English
DT Article
ID CAUSATIVE CLASSIFICATION; ATRIAL-FIBRILLATION; GENETICS NETWORK; COMMON
VARIANTS; METAANALYSIS; REPLICATION; POPULATION; IMPUTATION; SYSTEM;
TOAST
AB Background The discovery of disease-associated loci through genome-wide association studies (GWAS) is the leading genetic approach to the identification of novel biological pathways underlying diseases in humans. Until recently, GWAS in ischaemic stroke have been limited by small sample sizes and have yielded few loci associated with ischaemic stroke. We did a large-scale GWAS to identify additional susceptibility genes for stroke and its subtypes.
Methods To identify genetic loci associated with ischaemic stroke, we did a two-stage GWAS. In the first stage, we included 16 851 cases with state-of-the-art phenotyping data and 32 473 stroke-free controls. Cases were aged 16 to 104 years, recruited between 1989 and 2012, and subtypes of ischaemic stroke were recorded by centrally trained and certified investigators who used the web-based protocol, Causative Classification of Stroke (CCS). We constructed case-control strata by identifying samples that were genotyped on nearly identical arrays and were of similar genetic ancestral background. We cleaned and imputed data by use of dense imputation reference panels generated from whole-genome sequence data. We did genome-wide testing to identify stroke-associated loci within each stratum for each available phenotype, and we combined summary-level results using inverse variance-weighted fixed-effects meta-analysis. In the second stage, we did in-silico lookups of 1372 single nucleotide polymorphisms identified from the first stage GWAS in 20 941 cases and 364 736 unique stroke-free controls. The ischaemic stroke subtypes of these cases had previously been established with the Trial of Org 10 172 in Acute Stroke Treatment (TOAST) classification system, in accordance with local standards. Results from the two stages were then jointly analysed in a final meta-analysis.
Findings We identified a novel locus (G allele at rs12122341) at 1p13.2 near TSPAN2 that was associated with large artery atherosclerosis-related stroke (first stage odds ratio [OR] 1.21, 95% CI 1.13-1.30, p=4.50 x 10(-8); joint OR 1.19, 1.12-1.26, p=1.30 x 10(-9)). Our results also supported robust associations with ischaemic stroke for four other loci that have been reported in previous studies, including PITX2 (first stage OR 1.39, 1.29-1.49, p=3.26 x 10(-1).; joint OR 1.37, 1.30-1.45, p= 2.79 x 10(-32)) and ZFHX3 (fi rst stage OR 1.19, 1.11-1.27, p=2.93 x 10(-7); joint OR 1.17, 1.11-1.23, p=2.29 x 10(-10)) for cardioembolic stroke, and HDAC9 (first stage OR 1.29, 1.18-1.42, p=3.50 x 10(-8); joint OR 1.24, 1.15-1.33, p= 4.52 x 10(-9)) for large artery atherosclerosis stroke. The 12q24 locus near ALDH2, which has previously been associated with all ischaemic stroke but not with any specific subtype, exceeded genome-wide significance in the meta-analysis of small artery stroke (fi rst stage OR 1.20, 1.12-1.28, p=6.82 x 10(-8); joint OR 1.17, 1.11-1.23, p=2.92 x 10(-9)). Other loci associat ed with stroke in previous studies, including NINJ2, were not confirmed.
Interpretation Our results suggest that all ischaemic stroke-related loci previously implicated by GWAS are subtype specific. We identified a novel gene associated with large artery atherosclerosis stroke susceptibility. Follow-up studies will be necessary to establish whether the locus near TSPAN2 can be a target for a novel therapeutic approach to stroke prevention. In view of the subtype-specificity of the associations detected, the rich phenotyping data available in the Stroke Genetics Network (SiGN) are likely to be crucial for further genetic discoveries related to ischaemic stroke.
C1 [Rosand, Jonathan] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Rosand, Jonathan] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
RP Rosand, J (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RI JIMENEZ-CONDE, JORDI/C-1941-2012; rabionet, raquel/C-8379-2009;
Boncoraglio, Giorgio/B-8647-2011; Thijs, Vincent/C-3647-2009;
OI rabionet, raquel/0000-0001-5006-8140; Thijs,
Vincent/0000-0002-6614-8417; Williams, Stephen/0000-0003-2108-2757;
Rexrode, Kathryn/0000-0003-3387-8429; Mitchell,
Braxton/0000-0003-4920-4744; Tajuddin, Salman M./0000-0002-7919-8528
FU US National Institute of Neurological Disorders and Stroke, National
Institutes of Health
FX US National Institute of Neurological Disorders and Stroke, National
Institutes of Health.
NR 35
TC 5
Z9 5
U1 4
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1474-4422
EI 1474-4465
J9 LANCET NEUROL
JI Lancet Neurol.
PD FEB
PY 2016
VL 15
IS 2
BP 174
EP 184
DI 10.1016/S1474-4422(15)00338-5
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA DA9GC
UT WOS:000368116000015
ER
PT J
AU Hunsberger, JG
Rao, M
Kurtzberg, J
Bulte, JWM
Atala, A
LaFerla, FM
Greely, HT
Sawa, A
Gandy, S
Schneider, LS
Doraiswamy, PM
AF Hunsberger, Joshua G.
Rao, Mahendra
Kurtzberg, Joanne
Bulte, Jeff W. M.
Atala, Anthony
LaFerla, Frank M.
Greely, Henry T.
Sawa, Akira
Gandy, Sam
Schneider, Lon S.
Doraiswamy, P. Murali
TI Accelerating stem cell trials for Alzheimer's disease
SO LANCET NEUROLOGY
LA English
DT Article
ID UMBILICAL-CORD BLOOD; IPSC-DERIVED NEURONS; PARKINSONS-DISEASE; A-BETA;
REGENERATIVE MEDICINE; PEDIATRIC-PATIENTS; INFORMED-CONSENT;
DRUG-DEVELOPMENT; MOUSE MODELS; AMYLOID-BETA
AB At present, no effective cure or prophylaxis exists for Alzheimer's disease. Symptomatic treatments are modestly effective and off er only temporary benefit. Advances in induced pluripotent stem cell (iPSC) technology have the potential to enable development of so-called disease-in-a-dish personalised models to study disease mechanisms and reveal new therapeutic approaches, and large panels of iPSCs enable rapid screening of potential drug candidates. Different cell types can also be produced for therapeutic use. In 2015, the US Food and Drug Administration granted investigational new drug approval for the first phase 2A clinical trial of ischaemia-tolerant mesenchymal stem cells to treat Alzheimer's disease in the USA. Similar trials are either underway or being planned in Europe and Asia. Although safety and ethical concerns remain, we call for the acceleration of human stem cell-based translational research into the causes and potential treatments of Alzheimer's disease.
C1 [Hunsberger, Joshua G.; Atala, Anthony] Wake Forest Univ, Wake Forest Inst Regenerat Med, Winston Salem, NC 27109 USA.
[Rao, Mahendra] New York Stem Cell Fdn, New York, NY USA.
[Kurtzberg, Joanne] Duke Univ, Med Ctr, Robertson Clin & Translat Cell Therapy Program, Durham, NC USA.
[Bulte, Jeff W. M.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA.
[Bulte, Jeff W. M.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD USA.
[Sawa, Akira] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA.
[LaFerla, Frank M.] Univ Calif Irvine, Inst Memory Impairment & Neurol Disorders, Irvine, CA USA.
[Greely, Henry T.] Stanford Univ, Ctr Law & Biosci, Stanford, CA 94305 USA.
[Gandy, Sam] Icahn Sch Med Mt Sinai, Ctr Cognit Hlth, New York, NY 10029 USA.
[Gandy, Sam] Icahn Sch Med Mt Sinai, Natl Football League Neurol Care, New York, NY 10029 USA.
[Gandy, Sam] James J Peters VA Med Ctr, Bronx, NY USA.
[Schneider, Lon S.] Univ So Calif, Keck Sch Med, Alzheimers Dis Res Ctr, Los Angeles, CA 90033 USA.
[Doraiswamy, P. Murali] Duke Univ, Duke Inst Brain Sci, Durham, NC USA.
[Doraiswamy, P. Murali] Duke Univ, Dept Psychiat, Durham, NC 27706 USA.
RP Hunsberger, JG (reprint author), Wake Forest Univ, Wake Forest Inst Regenerat Med, Winston Salem, NC 27109 USA.
FU Accelerated Medicines Partnership [U01 AG046170]; David Werber Family
Trust; Cure Alzheimer's Fund; Veterans Affairs [I01RX000684]; US
National Institutes of Health; National Multiple Sclerosis Society; ALS
Association; Maryland Stem Cell Research Fund; Brain & Behavior Research
Foundation; Stanley Foundation; RUSK Foundation; Maryland Stem Cell
Research Funds
FX We acknowledge the contributions of all faculty members and participants
at our meeting for the valuable discussions. We are especially grateful
for the support of Marjorie Bekaert Thomas, Trustee for the Karen L
Wrenn Trust, whose vision led to this conference. The meeting on stem
cells and Alzheimer's disease, and the writing of this Personal View,
was funded by a gift from the Karen L Wrenn Trust to PMD through Duke
University. The Trust had no input in the content of this Personal View.
We also acknowledge support from Accelerated Medicines Partnership/U01
AG046170, the David Werber Family Trust, the Cure Alzheimer's Fund, and
Veterans Affairs (grant I01RX000684) (all to SG). JWMB, PMD, and AS have
been supported by grants from the US National Institutes of Health. JWMB
is also supported by the National Multiple Sclerosis Society, the ALS
Association, and the Maryland Stem Cell Research Fund. AS reports
receiving grants from the Brain & Behavior Research Foundation (formerly
the NARSAD), Stanley Foundation, RUSK Foundation, and Maryland Stem Cell
Research Funds during the writing of the manuscript. Figure 1 is
courtesy of Piotr Walczak and Miroslaw Janowski, Johns Hopkins
University, Baltimore, MD, USA.
NR 92
TC 3
Z9 4
U1 7
U2 52
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1474-4422
EI 1474-4465
J9 LANCET NEUROL
JI Lancet Neurol.
PD FEB
PY 2016
VL 15
IS 2
BP 219
EP 230
DI 10.1016/S1474-4422(15)00332-4
PG 12
WC Clinical Neurology
SC Neurosciences & Neurology
GA DA9GC
UT WOS:000368116000019
ER
PT J
AU Yu, JT
Zhang, C
AF Yu, Jin-Tai
Zhang, Can
TI Pathogenesis and Therapeutic Strategies in Alzheimer's Disease: From
Brain to Periphery
SO NEUROTOXICITY RESEARCH
LA English
DT Editorial Material
DE Alzheimer's disease; Amyloid-beta; Periphery; Pathogenesis; Therapy
ID PLASMA A-BETA; AMYLOID-BETA; MOUSE MODEL; CLEARANCE; NEPRILYSIN;
PROGRESS; BURDEN; MICE
AB Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative disorder. At present, there are no effective disease-modifying therapies, and the cause of the disease remains unclear. Previously, almost all researchers focus on the brain for exploring the pathogenesis and therapeutic strategies in AD. A recent study by Xiang et al. (Acta Neuropathol 130:487-499, 2015) reported the significance of the physiological capacity of peripheral tissues and organs in clearing brain-derived amyloid-beta (A beta), which opens a novel avenue to understand the AD pathogenesis and develop therapies for AD.
C1 [Yu, Jin-Tai] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94158 USA.
[Zhang, Can] Massachusetts Gen Hosp, Dept Neurol, Genet & Aging Res Unit, Charlestown, MA 02129 USA.
[Zhang, Can] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
RP Yu, JT (reprint author), Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, 675 Nelson Rising Lane,Suite 190,Box 1207, San Francisco, CA 94158 USA.
EM jintai.yu@ucsf.edu
NR 21
TC 0
Z9 1
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1029-8428
EI 1476-3524
J9 NEUROTOX RES
JI Neurotox. Res.
PD FEB
PY 2016
VL 29
IS 2
BP 197
EP 200
DI 10.1007/s12640-015-9576-2
PG 4
WC Neurosciences
SC Neurosciences & Neurology
GA DB0JK
UT WOS:000368194200001
PM 26597964
ER
PT J
AU Itagaki, T
Gubin, TA
Sayal, P
Jiang, YD
Kacmarek, RM
Anderson, TA
AF Itagaki, Taiga
Gubin, Tatyana A.
Sayal, Puneet
Jiang, Yandong
Kacmarek, Robert M.
Anderson, Thomas Anthony
TI The effectiveness of nasal mask vs face mask ventilation in
anesthetized, apneic pediatric subjects over 2years of age: a randomized
controlled trial
SO PEDIATRIC ANESTHESIA
LA English
DT Article
DE airway management; airway obstruction; anesthesia; pediatrics; mask;
ventilators; mechanical
ID UPPER AIRWAY COLLAPSIBILITY; NONINVASIVE VENTILATION; INTUBATION;
ANESTHESIA; PRESSURE; CHILDREN; SLEEP; PREOXYGENATION
AB Background: We hypothesized that anesthetized, apneic children could be ventilated equivalently or more efficiently by nasal mask ventilation ( NMV) than face mask ventilation ( FMV). The aim of this randomized controlled study was to test this hypothesis by comparing the expiratory tidal volume ( Vte) between NMV and FMV. Methods: After the induction of anesthesia, 41 subjects, 3- 17 years of age without anticipated difficult mask ventilation, were randomly assigned to receive either NMV or FMV with neck extension. Both groups were ventilated with pressure control ventilation ( PCV) at 20 cmH2O of peak inspiratory pressure ( PIP) with positive end- expiratory pressure ( PEEP) levels of 0, 5, and 10 cmH2O. An additional mouth closing maneuver ( MCM) was applied for the NMV group. Results: The Vte was higher in the FMV group compared with the NMV group ( median difference [ 95% CI]: 8.4 [ 5.5- 11.6] ml kg -1; P < 0.001) when MCM was not applied. NMV achieved less PEEP than FMV ( median difference [ 95% CI]: 5.0 [ 4.3- 5.3] cmH2O at 10 cmH2O; P < 0.001) though both groups achieved the set PIP level. In the NMV group, MCM markedly increased Vte ( median increase [ 95% CI]: 5.9 [ 2.5- 9.0] ml kg -1; P < 0.005) and PEEP ( median increase [ 95% CI]: 5.0 [ 0.6- 8.6] cmH(2)O at 10 cmH(2)O; P < 0.005); however, PEEP was highly variable and lower than that of FMV ( median difference [ 95% CI]: 2.5 [ 0.8- 8.5] cmH2O at 10 cmH2O; P < 0.05). Conclusions: In anesthetized, apneic children greater than 2 years of age ventilated with an anesthesia ventilator and neck extension, FMV established a greater Vte than NMV regardless of mouth status. NMV could not maintain the set PEEP level due to an air leak from the mouth. The MCM increased the Vte and PEEP.
C1 [Itagaki, Taiga; Gubin, Tatyana A.; Sayal, Puneet; Kacmarek, Robert M.; Anderson, Thomas Anthony] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
[Itagaki, Taiga; Kacmarek, Robert M.] Massachusetts Gen Hosp, Resp Care Serv, Boston, MA 02114 USA.
[Gubin, Tatyana A.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
[Jiang, Yandong] Vanderbilt Univ Sch Med, Dept Anesthesia, Nashville, TN USA.
RP Anderson, TA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
EM tanderson9@mgh.harvard.edu
FU Covidien; Venner Medical
FX The study protocol was approved by the Massachusetts General Hospital
Human Research Committee (Boston, MA, USA). This study work was
supported only by departmental sources. RM Kacmarek received research
grants from Covidien and Venner Medical. RM Kacmarek is a consultant for
Covidien and received honorarium for one lecture per year from Maquet.
The other authors disclose no conflict of interest.
NR 24
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1155-5645
EI 1460-9592
J9 PEDIATR ANESTH
JI Pediatr. Anesth.
PD FEB
PY 2016
VL 26
IS 2
BP 173
EP 181
DI 10.1111/pan.12822
PG 9
WC Anesthesiology; Pediatrics
SC Anesthesiology; Pediatrics
GA DA4RT
UT WOS:000367788700008
PM 26725988
ER
PT J
AU Johansen, T
Winkler, T
Kelly, VJ
Osorio-Valencia, JS
Greenblatt, EE
Harris, RS
Venegas, JG
AF Johansen, Troels
Winkler, Tilo
Kelly, Vanessa Jane
Osorio-Valencia, Juan Sebastian
Greenblatt, Elliot Eliyahu
Harris, Robert Scott
Venegas, Jose Gabriel
TI A method for mapping regional oxygen and CO2 transfer in the lung
SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY
LA English
DT Article
DE Pulmonary gas exchange; Lung imaging; O-2 uptake; CO2 elimination;
Ventilation/perfusion; Asthma
ID VENTILATION-PERFUSION INEQUALITY; HYPERPOLARIZED HE-3 MRI; GAS-EXCHANGE;
STATUS ALGORITHM; MATHEMATICAL-MODEL; PARTIAL-PRESSURE; BLOOD; ASTHMA;
PET; PH
AB This paper presents a novel approach to visualizing regional lung function, through quantitative three-dimensional maps of O-2 and CO2 transfer rates. These maps describe the contribution of anatomical regions to overall gas exchange and demonstrate how transfer rates of the two gas species' differ regionally.
An algorithm for generating such maps is presented, and for illustration, regional gas transfer maps were generated using values of ventilation and perfusion imaged by PET/CT for a healthy subject and an asthmatic patient after bronchoprovocation.
In a sensitivity analysis, compartment values of gas transfer showed minor sensitivity to imaging noise in the ventilation and perfusion data, and moderate sensitivity to estimation errors in global lung input values, chiefly global alveolar ventilation, followed by cardiac output and arterial-venous O-2 content difference.
Gas transfer maps offer an intuitive display of physiologically relevant lung function at a regional level, the potential for an improved understanding of pulmonary gas exchange in health and disease, and potentially a presurgical evaluation tool. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Johansen, Troels] Aarhus Univ Hosp, Dept Resp Dis, DK-8000 Aarhus C, Denmark.
[Johansen, Troels; Winkler, Tilo; Kelly, Vanessa Jane; Osorio-Valencia, Juan Sebastian; Greenblatt, Elliot Eliyahu; Venegas, Jose Gabriel] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Johansen, Troels; Winkler, Tilo; Kelly, Vanessa Jane; Osorio-Valencia, Juan Sebastian; Greenblatt, Elliot Eliyahu; Venegas, Jose Gabriel] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Osorio-Valencia, Juan Sebastian] Tech Univ Munich, Dept Informat, D-85748 Garching, Germany.
[Greenblatt, Elliot Eliyahu] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
[Harris, Robert Scott] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Pulm & Crit Care Unit, Boston, MA 02114 USA.
RP Johansen, T (reprint author), Aarhus Univ Hosp, Dept Resp Dis, Noerrebrogade 44,Byg 2B kld, DK-8000 Aarhus C, Denmark.
EM troels.johansen@clin.au.dk
RI Winkler, Tilo/B-5337-2009
OI Winkler, Tilo/0000-0002-7276-5550
FU NIH [HL68011]
FX The PET/CT data acquisition was sponsored by NIH grant HL68011.
NR 45
TC 3
Z9 3
U1 1
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1569-9048
EI 1878-1519
J9 RESP PHYSIOL NEUROBI
JI Respir. Physiol. Neuro.
PD FEB 1
PY 2016
VL 222
BP 29
EP 47
DI 10.1016/j.resp.2015.10.017
PG 19
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA DB0OY
UT WOS:000368208600005
PM 26563454
ER
PT J
AU Marti, JL
Holm, T
Randolph, G
AF Marti, Jennifer L.
Holm, Tammy
Randolph, Gregory
TI Universal Use of Intraoperative Nerve Monitoring by Recently
Fellowship-Trained Thyroid Surgeons is Common, Associated with Higher
Surgical Volume, and Impacts Intraoperative Decision-Making
SO WORLD JOURNAL OF SURGERY
LA English
DT Article
ID RECURRENT LARYNGEAL NERVE; METAANALYSIS; VISUALIZATION; PREVALENCE;
PATTERNS; INJURY
AB The value of routine use of intraoperative recurrent laryngeal nerve monitoring (IONM) in thyroid surgery is controversial. We analyzed the practices of recently fellowship-trained thyroid surgeons from two diverging surgical backgrounds with respect to IONM. We hypothesized that the majority of recently trained surgeons would use IONM, and that it would potentially influence their operative procedure.
A 21-question survey was sent to 56 fellowship-trained endocrine and head and neck surgeons who completed fellowships accredited by the American Association of Endocrine Surgeons or American Head and Neck Society within the past 10 years, examining the demographics of respondents, and details of IONM practice. Groups were compared using the Fisher exact and chi (2) tests.
The response rate for the survey was 76 % (42/56). Overall, 95 % use IONM for some or all of their cases. Sixty percent (n = 25) of respondents always use IONM during thyroid surgery, 36 % (n = 15) use it selectively, and 5 % (n = 2) never use it. We compared respondents who always use IONM (n = 25), to those who selectively or never use it (n = 17). Exposure to IONM during residency or fellowship did not influence use (p = 0.99). However, higher-volume surgeons were more likely to always use IONM (p = 0.036). Among users of IONM, the most common reason given for use was increased surgeon confidence (55 %) and improved safety (54 %). Over 90 % of respondents found reoperative cases and preoperative vocal cord paralysis to be indications for IONM. Among those who always used IONM, 64 % would alter extent of surgery based on IONM findings, compared to only 27 % of selective users.
A survey of recently trained endocrine and head and neck surgeons reveals that the vast majority (95 %) of these surgeons commonly use IONM during thyroid surgery. IONM was more commonly used by higher-volume surgeons. Routine users were more likely to modify surgery based on nerve integrity (i.e., not complete a total thyroidectomy if the nerve loses conduction signal).
C1 [Marti, Jennifer L.] Icahn Sch Med Mt Sinai, Mt Sinai Beth Israel, Dept Surg, Div Endocrine Surg, New York, NY 10003 USA.
[Holm, Tammy; Randolph, Gregory] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Endocrine Surg Serv,Dept Surg, Boston, MA 02115 USA.
[Randolph, Gregory] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Div Thyroid & Parathyroid Endocrine Surg, Boston, MA 02115 USA.
RP Marti, JL (reprint author), Icahn Sch Med Mt Sinai, Mt Sinai Beth Israel, Dept Surg, Div Endocrine Surg, 10 Union Sq East,Suite 4E11, New York, NY 10003 USA.
EM jmarti@chpnet.org
NR 19
TC 2
Z9 2
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-2313
EI 1432-2323
J9 WORLD J SURG
JI World J.Surg.
PD FEB
PY 2016
VL 40
IS 2
BP 337
EP 343
DI 10.1007/s00268-015-3238-7
PG 7
WC Surgery
SC Surgery
GA DA8TI
UT WOS:000368078700013
PM 26330239
ER
PT J
AU Sise, ME
Bloom, AK
Wisocky, J
Lin, MV
Gustafson, JL
Lundquist, AL
Steele, D
Thiim, M
Williams, WW
Hashemi, N
Kim, AY
Thadhani, R
Chung, RT
AF Sise, Meghan E.
Bloom, Allyson K.
Wisocky, Jessica
Lin, Ming V.
Gustafson, Jenna L.
Lundquist, Andrew L.
Steele, David
Thiim, Michael
Williams, Winfred W.
Hashemi, Nikroo
Kim, Arthur Y.
Thadhani, Ravi
Chung, Raymond T.
TI Treatment of Hepatitis C Virus-Associated Mixed Cryoglobulinemia with
Direct-Acting Antiviral Agents
SO HEPATOLOGY
LA English
DT Article
ID ALPHA/RIBAVIRIN/PROTEASE INHIBITOR COMBINATION; GENOTYPE 1; INFECTION;
THERAPY; SOFOSBUVIR; VASCULITIS; RITUXIMAB; GLOMERULONEPHRITIS;
INTERFERON; RIBAVIRIN
AB Hepatitis C virus (HCV) is the most common cause of mixed cryoglobulinemia syndrome (MCS). The efficacy and safety of all-oral direct-acting antiviral (DAA) therapy in HCV-associated MCS (HCV-MCS) is largely unknown. The authors studied case series of patients with HCV-MCS who were treated with sofosbuvir-based regimens and historical controls treated with pegylated interferon and ribavirin in a single health care network. HCV-MCS was defined by circulating cryoglobulin associated with systemic vasculitis symptoms. Renal involvement (n = 7) was established by kidney biopsy (n = 5) or by two or more of the following clinical findings: reduced kidney function, proteinuria, or hematuria with other causes excluded (n = 2). Twelve patients received DAA therapy between December 2013 and September 2014. Median age was 61 years, 58% were male, and 50% had cirrhosis. Median baseline serum creatinine was 0.97 mg/dL (range 0.7-2.47). Four patients received rituximab concurrent with DAA therapy. Sustained virological response rate at 12 weeks (SVR12) was 83% overall. Patients with glomerulonephritis who achieved SVR12 experienced an improvement in serum creatinine and a reduction in proteinuria. Cryoglobulin levels decreased in 89% of patients, with median percent decreasing from 1.5% to 0.5% and completely disappearing in four of nine cases who had cryoglobulins measured after treatment. Serious adverse events were infrequent (17%). In contrast, the historical cohort treated with pegylated interferon and ribavirin experienced only 10% SVR12, with 100% experiencing at least one adverse event and 50% experiencing premature discontinuation due to adverse events. Conclusion: SVR12 rates for sofosbuvir-based DAA regimens in HCV-MCS were 83%, significantly higher than historical controls treated with pegylated interferon and ribavirin; patients with glomerulonephritis experienced improvement in renal function, including those not concomitantly treated with immunosuppression.
C1 [Sise, Meghan E.; Lundquist, Andrew L.; Steele, David; Williams, Winfred W.; Thadhani, Ravi] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
[Bloom, Allyson K.; Kim, Arthur Y.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
[Wisocky, Jessica; Gustafson, Jenna L.; Thiim, Michael; Chung, Raymond T.] Massachusetts Gen Hosp, Dept Med, Gastrointestinal Div, Ctr Liver, Boston, MA 02114 USA.
[Lin, Ming V.; Hashemi, Nikroo] Brigham & Womens Hosp, Dept Med, Div Gastroenterol & Hepatol, 75 Francis St, Boston, MA 02115 USA.
RP Chung, RT (reprint author), Massachusetts Gen Hosp, GI Div, Ctr Liver, Warren 1007,55 Fruit St, Boston, MA 02114 USA.
EM rtchung@partners.org
FU NIH National Institutes of Health grants [K24 DK078772]; NIH [U19
AI082630]; ASN Foundation for Kidney Research
FX Supported by NIH National Institutes of Health grants K24 DK078772 (to
R.T.C.), NIH and U19 AI082630 (to R.T.C. and, A.Y.K.) and the, ASN
Foundation for Kidney Research Fellows Award (to M.E.S.).
NR 32
TC 19
Z9 21
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD FEB
PY 2016
VL 63
IS 2
BP 408
EP 417
DI 10.1002/hep.28297
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EL6VS
UT WOS:000394761100012
PM 26474537
ER
PT J
AU Gardner, RC
Rabinovici, GD
AF Gardner, Raquel C.
Rabinovici, Gil D.
TI Evaluating and treating neurobehavioral symptoms in professional
American football players: Lessons from a case series Respond
SO NEUROLOGY-CLINICAL PRACTICE
LA English
DT Letter
C1 [Gardner, Raquel C.; Rabinovici, Gil D.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Gardner, Raquel C.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
EM raquel.gardner@ucsf.edu
FU American Academy of Neurology; Alzheimer's Association; Department of
Veterans Affairs; NIH/NIA; UCSF Pepper Center Research Career
Development Core; GE Healthcare; Rockpointe; Tau Consortium; Medscape;
Avid Radiopharmaceuticals/Eli Lilly; John Douglas French Alzheimer's
Foundation; Hellman Family Foundation
FX R.C. Gardner has received funding for travel from the American Academy
of Neurology and the Alzheimer's Association and has received research
support from the Department of Veterans Affairs, NIH/NIA, and UCSF
Pepper Center Research Career Development Core. G.D. Rabinovici has
received funding for travel and/or speaker honoraria from Alzheimer's
Association, GE Healthcare, Rockpointe, Tau Consortium, and Medscape and
receives research support from Avid Radiopharmaceuticals/Eli Lilly,
NIH/NIA, Alzheimer's Association, John Douglas French Alzheimer's
Foundation, Hellman Family Foundation, and Tau Consortium.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0402
EI 2163-0933
J9 NEUROL-CLIN PRACT
JI Neurol.-Clin. Pract.
PD FEB
PY 2016
VL 6
IS 1
BP 7
EP 8
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA EI6IT
UT WOS:000392599600006
ER
PT J
AU Kraakevik, J
AF Kraakevik, Jeff
TI Crafting a positive professional digital profile to augment your
practice
SO NEUROLOGY-CLINICAL PRACTICE
LA English
DT Editorial Material
AB A digital profile is the sum content about a person on the Internet. A digital profile can be composed of personal or professional information shared on public Web sites posted personally or by others. One of the most effective ways to build a positive professional digital profile is through social media. It is increasingly important to maintain a positive digital profile as others mine the Internet to find out about a professional prior to meeting him or her. As the digital environment continues to grow, it will become increasingly difficult to neglect a professional digital profile without potential negative consequences. There are many benefits to creating a digital presence and using the tools available to learn about neurology and interact with other professionals and patients in ways that were not possible in the past. The spread of social media to a large part of the population makes it unlikely to go away.
C1 [Kraakevik, Jeff] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
EM kraakevik@ohsu.edu
NR 13
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0402
EI 2163-0933
J9 NEUROL-CLIN PRACT
JI Neurol.-Clin. Pract.
PD FEB
PY 2016
VL 6
IS 1
BP 87
EP 93
DI 10.1212/CPJ.0000000000000211
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA EI6IT
UT WOS:000392599600024
ER
PT J
AU Karam, CY
Paganoni, S
Joyce, N
Carter, GT
Bedlack, R
AF Karam, Chafic Y.
Paganoni, Sabrina
Joyce, Nanette
Carter, Gregory T.
Bedlack, Richard
TI Palliative Care Issues in Amyotrophic Lateral Sclerosis: An
Evidenced-Based Review
SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
LA English
DT Review
DE amyotrophic lateral sclerosis; palliative care; hospice; alternative
medicine; quality of life
ID QUALITY STANDARDS SUBCOMMITTEE; PLASMA HOMOCYSTEINE LEVELS; PRACTICE
PARAMETER UPDATE; TRANSGENIC MOUSE MODEL; BODY-MASS INDEX; DOUBLE-BLIND;
VITAMIN-E; NEUROMUSCULAR DISEASE; CREATINE MONOHYDRATE;
PULMONARY-FUNCTION
AB As palliative care physicians become increasingly involved in the care of patients with amyotrophic lateral sclerosis (ALS), they will be asked to provide guidance regarding the use of supplements, diet, exercise, and other common preventive medicine interventions. Moreover, palliative care physicians have a crucial role assisting patients with ALS in addressing health care decisions to maximize quality of life and cope with a rapidly disabling disease. It is therefore important for palliative care physicians to be familiar with commonly encountered palliative care issues in ALS. This article provides an evidenced-based review of palliative care options not usually addressed in national and international ALS guidelines.
C1 [Karam, Chafic Y.] Univ N Carolina, Sch Med, Dept Neurol, Chapel Hill, NC 27599 USA.
[Paganoni, Sabrina] Harvard Univ, Massachusetts Gen Hosp, Spaulding Rehabil Hosp, Cambridge, MA 02138 USA.
[Paganoni, Sabrina] Boston VA Healthcare Syst, Boston, MA USA.
[Joyce, Nanette] Calif State Univ Sacramento, Davis Med Sch, Dept Phys Med & Rehabil, Neuromusc Sect, Sacramento, CA 95819 USA.
[Carter, Gregory T.] St Lukes Rehabil Inst, Dept Phys Med & Rehabil, Spokane, WA USA.
[Bedlack, Richard] Duke Univ, Sch Med, Durham, NC USA.
[Bedlack, Richard] Durham Vet Affairs Med Ctr, Durham, NC USA.
RP Karam, CY (reprint author), Univ N Carolina, Dept Neurol, Campus Box 7025, Chapel Hill, NC 27599 USA.
EM chafickaram@gmail.com
FU NICHD NIH HHS [K12 HD001097]
NR 77
TC 1
Z9 1
U1 3
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-9091
EI 1938-2715
J9 AM J HOSP PALLIAT ME
JI Am. J. Hosp. Palliat. Med.
PD FEB
PY 2016
VL 33
IS 1
BP 84
EP 92
DI 10.1177/1049909114548719
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DA3UT
UT WOS:000367725300013
PM 25202033
ER
PT J
AU Spencer, NY
Yan, ZY
Cong, L
Zhang, YL
Engelhardt, JF
Stanton, RC
AF Spencer, Netanya Y.
Yan, Ziying
Cong, Le
Zhang, Yulong
Engelhardt, John F.
Stanton, Robert C.
TI Definitive localization of intracellular proteins: Novel approach using
CRISPR-Cas9 genome editing, with glucose 6-phosphate dehydrogenase as a
model
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE Glucose 6-phosphate dehydrogenase; CRISPR-Cas9 genome engineering;
Nuclear localization signal; Knockout cell lines; Dimer; Multimer
ID GREEN FLUORESCENT PROTEIN; NUCLEAR-LOCALIZATION; MAMMALIAN-CELLS;
ENZYME-CYTOCHEMISTRY; CAS9; SPECIFICITY; REVEALS; BINDING
AB Studies to determine subcellular localization and translocation of proteins are important because subcellular localization of proteins affects every aspect of cellular function. Such studies frequently utilize mutagenesis to alter amino acid sequences hypothesized to constitute subcellular localization signals. These studies often utilize fluorescent protein tags to facilitate live cell imaging. These methods are excellent for studies of monomeric proteins, but for multimeric proteins, they are unable to rule out artifacts from native protein subunits already present in the cells. That is, native monomers might direct the localization of fluorescent proteins with their localization signals obliterated. We have developed a method for ruling out such artifacts, and we use glucose 6-phosphate dehydrogenase (G6PD) as a model to demonstrate the method's utility. Because G6PD is capable of homodimerization, we employed a novel approach to remove interference from native G6PD. We produced a G6PD knockout somatic (hepatic) cell line using CRISPR-Cas9 mediated genome engineering. Transfection of G6PD knockout cells with G6PD fluorescent mutant proteins demonstrated that the major subcellular localization sequences of G6PD are within the N-terminal portion of the protein. This approach sets a new gold standard for similar studies of subcellular localization signals in all homodimerization-capable proteins. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Spencer, Netanya Y.; Stanton, Robert C.] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Spencer, Netanya Y.; Stanton, Robert C.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Yan, Ziying; Zhang, Yulong; Engelhardt, John F.] Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA.
[Cong, Le] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Stanton, Robert C.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Spencer, NY (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.
EM netanya.spencer@joslin.harvard.edu
FU University of Iowa Roy J. Carver Chair in Molecular Medicine; National
Institute of Diabetes and Digestive and Kidney Diseases [R01 DK051315,
K01 DK083429]
FX This work was supported by the University of Iowa Roy J. Carver Chair in
Molecular Medicine, and the National Institute of Diabetes and Digestive
and Kidney Diseases Grants R01 DK051315 (to JFE) and K01 DK083429 (to
NYS). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript. The
authors declare that they have no competing interests. Although we did
not make use of HeLa-specific genome data, we did use a HeLa cell line
in this project, and we wish to acknowledge our sincere gratitude to
Henrietta Lacks, now deceased, and her surviving family members for
their contributions to biomedical research.
NR 30
TC 2
Z9 3
U1 4
U2 40
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
EI 1096-0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD FEB 1
PY 2016
VL 494
BP 55
EP 67
DI 10.1016/j.ab.2015.11.002
PG 13
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA DA4HV
UT WOS:000367761900012
PM 26576833
ER
PT J
AU Albergotti, WG
Byrd, JK
Nance, M
Choi, EC
Koh, YW
Kim, S
Duvvuri, U
AF Albergotti, William G.
Byrd, James K.
Nance, Melonie
Choi, Eun Chang
Koh, Yoon Woo
Kim, Seungwon
Duvvuri, Umamaheswar
TI Robot-Assisted Neck Dissection Through a Modified Facelift Incision
SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY
LA English
DT Article
DE head and neck squamous cell carcinoma; head and neck surgery; neck
dissection; surgical outcomes; treatment of head and neck tumors
ID SQUAMOUS-CELL-CARCINOMA; POSTOPERATIVE MORBIDITY; RETROAURICULAR
APPROACH; ORAL-CAVITY; HEAD; SURGERY; CANCER; LYMPHEDEMA; PAROTIDECTOMY;
EXPERIENCE
AB Objectives: The aim of this study is to describe the feasibility as well as oncologic outcomes of robot-assisted neck dissection (RAND) through a modified facelift incision in an American population.
Study Design: Retrospective case series.
Setting: University tertiary care hospital.
Methods: All patients who underwent RAND between November 2012 and December 2014 were included. Medical records were reviewed for demographics, medical histories, staging, operative information, postoperative hospital course and complications, and oncologic outcomes.
Results: There were 11 RANDs identified among 10 patients. Five patients had known nodal metastasis at the time of surgery. Two patients had been previously irradiated. The average time of surgery was 284.4 72.3 minutes, including other associated procedures. The average lymph node yield was 28.5 +/- 9.3 nodes. There were no major complications. Average follow-up was 19.4 months. There was 1 supraclavicular recurrence in a previously irradiated patient. All patients are currently alive and without evidence of disease.
Conclusions: Robot-assisted neck dissection is a safe and feasible procedure that can be performed by surgeons with familiarity with neck dissection and robot-assisted surgery and who have been trained in RAND. Appropriate oncologic outcomes can be obtained in a patient wishing to avoid a noticeable scar.
C1 [Albergotti, William G.; Byrd, James K.; Nance, Melonie; Kim, Seungwon; Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15213 USA.
[Nance, Melonie; Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA.
[Choi, Eun Chang; Koh, Yoon Woo] Yonsei Univ, Dept Otorhinolaryngol, Coll Med, Seoul, South Korea.
RP Duvvuri, U (reprint author), Univ Pittsburgh, Inst Eye & Ear, Dept Otolaryngol, Med Ctr, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA.
EM duvuriu@upmc.edu
FU Intuitive Surgical, Inc.; Department of Veterans Affairs BLRD; PNC
Foundation
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: Dr Byrd
was funded by a clinical robotics training and research grant from
Intuitive Surgical, Inc. This work was supported in part by a Career
Development Award from the Department of Veterans Affairs BLR&D and the
PNC Foundation (U.D).
NR 29
TC 0
Z9 0
U1 1
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0003-4894
EI 1943-572X
J9 ANN OTO RHINOL LARYN
JI Ann. Otol. Rhinol. Laryngol.
PD FEB
PY 2016
VL 125
IS 2
BP 123
EP 129
DI 10.1177/0003489415601127
PG 7
WC Otorhinolaryngology
SC Otorhinolaryngology
GA DA5NM
UT WOS:000367849800004
PM 26282589
ER
PT J
AU Yao, WC
Bleier, BS
AF Yao, William C.
Bleier, Benjamin S.
TI Endoscopic management of orbital tumors
SO CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY
LA English
DT Review
DE endoscopic orbital surgery; endoscopic surgery; intraorbital tumor
resection; nasoseptal flap; orbital tumor
ID TRANSETHMOIDAL APPROACH; APEX; LESIONS; RECONSTRUCTION; HEMANGIOMAS;
SURGERY; ANATOMY; MUSCLE; SINUS; FLAP
AB Purpose of reviewOrbital tumors have been classically approached via external incision. The introduction of endoscopic surgery has revolutionized the management of sinus and skull base disorder. Similarly, endoscopic techniques have been increasingly utilized to access intraorbital tumors located in the medial and inferior orbit with excellent outcomes. The history of the procedure, surgical anatomy of the orbit, patient selection, surgical planning, and the surgical techniques are discussed in this article.
Recent findingsAlthough the endoscopic management of orbital tumors is still in its infancy, it has already demonstrated enhanced access to the posterior orbit and orbital apex with decreased morbidity relative to external approaches.
SummaryA multidisciplinary team approach, including an oculoplastic surgeon, is an essential component for the surgical planning and management. As the cumulative surgical experience increases, the indications for this approach will likely continue to expand.
C1 [Yao, William C.] Univ Texas Houston, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Houston, TX 77030 USA.
[Bleier, Benjamin S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol Head & Neck Surg, Boston, MA USA.
RP Yao, WC (reprint author), Univ Texas Houston, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, 6431 Fannin St,MSB 5-036, Houston, TX 77030 USA.
EM William.c.yao@uth.tmc.edu
FU Massachusetts Eye and Ear Infirmary
FX B.S.B. is a consultant for Arthrocare, Gyrus Olympus, and Karl Storz,
and may receive royalties from Massachusetts Eye and Ear Infirmary.
W.C.Y has no conflicts of interest.
NR 23
TC 1
Z9 1
U1 6
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1068-9508
EI 1531-6998
J9 CURR OPIN OTOLARYNGO
JI Curr. Opin. Otolaryngol. Head Neck Surg.
PD FEB
PY 2016
VL 24
IS 1
BP 57
EP 62
DI 10.1097/MOO.0000000000000215
PG 6
WC Otorhinolaryngology
SC Otorhinolaryngology
GA DA2BC
UT WOS:000367599300011
PM 26575515
ER
PT J
AU Bishop, MW
Janeway, KA
Gorlick, R
AF Bishop, Michael W.
Janeway, Katherine A.
Gorlick, Richard
TI Future directions in the treatment of osteosarcoma
SO CURRENT OPINION IN PEDIATRICS
LA English
DT Review
DE genomic complexity; immunotherapy; osteosarcoma; targeted therapy; TP53
ID HIGH-GRADE OSTEOSARCOMA; PRECLINICAL TESTING PROGRAM; CHILDRENS ONCOLOGY
GROUP; METASTATIC OSTEOSARCOMA; MURAMYL TRIPEPTIDE; ANTIBODY BLOCKADE;
STAGE 1; SORAFENIB; SURVIVAL; TRIAL
AB Purpose of reviewOverall survival rates for osteosarcoma have remained essentially unchanged over the past 3 decades despite attempts to improve outcome via dose intensification and modification based on response. This review describes recent findings from contemporary clinical trials, advances in the comprehension of osteosarcoma biology and genomic complexity, and potential opportunities using targeted and immune-mediated therapies.Recent findingsRecent results from international collaborative trials have failed to demonstrate an ability to improve outcomes using a design in which the randomized question is dictated based on histologic response to preoperative chemotherapy. Novel prognostic markers assessable at diagnosis are vital to identifying subsets of osteosarcoma. Clinical trials focus has now shifted to serial phase II studies of novel agents to evaluate for activity in recurrent and refractory disease. In-depth analyses have revealed profound genomic instability and heterogeneity across patients, with nearly universal TP53 aberration. Although driver mutational events have not clearly been established, frequent derangements in specific pathways may suggest opportunities for therapeutic exploitation. Genomic complexity may lend support to a role for immune-mediated therapies.SummaryRigorous preclinical investigations are potentially generating novel strategies for the treatment of osteosarcoma that will inform the next generation of clinical trials, with the opportunity to identify agents that will improve survival outcomes.
C1 [Bishop, Michael W.] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA.
[Bishop, Michael W.] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA.
[Janeway, Katherine A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gorlick, Richard] Childrens Hosp Montefiore, Div Pediat Hematol Oncol, Bronx, NY USA.
RP Gorlick, R (reprint author), Childrens Hosp Montefiore, 3415 Bainbridge Ave,Rosenthal Pavil,Room 300, Bronx, NY 10467 USA.
EM rgorlick@montefiore.org
FU NCATS NIH HHS [UL1 TR001425]; NCI NIH HHS [U01 CA199221, P30 CA013330]
NR 47
TC 2
Z9 4
U1 4
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8703
EI 1531-698X
J9 CURR OPIN PEDIATR
JI CURR. OPIN. PEDIATR.
PD FEB
PY 2016
VL 28
IS 1
BP 26
EP 33
DI 10.1097/MOP.0000000000000298
PG 8
WC Pediatrics
SC Pediatrics
GA DA4AJ
UT WOS:000367742200005
PM 26626558
ER
PT J
AU Held, KD
Woloschak, GE
AF Held, Kathryn D.
Woloschak, Gayle E.
TI NCRP PROGRAM AREA COMMITTEE 1: BASIC CRITERIA, EPIDEMIOLOGY,
RADIOBIOLOGYAND RISK
SO HEALTH PHYSICS
LA English
DT Article
DE National Council on Radiation Protection and Measurements; epidemiology;
radiation biology; radiation risk
AB NCRP Program Area Committee (PAC) 1 addresses fundamental issues on basic criteria, epidemiology, radiation biology, and risk with regard to radiation protection and measurements. PAC 1 has overseen the work of Scientific Committee 1-22, which produced a Commentary published in November 2014 and has four active committees working on reports or commentaries providing guidance to a number of U.S. government agencies in diverse areas, including effects of low dose and low energy radiations and space radiation.
C1 [Held, Kathryn D.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Woloschak, Gayle E.] Northeastern Univ, Chicago, IL USA.
RP Held, KD (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Cox 302,55 Fruit St, Boston, MA 02114 USA.
EM kheld@partners.org
RI Woloschak, Gayle/A-3799-2017
OI Woloschak, Gayle/0000-0001-9209-8954
NR 12
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0017-9078
EI 1538-5159
J9 HEALTH PHYS
JI Health Phys.
PD FEB
PY 2016
VL 110
IS 2
BP 98
EP 100
DI 10.1097/HP.0000000000000402
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA DA5CC
UT WOS:000367818700002
PM 26717156
ER
PT J
AU Brink, JA
Miller, DL
AF Brink, James A.
Miller, Donald L.
TI NCRP PROGRAM AREA COMMITTEE 4: RADIATION PROTECTION IN MEDICINE
SO HEALTH PHYSICS
LA English
DT Article
DE National Council on Radiation Protection and Measurements; fluoroscopy;
radiation protection; radiation; medical
AB Program Area Committee (PAC) 4 deals with issues in radiation protection in healthcare settings. NCRP Statement No. 11 was published at the end of 2014, and three active scientific committees (SC) are at workSC 4-5, SC 4-7, and SC 4-8. PAC 4 is also considering a number of topics that could be addressed by new scientific committees in the future.
C1 [Brink, James A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Miller, Donald L.] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD USA.
RP Brink, JA (reprint author), Massachusetts Gen Hosp, 175 Cambridge St,2nd Floor, Boston, MA 02114 USA.
EM jabrink@partners.org
NR 3
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0017-9078
EI 1538-5159
J9 HEALTH PHYS
JI Health Phys.
PD FEB
PY 2016
VL 110
IS 2
BP 106
EP 108
DI 10.1097/HP.0000000000000403
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA DA5CC
UT WOS:000367818700005
PM 26717159
ER
PT J
AU Berin, MC
Shreffler, WG
AF Berin, M. Cecilia
Shreffler, Wayne G.
TI Mechanisms Underlying Induction of Tolerance to Foods
SO IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Tolerance; Treg; Foxp3; IgE; IgG4; Immunotherapy; Microbiota
ID REGULATORY T-CELLS; CD103(+) DENDRITIC CELLS; PEANUT ORAL IMMUNOTHERAPY;
PROMOTES ALLERGIC SENSITIZATION; PEYERS-PATCHES; AUTOIMMUNE
ENCEPHALOMYELITIS; IMMUNE-RESPONSES; FOXP3 EXPRESSION; IGG ANTIBODIES;
GUT MICROBIOTA
AB Oral tolerance refers to a systemic immune nonresponsiyeness to antigens first encountered by the oral route, and a failure in development of this homeostatic process can result in food allergy. Clinical tolerance induced by allergen immunotherapy is associated with alterations in immune mechanisms relevant to the allergic response, including reduction of basophil reactivity, induction of IgG4, loss of effector Th2 cells, and induction of Tregs. The relative contribution of these immune changes to clinical tolerance to foods, and the duration of these immune changes after termination of immunotherapy, remains to be identified.
C1 [Berin, M. Cecilia] Icahn Sch Med Mt Sinai, Immunol Inst, Pediat Allergy & Immunol Mindich Child Hlth & Dev, New York, NY 10029 USA.
[Shreffler, Wayne G.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02129 USA.
RP Berin, MC (reprint author), Icahn Sch Med Mt Sinai, Immunol Inst, Pediat Allergy & Immunol Mindich Child Hlth & Dev, One Gustave L Levy Pl,Box 1198, New York, NY 10029 USA.
EM cecilia.berin@mssm.edu
FU NIDDK NIH HHS [P30 DK040561]
NR 74
TC 6
Z9 7
U1 3
U2 15
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8561
EI 1557-8607
J9 IMMUNOL ALLERGY CLIN
JI Immunol. Allerg. Clin. North Am.
PD FEB
PY 2016
VL 36
IS 1
BP 87
EP +
DI 10.1016/j.iac.2015.08.002
PG 17
WC Allergy; Immunology
SC Allergy; Immunology
GA DA4JR
UT WOS:000367766700009
PM 26617229
ER
PT J
AU Shumway, DA
Abu-Isa, E
Soto, DE
Do, TT
Jagsi, R
AF Shumway, Dean A.
Abu-Isa, Eyad
Soto, Daniel E.
Thy Thy Do
Jagsi, Reshma
TI Depigmentation Within the Radiation Field in Patients With Vitiligo
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID BREAST-CANCER; RADIOTHERAPY; CARCINOMA; SITE
C1 [Shumway, Dean A.; Abu-Isa, Eyad; Jagsi, Reshma] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.
[Thy Thy Do] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA.
[Soto, Daniel E.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Jagsi, R (reprint author), Univ Michigan, Dept Radiat Oncol, UHB2C490,SPC 5010,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM rjagsi@med.umich.edu
OI Jagsi, Reshma/0000-0001-6562-1228
NR 10
TC 0
Z9 0
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD FEB 1
PY 2016
VL 94
IS 2
BP 421
EP 422
DI 10.1016/j.ijrobp.2015.10.018
PG 2
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA DA0XX
UT WOS:000367522000025
PM 26853347
ER
PT J
AU Oral, E
Neils, AL
Doshi, BN
Fu, J
Muratoglu, OK
AF Oral, Ebru
Neils, Andrew L.
Doshi, Brinda N.
Fu, Jun
Muratoglu, Orhun K.
TI Effects of simulated oxidation on the in vitro wear and mechanical
properties of irradiated and melted highly crosslinked UHMWPE
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS
LA English
DT Article
DE joint replacement; oxidation; crosslink density; elongation-at-break;
tensile strength
ID MOLECULAR-WEIGHT POLYETHYLENE; TOTAL KNEE ARTHROPLASTY; TOTAL
HIP-ARTHROPLASTY; VIVO OXIDATION; PROPAGATION RESISTANCE; ACETABULAR
COMPONENTS; GAMMA-STERILIZATION; FATIGUE RESISTANCE; FREE-RADICALS;
VITAMIN-E
AB Radiation crosslinked ultrahigh molecular weight polyethylene (UHMWPE) have reduced the wear rate of the bearing surface in total joint arthroplasty and the incidence of peri-prosthetic bone loss due to wear particles. The oxidation potential afforded to the material by the trapped residual free radicals after irradiation was addressed in first generation crosslinked UHMWPEs by using thermal treatments such as annealing or melting after irradiation. Postirradiation melted crosslinked UHMWPE did not contain detectable free radicals at the time of implantation and was expected to be resistant against oxidation for the lifetime of the implants. Recent analyses of long-term retrievals showed it was possible for irradiated and melted UHMWPEs to oxidize in vivo but studies on the effects of oxidation on these materials have been limited. In this study, we determined the effects of in vitro aging on the wear and mechanical properties of irradiated and melted UHMWPE as a function of radiation dose and found that even small amount of oxidation (oxidation index of 0.1) can have detrimental effects on its mechanical properties. There was a gradual increase in the wear rate below an oxidation index of 1 and a drastic increase thereafter. Therefore, it was shown in a simulated environment that oxidation can have detrimental effects to the clinically relevant properties of irradiated and melted UHMWPEs. (c) 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 104B: 316-322, 2016.
C1 [Oral, Ebru; Neils, Andrew L.; Doshi, Brinda N.; Fu, Jun; Muratoglu, Orhun K.] Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA.
[Oral, Ebru; Fu, Jun; Muratoglu, Orhun K.] Harvard Univ, Sch Med, Dept Orthopaed Surg, Boston, MA 02115 USA.
RP Oral, E (reprint author), Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA.
EM eoral@partners.org
NR 53
TC 2
Z9 3
U1 4
U2 19
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4973
EI 1552-4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD FEB
PY 2016
VL 104
IS 2
BP 316
EP 322
DI 10.1002/jbm.b.33368
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA DA5HO
UT WOS:000367834100010
PM 25766106
ER
PT J
AU Browne, KC
Wray, TB
Stappenbeck, CA
Krenek, M
Simpson, TL
AF Browne, Kendall C.
Wray, Tyler B.
Stappenbeck, Cynthia A.
Krenek, Marketa
Simpson, Tracy L.
TI Alcohol Consumption, Craving, and Craving Control Efforts Assessed Daily
in the Context of Readiness to Change Among Individuals with Alcohol
Dependence and PTSD
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE Alcohol; PTSD; Craving; Motivation to change
ID POSTTRAUMATIC-STRESS-DISORDER; ECOLOGICAL MOMENTARY ASSESSMENT;
COMPULSIVE DRINKING SCALE; SUBSTANCE USE; CUE-REACTIVITY; PREDICTOR;
DRINKERS; VALIDITY; TRAUMA; MODEL
AB Research has demonstrated the positive association between alcohol craving and alcohol use and has identified craving as a central component of alcohol use disorders (AUD). Despite potential clinical implications, few studies have examined the relationship between craving and alcohol use in individuals with AUD and common psychiatric comorbidities or explored possible moderators of the craving-alcohol use relationship. The current study used daily monitoring data to: 1) replicate previous findings detecting a positive relationship between craving and alcohol use in individuals with AUD and co-occurring posttraumatic stress disorder (PTSD) and 2) extend these findings by examining the influence of initial change motivation on the craving-use relationship and within-day associations among craving, efforts to control craving, and alcohol consumption. Participants were 84 individuals with alcohol dependence and PTSD enrolled in an intervention study. Generalized estimating equations using pre-treatment baseline daily data revealed significant main effects for craving, craving control, and motivation to change alcohol use. Daily craving was positively related to alcohol use. Greater change motivation and craving control (i.e., efforts to resist craving, avoidance of thoughts and feelings related to craving) were negatively related to alcohol use. A significant interaction was detected between baseline change motivation and daily craving indicating that the association between craving and alcohol use was significantly stronger for those with low baseline change motivation. A significant interaction was also detected between craving control and daily craving, suggesting that participants were more likely to consume alcohol when experiencing high levels of craving if they reported low levels of craving control. Findings bolster the idea that efforts to prevent or ameliorate craving are critical to treatment success for individuals with AUD and PTSD who are seeking to reduce or quit drinking. Published by Elsevier Inc.
C1 [Browne, Kendall C.; Krenek, Marketa; Simpson, Tracy L.] VA Puget Sound Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98018 USA.
[Wray, Tyler B.; Simpson, Tracy L.] VA Puget Sound Healthcare Syst, Seattle, WA 98018 USA.
[Browne, Kendall C.; Stappenbeck, Cynthia A.; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Simpson, Tracy L.] VA Puget Sound Hlth Care, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98018 USA.
RP Simpson, TL (reprint author), VA Puget Sound Healthcare Syst, 1660 S Columbian Way,CESATE-116, Seattle, WA 98018 USA.
EM tracy.simpson@va.gov
FU NIH/NIAAA [R21 AA17130-01, R01 AA020252-01]
FX This material is the result of work supported by NIH/NIAAA awards (GRANT
R21 AA17130-01; R01 AA020252-01) to Dr. Tracy Simpson and by resources
from the Center of Excellence in Substance Abuse Treatment and Education
(CESATE), the Mental Illness Research, Education, and Clinical Center
(MIRECC), the US Department of Veterans Affairs Office of Academic
Affiliations, Advanced Fellowship Program in Mental Illness Research and
Treatment, and the VA Puget Sound Health Care System, Seattle, WA. The
views expressed in this article are those of the authors and do not
represent the views of the Department of Veteran Affairs or the United
States government. Dr. Tyler Wray is now affiliated with the Department
of Behavioral and Social Sciences, Brown University, School of Public
Health, 121 South Main St., Providence RI 02912.
NR 58
TC 1
Z9 1
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD FEB
PY 2016
VL 61
BP 34
EP 41
DI 10.1016/j.jsat.2015.09.005
PG 8
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA DA4HP
UT WOS:000367761200005
PM 26597623
ER
PT J
AU Serafini, K
Shipley, L
Stewart, DG
AF Serafini, Kelly
Shipley, Leandra
Stewart, David G.
TI Motivation and substance use outcomes among adolescents in a
school-based intervention
SO ADDICTIVE BEHAVIORS
LA English
DT Article
DE Stages of change; Adolescence; Substance use; Alcohol; Marijuana;
Motivation; Transtheoretical Model of Change
ID ALCOHOL PROBLEM INDEX; ABUSE TREATMENT; TRANSTHEORETICAL MODEL;
COLLEGE-STUDENTS; DRINKING; READINESS; CONSEQUENCES; SAMPLE; SCALE;
STAGE
AB The stages of change (Precontemplation, Contemplation, Preparation, Action, and Maintenance) have been well studied in adult populations. However, fewer studies have examined how the stages of change are related to adolescent substance use. Furthermore, there have been no studies that have examined how the stages of change relate to outcomes in a school-based intervention. To better capture adolescent motivation, we added an additional group to the Transtheoretical Model of Change, which we titled Coerced Action, to represent adolescents that made changes to their substance use despite low problem recognition (representing the internal motivation of Precontemplation and the change behaviors of the Action group). We then examined how the stages of change were related to a thorough assessment of substance use at baseline and corresponding treatment outcomes. Our sample consisted of 264 adolescents (mean age: 16.1,44.5% Caucasian, 37.5% female) who participated in an 8-week, school-based Motivational Enhancement intervention. Results indicated significant group differences across the stages of change in substance use patterns (alcohol use, negative consequences, affective dysregulation), as well as treatment outcomes (alcohol use and negative consequences). For instance, adolescents in the Action group demonstrated more negative consequences at 16 weeks follow-up than those in Precontemplation and Coerced Action, F(1, 3) = 8.23,p <.001. The Coerced Action group reported the most alcohol use at 16 weeks follow-up, although the finding was not significant when post-hoc tests were conducted. This study provides meaningful support for the assessment of motivation among adolescent substance users within school-based settings. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Serafini, Kelly] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06511 USA.
[Shipley, Leandra] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Stewart, David G.] Seattle Pacific Univ, Dept Clin Psychol, Seattle, WA 98119 USA.
RP Serafini, K (reprint author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06511 USA.
EM kelly.serafini@yale.edu
FU National Institute on Drug Abuse (NIDA) [T32DA007238-23, R03DA12974-01]
FX This research was supported in part through a National Institute on Drug
Abuse (NIDA) grantT32DA007238-23 (Petrakis) and R03DA12974-01 (Project
READY; PI: Stewart). We wish to acknowledge Michael Toohey, Ph.D., who
provided feedback on this project. We also wish to thank the
participants, research staff, and colleagues who participated in the
original clinical trial.
NR 35
TC 4
Z9 4
U1 5
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
EI 1873-6327
J9 ADDICT BEHAV
JI Addict. Behav.
PD FEB
PY 2016
VL 53
BP 74
EP 79
DI 10.1016/j.addbeh.2015.10.004
PG 6
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA CZ7KR
UT WOS:000367278800012
PM 26458191
ER
PT J
AU Hiraoka, R
Cook, AJ
Bivona, JM
Meyer, EC
Morissette, SB
AF Hiraoka, Regina
Cook, Andrew J.
Bivona, Jenny M.
Meyer, Eric C.
Morissette, Sandra B.
TI Acceptance and Commitment Therapy in the Treatment of Depression Related
to Military Sexual Trauma in a Woman Veteran: A Case Study
SO CLINICAL CASE STUDIES
LA English
DT Article
DE acceptance and commitment therapy; military sexual trauma; depression;
Veterans
ID AFGHANISTAN; OUTCOMES; ANXIETY; IRAQ
AB Depression is commonly reported by Veterans who have experienced military sexual trauma (MST). An increasing body of literature supports the use of Acceptance and Commitment Therapy (ACT) for the treatment of depression among civilians and military Veterans; however, additional research is needed, particularly among people exposed to trauma. This clinical case study describes the application of ACT with a 21-year-old woman Veteran who sought treatment for depression related to MST. The Veteran's depression symptoms decreased substantially over the course of therapy. Moreover, she demonstrated increased ability to attend to the present moment, tolerate feelings of uncertainty, and make decisions consistent with her chosen values. Treatment implications of these findings are discussed, with an emphasis on the unique aspects of using ACT in the treatment of MST-related depression among Veterans.
C1 [Hiraoka, Regina; Cook, Andrew J.; Bivona, Jenny M.; Meyer, Eric C.; Morissette, Sandra B.] Cent Texas Vet Hlth Care Syst, Waco, TX 76711 USA.
[Hiraoka, Regina; Cook, Andrew J.; Meyer, Eric C.; Morissette, Sandra B.] US Dept Vet Affairs, Washington, DC USA.
[Cook, Andrew J.; Meyer, Eric C.; Morissette, Sandra B.] Texas A&M Hlth Sci Ctr, Coll Med, Bryan, TX USA.
RP Hiraoka, R (reprint author), Cent Texas Vet Hlth Care Syst, 4800 Mem Dr, Waco, TX 76711 USA.
EM regina.hiraoka@va.gov
FU Veterans Health Administration
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This
research was supported by the Veterans Health Administration.
NR 26
TC 0
Z9 0
U1 4
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-6501
EI 1552-3802
J9 CLIN CASE STUD
JI Clin. Case Stud.
PD FEB
PY 2016
VL 15
IS 1
BP 84
EP 97
DI 10.1177/1534650115594004
PG 14
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA DA0FJ
UT WOS:000367472400006
ER
PT J
AU Walker, AM
Zhou, XF
Ananthakrishnan, AN
Weiss, LS
Shen, RJ
Sobel, RE
Bate, A
Reynolds, RF
AF Walker, Alexander M.
Zhou, Xiaofeng
Ananthakrishnan, Ashwin N.
Weiss, Lisa S.
Shen, Rongjun
Sobel, Rachel E.
Bate, Andrew
Reynolds, Robert F.
TI Computer-assisted expert case definition in electronic health records
SO INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS
LA English
DT Article
DE Health outcomes; Case definition; Electronic health records; Insurance
claims data; Safety surveillance
ID INFLAMMATORY-BOWEL-DISEASE; ACUTE LIVER-INJURY; NEURAL-NETWORKS;
IDENTIFICATION; COMPLICATIONS; VALIDATION; DATABASES; CANCER
AB Purpose: To describe how computer-assisted presentation of case data can lead experts to infer machine-implementable rules for case definition in electronic health records. As an illustration the technique has been applied to obtain a definition of acute liver dysfunction (ALD) in persons with inflammatory bowel disease (IBD).
Methods: The technique consists of repeatedly sampling new batches of case candidates from an enriched pool of persons meeting presumed minimal inclusion criteria, classifying the candidates by a machine-implementable candidate rule and by a human expert, and then updating the rule so that it captures new distinctions introduced by the expert. Iteration continues until an update results in an acceptably small number of changes to form a final case definition.
Results: The technique was applied to structured data and terms derived by natural language processing from text records in 29,336 adults with IBD. Over three rounds the technique led to rules with increasing predictive value, as the experts identified exceptions, and increasing sensitivity, as the experts identified missing inclusion criteria. In the final rule inclusion and exclusion terms were often keyed to an ALD onset date. When compared against clinical review in an independent test round, the derived final case definition had a sensitivity of 92% and a positive predictive value of 79%.
Conclusion: An iterative technique of machine-supported expert review can yield a case definition that accommodates available data, incorporates pre-existing medical knowledge, is transparent and is open to continuous improvement. The expert updates to rules may be informative in themselves. In this limited setting, the final case definition for ALD performed better than previous, published attempts using expert definitions. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Walker, Alexander M.] WHISCON, Newton, MA 02466 USA.
[Zhou, Xiaofeng; Weiss, Lisa S.; Shen, Rongjun; Sobel, Rachel E.; Bate, Andrew; Reynolds, Robert F.] Pfizer, Epidemiol Res & Dev, Worldwide Safety & Regulatory, New York, NY 10017 USA.
[Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Crohns & Colitis Ctr, Div Gastroenterol, Boston, MA 02114 USA.
RP Walker, AM (reprint author), WHISCON, 275 Grove St, Newton, MA 02466 USA.
EM AlecWalker@WHISCON.com
OI Walker, Alexander/0000-0001-9738-5127; Sobel, Rachel/0000-0002-4492-9562
FU Pfizer, Inc.
FX This work was conducted using Pfizer, Inc., internal funds and under a
research contract between Pfizer and World Health Information Science
Consultants. L.W., X.Z., R.S., R.E.S., A.B. and R.R. are employees and
shareholders of Pfizer, Inc. The views expressed herein are the authors'
and do not necessarily represent those of Pfizer, Inc.
NR 21
TC 1
Z9 1
U1 3
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 1386-5056
EI 1872-8243
J9 INT J MED INFORM
JI Int. J. Med. Inform.
PD FEB
PY 2016
VL 86
BP 62
EP 70
DI 10.1016/j.ijmedinf.2015.10.005
PG 9
WC Computer Science, Information Systems; Health Care Sciences & Services;
Medical Informatics
SC Computer Science; Health Care Sciences & Services; Medical Informatics
GA CZ8NS
UT WOS:000367357000009
PM 26725697
ER
PT J
AU Szot, P
Franklin, A
Miguelez, C
Wang, YQ
Vidaurrazaga, I
Ugedo, L
Sikkema, C
Wilkinson, CW
Raskind, MA
AF Szot, Patricia
Franklin, Allyn
Miguelez, Cristina
Wang, Yangqing
Vidaurrazaga, Igor
Ugedo, Luisa
Sikkema, Carl
Wilkinson, Charles W.
Raskind, Murray A.
TI Depressive-like behavior observed with a minimal loss of locus coeruleus
(LC) neurons following administration of 6-hydroxydopamine is associated
with electrophysiological changes and reversed with precursors of
norepinephrine
SO NEUROPHARMACOLOGY
LA English
DT Article
DE Locus coeruleus; 6-Hydroxydopamine; Forced swim test; Electrophysiology;
Depression
ID MILD COGNITIVE IMPAIRMENT; NORADRENERGIC NERVOUS-SYSTEM;
DOPAMINE-BETA-HYDROXYLASE; WISTAR-KYOTO RATS; ALZHEIMERS-DISEASE;
ANTIDEPRESSANT DRUGS; PARKINSONS-DISEASE; ANIMAL-MODEL; SENILE DEMENTIA;
DEFICIENT MICE
AB Depression is a common co-morbid condition most often observed in subjects with mild cognitive impairment (MCI) and during the early stages of Alzheimer's disease (AD). Dysfunction of the central noradrenergic nervous system is an important component in depression. In AD, locus coeruleus (LC) noradrenergic neurons are significantly reduced pathologically and the reduction of LC neurons is hypothesized to begin very early in the progression of the disorder; however, it is not known if dysfunction of the noradrenergic system due to early LC neuronal loss is involved in mediating depression in early AD. Therefore, the purpose of this study was to determine in an animal model if a loss of noradrenergic LC neurons results in depressive-like behavior. The LC noradrenergic neuronal population was reduced by the bilateral administration of the neurotoxin 6-hydroxydopamine (6-OHDA) directly into the LC. Forced swim test (FST) was performed three weeks after the administration of 6-OHDA (5, 10 and 14 mu g/mu l), animals administered the 5 mu g/mu l of 6-OHDA demonstrated a significant increase in immobility, indicating depressive-like behavior. This increase in immobility at the 5 mu g/mu l dose was observed with a minimal loss of LC noradrenergic neurons as compared to LC neuronal loss observed at 10 and 14 mu g/mu l dose. A significant positive correlation between the number of surviving LC neurons after 6-OHDA and FST immobile time was observed, suggesting that in animals with a minimal loss of LC neurons (or a greater number of surviving LC neurons) following 6-OHDA demonstrated depressive-like behavior. As the 6-OHDA-induced loss of LC neurons is increased, the time spent immobile is reduced. Depressive-like behavior was also observed with the 5 mu g/mu l dose of 6-OHDA with a second behavior test, sucrose consumption. FST increased immobility following 6-OHDA (5 mu g/mu l) was reversed by the administration of a single dose of L-1-3-4-dihydroxyphenylalanine (DOPA) or t-threo-3,4-dihydroxyphenylserine (DOPS) prior to behavioral assessment. Surviving LC neurons 3 weeks after 6-OHDA (5 mu g/mu l) demonstrated compensatory changes of increased firing frequency, a more irregular firing pattern, and a higher percentage of cells firing in bursts.
These results indicate that depressive-like behavior in mice is observed following the administration of 6-OHDA and the loss of LC noradrenergic neurons; however, the depressive-like behavior correlates positively with the number of surviving LC neurons with 6-OHDA administration. This data suggests the depression observed in MCI subjects and in the early stages of AD may due to the hypothesized early, minimal loss of LC neurons with remaining LC neurons being more active than normal. Published by Elsevier Ltd.
C1 [Szot, Patricia; Franklin, Allyn; Wang, Yangqing; Raskind, Murray A.] Vet Adm Puget Sound Hlth Care Syst, Educ & Clin Ctr, Mental Illness Res, Seattle, WA USA.
[Szot, Patricia; Wilkinson, Charles W.; Raskind, Murray A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Miguelez, Cristina; Vidaurrazaga, Igor; Ugedo, Luisa] Univ Basque Country, UPV EHU, Dept Pharmacol, Leioa, Spain.
[Sikkema, Carl; Wilkinson, Charles W.] Vet Adm Puget Sound Hlth Care Syst, Educ & Clin Ctr, Geriatr Res, Seattle, WA USA.
[Miguelez, Cristina] Univ Basque Country, UPV EHU, Dept Pharmacol, Vitoria, Spain.
RP Szot, P (reprint author), VA Puget Sound Hlth Care Syst, MIRECC, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM szot@uw.edu
RI Ugedo, Luisa/H-4244-2015;
OI Ugedo, Luisa/0000-0001-5993-0606; Miguelez, Cristina/0000-0001-6624-2932
FU Department of Veterans Affairs VISN 20 (Northwest Network) Mental
Illness Research, Education, and Clinical Center (MIRECC); Geriatric
Research, Education, and Clinical Center (GRECC); University of
Washington Department of Psychiatry and Behavioral Science; Basque
Government [UFI 11/32]; Spanish Government [FIS PI12/00613]
FX This work was supported by Department of Veterans Affairs VISN 20
(Northwest Network) Mental Illness Research, Education, and Clinical
Center (MIRECC; Patricia Szot, Allyn Franklin, Murray A Raskind),
Geriatric Research, Education, and Clinical Center (GRECC; Carl Sikkema,
Charles Wilkinson), University of Washington Department of Psychiatry
and Behavioral Science (Patricia Szsot, Murray A Raskind) and grants
form the Basque Government (UFI 11/32) and the Spanish Government (FIS
PI12/00613) (Cristiria Miguelez, Luisa Ugedo). These institutions had no
further competing financial interest in relation to the work described.
The authors declare no conflict of interest.
NR 62
TC 1
Z9 1
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
EI 1873-7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD FEB
PY 2016
VL 101
BP 76
EP 86
DI 10.1016/j.neuropharm.2015.09.003
PG 11
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DA0JQ
UT WOS:000367483800008
PM 26362360
ER
PT J
AU Bouchard, C
Peacock, ZS
Troulis, MJ
AF Bouchard, Carl
Peacock, Zachary S.
Troulis, Maria J.
TI Pediatric Vascular Tumors of the Head and Neck
SO ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Hemangiomas; Vascular; Lesions; Pediatric
ID GIANT-CELL GRANULOMA; JUVENILE NASOPHARYNGEAL ANGIOFIBROMA; ANEURYSMAL
BONE-CYSTS; INFANTILE HEMANGIOMAS; CALCITONIN THERAPY; ANTIANGIOGENIC
THERAPY; ALTERNATIVE TREATMENT; ENDOSCOPIC RESECTION; PYOGENIC
GRANULOMA; CONTROLLED-TRIAL
AB Oral and maxillofacial surgeons are often involved in the diagnosis and treatment of vascular neoplasms of the head and neck. An incorrect diagnosis may lead to improper or unnecessary treatment. This article reviews the diagnosis and management of vascular tumors.
C1 [Bouchard, Carl] Univ Laval, Ctr Hosp Univ Quebec, Hop Enfant Jesus, Quebec City, PQ, Canada.
[Peacock, Zachary S.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
[Troulis, Maria J.] Harvard Univ, Sch Dent Med, Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02115 USA.
RP Bouchard, C (reprint author), Univ Laval, Ctr Hosp Univ Quebec, Hop Enfant Jesus, Quebec City, PQ, Canada.
EM carlbchrd@gmail.com
NR 60
TC 0
Z9 0
U1 1
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1042-3699
EI 1558-1365
J9 ORAL MAXIL SURG CLIN
JI Oral Maxillofac. Surg. Clin. N. Am.
PD FEB
PY 2016
VL 28
IS 1
BP 105
EP +
DI 10.1016/j.coms.2015.07.010
PG 10
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA CZ6KI
UT WOS:000367209800011
PM 26293330
ER
PT J
AU Voog, JC
Paulus, R
Shipley, WU
Smith, MR
McGowan, DG
Jones, CU
Bahary, JP
Zeitzer, KL
Souhami, L
Leibenhaut, MH
Rotman, M
Husain, SM
Gore, E
Raben, A
Chafe, S
Sandler, HM
Efstathiou, JA
AF Voog, Justin C.
Paulus, Rebecca
Shipley, William U.
Smith, Matthew R.
McGowan, David G.
Jones, Christopher U.
Bahary, Jean-Paul
Zeitzer, Kenneth L.
Souhami, Luis
Leibenhaut, Mark H.
Rotman, Marvin
Husain, Siraj M.
Gore, Elizabeth
Raben, Adam
Chafe, Susan
Sandler, Howard M.
Efstathiou, Jason A.
TI Cardiovascular Mortality Following Short-term Androgen Deprivation in
Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08
SO EUROPEAN UROLOGY
LA English
DT Article
DE Prostate cancer; Hormone therapy; Radiation therapy; Cardiovascular
mortality; Androgen deprivation therapy; Survival
ID PHASE-III TRIAL; RADIATION-ONCOLOGY; RANDOMIZED-TRIAL; THERAPY;
RADIOTHERAPY; SUPPRESSION; RISK; MEN; DISEASE; CARCINOMA
AB Background: Androgen deprivation therapy (ADT) is associated with coronary heart disease and diabetes in men with prostate cancer (PCa); however, controversy exists regarding ADT and cardiovascular mortality (CVM) with limited data for lower risk disease.
Objective: We conducted a hypothesis-generating retrospective analysis to evaluate the relationship between short-course ADT and CVM in patients with clinically localized PCa enrolled in a phase III trial.
Design, setting, and participants: A total of 1979 men with clinically localized (T1b-2b, prostate-specific antigen [PSA] <20 ng/ml) PCa enrolled in Radiation Therapy Oncology Group (RTOG) 94-08 from 1994 to 2001. Patients were randomized to radiation therapy (RT) with or without short-course ADT (4 mo of gonadotropin-releasing hormone (GnRH) agonist therapy and antiandrogen). Median follow-up was 9.1 yr for survivors.
Outcome measurements and statistical analysis: The Cox proportional hazards model assessed overall survival. The Fine-Gray proportional hazards model assessed disease-specific survival (DSS) and CVM. Covariates included age, race, weight, baseline cardiovascular disease, baseline diabetes, baseline hypertension, Gleason score, T stage, and PSA.
Results and limitations: Short-course ADT improved overall survival and DSS and was not associated with an increased risk of CVM. Overall, 191 cardiovascular-related deaths were observed. At 10 yr, 83 patients (cumulative incidence rate: 10%) receiving RT and ADT versus 95 patients (cumulative incidence rate: 11%) receiving RT alone experienced CVM. The treatment arm was not associated with increased CVM (unadjusted hazard ratio: 1.07; confidence interval, 0.81-1.42; p = 0.62). Increased CVM was not observed in patients at low risk of PCa death or at high risk of cardiac-related death.
Conclusions: Data from patients enrolled in RTOG 94-08 support the hypothesis that ADT does not increase CVM risk in men with clinically localized PCa treated with short-course GnRH agonist therapy. These data support ADT use in settings with proven survival benefit.
Patient summary: We investigated the controversial relationship between hormone therapy and cardiovascular mortality in men with prostate cancer (PCa) treated with radiation in a large randomized trial. Our data suggest that hormone therapy does not increase the risk of cardiovascular death in patients with clinically localized PCa and support the use of such therapy in settings with proven survival benefit. (C) 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.
C1 [Voog, Justin C.] Harvard Radiat Oncol Program, Boston, MA USA.
[Paulus, Rebecca] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA.
[Shipley, William U.; Smith, Matthew R.; Efstathiou, Jason A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
[McGowan, David G.; Chafe, Susan] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
[Jones, Christopher U.; Leibenhaut, Mark H.] Sutter Canc Ctr, Radiol Associates Sacramento, Sacramento, CA USA.
[Bahary, Jean-Paul] CHUM Hosp Norte Dame, Montreal, PQ, Canada.
[Zeitzer, Kenneth L.] Albert Einstein Med Ctr, Dept Radiat Oncol, Philadelphia, PA 19141 USA.
[Souhami, Luis] McGill Univ, Montreal, PQ, Canada.
[Rotman, Marvin] Brooklyn MB CCOP SUNY Downstate, Brooklyn, NY USA.
[Husain, Siraj M.] Tom Baker Canc Clin, Calgary, AB, Canada.
[Gore, Elizabeth] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Raben, Adam] Christiana Care Hlth Serv Inc, CCOP, Newark, DE USA.
[Sandler, Howard M.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
RP Efstathiou, JA (reprint author), Harvard Univ, Sch Med, Dept Radiat Oncol, Massachusetts Gen Hosp, 100 Blossom St,Cox 3, Boston, MA 02114 USA.
EM jefstathiou@partners.org
FU National Cancer Institute [U10CA21661, U10CA180868, U10CA180822,
U10CA37422, U24CA180803]; Prostate Cancer Foundation
FX This project was supported by grants U10CA21661, U10CA180868,
U10CA180822, U10CA37422, and U24CA180803 from the National Cancer
Institute. Jason A. Efstathiou received support from the Prostate Cancer
Foundation Young Investigator Award. Matthew R. Smith received support
from the Prostate Cancer Foundation Challenge Award.
NR 28
TC 6
Z9 6
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
EI 1873-7560
J9 EUR UROL
JI Eur. Urol.
PD FEB
PY 2016
VL 69
IS 2
BP 204
EP 210
DI 10.1016/j.eururo.2015.08.027
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA CZ4LK
UT WOS:000367074400008
PM 26362090
ER
PT J
AU Voog, JC
Paulus, R
Efstathiou, JA
AF Voog, Justin C.
Paulus, Rebecca
Efstathiou, Jason A.
TI Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to
Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer:
Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol
2016;69:211-2 Outcomes for Favorable and Unfavorable Intermediate Risk
Prostate Cancer Patients Receiving Radiation Therapy With or Without
Short-term Androgen Deprivation Therapy
SO EUROPEAN UROLOGY
LA English
DT Editorial Material
ID BEAM RADIATION-THERAPY; DISEASE
C1 [Voog, Justin C.] Harvard Radiat Oncol Program, Boston, MA USA.
[Paulus, Rebecca] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA.
[Efstathiou, Jason A.] Harvard Univ, Sch Med, Dept Radiat Oncol, Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Efstathiou, JA (reprint author), Harvard Univ, Sch Med, Dept Radiat Oncol, Massachusetts Gen Hosp, Cox 3,100 Blossom St, Boston, MA 02114 USA.
EM jefstathiou@partners.org
FU NCI NIH HHS [U10 CA180868, U10 CA021661, U10 CA180822]
NR 8
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
EI 1873-7560
J9 EUR UROL
JI Eur. Urol.
PD FEB
PY 2016
VL 69
IS 2
BP 212
EP 213
DI 10.1016/j.eururo.2015.09.030
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA CZ4LK
UT WOS:000367074400010
PM 26443430
ER
PT J
AU Menendez, ME
Ring, D
AF Menendez, Mariano E.
Ring, David
TI Factors Associated with Greater Pain Intensity
SO HAND CLINICS
LA English
DT Article
DE Pain intensity; Nociception; Pathophysiology; Impairment; Illness;
Magnitude of disability
ID MUSCULOSKELETAL PAIN; TRAPEZIOMETACARPAL JOINT; OPERATIVE TREATMENT;
OPIOID USE; HEALTH; PRESCRIPTION; SATISFACTION; DEPRESSION; PREVALENCE;
DISABILITY
AB The intensity of pain reported for a given nociception is highly variable. Variation in pain intensity is best accounted for by stress, distress, and ineffective coping strategies. Among orthopedic surgery patients, greater intake of opioids is associated with greater pain intensity and decreased satisfaction with pain control, no matter the pathophysiology or nociception. The single most effective pain reliever is self-efficacy (the sense that one can manage and that everything will be okay).
C1 [Menendez, Mariano E.; Ring, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Yawkey Ctr,Dept Orthopaed Surg, Boston, MA 02114 USA.
RP Ring, D (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Yawkey Ctr,Dept Orthopaed Surg, 55 Fruit St,Suite 2100, Boston, MA 02114 USA.
EM dring@partners.org
NR 30
TC 1
Z9 1
U1 1
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-0712
EI 1558-1969
J9 HAND CLIN
JI Hand Clin.
PD FEB
PY 2016
VL 32
IS 1
BP 27
EP +
DI 10.1016/j.hcl.2015.08.004
PG 6
WC Orthopedics
SC Orthopedics
GA CZ2ST
UT WOS:000366955600005
PM 26611386
ER
PT J
AU Chan, JA
Kulke, MH
AF Chan, Jennifer A.
Kulke, Matthew H.
TI Neuroendocrine Tumors-Current and Future Clinical Advances Preface
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Editorial Material
C1 [Chan, Jennifer A.; Kulke, Matthew H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Chan, JA (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA.
EM jang@partners.org; Matthew_Kulke@dfci.harvard.edu
NR 0
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
EI 1558-1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD FEB
PY 2016
VL 30
IS 1
BP XIII
EP XIV
DI 10.1016/j.hoc.2015.09.012
PG 2
WC Oncology; Hematology
SC Oncology; Hematology
GA CZ6HQ
UT WOS:000367202200001
PM 26614379
ER
PT J
AU Demissei, BG
Cleland, JG
O'Connor, CM
Metra, M
Ponikowski, P
Teerlink, JR
Davison, B
Givertz, MM
Bloomfield, DM
Dittrich, H
van Veldhuisen, DJ
Hillege, HL
Voors, AA
Cotter, G
AF Demissei, Biniyam G.
Cleland, John G.
O'Connor, Christopher M.
Metra, Marco
Ponikowski, Piotr
Teerlink, John R.
Davison, Beth
Givertz, Michael M.
Bloomfield, Daniel M.
Dittrich, Howard
van Veldhuisen, Dirk J.
Hillege, Hans L.
Voors, Adriaan A.
Cotter, Gad
TI Procalcitonin-based indication of bacterial infection identifies high
risk acute heart failure patients
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Acute heart failure; Procalcitonin; Bacterial infection; Prognosis
ID C-REACTIVE PROTEIN; COMMUNITY-ACQUIRED PNEUMONIA; TERM PROGNOSIS;
DIAGNOSIS; TRIAL; OUTCOMES; ADULTS; ROLOFYLLINE; ANTAGONIST; BACTEREMIA
AB Background: Bacterial infections in patients hospitalized with acute heart failure are related to worse prognosis, but they can be difficult to diagnose. In this study we evaluated the prevalence, clinical correlates and association with outcomes of significantly elevated procalcitonin levels in patients hospitalized for acute heart failure without clear signs of bacterial infection.
Methods: 1781 patients from the PROTECT trial were included. Patients with a body temperature >38 degrees C, sepsis or active infection requiring IV antibiotics were excluded. Significant elevation of procalcitonin was considered present when levels exceeded 0.20 ng/mL. In-hospital and post-discharge outcomes were compared between groups of patients with and without elevated procalcitonin levels.
Results: Procalcitonin >= 0.20 ng/mL was seen in 6.0% of patients (N = 104). This group of patients had lower serum albumin, lower hemoglobin, higher leukocyte count, higher C-reactive protein, higher blood urea nitrogen, higher heart rate and more pulmonary rales. Interestingly, no significant differences were observed between the two groups in terms of severity of heart failure evidenced by left ventricular ejection fraction (LVEF) or B-type natriuretic peptide (BNP) levels. Patients with significantly elevated procalcitonin levels were more often classified as treatment failure or unchanged status, and had an increased risk of 30-day all-cause mortality even after adjustment for established prognosticators; HR = 2.3 (95% CI, 1.3-4.2), (P = 0.005).
Conclusion: Patients with acute heart failure and significantly elevated procalcitonin levels, indicating probable undiagnosed/untreated bacterial infection, had poorer in-hospital and post-discharge outcomes, despite similar severity of heart failure. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Demissei, Biniyam G.; van Veldhuisen, Dirk J.; Hillege, Hans L.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.
[Demissei, Biniyam G.; Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands.
[Cleland, John G.] Univ London Imperial Coll Sci Technol & Med, London, England.
[O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA.
[Metra, Marco] Univ Brescia, Brescia, Italy.
[Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland.
[Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
[Davison, Beth; Cotter, Gad] Momentum Res, Durham, NC USA.
[Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Bloomfield, Daniel M.] Brigham & Womens Hosp, Boston, MA USA.
[Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA.
[Dittrich, Howard] Univ Iowa, Carver Coll Med, Abboud Cardiovasc Res Ctr, Iowa City, IA 52242 USA.
RP Voors, AA (reprint author), Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM a.a.voors@umcg.nl
RI Ponikowski, Piotr/O-6454-2015;
OI Ponikowski, Piotr/0000-0002-3391-7064; Cleland, John/0000-0002-1471-7016
FU NovaCardia
FX The PROTECT trial was supported by NovaCardia, a subsidiary of Merck.
Alere and Singulex kindly provided assays and performed biomarker
measurements.
NR 32
TC 3
Z9 3
U1 1
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD FEB 1
PY 2016
VL 204
BP 164
EP 171
DI 10.1016/j.ijcard.2015.11.141
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CZ3MM
UT WOS:000367008200048
PM 26666342
ER
PT J
AU Lupon, J
Sanders-van Wijk, S
Januzzi, JL
de Antonio, M
Gaggin, HK
Pfisterer, M
Galan, A
Shah, R
Brunner-La Rocca, HP
Bayes-Genis, A
AF Lupon, Josep
Sanders-van Wijk, Sandra
Januzzi, James L.
de Antonio, Marta
Gaggin, Hanna K.
Pfisterer, Matthias
Galan, Amparo
Shah, Ravi
Brunner-La Rocca, Hans-Peter
Bayes-Genis, Antoni
TI Prediction of survival and magnitude of reverse remodeling using the
ST2-R2 score in heart failure: A multicenter study
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Heart failure; Reverse remodeling; LVEF; Biomarkers; ST2; Survival
ID CARDIAC RESYNCHRONIZATION THERAPY; DILATED CARDIOMYOPATHY; EJECTION
FRACTION; BIOMARKERS; IMPROVEMENT; GALECTIN-3; MORTALITY; PROTECT
AB Background: Cardiac remodeling and its reversibility are key in HF outcomes. The ST2-R2 score was recently developed to predict relevant left ventricular (LV) reverse remodeling (R2) in patients with heart failure (HF). In the present study we sought to validate the ST2-R2 score for grading improvement in LV ejection fraction (EF) and LV size at one year, and to evaluate its prognostic implication up to 4 years.
Methods: A total of 569 patients with baseline LVEF <40% from three international cohorts (Barcelona, TIME-CHF, and PROTECT) were included in the study. Patients were classified into four strata based on their ST2-R2 score, which took into account concentrations of the biomarker ST2, non-ischemic etiology, absence of left bundle branch block, HF duration, baseline LVEF, and beta-blocker treatment.
Results: A significant relationship was observed between ST2-R2 scores and changes in LVEF and indexed LV sizes. LVEF recovery (from + 5.6% to + 17.3%; p < 0.001), percentage reduction in LV end-systolic volume index (from - 6.1% to - 32.1%; p < 0.001) and in LV end-systolic diameter index (from - 1.1% to - 18.6%; p < 0.001) increased over the ST2-R2 strata. A similar trend was observed with diastolic parameters. Improvement in LV function and size was inversely predictive of mortality. Hazard ratios for risk of death, using the lower ST2-R2 score strata (<9) as a reference, were 0.49 (p < 0.001; score 9-11), 0.27 (p < 0.001; score 12-14), and 0.17 (p < 0.001; score 15-17).
Conclusions: The ST2-R2 score predicts reverse LV remodeling in HF patients and is useful for predicting mortality up to 4 years. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Lupon, Josep; de Antonio, Marta; Bayes-Genis, Antoni] Hosp Badalona Germans Trias & Pujol, Unitat Insuficiencia Cardiaca, Barcelona 08916, Spain.
[Lupon, Josep; Bayes-Genis, Antoni] Univ Autonoma Barcelona, Dept Med, E-08193 Barcelona, Spain.
[Sanders-van Wijk, Sandra; Brunner-La Rocca, Hans-Peter] Maastricht Univ Med Ctr MUMC, Dept Cardiol, Maastricht, Netherlands.
[Januzzi, James L.; Gaggin, Hanna K.; Shah, Ravi] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Pfisterer, Matthias] Univ Basel Hosp, Basel, Switzerland.
[Galan, Amparo] Hosp Badalona Germans Trias & Pujol, Serv Bioquim, Badalona, Spain.
RP Bayes-Genis, A (reprint author), Hosp Badalona Germans Trias & Pujol, Serv Cardiol, Carretera Canyet S-N, Barcelona 08916, Spain.
EM abayesgenis@gmail.com
OI Lupon, Josep/0000-0002-5601-9611
FU Horten Research Foundation (Lugano, Switzerland); European Commission's
Seventh Framework Program (FP7-HEALTH, EU-Mascara FP7 health) [278249];
European Commission's Seventh Framework Program (FP7-HEALTH HOMAGE)
[305507]; AstraZeneca Pharma; Novartis Pharma; MenariniPharma; Pfizer
Pharma; Servier; Roche Diagnostics; Roche Pharma; Merck Pharma
FX ST2 assays in the Barcelona cohort were performed by Critical
Diagnostics. The Company had no role in the design of the study or the
collection, management, analysis, or interpretation of the data.
TIME-CHF was supported by the Horten Research Foundation (Lugano,
Switzerland; $55% of the study's budget), as well as by the European
Commission's Seventh Framework Programs (FP7-HEALTH-2011, EU-Mascara FP7
health 2011 (Grant agreement no. 278249) and FP7-HEALTH-2012 HOMAGE
(grant agreement no. 305507)) and several smaller unrestricted grants
from AstraZeneca Pharma, Novartis Pharma, MenariniPharma, Pfizer Pharma,
Servier, Roche Diagnostics, Roche Pharma, and Merck Pharma. The sponsors
had no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; or in the
preparation of the manuscript.
NR 21
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD FEB 1
PY 2016
VL 204
BP 242
EP 247
DI 10.1016/j.ijcard.2015.11.163
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CZ3MM
UT WOS:000367008200062
PM 26682955
ER
PT J
AU Shin, MW
Bae, SJ
Wee, HJ
Lee, HJ
Ahn, BJ
Le, H
Lee, EJ
Kim, RH
Lee, HS
Seo, JH
Park, JH
Kim, KW
AF Shin, Min Wook
Bae, Sung-Jin
Wee, Hee-Jun
Lee, Hyo-Jong
Ahn, Bum Ju
Le, Hoang
Lee, Eun Ji
Kim, Ran Hee
Lee, Hye Shin
Seo, Ji Hae
Park, Ji-Hyeon
Kim, Kyu-Won
TI Ninjurin1 regulates lipopolysaccharide-induced inflammation through
direct binding
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE ninjurin1; lipopolysaccharide; lipopolysaccharide binding; inflammation;
macrophage
ID ADHESION MOLECULE; TNF-ALPHA; MYCOPLASMA-FERMENTANS; INNATE IMMUNITY;
CANCER; LPS; EXPRESSION; PROTEIN; RECOGNITION; RECEPTOR
AB Ninjurin1 is a transmembrane protein involved in macrophage migration and adhesion during inflammation. It was recently reported that repression of Ninjurin1 attenuated the lipopolysaccharide (LPS)-induced inflammatory response in macrophages; however, the precise mechanism by which Ninjurin1 modulates LPS-induced inflammation remains poorly understood. In the present study, we found that the interaction between Ninjurin1 and LPS contributed to the LPS-induced inflammatory response. Notably, pull-down assays using lysates from HEK293T cells transfected with human or mouse Ninjurin1 and biotinylated LPS (LPS-biotin) showed that LPS directly bound Ninjurin1. Subsequently, LPS binding assays with various truncated forms of Ninjurin1 protein revealed that amino acids (aa) 81-100 of Ninjurin1 were required for LPS binding. In addition, knockdown experiments using Ninj1 siRNA resulted in decreased nitric oxide (NO) and tumor necrosis factor-alpha (TNF alpha) secretion upon LPS treatment in Raw264.7 cells. Collectively, our results suggest that Ninjurin1 regulates the LPS-induced inflammatory response through its direct binding to LPS, thus, identifying Ninjurin1 as a putative target for the treatment of inflammatory diseases, such as sepsis and inflammation-associated carcinogenesis.
C1 [Shin, Min Wook; Bae, Sung-Jin; Wee, Hee-Jun; Ahn, Bum Ju; Le, Hoang; Lee, Eun Ji; Kim, Ran Hee; Lee, Hye Shin; Seo, Ji Hae; Park, Ji-Hyeon; Kim, Kyu-Won] Seoul Natl Univ, SNU Harvard NeuroVasc Protect Res Ctr, Coll Pharm, Seoul 151742, South Korea.
[Shin, Min Wook; Bae, Sung-Jin; Wee, Hee-Jun; Ahn, Bum Ju; Le, Hoang; Lee, Eun Ji; Kim, Ran Hee; Lee, Hye Shin; Seo, Ji Hae; Park, Ji-Hyeon; Kim, Kyu-Won] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea.
[Lee, Hyo-Jong] Inje Univ, Coll Pharm, Gimhae 621749, Gyugnam, South Korea.
[Ahn, Bum Ju] Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol & Neurol, Charlestown, MA 02129 USA.
[Ahn, Bum Ju] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Kim, Kyu-Won] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul 151742, South Korea.
[Kim, Kyu-Won] Seoul Natl Univ, GreenBio Sci & Technol, Crop Biotechnol Inst, Pyeongchang 25354, South Korea.
RP Kim, KW (reprint author), Seoul Natl Univ, SNU Harvard NeuroVasc Protect Res Ctr, Coll Pharm, Seoul 151742, South Korea.
EM qwonkim@snu.ac.kr
FU Global Research Laboratory Program [2011-0021874]; Global Core Research
Center (GCRC) Program [2011-0030001]; International Cooperation Program
[2014K2A1C2074279]; Basic Science Research Program through the National
Research Foundation (NRF) - Korean Ministry of Science, ICT and Future
Planning (MSIP) [2013R1A1A2058956]
FX This study was supported by the Global Research Laboratory Program
(2011-0021874), the Global Core Research Center (GCRC) Program
(2011-0030001), the International Cooperation Program
(2014K2A1C2074279), the Basic Science Research Program
(2013R1A1A2058956) through the National Research Foundation (NRF) funded
by the Korean Ministry of Science, ICT and Future Planning (MSIP).
NR 33
TC 1
Z9 1
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD FEB
PY 2016
VL 48
IS 2
BP 821
EP 828
DI 10.3892/ijo.2015.3296
PG 8
WC Oncology
SC Oncology
GA CZ1WV
UT WOS:000366897500039
PM 26677008
ER
PT J
AU Ali, A
Tawakol, A
AF Ali, Abdelrahman
Tawakol, Ahmed
TI FDG PET/CT Imaging of Carotid Atherosclerosis
SO NEUROIMAGING CLINICS OF NORTH AMERICA
LA English
DT Article
DE FDG-PET; Arterial inflammation; Atherosclerosis; Stroke; CVD
ID POSITRON-EMISSION-TOMOGRAPHY; PROSTHETIC VALVE ENDOCARDITIS; RANDOMIZED
CLINICAL-TRIAL; ACUTE CORONARY SYNDROME; PLAQUE INFLAMMATION; ARTERIAL
INFLAMMATION; F-18-FLUORODEOXYGLUCOSE UPTAKE; RHEUMATOID-ARTHRITIS;
CARDIAC SARCOIDOSIS; COMPUTED-TOMOGRAPHY
AB Atherosclerosis is a complex inflammatory process and an integral component of myocardial infarction and stroke. Atherosclerotic plaques can be detected using ultrasonography, myocardial perfusion imaging, coronary angiography, multidetector computed tomography (CT), and MR imaging. These modalities assess the luminal encroachment of the plaques or the structural features. Imaging plaque biology in concert with plaque structure may provide important insights. PET scanning using 18F fluorodeoxyglucose. (F-18 FDG-PET) is commonly combined with CT scanning to characterize oncological processes. This review examines the role of F-18 FDG-PET/CT imaging in the characterization of atherosclerotic plaque biology.
C1 [Ali, Abdelrahman; Tawakol, Ahmed] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac MR PET CT Program, Boston, MA USA.
[Tawakol, Ahmed] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
RP Tawakol, A (reprint author), Massachusetts Gen Hosp, Cardiac MR PET CT Program, 165 Cambridge St,Suite 400, Boston, MA 02114 USA.
EM atawakol@partners.org
NR 55
TC 2
Z9 2
U1 2
U2 15
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1052-5149
EI 1557-9867
J9 NEUROIMAG CLIN N AM
JI Neuroimaging Clin. N. Am.
PD FEB
PY 2016
VL 26
IS 1
BP 45
EP +
DI 10.1016/j.nic.2015.09.004
PG 12
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA CZ2QO
UT WOS:000366949900006
PM 26610659
ER
PT J
AU Leeman-Markowski, BA
Schachter, SC
AF Leeman-Markowski, Beth A.
Schachter, Steven C.
TI Treatment of Cognitive Deficits in Epilepsy
SO NEUROLOGIC CLINICS
LA English
DT Article
DE Epilepsy; Seizures; Cognition; Memory; Attention; Language; Executive
function; Neuropsychological
ID TEMPORAL-LOBE EPILEPSY; DEEP-BRAIN-STIMULATION; VAGUS NERVE-STIMULATION;
RANDOMIZED CONTROLLED-TRIAL; SEVERE ALZHEIMER-DISEASE; FOCAL INTERICTAL
SPIKES; QUALITY-OF-LIFE; ATTENTION-DEFICIT; HYPERACTIVITY DISORDER;
VERBAL MEMORY
AB Cognitive deficits, including attention, language, memory, and executive dysfunction, are common in the setting of epilepsy and can greatly impair quality of life. The etiology is often multifactorial and may be due to the underlying seizure disorder, adverse effects of treatment, and psychiatric comorbidities, among other factors. Management of cognitive deficits aims to address these underlying etiologies as well as provide rehabilitative strategies. Several investigational therapies are also currently under study. This article examines current and future treatments for cognitive dysfunction in epilepsy.
C1 [Leeman-Markowski, Beth A.] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA.
[Schachter, Steven C.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Massachusetts Gen Hosp,CIMIT, Boston, MA 02114 USA.
RP Leeman-Markowski, BA (reprint author), Emory Univ, Dept Neurol, 101 Woodruff Circle,Suite 6000, Atlanta, GA 30322 USA.
EM beth.a.leeman@emory.edu
NR 157
TC 1
Z9 1
U1 3
U2 19
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8619
EI 1557-9875
J9 NEUROL CLIN
JI Neurol. Clin.
PD FEB
PY 2016
VL 34
IS 1
BP 183
EP +
DI 10.1016/j.ncl.2015.08.008
PG 23
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CZ6HD
UT WOS:000367200900009
PM 26613999
ER
PT J
AU Sumner, JA
Duncan, L
Ratanatharathorn, A
Roberts, AL
Koenen, KC
AF Sumner, J. A.
Duncan, L.
Ratanatharathorn, A.
Roberts, A. L.
Koenen, K. C.
TI Research Letter: PTSD has shared polygenic contributions with bipolar
disorder and schizophrenia in women
SO PSYCHOLOGICAL MEDICINE
LA English
DT Letter
ID POSTTRAUMATIC-STRESS-DISORDER; VULNERABILITY; ASSOCIATION
C1 [Sumner, J. A.] Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, New York, NY 10032 USA.
[Sumner, J. A.; Ratanatharathorn, A.; Koenen, K. C.] Harvard Univ, Dept Epidemiol, TH Chan Sch Publ Hlth, Boston, MA USA.
[Duncan, L.; Koenen, K. C.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, stactr, Cambridge, MA USA.
[Duncan, L.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
[Duncan, L.] Broad Inst MIT & Harvard, Med & Populat Genet Program, Cambridge, MA USA.
[Ratanatharathorn, A.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA.
[Roberts, A. L.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA.
[Koenen, K. C.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
[Koenen, K. C.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Sumner, JA (reprint author), Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, 622 W 168th St,PH 9-315, New York, NY 10032 USA.
EM js4456@cumc.columbia.edu
FU National Institutes of Health [R01 MH078828, U01 MH094421, UM1 CA176726]
FX This study was supported by the National Institutes of Health grants R01
MH078828 (to Dr. Koenen), U01 MH094421 (for development of the Psych
Chip), and UM1 CA176726 (for NHS II infrastructure). We acknowledge the
Channing Division of Network Medicine, Department of Medicine, Brigham
and Women's Hospital, and Harvard Medical School for managing the NHS
II.
NR 6
TC 0
Z9 0
U1 2
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-2917
EI 1469-8978
J9 PSYCHOL MED
JI Psychol. Med.
PD FEB
PY 2016
VL 46
IS 3
BP 669
EP 671
DI 10.1017/S0033291715002135
PG 3
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA CZ5WG
UT WOS:000367172500020
PM 26464113
ER
PT J
AU Bolster, MB
AF Bolster, Marcy B.
TI Corticosteroids: Friends and Foes Preface
SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
LA English
DT Editorial Material
C1 [Bolster, Marcy B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Rheumatol Fellowship Training Program, Boston, MA 02114 USA.
RP Bolster, MB (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Rheumatol Fellowship Training Program, 55 Fruit St,Bulfinch 165, Boston, MA 02114 USA.
EM mbolster@mgh.harvard.edu
NR 0
TC 0
Z9 0
U1 1
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-857X
EI 1558-3163
J9 RHEUM DIS CLIN N AM
JI Rheum. Dis. Clin. North Am.
PD FEB
PY 2016
VL 42
IS 1
BP XV
EP XVI
DI 10.1016/j.rdc.2015.10.001
PG 2
WC Rheumatology
SC Rheumatology
GA CZ1RB
UT WOS:000366881900002
PM 26611560
ER
PT J
AU Keller, SF
Miloslavsky, EM
AF Keller, Sarah F.
Miloslavsky, Eli M.
TI Corticosteroids in Antineutrophil Cytoplasmic Antibody-Associated
Vasculitis
SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
LA English
DT Article
DE Glucocorticoids; ANCA-associated vasculitis; Granulomatosis with
polyangiitis; Microscopic polyangiitis
ID ANCA-ASSOCIATED VASCULITIS; WEGENERS-GRANULOMATOSIS; RANDOMIZED-TRIAL;
GLUCOCORTICOID THERAPY; RHEUMATOID-ARTHRITIS; SUBGLOTTIC STENOSIS;
MAINTENANCE THERAPY; MYCOPHENOLATE-MOFETIL; REMISSION MAINTENANCE; RENAL
VASCULITIS
AB Glucocorticoids (GCs) have been the cornerstone of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) therapy since their advent in the 1950s. There is considerable variation in their use, both with respect to dose and duration. Given considerable treatment-related morbidity and mortality, refining the role of GCs is becoming increasingly important. This article discusses the current role of GCs in various phases of AAV treatment, including remission induction, maintenance therapy, treatment of relapses, and the use of local GCs. It discusses current controversies relating to GC use as well as research efforts that seek to reduce GC toxicity in AAV.
C1 [Keller, Sarah F.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Miloslavsky, Eli M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rheumatol,Dept Med,Yawkey Ctr Outpatient Care, Boston, MA 02114 USA.
RP Miloslavsky, EM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rheumatol,Dept Med,Yawkey Ctr Outpatient Care, Suite 2C, Boston, MA 02114 USA.
EM emiloslavsky@mgh.harvard.edu
FU Genentech [224513]
FX Dr S.F. Keller has nothing to disclose. Dr E.M. Miloslavsky has received
research support from Genentech (#224513).
NR 60
TC 2
Z9 2
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-857X
EI 1558-3163
J9 RHEUM DIS CLIN N AM
JI Rheum. Dis. Clin. North Am.
PD FEB
PY 2016
VL 42
IS 1
BP 91
EP +
DI 10.1016/j.rdc.2015.08.010
PG 12
WC Rheumatology
SC Rheumatology
GA CZ1RB
UT WOS:000366881900009
PM 26611553
ER
PT J
AU Simeone, FJ
Bennett, DL
Chang, CY
Huang, AJ
Kattapuram, SV
Bredella, MA
Torriani, M
AF Simeone, F. Joseph
Bennett, Debbie L.
Chang, Connie Y.
Huang, Ambrose J.
Kattapuram, Susan V.
Bredella, Miriam A.
Torriani, Martin
TI Retrospective analysis of intravertebral collateral enhancement in
patients with central venous obstruction
SO SKELETAL RADIOLOGY
LA English
DT Article
DE Intravertebral collateral enhancement; Central venous obstruction; Vena
cava obstruction; Collateral venous pathways
ID VENA-CAVA OBSTRUCTION; VERTEBRAL BODY ENHANCEMENT; BONE-LESIONS;
SUPERIOR; CT
AB To compare prevalence and patterns of intravertebral collateral enhancement in patients with and without central venous obstruction (CVO).
Chest CTs performed between 1/1/2000 and 12/15/2012 with reports containing terms indicating CVO were identified. All contrast enhanced CTs were examined for the presence of CVO and collateral venous pathways. If intravertebral collateral enhancement was present, the pattern was recorded as nodular, linear, or both.
In 209 suspected cases of CVO, 53 (25 %) were confirmed with obstruction and 156 (75 %) were without obstruction. In patients with CVO, 47 % (25/53) demonstrated collateral venous flow through an intravertebral marrow pathway compared to 5 % (8/156) of patients without CVO (P < 0.0001). The most common level of enhancement was the upper thoracic spine, involving only the vertebral body. Nodular, linear, and combined nodular-linear enhancement patterns were seen with similar frequency. Nodular intravertebral collateral enhancement was mistaken for sclerotic metastases in 33 % (3/9) of cases.
Intravertebral collateral enhancement was seen in almost half the patients with CVO and when nodular enhancement is present, it is important to differentiate between metastatic lesions and enhancement related to CVO.
C1 [Simeone, F. Joseph; Chang, Connie Y.; Huang, Ambrose J.; Kattapuram, Susan V.; Bredella, Miriam A.; Torriani, Martin] Massachusetts Gen Hosp, Dept Radiol, Div Musculoskeletal Imaging & Intervent, Boston, MA 02114 USA.
[Simeone, F. Joseph; Chang, Connie Y.; Huang, Ambrose J.; Kattapuram, Susan V.; Bredella, Miriam A.; Torriani, Martin] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Bennett, Debbie L.] St Louis Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA.
RP Simeone, FJ (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Musculoskeletal Imaging & Intervent, 55 Fruit St YAW 6033, Boston, MA 02114 USA.
EM FSIMEONE@PARTNERS.ORG; bennettdl@slu.edu; cychang@mgh.harvard.edu;
ajhuang@mgh.harvard.edu; skattapuram@mgh.harvard.edu;
mbredella@mgh.harvard.edu; mtorriani@mgh.harvard.edu
NR 11
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-2348
EI 1432-2161
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD FEB
PY 2016
VL 45
IS 2
BP 163
EP 168
DI 10.1007/s00256-015-2274-6
PG 6
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA CZ3LA
UT WOS:000367004400002
PM 26497542
ER
PT J
AU Singhal, V
Miller, KK
Torriani, M
Bredella, MA
AF Singhal, Vibha
Miller, Karen K.
Torriani, Martin
Bredella, Miriam A.
TI Short- and long-term reproducibility of marrow adipose tissue
quantification by 1H-MR spectroscopy
SO SKELETAL RADIOLOGY
LA English
DT Article
DE Proton MR spectroscopy; Marrow adipose tissue; Reproducibility
ID PROTON MR SPECTROSCOPY; BONE-MINERAL DENSITY; BODY-COMPOSITION;
FAT-CONTENT; ANOREXIA-NERVOSA; WOMEN; OSTEOPOROSIS; MICROARCHITECTURE;
DISEASE; OBESITY
AB To assess short- and long-term reproducibility of marrow adipose tissue (MAT) quantification by 1H-MR spectroscopy.
Our study was IRB-approved and HIPAA compliant. Written informed consent was obtained. We studied 20 overweight/obese but otherwise healthy subjects (12 female, 8 male) with a mean age of 37 +/- 6 years. All subjects underwent proton magnetic resonance spectroscopy (1H-MRS) of the fourth lumbar vertebral body using a single-voxel point-resolved spatially localized spectroscopy sequence without water suppression at 3 T. Measurements were repeated after 6 weeks and 6 months using identical scanning protocols. The following clinical parameters were collected, weight, BMI, exercise status, and trabecular bone mineral density (BMD), by quantitative computed tomography. Short- (baseline, 6 weeks) and long-term (baseline, 6 months) reproducibility of MAT was assessed by the coefficient of variance (CV), standard deviation (SD), and interclass correlation coefficients (ICCs). Short- and long-term changes in clinical parameters were assessed by paired t-test.
For short-term reproducibility between baseline and 6-week scans, the CV was 9.9 %, SD was 0.08, and ICC was 0.97 (95 % CI 0.94-099). For long-term reproducibility between baseline and 6-month scans, the CV was 12.0 %, SD was 0.10, and ICC was 0.95 (95 % CI 0.88 to 0.98). There was no significant short- or long-term change in clinical parameters (weight, BMI, exercise status, BMD) (p > 0.2).
1H-MRS is a reproducible method for short- and long-term quantification of MAT. Our results can guide sample size calculations for interventional and longitudinal studies.
C1 [Singhal, Vibha] Massachusetts Gen Hosp, Pediat Endocrine Unit, Boston, MA USA.
[Singhal, Vibha; Miller, Karen K.; Torriani, Martin; Bredella, Miriam A.] Harvard Univ, Sch Med, Boston, MA USA.
[Singhal, Vibha; Miller, Karen K.] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA USA.
[Torriani, Martin; Bredella, Miriam A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02144 USA.
RP Bredella, MA (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02144 USA.
EM mbredella@mgh.harvard.edu
FU National Institutes of Health [R01 HL-077674, UL1 RR 025758, K23
RR-23090]
FX This research was supported by the National Institutes of Health grants
R01 HL-077674, UL1 RR 025758, and K23 RR-23090.
NR 27
TC 4
Z9 4
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-2348
EI 1432-2161
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD FEB
PY 2016
VL 45
IS 2
BP 221
EP 225
DI 10.1007/s00256-015-2292-4
PG 5
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA CZ3LA
UT WOS:000367004400009
PM 26563561
ER
PT J
AU Chang, CY
Simeone, FJ
Huang, AJ
AF Chang, Connie Y.
Simeone, F. Joseph
Huang, Ambrose J.
TI battery powered bone drill: caution needed in densely blastic lesions
Response
SO SKELETAL RADIOLOGY
LA English
DT Letter
C1 [Chang, Connie Y.] Massachusetts Gen Hosp, Div Musculoskeletal Imaging & Intervent, Dept Radiol, Boston, MA 02114 USA.
[Simeone, F. Joseph; Huang, Ambrose J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Chang, CY (reprint author), Massachusetts Gen Hosp, Div Musculoskeletal Imaging & Intervent, Dept Radiol, Boston, MA 02114 USA.
EM cychang@mgh.harvard.edu; fsimeone@mgh.harvard.edu;
ajhuang@mgh.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-2348
EI 1432-2161
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD FEB
PY 2016
VL 45
IS 2
BP 283
EP 283
DI 10.1007/s00256-015-2304-4
PG 1
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA CZ3LA
UT WOS:000367004400018
PM 26608799
ER
PT J
AU Servais, E
Swanson, SJ
AF Servais, Elliot
Swanson, Scott J.
TI Thoracoscopic Management of Pulmonary Metastases
SO THORACIC SURGERY CLINICS
LA English
DT Article
DE VATS metastasectomy; Thoracoscopic surgery; Pulmonary metastasectomy;
Minimally invasive surgery
ID LYMPH-NODE DISSECTION; VATS LOBECTOMY; LUNG-CANCER; SURGERY; RESECTION;
THORACOTOMY; PALPATION; NODULES; CHEST
AB In appropriately selected patients, resection of pulmonary metastases from various primary tumors can lead to improved survival. Metastasectomy has traditionally been performed by open thoracotomy; however, thoracoscopic resection offers the important benefits of a less invasive approach with more expeditious recovery. Concerns regarding missed lesions during thoracoscopy have not been realized in analyses of survival and may be offset by a policy of repeat metastasectomy for pulmonary recurrences. Despite the relative paucity of prospective trials, the preponderance of data supports the use of video-assisted thoracic surgery for pulmonary nnetastasectomy, which represents our preferred strategy for these patients.
C1 [Servais, Elliot] Harvard Univ, Cardiothorac Surg, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Swanson, Scott J.] Harvard Univ, Minimally Invas Thorac Surg, Brigham & Womens Hosp, Dana Farber Canc Inst,Canc Affairs,Dept Surg,Med, Boston, MA 02115 USA.
RP Swanson, SJ (reprint author), Harvard Univ, Minimally Invas Thorac Surg, Brigham & Womens Hosp, Dana Farber Canc Inst,Canc Affairs,Dept Surg,Med, 75 Francis St, Boston, MA 02115 USA.
EM sjswanson@partners.org
NR 35
TC 2
Z9 2
U1 1
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1547-4127
J9 THORAC SURG CLIN
JI Thorac. Surg. Clin.
PD FEB
PY 2016
VL 26
IS 1
BP 91
EP +
DI 10.1016/j.thorsurg.2015.09.011
PG 8
WC Respiratory System; Surgery
SC Respiratory System; Surgery
GA CZ6KJ
UT WOS:000367209900012
PM 26611514
ER
PT J
AU Lucia, U
Ponzetto, A
Deisboeck, TS
AF Lucia, Umberto
Ponzetto, Antonio
Deisboeck, Thomas S.
TI Investigating the impact of electromagnetic fields on human cells: A
thermodynamic perspective
SO PHYSICA A-STATISTICAL MECHANICS AND ITS APPLICATIONS
LA English
DT Article
DE Electromagnetic waves; Entropy generation; Magnetic resonance imaging;
MRI; Thermodynamic approach to biomedicine
ID YEAST-CELLS; ENTROPY GENERATION; MAGNETIC-FIELD; GLIOMA-CELLS; MEMBRANE;
SYSTEMS; GROWTH
AB The consequences of the interactions of electromagnetic waves, as used in conventional MRI technology, with human cells are not fully understood. To analyze these interactions, a novel thermodynamic approach is presented that is based on the relationship between electromagnetic and thermodynamic quantities. The theoretical results indicate that the waves' impact is largest at high magnetic field strengths and at low frequencies. This is the first step towards a clinically useful framework to quantitatively assess MRI impact including a potential trade-off between the desired increase in spatial resolution that higher magnetic field strengths yield for diagnostic purposes and the danger this may pose for cell membranes, and by extension, for the tissues investigated. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Lucia, Umberto] Politecn Torino, Dipartimento Energia, I-10129 Turin, Italy.
[Ponzetto, Antonio] Univ Turin, Dept Med Sci, I-10126 Turin, Italy.
[Deisboeck, Thomas S.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA.
[Deisboeck, Thomas S.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Deisboeck, Thomas S.] ThinkMotu LLC, Wellesley, MA 02481 USA.
RP Lucia, U (reprint author), Politecn Torino, Dipartimento Energia, Corso Duca Abruzzi 24, I-10129 Turin, Italy.
EM umberto.lucia@polito.it; antonio.ponzetto@unito.it;
deisboec@helix.mgh.harvard.edu
OI Lucia, Umberto/0000-0002-3123-2133; ponzetto,
antonio/0000-0002-1551-3664
FU EU [265772]
FX AP was supported by EU grant 'EM-safety and Hazard mitigation by proper
EV design' (Project No. 265772).
NR 38
TC 4
Z9 4
U1 2
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4371
EI 1873-2119
J9 PHYSICA A
JI Physica A
PD FEB 1
PY 2016
VL 443
BP 42
EP 48
DI 10.1016/j.physa.2015.09.074
PG 7
WC Physics, Multidisciplinary
SC Physics
GA CW5QX
UT WOS:000365052700005
ER
PT J
AU Bergman, AA
Jaynes, HA
Gonzalvo, JD
Hudmon, KS
Frankel, RM
Kobylinski, AL
Zillich, AJ
AF Bergman, Alicia A.
Jaynes, Heather A.
Gonzalvo, Jasmine D.
Hudmon, Karen Suchanek
Frankel, Richard M.
Kobylinski, Amanda L.
Zillich, Alan J.
TI Pharmaceutical Role Expansion and Developments in Pharmacist-Physician
Communication
SO HEALTH COMMUNICATION
LA English
DT Article
ID MEDICAL HOME; PRIMARY-CARE; ORDER ENTRY; COLLABORATION; MANAGEMENT;
COMPETENCES; AVIATION; TEAMS; FACE
AB Expanded clinical pharmacist professional roles in the team-based patient-centered medical home (PCMH) primary care environment require cooperative and collaborative relationships among pharmacists and primary care physicians (PCPs), but many PCPs have not previously worked in such a direct fashion with pharmacists. Additional roles, including formulary control, add further elements of complexity to the clinical pharmacist-PCP relationship that are not well described. Our objective was to characterize the nature of clinical pharmacist-PCP interprofessional collaboration across seven federally funded hospitals and associated primary care clinics, following pharmacist placement in primary care clinics and incorporation of expanded pharmacist roles. In-depth and semistructured interviews were conducted with 25 practicing clinical pharmacists and 17 PCPs. Qualitative thematic analysis revealed three major themes: (1) the complexities of electronic communication (particularly electronic nonformulary requests) as contributing to interprofessional tensions or misunderstandings for both groups, (2) the navigation of new roles and traditional hierarchy, with pharmacists using indirect communication to prevent PCP defensiveness to recommendations, and (3) a preference for onsite colocation for enhanced communication and professional relationships. Clinical pharmacists' indirect communication practices may hold important implications for patient safety in the context of medication use, and it is important to foster effective communication skills and an environment where all team members across hierarchies can feel comfortable speaking up to reduce error when problems are suspected. Also, the lack of institutional communication about managing drug formulary issues and related electronic nonformulary request processes was apparent in this study and merits further attention for both researchers and practitioners.
C1 [Bergman, Alicia A.; Frankel, Richard M.; Kobylinski, Amanda L.; Zillich, Alan J.] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA.
[Jaynes, Heather A.; Gonzalvo, Jasmine D.; Hudmon, Karen Suchanek] Purdue Univ, Coll Pharm, W Lafayette, IN 47907 USA.
RP Bergman, AA (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Innovat Implementat & Policy, 16111 Plummer St,Bldg 25, North Hills, CA 91343 USA.
EM Alicia.Bergman@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development [PI: Zillich-CDA RCD06304-1];
Department of Veterans Affairs, Veterans Health Administration Health
Services Research and Development (HSR&D) Associated Health Fellowship
Program (Bergman); Purdue/Lilly Foundation grant
FX The project reported here was supported by the Department of Veterans
Affairs, Veterans Health Administration, Health Services Research and
Development (PI: Zillich-CDA RCD06304-1), the Department of Veterans
Affairs, Veterans Health Administration Health Services Research and
Development (HSR&D) Associated Health Fellowship Program (Bergman), and
partially supported by a Purdue/Lilly Foundation grant. The views
expressed in this article are those of the authors and do not
necessarily represent the views of the Department of Veterans Affairs or
the U.S. government.
NR 45
TC 0
Z9 0
U1 4
U2 34
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1041-0236
EI 1532-7027
J9 HEALTH COMMUN
JI Health Commun.
PD FEB 1
PY 2016
VL 31
IS 2
BP 161
EP 170
DI 10.1080/10410236.2014.940672
PG 10
WC Communication; Health Policy & Services
SC Communication; Health Care Sciences & Services
GA CU7WD
UT WOS:000363751600003
PM 26266465
ER
PT J
AU Chebl, RB
Madden, B
Belsky, J
Harmouche, E
Yessayan, L
AF Chebl, Ralphe Bou
Madden, Bryan
Belsky, Justin
Harmouche, Elie
Yessayan, Lenar
TI Diagnostic value of end tidal capnography in patients with hyperglycemia
in the emergency department
SO BMC EMERGENCY MEDICINE
LA English
DT Article
DE Capnography; Diabetic ketoacidosis; Emergency department
ID DIABETIC-KETOACIDOSIS; BETA-HYDROXYBUTYRATE; ARTERIAL; PH
AB Background: Diabetic Ketoacidosis (DKA) is a potentially life-threatening emergency that requires prompt diagnosis and treatment. In paediatric populations an end tidal capnography value greater than 36 mmHg was found to be 100 % sensitive in ruling out DKA.
Methods: A cross sectional observational study of adults >= 17 years of age presenting to the emergency department between January 2014 and May 2014 with glucose > 550 mg/dL. In all patients, nasal capnography and venous blood gas analysis were performed prior to any insulin or intravenous fluid administration. The diagnosis of DKA was based on the presence of anion gap metabolic acidosis, hyperglycaemia and ketonemia. The overall diagnostic performance (area under the curve [AUC]), sensitivity, specificity and likelihood ratios at different end tidal CO2 (ETCO2) cut-offs were determined.
Results: 71 patients were enrolled in the study of which 21 (30 %) met the diagnosis of DKA. The area under the curve for ETCO2 was 0.95 with a 95 % CI of 0.91 to 0.99. Test sensitivity for DKA at ETCO2 level >= 35 mmHg was 100 % (95 % CI, 83.9-100). An ETCO2 level >= 21 mmHg was 100 % specific (95 % CI, 92.9-100.0) for DKA.
Conclusion: Nasal capnography exhibits favourable diagnostic performance in detecting patients with or without DKA among those who present to the emergency department with a glucometer reading > 550 mg/dL.
C1 [Chebl, Ralphe Bou] Amer Univ Beirut, Dept Emergency Med, Beirut, Lebanon.
[Chebl, Ralphe Bou; Madden, Bryan; Harmouche, Elie] Henry Ford Hosp, Dept Emergency Med, Detroit, MI 48202 USA.
[Belsky, Justin] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Yessayan, Lenar] Henry Ford Hosp, Div Nephrol & Hypertens, Detroit, MI 48202 USA.
[Yessayan, Lenar] Henry Ford Hosp, Div Pulm & Crit Care Med, Detroit, MI 48202 USA.
RP Chebl, RB (reprint author), Amer Univ Beirut, Dept Emergency Med, Beirut, Lebanon.; Chebl, RB (reprint author), Henry Ford Hosp, Dept Emergency Med, Detroit, MI 48202 USA.
EM rb94@aub.edu.lb
NR 15
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-227X
J9 BMC EMERG MED
JI BMC Emerg. Med.
PD JAN 29
PY 2016
VL 16
AR 7
DI 10.1186/s12873-016-0072-7
PG 7
WC Emergency Medicine
SC Emergency Medicine
GA DO9QI
UT WOS:000378121200001
ER
PT J
AU Russo, SG
Nickel, EA
Leissner, KB
Schwerdtfeger, K
Bauer, M
Roessler, MS
AF Russo, Sebastian G.
Nickel, Eike A.
Leissner, Kay B.
Schwerdtfeger, Katrin
Bauer, Martin
Roessler, Markus S.
TI Use of the GlideScope (R)-Ranger for pre-hospital intubations by
anaesthesia trained emergency physicians - an observational study
SO BMC EMERGENCY MEDICINE
LA English
DT Article
DE Airway management; Pre-hospital; Videolaryngoscopy; GlideScope;
Intubating laryngeal mask airway
ID AIRWAY MANAGEMENT; VIDEO-LARYNGOSCOPY; ENDOTRACHEAL INTUBATION;
DIFFICULT AIRWAY; LARYNGEAL MASK; VIDEOLARYNGOSCOPE; MULTICENTER;
AMBULANCE; SUCCESS; SERVICE
AB Background: Pre-hospital endotracheal intubation is more difficult than in the operating room (OR). Therefore, enhanced airway management devices such as video laryngoscopes may be helpful to improve the success rate of pre-hospital intubation. We describe the use of the Glidescope(R)-Ranger (GS-R) as an alternative airway tool used at the discretion of the emergency physician (EP) in charge.
Methods: During a 3.5 year period, the GS-R was available to be used either as the primary or backup tool for pre-hospital intubation by anaesthesia trained EP with limited expertise using angulated videolaryngoscopes.
Results: During this period 672 patients needed pre-hospital intubation of which the GS-R was used in 56 cases. The overall GS-R success rate was 66 % (range of 34-100 % among EP). The reasons for difficulties or failure included inexperience of the EP with the GS-R, impaired view due to secretion, vomitus, blood or the inability to see the screen in very bright environment due to sunlight.
Conclusion: Special expertise and substantial training is needed to successfully accomplish tracheal intubation with the GS-R in the pre-hospital setting. Providers inexperienced with DL as well as video-assisted intubation should not expect to be able to perform tracheal intubation easily just because a videolaryngoscope is available. Additionally, indirect laryngoscopy might be difficult or even impossible to achieve in the pre-hospital setting due to impeding circumstances such as blood, secretions or bright sun-light. Therefore, videolaryngoscopes, here the GS-R, should not be considered as the "Holy Grail" of endotracheal intubation, neither for the experts nor for inexperienced providers.
C1 [Russo, Sebastian G.; Nickel, Eike A.; Schwerdtfeger, Katrin; Bauer, Martin; Roessler, Markus S.] Univ Hosp Gottingen, Dept Anaesthesiol, D-370799 Gottingen, Germany.
[Nickel, Eike A.] HELIOS Klinikum Emil von Behring, Dept Anaesthesiol & Pain Med, Berlin, Germany.
[Leissner, Kay B.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Dept Anesthesiol, Boston, MA USA.
RP Russo, SG (reprint author), Univ Hosp Gottingen, Dept Anaesthesiol, D-370799 Gottingen, Germany.
EM s.russo@medizin.uni-goettingen.de
NR 22
TC 3
Z9 3
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-227X
J9 BMC EMERG MED
JI BMC Emerg. Med.
PD JAN 29
PY 2016
VL 16
AR 8
DI 10.1186/s12873-016-0069-2
PG 7
WC Emergency Medicine
SC Emergency Medicine
GA DO9QI
UT WOS:000378121200002
PM 26830474
ER
PT J
AU Grilli, MD
Verfaellie, M
AF Grilli, Matthew D.
Verfaellie, Mieke
TI Experience-near but not experience-far autobiographical facts depend on
the medial temporal lobe for retrieval: Evidence from amnesia
SO NEUROPSYCHOLOGIA
LA English
DT Article
DE Personal semantics; Autobiographical memory; Self; Semantic memory;
Episodic memory
ID EPISODIC FUTURE THINKING; SEMANTIC MEMORY; RELATIONAL MEMORY; DAMAGE;
SELF; RECALL
AB This paper addresses the idea that there may be two types of autobiographical facts with distinct cognitive and neural mechanisms: "Experience-near" autobiographical facts, which contain spatiotemporal content derived from personal experience and thus depend on the medial temporal lobe (MTL) for retrieval, and "experience-far" autobiographical facts, which are abstract memories and thus rely on neocortical brain regions involved in retrieval of general semantic memory. To investigate this conceptual model of autobiographical fact knowledge, we analyzed the nature of autobiographical facts that were generated by 8 individuals with MTL amnesia and 12 control participants in a recent study of identity and memory [Grilli, M.D., & Verfaellie, M. (2015). Supporting the self-concept with memory: insight from amnesia. Social Cognitive and Affective Neuroscience, 10, 1684-1692]. Results revealed that MTL amnesic participants generated fewer experience-near autobiographical facts than controls. Experience-far autobiographical fact generation was not impaired in amnesic participants with damage restricted to the MTL, but there was preliminary evidence to suggest that it may be impaired in amnesic participants with damage to the MTL and anterior lateral temporal lobe. These results support a cognitive and neural distinction between experience-near and experience-far autobiographical facts and have implications for understanding the contribution of autobiographical fact knowledge to self-related cognition. Published by Elsevier Ltd.
C1 [Grilli, Matthew D.; Verfaellie, Mieke] Boston Univ, Sch Med, VA Boston Healthcare Syst, Memory Disorders Res Ctr, Boston, MA 02118 USA.
RP Verfaellie, M (reprint author), VA Boston Healthcare Syst, 150 S Huntington Ave 151A, Boston, MA 02130 USA.
EM verf@bu.edu
FU Clinical Science Research and Development Service, Department of
Veterans Affairs [IO1CX000925]
FX This work was supported by: Clinical Science Research and Development
Service, Department of Veterans Affairs Grant IO1CX000925.
NR 31
TC 3
Z9 3
U1 1
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3932
EI 1873-3514
J9 NEUROPSYCHOLOGIA
JI Neuropsychologia
PD JAN 29
PY 2016
VL 81
BP 180
EP 185
DI 10.1016/j.neuropsychologia.2015.12.023
PG 6
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA DE2LS
UT WOS:000370459400016
PM 26721761
ER
PT J
AU Lucia, U
Ponzetto, A
Deisboeck, TS
AF Lucia, Umberto
Ponzetto, Antonio
Deisboeck, Thomas S.
TI Constructal approach to cell membranes transport: Amending the
'Norton-Simon' hypothesis for cancer treatment
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HIGH LACTATE LEVELS; ENTROPY GENERATION; TUMOR-GROWTH; IN-VIVO;
MULTICELLULAR TUMOR; CALCIUM-CHANNELS; TISSUE MECHANICS; VOLTAGE; MODEL;
METASTASES
AB To investigate biosystems, we propose a new thermodynamic concept that analyses ion, mass and energy flows across the cell membrane. This paradigm-shifting approach has a wide applicability to medically relevant topics including advancing cancer treatment. To support this claim, we revisit 'Norton-Simon' and evolving it from an already important anti-cancer hypothesis to a thermodynamic theorem in medicine. We confirm that an increase in proliferation and a reduction in apoptosis trigger a maximum of ATP consumption by the tumor cell. Moreover, we find that positive, membrane-crossing ions lead to a decrease in the energy used by the tumor, supporting the notion of their growth inhibitory effect while negative ions apparently increase the cancer's consumption of energy hence reflecting a growth promoting impact. Our results not only represent a thermodynamic proof of the original Norton-Simon hypothesis but, more concretely, they also advance the clinically intriguing and experimentally testable, diagnostic hypothesis that observing an increase in negative ions inside a cell in vitro, and inside a diseased tissue in vivo, may indicate growth or recurrence of a tumor. We conclude with providing theoretical evidence that applying electromagnetic field therapy early on in the treatment cycle may maximize its anti-cancer efficacy.
C1 [Lucia, Umberto] Politecn Torino, Dipartimento Energia, Corso Duca degli Abruzzi 24, I-10129 Turin, Italy.
[Ponzetto, Antonio] Univ Turin, Dept Med Sci, Corso AM Dogliotti 14, I-10126 Turin, Italy.
[Deisboeck, Thomas S.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA.
[Deisboeck, Thomas S.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Deisboeck, Thomas S.] ThinkMotu LLC, Wellesley, MA 02481 USA.
RP Lucia, U (reprint author), Politecn Torino, Dipartimento Energia, Corso Duca degli Abruzzi 24, I-10129 Turin, Italy.
EM umberto.lucia@polito.it
FU Harvard-MIT (HST) Martinos Center for Biomedical Imaging; Department of
Radiology at Massachusetts General Hospital, Harvard Medical School
FX This study has been supported in part by the Harvard-MIT (HST) Martinos
Center for Biomedical Imaging and the Department of Radiology at
Massachusetts General Hospital, Harvard Medical School (T.S.D.).
NR 72
TC 2
Z9 2
U1 2
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 29
PY 2016
VL 6
AR 19451
DI 10.1038/srep19451
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DC0RL
UT WOS:000368925300001
PM 26822208
ER
PT J
AU Kaufman, CK
Mosimann, C
Fan, ZP
Yang, S
Thomas, AJ
Ablain, J
Tan, JL
Fogley, RD
van Rooijen, E
Hagedorn, EJ
Ciarlo, C
White, RM
Matos, DA
Puller, AC
Santoriello, C
Liao, EC
Young, RA
Zon, LI
AF Kaufman, Charles K.
Mosimann, Christian
Fan, Zi Peng
Yang, Song
Thomas, Andrew J.
Ablain, Julien
Tan, Justin L.
Fogley, Rachel D.
van Rooijen, Ellen
Hagedorn, Elliott J.
Ciarlo, Christie
White, Richard M.
Matos, Dominick A.
Puller, Ann-Christin
Santoriello, Cristina
Liao, Eric C.
Young, Richard A.
Zon, Leonard I.
TI A zebrafish melanoma model reveals emergence of neural crest identity
during melanoma initiation
SO SCIENCE
LA English
DT Article
ID SUPER-ENHANCERS; TRANSCRIPTION FACTOR; INHIBITORY-ACTIVITY; CELL
IDENTITY; GENE; EXPRESSION; SOX10; CHROMATIN; DISEASE; SYSTEM
AB The "cancerized field" concept posits that cancer-prone cells in a given tissue share an oncogenic mutation, but only discreet clones within the field initiate tumors. Most benign nevi carry oncogenic BRAF(V600E) mutations but rarely become melanoma. The zebrafish crestin gene is expressed embryonically in neural crest progenitors (NCPs) and specifically reexpressed in melanoma. Live imaging of transgenic zebrafish crestin reporters shows that within a cancerized field (BRAF(V600E)-mutant; p53-deficient), a single melanocyte reactivates the NCP state, revealing a fate change at melanoma initiation in this model. NCP transcription factors, including sox10, regulate crestin expression. Forced sox10 overexpression in melanocytes accelerated melanoma formation, which is consistent with activation of NCP genes and super-enhancers leading to melanoma. Our work highlights NCP state reemergence as a key event in melanoma initiation.
C1 [Kaufman, Charles K.; Yang, Song; Thomas, Andrew J.; Ablain, Julien; Tan, Justin L.; Fogley, Rachel D.; van Rooijen, Ellen; Hagedorn, Elliott J.; Ciarlo, Christie; Santoriello, Cristina; Zon, Leonard I.] Childrens Hosp Boston, Howard Hughes Med Inst, Stem Cell Program, Boston, MA 02115 USA.
[Kaufman, Charles K.; Yang, Song; Thomas, Andrew J.; Ablain, Julien; Tan, Justin L.; Fogley, Rachel D.; van Rooijen, Ellen; Hagedorn, Elliott J.; Ciarlo, Christie; Santoriello, Cristina; Zon, Leonard I.] Childrens Hosp Boston, Howard Hughes Med Inst, Div Hematol Oncol, Boston, MA 02115 USA.
[Kaufman, Charles K.; Yang, Song; Ablain, Julien; van Rooijen, Ellen; Hagedorn, Elliott J.; Liao, Eric C.; Zon, Leonard I.] Harvard Stem Cell Inst, Boston, MA 02115 USA.
[Kaufman, Charles K.; Zon, Leonard I.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Kaufman, Charles K.; Ablain, Julien; van Rooijen, Ellen; Hagedorn, Elliott J.; Ciarlo, Christie; Liao, Eric C.; Zon, Leonard I.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Mosimann, Christian] Univ Zurich, Inst Mol Life Sci, CH-8057 Zurich, Switzerland.
[Fan, Zi Peng; Young, Richard A.] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
[Fan, Zi Peng] MIT, Computat & Syst Biol Program, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[White, Richard M.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY 10075 USA.
[Matos, Dominick A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02129 USA.
[Puller, Ann-Christin] Childrens Canc Ctr Hamburg, Inst Res, D-20246 Hamburg, Germany.
[Puller, Ann-Christin] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, D-20246 Hamburg, Germany.
[Santoriello, Cristina; Zon, Leonard I.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Liao, Eric C.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Young, Richard A.] MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
RP Zon, LI (reprint author), Childrens Hosp Boston, Howard Hughes Med Inst, Stem Cell Program, Boston, MA 02115 USA.; Zon, LI (reprint author), Childrens Hosp Boston, Howard Hughes Med Inst, Div Hematol Oncol, Boston, MA 02115 USA.; Zon, LI (reprint author), Harvard Stem Cell Inst, Boston, MA 02115 USA.; Zon, LI (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.; Zon, LI (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.; Zon, LI (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
EM zon@enders.tch.harvard.edu
RI Young, Richard/F-6495-2012
OI Young, Richard/0000-0001-8855-8647
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of
the National Institutes of Health [K08 AR061071]; European Molecular
Biology Organization; Human Frontier Science Program; Swiss National
Science Foundation; Ellison Foundation; V Foundation; Melanoma Research
Alliance; Howard Hughes Medical Institute; NIH [HG002668]; [R01
CA103846]
FX C.K.K. and research reported here is supported by the National Institute
of Arthritis and Musculoskeletal and Skin Diseases of the National
Institutes of Health under award K08 AR061071. C.M. received support
from a European Molecular Biology Organization long-term fellowship, a
Human Frontier Science Program long-term fellowship, and a Swiss
National Science Foundation advanced postdoctoral fellowship. L.I.Z. is
supported by R01 CA103846, the Ellison Foundation, the V Foundation, and
the Melanoma Research Alliance and is a Howard Hughes Medical Institute
Investigator. R.A.Y. is supported by NIH HG002668. Z.P.F. was supported
by NIH HG002668. E.J.H. is a Howard Hughes Medical Institute Fellow of
the Helen Hay Whitney Foundation. L.I.Z. is a founder and stock holder
of Fate, Inc. and Scholar Rock. R.A.Y. is a founder of Syros
Pharmaceuticals. The content is solely the responsibility of the authors
and does not necessarily represent the official views of the National
Institutes of Health. We thank the Massachusetts General Hospital DNA
Core for providing technical assistance with deep sequencing. We thank
J. Ablain for critical review of the manuscript, C. Ceol for the gift of
the zebrafish mitfa middle entry clone, and G. Musso for helpful
discussions on microarray data and GSEA. All microarray, Chip-seq, and
RNA-seq are deposited at Gene Expression Omnibus, ID GSE75356.
NR 53
TC 24
Z9 24
U1 9
U2 31
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JAN 29
PY 2016
VL 351
IS 6272
AR aad2197
DI 10.1126/science.aad2197
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DB9SW
UT WOS:000368858200026
ER
PT J
AU Latif, R
Lau, Z
Cheung, P
Felsenfeld, DP
Davies, TF
AF Latif, Rauf
Lau, Zerlina
Cheung, Pamela
Felsenfeld, Dan P.
Davies, Terry F.
TI The "TSH Receptor Glo Assay" - A High-Throughput Detection System for
Thyroid Stimulation
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE TSH receptor; small molecule; screening; high-throughput;
thyroid-stimulating hormone
ID SMALL-MOLECULE AGONISTS; THYROTROPIN RECEPTOR; GRAVES-DISEASE; HORMONE;
AUTOANTIBODIES; EXPRESSION; CLEAVAGE; ANTIBODY; BINDING
AB Background: To identify novel small molecules against the TSH receptor, we developed a sensitive transcription-based luciferase high-throughput screening (HIS) system named the TSHR-Glo Assay (TSHR-Glo).
Methods: This assay uses double-transfected Chinese hamster ovary cells stably expressing the human TSHR and a cAMP-response element (CRE) construct fused to an improved luciferase reporter gene.
Results: The assay was highly responsive toward TSH in a dose-dependent manner with a TSH sensitivity of 10(-10)M (10 +/- 1.12 mu U/ml) and thyroid-stimulating antibodies, a hallmark of Graves' disease, could also be detected. The assay was validated against the standard indicator of HTS performance - the Z-factor (Z') - producing a score of 0.895. Using the TSHR-Glo assay, we screened 48,224 compounds from a diverse chemical library in duplicate plates at a fixed dose of 17 mu M. Twenty molecules with the greatest activity out of 62 molecules that were identified by this technique were subsequently screened against the parent luciferase stable cell line in order to eliminate false positive stimulators.
Conclusion: Using this approach, we were able to identify specific agonists against the TSH receptor leading to the characterization of several TSH agonist molecules. Hence, the TSHR-Glo assay was a one-step cell-based HTS assay, which was successful in the discovery of novel small molecular agonists and for the detection of stimulating antibodies to the TSH receptor.
C1 [Latif, Rauf; Davies, Terry F.] Icahn Sch Med Mt Sinai, Dept Med, Thyroid Res Unit, New York, NY 10029 USA.
[Latif, Rauf; Davies, Terry F.] James J Peters VA Med Ctr, New York, NY USA.
[Lau, Zerlina; Cheung, Pamela; Felsenfeld, Dan P.] Icahn Sch Med Mt Sinai, Integrated Screening Core, Expt Therapeut Inst, New York, NY 10029 USA.
RP Latif, R (reprint author), Icahn Sch Med Mt Sinai, Dept Med, Thyroid Res Unit, New York, NY 10029 USA.; Latif, R (reprint author), James J Peters VA Med Ctr, New York, NY USA.
EM rauf.latif@mssm.edu
FU NIH [DK069713, DK052464]; David Owen Segal Fund; VA Merit Award program
FX This work was supported in part by NIH grants DK069713 and DK052464, the
David Owen Segal Fund, and the VA Merit Award program (to TD).
NR 30
TC 1
Z9 1
U1 5
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD JAN 28
PY 2016
VL 7
AR 3
DI 10.3389/fendo.2016.00003
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DP4XY
UT WOS:000378501800001
PM 26858688
ER
PT J
AU Lehavot, K
Williams, EC
Millard, SP
Bradley, KA
Simpson, TL
AF Lehavot, Keren
Williams, Emily C.
Millard, Steven P.
Bradley, Katharine A.
Simpson, Tracy L.
TI Association of Alcohol Misuse With Sexual Identity and Sexual Behavior
in Women Veterans
SO SUBSTANCE USE & MISUSE
LA English
DT Article
DE sexual orientation; AUDIT-C; lesbian and bisexual women; Women veterans;
alcohol disparities
ID SERVICES-TASK-FORCE; SUBSTANCE USE; MENTAL-HEALTH; ORIENTATION
DISPARITIES; DRINKING CONTEXTS; MINORITY VETERANS; BISEXUAL WOMEN;
UNITED-STATES; ADULT HEALTH; YOUNG-ADULTS
AB Background: Sexual minority women report greater alcohol misuse than heterosexual women in the general population, with more pronounced differences found among younger age groups. It is unknown whether these differences exist among women veterans. Objective: We evaluated differences in alcohol misuse across two dimensions of sexual orientation (identity and behavior) among women veterans, and examined whether these differences were modified by age. Methods: Women veterans were recruited via the internet to participate in an online survey. Participants provided information on their self-reported sexual identity and behavior and responded to the validated 3-item Alcohol Use Disorders Identification Test-Consumption questionnaire (AUDIT-C). Regression models were used to compare the prevalence of alcohol misuse (AUDIT-C >= 3) and severity (AUDIT-C scores) across sexual identity and behavior and to test effect modification by age. Results: Among the 702 participants (36% lesbian/bisexual), prevalence and severity of alcohol misuse varied by both sexual identity and behavior, but there were significant interactions with age. Prevalence and severity of alcohol misuse were higher among relatively younger self-identified lesbians compared to heterosexual women. Similarly, both prevalence and severity of alcohol misuse were generally higher among younger women who had any sex with women compared to those who had sex only with men. Conclusions/Importance: In this online study of women veterans, younger sexual minority women were more likely to screen positive for alcohol misuse, and they had more severe alcohol misuse, than their heterosexual counterparts. Prevention and treatment efforts focused specifically on sexual minority women veterans may be needed.
C1 [Lehavot, Keren; Williams, Emily C.; Bradley, Katharine A.] VA Puget Sound, VA Hlth Serv Res & Dev, Denver Seattle Ctr Innovat Vet Ctr & Value Driven, Seattle, WA USA.
[Lehavot, Keren; Millard, Steven P.; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr MIRECC, Seattle, WA 98108 USA.
[Lehavot, Keren; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Lehavot, Keren; Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA.
[Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA.
RP Lehavot, K (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div, 1660 S Columbian Way,116-POC, Seattle, WA 98108 USA.
EM klehavot@uw.edu
FU VISN-20 Mental Illness Research, Education, and Clinical Center
(MIRECC); VA Career Development Award from CSRD [CX000867]; VA Career
Development Award from HSRD [CDA 12-276]
FX This research was supported by a research grant to K. Lehavot and T.
Simpson from the VISN-20 Mental Illness Research, Education, and
Clinical Center (MIRECC). Drs. Lehavot and Williams are supported by VA
Career Development Awards from CSR&D (CX000867) and HSR&D (CDA 12-276),
respectively.
NR 45
TC 0
Z9 0
U1 4
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1082-6084
EI 1532-2491
J9 SUBST USE MISUSE
JI Subst. Use Misuse
PD JAN 28
PY 2016
VL 51
IS 2
BP 216
EP 229
DI 10.3109/10826084.2015.1092988
PG 14
WC Substance Abuse; Psychiatry; Psychology
SC Substance Abuse; Psychiatry; Psychology
GA DE3YX
UT WOS:000370567500008
PM 26800263
ER
PT J
AU Duda, T
Pertzev, A
Makino, CL
Sharma, RK
AF Duda, Teresa
Pertzev, Alexandre
Makino, Clint L.
Sharma, Rameshwar K.
TI Bicarbonate and Ca2+ Sensing Modulators Activate Photoreceptor ROS-GC1
Synergistically
SO FRONTIERS IN MOLECULAR NEUROSCIENCE
LA English
DT Article
DE bicarbonate; calcium-binding protein; guanylate cyclase (guanylyl
cyclase); guanylate cyclase; activating protein (GCAP);
phototransduction; S100 proteins; signal transduction; second messenger
ID MEMBRANE GUANYLATE-CYCLASE; LEBER CONGENITAL AMAUROSIS;
NATRIURETIC-FACTOR-RECEPTOR; SIGNAL-TRANSDUCTION; PROTEINS GCAPS;
FUNCTIONAL-CHARACTERIZATION; DIMERIZATION DOMAIN; ELECTRON-MICROSCOPY;
CARBONIC-ANHYDRASE; NEUROCALCIN-DELTA
AB Photoreceptor ROS-GC1 a prototype subfamily member of the membrane guanylate cyclase family, is a central component of phototransduction. It is a single transmembrane-spanning protein, composed of modular blocks. In rods, guanylate cyclase activating proteins (GCAPs) 1 and 2 bind to its juxtamembrane domain (JMD) and the C-terminal extension, respectively, to accelerate cyclic GMP synthesis when Ca2+ levels are low. In cones, the additional expression of the Ca2+-dependent guanylate cyclase activating protein (CD-GCAP) S100B which binds to its C-terminal extension, supports acceleration of cyclic GMP synthesis at high Ca2+ levels. Independent of Cat(2+), ROS-GC1 activity is also stimulated directly by bicarbonate binding to the core catalytic domain (CCD). Several enticing molecular features of this transduction system are revealed in the present study. In combination, bicarbonate and Ca2+ I-dependent modulators raised maximal ROS-GC activity to levels that exceeded the sum of their individual effects. The F514S mutation in ROS-GC1 that causes blindness in type 1 Leber's congenital amaurosis (LCA) severely reduced basal ROS-GC1 activity. GCAP2 and S100B Cat(2+) signaling modes remained functional, while the GCAP1-modulated mode was diminished. Bicarbonate nearly restored basal activity as well as GCAP2- and S100B-stimulated activities of the F514S mutant to normal levels but could not resurrect GCAP1 stimulation. We conclude that GCAP1 and GCAP2 forge distinct pathways through domain-specific modules of ROS-GC1 whereas the S100B and GCAP2 pathways may overlap. The synergistic interlinking of bicarbonate to GCAPs- and S100B-modulated pathways intensifies and tunes the dependence of cyclic GMP synthesis on intracellular Ca2+. Our study challenges the recently proposed GCAP1 and GCAP2 "overlapping" phototransduction model (Peshenko et al., 2015b).
C1 [Duda, Teresa; Pertzev, Alexandre; Sharma, Rameshwar K.] Salus Univ, Unit Regulatory & Mol Biol, Div Biochem Res, Elkins Pk, PA USA.
[Duda, Teresa; Pertzev, Alexandre; Sharma, Rameshwar K.] Salus Univ, Unit Regulatory & Mol Biol, Res Div Mol Biol, Elkins Pk, PA USA.
[Makino, Clint L.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
[Makino, Clint L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Duda, T (reprint author), Salus Univ, Unit Regulatory & Mol Biol, Div Biochem Res, Elkins Pk, PA USA.; Duda, T (reprint author), Salus Univ, Unit Regulatory & Mol Biol, Res Div Mol Biol, Elkins Pk, PA USA.
EM tduda@salus.edu
FU National Eye Institute [EY023980, EY014104]; Howe Laboratory Endowment
of the Massachusetts Eye and Ear Infirmary; Research to Prevent
Blindness, Inc.
FX This work was supported by the National Eye Institute: EY023980,
EY014104, the Howe Laboratory Endowment of the Massachusetts Eye and Ear
Infirmary, and by Research to Prevent Blindness, Inc. The authors are
solely responsible for the contents of this article, which do not
necessarily represent the official views of the National Eye Institute.
NR 63
TC 1
Z9 1
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1662-5099
J9 FRONT MOL NEUROSCI
JI Front. Molec. Neurosci.
PD JAN 28
PY 2016
VL 9
AR 5
DI 10.3389/fnmol.2013.00005
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA DE3UF
UT WOS:000370555100001
PM 26858600
ER
PT J
AU Li, JZ
Etemad, B
Ahmed, H
Aga, E
Bosch, RJ
Mellors, JW
Kuritzkes, DR
Lederman, MM
Para, M
Gandhi, RT
AF Li, Jonathan Z.
Etemad, Behzad
Ahmed, Hayat
Aga, Evgenia
Bosch, Ronald J.
Mellors, John W.
Kuritzkes, Daniel R.
Lederman, Michael M.
Para, Michael
Gandhi, Rajesh T.
TI The size of the expressed HIV reservoir predicts timing of viral rebound
after treatment interruption
SO AIDS
LA English
DT Article
DE biomarker; expressed reservoir; HIV; monitored antiretroviral pause;
treatment interruption; viral rebound
ID SUPPRESSIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; PCR ASSAY;
INFECTION; REPLICATION; TRIALS; LATENCY; PLASMA; TIME; CURE
AB Objectives:Therapies to achieve sustained antiretroviral therapy-free HIV remission will require validation in analytic treatment interruption (ATI) trials. Identifying biomarkers that predict time to viral rebound could accelerate the development of such therapeutics.Design:A pooled analysis of participants from six AIDS Clinical Trials Group ATI studies to identify predictors of viral rebound.Methods:Cell-associated DNA (CA-DNA) and CA-RNA were quantified in pre-ATI peripheral blood mononuclear cell samples, and residual plasma viremia was measured using the single-copy assay.Results:Participants who initiated antiretroviral therapy (ART) during acute/early HIV infection and those on a non-nucleoside reverse transcriptase inhibitor-containing regimen had significantly delayed viral rebound. Participants who initiated ART during acute/early infection had lower levels of pre-ATI CA-RNA (acute/early vs. chronic-treated: median <92 vs. 156 HIV-1 RNA copies/10(6) CD4(+) cells, P<0.01). Higher pre-ATI CA-RNA levels were significantly associated with shorter time to viral rebound (4 vs. 5-8 vs. >8 weeks: median 182 vs. 107 vs. <92 HIV-1 RNA copies/10(6) CD4(+) cells, Kruskal-Wallis P<0.01). The proportion of participants with detectable plasma residual viremia prior to ATI was significantly higher among those with shorter time to viral rebound.Conclusion:Higher levels of HIV expression while on ART are associated with shorter time to HIV rebound after treatment interruption. Quantification of the active HIV reservoir may provide a biomarker of efficacy for therapies that aim to achieve ART-free HIV remission.
C1 [Li, Jonathan Z.; Etemad, Behzad; Ahmed, Hayat; Kuritzkes, Daniel R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Cambridge, MA 02138 USA.
[Aga, Evgenia; Bosch, Ronald J.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
[Mellors, John W.] Univ Pittsburgh, Pittsburgh, PA USA.
[Lederman, Michael M.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Para, Michael] Ohio State Univ, Columbus, OH 43210 USA.
[Gandhi, Rajesh T.] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Gandhi, Rajesh T.] Harvard Univ, Sch Med, Ragon Inst, Boston, MA 02115 USA.
RP Li, JZ (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Cambridge, MA 02138 USA.; Li, JZ (reprint author), Brigham & Womens Hosp, Div Infect Dis, 65 Landsdowne St,Rm 421, Cambridge, MA 02139 USA.
EM jli@bwh.harvard.edu
FU Harvard University Center for AIDS Research [NIAID 5P30AI060354-08];
National Institutes of Health (NIH) [AI100699, AI36219, UM1 AI068634,
UM1 AI068636]
FX This work was supported in part by a grant from the Harvard University
Center for AIDS Research (to J.Z.L. and R.T.G., NIAID 5P30AI060354-08),
National Institutes of Health (NIH) grants AI100699 (to J.Z.L.), AI36219
(to M.M.L.), UM1 AI068634 (Statistical and Data Management Center of the
AIDS Clinical Trials Group), UM1 AI068636 (AIDS Clinical Trials Group),
and a subcontract from UM1 AI068636 to the Harvard Virology Support
Laboratory (to D.R.K.).
NR 45
TC 15
Z9 15
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JAN 28
PY 2016
VL 30
IS 3
BP 343
EP 353
DI 10.1097/QAD.0000000000000953
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DC6BN
UT WOS:000369304800002
PM 26588174
ER
PT J
AU Looby, SE
Fitch, KV
Srinivasa, S
Lo, J
Rafferty, D
Martin, A
Currier, JC
Grinspoon, S
Zanni, MV
AF Looby, Sara E.
Fitch, Kathleen V.
Srinivasa, Suman
Lo, Janet
Rafferty, Danielle
Martin, Amanda
Currier, Judith C.
Grinspoon, Steven
Zanni, Markella V.
TI Reduced ovarian reserve relates to monocyte activation and subclinical
coronary atherosclerotic plaque in women with HIV
SO AIDS
LA English
DT Article
DE cardiovascular diseases; HIV; menopause; ovarian reserve; women
ID ANTI-MULLERIAN HORMONE; RISK-FACTORS; ANTIMULLERIAN HORMONE; NATURAL
MENOPAUSE; INFECTED PATIENTS; HEART-DISEASE; ANGIOGRAPHY; SYMPTOMS;
COCAINE; MARKER
AB Objective:To investigate differences in subclinical coronary atherosclerotic plaque and markers of immune activation among HIV-infected and non-HIV-infected women categorized by degree of ovarian reserve and menopause status.
Design:Cross-sectional evaluation.
Methods:Seventy-four women (49 HIV-infected, 25 non-HIV-infected) without known cardiovascular disease (CVD) were classified as premenopausal, premenopausal with reduced ovarian reserve, or postmenopausal based on menstrual history and anti-Mullerian hormone (AMH) levels. Participants underwent contrast-enhanced coronary computed tomography angiography and immune phenotyping. Comparisons in coronary atherosclerotic plaque burden and immune markers were made between the HIV-infected and non-HIV-infected women overall and within the HIV-infected and non-HIV-infected women by reproductive classification group.
Results:Among the overall group of HIV-infected women, the women with reduced ovarian reserve (undetectable AMH) had a higher prevalence of coronary atherosclerotic plaque (52 versus 6%, P=0.0007) and noncalcified plaque (48 versus 6%, P=0.002), as well as higher levels of log sCD163 (P=0.0004) and log MCP-1 (P=0.006), compared with the premenopausal women with measurable AMH. Furthermore, reduced ovarian reserve in the HIV-infected group related to noncalcified plaque, controlling for traditional CVD risk factors (P=0.04) and sCD163 (P=0.03).
Conclusion:HIV-infected women with reduced ovarian reserve have increased subclinical coronary atherosclerotic plaque compared with premenopausal women in whom AMH is measurable. This relationship holds when controlling for CVD risk factors (including age) and immune activation. Our findings demonstrate that reduced ovarian reserve may contribute to CVD burden in HIV-infected women and support a comprehensive assessment of CVD risk prior to completion of menopause in this population.
C1 [Looby, Sara E.; Fitch, Kathleen V.; Srinivasa, Suman; Lo, Janet; Rafferty, Danielle; Martin, Amanda; Grinspoon, Steven; Zanni, Markella V.] Massachusetts Gen Hosp, Program Nutr Metab, 5 Longfellow Pl,Suite 207,55 Fruit St, Boston, MA 02114 USA.
[Looby, Sara E.; Fitch, Kathleen V.; Srinivasa, Suman; Lo, Janet; Rafferty, Danielle; Martin, Amanda; Grinspoon, Steven; Zanni, Markella V.] Harvard Univ, Sch Med, Boston, MA USA.
[Currier, Judith C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Zanni, MV (reprint author), Massachusetts Gen Hosp, Program Nutr Metab, 5 Longfellow Pl,Suite 207,55 Fruit St, Boston, MA 02114 USA.; Zanni, MV (reprint author), Harvard Univ, Sch Med, Boston, MA USA.; Zanni, MV (reprint author), Massachusetts Gen Hosp, 5 Longfellow Pl,Suite 207,55 Fruit St, Boston, MA 02114 USA.
EM mzanni@mgh.harvard.edu
FU Bristol Myers Squibb, Inc; National Institutes of Health [R01
HL095123-04, M01-RR-01066, 1 UL1 RR025758-01]; Harvard Clinical and
Translational Science Center, from the National Center for Research
Resources; Nutrition Obesity Research Center at Harvard [P30 DK040561]
FX This work was supported by Bristol Myers Squibb, Inc and the National
Institutes of Health and R01 HL095123-04 to S.G., M01-RR-01066 and 1 UL1
RR025758-01, Harvard Clinical and Translational Science Center, from the
National Center for Research Resources and P30 DK040561, Nutrition
Obesity Research Center at Harvard. Funding sources had no role in the
design of the study, data analysis or the writing of the manuscript.
NR 37
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JAN 28
PY 2016
VL 30
IS 3
BP 383
EP 393
DI 10.1097/QAD.0000000000000902
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DC6BQ
UT WOS:000369305100003
PM 26696388
ER
PT J
AU Depp, TB
McGinnis, KA
Kraemer, K
Akgun, KM
Edelman, EJ
Fiellin, DA
Butt, AA
Crystal, S
Gordon, AJ
Freiberg, M
Gibert, CL
Rimland, D
Bryant, KJ
Crothers, K
AF Depp, Timothy B.
McGinnis, Kathleen A.
Kraemer, Kevin
Akguen, Kathleen M.
Edelman, E. Jennifer
Fiellin, David A.
Butt, Adeel A.
Crystal, Stephen
Gordon, Adam J.
Freiberg, Matthew
Gibert, Cynthia L.
Rimland, David
Bryant, Kendall J.
Crothers, Kristina
TI Risk factors associated with acute exacerbation of chronic obstructive
pulmonary disease in HIV-infected and uninfected patients
SO AIDS
LA English
DT Article
DE acute exacerbation; AECOPD; AIDS/HIV; chronic obstructive pulmonary
disease; cigarette smoking; COPD; tobacco use; unhealthy alcohol use
ID ANTIRETROVIRAL THERAPY ERA; COPD EXACERBATIONS; UNITED-STATES;
LUNG-DISEASE; ALCOHOL-USE; CARE; HEALTH; VETERANS; EPIDEMIOLOGY;
MORTALITY
AB Objective:To determine the association between HIV infection and other risk factors for acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Design:Longitudinal, national Veterans Aging Cohort Study including 43 618 HIV-infected and 86 492 uninfected veterans.Methods:AECOPD was defined as an inpatient or outpatient COPD ICD-9 diagnosis accompanied by steroid and/or antibiotic prescription within 5 days. We calculated incidence rate ratios (IRR) and 95% confidence intervals (CI) for first AECOPD over 2 years and used Poisson regression models to adjust for risk factors.Results:Over 234099 person-years of follow-up, 1428 HIV-infected and 2104 uninfected patients had at least one AECOPD. HIV-infected patients had an increased rate of AECOPD compared with uninfected (18.8 vs. 13.3 per 1000 person-years, P<0.001). In adjusted models, AECOPD risk was greater in HIV-infected individuals overall (IRR 1.54; 95% CI 1.44-1.65), particularly in those with more severe immune suppression when stratified by CD4(+) cell count (cells/l) compared with uninfected (HIV-infected CD4(+)<200: IRR 2.30, 95% CI 2.10-2.53, HIV-infected CD4(+) 200-349: IRR 1.32, 95% CI 1.15-1.51, HIV-infected CD4(+)350: IRR 0.99, 95% CI 0.88-1.10). HIV infection also modified the association between current smoking and alcohol-related diagnoses with risk for AECOPD such that interaction terms for HIV and current smoking or HIV and alcohol-related diagnoses were each significantly associated with AECOPD.Conclusion:HIV infection, especially with lower CD4(+) cell count, is an independent risk factor for AECOPD. Enhanced susceptibility to harm from current smoking or unhealthy alcohol use in HIV-infected patients may also contribute to the greater rate of AECOPD. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Depp, Timothy B.] Univ S Carolina, Columbia, SC 29208 USA.
[Depp, Timothy B.; McGinnis, Kathleen A.; Kraemer, Kevin; Butt, Adeel A.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Kraemer, Kevin; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Akguen, Kathleen M.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Akguen, Kathleen M.; Edelman, E. Jennifer; Fiellin, David A.] Yale Univ, Sch Med, New Haven, CT USA.
[Butt, Adeel A.] Hamad Healthcare Qual Inst, Doha, Qatar.
[Butt, Adeel A.] Hamad Med Corp, Doha, Qatar.
[Crystal, Stephen] Rutgers State Univ, New Brunswick, NJ 08903 USA.
[Freiberg, Matthew] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Gibert, Cynthia L.] Washington DC VA Med Ctr, Washington, DC USA.
[Rimland, David] VA Med Ctr, Atlanta, GA USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
[Bryant, Kendall J.] NIAAA, NIH, Bethesda, MD USA.
[Crothers, Kristina] Univ Washington, Seattle, WA 98195 USA.
RP Crothers, K (reprint author), Univ Washington, Harborview Med Ctr, 325 9th Ave,POB 359762, Seattle, WA 98104 USA.
EM crothk@uw.edu
OI Edelman, E. Jennifer/0000-0002-9375-0489; Fiellin,
David/0000-0002-4006-010X; Crothers, Kristina/0000-0001-9702-0371
FU NIH/NHLBI [R01 HL090342]; NIAAA [U24-AA020794]; AHRQ [U19HS021,
R18HS023258, U10 AA013566]
FX NIH/NHLBI R01 HL090342, NIAAA U24-AA020794, AHRQ U19HS021, R18HS023258
and U10 AA013566.
NR 69
TC 5
Z9 5
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JAN 28
PY 2016
VL 30
IS 3
BP 455
EP 463
DI 10.1097/QAD.0000000000000940
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DC6CB
UT WOS:000369306300003
PM 26765938
ER
PT J
AU Maus, MV
AF Maus, Marcela V.
TI Innate immune signaling in CLL
SO BLOOD
LA English
DT Editorial Material
ID CHRONIC LYMPHOCYTIC-LEUKEMIA
C1 [Maus, Marcela V.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RP Maus, MV (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
NR 7
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD JAN 28
PY 2016
VL 127
IS 4
BP 376
EP +
DI 10.1182/blood-2015-11-679845
PG 3
WC Hematology
SC Hematology
GA DC5VI
UT WOS:000369288300004
PM 26823508
ER
PT J
AU Clapham, KR
Chu, AY
Wessel, J
Natarajan, P
Flannick, J
Rivas, MA
Sartori, S
Mehran, R
Baber, U
Fuster, V
Scott, RA
Rader, DJ
Boehnke, M
McCarthy, MI
Altshuler, DM
Kathiresan, S
Peloso, GM
AF Clapham, Katharine R.
Chu, Audrey Y.
Wessel, Jennifer
Natarajan, Pradeep
Flannick, Jason
Rivas, Manuel A.
Sartori, Samantha
Mehran, Roxana
Baber, Usman
Fuster, Valentin
Scott, Robert A.
Rader, Daniel J.
Boehnke, Michael
McCarthy, Mark I.
Altshuler, David M.
Kathiresan, Sekar
Peloso, Gina M.
TI A null mutation in ANGPTL8 does not associate with either plasma glucose
or type 2 diabetes in humans
SO BMC ENDOCRINE DISORDERS
LA English
DT Article
DE Betatrophin; Angiopoietin-like 8; rs145464906
ID LOW-FREQUENCY; VARIANTS; ANGPTL8/BETATROPHIN; SUSCEPTIBILITY;
BETATROPHIN; PROTEIN; DISEASE; DESIGN
AB Background: Experiments in mice initially suggested a role for the protein angiopoietin-like 8 (ANGPTL8) in glucose homeostasis. However, subsequent experiments in model systems have challenged this proposed role. We sought to better understand the importance of ANGPTL8 in human glucose homeostasis by examining the association of a null mutation in ANGPTL8 with fasting glucose levels and risk for type 2 diabetes.
Methods: A naturally-occurring null mutation in human ANGPTL8 (rs145464906; c.361C > T; p.Q121X) is carried by similar to 1 in 1000 individuals of European ancestry and is associated with higher levels of plasma high-density lipoprotein cholesterol, suggesting that this mutation has functional significance. We examined the association of p.Q121X with fasting glucose levels and risk for type 2 diabetes in up to 95,558 individuals (14,824 type 2 diabetics and 80,734 controls).
Results: We found no significant association of p.Q121X with either fasting glucose or type 2 diabetes (p-value = 0.90 and 0.65, respectively). Given our sample sizes, we had >98 % power to detect at least a 0.23 mmol/L effect on plasma glucose and >95 % power to detect a 70 % increase in risk for type 2 diabetes.
Conclusion: Disruption of ANGPTL8 function in humans does not seem to have a large effect on measures of glucose tolerance.
C1 [Clapham, Katharine R.; Natarajan, Pradeep; Rivas, Manuel A.; Kathiresan, Sekar; Peloso, Gina M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA.
[Chu, Audrey Y.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA.
[Chu, Audrey Y.] Natl Heart Lung & Blood Inst NHLBI Framingham Hea, Framingham, MA 01702 USA.
[Wessel, Jennifer] Fairbanks Sch Publ Hlth, Dept Epidemiol, Indianapolis, IN 46202 USA.
[Wessel, Jennifer] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
[Natarajan, Pradeep; Kathiresan, Sekar; Peloso, Gina M.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Natarajan, Pradeep; Kathiresan, Sekar; Peloso, Gina M.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Natarajan, Pradeep; Flannick, Jason; Rivas, Manuel A.; Altshuler, David M.; Kathiresan, Sekar; Peloso, Gina M.] Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Flannick, Jason; Altshuler, David M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Sartori, Samantha; Mehran, Roxana; Baber, Usman; Fuster, Valentin] Icahn Sch Med Mt Sinai, Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA.
[Scott, Robert A.] Univ Cambridge, Sch Clin Med, Inst Metab Sci, MRC Epidemiol Unit, Cambridge Biomed Campus, Cambridge CB2 0SL, England.
[Rader, Daniel J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Boehnke, Michael] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
[McCarthy, Mark I.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
[McCarthy, Mark I.] Univ Oxford, Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
[McCarthy, Mark I.] Churchill Hosp, Oxford NIHR Biomed Res Ctr, Oxford OX3 7LJ, England.
[Altshuler, David M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Peloso, Gina M.] Crosstown Ctr, 801 Massachusetts Ave,Third Floor, Boston, MA 02118 USA.
RP Peloso, GM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA.; Peloso, GM (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.; Peloso, GM (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.; Peloso, GM (reprint author), Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA.; Peloso, GM (reprint author), Crosstown Ctr, 801 Massachusetts Ave,Third Floor, Boston, MA 02118 USA.
EM gpeloso@bu.edu
RI Fuster, Valentin/H-4319-2015;
OI Fuster, Valentin/0000-0002-9043-9986; Natarajan,
Pradeep/0000-0001-8402-7435; Wessel, Jennifer/0000-0002-7031-0085
FU National Heart, Lung, and Blood Institute of National Institutes of
Health [K01HL125751]; Research Scholar award from Massachusetts General
Hospital (MGH); Howard Goodman Fellowship from MGH; Donovan Family
Foundation [R01HL107816]; Fondation Leducq
FX GMP is supported by the National Heart, Lung, and Blood Institute of the
National Institutes of Health under Award Number K01HL125751. SK is
supported by a Research Scholar award from the Massachusetts General
Hospital (MGH), the Howard Goodman Fellowship from MGH, the Donovan
Family Foundation, R01HL107816, and a grant from Fondation Leducq. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of
Health. The authors do not report any conflict of interest.
NR 15
TC 1
Z9 1
U1 2
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6823
J9 BMC ENDOCR DISORD
JI BMC Endocr. Disord.
PD JAN 28
PY 2016
VL 16
AR 7
DI 10.1186/s12902-016-0088-8
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DC4UO
UT WOS:000369216000001
PM 26822414
ER
PT J
AU Rouch, JD
Scott, A
Lei, NY
Solorzano-Vargas, RS
Wang, JF
Hanson, EM
Kobayashi, M
Lewis, M
Stelzner, MG
Dunn, JCY
Eckmann, L
Martin, MG
AF Rouch, Joshua D.
Scott, Andrew
Lei, Nan Ye
Solorzano-Vargas, R. Sergio
Wang, Jiafang
Hanson, Elaine M.
Kobayashi, Masae
Lewis, Michael
Stelzner, Matthias G.
Dunn, James C. Y.
Eckmann, Lars
Martin, Martin G.
TI Development of Functional Microfold (M) Cells from Intestinal Stem Cells
in Primary Human Enteroids
SO PLOS ONE
LA English
DT Article
ID EPITHELIAL M-CELLS; PATCH M-CELLS; NF-KAPPA-B; MESENCHYMAL TRANSITION;
TRANSEPITHELIAL TRANSPORT; MOUSE INTESTINE; PEYERS-PATCHES; IN-VITRO;
DIFFERENTIATION; EXPRESSION
AB Background & Aims
Intestinal microfold (M) cells are specialized epithelial cells that act as gatekeepers of luminal antigens in the intestinal tract. They play a critical role in the intestinal mucosal immune response through transport of viruses, bacteria and other particles and antigens across the epithelium to immune cells within Peyer's patch regions and other mucosal sites. Recent studies in mice have demonstrated that M cells are generated from Lgr5+ intestinal stem cells (ISCs), and that infection with Salmonella enterica serovar Typhimurium increases M cell formation. However, it is not known whether and how these findings apply to primary human small intestinal epithelium propagated in an in vitro setting.
Methods
Human intestinal crypts were grown as monolayers with growth factors and treated with recombinant RANKL, and assessed for mRNA transcripts, immunofluorescence and uptake of microparticles and S. Typhimurium.
Results
Functional M cells were generated by short-term culture of freshly isolated human intestinal crypts in a dose-and time-dependent fashion. RANKL stimulation of the monolayer cultures caused dramatic induction of the M cell-specific markers, SPIB, and Glycoprotein-2 (GP2) in a process primed by canonical WNT signaling. Confocal microscopy demonstrated a pseudopod phenotype of GP2-positive M cells that preferentially take up microparticles. Furthermore, infection of the M cell-enriched cultures with the M cell-tropic enteric pathogen, S. Typhimurium, led to preferential association of the bacteria with M cells, particularly at lower inoculum sizes. Larger inocula caused rapid induction of M cells.
Conclusions
Human intestinal crypts containing ISCs can be cultured and differentiate into an epithelial layer with functional M cells with characteristic morphological and functional properties. This study is the first to demonstrate that M cells can be induced to form from primary human intestinal epithelium, and that S. Typhimurium preferentially infect these cells in an in vitro setting. We anticipate that this model can be used to generate large numbers of M cells for further functional studies of these key cells of intestinal immune induction and their impact on controlling enteric pathogens and the intestinal microbiome.
C1 [Rouch, Joshua D.; Scott, Andrew; Dunn, James C. Y.] Univ Calif Los Angeles, Dept Surg, Div Pediat Surg, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Lei, Nan Ye; Kobayashi, Masae; Dunn, James C. Y.] Univ Calif Los Angeles, Dept Bioengn, Henry Samueli Sch Engn, Los Angeles, CA USA.
[Solorzano-Vargas, R. Sergio; Wang, Jiafang; Martin, Martin G.] Univ Calif Los Angeles, Dept Pediat, Div Gastroenterol & Nutr, Mattel Childrens Hosp, Los Angeles, CA 90024 USA.
[Solorzano-Vargas, R. Sergio; Wang, Jiafang; Martin, Martin G.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Hanson, Elaine M.; Eckmann, Lars] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
[Lewis, Michael] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol, Los Angeles, CA USA.
[Stelzner, Matthias G.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA.
[Martin, Martin G.] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA USA.
RP Martin, MG (reprint author), Univ Calif Los Angeles, Dept Pediat, Div Gastroenterol & Nutr, Mattel Childrens Hosp, Los Angeles, CA 90024 USA.; Martin, MG (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.; Martin, MG (reprint author), Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA USA.
EM mmartin@mednet.ucla.edu
RI Solorano, Sergio/D-4869-2016
FU Intestinal Stem Cell Consortium - National Institute of Diabetes and
Digestive and Kidney Diseases; National Institute of Allergy and
Infectious Diseases [DK085535]; NIDDK [DK083762, DK083319]; California
Institute for Regenerative Medicine [RT2-01985]
FX This work was supported by the Intestinal Stem Cell Consortium
(https://iscc.coh.org), a collaborative research project funded by the
National Institute of Diabetes and Digestive and Kidney Diseases and the
National Institute of Allergy and Infectious Diseases (DK085535); and
other grants from NIDDK (DK083762, and DK083319), and the California
Institute for Regenerative Medicine (RT2-01985).
NR 37
TC 3
Z9 3
U1 6
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 28
PY 2016
VL 11
IS 1
AR e0148216
DI 10.1371/journal.pone.0148216
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DC9GF
UT WOS:000369528400076
PM 26820624
ER
PT J
AU Natarajan, A
Ahn, R
Nelson, BD
Eckardt, M
Kamara, J
Kargbo, S
Kanu, P
Burke, TF
AF Natarajan, Abirami
Ahn, Roy
Nelson, Brett D.
Eckardt, Melody
Kamara, Jennifer
Kargbo, Sas
Kanu, Pity
Burke, Thomas F.
TI Use of prophylactic uterotonics during the third stage of labor: a
survey of provider practices in community health facilities in Sierra
Leone
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Article
DE Prophylactic uterotonics; Postpartum hemorrhage; Sierra Leone
ID ACTIVE MANAGEMENT; MATERNAL DEATH; STRATEGIES; TRIAL
AB Background: Postpartum hemorrhage remains the leading cause of maternal mortality worldwide. Administration of uterotonics during the third stage of labor is a simple and well established intervention that can significantly decrease the development of postpartum hemorrhage. Little is known about the use of prophylactic uterotonics in peripheral health centers, where the majority of normal deliveries occur. The purpose of this study is to assess health provider current practices and determinants to the use of prophylactic uterotonics in Sierra Leone, a country with one of the highest maternal mortality ratios worldwide.
Methods: This is a mixed methods study using descriptive cross-sectional survey and qualitative interviews in community health facilities in Freetown, Sierra Leone following a comprehensive training on postpartum hemorrhage. Facilities and providers were surveyed between May and June 2014. Qualitative methods were used to identify barriers and facilitators to the use of prophylactic uterotonics.
Results: A total of 134 providers were surveyed at 39 periphreal health facilities. Thirteen facilities (39 %) reported an inconsistent supply of oxytocin. The majority of facilities (64 %) stored oxytocin at room temperature. Provider level, in-service training, and leadership role were significantly associated with prophylactic uterotonic use. Overall, 62 % of providers reported routine use. Midwives were most likely to routinely administer uterotonics (93 %), followed by community health officers/assistants (78 %), maternal and child health aides (56 %), and state-enrolled community health nurses (52 %). Of the providers who received in-service training, 67 % reported routine use; of those with no in-service training, 42 % reported routine use. Qualitative analysis revealed that facility protocols, widespread availability, and provider perception of utility facilitated routine use. Common barriers reported included inconsistent supply of uterotonics, lack of knowledge regarding timely administration, and provider attitude regarding utility of uterotonics following normal deliveries.
Conclusion: There is considerable room for improvement in availability and administration of prophylactic uterotonics. Understanding barriers to routine use may aid in developing multifaceted pre-service and in-service training interventions designed to improve routine intrapartum care.
C1 [Natarajan, Abirami; Ahn, Roy; Nelson, Brett D.; Eckardt, Melody; Kamara, Jennifer; Burke, Thomas F.] Massachusetts Gen Hosp, Dept Emergency Med, Div Global Hlth & Human Rights, Zero Emerson Pl Suite 104, Boston, MA 02114 USA.
[Natarajan, Abirami; Ahn, Roy; Nelson, Brett D.; Burke, Thomas F.] Harvard Univ, Sch Med, 25 Shattuck St, Boston, MA 02115 USA.
[Kargbo, Sas; Kanu, Pity] Minist Hlth & Sanitat, 4th Floor Youyi Bldg, Freetown, Sierra Leone.
RP Natarajan, A (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Div Global Hlth & Human Rights, Zero Emerson Pl Suite 104, Boston, MA 02114 USA.
EM abirami_natarajan@hms.harvard.edu
OI Nelson, Brett/0000-0002-5049-1798
FU Saving Lives at Birth (Washington, DC, USA); Humanitarian Innovation
Fund; Ujenzi Charitable Trust; Harvard Medical School (Boston, MA, USA)
FX We would like to thank all of the health care providers who volunteered
their time to work as UBT champions and all health care providers who
participated in this study. We thank Tom Chittenden for his help with
the statistical analysis. Funding was provided by Saving Lives at Birth
(Washington, DC, USA), Humanitarian Innovation Fund, Ujenzi Charitable
Trust, and Harvard Medical School (Boston, MA, USA).
NR 19
TC 0
Z9 0
U1 2
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD JAN 28
PY 2016
VL 16
AR 23
DI 10.1186/s12884-016-0809-z
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DB9YM
UT WOS:000368873600001
PM 26821645
ER
PT J
AU Hu, H
Juvekar, A
Lyssiotis, CA
Lien, EC
Albeck, JG
Oh, D
Varma, G
Hung, YP
Ullas, S
Lauring, J
Seth, P
Lundquist, MR
Tolan, DR
Grant, AK
Needleman, DJ
Asara, JM
Cantley, LC
Wulf, GM
AF Hu, Hai
Juvekar, Ashish
Lyssiotis, Costas A.
Lien, Evan C.
Albeck, John G.
Oh, Doogie
Varma, Gopal
Hung, Yin Pun
Ullas, Soumya
Lauring, Josh
Seth, Pankaj
Lundquist, Mark R.
Tolan, Dean R.
Grant, Aaron K.
Needleman, Daniel J.
Asara, John M.
Cantley, Lewis C.
Wulf, Gerburg M.
TI Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of
Aldolase from the Actin Cytoskeleton
SO CELL
LA English
DT Article
ID BREAST-CANCER; F-ACTIN; INHIBITOR; METABOLISM; ACTIVATION; PATHWAY;
KINASE; CELLS; RAC; DEHYDROGENASE
AB The phosphoinositide 3-kinase (PI3K) pathway regulates multiple steps in glucose metabolism and also cytoskeletal functions, such as cell movement and attachment. Here, we show that PI3K directly coordinates glycolysis with cytoskeletal dynamics in an AKT-independent manner. Growth factors or insulin stimulate the PI3K-dependent activation of Rac, leading to disruption of the actin cytoskeleton, release of filamentous actin-bound aldolase A, and an increase in aldolase activity. Consistently, PI3K inhibitors, but not AKT, SGK, or mTOR inhibitors, cause a significant decrease in glycolysis at the step catalyzed by aldolase, while activating PIK3CA mutations have the opposite effect. These results point toward a master regulatory function of PI3K that integrates an epithelial cell's metabolism and its form, shape, and function, coordinating glycolysis with the energy-intensive dynamics of actin remodeling.
C1 [Hu, Hai; Juvekar, Ashish; Wulf, Gerburg M.] Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, Boston, MA 02215 USA.
[Hu, Hai; Juvekar, Ashish; Wulf, Gerburg M.] Harvard Univ, Med Sch HMS, Boston, MA 02215 USA.
[Lyssiotis, Costas A.; Lundquist, Mark R.; Cantley, Lewis C.] Weill Cornell Med, Meyer Canc Ctr, New York, NY 10065 USA.
[Lien, Evan C.] BIDMC, Dept Pathol, Boston, MA 02215 USA.
[Albeck, John G.] HMS, Dept Cell Biol, Boston, MA 02215 USA.
[Oh, Doogie; Needleman, Daniel J.] Harvard Univ, FAS Ctr Syst Biol, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
[Varma, Gopal; Grant, Aaron K.] BIDMC Boston, Dept Radiol, Boston, MA 02215 USA.
[Hung, Yin Pun] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
[Lauring, Josh] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA.
[Seth, Pankaj] BIDMC, Div Interdisciplinary Med, Boston, MA 02215 USA.
[Tolan, Dean R.] Boston Univ, Dept Biol, Boston, MA 02215 USA.
[Asara, John M.] BIDMC, Div Signal Transduct, Boston, MA 02215 USA.
[Ullas, Soumya] BIDMC, Longwood Small Anim Imaging Facil, Boston, MA 02215 USA.
[Lyssiotis, Costas A.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
[Albeck, John G.] Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA.
RP Wulf, GM (reprint author), Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, Boston, MA 02215 USA.; Wulf, GM (reprint author), Harvard Univ, Med Sch HMS, Boston, MA 02215 USA.
EM gwulf@bidmc.harvard.edu
RI Cantley, Lewis/D-1800-2014;
OI Cantley, Lewis/0000-0002-1298-7653; Lien, Evan/0000-0001-7866-4761;
Lauring, Josh/0000-0002-4312-704X
FU Breast Cancer Research Foundation (BCRF); Mary Kay Ash Foundation; Men's
Initiative of DFHCC; Breast Cancer Alliance; NIH [GM041890, R21
EB014471, R01 CA169470]; NIH NCI [5P01CA120964-05, 5P30CA006516-46]; NSF
[DBI-0959721, DMR-0820484]; United States-Israel Binational Science
Foundation (BSF) [2009271]; Damon Runyon Cancer Research Foundation;
Stand Up to Cancer Dream Team Translational Research Grant
[SU2C-AACR-DT0209]; [R01CA152330-0]
FX L.C.C. and G.M.W. are supported by a Stand Up to Cancer Dream Team
Translational Research Grant, (SU2C-AACR-DT0209), by the Breast Cancer
Research Foundation (BCRF), the Mary Kay Ash Foundation, the Men's
Initiative of DFHCC, and the Breast Cancer Alliance; L.C.C. by NIH grant
GM041890; J.M.A. in part by NIH NCI grants 5P01CA120964-05 and
5P30CA006516-46; A.K.G., P.S., and G.V. in part by NIH R21 EB014471 and
R01 CA169470; and P.S. in part by R01CA152330-0. D.J.N. is supported in
part by NSF DBI-0959721 and DMR-0820484 and the United States-Israel
Binational Science Foundation (BSF 2009271); and C.A.L. by a Dale F.
Frey award from the Damon Runyon Cancer Research Foundation.
NR 36
TC 11
Z9 12
U1 12
U2 33
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD JAN 28
PY 2016
VL 164
IS 3
BP 433
EP 446
DI 10.1016/j.cell.2015.12.042
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DC0KU
UT WOS:000368906800014
PM 26824656
ER
PT J
AU Haradhvala, NJ
Polak, P
Stojanov, P
Covington, KR
Shinbrot, E
Hess, JM
Rheinbay, E
Kim, J
Maruvka, YE
Braunstein, LZ
Kamburov, A
Hanawalt, PC
Wheeler, DA
Koren, A
Lawrence, MS
Getz, G
AF Haradhvala, Nicholas J.
Polak, Paz
Stojanov, Petar
Covington, Kyle R.
Shinbrot, Eve
Hess, Julian M.
Rheinbay, Esther
Kim, Jaegil
Maruvka, Yosef E.
Braunstein, Lior Z.
Kamburov, Atanas
Hanawalt, Philip C.
Wheeler, David A.
Koren, Amnon
Lawrence, Michael S.
Getz, Gad
TI Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA
Damage and Repair
SO CELL
LA English
DT Article
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; 21 BREAST CANCERS; SOMATIC MUTATIONS;
REPLICATION; SIGNATURES; EVOLUTION; GENES; MUTAGENESIS; PATTERNS;
ORIGINS
AB Mutational processes constantly shape the somatic genome, leading to immunity, aging, cancer, and other diseases. When cancer is the outcome, we are afforded a glimpse into these processes by the clonal expansion of the malignant cell. Here, we characterize a less explored layer of the mutational landscape of cancer: mutational asymmetries between the two DNA strands. Analyzing whole-genome sequences of 590 tumors from 14 different cancer types, we reveal widespread asymmetries across mutagenic processes, with transcriptional ("T-class'') asymmetry dominating UV-, smoking-, and liver-cancer-associated mutations and replicative ("R-class'') asymmetry dominating POLE-, APOBEC-, and MSI-associated mutations. We report a striking phenomenon of transcription-coupled damage (TCD) on the non-transcribed DNA strand and provide evidence that APOBEC mutagenesis occurs on the lagging-strand template during DNA replication. As more genomes are sequenced, studying and classifying their asymmetries will illuminate the underlying biological mechanisms of DNA damage and repair.
C1 [Haradhvala, Nicholas J.; Polak, Paz; Rheinbay, Esther; Maruvka, Yosef E.; Kamburov, Atanas; Getz, Gad] Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA.
[Haradhvala, Nicholas J.; Polak, Paz; Rheinbay, Esther; Maruvka, Yosef E.; Kamburov, Atanas; Getz, Gad] Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA.
[Haradhvala, Nicholas J.; Polak, Paz; Hess, Julian M.; Rheinbay, Esther; Kim, Jaegil; Maruvka, Yosef E.; Braunstein, Lior Z.; Kamburov, Atanas; Koren, Amnon; Lawrence, Michael S.; Getz, Gad] Broad Inst Harvard & MIT, 415 Main St, Cambridge, MA 02142 USA.
[Polak, Paz; Kamburov, Atanas; Getz, Gad] Harvard Univ, Sch Med, 25 Shattuck St, Boston, MA 02115 USA.
[Stojanov, Petar] Carnegie Mellon Univ, Sch Comp Sci, 5000 Forbes Ave, Pittsburgh, PA 15213 USA.
[Covington, Kyle R.; Shinbrot, Eve; Wheeler, David A.] Baylor Coll Med, 1 Baylor Plaza, Houston, TX 77030 USA.
[Hanawalt, Philip C.] Stanford Univ, Dept Biol, 450 Serra Mall, Stanford, CA 94305 USA.
[Koren, Amnon] Cornell Univ, Dept Mol Biol & Genet, 526 Campus Rd, Ithaca, NY 14853 USA.
RP Getz, G (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA.; Getz, G (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA.; Lawrence, MS; Getz, G (reprint author), Broad Inst Harvard & MIT, 415 Main St, Cambridge, MA 02142 USA.; Getz, G (reprint author), Harvard Univ, Sch Med, 25 Shattuck St, Boston, MA 02115 USA.
EM lawrence@broadinstitute.org; gadgetz@broadinstitute.org
FU NIH TCGA Genome Data Analysis Center [U24CA143845]; NHGRI Genome
Sequencing Center [U54HG003067]; NHGRI [U54HG003273]; G.G.'s startup
funds at MGH
FX We thank Ashok Bhagwat and Steven Roberts and their collaborators for
sharing their unpublished data with us and allowing us to reference them
in this work. We thank John Iafrate for valuable insights about the
relevance of strand asymmetry in carcinogenesis. G.G. was partially
funded by the Paul C. Zamecnik, MD, Chair in Oncology at Massachusetts
General Hospital. G. G. and M.S.L. were partially funded by the NIH TCGA
Genome Data Analysis Center (U24CA143845). M.S.L. was partially funded
by the NHGRI Genome Sequencing Center (U54HG003067). E.S., K.R.C., and
D.A.W. were partially funded by NHGRI grant (U54HG003273). N.J.H., P.P.,
Y.E.M., and A. Kamburov were funded by G.G.'s startup funds at MGH.
NR 68
TC 22
Z9 22
U1 16
U2 40
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD JAN 28
PY 2016
VL 164
IS 3
BP 538
EP 549
DI 10.1016/j.cell.2015.12.050
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DC0KU
UT WOS:000368906800022
PM 26806129
ER
PT J
AU Ceccarelli, M
Barthel, FP
Malta, TM
Sabedot, TS
Salama, SR
Murray, BA
Morozova, O
Newton, Y
Radenbaugh, A
Pagnotta, SM
Anjum, S
Wang, JG
Manyam, G
Zoppoli, P
Ling, S
Rao, AA
Grifford, M
Cherniack, AD
Zhang, HL
Poisson, L
Carlotti, CG
Tirapelli, DPD
Rao, A
Mikkelsen, T
Lau, CC
Yung, WKA
Rabadan, R
Huse, J
Brat, DJ
Lehman, NL
Barnholtz-Sloan, JS
Zheng, S
Hess, K
Rao, G
Meyerson, M
Beroukhim, R
Cooper, L
Akbani, R
Wrensch, M
Haussler, D
Aldape, KD
Laird, PW
Gutmann, DH
Noushmehr, H
Iavarone, A
Verhaak, RGW
AF Ceccarelli, Michele
Barthel, Floris P.
Malta, Tathiane M.
Sabedot, Thais S.
Salama, Sofie R.
Murray, Bradley A.
Morozova, Olena
Newton, Yulia
Radenbaugh, Amie
Pagnotta, Stefano M.
Anjum, Samreen
Wang, Jiguang
Manyam, Ganiraju
Zoppoli, Pietro
Ling, Shiyun
Rao, Arjun A.
Grifford, Mia
Cherniack, Andrew D.
Zhang, Hailei
Poisson, Laila
Carlotti, Carlos Gilberto, Jr.
Tirapelli, Daniela Pretti da Cunha
Rao, Arvind
Mikkelsen, Tom
Lau, Ching C.
Yung, W. K. Alfred
Rabadan, Raul
Huse, Jason
Brat, Daniel J.
Lehman, Norman L.
Barnholtz-Sloan, Jill S.
Zheng, Siyuan
Hess, Kenneth
Rao, Ganesh
Meyerson, Matthew
Beroukhim, Rameen
Cooper, Lee
Akbani, Rehan
Wrensch, Margaret
Haussler, David
Aldape, Kenneth D.
Laird, Peter W.
Gutmann, David H.
Noushmehr, Houtan
Iavarone, Antonio
Verhaak, Roel G. W.
CA TCGA Res Network
TI Molecular Profiling Reveals Biologically Discrete Subsets and Pathways
of Progression in Diffuse Glioma
SO CELL
LA English
DT Article
ID TERT PROMOTER MUTATIONS; PILOCYTIC ASTROCYTOMA; GENOMIC ANALYSIS;
BRAIN-TUMORS; GRADE II; GLIOBLASTOMA; EXPRESSION; CANCER; CELLS; IDH1
AB Therapy development for adult diffuse glioma is hindered by incomplete knowledge of somatic glioma driving alterations and suboptimal disease classification. We defined the complete set of genes associated with 1,122 diffuse grade II-III-IV gliomas from The Cancer Genome Atlas and used molecular profiles to improve disease classification, identify molecular correlations, and provide insights into the progression from low- to high-grade disease. Whole-genome sequencing data analysis determined that ATRX but not TERT promoter mutations are associated with increased telomere length. Recent advances in glioma classification based on IDH mutation and 1p/19q co-deletion status were recapitulated through analysis of DNA methylation profiles, which identified clinically relevant molecular subsets. A subtype of IDH mutant glioma was associated with DNA demethylation and poor outcome; a group of IDH-wild-type diffuse glioma showed molecular similarity to pilocytic astrocytoma and relatively favorable survival. Understanding of cohesive disease groups may aid improved clinical outcomes.
C1 [Ceccarelli, Michele; Anjum, Samreen] Hamad Bin Khalifa Univ, Qatar Comp Res Inst, POB 5825, Doha, Qatar.
[Ceccarelli, Michele; Pagnotta, Stefano M.] Univ Sannio, Dept Sci & Technol, I-82100 Benevento, Italy.
[Barthel, Floris P.; Manyam, Ganiraju; Ling, Shiyun; Rao, Arvind; Yung, W. K. Alfred; Zheng, Siyuan; Hess, Kenneth; Rao, Ganesh; Akbani, Rehan; Verhaak, Roel G. W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Dept Bioinformat & Computat Biol,Dept Neurosurg, Dept Genom Med,Dept Biostat,Dept Neurooncol, Houston, TX 77030 USA.
[Barthel, Floris P.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Oncol Grad Sch Amsterdam, NL-1081 HV Amsterdam, Netherlands.
[Malta, Tathiane M.; Sabedot, Thais S.; Carlotti, Carlos Gilberto, Jr.; Tirapelli, Daniela Pretti da Cunha; Noushmehr, Houtan] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Surg & Anat, Dept Genet CISBi NAP, BR-14049900 Ribeirao Preto, SP, Brazil.
[Malta, Tathiane M.; Sabedot, Thais S.; Carlotti, Carlos Gilberto, Jr.; Tirapelli, Daniela Pretti da Cunha; Noushmehr, Houtan] Univ Sao Paulo, Ribeirao Preto Med Sch, Ctr Integrat Syst Biol CISBi, NAP USP, BR-14049900 Ribeirao Preto, SP, Brazil.
[Salama, Sofie R.; Morozova, Olena; Newton, Yulia; Radenbaugh, Amie; Rao, Arjun A.; Grifford, Mia; Haussler, David] Univ Calif Santa Cruz, Genom Inst, Santa Cruz, CA 95064 USA.
[Murray, Bradley A.; Cherniack, Andrew D.; Zhang, Hailei; Meyerson, Matthew; Beroukhim, Rameen] MIT, Eli & Edythe L Broad Inst, Cambridge, MA 02142 USA.
[Murray, Bradley A.; Cherniack, Andrew D.; Zhang, Hailei; Meyerson, Matthew; Beroukhim, Rameen] Harvard Univ, Cambridge, MA 02142 USA.
[Pagnotta, Stefano M.] BIOGEM Ist Ric Genetiche G Salvatore, I-83031 Campo Reale, Ariano Irpino, Italy.
[Wang, Jiguang; Zoppoli, Pietro; Rabadan, Raul; Iavarone, Antonio] Columbia Univ, Med Ctr, Dept Syst Biol & Biomed Informat, Dept Neurol,Dept Pathol,Inst Canc Genet, New York, NY 10032 USA.
[Poisson, Laila; Mikkelsen, Tom] Henry Ford Hosp, Detroit, MI 48202 USA.
[Lau, Ching C.] Childrens Hosp, Houston, TX 77030 USA.
[Lau, Ching C.] Baylor Coll Med, Houston, TX 77030 USA.
[Huse, Jason] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
[Brat, Daniel J.; Cooper, Lee] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Lehman, Norman L.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.
[Barnholtz-Sloan, Jill S.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
[Meyerson, Matthew; Beroukhim, Rameen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Beroukhim, Rameen] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA.
[Wrensch, Margaret] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94158 USA.
[Aldape, Kenneth D.] Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada.
[Laird, Peter W.] Van Andel Res Inst, Grand Rapids, MI 49503 USA.
[Gutmann, David H.] Washington Univ, Sch Med, St Louis, MO 63110 USA.
RP Verhaak, RGW (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Dept Bioinformat & Computat Biol,Dept Neurosurg, Dept Genom Med,Dept Biostat,Dept Neurooncol, Houston, TX 77030 USA.; Noushmehr, H (reprint author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Surg & Anat, Dept Genet CISBi NAP, BR-14049900 Ribeirao Preto, SP, Brazil.; Iavarone, A (reprint author), Columbia Univ, Med Ctr, Dept Syst Biol & Biomed Informat, Dept Neurol,Dept Pathol,Inst Canc Genet, New York, NY 10032 USA.
EM houtan@usp.br; ai2102@columbia.edu; rverhaak@mdanderson.org
RI Lehman, Norman/A-7351-2015; Manyam, Ganiraju/E-9150-2012; Carlotti,
Carlos/C-1608-2012; Sarraf Sabedot, Thais/J-2349-2016; Malta,
Tathiane/N-1686-2013; Marra, Marco/B-5987-2008; Miller,
Ryan/B-9365-2008; Coetzee, Simon/C-1218-2014;
OI PAGNOTTA, Stefano Maria/0000-0002-8298-9777; Rao,
Arjun/0000-0003-4480-3190; Manyam, Ganiraju/0000-0001-6006-8961;
Carlotti, Carlos/0000-0002-7055-0564; Malta,
Tathiane/0000-0003-1129-5791; Miller, Ryan/0000-0002-0096-8762; Coetzee,
Simon/0000-0003-4267-5930; Ceccarelli, Michele/0000-0002-4702-6617;
Perou, Charles/0000-0001-9827-2247
FU NIH [U24CA143883, U24CA143858, U24CA143840, U24CA143799, U24CA143835,
U24CA143845, U24CA143882, U24CA143867, U24CA143866, U24CA143848,
U24CA144025, U54HG003067, U54HG003079, U54HG003273]; Cancer Prevention &
Research Institute of Texas (CPRIT) [R140606]; Sao Paulo Research
Foundation (FAPESP) [2014/02245-3, 2015/07925-5, 2015/02844-7,
2015/08321-3]; Novartis; Bayer; [U24CA126543]; [U24CA126544];
[U24CA126546]; [U24CA126551]; [U24CA126554]; [U24CA126561];
[U24CA126563]; [U24CA143731]; [U24CA143843]; [P30CA016672]; [P50
CA127001]; [U54CA193313]; [R01CA179044]; [R01CA185486]; [R01
CA190121]; [P01 CA085878]
FX This study was supported by NIH grants U24CA143883, U24CA143858,
U24CA143840, U24CA143799, U24CA143835, U24CA143845, U24CA143882,
U24CA143867, U24CA143866, U24CA143848, U24CA144025, U54HG003067,
U54HG003079, U54HG003273, U24CA126543, U24CA126544, U24CA126546,
U24CA126551, U24CA126554, U24CA126561, U24CA126563, U24CA143731,
U24CA143843, P30CA016672, P50 CA127001, U54CA193313, R01CA179044,
R01CA185486, R01 CA190121, and P01 CA085878; Cancer Prevention &
Research Institute of Texas (CPRIT) R140606; and Sao Paulo Research
Foundation (FAPESP) 2014/02245-3, 2015/07925-5, 2015/02844-7, and
2015/08321-3. D.J.W. is a consultant for Zymo Research Corporation. R.B.
is a consultant for and received grant funding from Novartis. A.D.C. and
M.M. received grant support from Bayer.
NR 41
TC 76
Z9 79
U1 19
U2 40
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD JAN 28
PY 2016
VL 164
IS 3
BP 550
EP 563
DI 10.1016/j.cell.2015.12.028
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DC0KU
UT WOS:000368906800023
PM 26824661
ER
PT J
AU Zech, SG
Kohlmann, A
Zhou, TJ
Li, F
Squillace, RM
Parillon, LE
Greenfield, MT
Miller, DP
Qi, JW
Thomas, RM
Wang, YH
Xu, YJ
Miret, JJ
Shakespeare, WC
Zhu, XT
Dalgarno, DC
AF Zech, Stephan G.
Kohlmann, Anna
Zhou, Tianjun
Li, Feng
Squillace, Rachel M.
Parillon, Lois E.
Greenfield, Matthew T.
Miller, David P.
Qi, Jiwei
Thomas, R. Mathew
Wang, Yihan
Xu, Yongjin
Miret, Juan J.
Shakespeare, William C.
Zhu, Xiaotian
Dalgarno, David C.
TI Novel Small Molecule Inhibitors of Choline Kinase Identified by
Fragment-Based Drug Discovery
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID TARGET RESIDENCE TIME; MAGNETIC-RESONANCE-SPECTROSCOPY; TRANSFER
DIFFERENCE NMR; ANTITUMOR STRATEGY; LEAD OPTIMIZATION; LIPID-METABOLISM;
ALPHA; BINDING; CANCER; CELLS
AB Choline kinase alpha (ChoK alpha) is an enzyme involved in the synthesis of phospholipids and thereby plays key roles in regulation of cell proliferation, oncogenic transformation, and human carcinogenesis. Since several inhibitors of ChoK alpha display antiproliferative activity in both cellular and animal models, this novel oncogene has recently gained interest as a promising small molecule target for cancer therapy. Here we summarize our efforts to further validate ChoK? as an oncogenic target and explore the activity of novel small molecule inhibitors of ChoK?. Starting from weakly binding fragments, we describe a structure based lead discovery approach, which resulted in novel highly potent inhibitors of ChoK alpha. In cancer cell lines, our lead compounds exhibit a dose-dependent decrease of phosphocholine, inhibition of cell growth, and induction of apoptosis at low micromolar concentrations. The druglike lead series presented here is optimizable for improvements in cellular potency, drug target residence time, and pharmacokinetic parameters. These inhibitors may be utilized not only to further validate ChoK alpha as antioncogenic target but also as novel chemical matter that may lead to antitumor agents that specifically interfere with cancer cell metabolism.
C1 [Zech, Stephan G.; Kohlmann, Anna; Zhou, Tianjun; Li, Feng; Squillace, Rachel M.; Parillon, Lois E.; Greenfield, Matthew T.; Miller, David P.; Qi, Jiwei; Thomas, R. Mathew; Wang, Yihan; Xu, Yongjin; Miret, Juan J.; Shakespeare, William C.; Zhu, Xiaotian; Dalgarno, David C.] ARIAD Pharmaceut Inc, 26 Landsdowne St, Cambridge, MA 02139 USA.
[Squillace, Rachel M.] Fdn Med, 150 Second St, Cambridge, MA 02141 USA.
[Parillon, Lois E.] Siemens Healthcare Diagnost, 333 Coney St, Walpole, MA 02032 USA.
[Miller, David P.] Vaxess Technol, 700 Main St, Cambridge, MA 02139 USA.
[Thomas, R. Mathew] Cerulean Pharma Inc, 840 Mem Dr, Cambridge, MA 02139 USA.
[Wang, Yihan] Boston Ibio Inc, 32 Leonard Ave, Newton, MA 02465 USA.
[Miret, Juan J.] Dana Farber Canc Inst, Belfer Inst, 77 Louis Pasteur Ave, Boston, MA 02115 USA.
RP Zech, SG (reprint author), ARIAD Pharmaceut Inc, 26 Landsdowne St, Cambridge, MA 02139 USA.
EM Stephan.Zech@ariad.com
NR 52
TC 5
Z9 5
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD JAN 28
PY 2016
VL 59
IS 2
BP 671
EP 686
DI 10.1021/acs.jmedchem.5b01552
PG 16
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA DC3JN
UT WOS:000369115700013
PM 26700752
ER
PT J
AU Roberts, AW
Davids, MS
Pagel, JM
Kahl, BS
Puvvada, SD
Gerecitano, JF
Kipps, TJ
Anderson, MA
Brown, JR
Gressick, L
Wong, S
Dunbar, M
Zhu, M
Desai, MB
Cerri, E
Enschede, SH
Humerickhouse, RA
Wierda, WG
Seymour, JF
AF Roberts, Andrew W.
Davids, Matthew S.
Pagel, John M.
Kahl, Brad S.
Puvvada, Soham D.
Gerecitano, John F.
Kipps, Thomas J.
Anderson, Mary Ann
Brown, Jennifer R.
Gressick, Lori
Wong, Shekman
Dunbar, Martin
Zhu, Ming
Desai, Monali B.
Cerri, Elisa
Enschede, Sari Heitner
Humerickhouse, Rod A.
Wierda, William G.
Seymour, John F.
TI Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID KINASE INHIBITOR IBRUTINIB; INTERNATIONAL WORKSHOP; ANTITUMOR-ACTIVITY;
DOSE-ESCALATION; PHASE-I; RITUXIMAB; FLUDARABINE; CYCLOPHOSPHAMIDE;
CHEMOIMMUNOTHERAPY; APOPTOSIS
AB BACKGROUND
New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells.
METHODS
We conducted a phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL or small lymphocytic lymphoma (SLL) to assess safety, pharmacokinetic profile, and efficacy. In the dose-escalation phase, 56 patients received active treatment in one of eight dose groups that ranged from 150 to 1200 mg per day. In an expansion cohort, 60 additional patients were treated with a weekly stepwise ramp-up in doses as high as 400 mg per day.
RESULTS
The majority of the study patients had received multiple previous treatments, and 89% had poor prognostic clinical or genetic features. Venetoclax was active at all dose levels. Clinical tumor lysis syndrome occurred in 3 of 56 patients in the dose-escalation cohort, with one death. After adjustments to the dose-escalation schedule, clinical tumor lysis syndrome did not occur in any of the 60 patients in the expansion cohort. Other toxic effects included mild diarrhea (in 52% of the patients), upper respiratory tract infection (in 48%), nausea (in 47%), and grade 3 or 4 neutropenia (in 41%). A maximum tolerated dose was not identified. Among the 116 patients who received venetoclax, 92 (79%) had a response. Response rates ranged from 71 to 79% among patients in subgroups with an adverse prognosis, including those with resistance to fludarabine, those with chromosome 17p deletions (deletion 17p CLL), and those with unmutated IGHV. Complete remissions occurred in 20% of the patients, including 5% who had no minimal residual disease on flow cytometry. The 15-month progression-free survival estimate for the 400-mg dose groups was 69%.
CONCLUSIONS
Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL, including those with poor prognostic features.
C1 [Roberts, Andrew W.; Anderson, Mary Ann] Royal Melbourne Hosp, Dept Clin Haematol, Parkville, Vic 3050, Australia.
[Roberts, Andrew W.; Anderson, Mary Ann] Royal Melbourne Hosp, Bone Marrow Transplantat Unit, Parkville, Vic 3050, Australia.
[Roberts, Andrew W.; Anderson, Mary Ann] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Canc & Haematol, Parkville, Vic 3050, Australia.
[Roberts, Andrew W.; Seymour, John F.] Victorian Comprehens Canc Ctr, Parkville, Vic, Australia.
[Roberts, Andrew W.; Seymour, John F.] Univ Melbourne, Melbourne, Vic, Australia.
[Seymour, John F.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Davids, Matthew S.; Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Pagel, John M.] Swedish Med Ctr, Seattle, WA USA.
[Kahl, Brad S.] Washington Univ, St Louis, MO 63130 USA.
[Puvvada, Soham D.] Univ Arizona, Tucson, AZ USA.
[Gerecitano, John F.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
[Gerecitano, John F.] Weill Cornell Med Coll, New York, NY USA.
[Kipps, Thomas J.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Gressick, Lori; Wong, Shekman; Dunbar, Martin; Zhu, Ming; Desai, Monali B.; Cerri, Elisa; Enschede, Sari Heitner; Humerickhouse, Rod A.] AbbVie, N Chicago, IL USA.
[Wierda, William G.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
RP Roberts, AW (reprint author), Royal Melbourne Hosp, Melbourne, Vic 3050, Australia.
EM andrew.roberts@mh.org.au
FU AbbVie; Genentech
FX Funded by AbbVie and Genentech; ClinicalTrials.gov number, NCT01328626.
NR 37
TC 151
Z9 152
U1 29
U2 54
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 28
PY 2016
VL 374
IS 4
BP 311
EP 322
DI 10.1056/NEJMoa1513257
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA DB8IJ
UT WOS:000368760100005
PM 26639348
ER
PT J
AU Byrd, JC
Harrington, B
O'Brien, S
Jones, JA
Schuh, A
Devereux, S
Chaves, J
Wierda, WG
Awan, FT
Brown, JR
Hillmen, P
Stephens, DM
Ghia, P
Barrientos, JC
Pagel, JM
Woyach, J
Johnson, D
Huang, J
Wang, X
Kaptein, A
Lannutti, BJ
Covey, T
Fardis, M
McGreivy, J
Hamdy, A
Rothbaum, W
Izumi, R
Diacovo, TG
Johnson, AJ
Furman, RR
AF Byrd, John C.
Harrington, Bonnie
O'Brien, Susan
Jones, Jeffrey A.
Schuh, Anna
Devereux, Steve
Chaves, Jorge
Wierda, William G.
Awan, Farrukh T.
Brown, Jennifer R.
Hillmen, Peter
Stephens, Deborah M.
Ghia, Paolo
Barrientos, Jacqueline C.
Pagel, John M.
Woyach, Jennifer
Johnson, Dave
Huang, Jane
Wang, Xiaolin
Kaptein, Allard
Lannutti, Brian J.
Covey, Todd
Fardis, Maria
McGreivy, Jesse
Hamdy, Ahmed
Rothbaum, Wayne
Izumi, Raquel
Diacovo, Thomas G.
Johnson, Amy J.
Furman, Richard R.
TI Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID TYROSINE KINASE INHIBITOR; B-CELL RECEPTOR; X-LINKED AGAMMAGLOBULINEMIA;
OPEN-LABEL; IN-VIVO; IBRUTINIB; BTK; PCI-32765; ACTIVATION; LYMPHOMA
AB BACKGROUND
Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index. Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors.
METHODS
In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib. Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion.
RESULTS
The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated immunoglobulin heavy-chain variable genes. No dose-limiting toxic effects occurred during the dose-escalation portion of the study. The most common adverse events observed were headache (in 43% of the patients), diarrhea (in 39%), and increased weight (in 26%). Most adverse events were of grade 1 or 2. At a median follow-up of 14.3 months, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease. Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%. No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred.
CONCLUSIONS
In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.
C1 [Byrd, John C.; Jones, Jeffrey A.; Awan, Farrukh T.; Woyach, Jennifer; Johnson, Amy J.] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA.
[Harrington, Bonnie] Coll Vet Med, Dept Vet Biosci, Columbus, OH USA.
[O'Brien, Susan] Univ Calif Irvine, UC Irvine Hlth Chao Family Comprehens Canc Ctr, Orange, CA USA.
[Schuh, Anna] Univ Oxford, Oxford, England.
[Devereux, Steve] Kings Coll Hosp London, NHS Fdn Trust, London, England.
[Hillmen, Peter] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England.
[Chaves, Jorge] Northwest Med Specialties, Tacoma, WA USA.
[Pagel, John M.] Swedish Canc Inst, Seattle, WA USA.
[Wierda, William G.] Univ Texas Houston, Div Canc Med, Dept Leukemia, Houston, TX USA.
[Wierda, William G.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Brown, Jennifer R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Stephens, Deborah M.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
[Ghia, Paolo] Univ Vita Salute San Raffaele, Milan, Italy.
[Ghia, Paolo] Ist Sci San Raffaele, Milan, Italy.
[Barrientos, Jacqueline C.] Hofstra North Shore LIJ Sch Med, Chron Lymphocyt Leukemia Res & Treatment Ctr, Lake Success, NY USA.
[Diacovo, Thomas G.] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY USA.
[Furman, Richard R.] Weill Cornell Med Ctr, New York Presbyterian, New York, NY USA.
[Johnson, Dave; Huang, Jane; Wang, Xiaolin; Kaptein, Allard; Lannutti, Brian J.; Covey, Todd; Fardis, Maria; McGreivy, Jesse; Hamdy, Ahmed; Rothbaum, Wayne; Izumi, Raquel] Acerta Pharma, Oss, Netherlands.
RP Byrd, JC (reprint author), B302 Starling Loving Hall,320 W 10th Ave, Columbus, OH 43210 USA.
EM john.byrd@osumc.edu
RI Woyach, Jennifer/F-1087-2015; Jones, Jeffrey/E-3321-2011; Ghia,
Paolo/K-7138-2016; Awan, Farrukh/L-5642-2016; Devereux,
Stephen/B-4766-2009;
OI Ghia, Paolo/0000-0003-3750-7342; Awan, Farrukh/0000-0003-1813-9812;
Devereux, Stephen/0000-0002-8046-0386; Stephens,
Deborah/0000-0001-9188-5008
FU Acerta Pharma
FX Funded by the Acerta Pharma and others; ClinicalTrials.gov number,
NCT02029443.
NR 32
TC 68
Z9 69
U1 7
U2 14
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 28
PY 2016
VL 374
IS 4
BP 323
EP 332
DI 10.1056/NEJMoa1509981
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA DB8IJ
UT WOS:000368760100006
PM 26641137
ER
PT J
AU Goldstein, D
Moskowitz, AJ
Gelijns, AC
Ailawadi, G
Parides, MK
Perrault, LP
Hung, JW
Voisine, P
Dagenais, F
Gillinov, AM
Thourani, V
Argenziano, M
Gammie, JS
Mack, M
Demers, P
Atluri, P
Rose, EA
O'Sullivan, K
Williams, DL
Bagiella, E
Michler, RE
Weisel, RD
Miller, MA
Geller, NL
Taddei-Peters, WC
Smith, PK
Moquete, E
Overbey, JR
Kron, IL
O'Gara, PT
Acker, MA
AF Goldstein, D.
Moskowitz, A. J.
Gelijns, A. C.
Ailawadi, G.
Parides, M. K.
Perrault, L. P.
Hung, J. W.
Voisine, P.
Dagenais, F.
Gillinov, A. M.
Thourani, V.
Argenziano, M.
Gammie, J. S.
Mack, M.
Demers, P.
Atluri, P.
Rose, E. A.
O'Sullivan, K.
Williams, D. L.
Bagiella, E.
Michler, R. E.
Weisel, R. D.
Miller, M. A.
Geller, N. L.
Taddei-Peters, W. C.
Smith, P. K.
Moquete, E.
Overbey, J. R.
Kron, I. L.
O'Gara, P. T.
Acker, M. A.
CA CTSN
TI Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral
Regurgitation
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID HEART-FAILURE; VALVE ANNULOPLASTY; DILATED CARDIOMYOPATHY;
MYOCARDIAL-INFARCTION; RING ANNULOPLASTY; REPAIR; REPLACEMENT;
PREDICTORS; RECURRENCE; MECHANISM
AB BACKGROUND
In a randomized trial comparing mitral-valve repair with mitral-valve replacement in patients with severe ischemic mitral regurgitation, we found no significant difference in the left ventricular end-systolic volume index (LVESVI), survival, or adverse events at 1 year after surgery. However, patients in the repair group had significantly more recurrences of moderate or severe mitral regurgitation. We now report the 2-year outcomes of this trial.
METHODS
We randomly assigned 251 patients to mitral-valve repair or replacement. Patients were followed for 2 years, and clinical and echocardiographic outcomes were assessed.
RESULTS
Among surviving patients, the mean (+/- SD) 2-year LVESVI was 52.6 +/- 27.7 ml per square meter of body-surface area with mitral-valve repair and 60.6 +/- 39.0 ml per square meter with mitral-valve replacement (mean changes from baseline, -9.0 ml per square meter and -6.5 ml per square meter, respectively). Two-year mortality was 19.0% in the repair group and 23.2% in the replacement group (hazard ratio in the repair group, 0.79; 95% confidence interval, 0.46 to 1.35; P=0.39). The rank-based assessment of LVESVI at 2 years (incorporating deaths) showed no significant between-group difference (z score = -1.32, P=0.19). The rate of recurrence of moderate or severe mitral regurgitation over 2 years was higher in the repair group than in the replacement group (58.8% vs. 3.8%, P < 0.001). There were no significant between-group differences in rates of serious adverse events and overall readmissions, but patients in the repair group had more serious adverse events related to heart failure (P=0.05) and cardiovascular readmissions (P=0.01). On the Minnesota Living with Heart Failure questionnaire, there was a trend toward greater improvement in the replacement group (P=0.07).
CONCLUSIONS
In patients undergoing mitral-valve repair or replacement for severe ischemic mitral regurgitation, we observed no significant between-group difference in left ventricular reverse remodeling or survival at 2 years. Mitral regurgitation recurred more frequently in the repair group, resulting in more heart-failure-related adverse events and cardiovascular admissions.
C1 [Goldstein, D.; Michler, R. E.] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Cardiothorac Surg, New York, NY USA.
[Moskowitz, A. J.; Gelijns, A. C.; Parides, M. K.; O'Sullivan, K.; Williams, D. L.; Bagiella, E.; Moquete, E.; Overbey, J. R.] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, Int Ctr Hlth Outcomes & Innovat Res, New York, NY 10029 USA.
[Rose, E. A.] Icahn Sch Med Mt Sinai, Cardiovasc Inst, New York, NY USA.
[Argenziano, M.] Columbia Univ, Coll Phys & Surg, Dept Surg, Div Cardiothorac Surg, New York, NY USA.
[Ailawadi, G.; Kron, I. L.] Univ Virginia, Sch Med, Div Thorac & Cardiovasc Surg, Charlottesville, VA 22908 USA.
[Perrault, L. P.; Demers, P.] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada.
[Voisine, P.; Dagenais, F.] Inst Univ Cardiol Quebec, Hop Laval, Quebec City, PQ, Canada.
[Weisel, R. D.] Univ Toronto, Peter Munk Cardiac Ctr, Toronto, ON, Canada.
[Weisel, R. D.] Univ Toronto, Div Cardiovasc Surg, Toronto Gen Hosp, Univ Hlth Network, Toronto, ON, Canada.
[Weisel, R. D.] Univ Toronto, Div Cardiac Surg, Toronto, ON, Canada.
[Hung, J. W.] Massachusetts Gen Hosp, Echocardiog Core Lab, Boston, MA 02114 USA.
[O'Gara, P. T.] Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA.
[Gillinov, A. M.] Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Cleveland, OH USA.
[Thourani, V.] Emory Univ, Sch Med, Div Cardiothorac Surg, Clin Res Unit, Atlanta, GA 30322 USA.
[Gammie, J. S.] Univ Maryland, Baltimore, MD 21201 USA.
[Miller, M. A.; Taddei-Peters, W. C.] NHLBI, Div Cardiovasc Sci, Bldg 10, Bethesda, MD 20892 USA.
[Geller, N. L.] NHLBI, Off Biostat Res, Bldg 10, Bethesda, MD 20892 USA.
[Mack, M.] Baylor Res Inst, Dallas, TX USA.
[Atluri, P.; Acker, M. A.] Univ Penn, Sch Med, Div Cardiovasc Surg, Dept Surg, Philadelphia, PA 19104 USA.
[Smith, P. K.] Duke Univ, Med Ctr, Dept Surg, Div Cardiovasc & Thorac Surg, Durham, NC 27710 USA.
RP Gelijns, AC (reprint author), Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, 1 Gustave L Levy Pl,Box 1077, New York, NY 10029 USA.
EM annetine.gelijns@mssm.edu
OI Moskowitz, Alan/0000-0002-4412-9450; Browndyke,
Jeffrey/0000-0002-8573-7073
FU National Institutes of Health and Canadian Institutes of Health Research
FX Funded by the National Institutes of Health and Canadian Institutes of
Health Research; ClinicalTrials.gov number, NCT00807040.
NR 43
TC 49
Z9 50
U1 1
U2 8
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 28
PY 2016
VL 374
IS 4
BP 344
EP 353
DI 10.1056/NEJMoa1512913
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA DB8IJ
UT WOS:000368760100008
PM 26550689
ER
PT J
AU Heher, E
Markmann, JF
AF Heher, Eliot
Markmann, James F.
TI The Clearer BENEFITS of Belatacept
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID CALCINEURIN INHIBITORS; RENAL-TRANSPLANTATION; CELLS
C1 [Heher, Eliot] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA.
[Markmann, James F.] Massachusetts Gen Hosp, Div Abdominal Transplant Surg, Boston, MA 02114 USA.
[Heher, Eliot; Markmann, James F.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA.
RP Heher, E (reprint author), Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA.; Heher, E (reprint author), Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA.
NR 8
TC 1
Z9 1
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 28
PY 2016
VL 374
IS 4
BP 388
EP 389
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA DB8IJ
UT WOS:000368760100016
PM 26816017
ER
PT J
AU Kleinstiver, BP
Pattanayak, V
Prew, MS
Tsai, SQ
Nguyen, NT
Zheng, ZL
Joung, JK
AF Kleinstiver, Benjamin P.
Pattanayak, Vikram
Prew, Michelle S.
Tsai, Shengdar Q.
Nguyen, Nhu T.
Zheng, Zongli
Joung, J. Keith
TI High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide
off-target effects
SO NATURE
LA English
DT Article
ID RNA-GUIDED ENDONUCLEASES; CAS SYSTEMS; ENGINEERED NUCLEASES; CRISPR/CAS9
SYSTEMS; DNA RECOGNITION; HUMAN-CELLS; DUAL-RNA; SPECIFICITY; CLEAVAGE;
TALENS
AB CRISPR-Cas9 nucleases are widely used for genome editing but can induce unwanted off-target mutations. Existing strategies for reducing genome-wide off-target effects of the widely used Streptococcus pyogenes Cas9 (SpCas9) are imperfect, possessing only partial or unproven efficacies and other limitations that constrain their use. Here we describe SpCas9-HF1, a high-fidelity variant harbouring alterations designed to reduce non-specific DNA contacts. SpCas9-HF1 retains on-target activities comparable to wild-type SpCas9 with > 85% of single-guide RNAs (sgRNAs) tested in human cells. Notably, with sgRNAs targeted to standard non-repetitive sequences, SpCas9-HF1 rendered all or nearly all off-target events undetectable by genome-wide break capture and targeted sequencing methods. Even for atypical, repetitive target sites, the vast majority of off-target mutations induced by wild-type SpCas9 were not detected with SpCas9-HF1. With its exceptional precision, SpCas9-HF1 provides an alternative to wild-type SpCas9 for research and therapeutic applications. More broadly, our results suggest a general strategy for optimizing genome-wide specificities of other CRISPR-RNA-guided nucleases.
C1 [Kleinstiver, Benjamin P.; Pattanayak, Vikram; Prew, Michelle S.; Tsai, Shengdar Q.; Nguyen, Nhu T.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Canc Res, Mol Pathol Unit, Charlestown, MA 02129 USA.
[Kleinstiver, Benjamin P.; Pattanayak, Vikram; Prew, Michelle S.; Tsai, Shengdar Q.; Nguyen, Nhu T.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Charlestown, MA 02129 USA.
[Kleinstiver, Benjamin P.; Pattanayak, Vikram; Tsai, Shengdar Q.; Joung, J. Keith] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Zheng, Zongli] City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
RP Joung, JK (reprint author), Massachusetts Gen Hosp, Ctr Canc Res, Mol Pathol Unit, Charlestown, MA 02129 USA.; Joung, JK (reprint author), Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Charlestown, MA 02129 USA.; Joung, JK (reprint author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
EM jjoung@mgh.harvard.edu
RI Zheng, Zongli/B-2917-2011
OI Zheng, Zongli/0000-0003-4849-4903
FU Natural Sciences and Engineering Research Council of Canada Postdoctoral
Fellowship; Massachusetts General Hospital (MGH) Department of
Pathology; MGH Tosteson; Fund for Medical Discovery Fellowship; US
National Institutes of Health (NIH) Director's Pioneer Award [DP1
GM105378]; NIH [R01 GM107427, R01 GM088040]; Jim and Ann Orr MGH
Research Scholar Award
FX B.P.K. is supported by a Natural Sciences and Engineering Research
Council of Canada Postdoctoral Fellowship. V.P. was supported by the
Massachusetts General Hospital (MGH) Department of Pathology. S.Q.T. is
supported by an MGH Tosteson and Fund for Medical Discovery Fellowship.
J.K.J. is supported by a US National Institutes of Health (NIH)
Director's Pioneer Award (DP1 GM105378), NIH R01 GM107427, NIH R01
GM088040, and the Jim and Ann Orr MGH Research Scholar Award.
NR 45
TC 197
Z9 205
U1 69
U2 201
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JAN 28
PY 2016
VL 529
IS 7587
BP 490
EP +
DI 10.1038/nature16526
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DB7DD
UT WOS:000368673800029
PM 26735016
ER
PT J
AU Guglietta, PM
Moran, CJ
Ryan, DP
Sagar, P
Huck, AE
AF Guglietta, Patricia M.
Moran, Christopher J.
Ryan, Daniel P.
Sagar, Pallavi
Huck, Amelia E.
TI Case 3-2016: A 9-Year-Old Girl with Intermittent Abdominal Pain
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID HELICOBACTER-PYLORI INFECTION; INTESTINAL MALROTATION; CELIAC-DISEASE;
CHILDREN; SPLEEN; RECOMMENDATIONS; ESOPHAGITIS; GUIDELINES; SYMPTOMS;
NASPGHAN
C1 [Guglietta, Patricia M.; Moran, Christopher J.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Ryan, Daniel P.] Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA.
[Sagar, Pallavi] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Huck, Amelia E.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Guglietta, Patricia M.; Moran, Christopher J.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Ryan, Daniel P.] Harvard Univ, Sch Med, Dept Pediat Surg, Boston, MA 02115 USA.
[Sagar, Pallavi] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Huck, Amelia E.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Guglietta, PM (reprint author), Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
FU Janssen Scientific; Actavis Labs
FX Dr. Moran reports receiving consulting fees from Janssen Scientific and
grant support through his institution from Actavis Labs. No other
potential conflict of interest relevant to this article was reported.
NR 24
TC 0
Z9 0
U1 0
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 28
PY 2016
VL 374
IS 4
BP 373
EP 382
DI 10.1056/NEJMcpc1413305
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA DB8IJ
UT WOS:000368760100013
PM 26816015
ER
PT J
AU Yu, L
Morishima, C
Ioannou, GN
AF Yu, Lei
Morishima, Chihiro
Ioannou, George N.
TI Sex difference in liver-related mortality and transplantation associated
with dietary cholesterol in chronic hepatitis C virus infection
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Diets; Cholesterol; Cirrhosis; Sex differences; Hepatitis C virus
ID LONG-TERM TREATMENT; TOTAL-ENERGY INTAKE; DISEASE PROGRESSION; FIBROSIS
PROGRESSION; CIRRHOSIS TRIAL; UNITED-STATES; GENOTYPE 1; THERAPY;
INTERFERON; MODEL
AB Dietary cholesterol induces hepatic inflammation and fibrosis in animals. We aimed to determine whether dietary cholesterol affects liver-related mortality in hepatitis C virus (HCV)-infected patients. We performed a retrospective cohort study using extended follow-up data from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. The study included HCV patients with advanced fibrosis and compensated cirrhosis. The analysis included 657 patients who completed two FFQ. We assessed whether cholesterol intake, measured in mg/4184 kJ (mg/1000 kcal) of energy intake, was associated with liver-related death or transplantation. In 4.7 (SD 1.6) years, the incidence of liver-related death (n 46) or transplantation (n 52) was 31.8/1000 person-years. The relationship between cholesterol intake and liver-related death or transplantation was significantly different between men and women (test for interaction, P value = 0.01). Each higher quartile of cholesterol intake was associated with an increased risk for liver-related death or transplantation in women (adjusted hazard ratio (AHR) 1.83; 95 % CI 1.12, 2.99; P-trend= 0.02), but not in men (AHR 0.96; 95 % CI 0.76, 1.22; P-trend = 0.73). Compared with women whose cholesterol intake was within the recommended guidelines (300 mg/d with a 8368 kJ (2000 kcal) diet), women who consumed more cholesterol had significantly increased risk for liver-related death or transplantation (AHR 4.04; 95 % CI 1.42, 11.5). High dietary cholesterol was associated with an increased risk for liver-related death and transplantation in HCV-infected women with advanced fibrosis or compensated cirrhosis. Future studies should assess whether reducing cholesterol intake, among women who consume an excessive amount, can decrease HCV-related mortality.
C1 [Yu, Lei; Ioannou, George N.] Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA.
[Morishima, Chihiro] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
[Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Yu, L (reprint author), Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA.
EM leiy@medicine.washington.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK); Research Enhancement Award Program, Office of Research and
Development, Veterans Affairs United States
FX The Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C)
Trial was conducted by the HALT-C investigators and supported by the
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK). The data from the HALT-C Trial reported here was supplied by
the NIDDK Central Repository. This manuscript does not necessarily
reflect the opinions or views of the HALT-C study, the NIDDK Central
Repository or the NIDDK. G. N. I. is supported by Research Enhancement
Award Program, Office of Research and Development, Veterans Affairs
United States.
NR 38
TC 0
Z9 1
U1 0
U2 4
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD JAN 28
PY 2016
VL 115
IS 2
BP 193
EP 201
DI 10.1017/S0007114515004158
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CZ6UJ
UT WOS:000367236200001
PM 26541123
ER
PT J
AU Gouse, H
Magidson, JF
Burnhams, W
Remmert, JE
Myers, B
Joska, JA
Carrico, AW
AF Gouse, Hetta
Magidson, Jessica F.
Burnhams, Warren
Remmert, Jocelyn E.
Myers, Bronwyn
Joska, John A.
Carrico, Adam W.
TI Implementation of Cognitive-Behavioral Substance Abuse Treatment in
Sub-Saharan Africa: Treatment Engagement and Abstinence at Treatment
Exit
SO PLOS ONE
LA English
DT Article
ID CONTINGENCY MANAGEMENT; MATRIX MODEL; SOUTH-AFRICA; CAPE-TOWN;
METAANALYSIS; ALCOHOL; ACCESS
AB Aims
This study documented the treatment cascade for engagement in care and abstinence at treatment exit as well as examined correlates of these outcomes for the first certified Matrix Model (R) substance abuse treatment site in Sub-Saharan Africa.
Design
This retrospective chart review conducted at a resource-limited community clinic in Cape Town, South Africa, assessed treatment readiness and substance use severity at treatment entry as correlates of the number of sessions attended and biologically confirmed abstinence at treatment exit among 986 clients who initiated treatment from 2009-2014. Socio-demographic and clinical correlates of treatment outcomes were examined using logistic regression, modeling treatment completion and abstinence at treatment exit separately.
Results
Of the 2,233 clients who completed screening, approximately 44% (n = 986) initiated treatment. Among those who initiated treatment, 45% completed at least four group sessions, 30% completed early recovery skills training (i.e., at least eight group sessions), and 13% completed the full 16-week program. Approximately half (54%) of clients who provided a urine sample had negative urine toxicology results for any substance at treatment exit. Higher motivation at treatment entry was independently associated with greater odds of treatment completion and negative urine toxicology results at treatment exit.
Conclusions
Findings provide initial support for the successful implementation the Matrix Model in a resource-limited setting. Motivational enhancement interventions could support treatment initiation, promote sustained engagement in treatment, and achieve better treatment outcomes.
C1 [Gouse, Hetta; Joska, John A.] HIV Mental Hlth Res Unit, Dept Psychiat & Mental Hlth, Cape Town, South Africa.
[Magidson, Jessica F.; Remmert, Jocelyn E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Magidson, Jessica F.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Burnhams, Warren] City Cape Town Hlth, Subst Abuse, Cape Town, South Africa.
[Myers, Bronwyn] South African Med Res Council, Alcohol Tobacco & Other Drug Res Unit, Cape Town, South Africa.
[Carrico, Adam W.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
RP Gouse, H (reprint author), HIV Mental Hlth Res Unit, Dept Psychiat & Mental Hlth, Cape Town, South Africa.
EM hetta.gouse@uct.ac.za
FU NIDA NIH HHS [K23 DA041901]; NIMH NIH HHS [T32 MH093310]
NR 23
TC 1
Z9 1
U1 2
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 27
PY 2016
VL 11
IS 1
AR e0147900
DI 10.1371/journal.pone.0147900
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DC9GD
UT WOS:000369528200062
PM 26816208
ER
PT J
AU Widger, K
Friedrichsdorf, S
Wolfe, J
Liben, S
Pole, JD
Bouffet, E
Greenberg, M
Husain, A
Siden, H
Whitlock, JA
Rapoport, A
AF Widger, Kimberley
Friedrichsdorf, Stefan
Wolfe, Joanne
Liben, Stephen
Pole, Jason D.
Bouffet, Eric
Greenberg, Mark
Husain, Amna
Siden, Harold
Whitlock, James A.
Rapoport, Adam
TI Protocol: Evaluating the impact of a nationwide train-the-trainer
educational initiative to enhance the quality of palliative care for
children with cancer
SO BMC PALLIATIVE CARE
LA English
DT Article
DE Pediatrics; Palliative care; Cancer; Quality care; Education; Knowledge
translation
ID OF-LIFE CARE; SYMPTOM ASSESSMENT; PARENTS; END; SUPPORT; DEATH; SCALE
AB Background: There are identified gaps in the care provided to children with cancer based on the self-identified lack of education for health care professionals in pediatric palliative care and in the perceptions of bereaved parents who describe suboptimal care. In order to address these gaps, we will implement and evaluate a national roll-out of Education in Palliative and End-of-Life Care for Pediatrics (EPEC (R)-Pediatrics), using a 'Train-the-Trainer' model.
Methods/design: In this study we are using a pre-post-test design and an integrated knowledge translation approach to assess the impact of the educational roll-out in four areas: 1) self-assessed knowledge of health professionals; 2) knowledge dissemination outcomes; 3) practice change outcomes; and 4) quality of palliative care. The quality of palliative care will be assessed using data from three sources: a) parent and child surveys about symptoms, quality of life and care provided; b) health record reviews of deceased patients; and c) bereaved parent surveys about end-of-life and bereavement care. After being trained in EPEC (R)-Pediatrics, 'Master Facilitators' will train 'Regional Teams' affiliated with 16 pediatric oncology programs in Canada. Each team will consist of three to five health professionals representing oncology, palliative care, and the community. Each team member will complete online modules and attend one of two face-to-face conferences, where they will receive training and materials to teach the EPEC (R)-Pediatrics curriculum to 'End-Users' in their region. Regional Teams will also choose a Tailored Implementation of Practice Standards (TIPS) Kit to guide implementation of a quality improvement project in their region; support will be provided via quarterly meetings with Co-Leads and via a listserv and webinars with other teams.
Discussion: Through this study we aim to raise the level of pediatric palliative care education amongst health care professionals in Canada. Our study will be a significant step forward in evaluation of the impact of EPEC (R)-Pediatrics both on dissemination outcomes and on care quality at a national level. Based on the anticipated success of our project we hope to expand the EPEC (R)-Pediatrics roll-out to health professionals who care for children with non-oncological life-threatening conditions.
C1 [Widger, Kimberley] Univ Toronto, Lawrence S Bloomberg Fac Nursing, 130-155 Coll St, Toronto, ON M5T 1P8, Canada.
[Widger, Kimberley; Rapoport, Adam] Hosp Sick Children, Pediat Adv Care Team, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
[Friedrichsdorf, Stefan] Childrens Hosp & Clin Minnesota, Dept Pain Med Palliat Care & Integrat Med, 2525 Chicago Ave South, Minneapolis, MN 55404 USA.
[Wolfe, Joanne] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Pediat Palliat Care Serv, 450 Brookline Ave, Boston, MA 02215 USA.
[Liben, Stephen] McGill Univ, Montreal Childrens Hosp, Pediat Palliat Care Program, 2300 Rue Tupper, Montreal, PQ H3H 1P3, Canada.
[Pole, Jason D.] Pediat Oncol Grp Ontario, 480 Univ Ave,Suite 1014, Toronto, ON M5G 1V2, Canada.
[Bouffet, Eric] Hosp Sick Children, Brain Tumor Program, Div Hematol Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
[Greenberg, Mark] Pediat Oncol Grp Ontario, Policy & Clin Affairs, 480 Univ Ave,Suite 1014, Toronto, ON M5G 1V2, Canada.
[Husain, Amna] Univ Toronto, Dept Family & Community Med, Temmy Latner Ctr Palliat Care, Mt Sinai Hosp, 60 Murray St,4th Floor, Toronto, ON M5T 3L9, Canada.
[Siden, Harold] Univ British Columbia, Canuck Pl Childrens Hosp, 1690 Matthews Ave, Vancouver, BC V6J 2T2, Canada.
[Siden, Harold] Univ British Columbia, Dept Pediat, 1690 Matthews Ave, Vancouver, BC V6J 2T2, Canada.
[Whitlock, James A.] Hosp Sick Children, Dept Hematol Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
RP Widger, K (reprint author), Univ Toronto, Lawrence S Bloomberg Fac Nursing, 130-155 Coll St, Toronto, ON M5T 1P8, Canada.; Widger, K (reprint author), Hosp Sick Children, Pediat Adv Care Team, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM kim.widger@utoronto.ca
OI Widger, Kimberley /0000-0001-8132-061X
FU Canadian Partnership Against Cancer; Career Development Award from the
Canadian Child Health Clinician Scientist Program; National Institutes
of Health (NIH) [1R25CA151000-01]
FX This project is funded by the Canadian Partnership Against Cancer. KW is
supported by a Career Development Award from the Canadian Child Health
Clinician Scientist Program. The development and initial implementation
of EPEC (R)-Pediatrics is funded by the National Institutes of Health
(NIH) (Grant #1R25CA151000-01). We wish to thank our Project Manager,
Michelle Goertzen, and our Research Fellows, Drs. Jacqui Duc and Kelly
Johnston, for their assistance in preparing this manuscript, creating
data collection forms in REDCap (TM) and preparing ethics applications.
NR 34
TC 1
Z9 1
U1 3
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-684X
J9 BMC PALLIAT CARE
JI BMC Palliat. Care
PD JAN 27
PY 2016
VL 15
AR 12
DI 10.1186/s12904-016-0085-8
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA DC1ML
UT WOS:000368980300001
PM 26818836
ER
PT J
AU Diamandis, P
Ferrer-Luna, R
Huang, RY
Folkerth, RD
Ligon, AH
Wen, PY
Beroukhim, R
Ligon, KL
Ramkissoon, SH
AF Diamandis, Phedias
Ferrer-Luna, Ruben
Huang, Raymond Y.
Folkerth, Rebecca D.
Ligon, Azra H.
Wen, Patrick Y.
Beroukhim, Rameen
Ligon, Keith L.
Ramkissoon, Shakti H.
TI Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion
in Glioblastoma
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article
DE NAB2-STAT6; Glioblastoma; Next generation sequencing
ID COPY NUMBER; GLIOMAS; TEMOZOLOMIDE; LANDSCAPE; NEOPLASMS; TUMOR
AB Background: Molecular profiling has uncovered genetic subtypes of glioblastoma (GBM), including tumors with IDH1 mutations that confer increase survival and improved response to standard-of-care therapies. By mapping the genetic landscape of brain tumors in routine clinical practice, we enable rapid identification of targetable genetic alterations.
Case Presentation: A 29-year-old male presented with new onset seizures prompting neuroimaging studies, which revealed an enhancing 5 cm intra-axial lesion involving the right parietal lobe. He underwent a subtotal resection and pathologic examination revealed glioblastoma with mitoses, microvascular proliferation and necrosis. Immunohistochemical (IHC) analysis showed diffuse expression of GFAP, OLIG2 and SOX2 consistent with a tumor of glial lineage. Tumor cells were positive for IDH1(R132H) and negative for ATRX. Clinical targeted-exome sequencing (DFBWCC Oncopanel) identified multiple functional variants including IDH1 (p.R132H), TP53 (p.Y126_splice), ATRX (p.R1302fs*), HNF1A (p.R263H) and NF1 (p.H2592del) variants and a NAB2-STAT6 gene fusion event involving NAB2 exon 3 and STAT6 exon 18. Array comparative genomic hybridization (aCGH) further revealed a focal amplification of NAB2 and STAT6. IHC analysis demonstrated strong heterogenous STAT6 nuclear localization (in 20 % of tumor cells).
Conclusions: While NAB2:STAT6 fusions are common in solitary fibrous tumors (SFT), we report this event for the first time in a newly diagnosed, secondary-type GBM or any other non-SFT. Our study further highlights the value of comprehensive genomic analyses in identifying patient-specific targetable mutations and rearrangements.
C1 [Diamandis, Phedias] Univ Toronto, Dept Lab Med & Pathobiol, Neuropathol Program, 27 Kings Coll Circle, Toronto, ON M5S, Canada.
[Diamandis, Phedias; Folkerth, Rebecca D.; Ligon, Azra H.; Ligon, Keith L.; Ramkissoon, Shakti H.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
[Ferrer-Luna, Ruben; Beroukhim, Rameen; Ligon, Keith L.] Broad Inst MIT & Harvard, Canc Program, 415 Main St, Cambridge, MA 02142 USA.
[Ferrer-Luna, Ruben; Beroukhim, Rameen] Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave, Boston, MA 02115 USA.
[Huang, Raymond Y.] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.
[Folkerth, Rebecca D.; Ligon, Azra H.; Ligon, Keith L.; Ramkissoon, Shakti H.] Harvard Univ, Sch Med, Dept Pathol, 25 Shattuck St, Boston, MA 02115 USA.
[Folkerth, Rebecca D.; Ligon, Keith L.; Ramkissoon, Shakti H.] Boston Childrens Hosp, Dept Pathol, 300 Longwood Ave, Boston, MA 02115 USA.
[Wen, Patrick Y.; Ligon, Keith L.; Ramkissoon, Shakti H.] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA.
RP Ramkissoon, SH (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.; Ramkissoon, SH (reprint author), Harvard Univ, Sch Med, Dept Pathol, 25 Shattuck St, Boston, MA 02115 USA.; Ramkissoon, SH (reprint author), Boston Childrens Hosp, Dept Pathol, 300 Longwood Ave, Boston, MA 02115 USA.; Ramkissoon, SH (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA.
EM sramkissoon@partners.org
OI Diamandis, Phedias/0000-0001-5291-9068
FU NINDS NIH HHS [K08 NS087118]
NR 15
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD JAN 27
PY 2016
VL 11
AR 13
DI 10.1186/s13000-016-0455-9
PG 5
WC Pathology
SC Pathology
GA DC1KW
UT WOS:000368976200001
PM 26817999
ER
PT J
AU McCarthy, RC
Lu, DY
Alkhateeb, A
Gardeck, AM
Lee, CH
Wessling-Resnick, M
AF McCarthy, Ryan C.
Lu, Dah-Yuu
Alkhateeb, Ahmed
Gardeck, Andrew M.
Lee, Chih-Hao
Wessling-Resnick, Marianne
TI Characterization of a novel adult murine immortalized microglial cell
line and its activation by amyloid-beta
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE BV-2 cells; Neurodegeneration; Microglia; Neuroinflammation; IMG cells;
Amyloid-beta
ID CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASE;
MICE; NEUROINFLAMMATION; PHAGOCYTOSIS; INFLAMMATION; MACROPHAGES;
DYSFUNCTION; EXPRESSION
AB Background: Alzheimer's disease is associated with amyloid-beta (A beta)-induced microglia activation. This pro-inflammatory response promotes neuronal damage, and therapies are sought to limit microglial activation. Screening efforts to develop new pharmacological inhibitors require a robust in vitro cell system. Current models lack significant responses to A beta, and their use in examining age-related neurodegenerative diseases is questionable. For example, the commonly used BV-2 microglial line was derived from embryonic mononuclear cells and its activation by various stimuli is limited. To this end, we have established a new immortalized microglial (IMG) cell line from adult murine brain. The objective of this study was to characterize A beta-induced activation of IMG cells, and here, we demonstrate the ability of cannabinoids to significantly reduce this inflammatory response.
Methods: Microglial cells derived from adult murine brain were immortalized via infection with the v-raf/v-myc retrovirus under conditions that selectively promote microglia growth. The presence or absence of markers CD11b and F4/80 (microglial), NeuN (neuronal), and GFAP (astrocytic) was assessed by immunofluorescence microscopy and western blotting. Using IMG and BV-2 cells, levels of pro-and anti-inflammatory transcripts in response to extracellular stimuli were determined by quantitative PCR (qPCR). Phagocytosis of fluorescent beads and fluorescein isothiocyanate (FITC)-labeled A beta oligomers was assessed using flow cytometry and fluorescence microscopy. FITC-A beta uptake was quantified using a fluorescence plate reader. The ability of cannabinoids to mitigate A beta-induced expression of inducible nitric oxide synthase (iNOS) was evaluated.
Results: IMG cells express the microglial markers CD11b and F4/80 but not NeuN or GFAP. Relative to BV-2 cells, IMG cells increased iNOS (>200-fold) and Arg-1 (>100-fold) in response to pro-and anti-inflammatory stimuli. IMG cells phagocytose foreign particles and A beta oligomers, with the latter trafficked to phagolysosomes. A beta-induced activation of IMG cells was suppressed by delta-9-tetrahydrocannabinol and the CB2-selective agonist JWH-015 in a time-and concentration-dependent manner.
Conclusions: IMG cells recapitulate key features of microglial cell activation. As an example of their potential pharmacological use, cannabinoids were shown to reduce activation of A beta-induced iNOS gene expression. IMG cells hold promising potential for drug screening, mechanistic studies, and functional investigations directed towards understanding how A beta interacts with microglia.
C1 [McCarthy, Ryan C.; Lu, Dah-Yuu; Alkhateeb, Ahmed; Gardeck, Andrew M.; Lee, Chih-Hao; Wessling-Resnick, Marianne] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.
[Lu, Dah-Yuu] China Med Univ, Grad Inst Neural & Cognit Sci, Taichung, Taiwan.
[Alkhateeb, Ahmed] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Alkhateeb, Ahmed] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Wessling-Resnick, M (reprint author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.
EM wessling@hsph.harvard.edu
FU National Institutes of Health grants from the National Institute of
Environmental Health Sciences [R01 ES0146380]; National Institute of
Diabetes and Digestive and Kidney Diseases [R01 DK075046]; National
Institute of Environmental Health Sciences [T32 ES016645]
FX This study was supported by the National Institutes of Health grants
from the National Institute of Environmental Health Sciences to MW-R
(R01 ES0146380) and the National Institute of Diabetes and Digestive and
Kidney Diseases to C-HL (R01 DK075046). RCM is supported by the National
Institute of Environmental Health Sciences grant T32 ES016645. We thank
Dr. Daniel J. Kosman for his generous donation of the C6 glioma cells
and GFAP antibody. IMG cells have been deposited at KeraFAST.
NR 42
TC 4
Z9 4
U1 2
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD JAN 27
PY 2016
VL 13
AR 21
DI 10.1186/s12974-016-0484-z
PG 15
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA DC0DJ
UT WOS:000368886900002
PM 26819091
ER
PT J
AU Gong, B
Radulovic, M
Figueiredo-Pereira, ME
Cardozo, C
AF Gong, Bing
Radulovic, Miroslav
Figueiredo-Pereira, Maria E.
Cardozo, Christopher
TI The Ubiquitin-Proteasome System: Potential Therapeutic Targets for
Alzheimer's Disease and Spinal Cord Injury
SO FRONTIERS IN MOLECULAR NEUROSCIENCE
LA English
DT Review
DE ubiquitin-proteasome system; Alzheimer's disease; spinal cord injuries;
beta-amyloid clearance; neuroregeneration
ID AMYLOID PRECURSOR PROTEIN; TERMINAL HYDROLASE L1;
AMYOTROPHIC-LATERAL-SCLEROSIS; PERIPHERAL NERVOUS-SYSTEM; FOCAL
CEREBRAL-ISCHEMIA; BETA-SECRETASE BACE1; OXIDATIVE STRESS;
NEURODEGENERATIVE DISEASE; MITOCHONDRIAL DYSFUNCTION; TRANSIENT ISCHEMIA
AB The ubiquitin-proteasome system (UPS) is a crucial protein degradation system in eukaryotes. Herein, we will review advances in the understanding of the role of several proteins of the UPS in Alzheimer's disease (AD) and functional recovery after spinal cord injury (SCI). The UPS consists of many factors that include E3 ubiquitin ligases, ubiquitin hydrolases, ubiquitin and ubiquitin-like molecules, and the proteasome itself. An extensive body of work links UPS dysfunction with AD pathogenesis and progression. More recently, the UPS has been shown to have vital roles in recovery of function after SCI. The ubiquitin hydrolase (Uch-L1) has been proposed to increase cellular levels of mono-ubiquitin and hence to increase rates of protein turnover by the UPS. A low Uch-L1 level has been linked with A beta accumulation in AD and reduced neuroregeneration after SCI. One likely mechanism for these beneficial effects of Uch-L1 is reduced turnover of the PKA regulatory subunit and consequently, reduced signaling via CREB. The neuron-specific F-box protein Fbx2 ubiquitinates beta-secretase thus targeting it for proteasomal degradation and reducing generation of A beta. Both Uch-L1 and Fbx2 improve synaptic plasticity and cognitive function in mouse AD models. The role of Fbx2 after SCI has not been examined, but abolishing B-secretase reduces neuronal recovery after SCI, associated with reduced myelination. UBB(+)1, which arises through a frame-shift mutation in the ubiquitin gene that adds 19 amino acids to the C-terminus of ubiquitin, inhibits proteasomal function and is associated with increased neurofibrillary tangles in patients with AD, Pick's disease and Down's syndrome. These advances in understanding of the roles of the UPS in AD and SCI raise new questions but, also, identify attractive and exciting targets for potential, future therapeutic interventions.
C1 [Gong, Bing; Radulovic, Miroslav; Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Gong, Bing; Radulovic, Miroslav; Cardozo, Christopher] James J Peters Vet Affairs Med Ctr, Med, Bronx, NY USA.
[Radulovic, Miroslav; Cardozo, Christopher] Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY USA.
[Figueiredo-Pereira, Maria E.] CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA.
[Figueiredo-Pereira, Maria E.] CUNY Grad Sch & Univ Ctr, New York, NY 10036 USA.
RP Cardozo, C (reprint author), Mt Sinai Sch Med, Dept Med, New York, NY USA.; Cardozo, C (reprint author), James J Peters Vet Affairs Med Ctr, Med, Bronx, NY USA.; Cardozo, C (reprint author), Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY USA.
EM christopher.cardozo@va.gov
FU Alzheimer's Association [IIRG-12-242345]; Rehabilitation Research and
Development Service Center for the Medical Consequences of Spinal Cord
Injury [B9212C]
FX The studies described here were supported in part by grant from
Alzheimer's Association (IIRG-12-242345) to BC and by the Rehabilitation
Research and Development Service Center for the Medical Consequences of
Spinal Cord Injury (B9212C). We thank Dr. Anand and Mr. Jin for critical
reading of the manuscript and preparation of the figures.
NR 172
TC 5
Z9 5
U1 4
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1662-5099
J9 FRONT MOL NEUROSCI
JI Front. Molec. Neurosci.
PD JAN 26
PY 2016
VL 9
AR 4
DI 10.3389/fnmol.2015.00004
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA DE3UD
UT WOS:000370554900002
PM 26858599
ER
PT J
AU Xu, NQ
Fang, WF
Mu, LB
Tang, YN
Gao, L
Ren, SX
Cao, DF
Zhou, LX
Zhang, AQ
Liu, DR
Zhou, CC
Wong, KK
Yu, L
Zhang, L
Chen, L
AF Xu, Naiqing
Fang, Wenfeng
Mu, Libing
Tang, Yanna
Gao, Lei
Ren, Shengxiang
Cao, Dengfeng
Zhou, Lixin
Zhang, Aiqun
Liu, Deruo
Zhou, Caicun
Wong, Kwok-Kin
Yu, Lei
Zhang, Li
Chen, Liang
TI Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic
target in non-small cell lung cancer
SO ONCOTARGET
LA English
DT Article
DE EGFR; transgenic mouse model; tyrosine kinase inhibitor; lung cancer
ID GROWTH-FACTOR-RECEPTOR; RANDOMIZED PHASE-3 TRIAL; KINASE DOMAIN
MUTATIONS; GENE COPY NUMBER; 1ST-LINE TREATMENT; OPEN-LABEL; GEFITINIB
SENSITIVITY; MOLECULAR PREDICTORS; EXPRESSION; ERLOTINIB
AB Current guidelines for lung cancer treatment with EGFR tyrosine kinase inhibitors (TKI) include only patients with mutated EGFR, although some patients with wildtype EGFR (wt-EGFR) have exhibited positive responses to this therapy as well. Biomarkers predicting the benefit from EGFR-TKIs treatment remain to be determined for patients with wild-type EGFR.
Here, we report that wt-EGFR overexpression transformed cells in vitro and induced tumorigenesis in vivo in transgenic mouse models. Wt-EGFR driven lung cancer was hypersensitive to TKI treatment in mouse model. Lung cancer patients with high-expression of wt-EGFR showed longer Overall Survival in comparison to low-expression patients after TKI treatment. Our data therefore suggest that treatment with EGFR inhibitors should be extended to include not only patients with mutated EGFR but also a subset of patients with overexpression of wt-EGFR.
C1 [Xu, Naiqing; Chen, Liang] Peking Union Med Coll, Grad Sch, Beijing 100021, Peoples R China.
[Xu, Naiqing; Gao, Lei; Chen, Liang] Natl Inst Biol Sci, Beijing, Peoples R China.
[Xu, Naiqing; Chen, Liang] Chinese Acad Med Sci, Beijing 100730, Peoples R China.
[Fang, Wenfeng; Tang, Yanna; Zhang, Li] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China.
[Mu, Libing] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China.
[Ren, Shengxiang; Zhou, Caicun] Shanghai Pulm Hosp, Shanghai, Peoples R China.
[Cao, Dengfeng] Chinese Acad Med Sci, Canc Hosp & Inst, Beijing 100730, Peoples R China.
[Zhou, Lixin] Peking Univ, Canc Hosp, Beijing 100871, Peoples R China.
[Zhang, Aiqun] Gen Hosp Peoples Liberat Army, Beijing, Peoples R China.
[Liu, Deruo] China Japan Friendship Hosp, Dept Thorac Surg, Beijing, Peoples R China.
[Wong, Kwok-Kin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Yu, Lei] Capital Med Univ, Beijing Tongren Hosp, Beijing, Peoples R China.
[Chen, Liang] Collaborat Innovat Ctr Canc Med, Natl Inst Biol Sci, Beijing, Peoples R China.
RP Chen, L (reprint author), Peking Union Med Coll, Grad Sch, Beijing 100021, Peoples R China.; Chen, L (reprint author), Natl Inst Biol Sci, Beijing, Peoples R China.; Chen, L (reprint author), Chinese Acad Med Sci, Beijing 100730, Peoples R China.; Zhang, L (reprint author), Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China.; Chen, L (reprint author), Collaborat Innovat Ctr Canc Med, Natl Inst Biol Sci, Beijing, Peoples R China.
EM zhangli@sysucc.org.cn; chenliang@nibs.ac.cn
FU Chinese Ministry of Science and Technology grant (973 grant)
[2011CB812401]; National Natural Science Foundation of China [81472606];
Beijing Municipal Government
FX This work was funded by Chinese Ministry of Science and Technology grant
(973 grant) 2011CB812401, National Natural Science Foundation of China
grant 81472606 and the Beijing Municipal Government to L.C..
NR 47
TC 1
Z9 1
U1 2
U2 2
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 26
PY 2016
VL 7
IS 4
BP 3884
EP 3896
PG 13
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DD5HA
UT WOS:000369952400019
PM 26646697
ER
PT J
AU Park, C
Ha, SY
Kim, ST
Kim, HC
Heo, JS
Park, YS
Lauwers, G
Lee, J
Kim, KM
AF Park, Charny
Ha, Sang Yun
Kim, Seung Tae
Kim, Hee Cheol
Heo, Jin Seok
Park, Young Suk
Lauwers, Gregory
Lee, Jeeyun
Kim, Kyoung-Mee
TI Identification of the BRAF V600E mutation in gastroenteropancreatic
neuroendocrine tumors
SO ONCOTARGET
LA English
DT Article
DE neuroendocrine tumors; BRAFV600E mutation; pazopanib
ID CARCINOID-TUMORS; ENDOCRINE TUMORS; EPIDEMIOLOGY; RESISTANCE; DISCOVERY;
MELANOMA; SURVIVAL; SAMPLES; GENES
AB Genomic profiles of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are still insufficiently understood, and the genetic alterations associated with drug responses have not been studied. Here, we performed whole exome sequencing of 12 GEP-NETs from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for pazopanib, and integrated our results with previously published results on pancreas (n = 12) and small intestine NETs (n = 50). The mean numbers of somatic mutations in each case varied widely from 20 to 4682. Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL. TP53 was recurrently mutated in three cases, whereas CNBD1 and RB1 mutations were identified in two cases. Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment. We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 GEP-NETs from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing. All tumor specimens were obtained before chemotherapy. In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients.
C1 [Park, Charny; Ha, Sang Yun; Kim, Kyoung-Mee] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea.
[Kim, Seung Tae; Park, Young Suk; Lee, Jeeyun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea.
[Kim, Hee Cheol; Heo, Jin Seok] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul, South Korea.
[Lauwers, Gregory] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Kim, KM (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea.; Lee, J (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea.
EM jyunlee@skku.edu; kkmkys@skku.edu
RI Lee, Jee Yun/C-9646-2011; kim, st/O-5928-2014
FU Korean Health Technology R & D Project, Ministry of Health & Welfare,
Republic of Korea [HI14C3418]
FX We would like to express our gratitude to Dr. Joshua Francis and Dr.
Matthew Meyerson at the Department of Medical Oncology, Dana-Farber
Cancer Institute, Boston, Massachusetts 02215, USA, and Broad Institute
of Harvard and MIT, Cambridge, Massachusetts 02142, USA, for genomic
profiling of our tumor specimens, genomic analysis and helpful
scientific advice. This work was partially supported by a grant from the
Korean Health Technology R & D Project, Ministry of Health & Welfare,
Republic of Korea (HI14C3418).
NR 33
TC 2
Z9 3
U1 1
U2 5
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 26
PY 2016
VL 7
IS 4
BP 4024
EP 4035
PG 12
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DD5HA
UT WOS:000369952400029
PM 26684240
ER
PT J
AU Choi, PW
Yang, JZ
Ng, SK
Feltmate, C
Muto, MG
Hasselblatt, K
Lafferty-Whyte, K
JeBailey, L
MacConaill, L
Welch, WR
Fong, WP
Berkowitz, RS
Ng, SW
AF Choi, Pui-Wah
Yang, Junzheng
Ng, Shu-Kay
Feltmate, Colleen
Muto, Michael G.
Hasselblatt, Kathleen
Lafferty-Whyte, Kyle
JeBailey, Lellean
MacConaill, Laura
Welch, William R.
Fong, Wing-Ping
Berkowitz, Ross S.
Ng, Shu-Wing
TI Loss of E-cadherin disrupts ovarian epithelial inclusion cyst formation
and collective cell movement in ovarian cancer cells
SO ONCOTARGET
LA English
DT Article
DE ovarian cancer; three-dimensional culture; inclusion cyst; tumor
invasion; collective movement
ID SURFACE EPITHELIUM; MIR-200 FAMILY; MOUSE-MODEL; LAYING HEN; EXPRESSION;
INVASION; TRANSITION; CARCINOMA; MORPHOGENESIS; 3D
AB Increased inclusion cyst formation in the ovary is associated with ovarian cancer development. We employed in vitro three-dimensional (3D) organotypic models formed by normal human ovarian surface epithelial (OSE) cells and ovarian cancer cells to study the morphologies of normal and cancerous ovarian cortical inclusion cysts and the molecular changes during their transitions into stromal microenvironment. When compared with normal cysts that expressed tenascin, the cancerous cysts expressed high levels of laminin V and demonstrated polarized structures in Matrigel; and the cancer cells migrated collectively when the cyst structures were positioned in a stromal-like collagen I matrix. The molecular markers identified in the in vitro 3D models were verified in clinical samples. Network analysis of gene expression of the 3D structures indicates concurrent downregulation of transforming growth factor beta pathway genes and high levels of E-cadherin and microRNA200 (miR200) expression in the cancerous cysts and the migrating cancer cells. Transient silencing of E-cadherin expression in ovarian cancer cells disrupted cyst structures and inhibited collective cell migration. Taken together, our studies employing 3D models have shown that E-cadherin is crucial for ovarian inclusion cyst formation and collective cancer cell migration.
C1 [Choi, Pui-Wah; Fong, Wing-Ping] Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Hong Kong, Peoples R China.
[Choi, Pui-Wah; Yang, Junzheng; Feltmate, Colleen; Muto, Michael G.; Hasselblatt, Kathleen; Berkowitz, Ross S.; Ng, Shu-Wing] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, 75 Francis St, Boston, MA 02115 USA.
[Ng, Shu-Kay] Griffith Univ, Sch Med, Meadowbrook, Qld 4131, Australia.
[Lafferty-Whyte, Kyle; JeBailey, Lellean] Thomson Reuters, GeneGo, New York, NY USA.
[MacConaill, Laura] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
[Welch, William R.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
RP Fong, WP (reprint author), Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Hong Kong, Peoples R China.; Ng, SW (reprint author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, 75 Francis St, Boston, MA 02115 USA.
EM wpfong@cuhk.edu.hk; sng@partners.org
FU Global Scholarship Program-CNOOC grant; Chinese University of Hong Kong;
Robert and Deborah First Fund; Sperling Family Fund Foundation; Ruth N.
White Gynecologic Oncology Research Fund; Women's Cancer Program;
Gillette Center for Women's Cancer from Dana-Farber Cancer Institute;
Ovarian Cancer Research Foundation; Adler Foundation, Inc.; Dana Farber
Cancer Institute
FX This work was partly supported by a Global Scholarship Program-CNOOC
grant (to PWC), a Direct Grant for Research (2010/2011) of the Chinese
University of Hong Kong (to WPF). We acknowledge the support of the
Robert and Deborah First Fund, the Sperling Family Fund Foundation, Ruth
N. White Gynecologic Oncology Research Fund, Women's Cancer Program and
Gillette Center for Women's Cancer from Dana-Farber Cancer Institute,
Ovarian Cancer Research Foundation, Adler Foundation, Inc., and Friends
of Dana Farber Cancer Institute to The Laboratory of Gynecologic
Oncology at Brigham and Women's Hospital.
NR 50
TC 4
Z9 4
U1 1
U2 5
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 26
PY 2016
VL 7
IS 4
BP 4110
EP 4121
PG 12
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DD5HA
UT WOS:000369952400035
PM 26684027
ER
PT J
AU Piccini, JP
Hellkamp, AS
Washam, JB
Becker, RC
Breithardt, G
Berkowitz, SD
Halperin, JL
Hankey, GJ
Hacke, W
Mahaffey, KW
Nessel, CC
Singer, DE
Fox, KAA
Patel, MR
AF Piccini, Jonathan P.
Hellkamp, Anne S.
Washam, Jeffrey B.
Becker, Richard C.
Breithardt, Guenter
Berkowitz, Scott D.
Halperin, Jonathan L.
Hankey, Graeme J.
Hacke, Werner
Mahaffey, Kenneth W.
Nessel, Christopher C.
Singer, Daniel E.
Fox, Keith A. A.
Patel, Manesh R.
TI Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin
in the Prevention of Stroke in Patients With Nonvalvular Atrial
Fibrillation
SO CIRCULATION
LA English
DT Article
DE atrial fibrillation; factor Xa; pharmacokinetics; polypharmacy;
rivaroxaban; warfarin
ID RISK; CARE; AF
AB Background Patients with atrial fibrillation (AF) often take multiple medications.
Methods and Results We examined characteristics and compared adjusted outcomes between rivaroxaban and warfarin according to number of concomitant baseline medications and the presence of combined cytochrome P450 3A4 and P-glycoprotein inhibitors in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study. At baseline, 5101 patients (36%) were on 0 to 4 medications, 7298 (51%) were on 5 to 9, and 1865 (13%) were on 10. Although polypharmacy was not associated with higher risk of stroke or non-central nervous system embolism (adjusted hazard ratio, 1.02 for 10 versus 0-4 medications; 95% confidence interval, 0.76-1.38), it was associated with higher risks of the combined end point of stroke, non-central nervous system embolism, vascular death, or myocardial infarction (adjusted hazard ratio, 1.41 for 10 versus 0-4 medications; 95% confidence interval, 1.18-1.68) and nonmajor clinically relevant or major bleeding (adjusted hazard ratio, 1.47 for 10 versus 0-4 medications; 95% confidence interval, 1.31-1.65). There was no significant difference in primary efficacy (adjusted interaction P=0.99) or safety outcomes (adjusted interaction P=0.87) between treatment groups by number of medications. Patients treated with 0 to 4 medications had lower rates of major bleeding with rivaroxaban (adjusted hazard ratio, 0.71; 95% confidence interval, 0.52-0.95; interaction P=0.0074). There was no evidence of differential outcomes in those treated with 1 combined cytochrome P450 3A4 and P-glycoprotein inhibitors.
Conclusions In a population of patients with atrial fibrillation, two thirds were on 5 medications. Increasing medication use was associated with higher risk of bleeding but not stroke. Rivaroxaban was tolerated across complex patients on multiple medications.
C1 [Piccini, Jonathan P.; Hellkamp, Anne S.; Patel, Manesh R.] Duke Clin Res Inst, Durham, NC USA.
[Piccini, Jonathan P.; Washam, Jeffrey B.; Patel, Manesh R.] Duke Univ, Med Ctr, Duke Heart Ctr, Room 0311 Terrace Level,2400 Pratt St, Durham, NC 27705 USA.
[Becker, Richard C.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA.
[Breithardt, Guenter] Hosp Univ Munster, Munster, Germany.
[Berkowitz, Scott D.] Bayer HealthCare Pharmaceut, Whippany, NJ USA.
[Halperin, Jonathan L.] Mt Sinai Med Ctr, Zena & Michael A Wiener Cardiovascular Inst, New York, NY 10029 USA.
[Hankey, Graeme J.] Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia.
[Hacke, Werner] Heidelberg Univ, Heidelberg, Germany.
[Mahaffey, Kenneth W.] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA.
[Nessel, Christopher C.] Janssen Pharmaceut Res & Dev, Raritan, NJ USA.
[Singer, Daniel E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Singer, Daniel E.] Harvard Univ, Sch Med, Boston, MA USA.
[Fox, Keith A. A.] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
[Fox, Keith A. A.] Royal Infirm, Edinburgh, Midlothian, Scotland.
RP Piccini, JP (reprint author), Duke Clin Res Inst, Durham, NC USA.; Piccini, JP (reprint author), Duke Univ, Med Ctr, Duke Heart Ctr, Room 0311 Terrace Level,2400 Pratt St, Durham, NC 27705 USA.; Piccini, JP (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, Room 0311 Terrace Level,2400 Pratt St, Durham, NC 27705 USA.
EM jonathan.piccini@duke.edu
RI Hankey, Graeme /H-4968-2014
OI Hankey, Graeme /0000-0002-6044-7328
FU Johnson & Johnson Pharmaceutical Research & Development (Raritan, NJ);
Bayer HealthCare AG (Leverkusen, Germany)
FX ROCKET AF was supported by Johnson & Johnson Pharmaceutical Research &
Development (Raritan, NJ) and Bayer HealthCare AG (Leverkusen, Germany).
NR 16
TC 13
Z9 13
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD JAN 26
PY 2016
VL 133
IS 4
BP 352
EP 360
DI 10.1161/CIRCULATIONAHA.115.018544
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DC5KE
UT WOS:000369259100003
PM 26673560
ER
PT J
AU Ma, JT
McKeown, NM
Hwang, SJ
Hoffmann, U
Jacques, PF
Fox, CS
AF Ma, Jiantao
McKeown, Nicola M.
Hwang, Shih-Jen
Hoffmann, Udo
Jacques, Paul F.
Fox, Caroline S.
TI Sugar-Sweetened Beverage Consumption Is Associated With Change of
Visceral Adipose Tissue Over 6 Years of Follow-Up
SO CIRCULATION
LA English
DT Article
DE obesity; subcutaneous adipose tissue; visceral adipose tissue
ID FOOD-FREQUENCY QUESTIONNAIRE; LIPOPROTEIN-LIPASE; METABOLIC SYNDROME;
UNITED-STATES; FRUCTOSE; DISEASE; FAT; REPRODUCIBILITY; VALIDITY;
INSULIN
AB Background Sugar-sweetened beverage (SSB) intake has been linked to abnormal abdominal adipose tissue. We examined the prospective association of habitual SSB intake and change in visceral adipose tissue (VAT) and subcutaneous adipose tissue.
Methods and Results The quantity (volume, cm(3)) and quality (attenuation, Hounsfield Unit) of abdominal adipose tissue were measured using computed tomography in 1003 participants (mean age 45.3 years, 45.0% women) at examination 1 and 2 in the Framingham's Third Generation cohort. The 2 exams were approximate to 6 years apart. At baseline, SSB and diet soda intake were assessed using a valid food frequency questionnaire. Participants were categorized into 4 groups: none to <1 serving/mo (nonconsumers), 1 serving/mo to <1 serving/week, 1 serving/week to 1 serving/d, and 1 serving/d (daily consumers) of either SSB or diet soda. After adjustment for multiple confounders including change in body weight, higher SSB intake was associated with greater change in VAT volume (P trend<0.001). VAT volume increased by 658 cm(3) (95% confidence interval [CI], 602 to 713), 649 cm(3) (95% CI, 582 to 716), 707 cm(3) (95% CI, 657 to 757), and 852 cm(3) (95% CI, 760 to 943) from nonconsumers to daily consumers. Higher SSB intake was also associated with greater decline of VAT attenuation (P trend=0.007); however, the association became nonsignificant after additional adjustment for VAT volume change. In contrast, diet soda consumption was not associated with change in abdominal adipose tissue.
Conclusions Regular SSB intake was associated with adverse change in both VAT quality and quantity, whereas we observed no such association for diet soda.
C1 [Ma, Jiantao; Hwang, Shih-Jen; Fox, Caroline S.] NHLBI, Framingham Heart Study & Populat Sci Branch, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.
[McKeown, Nicola M.; Jacques, Paul F.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Nutr Epidemiol Program, Boston, MA 02111 USA.
[Hoffmann, Udo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA.
RP Fox, CS (reprint author), NHLBI, Framingham Heart Study & Populat Sci Branch, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.
EM foxa@nhlbi.nih.gov
FU Framingham Heart Study (FHS) of National Heart, Lung, and Blood
Institute (NHLBI) of National Institute of Health; Boston University
School of Medicine; NHLBI FHS [N01-HC-25195]
FX This work was conducted in part using resources and data from the
Framingham Heart Study (FHS) of the National Heart, Lung, and Blood
Institute (NHLBI) of the National Institute of Health and Boston
University School of Medicine. This work was supported by the NHLBI FHS
(N01-HC-25195).
NR 35
TC 2
Z9 2
U1 3
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD JAN 26
PY 2016
VL 133
IS 4
BP 370
EP 377
DI 10.1161/CIRCULATIONAHA.115.018704
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DC5KE
UT WOS:000369259100005
PM 26755505
ER
PT J
AU Ghaoui, R
Palmio, J
Brewer, J
Lek, M
Needham, M
Evila, A
Hackman, P
Jonson, PH
Penttila, S
Vihola, A
Huovinen, S
Lindfors, M
Davis, RL
Waddell, L
Kaur, S
Yiannikas, C
North, K
Clarke, N
MacArthur, DG
Sue, CM
Udd, B
AF Ghaoui, Roula
Palmio, Johanna
Brewer, Janice
Lek, Monkol
Needham, Merrilee
Evila, Anni
Hackman, Peter
Jonson, Per-Harald
Penttila, Sini
Vihola, Anna
Huovinen, Sanna
Lindfors, Mikaela
Davis, Ryan L.
Waddell, Leigh
Kaur, Simran
Yiannikas, Con
North, Kathryn
Clarke, Nigel
MacArthur, Daniel G.
Sue, Carolyn M.
Udd, Bjarne
TI Mutations in HSPB8 causing a new phenotype of distal myopathy and motor
neuropathy
SO NEUROLOGY
LA English
DT Article
ID MARIE-TOOTH DISEASE; GIRDLE MUSCULAR-DYSTROPHY; HEAT-SHOCK-PROTEIN;
PEDIGREE; DNAJB6; 2L
AB Objective:To report novel disease and pathology due to HSPB8 mutations in 2 families with autosomal dominant distal neuromuscular disease showing both myofibrillar and rimmed vacuolar myopathy together with neurogenic changes.Methods:We performed whole-exome sequencing (WES) in tandem with linkage analysis and candidate gene approach as well as targeted next-generation sequencing (tNGS) to identify causative mutations in 2 families with dominant rimmed vacuolar myopathy and a motor neuropathy. Pathogenic variants and familial segregation were confirmed using Sanger sequencing.Results:WES and tNGS identified a heterozygous change in HSPB8 in both families: c.421A > G p.K141E in family 1 and c.151insC p.P173SfsX43 in family 2. Affected patients had a distal myopathy that showed myofibrillar aggregates and rimmed vacuoles combined with a clear neurogenic component both on biopsy and neurophysiologic studies. MRI of lower limb muscles demonstrated diffuse tissue changes early in the disease stage progressing later to fatty replacement typical of a myopathy.Conclusion:We expand the understanding of disease mechanisms, tissue involvement, and phenotypic outcome of HSPB8 mutations. HSPB8 is part of the chaperone-assisted selective autophagy (CASA) complex previously only associated with Charcot-Marie-Tooth type 2L (OMIM 60673) and distal hereditary motor neuronopathy type IIa. However, we now demonstrate that patients can develop a myopathy with histologic features of myofibrillar myopathy with aggregates and rimmed vacuoles, similar to the pathology in myopathies due to gene defects in other compounds of the CASA complex such as BAG3 and DNAJB6 after developing the early neurogenic effects.
C1 [Ghaoui, Roula; Waddell, Leigh; Kaur, Simran; Clarke, Nigel] Childrens Hosp, Inst Neurosci & Muscle Res, Kids Res Inst, Westmead, NSW, Australia.
[Ghaoui, Roula; Davis, Ryan L.; Waddell, Leigh; Kaur, Simran; Yiannikas, Con; Clarke, Nigel; Sue, Carolyn M.] Univ Sydney, Sydney, NSW 2006, Australia.
[Palmio, Johanna; Penttila, Sini; Lindfors, Mikaela; Udd, Bjarne] Tampere Univ Hosp, Neuromuscular Res Ctr, Dept Neurol, Tampere, Finland.
[Huovinen, Sanna] Tampere Univ Hosp, Dept Pathol, Fimlab Labs, Tampere, Finland.
[Huovinen, Sanna] Univ Tampere, FIN-33101 Tampere, Finland.
[Brewer, Janice] Royal N Shore Hosp, Dept Pathol, Sydney, NSW, Australia.
[Lek, Monkol; MacArthur, Daniel G.] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Needham, Merrilee] Univ Western Australia, Western Australian Neurosci Res Inst, Perth, WA 6009, Australia.
[Evila, Anni; Hackman, Peter; Jonson, Per-Harald; Vihola, Anna; Udd, Bjarne] Univ Helsinki, Folkhalsan Inst Genet, FIN-00014 Helsinki, Finland.
[Evila, Anni; Hackman, Peter; Jonson, Per-Harald; Vihola, Anna; Udd, Bjarne] Univ Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland.
[Davis, Ryan L.; Yiannikas, Con; Sue, Carolyn M.] Royal N Shore Hosp, Dept Neurogenet, Kolling Inst, St Leonards, NSW, Australia.
[North, Kathryn] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
[Lek, Monkol; MacArthur, Daniel G.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Udd, Bjarne] Vaasa Cent Hosp, Dept Neurol, Vaasa, Finland.
RP Sue, CM (reprint author), Univ Sydney, Sydney, NSW 2006, Australia.; Udd, B (reprint author), Tampere Univ Hosp, Neuromuscular Res Ctr, Dept Neurol, Tampere, Finland.; Udd, B (reprint author), Univ Helsinki, Folkhalsan Inst Genet, FIN-00014 Helsinki, Finland.; Udd, B (reprint author), Univ Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland.; Sue, CM (reprint author), Royal N Shore Hosp, Dept Neurogenet, Kolling Inst, St Leonards, NSW, Australia.; Udd, B (reprint author), Vaasa Cent Hosp, Dept Neurol, Vaasa, Finland.
EM Carolyn.sue@sydney.edu.au; Bjarne.udd@netikka.fi
FU Australian National Health and Medical Research Council (NHMRC)
[APP1074954, APP1031893, APP1022707, APP1035828, APP1008433,
APP1037797]; Muscular Dystrophy New South Wales; National Human Genome
Research Institute of the NIH [U54 HG003067]; Juselius Foundation;
Finnish Academy; Folkhalsan Foundation
FX This project was supported by Australian National Health and Medical
Research Council (NHMRC) grants: APP1074954 (R. Ghaoui), APP1031893 and
APP1022707 (K.N. North and N.F. Clarke), APP1035828 (N.F. Clarke),
APP1008433 (C.M. Sue), APP1037797 (R.L. Davis), and Muscular Dystrophy
New South Wales (R. Ghaoui). Exome sequencing was supported by grants
from the National Human Genome Research Institute of the NIH (Medical
Sequencing Program grant U54 HG003067 to the Broad Institute principal
investigator, E. Lander). Also supported by Juselius Foundation, Finnish
Academy, and the Folkhalsan Foundation (B. Udd).
NR 18
TC 8
Z9 8
U1 3
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JAN 26
PY 2016
VL 86
IS 4
BP 391
EP 398
DI 10.1212/WNL.0000000000002324
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA DC5LV
UT WOS:000369263400007
PM 26718575
ER
PT J
AU Choi, YE
Meghani, K
Brault, ME
Leclerc, L
He, YZJ
Day, TA
Elias, KM
Drapkin, R
Weinstock, DM
Dao, F
Shih, KK
Matulonis, U
Levine, DA
Konstantinopoulos, PA
Chowdhury, D
AF Choi, Young Eun
Meghani, Khyati
Brault, Marie-Eve
Leclerc, Lucas
He, Yizhou J.
Day, Tovah A.
Elias, Kevin M.
Drapkin, Ronny
Weinstock, David M.
Dao, Fanny
Shih, Karin K.
Matulonis, Ursula
Levine, Douglas A.
Konstantinopoulos, Panagiotis A.
Chowdhury, Dipanjan
TI Platinum and PARP Inhibitor Resistance Due to Overexpression of
MicroRNA-622 in BRCA1-Mutant Ovarian Cancer
SO CELL REPORTS
LA English
DT Article
ID DNA-DAMAGE; CELL-CYCLE; HOMOLOGOUS RECOMBINATION; REPAIR; DEFICIENCY;
RESECTION; BREAKS; 53BP1; KU
AB High-grade serous ovarian carcinomas (HGSOCs) with BRCA1/2 mutations exhibit improved outcome and sensitivity to double-strand DNA break (DSB)inducing agents (i.e., platinum and poly(ADP-ribose) polymerase inhibitors [PARPis]) due to an underlying defect in homologous recombination (HR). However, resistance to platinum and PARPis represents a significant barrier to the long-term survival of these patients. Although BRCA1/2-reversion mutations are a clinically validated resistance mechanism, they account for less than half of platinum-resistant BRCA1/2-mutated HGSOCs. We uncover a resistance mechanism by which a microRNA, miR-622, induces resistance to PARPis and platinum in BRCA1 mutant HGSOCs by targeting the Ku complex and restoring HR-mediated DSB repair. Physiologically, miR-622 inversely correlates with Ku expression during the cell cycle, suppressing non-homologous end-joining and facilitating HR-mediated DSB repair in S phase. Importantly, high expression of miR-622 in BRCA1-deficient HGSOCs is associated with worse outcome after platinum chemotherapy, indicating microRNA-mediated resistance through HR rescue.
C1 [Choi, Young Eun; Meghani, Khyati; Brault, Marie-Eve; Leclerc, Lucas; He, Yizhou J.; Chowdhury, Dipanjan] Harvard Univ, Dana Farber Canc Inst, Div Genom Stabil & DNA Repair, Dept Radiat Oncol,Sch Med, Boston, MA 02215 USA.
[Day, Tovah A.; Weinstock, David M.; Matulonis, Ursula; Konstantinopoulos, Panagiotis A.] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA.
[Elias, Kevin M.] Brigham & Womens Hosp, Dept Obstet & Gynecol & Reprod Biol, Div Gynecol Oncol, Boston, MA 02215 USA.
[Drapkin, Ronny] Univ Penn, Perelman Sch Med, Dept Obstet & Gynecol, Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA.
[Dao, Fanny; Shih, Karin K.; Levine, Douglas A.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA.
RP Chowdhury, D (reprint author), Harvard Univ, Dana Farber Canc Inst, Div Genom Stabil & DNA Repair, Dept Radiat Oncol,Sch Med, Boston, MA 02215 USA.; Konstantinopoulos, PA (reprint author), Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA.
EM panagiotis_konstantinopoulos@dfci.harvard.edu;
dipanjan_chowdhury@dfci.harvard.edu
RI Drapkin, Ronny/E-9944-2016;
OI Drapkin, Ronny/0000-0002-6912-6977; He, Yizhou/0000-0002-1396-7275
FU Basic Scholar Grant (American Cancer Society); Leukemia and Lymphoma
Society Scholar Grant; Claudia Adams Barr Program for Innovative Cancer
Research; Breast SPORE Pilot Award; Robert and Deborah First Fund; Mary
Kay Foundation; Susan Smith Center for Women's Cancers; Department of
Defense Ovarian Cancer Academy Award [W81XWH-10-1-0585]; [R01
AI101897-01]; [R01CA142698-07]
FX D.C. is supported by grants R01 AI101897-01 (NIAID) and R01CA142698-07
(NCI), a Basic Scholar Grant (American Cancer Society), a Leukemia and
Lymphoma Society Scholar Grant, the Claudia Adams Barr Program for
Innovative Cancer Research, a Breast SPORE Pilot Award, the Robert and
Deborah First Fund, and the Mary Kay Foundation. P.A.K. is supported by
the Susan Smith Center for Women's Cancers and a Department of Defense
Ovarian Cancer Academy Award (W81XWH-10-1-0585). The Brca1-/-
MEFs were a gift from Andre Nussenzweig, and NHEJ reporter construct was
a gift from Jeremy Stark.
NR 29
TC 3
Z9 3
U1 1
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD JAN 26
PY 2016
VL 14
IS 3
BP 429
EP 439
DI 10.1016/j.celrep.2015.12.046
PG 11
WC Cell Biology
SC Cell Biology
GA DB7NF
UT WOS:000368701600004
PM 26774475
ER
PT J
AU Heyn, H
Vidal, E
Ferreira, HJ
Vizoso, M
Sayols, S
Gomez, A
Moran, S
Boque-Sastre, R
Guil, S
Martinez-Cardus, A
Lin, CY
Royo, R
Sanchez-Mut, JV
Martinez, R
Gut, M
Torrents, D
Orozco, M
Gut, I
Young, RA
Esteller, M
AF Heyn, Holger
Vidal, Enrique
Ferreira, Humberto J.
Vizoso, Miguel
Sayols, Sergi
Gomez, Antonio
Moran, Sebastian
Boque-Sastre, Raquel
Guil, Sonia
Martinez-Cardus, Anna
Lin, Charles Y.
Royo, Romina
Sanchez-Mut, Jose V.
Martinez, Ramon
Gut, Marta
Torrents, David
Orozco, Modesto
Gut, Ivo
Young, Richard A.
Esteller, Manel
TI Epigenomic analysis detects aberrant super-enhancer DNA methylation in
human cancer
SO GENOME BIOLOGY
LA English
DT Article
DE Super-enhancer; DNA methylation; Epigenomics; Cancer
ID REGULATORY ELEMENTS; CONTROL REGION; CELL IDENTITY; HUMAN GENOME; GENE;
TRANSCRIPTION; EXPRESSION; FEATURES; INHIBITION; CLONING
AB Background: One of the hallmarks of cancer is the disruption of gene expression patterns. Many molecular lesions contribute to this phenotype, and the importance of aberrant DNA methylation profiles is increasingly recognized. Much of the research effort in this area has examined proximal promoter regions and epigenetic alterations at other loci are not well characterized.
Results: Using whole genome bisulfite sequencing to examine uncharted regions of the epigenome, we identify a type of far reaching DNA methylation alteration in cancer cells of the distal regulatory sequences described as super-enhancers. Human tumors undergo a shift in super-enhancer DNA methylation profiles that is associated with the transcriptional silencing or the overactivation of the corresponding target genes. Intriguingly, we observe locally active fractions of super-enhancers detectable through hypomethylated regions that suggest spatial variability within the large enhancer clusters. Functionally, the DNA methylomes obtained suggest that transcription factors contribute to this local activity of super-enhancers and that trans-acting factors modulate DNA methylation profiles with impact on transforming processes during carcinogenesis.
Conclusions: We develop an extensive catalogue of human DNA methylomes at base resolution to better understand the regulatory functions of DNA methylation beyond those of proximal promoter gene regions. CpG methylation status in normal cells points to locally active regulatory sites at super-enhancers, which are targeted by specific aberrant DNA methylation events in cancer, with putative effects on the expression of downstream genes.
C1 [Heyn, Holger; Vidal, Enrique; Ferreira, Humberto J.; Vizoso, Miguel; Sayols, Sergi; Gomez, Antonio; Moran, Sebastian; Boque-Sastre, Raquel; Guil, Sonia; Martinez-Cardus, Anna; Sanchez-Mut, Jose V.; Esteller, Manel] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08908, Catalonia, Spain.
[Lin, Charles Y.; Young, Richard A.] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
[Lin, Charles Y.] MIT, Computat & Syst Biol Program, Cambridge, MA 02139 USA.
[Lin, Charles Y.] Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
[Royo, Romina; Torrents, David; Orozco, Modesto] Joint Biomed Res Inst Barcelona Supercomp Ctr IRB, Program Computat Biol, Baldiri Reixac 10-12, Barcelona 08028, Catalonia, Spain.
[Martinez, Ramon] Univ Gottingen, Dept Neurosurg, Robert Koch Str 40, D-37075 Gottingen, Germany.
[Gut, Marta] Ctr Nacl Anal Genom, Barcelona, Catalonia, Spain.
[Torrents, David; Esteller, Manel] ICREA, Barcelona 08010, Catalonia, Spain.
[Orozco, Modesto] Inst Res Biomed IRB Barcelona, Baldiri Reixac 10-12, Barcelona 08028, Catalonia, Spain.
[Orozco, Modesto] Univ Barcelona, Dept Biochem & Mol Biol, E-08028 Barcelona, Catalonia, Spain.
[Young, Richard A.] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Esteller, Manel] Univ Barcelona, Dept Physiol Sci 2, Sch Med, E-08036 Barcelona, Catalonia, Spain.
RP Heyn, H; Esteller, M (reprint author), Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08908, Catalonia, Spain.
EM hheyn@idibell.cat; mesteller@idibell.cat
RI Moran, Sebastian /G-5293-2013; Guil, Sonia/M-8036-2015; Torrents,
David/G-5785-2015;
OI Heyn, Holger/0000-0002-3276-1889; Moran, Sebastian /0000-0003-4192-8983;
Guil, Sonia/0000-0002-2257-3331; Torrents, David/0000-0002-6086-9037;
Ferreira, Humberto/0000-0003-0834-2956; Esteller,
Manel/0000-0003-4490-6093; Sayols, Sergi/0000-0002-3877-4170
FU European Research Council (ERC), grant EPINORC [268626]; MICINN Projects
[SAF2011-22803, BFU2011-28549]; Ministerio de Economia y Competitividad
(MINECO); Cellex Foundation; AGAUR Catalan Government Project
[2009SGR1315]; Institute of Health Carlos III (ISCIII), under the
Spanish Cancer Research Network (RTICC) [RD12/0036/0039]; Sandra Ibarra
Foundation, under IV ghd Grants for breast cancer research; Olga Torres
Foundation; European Community [HEALTH-F5-2011-282510 - BLUEPRINT];
Health and Science Departments of the Generalitat de Catalunya; Spanish
Institute of Health Carlos III (ISCIII) [CP14/00229]; European
Development Regional Fund, 'A way to achieve Europe' ERDF
[SAF2014-55000-R]; Institute of Health Carlos III (ISCIII), under the
Integrated Project of Excellence [PIE13/00022]; Institute of Health
Carlos III (ISCIII) [PI11/00321]
FX The research leading to these results received funding from: the
European Research Council (ERC), grant EPINORC, under agreement number
268626; MICINN Projects - SAF2011-22803 and BFU2011-28549; Ministerio de
Economia y Competitividad (MINECO), co-financed by the European
Development Regional Fund, 'A way to achieve Europe' ERDF, under grant
number SAF2014-55000-R; the Cellex Foundation; AGAUR Catalan Government
Project #2009SGR1315; the Institute of Health Carlos III (ISCIII), under
the Spanish Cancer Research Network (RTICC) number RD12/0036/0039, the
Integrated Project of Excellence number PIE13/00022 (ONCOPROFILE) and
the research grant PI11/00321; the Sandra Ibarra Foundation, under IV
ghd Grants for breast cancer research; the Olga Torres Foundation; the
European Community's Seventh Framework Programme (FP7/2007-2013), grant
HEALTH-F5-2011-282510 - BLUEPRINT, and the Health and Science
Departments of the Generalitat de Catalunya. H.H. is a Miguel Servet
(CP14/00229) researcher funded by the Spanish Institute of Health Carlos
III (ISCIII). D.T. and M.E. are ICREA Research Professors.
NR 56
TC 15
Z9 15
U1 21
U2 57
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-6906
EI 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PD JAN 26
PY 2016
VL 17
AR 11
DI 10.1186/s13059-016-0879-2
PG 16
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DC0JU
UT WOS:000368903900002
PM 26813288
ER
PT J
AU Barnhart, C
McClymont, K
Smith, AK
Au-Yeung, A
Lee, SJ
AF Barnhart, Caroline
McClymont, Keelan
Smith, Alex K.
Au-Yeung, Alvin
Lee, Sei J.
TI "Everyone else gets ice cream here more often than I do-It burns me up"
- Perspectives on Diabetes Care from Nursing Home Residents and their
Doctors
SO BMC GERIATRICS
LA English
DT Article
DE Diabetes mellitus; Quality of Life; Geriatrics; Fingerstick
ID OLDER PATIENTS; MELLITUS; PREVALENCE; MANAGEMENT; PEOPLE; ADULTS; GOALS
AB Background: To explore the perspectives of nursing home (NH) residents with diabetes and their doctors regarding the burdens of living with diabetes and diabetes treatments.
Methods: Qualitative study of nursing home residents aged 65 and older with diabetes (n = 14) and nursing home physicians (n = 9) at a Department of Veterans Affairs nursing home (known as the Community Living Center). A semi-structured interview was used to elicit nursing home residents' and physicians' perspectives on the burden of diabetes and diabetes treatments. Transcripts were analyzed using constant comparative methods.
Results: The mean age of the nursing home residents was 74; Most (93 %) were male and 50 % self-identified themselves as white. The mean age of nursing home physicians was 39 and 55 % were geriatricians. Dietary restrictions, loss of independence and fingersticks/insulin were noted to be the most burdensome aspects of diabetes. Nursing home residents with a more positive outlook were generally more engaged in their care, while nursing home residents with a more pessimistic outlook were less engaged, allowing their physicians to assume complete control of their care. While physicians noted the potential negative impact of dietary restrictions, nursing home residents' comments suggest that physicians underestimate the burden of dietary restrictions.
Conclusions: Veterans Affairs nursing home residents were substantially burdened by their diabetes treatments, especially dietary restrictions and fingerstick monitoring. Since there is little evidence that dietary restrictions improve outcomes, fewer dietary restrictions may be appropriate and lead to lower treatment burdens for nursing home residents with diabetes.
C1 [Barnhart, Caroline; McClymont, Keelan; Smith, Alex K.; Au-Yeung, Alvin; Lee, Sei J.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Barnhart, Caroline; McClymont, Keelan; Smith, Alex K.; Au-Yeung, Alvin; Lee, Sei J.] Univ Calif San Francisco, San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,Bldg 1,Room 220 F, San Francisco, CA 94121 USA.
RP Lee, SJ (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA.; Lee, SJ (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,Bldg 1,Room 220 F, San Francisco, CA 94121 USA.
EM sei.lee@ucsf.edu
FU National Institute on Aging at the National Institutes of Health;
American Federation for Aging Research [K23AG040779]; UCSF Claude D.
Pepper Older Americans Independence Center [P30AG044281]
FX This work was supported by the National Institute on Aging at the
National Institutes of Health and the American Federation for Aging
Research through the Beeson Career Development [K23AG040779]. This work
was also supported by the UCSF Claude D. Pepper Older Americans
Independence Center [P30AG044281].
NR 24
TC 0
Z9 0
U1 3
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2318
J9 BMC GERIATR
JI BMC Geriatr.
PD JAN 26
PY 2016
VL 16
AR 28
DI 10.1186/s12877-016-0199-0
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA DB5SG
UT WOS:000368573300001
PM 26813788
ER
PT J
AU Siu, AL
Bibbins-Domingo, K
Grossman, DC
Baumann, LC
Davidson, KW
Ebell, M
Garcia, FAR
Gillman, M
Herzstein, J
Kemper, AR
Krist, AH
Kurth, AE
Owens, DK
Phillips, WR
Phipps, MG
Pignone, MP
AF Siu, Albert L.
Bibbins-Domingo, Kirsten
Grossman, David C.
Baumann, Linda Ciofu
Davidson, Karina W.
Ebell, Mark
Garcia, Francisco A. R.
Gillman, Matthew
Herzstein, Jessica
Kemper, Alex R.
Krist, Alex H.
Kurth, Ann E.
Owens, Douglas K.
Phillips, William R.
Phipps, Maureen G.
Pignone, Michael P.
CA USPSTF
TI Screening for Depression in Adults US Preventive Services Task Force
Recommendation Statement
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; PRIMARY-CARE;
POSTPARTUM DEPRESSION; PERINATAL DEPRESSION; POSTNATAL DEPRESSION;
QUALITY IMPROVEMENT; WOMEN; PHARMACOTHERAPY; SYMPTOMATOLOGY
AB DESCRIPTION Update of the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for depression in adults.
METHODS The USPSTF reviewed the evidence on the benefits and harms of screening for depression in adult populations, including older adults and pregnant and postpartum women; the accuracy of depression screening instruments; and the benefits and harms of depression treatment in these populations.
POPULATION This recommendation applies to adults 18 years and older.
RECOMMENDATION The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. (B recommendation)
C1 [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA.
[Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA.
[Baumann, Linda Ciofu] Univ Wisconsin, Madison, WI 53706 USA.
[Davidson, Karina W.] Columbia Univ, New York, NY USA.
[Ebell, Mark] Univ Georgia, Athens, GA 30602 USA.
[Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA.
[Gillman, Matthew] Harvard Univ, Sch Med, Boston, MA USA.
[Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Kemper, Alex R.] Duke Univ, Durham, NC USA.
[Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA 23284 USA.
[Kurth, Ann E.] NYU, New York, NY USA.
[Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA.
[Phillips, William R.] Univ Washington, Seattle, WA 98195 USA.
[Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA.
[Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA.
RP Siu, AL (reprint author), Mt Sinai Sch Med, New York, NY USA.; Siu, AL (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
EM albert.siu@mssm.edu
OI Phillips, William/0000-0003-2802-4349
FU USPSTF
FX The USPSTF is an independent, voluntary body. The US Congress mandates
that the Agency for Healthcare Research and Quality (AHRQ) support the
operations of the USPSTF.
NR 34
TC 80
Z9 81
U1 5
U2 14
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JAN 26
PY 2016
VL 315
IS 4
BP 380
EP 387
DI 10.1001/jama.2015.18392
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA DB5YI
UT WOS:000368589500016
PM 26813211
ER
PT J
AU Ashburner, JM
Go, AS
Chang, YC
Fang, MC
Fredman, L
Applebaum, KM
Singer, DE
AF Ashburner, Jeffrey M.
Go, Alan S.
Chang, Yuchiao
Fang, Margaret C.
Fredman, Lisa
Applebaum, Katie M.
Singer, Daniel E.
TI Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF
Patients ATRIA Study
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE atrial fibrillation; diabetes mellitus; stroke
ID STRATIFICATION SCHEMES; ATHEROSCLEROSIS RISK; FIBRILLATION ATRIA;
PREDICTING STROKE; ANTICOAGULATION; PREVENTION; TRIALS; ASSOCIATION;
COMMUNITIES; POPULATION
AB BACKGROUND Diagnosed diabetes mellitus (DM) is a consistently documented risk factor for ischemic stroke in patients with atrial fibrillation (AF).
OBJECTIVES The purpose of this study was to assess the association between duration of diabetes and elevated hemoglobin A1c (HbA1c) with risk of stroke among diabetic patients with AF.
METHODS We assessed this association in the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) California community-based cohort of AF patients (study years 1996 to 2003) where all events were clinician adjudicated. We used Cox proportional hazards regression to estimate the rate of ischemic stroke in diabetic patients according to time-varying measures of estimated duration of diabetes (>= 3 years compared with <3 years) and HbA1c values (>= 9.0% and 7.0% to 8.9% compared with <7.0%), focusing on periods where patients were not anticoagulated.
RESULTS There were 2,101 diabetic patients included in the duration analysis: 40% with duration <3 years and 60% with duration >= 3 years at baseline. Among 1,933 diabetic patients included in the HbA1c analysis, 46% had HbA1c <7.0%, 36% between 7.0% and 8.9%, and 19% >= 9.0% at baseline. Duration of diabetes >= 3 years was associated with an increased rate of ischemic stroke compared with duration <3 years (adjusted hazard ratio [HR]: 1.74, 95% confidence interval [CI]: 1.10 to 2.76). The increased stroke rate was observed in older (age >= 75 years) and younger (age <75 years) individuals. Neither poor glycemic control (HbA1c >= 9.0%, adjusted HR: 1.04, 95% CI: 0.57 to 1.92) nor moderately increased HbA1c (7.0% to 8.9%, adjusted HR: 1.21, 95% CI: 0.77 to 1.91) were significantly associated with an increased rate of ischemic stroke compared with patients who had HbA1c <7.0%.
CONCLUSIONS Duration of diabetes is a more important predictor of ischemic stroke than glycemic control in patients who have diabetes and AF. (C) 2016 by the American College of Cardiology Foundation.
C1 [Ashburner, Jeffrey M.; Chang, Yuchiao; Singer, Daniel E.] Massachusetts Gen Hosp, Div Gen Internal Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
[Ashburner, Jeffrey M.; Chang, Yuchiao; Singer, Daniel E.] Harvard Univ, Sch Med, Boston, MA USA.
[Ashburner, Jeffrey M.; Fredman, Lisa] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Epidemiol Biostat & Med, San Francisco, CA 94143 USA.
[Go, Alan S.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA.
[Fang, Margaret C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Applebaum, Katie M.] George Washington Univ, Sch Publ Hlth & Hlth Serv, Dept Environm & Occupat Hlth, Washington, DC USA.
[Applebaum, Katie M.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
RP Ashburner, JM (reprint author), Massachusetts Gen Hosp, Div Gen Internal Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM jashburner@mgh.harvard.edu
FU National Institute on Aging [R01 AG15478, K23 AG028978]; National Heart,
Lung, and Blood Institute [U19 HL91179, RC2HL101589]; Eliot B. and Edith
C. Shoolman fund of the Massachusetts General Hospital; iRhythm; CSL
Behring
FX This study was supported by the National Institute on Aging (R01 AG15478
and K23 AG028978), the National Heart, Lung, and Blood Institute (U19
HL91179 and RC2HL101589), and the Eliot B. and Edith C. Shoolman fund of
the Massachusetts General Hospital. The funding sources had no role in
study design, data collection, data analysis, data interpretation, or
preparation of the manuscript. Dr. Go has received a research grant from
iRhythm and CSL Behring. Dr. Singer serves as a consultant/advisory
board member for Boehringer Ingelheim, Bristol-Myers Squibb,
Daiichi-Sankyo, CVS Heath, Johnson & Johnson, Medtronic, Pfizer, and St.
Jude Medical on matters related to preventing stroke in atrial
fibrillation; and has research contracts with Medtronic, Inc., related
to atrial fibrillation and risk of stroke, with Johnson & Johnson
related to stroke prevention in atrial fibrillation, and with
Bristol-Myers Squibb related to atrial fibrillation and risk of stroke.
All other authors have reported that they have no relationships relevant
to the contents of this paper.
NR 29
TC 9
Z9 9
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD JAN 26
PY 2016
VL 67
IS 3
BP 239
EP 247
DI 10.1016/j.jacc.2015.10.080
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DB5NM
UT WOS:000368560900001
PM 26796386
ER
PT J
AU Dal-Bianco, JP
Aikawa, E
Bischoff, J
Guerrero, JL
Hjortnaes, J
Beaudoin, J
Szymanski, C
Bartko, PE
Seybolt, MM
Handschumacher, MD
Sullivan, S
Garcia, ML
Mauskapf, A
Titus, JS
Wylie-Sears, J
Irvin, WS
Chaput, M
Messas, E
Hagege, AA
Carpentier, A
Levine, RA
AF Dal-Bianco, Jacob P.
Aikawa, Elena
Bischoff, Joyce
Guerrero, J. Luis
Hjortnaes, Jesper
Beaudoin, Jonathan
Szymanski, Catherine
Bartko, Philipp E.
Seybolt, Margo M.
Handschumacher, Mark D.
Sullivan, Suzanne
Garcia, Michael L.
Mauskapf, Adam
Titus, James S.
Wylie-Sears, Jill
Irvin, Whitney S.
Chaput, Miguel
Messas, Emmanuel
Hagege, Albert A.
Carpentier, Alain
Levine, Robert A.
CA Leducq Transatlantic Mitral
TI Myocardial Infarction Alters Adaptation of the Tethered Mitral Valve
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE echocardiography; endothelial-to-mesenchymal transition; inflammation;
mitral regurgitation; papillary muscle
ID GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; INTERSTITIAL-CELLS;
HEART-FAILURE; TGF-BETA; 3-DIMENSIONAL ECHOCARDIOGRAPHY; COMPENSATORY
MECHANISM; LEAFLET ADAPTATION; COLLAGEN-SYNTHESIS; CARDIAC FIBROSIS
AB BACKGROUND In patients with myocardial infarction (MI), leaflet tethering by displaced papillary muscles induces mitral regurgitation (MR), which doubles mortality. Mitral valves (MVs) are larger in such patients but fibrosis sets in counterproductively. The investigators previously reported that experimental tethering alone increases mitral valve area in association with endothelial-to-mesenchymal transition.
OBJECTIVES The aim of this study was to explore the clinically relevant situation of tethering and MI, testing the hypothesis that ischemic milieu modifies mitral valve adaptation.
METHODS Twenty-three adult sheep were examined. Under cardiopulmonary bypass, the papillary muscle tips in 6 sheep were retracted apically to replicate tethering, short of producing MR (tethered alone). Papillary muscle retraction was combined with apical MI created by coronary ligation in another 6 sheep (tethered plus MI), and left ventricular remodeling was limited by external constraint in 5 additional sheep (left ventricular constraint). Six sham-operated sheep were control subjects. Diastolic mitral valve surface area was quantified by 3-dimensional echocardiography at baseline and after 58 + 5 days, followed by histopathology and flow cytometry of excised leaflets.
RESULTS Tethered plus MI leaflets were markedly thicker than tethered-alone valves and sham control subjects. Leaflet area also increased significantly. Endothelial-to-mesenchymal transition, detected as alpha-smooth muscle actin-positive endothelial cells, significantly exceeded that in tethered-alone and control valves. Transforming growth factor-beta, matrix metalloproteinase expression, and cellular proliferation were markedly increased. Uniquely, tethering plus MI showed endothelial activation with vascular adhesion molecule expression, neovascularization, and cells positive for CD45, considered a hematopoietic cell marker. Tethered plus MI findings were comparable with external ventricular constraint.
CONCLUSIONS MI altered leaflet adaptation, including a profibrotic increase in valvular cell activation, CD45-positive cells, and matrix turnover. Understanding cellular and molecular mechanisms underlying leaflet adaptation and fibrosis could yield new therapeutic opportunities for reducing ischemic MR. (C) 2016 by the American College of Cardiology Foundation.
C1 [Dal-Bianco, Jacob P.; Beaudoin, Jonathan; Szymanski, Catherine; Bartko, Philipp E.; Handschumacher, Mark D.; Chaput, Miguel; Levine, Robert A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Ultrasound Lab, Boston, MA USA.
[Guerrero, J. Luis; Seybolt, Margo M.; Sullivan, Suzanne; Garcia, Michael L.; Mauskapf, Adam; Titus, James S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Surg Cardiovasc Lab, Boston, MA USA.
[Dal-Bianco, Jacob P.; Aikawa, Elena; Bischoff, Joyce; Beaudoin, Jonathan; Szymanski, Catherine; Chaput, Miguel; Messas, Emmanuel; Hagege, Albert A.; Carpentier, Alain; Levine, Robert A.] Fdn Leducq, Leducq Transatlant Mitral Network, Paris, France.
[Aikawa, Elena; Hjortnaes, Jesper; Irvin, Whitney S.] Brigham & Womens Hosp, Dept Med, Ctr Excellence Vasc Biol, Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.
[Aikawa, Elena; Bischoff, Joyce; Hjortnaes, Jesper; Wylie-Sears, Jill; Irvin, Whitney S.] Harvard Univ, Sch Med, Boston, MA USA.
[Bischoff, Joyce; Wylie-Sears, Jill] Boston Childrens Hosp, Vasc Biol Program, Boston, MA USA.
[Bischoff, Joyce] Boston Childrens Hosp, Dept Surg, Boston, MA USA.
[Messas, Emmanuel; Hagege, Albert A.; Carpentier, Alain; Levine, Robert A.] Univ Paris 05, Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, INSERM,U633,Dept Cardiol, Paris, France.
[Messas, Emmanuel; Hagege, Albert A.; Carpentier, Alain; Levine, Robert A.] Univ Paris 05, Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, INSERM,U633,Dept Cardiovasc Surg, Paris, France.
RP Levine, RA (reprint author), Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St,Yawkey 5068, Boston, MA 02114 USA.
EM rlevine@partners.org
OI Bischoff, Joyce/0000-0002-6367-1974
FU Fondation Leducq (Paris, France) [07CVD04]; National Heart, Lung, and
Blood Institute of the National Institutes of Health [R01HL109506];
National Institutes of Health [K24 HL67434]; American Society of
Echocardiography Career Development Award; Erwin-Schrodinger Stipend
(FWF Austrian Science Fund); Harvard University, affiliated academic
health care centers; Harvard Catalyst, The Harvard Clinical and
Translational Science Center (National Center for Research Resources);
Harvard Catalyst, The Harvard Clinical and Translational Science Center
(National Center for Advancing Translational Sciences, National
Institutes of Health award) [UL1 TR001102]
FX This work was supported in part by grant 07CVD04 from Fondation Leducq
(Paris, France) for the Transatlantic MITRAL Network of Excellence and
by the National Heart, Lung, and Blood Institute of the National
Institutes of Health under award number R01HL109506 to Drs. Levine,
Aikawa, and Bischoff. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Institutes of Health. Additional support was from grant K24
HL67434 from the National Institutes of Health, an American Society of
Echocardiography Career Development Award, and an Erwin-Schrodinger
Stipend (FWF Austrian Science Fund). The biostatistical work was
conducted with support from Harvard Catalyst, The Harvard Clinical and
Translational Science Center (National Center for Research Resources and
the National Center for Advancing Translational Sciences, National
Institutes of Health award UL1 TR001102), and financial contributions
from Harvard University and its affiliated academic health care centers.
The content is solely the responsibility of the authors and does not
necessarily represent the official views of Harvard Catalyst, Harvard
University, and its affiliated academic health care centers or the
National Institutes of Health. The authors have reported that they have
no relationships relevant to the contents of this paper to disclose.
Drs. Dal-Bianco, Aikawa, and Bischoff contributed equally to this work.
NR 49
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD JAN 26
PY 2016
VL 67
IS 3
BP 275
EP 287
DI 10.1016/j.jacc.2015.10.092
PG 13
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DB5NM
UT WOS:000368560900007
PM 26796392
ER
PT J
AU Olabisi, OA
Zhang, JY
VerPlank, L
Zahler, N
DiBartolo, S
Heneghan, JF
Schlondorff, JS
Suh, JH
Yan, P
Alper, SL
Friedman, DJ
Pollak, MR
AF Olabisi, Opeyemi A.
Zhang, Jia-Yue
VerPlank, Lynn
Zahler, Nathan
DiBartolo, Salvatore, III
Heneghan, John F.
Schloendorff, Johannes S.
Suh, Jung Hee
Yan, Paul
Alper, Seth L.
Friedman, David J.
Pollak, Martin R.
TI APOL1 kidney disease risk variants cause cytotoxicity by depleting
cellular potassium and inducing stress-activated protein kinases
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE apolipoprotein L1; kidney; African-American; genetics; protein kinase
ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; HIV-ASSOCIATED NEPHROPATHY;
TRYPANOSOME LYTIC FACTOR; LIPID-BINDING PROTEIN; APOLIPOPROTEIN L1;
NEPHROTIC SYNDROME; RENAL-DISEASE; HUMAN SERUM; P38; PODOCYTE
AB Two specific genetic variants of the apolipoprotein L1 (APOL1) gene are responsible for the high rate of kidney disease in people of recent African ancestry. Expression in cultured cells of these APOL1 risk variants, commonly referred to as G1 and G2, results in significant cytotoxicity. The underlying mechanism of this cytotoxicity is poorly understood. We hypothesized that this cytotoxicity is mediated by APOL1 risk variant-induced dysregulation of intracellular signaling relevant for cell survival. To test this hypothesis, we conditionally expressed WT human APOL1 (G0), the APOL1 G1 variant, or the APOL1 G2 variant in human embryonic kidney cells (T-REx-293) using a tetracycline-mediated (Tet-On) system. We found that expression of either G1 or G2 APOL1 variants increased apparent cell swelling and cell death compared with G0-expressing cells. These manifestations of cytotoxicity were preceded by G1 or G2 APOL1-induced net efflux of intracellular potassium as measured by X-ray fluorescence, resulting in the activation of stress-activated protein kinases (SAPKs), p38 MAPK, and JNK. Prevention of net K+ efflux inhibited activation of these SAPKs by APOL1 G1 or G2. Furthermore, inhibition of SAPK signaling and inhibition of net K+ efflux abrogated cytotoxicity associated with expression of APOL1 risk variants. These findings in cell culture raise the possibility that nephrotoxicity of APOL1 risk variants may be mediated by APOL1 risk variant-induced net loss of intracellular K+ and subsequent induction of stress-activated protein kinase pathways.
C1 [Olabisi, Opeyemi A.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
[Olabisi, Opeyemi A.; Zhang, Jia-Yue; DiBartolo, Salvatore, III; Heneghan, John F.; Schloendorff, Johannes S.; Suh, Jung Hee; Yan, Paul; Alper, Seth L.; Friedman, David J.; Pollak, Martin R.] Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA.
[Olabisi, Opeyemi A.; Zhang, Jia-Yue; Heneghan, John F.; Schloendorff, Johannes S.; Suh, Jung Hee; Yan, Paul; Alper, Seth L.; Friedman, David J.; Pollak, Martin R.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[VerPlank, Lynn; Zahler, Nathan] Icagen Inc, Durham, NC 27703 USA.
[Heneghan, John F.; Alper, Seth L.; Friedman, David J.] Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA 02215 USA.
RP Pollak, MR (reprint author), Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA.
EM mpollak@bidmc.harvard.edu
FU NIH [MD007898, MD007092, T32-DK007199, T32-DK07540]; NephCure
Foundation; Ellison Foundation
FX We thank Anna Besschetnova and Chi-Wing Chow for help and advice. This
work was supported by NIH Grants MD007898 and MD007092 (to M.R.P,
D.J.F., and S.L.A.), as well as by grants from the NephCure and Ellison
Foundations (to M.R.P.). O.A.O. and J.H.S. were supported in part by NIH
Grant T32-DK007199. O.A.O. was also supported by NIH Grant T32-DK07540.
NR 59
TC 14
Z9 15
U1 2
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 26
PY 2016
VL 113
IS 4
BP 830
EP 837
DI 10.1073/pnas.1522913113
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DB6IJ
UT WOS:000368617900024
PM 26699492
ER
PT J
AU Krienen, FM
Yeo, BTT
Ge, T
Buckner, RL
Sherwood, CC
AF Krienen, Fenna M.
Yeo, B. T. Thomas
Ge, Tian
Buckner, Randy L.
Sherwood, Chet C.
TI Transcriptional profiles of supragranular-enriched genes associate with
corticocortical network architecture in the human brain
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE corticocortical connectivity; human transcriptome; association cortex;
supragranular; brain evolution
ID INTRINSIC FUNCTIONAL CONNECTIVITY; ADULT HUMAN BRAIN; GAMMA-SYNUCLEIN;
PYRAMIDAL CELL; MACAQUE MONKEY; CEREBRAL-CORTEX; RHESUS-MONKEY;
EVOLUTION; EXPRESSION; NEOCORTEX
AB The human brain is patterned with disproportionately large, distributed cerebral networks that connect multiple association zones in the frontal, temporal, and parietal lobes. The expansion of the cortical surface, along with the emergence of long-range connectivity networks, may be reflected in changes to the underlying molecular architecture. Using the Allen Institute's human brain transcriptional atlas, we demonstrate that genes particularly enriched in supragranular layers of the human cerebral cortex relative to mouse distinguish major cortical classes. The topography of transcriptional expression reflects large-scale brain network organization consistent with estimates from functional connectivity MRI and anatomical tracing in nonhuman primates. Microarray expression data for genes preferentially expressed in human upper layers (II/III), but enriched only in lower layers (V/VI) of mouse, were cross-correlated to identify molecular profiles across the cerebral cortex of postmortem human brains (n = 6). Unimodal sensory and motor zones have similar molecular profiles, despite being distributed across the cortical mantle. Sensory/motor profiles were anti-correlated with paralimbic and certain distributed association network profiles. Tests of alternative gene sets did not consistently distinguish sensory and motor regions from paralimbic and association regions: (i) genes enriched in supragranular layers in both humans and mice, (ii) genes cortically enriched in humans relative to nonhuman primates, (iii) genes related to connectivity in rodents, (iv) genes associated with human and mouse connectivity, and (v) 1,454 gene sets curated from known gene ontologies. Molecular innovations of upper cortical layers may be an important component in the evolution of long-range corticocortical projections.
C1 [Krienen, Fenna M.; Sherwood, Chet C.] George Washington Univ, Ctr Adv Study Human Paleobiol, Dept Anthropol, Washington, DC 20052 USA.
[Krienen, Fenna M.; Sherwood, Chet C.] George Washington Univ, Inst Neurosci, Washington, DC 20052 USA.
[Yeo, B. T. Thomas] Natl Univ Singapore, Singapore Inst Neurotechnol, Clin Imaging Res Ctr, Dept Elect & Comp Engn, Singapore 117583, Singapore.
[Yeo, B. T. Thomas] Natl Univ Singapore, Memory Networks Program, Singapore 117583, Singapore.
[Yeo, B. T. Thomas; Ge, Tian; Buckner, Randy L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Ge, Tian] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Boston, MA 02114 USA.
[Buckner, Randy L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Buckner, Randy L.] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.
[Buckner, Randy L.] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA.
[Krienen, Fenna M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
RP Krienen, FM (reprint author), George Washington Univ, Ctr Adv Study Human Paleobiol, Dept Anthropol, Washington, DC 20052 USA.; Krienen, FM (reprint author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
EM fenna_krienen@hms.harvard.edu
OI Yeo, B.T. Thomas/0000-0002-0119-3276
FU Center for Brain Science Neuroinformatics Research Group; Athinoula A.
Martinos Center for Biomedical Imaging; Center for Human Genetics
Research; George Washington University Centers and Institute's
Facilitating Fund Intramural Award; Singapore MOE Tier 2
[MOE2014-T2-2-016]; National University of Singapore Strategic Research
Grant [DPRT/944/09/14]; National University of Singapore School of
Medicine [R185000271720]; Singapore National Medical Research Council
[CBRG14nov007, NMRC/CG/013/2013]; National University of Singapore Young
Investigator Award; James S. McDonnell Foundation [220020293];
Massachusetts General Hospital Executive Committee on Research Tosteson
Postdoctoral Fellowship award; Athinoula A. Martinos Center for
Biomedical Imaging at the Massachusetts General Hospital [1S10RR023401,
1S10RR019307, 1S10RR023043]; National University of Singapore Tier 1
FX We thank Steven McCarroll and Arpiar Saunders for helpful discussions.
Data were provided (in part) by the Brain Genomics Superstruct Project
of Harvard University and Massachusetts General Hospital, (Principal
Investigators: R.L.B., Joshua Roffman, and Jordan Smoller), with support
from the Center for Brain Science Neuroinformatics Research Group, the
Athinoula A. Martinos Center for Biomedical Imaging, and the Center for
Human Genetics Research. This work was supported by a George Washington
University Centers and Institute's Facilitating Fund Intramural Award to
the Mind-Brain Institute; National University of Singapore Tier 1,
Singapore MOE Tier 2 (MOE2014-T2-2-016); National University of
Singapore Strategic Research Grant DPRT/944/09/14; National University
of Singapore School of Medicine Grant R185000271720; Singapore National
Medical Research Council CBRG14nov007, NMRC/CG/013/2013, National
University of Singapore Young Investigator Award; the James S. McDonnell
Foundation (220020293); and a Massachusetts General Hospital Executive
Committee on Research Tosteson Postdoctoral Fellowship award (to T.G.).
This research also used resources provided by the Center for Functional
Neuroimaging Technologies (P41EB015896), and instruments supported by
Grants 1S10RR023401, 1S10RR019307, and 1S10RR023043 from the Athinoula
A. Martinos Center for Biomedical Imaging at the Massachusetts General
Hospital.
NR 77
TC 4
Z9 4
U1 4
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 26
PY 2016
VL 113
IS 4
BP E469
EP E478
DI 10.1073/pnas.1510903113
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DB6IJ
UT WOS:000368617900011
PM 26739559
ER
PT J
AU Glabska, HT
Norheim, E
Devor, A
Dale, AM
Einevoll, GT
Wojcik, DK
AF Glabska, Helena T.
Norheim, Eivind
Devor, Anna
Dale, Anders M.
Einevoll, Gaute T.
Wojcik, Daniel K.
TI Generalized Laminar Population Analysis (gLPA) for Interpretation of
Multielectrode Data from Cortex
SO FRONTIERS IN NEUROINFORMATICS
LA English
DT Article
DE LFP analysis; local field potential (LFP); model-based analysis; signal
decomposition; computational neuroscience; multi-unit activity; MUA;
thalamocortical
ID CURRENT-SOURCE-DENSITY; INDEPENDENT COMPONENT ANALYSIS; FIELD
POTENTIALS; FIRING RATES; RECORDINGS; MODEL; DYNAMICS; SPIKES; EEG
AB Laminar population analysis (LPA) is a method for analysis of electrical data recorded by linear multielectrodes passing through all lamina of cortex. Like principal components analysis (PCA) and independent components analysis (ICA), LPA offers a way to decompose the data into contributions from separate cortical populations. However, instead of using purely mathematical assumptions in the decomposition, LPA is based on physiological constraints, i.e., that the observed LFP (low-frequency part of signal) is driven by action-potential firing as observed in the MUA (multi-unit activity; high-frequency part of the signal). In the presently developed generalized laminar population analysis (gLPA) the set of basis functions accounting for the LFP data is extended compared to the original LPA, thus allowing for a better fit of the model to experimental data. This enhances the risk for overfitting, however, and we therefore tested various versions of gLPA on virtual LFP data in which we knew the ground truth. These synthetic data were generated by biophysical forward-modeling of electrical signals from network activity in the comprehensive, and well-known, thalamocortical network model developed by Traub and coworkers. The results for the Traub model imply that while the laminar components extracted by the original LPA method overall are in fair agreement with the ground-truth laminar components, the results may be improved by use of gLPA method with two (gLPA-2) or even three (gLPA-3) postsynaptic LFP kernels per laminar population.
C1 [Glabska, Helena T.; Wojcik, Daniel K.] Polish Acad Sci, M Nencki Inst Expt Biol, Dept Neurophysiol, Lab Neuroinformat, Warsaw, Poland.
[Norheim, Eivind; Einevoll, Gaute T.] Norwegian Univ Life Sci, Dept Math Sci & Technol, As, Norway.
[Devor, Anna; Dale, Anders M.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
[Devor, Anna; Dale, Anders M.] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA.
[Devor, Anna] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Einevoll, Gaute T.] Univ Oslo, Dept Phys, Oslo, Norway.
RP Wojcik, DK (reprint author), Polish Acad Sci, M Nencki Inst Expt Biol, Dept Neurophysiol, Lab Neuroinformat, Warsaw, Poland.; Einevoll, GT (reprint author), Norwegian Univ Life Sci, Dept Math Sci & Technol, As, Norway.; Einevoll, GT (reprint author), Univ Oslo, Dept Phys, Oslo, Norway.
EM gaute.einevoll@nmbu.no; d.wojcik@nencki.gov.pl
RI Wojcik, Daniel/C-6334-2008
OI Wojcik, Daniel/0000-0003-0812-9872
FU EC [269921]; Polish Ministry for Science and Higher Education
[5428/B/P01/2010/39, 2948/7.PR/2013/2]; Polish Ministry of Regional
Development [POIG.02.03.00-00-003/09, POIG.02.03.00-00-018/08]
FX This work is supported by the EC-EP7 under grant agreement no. 269921
("BrainScaleS"), and the Polish Ministry for Science and Higher
Education (grants 5428/B/P01/2010/39 and 2948/7.PR/2013/2), the Polish
Ministry of Regional Development (grant POIG.02.03.00-00-003/09,
POIG.02.03.00-00-018/08).
NR 39
TC 1
Z9 1
U1 2
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1662-5196
J9 FRONT NEUROINFORM
JI Front. Neuroinformatics
PD JAN 25
PY 2016
VL 10
AR 1
DI 10.3389/fninf.2016.00001
PG 15
WC Mathematical & Computational Biology; Neurosciences
SC Mathematical & Computational Biology; Neurosciences & Neurology
GA DE4QA
UT WOS:000370613400001
PM 26834620
ER
PT J
AU Rasheed, H
McKinney, C
Stamp, LK
Dalbeth, N
Topless, RK
Day, R
Kannangara, D
Williams, K
Smith, M
Janssen, M
Jansen, TL
Joosten, LA
Radstake, TR
Riches, PL
Tausche, AK
Liote, F
Lu, L
Stahl, EA
Choi, HK
So, A
Merriman, TR
AF Rasheed, Humaira
McKinney, Cushla
Stamp, Lisa K.
Dalbeth, Nicola
Topless, Ruth K.
Day, Richard
Kannangara, Diluk
Williams, Kenneth
Smith, Malcolm
Janssen, Matthijs
Jansen, Tim L.
Joosten, Leo A.
Radstake, Timothy R.
Riches, Philip L.
Tausche, Anne-Kathrin
Liote, Frederic
Lu, Leo
Stahl, Eli A.
Choi, Hyon K.
So, Alexander
Merriman, Tony R.
TI The Toll-Like Receptor 4 (TLR4) Variant rs2149356 and Risk of Gout in
European and Polynesian Sample Sets
SO PLOS ONE
LA English
DT Article
ID ASSOCIATION; DISEASE; SUSCEPTIBILITY; POLYMORPHISMS; ARTHRITIS; GENE
AB Deposition of crystallized monosodium urate (MSU) in joints as a result of hyperuricemia is a central risk factor for gout. However other factors must exist that control the progression from hyperuricaemia to gout. A previous genetic association study has implicated the toll-like receptor 4 (TLR4) which activates the NLRP3 inflammasome via the nuclear factor-kappa B signaling pathway upon stimulation by MSU crystals. The T-allele of single nucleotide polymorphism rs2149356 in TLR4 is a risk factor associated with gout in a Chinese study. Our aim was to replicate this observation in participants of European and New Zealand Polynesian (Maori and Pacific) ancestry. A total of 2250 clinically-ascertained prevalent gout cases and 13925 controls were used. Non-clinically-ascertained incident gout cases and controls from the Health Professional Follow-up (HPFS) and Nurses Health Studies (NHS) were also used. Genotypes were derived from genome-wide genotype data or directly obtained using Taqman. Logistic regression analysis was done including age, sex, diuretic exposure and ancestry as covariates as appropriate. The T-allele increased the risk of gout in the clinically-ascertained European samples (OR = 1.12, P = 0.012) and decreased the risk of gout in Polynesians (OR = 0.80, P = 0.011). There was no evidence for association in the HPFS or NHS sample sets. In conclusion TLR4 SNP rs2143956 associates with gout risk in prevalent clinically-ascertained gout in Europeans, in a direction consistent with previously published results in Han Chinese. However, with an opposite direction of association in Polynesians and no evidence for association in a non-clinically-ascertained incident gout cohort this variant should be analysed in other international gout genetic data sets to determine if there is genuine evidence for association.
C1 [Rasheed, Humaira; McKinney, Cushla; Topless, Ruth K.; Merriman, Tony R.] Univ Otago, Dept Biochem, Dunedin, New Zealand.
[Rasheed, Humaira] Univ Engn & Technol, Lahore, Pakistan.
[Stamp, Lisa K.] Univ Otago, Dept Med, Christchurch, New Zealand.
[Dalbeth, Nicola] Univ Auckland, Dept Med, Auckland 1, New Zealand.
[Day, Richard; Kannangara, Diluk; Williams, Kenneth] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia.
[Day, Richard; Kannangara, Diluk; Williams, Kenneth] St Vincents Hosp, Dept Clin Pharmacol & Toxicol, Sydney, NSW 2010, Australia.
[Smith, Malcolm] Flinders Med Ctr, Dept Med, Adelaide, SA, Australia.
[Smith, Malcolm] Repatriat Gen Hosp, Adelaide, SA, Australia.
[Janssen, Matthijs] Rijnstate Hosp, Dept Rheumatol, Arnhem, Netherlands.
[Jansen, Tim L.] VieCuri Med Ctr, Dept IQ HealthCare, Venlo, Netherlands.
[Joosten, Leo A.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6525 ED Nijmegen, Netherlands.
[Joosten, Leo A.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, NL-6525 ED Nijmegen, Netherlands.
[Radstake, Timothy R.] Univ Med Ctr Utrecht, Dept Immunol, Lab Translat Immunol, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands.
[Riches, Philip L.] Univ Edinburgh, Inst Genet & Mol Med, Rheumat Dis Unit, Edinburgh, Midlothian, Scotland.
[Tausche, Anne-Kathrin] Univ Clin Carl Gustav Carus, Dept Rheumatol, Dresden, Germany.
[Liote, Frederic] Hosp Lariboisiere, INSERM, UMR S 1132, Paris, France.
[Liote, Frederic] Univ Paris Diderot, Sorbonne Paris Cite, UFR Med, Paris, France.
[Lu, Leo; Choi, Hyon K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA USA.
[Stahl, Eli A.] Icahn Sch Med Mt Sinai, Inst Genom & Multiscale Biol, New York, NY 10029 USA.
[So, Alexander] Univ Lausanne, Lab Rheumatol, Serv Rheumatol, DAL,CHUV, Lausanne, Switzerland.
RP Merriman, TR (reprint author), Univ Otago, Dept Biochem, Dunedin, New Zealand.
OI Kannangara, Diluk/0000-0003-1463-7320; Merriman,
Tony/0000-0003-0844-8726
FU Health Research Council of New Zealand [11/1075, 14/527]; Arthritis New
Zealand; New Zealand Lottery Health; University of Otago and Arthritis
Australia; National Human Genome Research Institute [U01HG004402];
National Institutes of Health [HHSN268200625226C, UL1RR025005]; NIH
Roadmap for Medical Research; National Heart, Lung, and Blood Institute
(NHLBI) in collaboration with Boston University; [N01-HC-55015];
[N01-HC-55016]; [N01-HC-55018]; [N01-HC-55019]; [N01-HC55020];
[N01-HC-55021]; [N01-HC-55022]; [R01HL087641]; [R01HL59367];
[R01HL086694]
FX This work was supported by the Health Research Council of New Zealand
(11/1075, 14/527), Arthritis New Zealand, New Zealand Lottery Health,
the University of Otago and Arthritis Australia. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript. The Atherosclerosis Risk in Communities
study is supported by contracts N01-HC-55015, N01-HC-55016,
N01-HC-55018, N01-HC-55019, N01-HC55020, N01-HC-55021, N01-HC-55022,
R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research
Institute contract U01HG004402; and National Institutes of Health
contract HHSN268200625226C. Infrastructure was partly supported by Grant
Number UL1RR025005, a component of the National Institutes of Health and
NIH Roadmap for Medical Research. The Framingham Heart Study and the
Framingham SHARe project are conducted and supported by the National
Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston
University.
NR 24
TC 1
Z9 1
U1 3
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 25
PY 2016
VL 11
IS 1
AR e0147939
DI 10.1371/journal.pone.0147939
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DC9FZ
UT WOS:000369527800247
PM 26808548
ER
PT J
AU Cadoni, S
Liggi, M
Falt, P
Sanna, S
Argiolas, M
Fanari, V
Gallittu, P
Mura, D
Porcedda, ML
Smajstrla, V
Erriu, M
Leung, FW
AF Cadoni, Sergio
Liggi, Mauro
Falt, Premysl
Sanna, Stefano
Argiolas, Mariangela
Fanari, Viviana
Gallittu, Paolo
Mura, Donatella
Porcedda, Maria L.
Smajstrla, Vit
Erriu, Matteo
Leung, Felix W.
TI Evidence to suggest adoption of water exchange deserves broader
consideration: Its pain alleviating impact occurs in 90% of
investigators
SO WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
DE Colonoscopy; Painless colonoscopy; Water immersion; Water exchange;
Colonoscopy pain
ID IRRITABLE-BOWEL-SYNDROME; RANDOMIZED CONTROLLED-TRIAL; UNSEDATED
COLONOSCOPY; AIDED COLONOSCOPY; AIR INSUFFLATION; PERCEPTION;
DIFFICULTY; IMMERSION; ENDOSCOPY; SEDATION
AB AIM: To determine variations in colonoscopy real-time insertion pain among investigators using three different insertion techniques.
METHODS: From March 2013 through June 2014, 18-85-year-old diagnostic and 50-70-year-old screening patients were enrolled at each center to on-demand sedation colonoscopy with water exchange (WE), water immersion (WI) and insufflation with air or CO2 for insertion and withdrawal [air or carbon dioxide (AICD)]. Data were aggregated for analysis. Primary outcome: Variations in real-time maximum insertion pain (0 = none, 1-2 = discomfort, 10 = worst).
RESULTS: One thousand and ninety-one cases analyzed: WE (n = 371); WI (n = 338); AICD (n = 382). Demographics and indications were comparable. The WE group had the lowest real-time maximum insertion pain score, mean (95% CI): WE 2.8 (2.6-3.0), WI 3.8 (3.5-4.1) and AICD 4.4 (4.1-4.7), P < 0.0005. Ninety percent of the colonoscopists were able to use water exchange to significantly decrease maximum insertion pain scores. One investigator had high insertion pain in all groups, nonetheless WE achieved the lowest real-time maximum insertion pain score. WE had the highest proportions of patients with painless unsedated colonoscopy (vs WI, P = 0.013; vs AICD, P < 0.0005); unsedated colonoscopy with only minor discomfort (vs AICD, P < 0.0005), and completion without sedation (vs AICD, P < 0.0005).
CONCLUSION: Aggregate data confirm superiority of WE in lowering colonoscopy real-time maximum insertion pain and need for sedation. Ninety percent of investigators were able to use water exchange to significantly decrease maximum insertion pain scores. Our results suggest that the technique deserves consideration in a broader scale.
C1 [Cadoni, Sergio; Liggi, Mauro; Gallittu, Paolo; Mura, Donatella] St Barbara Hosp, Digest Endoscopy Unit, Via San Leonardo 1, I-09016 Iglesias, Italy.
[Falt, Premysl; Smajstrla, Vit] Vitkovice Hosp, Ctr Digest Dis, Ostrava 70384, Czech Republic.
[Sanna, Stefano; Argiolas, Mariangela; Fanari, Viviana; Porcedda, Maria L.] NS di Bonaria Hosp, Digest Endoscopy Unit, I-09037 San Gavino Monreale, Italy.
[Erriu, Matteo] Univ Cagliari, Dept Surg Sci, I-09121 Cagliari, Italy.
[Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA 91343 USA.
[Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA.
RP Cadoni, S (reprint author), St Barbara Hosp, Digest Endoscopy Unit, Via San Leonardo 1, I-09016 Iglesias, Italy.
EM cadonisergio@gmail.com
NR 40
TC 0
Z9 0
U1 0
U2 2
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1948-5190
J9 WORLD J GASTROINTEST
JI World J. Gastrointest. Endosc.
PD JAN 25
PY 2016
VL 8
IS 2
BP 113
EP 121
DI 10.4253/wjge.v8.i2.113
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA DD1UM
UT WOS:000369707500008
PM 26839651
ER
PT J
AU Belkind-Gerson, J
Hotta, R
Whalen, M
Nayyar, N
Nagy, N
Cheng, L
Zuckerman, A
Goldstein, AM
Dietrich, J
AF Belkind-Gerson, Jaime
Hotta, Ryo
Whalen, Michael
Nayyar, Naema
Nagy, Nandor
Cheng, Lily
Zuckerman, Aaron
Goldstein, Allan M.
Dietrich, Jorg
TI Engraftment of enteric neural progenitor cells into the injured adult
brain
SO BMC NEUROSCIENCE
LA English
DT Article
DE Enteric neuronal progenitor cells; Stem cells; Brain injury; Cell
transplantation; Brain repair
ID STEM-CELLS; HIPPOCAMPAL NEUROGENESIS; NERVOUS-SYSTEM; EUROPE 2010;
NEURONS; DISORDERS; DISEASE; MOUSE; MICE; GUT
AB Background: A major area of unmet need is the development of strategies to restore neuronal network systems and to recover brain function in patients with neurological disease. The use of cell-based therapies remains an attractive approach, but its application has been challenging due to the lack of suitable cell sources, ethical concerns, and immune-mediated tissue rejection. We propose an innovative approach that utilizes gut-derived neural tissue for cell-based therapies following focal or diffuse central nervous system injury.
Results: Enteric neuronal stem and progenitor cells, able to differentiate into neuronal and glial lineages, were isolated from the postnatal enteric nervous system and propagated in vitro. Gut-derived neural progenitors, genetically engineered to express fluorescent proteins, were transplanted into the injured brain of adult mice. Using different models of brain injury in combination with either local or systemic cell delivery, we show that transplanted enteric neuronal progenitor cells survive, proliferate, and differentiate into neuronal and glial lineages in vivo. Moreover, transplanted cells migrate extensively along neuronal pathways and appear to modulate the local microenvironment to stimulate endogenous neurogenesis.
Conclusions: Our findings suggest that enteric nervous system derived cells represent a potential source for tissue regeneration in the central nervous system. Further studies are needed to validate these findings and to explore whether autologous gut-derived cell transplantation into the injured brain can result in functional neurologic recovery.
C1 [Belkind-Gerson, Jaime; Whalen, Michael] Harvard Univ, Sch Med, Dept Pediat, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hotta, Ryo; Nagy, Nandor; Cheng, Lily; Zuckerman, Aaron; Goldstein, Allan M.] Harvard Univ, Sch Med, Dept Pediat Surg, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nayyar, Naema; Dietrich, Jorg] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Div Neurooncol, Boston, MA 02114 USA.
[Nayyar, Naema; Dietrich, Jorg] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Belkind-Gerson, Jaime; Goldstein, Allan M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pediat Neurogastroenterol Program, 175 Cambridge St 575, Boston, MA 02114 USA.
RP Belkind-Gerson, J (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pediat Neurogastroenterol Program, 175 Cambridge St 575, Boston, MA 02114 USA.
EM jbelkindgerson@mgh.harvard.edu
NR 36
TC 1
Z9 1
U1 2
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2202
J9 BMC NEUROSCI
JI BMC Neurosci.
PD JAN 25
PY 2016
VL 17
AR 5
DI 10.1186/s12868-016-0238-y
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA DC4BM
UT WOS:000369164800001
PM 26810757
ER
PT J
AU Rajagopal, J
Stanger, BZ
AF Rajagopal, Jayaraj
Stanger, Ben Z.
TI Plasticity in the Adult: How Should the Waddington Diagram Be Applied to
Regenerating Tissues?
SO DEVELOPMENTAL CELL
LA English
DT Review
ID STEM-CELLS; DROSOPHILA TESTIS; EPITHELIAL-CELLS; BETA-CELLS; IN-VIVO;
DEDIFFERENTIATION; NICHE; CONVERSION; OCCURS; AGE
AB Conrad Waddington's eponymous 1957 diagram provided a metaphorical framework for considering how sequential developmental fate decisions allow an egg to develop into an embryo. In recent years, the Waddington diagram has been repurposed to illustrate how cellular identity changes in the context of reprogramming. In this Perspective, we revisit the Waddington diagram in light of the emerging recognition that plasticity is part and parcel of adult regeneration. Specifically, we speculate that the "epigenetic landscapes" that define identity in adult tissues are dynamic, facilitating cellular de-differentiation and trans-differentiation in the setting of injury.
C1 [Rajagopal, Jayaraj] Massachusetts Gen Hosp, Ctr Regenerat Med, Harvard Stem Cell Inst, Boston, MA 02114 USA.
[Rajagopal, Jayaraj] Massachusetts Gen Hosp, Harvard Stem Cell Inst, Dept Med, Boston, MA 02114 USA.
[Stanger, Ben Z.] Univ Penn, Perelman Sch Med, Inst Regenerat Med, Dept Med, Philadelphia, PA 19104 USA.
[Stanger, Ben Z.] Univ Penn, Perelman Sch Med, Inst Regenerat Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.
RP Rajagopal, J (reprint author), Massachusetts Gen Hosp, Ctr Regenerat Med, Harvard Stem Cell Inst, Boston, MA 02114 USA.; Rajagopal, J (reprint author), Massachusetts Gen Hosp, Harvard Stem Cell Inst, Dept Med, Boston, MA 02114 USA.; Stanger, BZ (reprint author), Univ Penn, Perelman Sch Med, Inst Regenerat Med, Dept Med, Philadelphia, PA 19104 USA.; Stanger, BZ (reprint author), Univ Penn, Perelman Sch Med, Inst Regenerat Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.
EM jrajagopal@mgh.harvard.edu; bstanger@exchange.upenn.edu
NR 19
TC 4
Z9 4
U1 1
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1534-5807
EI 1878-1551
J9 DEV CELL
JI Dev. Cell
PD JAN 25
PY 2016
VL 36
IS 2
BP 133
EP 137
DI 10.1016/j.devcel.2015.12.021
PG 5
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA DC6TV
UT WOS:000369353400004
PM 26812013
ER
PT J
AU Penney, LS
Ritenbaugh, C
Elder, C
Schneider, J
Deyo, RA
DeBar, LL
AF Penney, Lauren S.
Ritenbaugh, Cheryl
Elder, Charles
Schneider, Jennifer
Deyo, Richard A.
DeBar, Lynn L.
TI Primary care physicians, acupuncture and chiropractic clinicians, and
chronic pain patients: a qualitative analysis of communication and care
coordination patterns
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Chronic musculoskeletal pain; Complementary and alternative medicine;
Managed care system; Interprofessional communication; Chronic care;
Acupuncture; Chiropractic
ID LOW-BACK-PAIN; ALTERNATIVE MEDICINE; HEALTH-CARE; COMPLEMENTARY
PRACTITIONERS; RANDOMIZED-TRIAL; OLDER PATIENTS; INTEGRATION;
MANIPULATION; PREVALENCE; CHALLENGE
AB Background: A variety of people, with multiple perspectives, make up the system comprising chronic musculoskeletal pain (CMP) treatment. While there are frequently problems in communication and coordination of care within conventional health systems, more opportunities for communicative disruptions seem possible when providers use different explanatory models and are not within the same health management system. We sought to describe the communication system surrounding the management of chronic pain from the perspectives of allopathic providers, acupuncture and chiropractor (A/C) providers, and CMP patients.
Methods: We collected qualitative data from CMP patients (n = 90) and primary care physicians (PCPs) (n = 25) in a managed care system, and community acupuncture and chiropractic care providers (n = 14) who received high levels of referrals from the system, in the context of a longitudinal study of CMP patients' experience.
Results: Multiple points of divergence and communicative barriers were identified among the main stakeholders in the system. Those that were most frequently mentioned included issues surrounding the referral process (requesting, approving) and lack of consistent information flow back to providers that impairs overall management of patient care. We found that because of these problems, CMP patients were frequently tasked and sometimes overwhelmed with integrating and coordinating their own care, with little help from the system.
Conclusions: Patients, PCPs, and A/C providers desire more communication; thus systems need to be created to facilitate more open communication which could positively benefit patient outcomes.
C1 [Penney, Lauren S.] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
[Ritenbaugh, Cheryl] Univ Arizona, Dept Family & Community Med, 1450 N Cherry Ave, Tucson, AZ 85719 USA.
[Elder, Charles; Schneider, Jennifer; DeBar, Lynn L.] Kaiser Permanente Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Family Med, Mail Code FM,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
RP DeBar, LL (reprint author), Kaiser Permanente Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA.
EM lynn.debar@kpchr.org
FU National Institutes of Health, National Center for Complementary and
Alternative Medicine Grant [R01 AT005896]
FX The authors gratefully acknowledge that our study received funding
support from the National Institutes of Health, National Center for
Complementary and Alternative Medicine Grant (R01 AT005896).
NR 44
TC 0
Z9 0
U1 2
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD JAN 25
PY 2016
VL 16
AR 30
DI 10.1186/s12906-016-1005-4
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA DB9ZO
UT WOS:000368876600002
PM 26810302
ER
PT J
AU Liu, X
Mao, K
Yu, AYH
Omairi-Nasser, A
Austin, J
Glick, BS
Yip, CK
Klionsky, DJ
AF Liu, Xu
Mao, Kai
Yu, Angela Y. H.
Omairi-Nasser, Amin
Austin, Jotham, II
Glick, Benjamin S.
Yip, Calvin K.
Klionsky, Daniel J.
TI The Atg17-Atg31-Atg29 Complex Coordinates with Atg11 to Recruit the Vam7
SNARE and Mediate Autophagosome-Vacuole Fusion
SO CURRENT BIOLOGY
LA English
DT Article
ID SACCHAROMYCES-CEREVISIAE; TARGETING PATHWAY; YEAST; TRANSPORT; PROTEINS;
ADAPTATIONS; BIOGENESIS; DROSOPHILA; MACHINERY; CLEARANCE
AB Macroautophagy (hereafter autophagy) is an evolutionarily conserved process in which portions of the cytoplasm are engulfed, degraded, and subsequently recycled. The Atg17-Atg31-Atg29 complex translocates to the phagophore assembly site (PAS), where an autophagosome forms, at a very early stage of autophagy, playing a vital role in autophagy induction. Here, we identified a novel role of this complex in a late stage of autophagy where it coordinates with Atg11 to regulate autophagy-specific fusion with the vacuole. Atg17 and Atg11 interact with the vacuolar SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) Vam7 independently of each other. Several hydrophobic residues in helix 1 and helix 4 of Atg17 and the SNARE domain of Vam7 mediate the Atg17-Vam7 interaction. An F317D mutation of Atgl 7, which diminishes its interaction with Vam7 without affecting its interaction with Atg13 or Atg31, leads to a defect in the fusion of autophagosomes with the vacuole and decreased autophagy activity. These results provide the first demonstration that the Atg17-Atg31-Atg29 complex functions in both early and late stages of autophagy and also provide a mechanistic explanation for the coordination of autophagosome completion and fusion with the vacuole.
C1 [Liu, Xu; Mao, Kai; Klionsky, Daniel J.] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.
[Liu, Xu; Mao, Kai; Klionsky, Daniel J.] Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.
[Yu, Angela Y. H.; Yip, Calvin K.] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada.
[Omairi-Nasser, Amin; Glick, Benjamin S.] Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58Th St, Chicago, IL 60637 USA.
[Austin, Jotham, II] Univ Chicago, Electron Microscopy Core Facil, Chicago, IL 60637 USA.
[Mao, Kai] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol, Boston, MA 02114 USA.
[Mao, Kai] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.
RP Klionsky, DJ (reprint author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.; Klionsky, DJ (reprint author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.
EM klionsky@umich.edu
FU NIH [GM053396, P30 CA014599]; Canadian Institutes of Health Research
[MOP-126126]; University of British Columbia; Biological Systems Science
Division, Office of Biological and Environmental Research, Office of
Science, US Department of Energy [DE-AC02-06CH11357]
FX This work was supported by NIH grant GM053396 to D.J.K.; an operating
grant from the Canadian Institutes of Health Research (MOP-126126) and
startup funds from the University of British Columbia to C.K.Y.; and
funding through the Biological Systems Science Division, Office of
Biological and Environmental Research, Office of Science, US Department
of Energy, under contract DE-AC02-06CH11357 with B.S.G. Fluorescence
microscopy was performed at the Integrated Microscopy Core Facility, and
electron microscopy was performed at the Electron Microscopy Core
Facility, with support for both facilities coming from the NIH-funded
Cancer Center Support Grant P30 CA014599.
NR 47
TC 7
Z9 7
U1 3
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD JAN 25
PY 2016
VL 26
IS 2
BP 150
EP 160
DI 10.1016/j.cub.2015.11.054
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DC1JJ
UT WOS:000368972300017
PM 26774783
ER
PT J
AU Hazan, R
Que, YA
Maura, D
Strobel, B
Majcherczyk, PA
Hopper, LR
Wilbur, DJ
Hreha, TN
Barquera, B
Rahme, LG
AF Hazan, Ronen
Que, Yok Ai
Maura, Damien
Strobel, Benjamin
Majcherczyk, Paul Anthony
Hopper, Laura Rose
Wilbur, David J.
Hreha, Teri N.
Barquera, Blanca
Rahme, Laurence G.
TI Auto Poisoning of the Respiratory Chain by a Quorum-Sensing-Regulated
Molecule Favors Biofilm Formation and Antibiotic Tolerance
SO CURRENT BIOLOGY
LA English
DT Article
ID MEDIATED CELL-DEATH; PSEUDOMONAS-AERUGINOSA; PERMEABILITY TRANSITION;
ESCHERICHIA-COLI; RHODOBACTER-SPHAEROIDES; BACTERIAL BIOFILMS; LYSIS;
MECHANISM; APOPTOSIS; MUTANTS
AB Bacterial programmed cell death and quorum sensing are direct examples of prokaryote group behaviors, wherein cells coordinate their actions to function cooperatively like one organism for the benefit of the whole culture. We demonstrate here that 2-n-heptyl--hydroxyquinoline-N-oxide (HQNO), a Pseudomonas aeruginosa quorum-sensing-regulated low-molecular-weight excreted molecule, triggers autolysis by self-perturbing the electron transfer reactions of the cytochrome bc(1) complex. HQNO induces specific self-poisoning by disrupting the flow of electrons through the respiratory chain at the cytochrome bc(1) complex, causing a leak of reducing equivalents to O-2 whereby electrons that would normally be passed to cytochrome c are donated directly to O-2. The subsequent mass production of reactive oxygen species (ROS) reduces membrane potential and disrupts membrane integrity, causing bacterial cell autolysis and DNA release. DNA subsequently promotes biofilm formation and increases antibiotic tolerance to beta-actams, suggesting that HQNO-dependent cell autolysis is advantageous to the bacterial populations. These data identify both a new programmed cell death system and a novel role for HQNO as a critical inducer of biofilm formation and antibiotic tolerance. This newly identified pathway suggests intriguing mechanistic similarities with the initial mitochondrial-mediated steps of eukaryotic apoptosis.
C1 [Hazan, Ronen; Que, Yok Ai; Maura, Damien; Strobel, Benjamin; Hopper, Laura Rose; Rahme, Laurence G.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Hazan, Ronen; Que, Yok Ai; Maura, Damien; Strobel, Benjamin; Hopper, Laura Rose; Rahme, Laurence G.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
[Hazan, Ronen; Que, Yok Ai; Maura, Damien; Strobel, Benjamin; Hopper, Laura Rose; Rahme, Laurence G.] Massachusetts Gen Hosp, Ctr Surg Innovat & Bioengn, Dept Surg, Boston, MA 02114 USA.
[Hazan, Ronen; Que, Yok Ai; Maura, Damien; Rahme, Laurence G.] Shriners Hosp Children Boston, Boston, MA 02114 USA.
[Majcherczyk, Paul Anthony] Univ Lausanne, Dept Fundamental Microbiol, CH-1015 Lausanne, Switzerland.
[Wilbur, David J.] Tufts Univ, Dept Chem, Medford, MA 02155 USA.
[Hreha, Teri N.; Barquera, Blanca] Rensselaer Polytech Inst, CBIS, Dept Biol Sci, 110 8th St, Troy, NY 12180 USA.
[Hazan, Ronen] Hebrew Univ Jerusalem, Inst Dent Sci, POB 12272, IL-91120 Jerusalem, Israel.
[Hazan, Ronen] Hebrew Univ Jerusalem, Sch Dent Med, POB 12272, IL-91120 Jerusalem, Israel.
[Que, Yok Ai] Univ Lausanne, Dept Fundamental Microbiol, CH-1015 Lausanne, Switzerland.
RP Rahme, LG (reprint author), Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.; Rahme, LG (reprint author), Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.; Rahme, LG (reprint author), Massachusetts Gen Hosp, Ctr Surg Innovat & Bioengn, Dept Surg, Boston, MA 02114 USA.; Rahme, LG (reprint author), Shriners Hosp Children Boston, Boston, MA 02114 USA.
EM rahme@molbio.mgh.harvard.edu
FU research grants Shriners [8770]; Cystic Fibrosis Foundation [11P0];
NIAID [R33AI105902, R56AI063433]; Shriners Hospitals Research Fellowship
[8494]; Swiss National Science Foundation/Swiss Medical Association
(FMH) [PASMP3-123226]; SICPA Foundation; [NSF-MCB1052234]
FX This work was supported by research grants Shriners #8770, Cystic
Fibrosis Foundation #11P0, and NIAID R33AI105902 and R56AI063433 to
L.G.R. R.H. was supported by Shriners Hospitals Research Fellowship
#8494. Y.A.Q. was supported by Swiss National Science Foundation/Swiss
Medical Association (FMH) grant #PASMP3-123226 and a grant from the
SICPA Foundation. B.B. and T.N.H. were supported by research grant
NSF-MCB1052234 to B.B. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript. We thank Drs. Scott Stachel and Alicia Ballok for the
critical reading of this manuscript. This work is dedicated to the
memory of Scott Stachel.
NR 50
TC 4
Z9 4
U1 4
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD JAN 25
PY 2016
VL 26
IS 2
BP 195
EP 206
DI 10.1016/j.cub.2015.11.056
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DC1JJ
UT WOS:000368972300021
PM 26776731
ER
PT J
AU Bai, JW
Boulet, G
Halpern, EM
Lovblom, LE
Eldelekli, D
Keenan, HA
Brent, M
Paul, N
Bril, V
Cherney, DZI
Weisman, A
Perkins, BA
AF Bai, Johnny W.
Boulet, Genevieve
Halpern, Elise M.
Lovblom, Leif E.
Eldelekli, Devrim
Keenan, Hillary A.
Brent, Michael
Paul, Narinder
Bril, Vera
Cherney, David Z. I.
Weisman, Alanna
Perkins, Bruce A.
TI Cardiovascular disease guideline adherence and self-reported statin use
in longstanding type 1 diabetes: results from the Canadian study of
longevity in diabetes cohort
SO CARDIOVASCULAR DIABETOLOGY
LA English
DT Article
DE Type 1 diabetes; Cardiovascular disease; HMG-CoA reductase inhibitor
(3-hydroxy-3-methyl-glutaryl-CoA reductase); Statin; Adherence
ID CORONARY-HEART-DISEASE; PRIMARY PREVENTION; CHOLESTEROL LEVELS;
MORTALITY; POPULATION; DURATION; THERAPY; PEOPLE; COMPLICATIONS;
NONADHERENCE
AB Background: Older patients with longstanding type 1 diabetes have high cardiovascular disease (CVD) risk such that statin therapy is recommended independent of prior CVD events. We aimed to determine self-reported CVD prevention guideline adherence in patients with longstanding diabetes.
Research design and methods: 309 Canadians with over 50 years of type 1 diabetes completed a medical questionnaire for presence of lifestyle and pharmacological interventions, stratified into primary or secondary CVD prevention subgroups based on absence or presence of self-reported CVD events, respectively. Associations with statin use were analyzed using multivariable logistic regression.
Results: The 309 participants had mean +/- SD age 65.7 +/- 8.5 years, median diabetes duration 54.0 [IQR 51.0, 59.0] years, and HbA1c of 7.5 +/- 1.1 % (58 mmol/mol). 159 (52.7 %) participants reported diet adherence, 296 (95.8 %) smoking avoidance, 217 (70.5 %) physical activity, 218 (71.5 %) renin-angiotensin-system inhibitor use, and 220 (72.1 %) statin use. Physical activity was reported as less common in the secondary prevention subgroup, and current statin use was significantly lower in the primary prevention subgroup (65.5 % vs. 84.8 %, p = 0.0004). In multivariable logistic regression, the odds of statin use was 0.38 [95 % CI 0.15-0.95] in members of the primary compared to the secondary prevention subgroup, adjusting for age, sex, hypertension history, body mass, HbA1c, cholesterol, microvascular complications, acetylsalicylic acid use, and renin-angiotensin system inhibitor use.
Conclusion: Despite good self-reported adherence to general CVD prevention guidelines, against the principles of these guidelines we found that statin use was substantially lower in those without CVD history. Interventions are needed to improve statin use in older type 1 diabetes patients without a history of CVD.
C1 [Bai, Johnny W.; Boulet, Genevieve; Halpern, Elise M.; Lovblom, Leif E.; Eldelekli, Devrim; Weisman, Alanna; Perkins, Bruce A.] Univ Toronto, Mt Sinai Hosp, Div Endocrinol & Metab, Dept Med,Leadership Sinai Ctr Diabet, L5-210,60 Murray St,Mail Box 16, Toronto, ON M5T 3L9, Canada.
[Keenan, Hillary A.] Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.
[Brent, Michael] Univ Toronto, Dept Med, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
[Paul, Narinder] Univ Hlth Network, Div Cardiothorac Radiol, Joint Dept Med Imaging, Toronto, ON, Canada.
[Bril, Vera] Univ Toronto, Univ Hlth Network, Ellen & Martin Prosserman Ctr Neuromuscular Dis, Krembil Neurosci Ctr,Div Neurol,Dept Med, Toronto, ON, Canada.
[Cherney, David Z. I.] Univ Toronto, Dept Med, Div Nephrol, Toronto, ON, Canada.
RP Perkins, BA (reprint author), Univ Toronto, Mt Sinai Hosp, Div Endocrinol & Metab, Dept Med,Leadership Sinai Ctr Diabet, L5-210,60 Murray St,Mail Box 16, Toronto, ON M5T 3L9, Canada.
EM BPerkins@mtsinai.on.ca
FU University of Toronto CREMS Summer Research Program; JDRF Canadian
Clinical Trial Network; Medtronic; Boehringer Ingelheim; AstraZeneca;
Merck; Canadian Diabetes Association, JDRF Canada and its Canadian
Clinical Trial Network
FX JWB has received funding from the University of Toronto CREMS Summer
Research Program and AW has received a post-doctoral fellowship award
from the JDRF Canadian Clinical Trial Network. BAP has received speaker
honoraria from Medtronic Inc., Johnson and Johnson, Roche, Glaxo Smith
Kline Canada, Novo Nordisk and Sanofi; has received research grant
support from Medtronic and Boehringer Ingelheim; and serves as a
consultant for Neurometrix. DZIC has received speaker honoraria from
Janssen, AstraZeneca, Boehringer Ingelheim, Lilly and Merck and has
received research grant support from AstraZeneca, Merck and Boehringer
Ingelheim. We are grateful to the Canadian Diabetes Association, JDRF
Canada and its Canadian Clinical Trial Network for their support.
NR 43
TC 2
Z9 2
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2840
J9 CARDIOVASC DIABETOL
JI Cardiovasc. Diabetol.
PD JAN 25
PY 2016
VL 15
AR 14
DI 10.1186/s12933-015-0318-9
PG 10
WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism
SC Cardiovascular System & Cardiology; Endocrinology & Metabolism
GA DC0JG
UT WOS:000368902400001
PM 26809442
ER
PT J
AU Miyazaki, Y
Song, JW
Takahashi, E
AF Miyazaki, Yuta
Song, Jae W.
Takahashi, Emi
TI Asymmetry of Radial and Symmetry of Tangential Neuronal Migration
Pathways in Developing Human Fetal Brains
SO FRONTIERS IN NEUROANATOMY
LA English
DT Article
DE development; radial migration; ganglionic eminence; human; diffusion
imaging; tractography
ID HUMAN CEREBRAL-CORTEX; RESOLUTION DIFFUSION TRACTOGRAPHY; CORTICAL
GABAERGIC NEURONS; X-LINKED MALFORMATIONS; HUMAN NEOCORTEX;
WHITE-MATTER; TELENCEPHALIC ORIGIN; SUBVENTRICULAR ZONE; BIPOLAR
DISORDER; BASAL FOREBRAIN
AB The radial and tangential neural migration pathways are two major neuronal migration streams in humans that are critical during corticogenesis. Corticogenesis is a complex process of neuronal proliferation that is followed by neuronal migration and the formation of axonal connections. Existing histological assessments of these two neuronal migration pathways have limitations inherent to microscopic studies and are confined to small anatomic regions of interest (ROls). Thus, little evidence is available about their threedimensional (3-D) fiber pathways and development throughout the entire brain. In this study, we imaged and analyzed radial and tangential migration pathways in the whole human brain using high -angular resolution diffusion MR imaging (HARDI) tractography. We imaged ten fixed, postmortem fetal (17 gestational weeks ((3V@. 18 GW, 19 (lW, three 20 GW, three 21 GW and 22 GW) and eight in vivo newborn (two 30 GW, 34 GW, 35 GW and four 40 Gq brains with no neurological/pathological conditions. We statistically compared the volume of the left and right radial and tangential migration pathways, and the volume of the radial migration pathways of the anterior and posterior regions of the brain. In specimens 22 GW or younger, the volume of radial migration pathways of the left hemisphere was significantly larger than that of the right hemisphere. The volume of posterior radial migration pathways was also larger when compared to the anterior pathways in specimens 22 GW or younger. In contrast, no significant differences were observed in the radial migration pathways of brains older than 22 GW. Moreover, our study did not identify any significant differences in volumetric laterality in the tangential migration pathways. These results suggest that these two neuronal migration pathways develop and regress differently, and radial neuronal migration varies regionally based on hemispheric and anterior -posterior laterality, potentially explaining regional differences in the amount of excitatory neurons that migrate along the radial scaffold.
C1 [Miyazaki, Yuta] Chiba Univ, Sch Med, Dept Med, Chiba, Japan.
[Song, Jae W.] Yale Univ, Sch Med, Dept Radiol & Biomed Imaging, New Haven, CT USA.
[Takahashi, Emi] Harvard Univ, Sch Med, Dept Med, Boston Childrens Hosp,Div Newborn Med, Boston, MA USA.
[Takahashi, Emi] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Takahashi, Emi] Harvard Univ, Sch Med, Fetal Neonatal Neuroimaging & Dev Sci Ctr, Boston Childrens Hosp, Boston, MA 02115 USA.
RP Takahashi, E (reprint author), Harvard Univ, Sch Med, Dept Med, Boston Childrens Hosp,Div Newborn Med, Boston, MA USA.; Takahashi, E (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.; Takahashi, E (reprint author), Harvard Univ, Sch Med, Fetal Neonatal Neuroimaging & Dev Sci Ctr, Boston Childrens Hosp, Boston, MA 02115 USA.
EM emi@nmr.mgh.harvard.edu
FU Boston Children's Hospital (BCH); NICHD [R01HD078561, R21HD069001,
R03NS091587]; Biomedical Technology Program of the National Center for
Research Resources (NCRR), National Institutes of Health [P41RR14075];
NCRR Shared Instrumentation Grant Program [NIH S10RR023401, S10RR019307,
S10RR023043]; High-End Instrumentation Grant Program [NIH S10RR016811];
[NIH MH081896]
FX This work was supported by Boston Children's Hospital (BCH), NICHD
(R01HD078561, R21HD069001, R03NS091587; ET). This research was carried
out in part at the Athinoula A. Martinos Center for Biomedical Imaging
at the Massachusetts General Hospital, using resources provided by the
Center for Functional Neuroimaging Technologies, NIH P41RR14075, a P41
Regional Resource supported by the Biomedical Technology Program of the
National Center for Research Resources (NCRR), National Institutes of
Health. This work also involved the use of instrumentation supported by
the NCRR Shared Instrumentation Grant Program (NIH S10RR023401,
S10RR019307, and S10RR023043) and High-End Instrumentation Grant Program
(NIH S10RR016811). This study was conducted partly using postmortem
human brain specimens from the tissue collection at the Department of
Neurobiology at Yale University School of Medicine (supported by grant
NIH MH081896), which form a part of the BrainSpan Consortium collection
(http://www.brainspan.org). The other brain specimens were kindly
provided by Dr. Rebecca D. Folkerth, Brigham and Women's Hospital,
Boston Children's Hospital and Harvard Medical School.
NR 75
TC 0
Z9 0
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1662-5129
J9 FRONT NEUROANAT
JI Front. Neuroanat.
PD JAN 25
PY 2016
VL 10
AR 2
DI 10.3389/fnana.2016.00002
PG 10
WC Anatomy & Morphology; Neurosciences
SC Anatomy & Morphology; Neurosciences & Neurology
GA DB6NX
UT WOS:000368632800001
PM 26834572
ER
PT J
AU Chen, HI
Jgamadze, D
Serruya, MD
Cullen, DK
Wolf, JA
Smith, DH
AF Chen, H. Isaac
Jgamadze, Dennis
Serruya, Mijail D.
Cullen, D. Kacy
Wolf, John A.
Smith, Douglas H.
TI Neural Substrate Expansion for the Restoration of Brain Function
SO FRONTIERS IN SYSTEMS NEUROSCIENCE
LA English
DT Review
DE axons; brain repair; neural interfaces; neuronal networks; stem cells;
tissue engineering
ID PLURIPOTENT STEM-CELLS; LONG-TERM SURVIVAL; CORTICAL-NEURONS; MOTOR
CORTEX; IN-VIVO; SUBVENTRICULAR ZONE; AXON REGENERATION;
CEREBRAL-CORTEX; ADULT BRAIN; 3D CULTURE
AB Restoring neurological and cognitive function in individuals who have suffered brain damage is one of the principal objectives of modern translational neuroscience. Electrical stimulation approaches, such as deep-brain stimulation, have achieved the most clinical success, but they ultimately may be limited by the computational capacity of the residual cerebral circuitry. An alternative strategy is brain substrate expansion, in which the computational capacity of the brain is augmented through the addition of new processing units and the reconstitution of network connectivity. This latter approach has been explored to some degree using both biological and electronic means but thus far has not demonstrated the ability to reestablish the function of large-scale neuronal networks. In this review, we contend that fulfilling the potential of brain substrate expansion will require a significant shift from current methods that emphasize direct manipulations of the brain (e.g., injections of cellular suspensions and the implantation of multi-electrode arrays) to the generation of more sophisticated neural tissues and neural-electric hybrids in vitro that are subsequently transplanted into the brain. Drawing from neural tissue engineering, stem cell biology, and neural interface technologies, this strategy makes greater use of the manifold techniques available in the laboratory to create biocompatible constructs that recapitulate brain architecture and thus are more easily recognized and utilized by brain networks.
C1 [Chen, H. Isaac; Jgamadze, Dennis; Cullen, D. Kacy; Wolf, John A.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
[Chen, H. Isaac; Cullen, D. Kacy; Wolf, John A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Serruya, Mijail D.] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA.
RP Chen, HI (reprint author), Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.; Chen, HI (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
EM isaac.chen@uphs.upenn.edu
FU RRD VA [IK2 RX001479]
NR 107
TC 0
Z9 0
U1 6
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1662-5137
J9 FRONT SYST NEUROSCI
JI Front. Syst. Neurosci.
PD JAN 25
PY 2016
VL 10
AR 1
DI 10.3389/fnsys.2016.00001
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA DB6HG
UT WOS:000368614700001
PM 26834579
ER
PT J
AU Graf, SA
Gopal, AK
AF Graf, Solomon A.
Gopal, Ajay K.
TI Idelalisib for the treatment of non-Hodgkin lymphoma
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE Idelalisib; B-cell; lymphoma; indolent
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; MANTLE-CELL LYMPHOMA; FOLLICULAR LYMPHOMA;
INDOLENT LYMPHOMA; PHASE-II; PHOSPHATIDYLINOSITOL 3-KINASE-DELTA;
PHOSPHOINOSITIDE 3-KINASE; PROTEASOME INHIBITOR; COMBINATION THERAPY;
UNTREATED PATIENTS
AB IntroductionB-cell Non-Hodgkin lymphomas (B-NHLs) include a number of disease subtypes, each defined by the tempo of disease progression and the identity of the cancerous cell. Idelalisib is a potent, selective inhibitor of the delta isoform of phosphatidylinositol-3-kinase (PI3K), a lipid kinase whose over-activity in B-NHL drives disease progression. Idelalisib has demonstrated activity in indolent B-NHL (iB-NHL) and is approved for use as monotherapy in patients with follicular lymphoma and small lymphocytic lymphoma and in combination with rituximab in patients with chronic lymphocytic leukemia.Areas CoveredHerein we review the development and pharmacology of idelalisib, its safety and efficacy in clinical studies of iB-NHL, and its potential for inclusion in future applications in iB-NHL and in combination with other therapies.Expert OpinionIdelalisib adds to the growing arsenal of iB-NHL pharmacotherapeutics and to the progression of the field toward precision agents with good efficacy and reduced toxicities. Nevertheless, idelalisib carries important risks that require careful patient counseling and monitoring. The appropriate sequencing of idelalisib with other proven treatment options in addition to its potential for combination with established or novel drugs will be borne out in ongoing and planned investigations.
C1 [Graf, Solomon A.; Gopal, Ajay K.] Univ Washington, Dept Med, Seattle, WA USA.
[Graf, Solomon A.; Gopal, Ajay K.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Graf, Solomon A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Gopal, AK (reprint author), Univ Washington, Med, 825 Eastlake Ave E, Seattle, WA USA.
EM agopal@u.washington.edu
FU NCI [P01CA44991, K24CA184039]; Fred Hutchinson Cancer Research
Center/University of Washington Cancer Consortium Cancer Center [P30
CA015704]; NIH [5T32HL007093]; Seattle Genetics Inc; Gilead Sciences;
Janssen Pharmaceuticals; Spectrum Pharmaceuticals
FX This work was supported by research funding from NCI P01CA44991,
K24CA184039, Fred Hutchinson Cancer Research Center/University of
Washington Cancer Consortium Cancer Center Support Grant P30 CA015704,
and gifts from Frank and Betty Vandermeer, Don and Debbie Hunkins, and
the Mary Aileen Wright Memorial Fund. S.A.G. received support from NIH
5T32HL007093. A Gopal has received consulting fees from Seattle Genetics
Inc, Gilead Sciences, Janssen Pharmaceuticals and Spectrum
Pharmaceuticals within the last 12 months. The authors have no other
relevant affiliations or financial involvement with any organization or
entity with a financial interest in or financial conflict with the
subject matter or materials discussed in the manuscript apart from those
disclosed
NR 69
TC 5
Z9 5
U1 1
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD JAN 22
PY 2016
VL 17
IS 2
BP 265
EP 274
DI 10.1517/14656566.2016.1135130
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DD8HT
UT WOS:000370167700001
PM 26818003
ER
PT J
AU Mananga, ES
Charpentier, T
AF Mananga, Eugene Stephane
Charpentier, Thibault
TI On the Floquet-Magnus expansion: Applications in solid-state nuclear
magnetic resonance and physics
SO PHYSICS REPORTS-REVIEW SECTION OF PHYSICS LETTERS
LA English
DT Review
ID ANGLE-SPINNING NMR; RADIOFREQUENCY PULSE SEQUENCES; DEPENDENT
SCHRODINGER-EQUATION; AVERAGE HAMILTONIAN THEORY; QUANTUM-FIELD THEORY;
LIOUVILLE SUPERMATRIX APPROACH; LINEAR-DIFFERENTIAL EQUATIONS; UNIFORMLY
LABELED MOLECULE; ANISOTROPY CORRELATION NMR; CHEMICAL-SHIFT ANISOTROPY
AB Theoretical approaches are useful and powerful tools for more accurate and efficient spin dynamics simulation to understand experiments and devising new RF pulse sequence in nuclear magnetic resonance. Solid-state NMR is definitely a timely topic or area of research, and not many papers on the respective theories are available in the literature of nuclear magnetic resonance or physics reports. This report presents the power and the salient features of the promising theoretical approach called Floquet-Magnus expansion that is helpful to describe the time evolution of the spin system at all times in nuclear magnetic resonance. The report presents a broad view of algorithms of spin dynamics, based on promising and useful theory of Floquet-Magnus expansion. This theory provides procedures to control and describe the spin dynamics in solid-state NMR. Major applications of the Floquet-Magnus expansion are illustrated by simple solid-state NMR and physical applications such as in nuclear, atomic, molecular physics, and quantum mechanics, NMR, quantum field theory and high energy physics, electromagnetism, optics, general relativity, search of periodic orbits, and geometric control of mechanical systems. The aim of this report is to bring to the attention of the spin dynamics community, the bridge that exists between solid-state NMR and other related fields of physics and applied mathematics. This review article also discusses future potential theoretical directions in solid-state NMR. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Mananga, Eugene Stephane] Harvard Univ, Sch Med, 55 Fruit St, Boston, MA 02114 USA.
[Mananga, Eugene Stephane] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Div Nucl Med & Mol Imaging Phys, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
[Charpentier, Thibault] CEA, IRAMIS, CNRS UMR 3299, Serv Interdisciplinaire Syst Mol & Mat, F-91191 Gif Sur Yvette, France.
RP Mananga, ES (reprint author), Harvard Univ, Sch Med, 55 Fruit St, Boston, MA 02114 USA.; Mananga, ES (reprint author), Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Div Nucl Med & Mol Imaging Phys, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
EM emananga@gradcenter.cuny.edu; thibault.charpentier@cea.fr
RI Charpentier, Thibault/A-3557-2010
OI Charpentier, Thibault/0000-0002-3034-1389
FU National Institute of Health (NIH) of USA [R01-HL110241, T32 EB013180]
FX Eugene S. Mananga acknowledges assistance from Harvard University,
Harvard Medical School (HMS), Massachusetts General Hospital (MGH), and
the National Institute of Health (NIH) of USA, under Grants R01-HL110241
and T32 EB013180. The author particularly thanks the Division of Nuclear
Medicine and the Department of Radiology for allowing him to work
partially on this NMR and Physics Report during his NIHT32 tenure time
at Harvard and Massachusetts General Hospital. The authors are grateful
for encouragement and fruitful discussions with Professor Dr. Eduard B.
Fel'dman (Academy of Sciences of the Soviet Union, USSR) for reading the
manuscript and providing very useful advises particularly in the context
of Provotorov's theory. The first author recognizes that the idea of
writing a general review on various theories used to control the spin
dynamics in the field of nuclear magnetic resonance came to his mind for
the first time while he was a Postdoctorate Research Associate at the
National High Magnetic Field Laboratory of USA, working on the
application of Solid-State Nuclear Magnetic Resonance to Structural
Biology and Membrane Proteins. He was first, introduced to solid-state
nuclear magnetic resonance by Prof. Steven Greenbaum (City University of
New York-Hunter College) during his graduate work on "High Pressure NMR"
[210,211]. During and after his graduate studies, the first author has
benefited from enlightening discussions, mentorship, and strong support
from Prof. Joel Gersten (City College of New York). Special thanks for
that, as much as for the kind of hospitality extended to him during his
graduate studies at City College of the City University of New York. The
first author is also grateful to Emeritus University Distinguished
Professor of Physics, Herman Z. Cummins (City College of New York), for
giving him advanced tutoring on modern physics topics during the
preparation of the "hard Physics" qualifying exam of the Graduate
Center. He had his first interest to the technique of average
Hamiltonian theory (AHT) while working with Dr. Gregory Boutis (City
University of New York, Brooklyn College). The first author also gives
special thanks to Dr. Thibault Charpentier (French Atomic Energy
Commission, CEA-Saclay) for introducing him to the field of Floquet
theory during his work at CEA-Saclay. We thank collaboratoration with
Prof. Bingwen Hu (Shanghai Key Laboratory of Magnetic Resonance at East
China Normal University) and his helpful discussions. Advices and
intellectual support from Prof. Dennis Brown, Prof. Frederic Fahey, and
Prof. Arkadiusz Sitek (Harvard University, Massachusetts General
Hospital, and Boston Children Hospital) are acknowledged. Physics
teaching support from Prof. Lorcan Folan and Prof. Valery Sheverev (New
York University) is also acknowledged. Friendly discussions with Drs.
Christopher Renner, Michele Vittadello, and George Bennett (City
University of New York, HC, MEC, BCC) are appreciated. The author also
thanks Dr. Gael De Paepe (French Atomic Energy Commission, CEA-Grenoble)
for providing him his preprint article on TSAR. Finally, the author
thanks fruitful and illuminating lectures (Edward Witten, Philip
Anderson, etc.) on condensed matter theory during the 2015 summer school
(Princeton University and the Institute of Advanced Studies). The
contents of this paper are solely the responsibility of the author and
do not represent the official views of NIH/HMS/MGH.
NR 260
TC 3
Z9 3
U1 1
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0370-1573
EI 1873-6270
J9 PHYS REP
JI Phys. Rep.-Rev. Sec. Phys. Lett.
PD JAN 22
PY 2016
VL 609
BP 1
EP 49
DI 10.1016/j.physrep.2015.10.005
PG 49
WC Physics, Multidisciplinary
SC Physics
GA DC4RY
UT WOS:000369209200001
ER
PT J
AU Roh, J
Rhee, J
Chaudhari, V
Rosenzweig, A
AF Roh, Jason
Rhee, James
Chaudhari, Vinita
Rosenzweig, Anthony
TI The Role of Exercise in Cardiac Aging From Physiology to Molecular
Mechanisms
SO CIRCULATION RESEARCH
LA English
DT Review
DE aging; cardiovascular diseases; exercise; heart; phenotype
ID PRESERVED EJECTION FRACTION; CHRONIC HEART-FAILURE; GROWTH-FACTOR-I;
MITOCHONDRIAL-DNA MUTATIONS; LEFT-VENTRICULAR COMPLIANCE; OXIDATIVE
STRESS-RESPONSE; ADENOVIRAL GENE-TRANSFER; AGE-ASSOCIATED CHANGES; HUMAN
SKELETAL-MUSCLE; TRAINED OLD RATS
AB Aging induces structural and functional changes in the heart that are associated with increased risk of cardiovascular disease and impaired functional capacity in the elderly. Exercise is a diagnostic and therapeutic tool, with the potential to provide insights into clinical diagnosis and prognosis, as well as the molecular mechanisms by which aging influences cardiac physiology and function. In this review, we first provide an overview of how aging impacts the cardiac response to exercise, and the implications this has for functional capacity in older adults. We then review the underlying molecular mechanisms by which cardiac aging contributes to exercise intolerance, and conversely how exercise training can potentially modulate aging phenotypes in the heart. Finally, we highlight the potential use of these exercise models to complement models of disease in efforts to uncover new therapeutic targets to prevent or treat heart disease in the aging population.
C1 [Roh, Jason; Rhee, James; Chaudhari, Vinita; Rosenzweig, Anthony] Massachusetts Gen Hosp, Div Cardiovasc, Boston, MA 02114 USA.
[Roh, Jason] Massachusetts Gen Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02114 USA.
[Rhee, James] Harvard Univ, Sch Med, Boston, MA USA.
RP Rosenzweig, A (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St,Bigelow 800,Mailstop 817, Boston, MA 02114 USA.
EM arosenzweig@partners.org
FU National Institutes of Health [R01HL110733, R01HL122987, T32HL073734,
T32GM007592]; LaDue Fellowship Award from Harvard Medical School
FX This work was supported by grants from the National Institutes of Health
(A. Rosenzweig [R01HL110733 and R01HL122987], Dr Roh [T32HL073734], and
J. Rhee [T32GM007592]). Roh was also supported by a LaDue Fellowship
Award from Harvard Medical School. A. Rosenzweig is a principal faculty
member of the Harvard Stem Cell Institute.
NR 220
TC 3
Z9 3
U1 3
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD JAN 22
PY 2016
VL 118
IS 2
BP 279
EP 295
DI 10.1161/CIRCRESAHA.115.305250
PG 17
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Hematology
GA DB7WZ
UT WOS:000368729100014
PM 26838314
ER
PT J
AU Sinha, P
Aarnisalo, P
Chubb, R
Poulton, IJ
Guo, J
Nachtrab, G
Kimura, T
Swami, S
Saeed, H
Chen, M
Weinstein, LS
Schipani, E
Sims, NA
Kronenberg, HM
Wu, JY
AF Sinha, Partha
Aarnisalo, Piia
Chubb, Rhiannon
Poulton, Ingrid J.
Guo, Jun
Nachtrab, Gregory
Kimura, Takaharu
Swami, Srilatha
Saeed, Hamid
Chen, Min
Weinstein, Lee S.
Schipani, Ernestina
Sims, Natalie A.
Kronenberg, Henry M.
Wu, Joy Y.
TI Loss of G(s)alpha in the Postnatal Skeleton Leads to Low Bone Mass and a
Blunted Response to Anabolic Parathyroid Hormone Therapy
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID OSTEOBLASTIC CELLS; MESENCHYMAL PROGENITORS; POSTMENOPAUSAL WOMEN;
INTERMITTENT PTH; PHOSPHOLIPASE-C; MINERAL DENSITY; PROTEIN-KINASE;
IN-VIVO; DIFFERENTIATION; RECEPTOR
AB Parathyroid hormone (PTH) is an important regulator of osteoblast function and is the only anabolic therapy currently approved for treatment of osteoporosis. The PTH receptor (PTH1R) is a G protein-coupled receptor that signals via multiple G proteins including G(s)alpha. Mice expressing a constitutively active mutant PTH1R exhibited a dramatic increase in trabecular bone that was dependent upon expression of G(s)alpha in the osteoblast lineage. Postnatal removal of G(s)alpha in the osteoblast lineage (P-G(s)alpha(OsxKO) mice) yielded markedly reduced trabecular and cortical bone mass. Treatment with anabolic PTH(1-34) (80 mu g/kg/day) for 4 weeks failed to increase trabecular bone volume or cortical thickness in male and female P-G(s)alpha(OsxKO) mice. Surprisingly, in both male and female mice, PTH administration significantly increased osteoblast numbers and bone formation rate in both control and P-G(s)alpha(OsxKO) mice. In mice that express a mutated PTH1R that activates adenylyl cyclase and protein kinase A (PKA) via G(s)alpha but not phospholipase C via G(q/11) (D/D mice), PTH significantly enhanced bone formation, indicating that phospholipase C activation is not required for increased bone turnover in response to PTH. Therefore, although the anabolic effect of intermittent PTH treatment on trabecular bone volume is blunted by deletion of G(s)alpha in osteoblasts, PTH can stimulate osteoblast differentiation and bone formation. Together these findings suggest that alternative signaling pathways beyond G(s)alpha and G(q/11) act downstream of PTH on osteoblast differentiation.
C1 [Sinha, Partha; Aarnisalo, Piia; Chubb, Rhiannon; Guo, Jun; Nachtrab, Gregory; Kronenberg, Henry M.; Wu, Joy Y.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Aarnisalo, Piia] Univ Helsinki, Dept Clin Chem, Helsinki 00029, Finland.
[Aarnisalo, Piia] Univ Helsinki, Cent Hosp, HUSLAB, Lab Serv, Helsinki 00029, Finland.
[Poulton, Ingrid J.; Sims, Natalie A.] Univ Melbourne, St Vincents Inst, Fitzroy, Vic 3065, Australia.
[Poulton, Ingrid J.; Sims, Natalie A.] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia.
[Kimura, Takaharu; Swami, Srilatha; Saeed, Hamid; Wu, Joy Y.] Stanford Univ, Sch Med, Div Endocrinol, 300 Pasteur Dr,S-025, Stanford, CA 94305 USA.
[Chen, Min; Weinstein, Lee S.] NIDDK, NIH, Metab Dis Branch, Bethesda, MD 20892 USA.
[Schipani, Ernestina] Univ Michigan, Dept Orthoped Surg, Ann Arbor, MI 48109 USA.
[Schipani, Ernestina] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA.
RP Wu, JY (reprint author), Stanford Univ, Sch Med, Div Endocrinol, 300 Pasteur Dr,S-025, Stanford, CA 94305 USA.
EM jywu1@stanford.edu
FU National Institutes of Health [AR054741, AR059942, AR061228, DK011794];
NIDDK Intramural Research Program
FX This work was supported by National Institutes of Health Grants AR054741
and AR059942 (to J. Y. W.), AR061228 (to P. S.), and DK011794 (to H. M.
K.) and the NIDDK Intramural Research Program (to M. C. and L. S. W.).
The authors declare that they have no conflicts of interest with the
contents of this article. The content is solely the responsibility of
the authors and does not necessarily represent the official views of the
National Institutes of Health.
NR 50
TC 4
Z9 4
U1 1
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 22
PY 2016
VL 291
IS 4
BP 1631
EP 1642
DI 10.1074/jbc.M115.679753
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DB6JI
UT WOS:000368620700008
PM 26598522
ER
PT J
AU Novgorodov, SA
Riley, CL
Keffler, JA
Yu, J
Kindy, MS
Macklin, WB
Lombard, DB
Gudz, TI
AF Novgorodov, Sergei A.
Riley, Christopher L.
Keffler, Jarryd A.
Yu, Jin
Kindy, Mark S.
Macklin, Wendy B.
Lombard, David B.
Gudz, Tatyana I.
TI SIRT3 Deacetylates Ceramide Synthases IMPLICATIONS FOR MITOCHONDRIAL
DYSFUNCTION AND BRAIN INJURY
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID FOCAL CEREBRAL-ISCHEMIA; MANGANESE SUPEROXIDE-DISMUTASE; PERMEABILITY
TRANSITION PORE; RADIATION-INDUCED APOPTOSIS; OXYGEN SPECIES GENERATION;
REACTIVE OXYGEN; CYCLOPHILIN-D; CELL-DEATH; SERINE PALMITOYLTRANSFERASE;
SPHINGOLIPID BIOSYNTHESIS
AB Experimental evidence supports the role of mitochondrial ceramide accumulation as a cause of mitochondrial dysfunction and brain injury after stroke. Herein, we report that SIRT3 regulates mitochondrial ceramide biosynthesis via deacetylation of ceramide synthase (CerS) 1, 2, and 6. Reciprocal immunoprecipitation experiments revealed that CerS1, CerS2, and CerS6, but not CerS4, are associated with SIRT3 in cerebral mitochondria. Furthermore, CerS1, -2, and -6 are hyperacetylated in the mitochondria of SIRT3-null mice, and SIRT3 directly deacetylates the ceramide synthases in aNAD(+)-dependent manner that increases enzyme activity. Investigation of the SIRT3 role in mitochondrial response to brain ischemia/reperfusion (IR) showed that SIRT3-mediated deacetylation of ceramide synthases increased enzyme activity and ceramide accumulation after IR. Functional studies demonstrated that absence of SIRT3 rescued the IR-induced blockade of the electron transport chain at the level of complex III, attenuated mitochondrial outer membrane permeabilization, and decreased reactive oxygen species generation and protein carbonyls in mitochondria. Importantly, Sirt3 gene ablation reduced the brain injury after IR. These data support the hypothesis that IR triggers SIRT3-dependent deacetylation of ceramide synthases and the elevation of ceramide, which could inhibit complex III, leading to increased reactive oxygen species generation and brain injury. The results of these studies highlight a novel mechanism of SIRT3 involvement in modulating mitochondrial ceramide biosynthesis and suggest an important role of SIRT3 in mitochondrial dysfunction and brain injury after experimental stroke.
C1 [Riley, Christopher L.; Kindy, Mark S.; Gudz, Tatyana I.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
[Novgorodov, Sergei A.; Keffler, Jarryd A.; Yu, Jin; Gudz, Tatyana I.] Med Univ S Carolina, Dept Neurosci Med, Charleston, SC 29425 USA.
[Macklin, Wendy B.] Univ Colorado, Dept Cell & Dev Biol, Aurora, CO 80045 USA.
[Lombard, David B.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
[Lombard, David B.] Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA.
RP Gudz, TI (reprint author), 114 Doughty St, Charleston, SC 29425 USA.
EM gudz@musc.edu
FU National Institutes of Health [R01NS083544, R01GM101171, P30 GM103339];
Veterans Affairs Merit Award [I01BX001104]
FX This work was supported in part by National Institutes of Health Grants
R01NS083544 (to T. I. G.), R01GM101171 (to D. B. L.), and P30 GM103339
(to Lipidomics Core Facility. Medical University of South Carolina) and
Veterans Affairs Merit Award I01BX001104 (to T. I. G.). The authors
declare that they have no conflicts of interest with the contents of
this article. The content is solely the responsibility of the authors
and does not necessarily represent the official views of the National
Institutes of Health.
NR 81
TC 4
Z9 4
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 22
PY 2016
VL 291
IS 4
BP 1957
EP 1973
DI 10.1074/jbc.M115.668228
PG 17
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DB6JI
UT WOS:000368620700033
PM 26620563
ER
PT J
AU Belstrom, D
Holmstrup, P
Bardow, A
Kokaras, A
Fiehn, NE
Paster, BJ
AF Belstrom, Daniel
Holmstrup, Palle
Bardow, Allan
Kokaras, Alexis
Fiehn, Nils-Erik
Paster, Bruce J.
TI Temporal Stability of the Salivary Microbiota in Oral Health
SO PLOS ONE
LA English
DT Article
ID PERIODONTAL-DISEASE; BIOMARKERS; INDIVIDUALS; PATTERNS; DIAGNOSTICS;
DIVERSITY; ANALYTES; LESIONS; COHORT; ADULTS
AB Objectives
Saliva is a biological fluid suitable for biomarker analysis, and differences in the salivary microbiota in oral health and disease have been reported. For such comparative analyses, time of sampling is critical since the bacterial composition may vary throughout the day, i.e., diurnal variation. The purpose of this study is to compare the salivary microbiome over time to determine the optimal time for sampling.
Design
Stimulated saliva samples were collected from 5 orally healthy individuals in 4 h intervals for 24 h, and collection was repeated 7 days later (number of samples per person, n = 12, total number of samples, n = 60). Salivary microbiota was analyzed using the Human Oral Microbe Identification using Next Generation Sequencing (HOMINGS), and statistical analysis was performed using the Kruskal-Wallis test with Benjamini-Hochberg's correction for multiple comparisons, cluster analysis, principal component analysis and correspondence analysis.
Results
From a total of 60 saliva samples, 477 probe targets were collectively identified with a mean number of probes per sample of 207 (range: 153-307). Little or no variation in microbial profiles within subjects was observed over time.
Conclusions
Although there was considerable variation between subjects, microbial profiles within subjects were stable throughout a 24 hour period and after 1 week. Since there is little or no evidence of diurnal variation of the salivary microbiome, time of sampling of saliva is not critical for perturbation or other microbial studies.
C1 [Belstrom, Daniel; Holmstrup, Palle] Univ Copenhagen, Sect Periodontol Microbiol & Community Dent, Fac Hlth & Med Sci, Sch Dent, Copenhagen, Denmark.
[Bardow, Allan] Univ Copenhagen, Sch Dent, Dept Oral Med, Copenhagen, Denmark.
[Kokaras, Alexis; Paster, Bruce J.] Forsyth Inst, Dept Microbiol, Cambridge, MA USA.
[Fiehn, Nils-Erik] Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark.
[Paster, Bruce J.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, 188 Longwood Ave, Boston, MA 02115 USA.
RP Belstrom, D (reprint author), Univ Copenhagen, Sect Periodontol Microbiol & Community Dent, Fac Hlth & Med Sci, Sch Dent, Copenhagen, Denmark.
EM dbel@sund.ku.dk
FU Danish Dental Association; Danish Foundation of Mutual Efforts in Dental
Care; Trygfonden; Simon Spies Foundation; NIH [DE021565]
FX This study was supported by external financial support by: the Danish
Dental Association, the Danish Foundation of Mutual Efforts in Dental
Care, Trygfonden, and the Simon Spies Foundation. It was also funded in
part from NIH grant DE021565 (BJP). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript
NR 35
TC 5
Z9 5
U1 3
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 22
PY 2016
VL 11
IS 1
AR e0147472
DI 10.1371/journal.pone.0147472
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DB6WB
UT WOS:000368655300111
PM 26799067
ER
PT J
AU Cahill, CM
Zhu, WS
Oziolor, E
Yang, YJ
Tam, B
Rajanala, S
Rogers, JT
Walker, WA
AF Cahill, Catherine M.
Zhu, Weishu
Oziolor, Elias
Yang, Yao-Jong
Tam, Bosco
Rajanala, Susruthi
Rogers, Jack T.
Walker, W. Allan
TI Differential Expression of the Activator Protein 1 Transcription Factor
Regulates Interleukin-1 beta Induction of Interleukin 6 in the
Developing Enterocyte
SO PLOS ONE
LA English
DT Article
ID DEVELOPING HUMAN INTESTINE; EPITHELIAL-CELL LINE; C-JUN; NECROTIZING
ENTEROCOLITIS; SIGNAL-TRANSDUCTION; AP-1; IL-6; PATHWAY; INJURY;
INFLAMMATION
AB The innate immune response is characterized by activation of transcription factors, nuclear factor kappa B and activator protein-1 and their downstream targets, the pro-inflammatory cytokines including interleukin 1 beta and interleukin 6. Normal development of this response in the intestine is critical to survival of the human neonate and delays can cause the onset of devastating inflammatory diseases such as necrotizing enterocolitis. Previous studies have addressed the role of nuclear factor kappa B in the development of the innate immune response in the enterocyte, however despite its central role in the control of multiple pro-inflammatory cytokine genes, little is known on the role of Activator Protein 1 in this response in the enterocyte. Here we show that the canonical Activator Protein 1 members, cJun and cFos and their upstream kinases JNK and p38 play an essential role in the regulation of interleukin 6 in the immature enterocyte. Our data supports a model whereby the cFos/cJun heterodimer and the more potent cJun homodimer downstream of JNK are replaced by less efficient JunD containing dimers, contributing to the decreased responsiveness to interleukin 1 beta and decreased interleukin 6 secretion observed in the mature enterocyte. The tissue specific expression of JunB in colonocytes and colon derived tissues together with its ability to repress Interleukin-1 beta induction of an Interleukin-6 gene reporter in the NCM-460 colonocyte suggests that induction of JunB containing dimers may offer an attractive therapeutic strategy for the control of IL-6 secretion during inflammatory episodes in this area of the intestine
C1 [Cahill, Catherine M.; Tam, Bosco; Rajanala, Susruthi; Rogers, Jack T.] Massachusetts Gen Hosp, Dept Psychiat, Neurochem Lab, Charlestown, MA USA.
[Cahill, Catherine M.; Zhu, Weishu; Tam, Bosco; Rajanala, Susruthi; Rogers, Jack T.; Walker, W. Allan] Harvard Univ, Sch Med, Charlestown, MA USA.
[Zhu, Weishu; Walker, W. Allan] Massachusetts Gen Hosp Children, Dept Pediat, Mucosal Immunol & Biol Res Ctr, Charlestown, MA USA.
[Oziolor, Elias] Baylor Univ, Dept Environm Sci, One Bear Pl 97266, Waco, TX 76798 USA.
[Yang, Yao-Jong] Natl Cheng Kung Univ, Dept Pediat, Tainan 701, Taiwan.
[Yang, Yao-Jong] Natl Cheng Kung Univ, Dept Internal Med, Tainan 701, Taiwan.
RP Cahill, CM (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Neurochem Lab, Charlestown, MA USA.
EM ccahill@helix.mgh.harvard.edu
RI Oziolor, Elias/P-6961-2016
OI Oziolor, Elias/0000-0002-4078-1054
FU National Institute of Child Health and Human Development
[R01HD012437Supplement29, R01HD012437]; National Institute of
Neurological Disorders and Stroke [NS077079-01A1]
FX External Funding was obtained as follows: CMC R01HD012437Supplement29
(National Institute of Child Health and Human Development,
https://www.nichd.nih.gov/Pages/index.aspx), WAW R01HD012437 (National
Institute of Child Health and Human Development,
https://www.nichd.nih.gov/Pages/index.aspx), JTR NS077079-01A1 (National
Institute of Neurological Disorders and Stroke
http://www.ninds.nih.gov/). The funders had no role in study design,
data collection and analysis, decision to publish or preparation of the
manuscript.
NR 49
TC 2
Z9 2
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 22
PY 2016
VL 11
IS 1
AR e0145184
DI 10.1371/journal.pone.0145184
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DB6WB
UT WOS:000368655300003
PM 26799482
ER
PT J
AU Toro, ML
Eke, C
Pearlman, J
AF Toro, Maria L.
Eke, Chika
Pearlman, Jonathan
TI The impact of the World Health Organization 8-steps in wheelchair
service provision in wheelchair users in a less resourced setting: a
cohort study in Indonesia
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
DE Wheelchairs; Wheelchair service provision; Quality of life;
Participation; Wheelchair skills; Less resourced settings
ID SPINAL-CORD-INJURY; ASSISTIVE TECHNOLOGY USE; LOW-COST WHEELCHAIR;
QUALITY-OF-LIFE; DEVELOPING-COUNTRIES; ADVERSE CONSEQUENCES; SKILLS;
REHABILITATION; DISABILITIES; CONVENTION
AB Background: For people who have a mobility impairment, access to an appropriate wheelchair is an important step towards social inclusion and participation. The World Health Organization Guidelines for the Provision of Manual Wheelchairs in Less Resourced Settings emphasize the eight critical steps for appropriate wheelchair services, which include: referral, assessment, prescription, funding and ordering, product preparation, fitting and adjusting, user training, and follow-up and maintenance/repairs. The purpose of this study was to investigate how the provision of wheelchairs according to the World Health Organization's service provision process by United Cerebral Palsy Wheels for Humanity in Indonesia affects wheelchair recipients compared to wait-listed controls.
Methods: This study used a convenience sample (N = 344) of Children, Children with proxies, Adults, and Adults with proxies who were on a waiting list to receive a wheelchair as well as those who received one. Interviews were conducted at baseline and a 6 month follow-up to collect the following data: Demographics and wheelchair use questions, the World Health Organization Quality of Life-BREF, Functional Mobility Assessment, Craig Handicap Assessment Recording Technique Short Form. The Wheelchair Assessment Checklist and Wheelchair Skills Test Questionnaire were administered at follow up only.
Results: 167 participants were on the waiting list and 142 received a wheelchair. Physical health domain in the World Health Organization Quality of Life-BREF improved significantly for women who received a wheelchair (p = 0.044) and environmental health improved significantly for women and men who received a wheelchair as compared to those on the waiting list (p < 0.017). Satisfaction with the mobility device improved significantly for Adults with proxies and Children with proxies as compared to the waiting list (p < 0.022). Only 11 % of Adults who received a wheelchair reported being able to perform a "wheelie". The condition of Roughrider wheelchairs was significantly better than the condition of kids wheelchairs for Children with proxies as measured by the Wheelchair Assessment Checklist (p = 0.019).
Conclusions: Wheelchair provision according to World Health Organization's 8-Steps in a less-resourced setting has a range of positive outcomes including increased satisfaction with the mobility device and better quality of life. Wheelchair provision service could be improved by providing more hours of wheelchair skills training. There is a need for outcome measures that are validated across cultures and languages.
C1 [Toro, Maria L.; Pearlman, Jonathan] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA.
[Toro, Maria L.; Pearlman, Jonathan] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
[Toro, Maria L.] Escuela Ingn Antioquia, Programa Ingn Biomed, Envigado, Antioquia, Colombia.
[Toro, Maria L.] Univ CES, Envigado, Antioquia, Colombia.
[Eke, Chika] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
RP Pearlman, J (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA.; Pearlman, J (reprint author), Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
EM Jlp46@pitt.edu
FU United States Agency for International Development grant
[GPO-A-00-04-00021-00 SPANS 001]; National Science Foundation; ASPIRE
Grant [1262670]; VA Center Grant [B6789C]
FX Funding provided by United States Agency for International Development
grant to World Learning GPO-A-00-04-00021-00 SPANS 001, the National
Science Foundation, ASPIRE Grant #1262670 and VA Center Grant #B6789C.
The contents of this paper do not represent the views of the Department
of Veterans Affairs or the United States Government. The authors would
like to thank the personnel of UCP Wheels for Humanity and UCP Roda
Untuk Kemanusiaan specially Heny Prabaningrum. The authors will like to
thank Dr. Andi Saptono for his contribution during the on-site training
week in Indonesia.
NR 72
TC 1
Z9 1
U1 1
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD JAN 22
PY 2016
VL 16
AR 26
DI 10.1186/s12913-016-1268-y
PG 12
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DB5SL
UT WOS:000368573800001
PM 26801984
ER
PT J
AU Nossenson, N
Magal, A
Messer, H
AF Nossenson, Nir
Magal, An
Messer, Hagit
TI Detection of stimuli from multi-neuron activity: Empirical study and
theoretical implications
SO NEUROCOMPUTING
LA English
DT Article
DE Stimulus detection; Gaussian signal in Gaussian noise;
Electrophysiology; Multi unit activity; Decision making; Glutamate
uptake rate
ID AUDITORY-NERVE FIBERS; ENERGY DETECTION; GLUTAMATE UPTAKE;
DECISION-MAKING; NORMAL WAKEFULNESS; RESPONSE PATTERNS; ASTROCYTES;
CALCIUM; SIGNALS; MODELS
AB We report on detection results obtained in 20 experiments in which the presence of an external auditory stimulus had to be detected from observing electrophysiological multi-unit activity in the brain stem of rats. The performance of the optimal Gaussian-signal-in-Gaussian-noise (model-based) detector is compared to that of the energy detector which is widely used in electrophysiology as well as in many other disciplines with similar signal characteristics. It is shown that the optimal model based detector is indeed superior, but the performance gap in favor of the optimal detector is substantial mainly in very low probabilities of false alarm errors. The performance of the energy detector is close to optimum in moderate and high probabilities of false alarm error. Furthermore, the energy detector is shown to be more resilient to isolated and short, yet intense disturbances. We discuss a conjecture inspired by the model underlying the optimal detector and the empirical results, that the neural tissue itself executes a modified energy detection scheme, and we review experimental results from the literature that allegedly support this conjecture. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Nossenson, Nir] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Nossenson, Nir] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Magal, An] Tel Aviv Univ, Sch Psychol Sci, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel.
[Messer, Hagit] Tel Aviv Univ, Sch Elect Engn, IL-69978 Tel Aviv, Israel.
RP Nossenson, N (reprint author), Massachusetts Gen Hosp, Dept Neurol, 50 Blossom St, Boston, MA 02114 USA.
EM nnossenson@mgh.harvard.edu; poochoor@gmail.com; messer@eng.tau.ac.il
NR 65
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-2312
EI 1872-8286
J9 NEUROCOMPUTING
JI Neurocomputing
PD JAN 22
PY 2016
VL 174
BP 822
EP 837
DI 10.1016/j.neucom.2015.10.007
PN B
PG 16
WC Computer Science, Artificial Intelligence
SC Computer Science
GA CZ7JY
UT WOS:000367276900027
ER
PT J
AU Tabebordbar, M
Zhu, KX
Cheng, JKW
Chew, WL
Widrick, JJ
Yan, WX
Maesner, C
Wu, EY
Xiao, R
Ran, FA
Cong, L
Zhang, F
Vandenberghe, LH
Church, GM
Wagers, AJ
AF Tabebordbar, Mohammadsharif
Zhu, Kexian
Cheng, Jason K. W.
Chew, Wei Leong
Widrick, Jeffrey J.
Yan, Winston X.
Maesner, Claire
Wu, Elizabeth Y.
Xiao, Ru
Ran, F. Ann
Cong, Le
Zhang, Feng
Vandenberghe, Luk H.
Church, George M.
Wagers, Amy J.
TI In vivo gene editing in dystrophic mouse muscle and muscle stem cells
SO SCIENCE
LA English
DT Article
ID MUSCULAR-DYSTROPHY; EXONS 45-55; DMD GENE; MICE; DNA; MUTATION; SYSTEM;
CAS9
AB Frame-disrupting mutations in the DMD gene, encoding dystrophin, compromise myofiber integrity and drive muscle deterioration in Duchenne muscular dystrophy (DMD). Removing one or more exons from the mutated transcript can produce an in-frame mRNA and a truncated, but still functional, protein. In this study, we developed and tested a direct gene-editing approach to induce exon deletion and recover dystrophin expression in the mdx mouse model of DMD. Delivery by adeno-associated virus (AAV) of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 endonucleases coupled with paired guide RNAs flanking the mutated Dmd exon23 resulted in excision of intervening DNA and restored the Dmd reading frame in myofibers, cardiomyocytes, and muscle stem cells after local or systemic delivery. AAV-Dmd CRISPR treatment partially recovered muscle functional deficiencies and generated a pool of endogenously corrected myogenic precursors in mdx mouse muscle.
C1 [Tabebordbar, Mohammadsharif; Zhu, Kexian; Cheng, Jason K. W.; Maesner, Claire; Wu, Elizabeth Y.; Wagers, Amy J.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Tabebordbar, Mohammadsharif; Zhu, Kexian; Cheng, Jason K. W.; Maesner, Claire; Wu, Elizabeth Y.; Wagers, Amy J.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Tabebordbar, Mohammadsharif; Chew, Wei Leong] Harvard Univ, Sch Med, Biol & Biomed Sci Program, Boston, MA 02115 USA.
[Zhu, Kexian] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
[Chew, Wei Leong; Church, George M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Widrick, Jeffrey J.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Genet & Program Genom, Boston, MA 02115 USA.
[Yan, Winston X.; Ran, F. Ann; Cong, Le; Zhang, Feng] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Yan, Winston X.; Ran, F. Ann; Cong, Le; Zhang, Feng] MIT, Dept Brain & Cognit Sci, McGovern Inst Brain Res, Cambridge, MA 02139 USA.
[Yan, Winston X.; Ran, F. Ann; Cong, Le; Zhang, Feng] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
[Xiao, Ru; Vandenberghe, Luk H.] Sr,hepens Eye Res Inst, Grousbeck Gene Therapy Ctr, Boston, MA 02114 USA.
[Xiao, Ru; Vandenberghe, Luk H.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
RP Wagers, AJ (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
EM amy_wagers@harvard.edu
OI Zhu, Kexian/0000-0002-2321-5085
FU Howard Hughes Medical Institute; NIH [1DP2OD004345, 5U01HL100402,
5PN2EY018244]; National Institute of General Medical Sciences (NIGMS),
NIH [T2GM007753]; National Institute of Mental Health, NIH
[5DP1-MH100706]; National Institute of Diabetes and Digestive and Kidney
Diseases, NIH [5R01DK097768-03]; Waterman Award from the NSF; Keck
Foundation; New York Stem Cell Foundation; Damon Runyon Foundation;
Searle Scholars Foundation; Merkin Foundation; Vallee Foundation; B.
Metcalfe; National Science Scholarship from the Agency for Science,
Technology, and Research (A*STAR), Singapore; National Human Genome
Research Institute (NIGMS), NIH, Centers of Excellence in Genomic
Science [P50 HG005550]; Regeneron Pharmaceuticals; Cowen; Jefferies;
Sectoral
FX We thank the Harvard Department of Stem Cell and Regenerative
Biology-Harvard Stem Cell Institute Flow Cytometry Core, the Schepens
Eye Research Institute-Massachusetts Eye and Ear Institute Gene Transfer
Vector Core, the Parker lab at Harvard and J. Goldstein for technical
assistance. Work was funded in part by grants from Howard Hughes Medical
Institute and NIH (1DP2OD004345, 5U01HL100402, and 5PN2EY018244) to
A.J.W. M.T. is an Albert J. Ryan fellow. F.A.R. is a Junior Fellow at
the Harvard Society of Fellows. W.X.Y. was supported by T2GM007753 from
the National Institute of General Medical Sciences (NIGMS), NIH. F.Z. is
a New York Stem Cell Foundation Robertson Investigator and is supported
by National Institute of Mental Health, NIH (5DP1-MH100706) and National
Institute of Diabetes and Digestive and Kidney Diseases, NIH
(5R01DK097768-03); a Waterman Award from the NSF; the Keck, New York
Stem Cell, Damon Runyon, Searle Scholars, Merkin, and Vallee
Foundations; and B. Metcalfe. W.L.C. is supported by the National
Science Scholarship from the Agency for Science, Technology, and
Research (A*STAR), Singapore. G.M.C. is supported for this work by
National Human Genome Research Institute (NIGMS), NIH, Centers of
Excellence in Genomic Science, P50 HG005550. Content is solely the
responsibility of the authors and does not necessarily represent the
official views of NIGMS or NIH. M.T., A.J.W., W.L.C., and G.M.C. are
inventors on a patent application (PCT/US15/63181) filed by Harvard
University related to in vivo genetic modifications and gene editing in
muscle. G.M.C. is an inventor on issued patents (US9023649 and
US9074199) filed by Harvard University related to CRISPR. L.H.V. is an
inventor on a patent application (US2007036760) filed by the University
of Pennsylvania related to AAV capsid sequences. F.Z., L.C., F.A.R., and
W.Y. are inventors on patents and patent applications (8,865,406;
8,906,616; and accepted EP 2898075, from international patent
application WO 2014/093635) filed by the Broad Institute related to
SaCas9-optimized components and systems. A.J.W. is an advisor for Fate
Therapeutics. G.M.C and F.Z. are founders and scientific advisors of
Editas Medicine, and F.Z. is a scientific advisor for Horizon Discovery.
G.M.C. has equity in Caribou/Intellia, Egenesis, and Editas (for full
disclosure list, see: http://arep.med.harvard.edu/gmc/tech.html). L.H.V.
is cofounder, shareholder, member of the scientific advisory board, and
consultant for GenSight Biologics, a consultant to Novartis and Eleven
Bio, and has received honoraria and consulting fees from Regeneron
Pharmaceuticals and Cowen, Jefferies, and Sectoral. AAV9 vector
sequences are available through a material transfer agreement (MTA) from
the University of Pennsylvania. SaCas9 plasmids are openly available
through a Uniform Biological MTA from Addgene.
NR 26
TC 109
Z9 112
U1 38
U2 106
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JAN 22
PY 2016
VL 351
IS 6271
BP 407
EP 411
DI 10.1126/science.aad5177
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DB3VH
UT WOS:000368440500046
PM 26721686
ER
PT J
AU Benarroch-Popivker, D
Pisano, S
Mendez-Bermudez, A
Lototska, L
Kaur, P
Bauwens, S
Djerbi, N
Latrick, CM
Fraisier, V
Pei, B
Gay, A
Jaune, E
Foucher, K
Cherfils-Vicini, J
Aeby, E
Miron, S
Londono-Vallejo, A
Ye, J
Le Du, MH
Wang, H
Gilson, E
Giraud-Panis, MJ
AF Benarroch-Popivker, Delphine
Pisano, Sabrina
Mendez-Bermudez, Aaron
Lototska, Liudmyla
Kaur, Parminder
Bauwens, Serge
Djerbi, Nadir
Latrick, Chrysa M.
Fraisier, Vincent
Pei, Bei
Gay, Alexandre
Jaune, Emilie
Foucher, Kevin
Cherfils-Vicini, Julien
Aeby, Eric
Miron, Simona
Londono-Vallejo, Arturo
Ye, Jing
Le Du, Marie-Helene
Wang, Hong
Gilson, Eric
Giraud-Panis, Marie-Josephe
TI TRF2-Mediated Control of Telomere DNA Topology as a Mechanism for
Chromosome-End Protection
SO MOLECULAR CELL
LA English
DT Article
ID TOPOISOMERASE-II; DAMAGE RESPONSE; DYSFUNCTIONAL TELOMERES; PROTEINS
TRF1; BINDING; LOOP; COMPLEX; DOMAIN; PROLIFERATION; LOCALIZATION
AB The shelterin proteins protect telomeres against activation of the DNA damage checkpoints and recombinational repair. We show here that a dimer of the shelterin subunit TRF2 wraps similar to 90 bp of DNA through several lysine and arginine residues localized around its homodimerization domain. The expression of a wrapping-deficient TRF2 mutant, named Top-less, alters telomeric DNA topology, decreases the number of terminal loops (t-loops), and triggers the ATM checkpoint, while still protecting telomeres against non-homologous end joining (NHEJ). In Top-less cells, the protection against NHEJ is alleviated if the expression of the TRF2-interacting protein RAP1 is reduced. We conclude that a distinctive topological state of telomeric DNA, controlled by the TRF2-dependent DNA wrapping and linked to t-loop formation, inhibits both ATM activation and NHEJ. The presence of RAP1 at telomeres appears as a backup mechanism to prevent NHEJ when topology-mediated telomere protection is impaired.
C1 [Benarroch-Popivker, Delphine; Pisano, Sabrina; Mendez-Bermudez, Aaron; Lototska, Liudmyla; Bauwens, Serge; Djerbi, Nadir; Latrick, Chrysa M.; Pei, Bei; Gay, Alexandre; Jaune, Emilie; Foucher, Kevin; Cherfils-Vicini, Julien; Gilson, Eric; Giraud-Panis, Marie-Josephe] Univ Nice Sophia Antipolis, CNRS UMR7284, INSERM U1081, Inst Res Canc & Aging,Nice IRCAN,Fac Med, F-06189 Nice, France.
[Mendez-Bermudez, Aaron; Ye, Jing; Gilson, Eric] Shanghai Jiao Tong Univ, Pole Sino Francais Rech Sci Vivant & Genom, Int Lab Hematol & Canc, Ruijin Hosp,Sch Med,CNRS,INSERM,Nice Univ,Shangha, Shanghai 200025, Peoples R China.
[Kaur, Parminder; Wang, Hong] N Carolina State Univ, Dept Phys, Raleigh, NC 27695 USA.
[Fraisier, Vincent] UMR 144 CNRS Inst Curie, Nikon Imaging Ctr, Cell & Tissue Imaging Platform PICT IBiSA, F-75248 Paris 05, France.
[Aeby, Eric] Ecole Polytech Fed Lausanne, Swiss Inst Expt Canc Res ISREC, Sch Life Sci, CH-1015 Lausanne, Switzerland.
[Miron, Simona] Univ Paris 11, CNRS, CEA, Inst Integrat Biol Cell I2BC,CEA Saclay, F-91191 Gif Sur Yvette, France.
[Londono-Vallejo, Arturo] Inst Curie, Telomeres & Canc Lab, UMR3244, F-75248 Paris, France.
[Gilson, Eric] CHU Nice, Dept Genet, F-06202 Nice, France.
[Gay, Alexandre] Univ Paris Diderot, CNRS UMR7212, INSERM UMR944, Sorbonne Paris Cite,Hop St Louis, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.
[Latrick, Chrysa M.] Univ Strasbourg, CNRS, INSERM, Dept Genom Fonct & Canc,Inst Genet & Biol Mol & C, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.
[Miron, Simona] Inst Biochem, Splaiul Independentei 296, Bucharest 060031 17, Romania.
[Aeby, Eric] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Aeby, Eric] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
RP Gilson, E; Giraud-Panis, MJ (reprint author), Univ Nice Sophia Antipolis, CNRS UMR7284, INSERM U1081, Inst Res Canc & Aging,Nice IRCAN,Fac Med, F-06189 Nice, France.; Gilson, E (reprint author), Shanghai Jiao Tong Univ, Pole Sino Francais Rech Sci Vivant & Genom, Int Lab Hematol & Canc, Ruijin Hosp,Sch Med,CNRS,INSERM,Nice Univ,Shangha, Shanghai 200025, Peoples R China.; Gilson, E (reprint author), CHU Nice, Dept Genet, F-06202 Nice, France.
EM eric.gilson@unice.fr; giraud-panis@unice.fr
RI Wang, Hong/F-3164-2014; Aeby, Eric/A-4819-2017; Benarroch,
Delphine/E-9983-2017;
OI Wang, Hong/0000-0003-0165-3559; Aeby, Eric/0000-0002-0463-4444; Latrick,
Chrysa/0000-0003-4497-7908
FU ARC; Conseil General 06 de la Region Provence Alpes-Cote d'Azur; FEDER;
le Minitere de l'Enseignement Superieur; la region Provence Alpes-Cote
d'Azur; l'INSERM; Fondation ARC; Ligue Contre le Cancer (EG Equipe
labellise); ANR ("Teloloop'') [ANR-1582-30020690]; Institut Nationale du
Cancer (INCa) (TELOCHROM); "Investments for the Future'' LABEX SIGNALIFE
[ANR-11-LABX-0028-01]; NIH [NIH R01GM107559]
FX We greatly thank Joachim Lingner for the HeLa cell line used in this
study. This work was performed using the genomic, PICMI (supported by
ARC and the Conseil General 06 de la Region Provence Alpes-Cote d'Azur),
and CYTOMED (supported by FEDER, le Minitere de l'Enseignement
Superieur, la region Provence Alpes-Cote d'Azur, and l'INSERM)
facilities of IRCAN; we are very grateful for the help they provided. We
are also indebted to Isabelle Zanella-Cleon for mass spectrometry
analysis (Centre Commun de Micro-analyse des Proteines, IBCP Lyon). We
acknowledge the PICT-IBiSA platform of the Institut Curie, member of the
French National Research Infrastructure France-BioImaging
(ANR-10-INSB-04). We are grateful to Matteo de Chiara and Silvia Bottini
for the script of 2D probability density map on R. The AFM facility of
PICMI was supported by the ARC and Conseil General 06 de la Region
Provence Alpes-Cote d'Azur. This work was supported by grants from the
Fondation ARC, Ligue Contre le Cancer (EG Equipe labellise), ANR
("Teloloop'' ANR-1582-30020690), Institut Nationale du Cancer (INCa)
(TELOCHROM), "Investments for the Future'' LABEX SIGNALIFE (reference
ANR-11-LABX-0028-01), and an NIH grant for DREEM experiments (NIH
R01GM107559).
NR 64
TC 15
Z9 15
U1 8
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD JAN 21
PY 2016
VL 61
IS 2
BP 274
EP 286
DI 10.1016/j.molcel.2015.12.009
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DG8HX
UT WOS:000372325400010
PM 26774283
ER
PT J
AU Suh, H
Ficarro, SB
Kang, UB
Chun, YJ
Marto, JA
Buratowski, S
AF Suh, Hyunsuk
Ficarro, Scott B.
Kang, Un-Beom
Chun, Yujin
Marto, Jarrod A.
Buratowski, Stephen
TI Direct Analysis of Phosphorylation Sites on the Rpb1 C-Terminal Domain
of RNA Polymerase II
SO MOLECULAR CELL
LA English
DT Article
ID CTD CODE; TRANSCRIPTION TERMINATION; KINASE; ELONGATION; RECRUITMENT;
PHOSPHATASE; COMPLEX; CYCLE; CTK1
AB Dynamic interactions between RNA polymerase II and various mRNA-processing and chromatin-modifying enzymes are mediated by the changing phosphorylation pattern on the C-terminal domain (CTD) of polymerase subunit Rpb1 during different stages of transcription. Phosphorylations within the repetitive heptamer sequence (YSPTSPS) of CTD have primarily been defined using antibodies, but these do not distinguish different repeats or allow comparative quantitation. Using a CTD modified for mass spectrometry (msCTD), we show that Ser5-P and Ser2-P occur throughout the length of CTD and are far more abundant than other phosphorylation sites. msCTD extracted from cells mutated in several CTD kinases or phosphatases showed the expected changes in phosphorylation. Furthermore, msCTD associated with capping enzyme was enriched for Ser5-P while that bound to the transcription termination factor Rtt103 had higher levels of Ser2-P. These results suggest a relatively sparse and simple "CTD code.''
C1 [Suh, Hyunsuk; Ficarro, Scott B.; Kang, Un-Beom; Chun, Yujin; Marto, Jarrod A.; Buratowski, Stephen] Harvard Univ, Dept Biochem Chem & Mol Pharmacol, Sch Med, Boston, MA 02115 USA.
[Suh, Hyunsuk; Ficarro, Scott B.; Kang, Un-Beom; Marto, Jarrod A.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Suh, Hyunsuk; Ficarro, Scott B.; Kang, Un-Beom; Marto, Jarrod A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02115 USA.
RP Buratowski, S (reprint author), Harvard Univ, Dept Biochem Chem & Mol Pharmacol, Sch Med, Boston, MA 02115 USA.
EM steveb@hms.harvard.edu
FU DFCI/Blais Proteomics Center; NIH [GM56663]
FX This work was supported by DFCI/Blais Proteomics Center support to
J.A.M. and NIH grant GM56663 to S.B. We thank Mike Eck (HMS), Eun-Young
Park (HMS), Craig Kaplan (Texas A&M), and Claire Moore (Tufts
University) for materials; Byung-hoon Lee (HMS), Nahid Iglesias (HMS),
Tim Sikorski (HMS), and Dane Hazelbaker (HMS) for technical advice;
So-Young Hwang (HMS), J.A.M. lab members, and S.B. lab members for
helpful discussions; and Dirk Eick for antibodies and discussion of
unpublished results.
NR 26
TC 15
Z9 15
U1 8
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD JAN 21
PY 2016
VL 61
IS 2
BP 297
EP 304
DI 10.1016/j.molcel.2015.12.021
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DG8HX
UT WOS:000372325400012
PM 26799764
ER
PT J
AU Montalescot, G
Sabatine, MS
AF Montalescot, Gilles
Sabatine, Marc S.
TI Oral dual antiplatelet therapy: what have we learnt from recent trials?
SO EUROPEAN HEART JOURNAL
LA English
DT Review
DE Acute coronary syndromes; Stents; P2Y12 antagonists; Thienopyridines;
Aspirin
ID PERCUTANEOUS CORONARY INTERVENTION; ST-SEGMENT ELEVATION; ELUTING STENT
IMPLANTATION; RANDOMIZED MULTICENTER TRIAL; PRIOR MYOCARDIAL-INFARCTION;
CLOPIDOGREL PRETREATMENT; SECONDARY PREVENTION; PCI; PRASUGREL; EVENTS
AB International guidelines recommend the use of aspirin treatment immediately and indefinitely in coronary patients. The optimal time to start and the duration of dual antiplatelet therapy (DAPT; aspirin plus a P2Y12 inhibitor) have not been clearly established. Recent clinical trials have provided important new information allowing for evidence-based decisions regarding timing of initiation and duration of DAPT. The benefit-to-risk ratio of DAPT pre-treatment appears to depend on the type of acute coronary syndrome, the time until angiography, and the onset of action of the drug. In stable patients undergoing percutaneous coronary intervention with the latest generation drug-eluting stents, patients should be treated for at least similar to 6 months. Shorter courses of therapy may be necessary when special conditions occur (e.g. surgery; oral anticoagulation). Longer courses of therapy may be reasonable in patients at low bleeding risk who are tolerating DAPT well. For patients with ACS, prolonged DAPT is beneficial and therefore reasonable as long as the patient is tolerating the therapy. Individualized management of DAPT must be seen as a dynamic prescription with regular re-evaluations of the risk-benefit to the patient according to changes in his/her clinical profile.
C1 [Montalescot, Gilles] Univ Paris 06, Hop La Pitie Salpetriere, AP HP, ACT Study Grp,Inst Cardiol, F-75013 Paris, France.
[Sabatine, Marc S.] Brigham & Womens Hosp, Div Cardiovasc Med, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.
[Sabatine, Marc S.] Harvard Univ, Sch Med, Boston, MA USA.
RP Montalescot, G (reprint author), Univ Paris 06, Hop La Pitie Salpetriere, AP HP, ACT Study Grp,Inst Cardiol, F-75013 Paris, France.
EM gilles.montalescot@psl.aphp.fr
FU Acuitude; Amgen; AstraZeneca; Bayer; Berlin Chimie AG;
Boehringer-Ingelheim; BMS; Brigham Women's Hospital; Cardiovascular
Research Foundation; CME Resources; Conway; Daiichi-Sankyo; Eli-Lilly;
Europa; Evidera; GLG; Hopitaux Universitaires Geneve; Lead-Up; McKinsey
Company; Medcon International; Menarini; Medtronic; MSD; Pfizer;
Sanofi-Aventis; Stentys; Medicines Company; TIMI Group; Universitat
Basel; WebMD; Williams Connolly; Zoll Medical; ADIR; Celladon;
Federation Francaise de Cardiologie; Gilead; ICAN; Janssen-Cilag; Recor;
Alnylam; Cubist; CVS Caremark; Intarcia; Merck; Brigham and Women's
Hospital from Abbott Laboratories; Critical Diagnostics; Eisai;
GlaxoSmithKline; Roche Diagnostics; Takeda
FX G.M. reports receiving consulting fees from Acuitude, Amgen,
AstraZeneca, Bayer, Berlin Chimie AG, Boehringer-Ingelheim, BMS, Brigham
Women's Hospital, Cardiovascular Research Foundation, CME Resources,
Conway, Daiichi-Sankyo, Eli-Lilly, Europa, Evidera, GLG, Hopitaux
Universitaires Geneve, Lead-Up, McKinsey & Company, Medcon
International, Menarini, Medtronic, MSD, Pfizer, Sanofi-Aventis,
Stentys, Medicines Company, TIMI Group, Universitat Basel, WebMD,
Williams & Connolly, Zoll Medical and grant support from ADIR, Amgen,
AstraZeneca, BMS, Celladon, Daiichi-Sankyo, Eli-Lilly, Federation
Francaise de Cardiologie, Gilead, ICAN, Janssen-Cilag, Pfizer, Recor,
Sanofi-Aventis, Stentys. M.S.S. reports receiving consulting fees from
Alnylam, Amgen, AstraZeneca, Cubist, CVS Caremark, Intarcia, Merck (all
<=$10 000 per year); and research grant support through Brigham and
Women's Hospital from Abbott Laboratories; Amgen; AstraZeneca; Critical
Diagnostics; Daiichi-Sankyo; Eisai; Gilead; GlaxoSmithKline; Intarcia;
Merck; Roche Diagnostics; Sanofi-aventis; Takeda (All >$10 000 per
year).
NR 37
TC 7
Z9 8
U1 2
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD JAN 21
PY 2016
VL 37
IS 4
BP 344
EP 352
DI 10.1093/eurheartj/ehv377
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DE9RL
UT WOS:000370975700012
PM 26248569
ER
PT J
AU Mauri, L
Elmariah, S
Yeh, RW
Cutlip, DE
Steg, PG
Windecker, S
Wiviott, SD
Cohen, DJ
Massaro, JM
D'Agostino, RB
Braunwald, E
Kereiakes, DJ
AF Mauri, Laura
Elmariah, Sammy
Yeh, Robert W.
Cutlip, Donald E.
Steg, P. Gabriel
Windecker, Stephan
Wiviott, Stephen D.
Cohen, David J.
Massaro, Joseph M.
D'Agostino, Ralph B., Sr.
Braunwald, Eugene
Kereiakes, Dean J.
CA DAPT Study Investigators
TI Causes of late mortality with dual antiplatelet therapy after coronary
stents
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Dual antiplatelet therapy; Mortality; Cancer; Thienopyridine
ID DRUG-ELUTING STENT; ACUTE MYOCARDIAL-INFARCTION; BARE METAL; CLOPIDOGREL
USE; TRIALS; INTERVENTION; DURATION; REVASCULARIZATION; IMPLANTATION;
METAANALYSIS
AB Aims In the dual antiplatelet therapy (DAPT) study, continued thienopyridine beyond 12 months after drug-eluting stent placement was associated with increased mortality compared with placebo. We sought to evaluate factors related to mortality in randomized patients receiving either drug-eluting or bare metal stents in the DAPT study.
Methods and results Patients were enrolled after coronary stenting, given thienopyridine and aspirin for 12 months, randomly assigned to continued thienopyridine or placebo for an additional 18 months (while taking aspirin), and subsequently treated with aspirin alone for another 3 months. A blinded independent adjudication committee evaluated deaths. Among 11 648 randomized patients, rates of all-cause mortality rates were 1.9 vs. 1.5% (continued thienopyridine vs. placebo, P = 0.07), cardiovascular mortality, 1.0 vs. 1.0% (P = 0.97), and non-cardiovascular mortality, 0.9 vs. 0.5% (P = 0.01) over the randomized period (Months 12-30). Rates of fatal bleeding were 0.2 vs. 0.1% (P = 0.81), and deaths related to any prior bleeding were 0.3 vs. 0.2% (P = 0.36), Months 12-33). Cancer incidence did not differ (2.0 vs. 1.6%, P = 0.12). Cancer-related deaths occurred in 0.6 vs. 0.3% (P = 0.02) and were rarely related to bleeding (0.1 vs. 0, P = 0.25). After excluding those occurring in patients with cancer diagnosed before enrolment, rates were 0.4 vs. 0.3% (P = 0.16).
Conclusion Bleeding accounted for a minority of deaths among patients treated with continued thienopyridine. Cancer-related death in association with thienopyridine therapy was mainly not related to bleeding and may be a chance finding. Caution is warranted when considering extended thienopyridine in patients with advanced cancer.
C1 [Mauri, Laura; Elmariah, Sammy; Yeh, Robert W.; Massaro, Joseph M.; D'Agostino, Ralph B., Sr.] Harvard Univ, Clin Res Inst, Clin Res Inst, Boston, MA USA.
[Mauri, Laura; Wiviott, Stephen D.; Braunwald, Eugene] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.
[Mauri, Laura; Elmariah, Sammy; Yeh, Robert W.; Cutlip, Donald E.; Wiviott, Stephen D.; Braunwald, Eugene] Harvard Univ, Sch Med, Boston, MA USA.
[Elmariah, Sammy; Yeh, Robert W.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cutlip, Donald E.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Steg, P. Gabriel] AP HP, Dept Hosp Univ Fibrosis Inflammat & Remodeling, Paris, France.
[Steg, P. Gabriel] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Heart & Lung Inst, London, England.
[Windecker, Stephan] Univ Hosp Bern, CH-3010 Bern, Switzerland.
[Cohen, David J.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA.
[Cohen, David J.] Univ Missouri, Sch Med, Kansas City, MO 64108 USA.
[Massaro, Joseph M.; D'Agostino, Ralph B., Sr.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Braunwald, Eugene] Univ Paris Diderot, INSERM U1148, Hop Bichat, Paris, France.
[Kereiakes, Dean J.] Christ Hosp, & Vasc Ctr, Lindner Ctr Res & Educ, Cincinnati, OH 45219 USA.
RP Mauri, L (reprint author), Harvard Univ, Clin Res Inst, Clin Res Inst, Boston, MA USA.; Mauri, L (reprint author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.; Mauri, L (reprint author), Harvard Univ, Sch Med, Boston, MA USA.
EM lmauri1@partners.org
FU Abbott; Boston Scientific; Cordis; Medtronic; Bristol-Myers Squibb
Company/Sanofi Pharmaceuticals Partnership; Eli Lilly and Company;
Daiichi Sankyo Company; US Department of Health and Human Services
[1RO1FD003870-01]
FX This work was supported by Abbott, Boston Scientific, Cordis, Medtronic,
Bristol-Myers Squibb Company/Sanofi Pharmaceuticals Partnership, Eli
Lilly and Company, and Daiichi Sankyo Company and the US Department of
Health and Human Services (1RO1FD003870-01).
NR 26
TC 13
Z9 13
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD JAN 21
PY 2016
VL 37
IS 4
BP 378
EP 385
DI 10.1093/eurheartj/ehv614
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DE9RL
UT WOS:000370975700017
PM 26586780
ER
PT J
AU Udell, JA
Bonaca, MP
Collet, JP
Lincoff, AM
Kereiakes, DJ
Costa, F
Lee, CW
Mauri, L
Valgimigli, M
Park, SJ
Montalescot, G
Sabatine, MS
Braunwald, E
Bhatt, DL
AF Udell, Jacob A.
Bonaca, Marc P.
Collet, Jean-Philippe
Lincoff, A. Michael
Kereiakes, Dean J.
Costa, Francesco
Lee, Cheol Whan
Mauri, Laura
Valgimigli, Marco
Park, Seung-Jung
Montalescot, Gilles
Sabatine, Marc S.
Braunwald, Eugene
Bhatt, Deepak L.
TI Long-term dual antiplatelet therapy for secondary prevention of
cardiovascular events in the subgroup of patients with previous
myocardial infarction: a collaborative meta-analysis of randomized
trials
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Dual antiplatelet therapy; Myocardial infarction; Stable coronary heart
disease; Clopidogrel; Prasugrel; Ticagrelor
ID ACUTE CORONARY SYNDROMES; ELUTING STENT IMPLANTATION; ASSOCIATION
TASK-FORCE; ST-SEGMENT ELEVATION; PRACTICE GUIDELINES; AMERICAN-COLLEGE;
ATHEROTHROMBOTIC EVENTS; NETWORK METAANALYSIS; CLINICAL-OUTCOMES; LATE
CONSEQUENCES
AB Aims Recent trials have examined the effect of prolonged dual antiplatelet therapy (DAPT) in a variety of patient populations, with heterogeneous results regarding benefit and safety, specifically with regard to cardiovascular and non-cardiovascular mortality. We performed a meta-analysis of randomized trials comparing more than a year of DAPT with aspirin alone in high-risk patients with a history of prior myocardial infarction (MI).
Methods and results A total of 33 435 patients were followed over a mean 31 months among one trial of patients with prior MI (63.3% of total) and five trials with a subgroup of patients that presented with, or had a history of, a prior MI (36.7% of total). Extended DAPT decreased the risk of major adverse cardiovascular events compared with aspirin alone (6.4 vs. 7.5%; risk ratio, RR 0.78, 95% confidence intervals, CI, 0.67-0.90; P=0.001) and reduced cardiovascular death (2.3 vs. 2.6%; RR 0.85, 95% CI 0.74-0.98; P=0.03), with no increase in non-cardiovascular death (RR 1.03, 95% CI 0.86-1.23; P=0.76). The resultant effect on all-cause mortality was an RR of 0.92 (95% CI 0.83-1.03; P=0.13). Extended DAPT also reduced MI (RR 0.70, 95% CI 0.55-0.88; P=0.003), stroke (RR 0.81, 95% CI 0.68-0.97; P=0.02), and stent thrombosis (RR 0.50, 95% CI 0.28-0.89; P=0.02). There was an increased risk of major bleeding (1.85 vs. 1.09%; RR 1.73, 95% CI 1.19-2.50; P=0.004) but not fatal bleeding (0.14 vs. 0.17%; RR 0.91, 95% CI 0.53-1.58; P=0.75).
Conclusion Compared with aspirin alone, DAPT beyond 1 year among stabilized high-risk patients with prior MI decreases ischaemic events, including significant reductions in the individual endpoints of cardiovascular death, recurrent MI, and stroke. Dual antiplatelet therapy beyond 1 year increases major bleeding, but not fatal bleeding or non-cardiovascular death.
C1 [Udell, Jacob A.] Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence, Univ Hlth Network, Peter Munk Cardiac Ctr, 76 Grenville St, Toronto, ON M5S 1B1, Canada.
[Udell, Jacob A.] Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence, Univ Hlth Network, Div Cardiovasc, 76 Grenville St, Toronto, ON M5S 1B1, Canada.
[Udell, Jacob A.] Univ Toronto, Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON M5S 1B1, Canada.
[Udell, Jacob A.] Univ Toronto, Womens Coll Hosp, Dept Med, Div Cardiovasc, Toronto, ON M5S 1B1, Canada.
[Bonaca, Marc P.; Sabatine, Marc S.; Braunwald, Eugene; Bhatt, Deepak L.] Harvard Univ, Sch Med, Brigham andWomens Hosp, TIMI Study Grp,Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA.
[Lincoff, A. Michael] Univ Paris 06, INSERM, Inst Cardiol, Hop La Pitie Salpetriere,AP HP,ACT Study Grp, Paris, France.
[Lincoff, A. Michael] Cleveland Clin, Coordinating Ctr Clin Res, Dept Cardiovasc Med, Cleveland, OH 44106 USA.
[Kereiakes, Dean J.] Christ Hosp, Heart & Vasc Ctr, Cincinnati, OH 45219 USA.
[Kereiakes, Dean J.] Christ Hosp, Lindner Ctr Res & Educ, Cincinnati, OH 45219 USA.
[Costa, Francesco; Valgimigli, Marco] Erasmus Med, Thoraxctr, NL-3015 CE Rotterdam, Netherlands.
[Lee, Cheol Whan; Park, Seung-Jung] Univ Ulsan, Coll Med, Asan Med Ctr, Inst Heart, Seoul, South Korea.
[Mauri, Laura] Harvard Univ, Brigham & Womens Hosp, Sch Med, Clin Res Inst, Boston, MA 02115 USA.
[Mauri, Laura] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA.
[Valgimigli, Marco] Univ Hosp Bern, CH-3010 Bern, Switzerland.
RP Udell, JA (reprint author), Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence, Univ Hlth Network, Peter Munk Cardiac Ctr, 76 Grenville St, Toronto, ON M5S 1B1, Canada.; Udell, JA (reprint author), Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence, Univ Hlth Network, Div Cardiovasc, 76 Grenville St, Toronto, ON M5S 1B1, Canada.; Udell, JA (reprint author), Univ Toronto, Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON M5S 1B1, Canada.; Udell, JA (reprint author), Univ Toronto, Womens Coll Hosp, Dept Med, Div Cardiovasc, Toronto, ON M5S 1B1, Canada.; Bhatt, DL (reprint author), Harvard Univ, Sch Med, Brigham andWomens Hosp, TIMI Study Grp,Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA.
EM jay.udell@utoronto.ca; dlbhattmd@post.harvard.edu
OI Costa, Francesco/0000-0002-3097-2834
FU Heart and Stroke Foundation of Canada; Women's College Research
Institute and Department of Medicine, Women's College Hospital; Peter
Munk Cardiac Centre, University Health Network; Department of Medicine
and Heart and Stroke Richard Lewar Centre of Excellence in
Cardiovascular Research, University of Toronto
FX There was no funding source for this study. Dr Udell was supported in
part by the Heart and Stroke Foundation of Canada and Women's College
Research Institute and Department of Medicine, Women's College Hospital;
Peter Munk Cardiac Centre, University Health Network; Department of
Medicine and Heart and Stroke Richard Lewar Centre of Excellence in
Cardiovascular Research, University of Toronto.
NR 56
TC 53
Z9 55
U1 8
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD JAN 21
PY 2016
VL 37
IS 4
BP 390
EP 399
DI 10.1093/eurheartj/ehv443
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DE9RL
UT WOS:000370975700020
PM 26324537
ER
PT J
AU Magnani, G
Storey, RF
Steg, G
Bhatt, DL
Cohen, M
Kuder, J
Im, K
Aylward, P
Ardissino, D
Isaza, D
Parkhomenko, A
Goudev, AR
Dellborg, M
Kontny, F
Corbalan, R
Medina, F
Jensen, EC
Held, P
Braunwald, E
Sabatine, MS
Bonaca, MP
AF Magnani, Giulia
Storey, Robert F.
Steg, Gabriel
Bhatt, Deepak L.
Cohen, Marc
Kuder, Julia
Im, Kyungah
Aylward, Philip
Ardissino, Diego
Isaza, Daniel
Parkhomenko, Alexander
Goudev, Assen R.
Dellborg, Mikael
Kontny, Frederic
Corbalan, Ramon
Medina, Felix
Jensen, Eva C.
Held, Peter
Braunwald, Eugene
Sabatine, Marc S.
Bonaca, Marc P.
TI Efficacy and safety of ticagrelor for long-term secondary prevention of
atherothrombotic events in relation to renal function: insights from the
PEGASUS-TIMI 54 trial
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Ticagrelor; Myocardial infarction; Secondary prevention; Renal
dysfunction
ID CHRONIC KIDNEY-DISEASE; ACUTE MYOCARDIAL-INFARCTION;
GLOMERULAR-FILTRATION-RATE; ST-SEGMENT ELEVATION; OUTCOMES; CLOPIDOGREL;
GUIDELINES; EQUATION; THERAPY
AB Aims We evaluated the relationship of renal function and ischaemic and bleeding risk as well as the efficacy and safety of ticagrelor in stable patients with prior myocardial infarction (MI).
Methods and results Patients with a history of MI 1-3 years prior from PEGASUS-TIMI 54 were stratified based on estimated glomerular filtration rate (eGFR), with < 60 mL/min/1.73 m(2) pre-specified for analysis of the effect of ticagrelor on the primary efficacy composite of cardiovascular death, MI, or stroke (major adverse cardiovascular events, MACE) and the primary safety endpoint of TIMI major bleeding. Of 20 898 patients, those with eGFR < 60 (N = 4849, 23.2%) had a greater risk of MACE at 3 years relative to those without, which remained significant after multivariable adjustment (hazard ratio, HRadj 1.54, 95% confidence interval, CI 1.27-1.85, P < 0.001). The relative risk reduction in MACE with ticagrelor was similar in those with eGFR < 60 (ticagrelor pooled vs. placebo: HR 0.81; 95% CI 0.68-0.96) vs. >= 60 (HR 0.88; 95% CI 0.77-1.00, P-interaction = 0.44). However, due to the greater absolute risk in the former group, the absolute risk reduction with ticagrelor was higher: 2.7 vs. 0.63%. Bleeding tended to occur more frequently in patients with renal dysfunction. The absolute increase in TIMI major bleeding with ticagrelor was similar in those with and without eGFR < 60 (1.19 vs. 1.43%), whereas the excess of minor bleeding tended to be more pronounced (1.93 vs. 0.69%).
Conclusion In patients with a history of MI, patients with renal dysfunction are at increased risk of MACE and consequently experience a particularly robust absolute risk reduction with long-term treatment with ticagrelor.
C1 [Magnani, Giulia; Bhatt, Deepak L.; Kuder, Julia; Im, Kyungah; Braunwald, Eugene; Sabatine, Marc S.; Bonaca, Marc P.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.
[Magnani, Giulia; Bhatt, Deepak L.; Kuder, Julia; Im, Kyungah; Braunwald, Eugene; Sabatine, Marc S.; Bonaca, Marc P.] Harvard Univ, Sch Med, 75 Francis St, Boston, MA USA.
[Storey, Robert F.] Univ Sheffield, Dept Cardiovasc Sci, Sheffield, S Yorkshire, England.
[Steg, Gabriel] Hop Bichat Claude Bernard, DHU FIRE, Dept Cardiol, F-75877 Paris, France.
[Steg, Gabriel] Univ Paris Diderot, Paris, France.
[Steg, Gabriel] INSERM U1148, Paris, France.
[Cohen, Marc] Rutgers New Jersey Med Sch, Dept Med, Div Cardiovasc, New York, NY USA.
[Aylward, Philip] Flinders Univ S Australia, Cardiac & Crit Care Serv, Div Med, Adelaide, SA 5001, Australia.
[Aylward, Philip] Med Ctr, Adelaide, SA, Australia.
[Ardissino, Diego] Azienda Osped Univ Parma, Div Cardiovasc, Parma, Italy.
[Isaza, Daniel] Fdn CardioInfantil, Bogota, Colombia.
[Parkhomenko, Alexander] Ukranian Strazhesko Inst Cardiol, Kiev, Ukraine.
[Goudev, Assen R.] Queen Giovanna Univ Hosp, Dept Cardiol, Sofia, Bulgaria.
[Dellborg, Mikael] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Mol & Clin Med Cardiol, Gothenburg, Sweden.
[Kontny, Frederic] Stavanger Univ Hosp, Dept Cardiol, Stavanger, Norway.
[Corbalan, Ramon] Pontificia Univ Catolica Chile, Div Cardiovasc, Alameda 340, Santiago, Chile.
[Medina, Felix] Hosp Nacl Cayetano Heredia, Lima, Peru.
[Jensen, Eva C.; Held, Peter] AstraZenecaAZ R&D, Molndal, Sweden.
RP Bonaca, MP (reprint author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.; Bonaca, MP (reprint author), Harvard Univ, Sch Med, 75 Francis St, Boston, MA USA.
EM mbonaca@partners.org
FU AstraZeneca
FX This study was supported by a grant from AstraZeneca.
NR 18
TC 11
Z9 11
U1 3
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD JAN 21
PY 2016
VL 37
IS 4
BP 400
EP 408
DI 10.1093/eurheartj/ehv482
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DE9RL
UT WOS:000370975700021
PM 26443023
ER
PT J
AU Golberg, A
Bruinsma, BG
Jaramillo, M
Yarmush, ML
Uygun, BE
AF Golberg, Alexander
Bruinsma, Bote G.
Jaramillo, Maria
Yarmush, Martin L.
Uygun, Basak E.
TI Rat liver regeneration following ablation with irreversible
electroporation
SO PEERJ
LA English
DT Article
DE Liver regeneration; Irreversible electroporation; Liver ablation; Pulsed
electric fields; Scarless regeneration; Progenitor cells; Hepatocytes
ID PULSED ELECTRIC-FIELDS; STEM-CELLS; GROWTH-FACTORS; ADULT-RAT;
PROGENITORS; EXPRESSION; PROLIFERATION; COMPARTMENT; CHALLENGES;
CYTOKINES
AB During the past decade, irreversible electroporation (IRE) ablation has emerged as a promising tool for the treatment of multiple diseases including hepatic cancer. However, the mechanisms behind the tissue regeneration following IRE ablation have not been investigated. Our results indicate that IRE treatment immediately kills the cells at the treatment site preserving the extracellular architecture, in effect causing in vivo decellularization. Over the course of 4 weeks, progenitor cell differentiation, through YAP and notch pathways, together with hepatocyte expansion led to almost complete regeneration of the ablated liver leading to the formation of hepatocyte like cells at the ablated zone. We did not observe significant scarring or tumor formation at the regenerated areas 6 months post IRE. Our study suggests a new model to study the regeneration of liver when the naive extracellular matrix is decellularized in vivo with completely preserved extracellular architecture.
C1 [Golberg, Alexander; Bruinsma, Bote G.; Jaramillo, Maria; Yarmush, Martin L.; Uygun, Basak E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA USA.
[Golberg, Alexander; Bruinsma, Bote G.; Jaramillo, Maria; Yarmush, Martin L.; Uygun, Basak E.] Shriners Hosp Children, Boston, MA USA.
[Golberg, Alexander] Tel Aviv Univ, Porter Sch Environm Studies, IL-69978 Tel Aviv, Israel.
[Bruinsma, Bote G.] Univ Amsterdam, Acad Med Ctr, Dept Surg, Surg Lab, NL-1105 AZ Amsterdam, Netherlands.
[Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ USA.
RP Golberg, A; Uygun, BE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA USA.; Golberg, A; Uygun, BE (reprint author), Shriners Hosp Children, Boston, MA USA.; Golberg, A (reprint author), Tel Aviv Univ, Porter Sch Environm Studies, IL-69978 Tel Aviv, Israel.
EM agolberg@gmail.com; buygun@mgh.harvard.edu
FU Claflin Distinguished Scholar Award from Massachusetts General Hospital
[2013A050726]
FX This work was supported by the Claflin Distinguished Scholar Award from
Massachusetts General Hospital (2013A050726) to Basak E. Uygun. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 45
TC 2
Z9 2
U1 2
U2 8
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD JAN 21
PY 2016
VL 4
AR e1571
DI 10.7717/peerj.1571
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DC7ML
UT WOS:000369404300002
PM 26819842
ER
PT J
AU Ghita, M
Coffey, CB
Butterworth, KT
McMahon, SJ
Schettino, G
Prise, KM
AF Ghita, Mihaela
Coffey, Caroline B.
Butterworth, Karl T.
McMahon, Stephen J.
Schettino, Giuseppe
Prise, Kevin M.
TI Impact of fractionation on out-of-field survival and DNA damage
responses following exposure to intensity modulated radiation fields
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE out-of-field effects; dose fractionation; cell survival; DNA damage
ID BYSTANDER; IRRADIATION; CELL; THERAPY
AB To limit toxicity to normal tissues adjacent to the target tumour volume, radiotherapy is delivered using fractionated regimes whereby the total prescribed dose is given as a series of sequential smaller doses separated by specific time intervals. The impact of fractionation on out-of-field survival and DNA damage responses was determined in AGO-1522 primary human fibroblasts and MCF-7 breast tumour cells using uniform and modulated exposures delivered using a 225 kVp x-ray source. Responses to fractionated schedules (two equal fractions delivered with time intervals from 4 h to 48 h) were compared to those following acute exposures. Cell survival and DNA damage repair measurements indicate that cellular responses to fractionated non-uniform exposures differ from those seen in uniform exposures for the investigated cell lines. Specifically, there is a consistent lack of repair observed in the out-of-field populations during intervals between fractions, confirming the importance of cell signalling to out-of-field responses in a fractionated radiation schedule, and this needs to be confirmed for a wider range of cell lines and conditions.
C1 [Ghita, Mihaela; Butterworth, Karl T.; McMahon, Stephen J.; Prise, Kevin M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, 97 Lisburn Rd, Belfast BT7 9AE, Antrim, North Ireland.
[Coffey, Caroline B.] Univ Nevada, Sch Med, Dept Pharmacol, Reno, NV 89557 USA.
[Schettino, Giuseppe] Natl Phys Lab, Teddington TW11 0LW, Middx, England.
[McMahon, Stephen J.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[McMahon, Stephen J.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Ghita, M (reprint author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, 97 Lisburn Rd, Belfast BT7 9AE, Antrim, North Ireland.
EM m.ghita@qub.ac.uk
RI Prise, Kevin/N-7872-2015
OI Prise, Kevin/0000-0001-6134-7946
FU Breast Cancer Campaign [2009MayPR03]; Cancer Research UK [C1513/A7047];
EU Marie Curie Fellowship [FP7-MC IOF-623630]
FX The authors acknowledge the support of Breast Cancer Campaign
(2009MayPR03) and Cancer Research UK (C1513/A7047). SJM is the holder of
an EU Marie Curie Fellowship (FP7-MC IOF-623630).
NR 19
TC 1
Z9 1
U1 0
U2 1
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD JAN 21
PY 2016
VL 61
IS 2
BP 515
EP 526
DI 10.1088/0031-9155/61/2/515
PG 12
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA DC9BV
UT WOS:000369516600008
PM 26683123
ER
PT J
AU Cai, WX
Dhou, S
Cifter, F
Myronakis, M
Hurwitz, MH
Williams, CL
Berbeco, RI
Seco, J
Lewis, JH
AF Cai, Weixing
Dhou, Salam
Cifter, Fulya
Myronakis, Marios
Hurwitz, Martina H.
Williams, Christopher L.
Berbeco, Ross I.
Seco, Joao
Lewis, John H.
TI 4D cone beam CT-based dose assessment for SBRT lung cancer treatment
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE 4D cone beam CT; SBRT; respiratory motion; treatment verification; dose
assessment
ID STEREOTACTIC BODY RADIOTHERAPY; 3D TUMOR-LOCALIZATION; X-RAY PROJECTION;
MOTION MODEL; RESPIRATORY MOTION; EPID DOSIMETRY; MONTE-CARLO; IMAGE;
VERIFICATION; FEASIBILITY
AB The purpose of this research is to develop a 4DCBCT-based dose assessment method for calculating actual delivered dose for patients with significant respiratory motion or anatomical changes during the course of SBRT. To address the limitation of 4DCT-based dose assessment, we propose to calculate the delivered dose using time-varying ('fluoroscopic') 3D patient images generated from a 4DCBCT-based motion model. The method includes four steps: (1) before each treatment, 4DCBCT data is acquired with the patient in treatment position, based on which a patient-specific motion model is created using a principal components analysis algorithm. (2) During treatment, 2D time-varying kV projection images are continuously acquired, from which time-varying 'fluoroscopic' 3D images of the patient are reconstructed using the motion model. (3) Lateral truncation artifacts are corrected using planning 4DCT images. (4) The 3D dose distribution is computed for each timepoint in the set of 3D fluoroscopic images, from which the total effective 3D delivered dose is calculated by accumulating deformed dose distributions. This approach is validated using six modified XCAT phantoms with lung tumors and different respiratory motions derived from patient data. The estimated doses are compared to that calculated using ground-truth XCAT phantoms. For each XCAT phantom, the calculated delivered tumor dose values generally follow the same trend as that of the ground truth and at most timepoints the difference is less than 5%. For the overall delivered dose, the normalized error of calculated 3D dose distribution is generally less than 3% and the tumor D95 error is less than 1.5%. XCAT phantom studies indicate the potential of the proposed method to accurately estimate 3D tumor dose distributions for SBRT lung treatment based on 4DCBCT imaging and motion modeling. Further research is necessary to investigate its performance for clinical patient data.
C1 [Cai, Weixing; Dhou, Salam; Cifter, Fulya; Myronakis, Marios; Hurwitz, Martina H.; Williams, Christopher L.; Berbeco, Ross I.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
[Cai, Weixing; Dhou, Salam; Cifter, Fulya; Myronakis, Marios; Hurwitz, Martina H.; Williams, Christopher L.; Berbeco, Ross I.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Seco, Joao] Massachusetts Gen Hosp, Dept Radiat Oncol, Francis H Burr Proton Therapy Ctr, Boston, MA 02114 USA.
[Seco, Joao] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Lewis, John H.] Calif State Univ Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA USA.
RP Cai, WX (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.; Cai, WX (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.; Lewis, JH (reprint author), Calif State Univ Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA USA.
EM wcai@lroc.harvard.edu; jlewisphysics@gmail.com
FU Varian Medical Systems, Inc.; Radiological Society of North America
[RSCH1206]
FX The authors would like to express their gratitude to Dr Seiko Nishioka
of the Department of Radiology, NTT Hospital, Sapporo, Japan and Dr
Hiroki Shirato of the Department of Radiation Medicine, Hokkaido
University School of Medicine, Sapporo, Japan for sharing the 3D patient
tumor position dataset with our group. This project was supported, in
part, through a Master Research Agreement with Varian Medical Systems,
Inc., Radiological Society of North America Research Scholar Grant No.
RSCH1206 (J.H.L.)
NR 31
TC 2
Z9 2
U1 0
U2 6
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD JAN 21
PY 2016
VL 61
IS 2
BP 554
EP 568
DI 10.1088/0031-9155/61/2/554
PG 15
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA DC9BV
UT WOS:000369516600011
PM 26683530
ER
PT J
AU Geng, CR
Moteabbed, M
Seco, J
Gao, YM
Xu, XG
Ramos-Mendez, J
Faddegon, B
Paganetti, H
AF Geng, Changran
Moteabbed, Maryam
Seco, Joao
Gao, Yiming
Xu, X. George
Ramos-Mendez, Jose
Faddegon, Bruce
Paganetti, Harald
TI Dose assessment for the fetus considering scattered and secondary
radiation from photon and proton therapy when treating a brain tumor of
the mother
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE proton therapy; Monte Carlo; computational phantom; fetus dose
ID IONIZING-RADIATION; PEDIATRIC-PATIENTS; PRENATAL EXPOSURE; 2ND CANCERS;
RADIOTHERAPY; PREGNANCY; NEUTRONS; IMRT; RISK; SIMULATION
AB The goal of this work was to determine the scattered photon dose and secondary neutron dose and resulting risk for the sensitive fetus from photon and proton radiotherapy when treating a brain tumor during pregnancy. Anthropomorphic pregnancy phantoms with three stages (3-, 6-, 9-month) based on ICRP reference parameters were implemented in Monte Carlo platform TOPAS, to evaluate the scattered dose and secondary neutron dose and dose equivalent. To evaluate the dose equivalent, dose averaged quality factors were considered for neutrons. This study compared three treatment modalities: passive scattering and pencil beam scanning proton therapy (PPT and PBS) and 6-MV 3D conformal photon therapy. The results show that, for 3D conformal photon therapy, the scattered photon dose equivalent to the fetal body increases from 0.011 to 0.030 mSv per treatment Gy with increasing stage of gestation. For PBS, the neutron dose equivalent to the fetal body was significantly lower, i.e. increasing from 1.5 x 10(-3) to 2.5 x 10(-3) mSv per treatment Gy with increasing stage of gestation. For PPT, the neutron dose equivalent of the fetus decreases from 0.17 to 0.13 mSv per treatment Gy with the growing fetus. The ratios of dose equivalents to the fetus for a 52.2 Gy(RBE) course of radiation therapy to a typical CT scan of the mother's head ranged from 3.4-4.4 for PBS, 30-41 for 3D conformal photon therapy and 180-500 for PPT, respectively. The attained dose to a fetus from the three modalities is far lower than the thresholds of malformation, severe mental retardation and lethal death. The childhood cancer excessive absolute risk was estimated using a linear no-threshold dose-response relationship. The risk would be 1.0 (95% CI: 0.6, 1.6) and 0.1 (95% CI: -0.01, 0.52) in 105 for the 9-month fetus for PBS with a prescribed dose of 52.2 Gy(RBE). The increased risks for PPT and photon therapy are about two and one orders of magnitude larger than that for PBS, respectively. We can conclude that a pregnant woman with a brain tumor could be treated with pencil beam scanning with acceptable risks to the fetus.
C1 [Geng, Changran; Moteabbed, Maryam; Seco, Joao; Paganetti, Harald] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Geng, Changran] Nanjing Univ Aeronaut & Astronaut, Dept Nucl Sci & Engn, Nanjing 210016, Jiangsu, Peoples R China.
[Gao, Yiming; Xu, X. George] Rensselaer Polytech Inst, Nucl Engn Program, Troy, NY 12180 USA.
[Ramos-Mendez, Jose; Faddegon, Bruce] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA.
[Moteabbed, Maryam; Seco, Joao; Paganetti, Harald] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Geng, CR; Paganetti, H (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.; Geng, CR (reprint author), Nanjing Univ Aeronaut & Astronaut, Dept Nucl Sci & Engn, Nanjing 210016, Jiangsu, Peoples R China.; Paganetti, H (reprint author), Harvard Univ, Sch Med, Boston, MA 02114 USA.
EM geng.chr@gmail.com; HPAGANETTI@mgh.harvard.edu
FU China Scholarship Council (CSC); National Natural Science Foundation of
China [11475087]
FX CG was funded by the China Scholarship Council (CSC) and the National
Natural Science Foundation of China (Grant No. 11475087). We would like
to thank the MGH Monte Carlo group for many fruitful discussions and the
Partners Research Computing group for maintaining the computer cluster.
NR 41
TC 1
Z9 1
U1 2
U2 7
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD JAN 21
PY 2016
VL 61
IS 2
BP 683
EP 695
DI 10.1088/0031-9155/61/2/683
PG 13
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA DC9BV
UT WOS:000369516600018
PM 26716718
ER
PT J
AU Yip, SSF
Coroller, TP
Sanford, NN
Huynh, E
Mamon, H
Aerts, HJWL
Berbeco, RI
AF Yip, Stephen S. F.
Coroller, Thibaud P.
Sanford, Nina N.
Huynh, Elizabeth
Mamon, Harvey
Aerts, Hugo J. W. L.
Berbeco, Ross I.
TI Use of registration-based contour propagation in texture analysis for
esophageal cancer pathologic response prediction
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE esophageal cancer; PET; treatment response prediction; deformable
registration; contour propagation
ID DEFORMABLE IMAGE REGISTRATION; FDG-PET RADIOMICS; CUBIC B-SPLINE;
F-18-FDG PET; UPTAKE HETEROGENEITY; INTRATUMORAL HETEROGENEITY; TUMOR
HETEROGENEITY; RADIATION-THERAPY; TRACER UPTAKE; NECK TUMORS
AB Change in PET-based textural features has shown promise in predicting cancer response to treatment. However, contouring tumour volumes on longitudinal scans is time-consuming. This study investigated the usefulness of contour propagation in texture analysis for the purpose of pathologic response prediction in esophageal cancer.
Forty-five esophageal cancer patients underwent PET/CT scans before and after chemo-radiotherapy. Patients were classified into responders and non-responders after the surgery. Physician-defined tumour ROIs on pretreatment PET were propagated onto the post-treatment PET using rigid and ten deformable registration algorithms. PET images were converted into 256 discrete values. Co-occurrence, run-length, and size zone matrix textures were computed within all ROIs. The relative difference of each texture at different treatment time-points was used to predict the pathologic responders. Their predictive value was assessed using the area under the receiver-operating-characteristic curve (AUC). Propagated ROIs from different algorithms were compared using Dice similarity index (DSI).
Contours propagated by the fast-demons, fast-free-form and rigid algorithms did not fully capture the high FDG uptake regions of tumours. Fast-demons propagated ROIs had the least agreement with other contours (DSI = 58%). Moderate to substantial overlap were found in the ROIs propagated by all other algorithms (DSI = 69%-79%). Rigidly propagated ROIs with co-occurrence texture failed to significantly differentiate between responders and non-responders (AUC = 0.58, q-value = 0.33), while the differentiation was significant with other textures (AUC = 0.71. 0.73, p < 0.009). Among the deformable algorithms, fast-demons (AUC = 0.68. 0.70, q-value < 0.03) and fast-free-form (AUC = 0.69. 0.74, q-value < 0.04) were the least predictive. ROIs propagated by all other deformable algorithms with any texture significantly predicted pathologic responders (AUC = 0.72. 0.78, q-value < 0.01).
Propagated ROIs using deformable registration for all textures can lead to accurate prediction of pathologic response, potentially expediting the temporal texture analysis process. However, fast-demons, fast-free-form, and rigid algorithms should be applied with care due to their inferior performance compared to other algorithms.
C1 [Yip, Stephen S. F.; Coroller, Thibaud P.; Sanford, Nina N.; Huynh, Elizabeth; Mamon, Harvey; Aerts, Hugo J. W. L.; Berbeco, Ross I.] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
[Yip, Stephen S. F.; Coroller, Thibaud P.; Sanford, Nina N.; Huynh, Elizabeth; Mamon, Harvey; Aerts, Hugo J. W. L.; Berbeco, Ross I.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Aerts, Hugo J. W. L.] Dana Farber Canc Inst, Dept Radiol, Boston, MA 02115 USA.
RP Yip, SSF (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
EM syip@lroc.harvard.edu
RI Aerts, Hugo/P-6350-2015;
OI Aerts, Hugo/0000-0002-2122-2003; Coroller, Thibaud/0000-0001-7662-8724
FU Brigham and Women's Hospital; National Institute of Health [U01CA190234,
U24CA194354]
FX This work is in part supported by the Kaye scholar grant from the
Brigham and Women's Hospital. The authors would like to acknowledge the
support from the National Institute of Health (U01CA190234 and
U24CA194354).
NR 74
TC 9
Z9 9
U1 1
U2 11
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD JAN 21
PY 2016
VL 61
IS 2
BP 906
EP 922
DI 10.1088/0031-9155/61/2/906
PG 17
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA DC9BV
UT WOS:000369516600031
PM 26738433
ER
PT J
AU Levman, J
Takahashi, E
AF Levman, Jacob
Takahashi, Emi
TI Multivariate Analyses Applied to Healthy Neurodevelopment in Fetal,
Neonatal, and Pediatric MRI
SO FRONTIERS IN NEUROANATOMY
LA English
DT Review
DE multivariate analysis; machine learning; fetal; neonatal; pediatric;
brain MRI
ID BRAIN-DEVELOPMENT; FUNCTIONAL MRI; WHITE-MATTER; CEREBRAL-CORTEX;
SEGMENTATION; CHILDREN; PREDICTION; NETWORKS; CONNECTIVITY; TRACTOGRAPHY
AB Multivariate analysis (MVA) is a class of statistical and pattern recognition techniques that involve the processing of data that contains multiple measurements per sample. MVA can be used to address a wide variety of neurological medical imaging related challenges including the evaluation of healthy brain development, the automated analysis of brain tissues and structures through image segmentation, evaluating the effects of genetic and environmental factors on brain development, evaluating sensory stimulation's relationship with functional brain activity and much more Compared to adult imaging, pediatric, neonatal and fetal imaging have attracted less attention from MVA researchers, however, recent years have seen remarkable MVA research growth in pre-adult populations. This paper presents the results of a systematic review of the literature focusing on MVA applied to healthy subjects in fetal, neonatal and pediatric magnetic resonance imaging (MRI) of the brain. While the results of this review demonstrate considerable interest from the scientific community in applications of MVA technologies in brain MRI, the field is still young and significant research growth will continue into the future.
C1 [Levman, Jacob; Takahashi, Emi] Harvard Univ, Div Newborn Med, Dept Med, Boston Childrens Hosp,Sch Med, Boston, MA USA.
[Levman, Jacob; Takahashi, Emi] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
RP Levman, J (reprint author), Harvard Univ, Div Newborn Med, Dept Med, Boston Childrens Hosp,Sch Med, Boston, MA USA.; Levman, J (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
EM jacob.levman@chikkens.haward.edu
FU National Institute of Health [R01HD078561, R03NS091587]
FX This article was supported by the National Institute of Health grants
R01HD078561 and R03NS091587 to ET.
NR 121
TC 1
Z9 1
U1 1
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1662-5129
J9 FRONT NEUROANAT
JI Front. Neuroanat.
PD JAN 21
PY 2016
VL 9
AR 163
DI 10.3389/fnana.2015.00163
PG 15
WC Anatomy & Morphology; Neurosciences
SC Anatomy & Morphology; Neurosciences & Neurology
GA DB3MG
UT WOS:000368415100001
ER
PT J
AU Wang, H
Kim, M
Normoyle, KP
Liano, D
AF Wang, Huan
Kim, Miri
Normoyle, Kieran P.
Liano, Daniel
TI Thermal Regulation of the Brain-An Anatomical and Physiological Review
for Clinical Neuroscientists
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Review
DE neuroanatomy; cerebrovasculature; cerebral thermoregulation; carotid
rete; cerebral circulation
ID MIDDLE MENINGEAL ARTERY; CEREBRAL-BLOOD-FLOW; CEREBROSPINAL-FLUID FLOW;
DURA-MATER; PIA MATER; TEMPERATURE; EVOLUTION; MAMMALS; HUMANS; HEAD
AB Humans, like all mammals and birds, maintain a near constant core body temperature of 36-37.5 degrees C over a broad range of environmental conditions and are thus referred to as endothermy. The evolution of the brain and its supporting structures in mammals and birds coincided with this development of endothermy. Despite the recognition that a more evolved and complicated brain with all of its temperature-dependent cerebral circuitry and neuronal processes would require more sophisticated thermal control mechanisms, the current understanding of brain temperature regulation remains limited. To optimize the development and maintenance of the brain in health and to accelerate its healing and restoration in illness, focused, and committed efforts are much needed to advance the fundamental understanding of brain temperature. To effectively study and examine brain temperature and its regulation, we must first understand relevant anatomical and physiological properties of thermoregulation in the head-neck regions.
C1 [Wang, Huan] Carle Fdn Hosp, Dept Neurosurg, Urbana, IL USA.
[Wang, Huan] Univ Illinois, Beckman Inst, Thermal Neurosci Lab, Urbana, IL 61801 USA.
[Wang, Huan; Kim, Miri; Normoyle, Kieran P.] Univ Illinois, Coll Med, Urbana, IL 61801 USA.
[Kim, Miri] Univ Illinois, Neurosci Program, Urbana, IL 61801 USA.
[Kim, Miri] Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA.
[Normoyle, Kieran P.; Liano, Daniel] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA.
[Normoyle, Kieran P.] Massachusetts Gen Hosp, Dept Child Neurol, Boston, MA 02114 USA.
[Liano, Daniel] Univ Illinois, Beckman Inst, NeuroTech Grp, Urbana, IL 61801 USA.
[Liano, Daniel] Cade Fdn Hosp, Dept Neurol, Urbana, IL USA.
RP Wang, H (reprint author), Carle Fdn Hosp, Dept Neurosurg, Urbana, IL USA.; Wang, H (reprint author), Univ Illinois, Beckman Inst, Thermal Neurosci Lab, Urbana, IL 61801 USA.; Wang, H (reprint author), Univ Illinois, Coll Med, Urbana, IL 61801 USA.
EM huanwang@illinois.edu
NR 57
TC 0
Z9 0
U1 3
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD JAN 21
PY 2016
VL 9
AR 528
DI 10.3389/fnins.2015.00528
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA DB5WV
UT WOS:000368585300002
ER
PT J
AU Kilcoyne, A
Kaplan, JL
Gee, MS
AF Kilcoyne, Aoife
Kaplan, Jess L.
Gee, Michael S.
TI Inflammatory bowel disease imaging: current practice and future
directions
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Imaging; Inflammatory bowel disease; Crohn's disease; Ulcerative
colitis; Computed tomography; Magnetic resonance imaging
ID MAGNETIC-RESONANCE ENTEROCLYSIS; DUAL-ENERGY CT; CROHNS-DISEASE; MR
ENTEROGRAPHY; CONVENTIONAL ENTEROCLYSIS; ABDOMINAL TUBERCULOSIS;
ULCERATIVE-COLITIS; CLINICAL-COURSE; FOLLOW-UP; WALL INFLAMMATION
AB The purpose of this paper is to evaluate the role of imaging in inflammatory bowel disease (IBD), including detection of extraluminal complications and extraintestinal manifestations of IBD, assessment of disease activity and treatment response, and discrimination of inflammatory from fibrotic strictures. IBD is a chronic idiopathic disease affecting the gastrointestinal tract that is comprised of two separate, but related intestinal disorders; Crohn's disease and ulcerative colitis. The paper discusses, in detail the pros and cons of the different IBD imaging modalities that need to be considered in order to optimize the imaging and clinical evaluation of patients with IBD. Historically, IBD evaluation of the bowel has included imaging to assess the portions of the small bowel that are inaccessible to optical endoscopic visualization. This traditionally was performed using barium fluoroscopic techniques; however, cross-sectional imaging techniques (computed tomography and magnetic resonance imaging) are being increasingly utilized for IBD evaluation because they can simultaneously assess mural and extramural IBD manifestations. Recent advances in imaging technology, that continue to improve the ability of imaging to noninvasively follow disease activity and treatment response, are also discussed. This review article summarizes the current imaging approach in inflammatory bowel disease as well as the role of emerging imaging modalities.
C1 [Kilcoyne, Aoife; Gee, Michael S.] Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02214 USA.
[Kaplan, Jess L.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02214 USA.
RP Kilcoyne, A (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02214 USA.
EM akilcoyne1@mgh.harvard.edu
NR 122
TC 1
Z9 1
U1 1
U2 2
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD JAN 21
PY 2016
VL 22
IS 3
BP 917
EP 932
DI 10.3748/wjg.v22.i3.917
PG 16
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DB5KD
UT WOS:000368552100003
PM 26811637
ER
PT J
AU Shu, SK
Lin, CY
He, HH
Witwicki, RM
Tabassum, DP
Roberts, JM
Janiszewska, M
Huh, SJ
Liang, Y
Ryan, J
Doherty, E
Mohammed, H
Guo, H
Stover, DG
Ekram, MB
Peluffo, G
Brown, J
D'Santos, C
Krop, IE
Dillon, D
McKeown, M
Ott, C
Qi, J
Ni, M
Rao, PK
Duarte, M
Wu, SY
Chiang, CM
Anders, L
Young, RA
Winer, EP
Letai, A
Barry, WT
Carroll, JS
Long, HW
Brown, M
Liu, XS
Meyer, CA
Bradner, JE
Polyak, K
AF Shu, Shaokun
Lin, Charles Y.
He, Housheng Hansen
Witwicki, Robert M.
Tabassum, Doris P.
Roberts, Justin M.
Janiszewska, Michalina
Huh, Sung Jin
Liang, Yi
Ryan, Jeremy
Doherty, Ernest
Mohammed, Hisham
Guo, Hao
Stover, Daniel G.
Ekram, Muhammad B.
Peluffo, Guillermo
Brown, Jonathan
D'Santos, Clive
Krop, Ian E.
Dillon, Deborah
McKeown, Michael
Ott, Christopher
Qi, Jun
Ni, Min
Rao, Prakash K.
Duarte, Melissa
Wu, Shwu-Yuan
Chiang, Cheng-Ming
Anders, Lars
Young, Richard A.
Winer, Eric P.
Letai, Antony
Barry, William T.
Carroll, Jason S.
Long, Henry W.
Brown, Myles
Liu, X. Shirley
Meyer, Clifford A.
Bradner, James E.
Polyak, Kornelia
TI Response and resistance to BET bromodomain inhibitors in triple-negative
breast cancer
SO NATURE
LA English
DT Article
ID SUPER-ENHANCERS; SELECTIVE-INHIBITION; CELL IDENTITY; RNA-SEQ; C-MYC;
INFLAMMATION; STRATEGY; LEUKEMIA; SUBTYPES; PP2A
AB Triple-negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy(1-3). BET bromodomain inhibitors, which have shown efficacy in several models of cancer(4-6), have not been evaluated in TNBC. These inhibitors displace BET bromodomain proteins such as BRD4 from chromatin by competing with their acetyl-lysine recognition modules, leading to inhibition of oncogenic transcriptional programs(7-9). Here we report the preferential sensitivity of TNBCs to BET bromodomain inhibition in vitro and in vivo, establishing a rationale for clinical investigation and further motivation to understand mechanisms of resistance. In paired cell lines selected for acquired resistance to BET inhibition from previously sensitive TNBCs, we failed to identify gatekeeper mutations, new driver events or drug pump activation. BET-resistant TNBC cells remain dependent on wild-type BRD4, which supports transcription and cell proliferation in a bromodomain-independent manner. Proteomic studies of resistant TNBC identify strong association with MED1 and hyper-phosphorylation of BRD4 attributable to decreased activity of PP2A, identified here as a principal BRD4 serine phosphatase. Together, these studies provide a rationale for BET inhibition in TNBC and present mechanism-based combination strategies to anticipate clinical drug resistance.
C1 [Shu, Shaokun; Lin, Charles Y.; He, Housheng Hansen; Witwicki, Robert M.; Tabassum, Doris P.; Roberts, Justin M.; Janiszewska, Michalina; Huh, Sung Jin; Ryan, Jeremy; Doherty, Ernest; Stover, Daniel G.; Ekram, Muhammad B.; Peluffo, Guillermo; Brown, Jonathan; Krop, Ian E.; Dillon, Deborah; McKeown, Michael; Ott, Christopher; Qi, Jun; Ni, Min; Winer, Eric P.; Letai, Antony; Long, Henry W.; Brown, Myles; Bradner, James E.; Polyak, Kornelia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Shu, Shaokun; Lin, Charles Y.; He, Housheng Hansen; Witwicki, Robert M.; Janiszewska, Michalina; Huh, Sung Jin; Ryan, Jeremy; Stover, Daniel G.; Ekram, Muhammad B.; Peluffo, Guillermo; Brown, Jonathan; Krop, Ian E.; McKeown, Michael; Ott, Christopher; Qi, Jun; Ni, Min; Winer, Eric P.; Letai, Antony; Barry, William T.; Brown, Myles; Bradner, James E.; Polyak, Kornelia] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Shu, Shaokun; Lin, Charles Y.; He, Housheng Hansen; Witwicki, Robert M.; Janiszewska, Michalina; Huh, Sung Jin; Ryan, Jeremy; Stover, Daniel G.; Ekram, Muhammad B.; Peluffo, Guillermo; Brown, Jonathan; Krop, Ian E.; McKeown, Michael; Ott, Christopher; Qi, Jun; Ni, Min; Winer, Eric P.; Letai, Antony; Barry, William T.; Brown, Myles; Bradner, James E.; Polyak, Kornelia] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[He, Housheng Hansen; Guo, Hao; Barry, William T.; Liu, X. Shirley; Meyer, Clifford A.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[He, Housheng Hansen; Guo, Hao; Barry, William T.; Liu, X. Shirley; Meyer, Clifford A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[He, Housheng Hansen; Liang, Yi] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 1L7, Canada.
[He, Housheng Hansen] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.
[Doherty, Ernest] Harvard Univ, Cambridge, MA 02138 USA.
[Mohammed, Hisham; D'Santos, Clive; Carroll, Jason S.] Univ Cambridge, Cambridge Inst, Canc Res UK, Cambridge CB2 0RE, England.
[Dillon, Deborah] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Dillon, Deborah] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Rao, Prakash K.; Duarte, Melissa; Long, Henry W.; Brown, Myles; Liu, X. Shirley; Polyak, Kornelia] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.
[Wu, Shwu-Yuan; Chiang, Cheng-Ming] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dept Biochem, Dallas, TX 75390 USA.
[Wu, Shwu-Yuan; Chiang, Cheng-Ming] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dept Pharmacol, Dallas, TX 75390 USA.
[Anders, Lars; Young, Richard A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Liu, X. Shirley; Bradner, James E.; Polyak, Kornelia] Broad Inst, Cambridge, MA 02142 USA.
RP Polyak, K (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
EM james_bradner@dfci.harvard.edu; kornelia_polyak@dfci.harvard.edu
RI Young, Richard/F-6495-2012;
OI Young, Richard/0000-0001-8855-8647; Stover, Daniel/0000-0001-9003-8165;
Brown, Myles/0000-0002-8213-1658
FU NIH DF/HCC SPORE in Breast Cancer [CA168504, CA080111, CA103867]; Susan
G. Komen Foundation; CPRIT [RP110471, RP140367]; Welch Foundation; US
Department of Defense CDMRP [BC122003, CA120184]; Princess Margaret
Cancer Foundation; Canada Foundation for Innovation; Ontario Research
Fund [CFI32372]; NSERC discovery grant [RGPIN-2015-04658]; Harvard
Ludwig Center for Cancer Research
FX We thank D. Silver and members of the Polyak and Bradner laboratories
for their critical reading of this manuscript and useful discussions. We
thank G. Brown for help with creating the word cloud figures. This work
was supported by the NIH DF/HCC SPORE in Breast Cancer CA168504 (K.P.,
E.P.W., I.E.K., D.D., W.T.B., and J.E.B.), CA080111 (K.P. and M.B.), and
CA103867 (C.M.C.), Susan G. Komen Foundation (S.S.), CPRIT RP110471 and
RP140367 (C.M.C), Welch Foundation (C.M.C.), US Department of Defense
CDMRP BC122003 (S.X.L.) and CA120184 (C.Y.L.), Princess Margaret Cancer
Foundation (H.H.H.), Canada Foundation for Innovation and Ontario
Research Fund CFI32372 (H.H.H.), NSERC discovery grant RGPIN-2015-04658
(H.H.H.), and the Harvard Ludwig Center for Cancer Research (J.E.B.,
M.B. and K.P.).
NR 36
TC 33
Z9 33
U1 25
U2 62
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JAN 21
PY 2016
VL 529
IS 7586
BP 413
EP +
DI 10.1038/nature16508
PG 24
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DB2QT
UT WOS:000368354800050
PM 26735014
ER
PT J
AU Powers, BW
Chaguturu, SK
AF Powers, Brian W.
Chaguturu, Sreekanth K.
TI ACOs and High-Cost Patients
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Powers, Brian W.; Chaguturu, Sreekanth K.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Powers, Brian W.] Harvard Univ, Sch Business, Boston, MA 02115 USA.
[Chaguturu, Sreekanth K.] Partners HealthCare, Boston, MA USA.
[Chaguturu, Sreekanth K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Powers, BW (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.
NR 4
TC 5
Z9 5
U1 2
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 21
PY 2016
VL 374
IS 3
BP 203
EP 205
DI 10.1056/NEJMp1511131
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA DB3IS
UT WOS:000368404800003
PM 26789867
ER
EF